<SEC-DOCUMENT>0001493152-23-016069.txt : 20230510
<SEC-HEADER>0001493152-23-016069.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510083030
ACCESSION NUMBER:		0001493152-23-016069
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39717
		FILM NUMBER:		23904468

	BUSINESS ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		248 ROUTE 25A
		STREET 2:		NO. 2
		CITY:			EAST SETAUKET
		STATE:			NY
		ZIP:			11733

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:LIXT="http://lixte.com/20230331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_LIXT_lixte.com_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001335105 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityCentralIndexKey">0001335105</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-03-31" id="xdx2ixbrl0079" name="us-gaap:AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-12-31" id="xdx2ixbrl0080" name="us-gaap:AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-03-31" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:RepaymentOfDeferredOfferingCosts" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_country_CN" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468" id="xdx2ixbrl0555" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468" id="xdx2ixbrl0557" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468" id="xdx2ixbrl0559" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468" id="xdx2ixbrl0561" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468" id="xdx2ixbrl0563" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468" id="xdx2ixbrl0565" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" id="xdx2ixbrl0701" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-11-062022-11-06_custom_FourOfficersMember" id="xdx2ixbrl0827" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_NonRelatedPartiesMember" id="xdx2ixbrl0854" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_NonRelatedPartiesMember" id="xdx2ixbrl0855" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0866" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0868" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0874" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0876" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lixt-20230331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_VendorOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_VendorTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_VendorThreeMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_VendorFourMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_VendorOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_VendorTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_country_ES">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-03-16</xbrli:startDate>
        <xbrli:endDate>2015-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember5713203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-112022-04-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-11</xbrli:startDate>
        <xbrli:endDate>2022-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-12_custom_PlacementAgentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-092023-03-10_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-09</xbrli:startDate>
        <xbrli:endDate>2023-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-092023-03-10_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-09</xbrli:startDate>
        <xbrli:endDate>2023-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-10_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CommonStockWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_DrKovachMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_DrJamesSMiserMDMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_FormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-29</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_NewIndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_NewIndependentDirectorMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_IndependentDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CashBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">LIXT:CashBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CashBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">LIXT:CashBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_StockBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_StockBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-13</xbrli:startDate>
        <xbrli:endDate>2020-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-06</xbrli:startDate>
        <xbrli:endDate>2022-10-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-13</xbrli:startDate>
        <xbrli:endDate>2020-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-30</xbrli:startDate>
        <xbrli:endDate>2020-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-11</xbrli:startDate>
        <xbrli:endDate>2020-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-04-09_custom_DrWinsonSzeChunHoMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrWinsonSzeChunHoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-09_srt_DirectorMember_custom_DrWinsonSzeChunHoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrWinsonSzeChunHoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_srt_DirectorMember_custom_DrWinsonSzeChunHoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrWinsonSzeChunHoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_DirectorMember_custom_DrWinsonSzeChunHoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrWinsonSzeChunHoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-10</xbrli:startDate>
        <xbrli:endDate>2021-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_MsReginaBrownMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-28</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_NonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:NonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-16</xbrli:startDate>
        <xbrli:endDate>2022-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-17_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_BasvanderBaanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-022022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-02</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-06-30_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-062022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-06</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_FourOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-06_custom_FiveNonOfficerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_NonRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_NonRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ClinicalTrialResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_OtherClinicalAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:OtherClinicalAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ClinicalResearchSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-102018-09-12_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-10</xbrli:startDate>
        <xbrli:endDate>2018-09-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-04</xbrli:startDate>
        <xbrli:endDate>2021-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-18</xbrli:startDate>
        <xbrli:endDate>2018-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExclusiveLicenseAgreementMember_custom_FirstFourYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">LIXT:FirstFourYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ExclusiveLicenseAgreementMember_custom_FiveYearsAndThereafterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">LIXT:FiveYearsAndThereafterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-082021-04-09_custom_EmploymentAgreementMember_custom_Dr.JamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:Dr.JamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-08</xbrli:startDate>
        <xbrli:endDate>2021-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_custom_FormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-052022-11-06_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-05</xbrli:startDate>
        <xbrli:endDate>2022-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-292022-10-01_custom_FormanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-29</xbrli:startDate>
        <xbrli:endDate>2022-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-12-23</xbrli:startDate>
        <xbrli:endDate>2013-12-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_NDAConsultingCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-09-12</xbrli:startDate>
        <xbrli:endDate>2015-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-092022-06-10_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-09</xbrli:startDate>
        <xbrli:endDate>2022-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-152023-04-17_custom_MRIGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001335105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-15</xbrli:startDate>
        <xbrli:endDate>2023-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20230101__20230331_zLMu3EpBImTf"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--DocumentQuarterlyReport_c20230101__20230331_zGB50CUmItW2"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_905_edei--DocumentPeriodEndDate_c20230101__20230331_zLyTTeCjQYSh"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20230101__20230331_zGG6G1NOnM96"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentTransitionReport_c20230101__20230331_zsvVLALsbdTi"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number: <span id="xdx_906_edei--EntityFileNumber_c20230101__20230331_zHrCDRlOw5yg"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityFileNumber">001-39717</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20230101__20230331_zUTtrkvq9I04"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityRegistrantName">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20230101__20230331_zL6tYxrp71si"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20230101__20230331_zIN9AFPqcrI6"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityTaxIdentificationNumber">20-2903526</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20230101__20230331_zYbN6S1MaHak"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressAddressLine1">680
East Colorado Boulevard</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20230101__20230331_z1cTOpNe9g8c"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressAddressLine2">Suite 180</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20230101__20230331_zJSW6oAf9iQ9"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressCityOrTown">Pasadena</ix:nonNumeric></span>,
<span id="xdx_908_edei--EntityAddressStateOrProvince_c20230101__20230331_zUYBa9biFxY"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20230101__20230331_zswZqlvae3B1"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressPostalZipCode">91101</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices, including Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--CityAreaCode_c20230101__20230331_zGexeX1goqm8"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_906_edei--LocalPhoneNumber_c20230101__20230331_zGwEHhMU8k12"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:LocalPhoneNumber">830-7092</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zj2Xk2IpxrIc"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zgyima5thgvi"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol">LIXT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_902_edei--SecurityExchangeName_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zBwQOFqvd5Sg"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_z2ZQRBXbHC4g"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle">Warrants
    to Purchase Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zihYoKE57GDj"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol">LIXTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_903_edei--SecurityExchangeName_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_zqcpSOzNAOQj"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityCurrentReportingStatus_c20230101__20230331_zBJz4g9PdlH6"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityInteractiveDataCurrent_c20230101__20230331_zBJfjMWuVye5"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;,
&#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20230101__20230331_z0MqdpGiTtv2"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_904_edei--EntitySmallBusiness_c20230101__20230331_zpQMzuS5Yr4c"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_903_edei--EntityEmergingGrowthCompany_c20230101__20230331_zHXbTiykBL94"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_90F_edei--EntityShellCompany_c20230101__20230331_z4woBbjnSGEh"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 1, 2023, the Company had <span id="xdx_90F_edei--EntityCommonStockSharesOutstanding_iI_c20230501_zJUh5hObnmn8" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-05-01" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,659,093</ix:nonFraction></span> shares of common stock, $0.0001 par value, issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I - FINANCIAL INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Condensed Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Balance Sheets &#8211; March 31, 2023 (Unaudited) and December 31, 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Operations (Unaudited) &#8211; Three Months Ended March 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) &#8211; Three Months Ended March 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; Three Months Ended March 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Condensed Consolidated Financial Statements (Unaudited) &#8211; Three Months Ended March 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>40</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II - OTHER INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A. Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;42</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Defaults Upon Senior Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5. Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6. Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;43</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#Z_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;44</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_001"></span>PART
I - FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Z_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_003"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_z9v04GJAjKei" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230331_zXznDBjPDiE7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zSEy7om1BNj7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzxow_zhOQlPn9HUr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,088,304</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,353,392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AdvancesOnResearchAndDevelopmentContractServices_i02I_pp0p0_maACzxow_zT3r43nLYNwh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advances on research and development contract services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">131,194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:AdvancesOnResearchAndDevelopmentContractServices" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">147,017</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_i02I_pp0p0_maACzxow_z1Y4ng08rtbk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzxow_zj0A3h9Z6YM2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,099</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzxow_maAz09H_zSmwm6qWGTah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,330,816</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,560,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_i01TI_pp0p0_mtAz09H_zWBr8gcnNvd1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,330,816</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,560,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pp0p0_maLCzlt7_zj1EHZ8I4vai" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued expenses, including $<span id="xdx_906_eus-gaap--AccountsPayableCurrent_iI_c20230331_zn8dZ6iMiU0c" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,972</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--AccountsPayableCurrent_iI_c20221231_z5Pz3Gl59ZLg" title="Related parties accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,982</ix:nonFraction></span> to <span id="xdx_90B_eus-gaap--AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_iI_dxL_c20230331_zJG0s7Lc4Yn7" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23RelatedPartyMember"><span id="xdx_90A_eus-gaap--AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_iI_dxL_c20221231_zCaEgEXH5Uyb" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23RelatedPartyMember"><span style="-sec-ix-hidden: xdx2ixbrl0079"><span style="-sec-ix-hidden: xdx2ixbrl0080">related parties</span></span></span></span> at March 31, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,764</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ResearchAndDevelopmentContractLiabilitiesCurrent_i02I_pp0p0_maLCzlt7_ztWWLQEsrjqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development contract liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzlt7_maLASEzriC_zZ2s9YPlM2Wb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">249,987</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">394,786</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzriC_zvxxEC9LTMH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0088">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0089">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_maSEzNet_zAjQPbGifKG" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Preferred Stock, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230331_zwA7cRlpW5Og" title="Preferred stock, par value"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_z2wMwa1YkPil" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331_zSNotw0y09Fa" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zKo4WzFgxh92" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; issued and outstanding &#8211; <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zqboOEfd1rI4" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zCeRAC7kHbf2" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zZxkHqugHQN9" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z0TSGpAigOL4" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of Series A Convertible Preferred Stock, $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zkr3twDzYath" title="Preferred stock, par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zuJwZXJCIj2i" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></ix:nonFraction></span></span> per share stated value, liquidation preference based on assumed conversion into common shares &#8211; <span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zz7YeYNOo6w1" title="Preferred stock, issuable upon conversion"><span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQQwd4HXMKUk" title="Preferred stock, issuable upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,167</ix:nonFraction></ix:nonFraction></span></span> shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maSEzNet_zUUBc2uUAn49" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock, $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230331_zNxRHGwrymV8" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zHzLG3Gfbyff" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; authorized &#8211; <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20230331_zm2sFwx0kmU2" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zLfWDwq8stPd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; issued and outstanding &#8211; <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20230331_zBSJFnzqm7J1" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20230331_zP72YSb1LOya" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,659,093</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20221231_zlugRlPXOzLb" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zuBiFidl3eg6" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,646,593</ix:nonFraction></ix:nonFraction></span></span> shares at March 31, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,665</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,664</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzNet_z0JxOFtJUfJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,341,522</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,058,262</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzNet_zqLVuEf3fu8f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">44,762,358</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">43,394,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquity_i02TI_pp0p0_maLASEzriC_mtSEzNet_zTsPF83tQGUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,080,829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,165,227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzriC_zs97VA32WHAh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,330,816</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,560,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Z_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_ztTouFpGsiRa" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20230331_zDcq2FQIvoPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20220331_zPQzoAJnqFZh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzyvZ_z8GvCeZh7t7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zJvfyLrG8kxf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_z3cztNe7N3Ya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i02_maOEz0wM_zhfh9wgIjcK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Compensation to related parties, including stock-based compensation of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230331_zp3vnjxrGCj5" title="Allocated share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,980</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220331_ziel5EPPUjl7" title="Allocated share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,672</ix:nonFraction></span> for the three months ended March 31, 2023 and 2022, respectively</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">519,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">565,922</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LegalFees_i02_pp0p0_maOEz0wM_zMgmJ2jFMNI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Patent and licensing legal and filing fees and costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">317,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">315,237</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherCostAndExpenseOperating_i02_pp0p0_maOEz0wM_zVe47Mg41Hmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Other costs and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">344,242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">314,743</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEz0wM_zZ5XVBRzE7jl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">458,450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEz0wM_msOILzyvZ_zK8rPnjBZhJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total costs and expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,370,147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,654,352</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzyvZ_maNILzp6v_zyLymt4jXJZ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,370,147</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,654,352</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--InvestmentIncomeNonoperating_maNILzp6v_zZuKvmdGkCg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,015</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestExpense_iN_pp0p0_di_msNILzp6v_zCLyWzeSuOck" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,861</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,494</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_maNILzp6v_zVlhJL3x1qLl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency gain (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzp6v_zYjjCYeijdSa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,367,659</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,656,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,649,510</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,746,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_005"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months Ended March 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_114_zTTBpuTnHWHf" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_zLdMYsbXHb7a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zLQpttdJnUej" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_ztfePPveGxQl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Paid-in</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Capital</p></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zkyiHnKElCDg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Accumulated</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Deficit</p></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B1_zf0JczJnj6Sk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Stockholders&#8217;</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Equity</p></td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Series A</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Convertible</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Paid-in</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Capital</p></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Accumulated</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Deficit</p></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Stockholders&#8217;</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Equity</p></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43C_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zPZzcajMMKV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance, December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zUx62UtC3nbj" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxW271RO1j22" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,646,593</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,664</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,058,262</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,394,699</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,165,227</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zrTgZw6Ss4Ce" style="vertical-align: bottom; background-color: White">
    <td>Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0211">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuI98cdpEOc2" title="Exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,280</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z6OlIcINpfGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,980</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zckTpRJ0IaB1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,367,659</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,367,659</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zmjKKBcRaZZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfRaXWz9TS1f" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWcsPpmQhWDb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,659,093</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,665</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,341,522</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,762,358</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,080,829</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zp8qPVCxMyA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfL43Nlpshq7" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZiNrK5ImnB2" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,746,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,371,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,082,164</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,790,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zGKTvRSn3Z1g" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zdXoS7YrXprd" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKrQt5Hpemj" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,746,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,371,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,082,164</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,790,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z3n12b78fuxj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,672</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zCkqsYc7z0J6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,656,918</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,656,918</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43E_c20220101__20220331_eus-gaap--StockholdersEquity_iE_z7cBbGyEU2af" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zGipJWlvIRx2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9RJSCekGJJ7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,746,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,374</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,710,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,739,082</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,473,092</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20220101__20220331_eus-gaap--StockholdersEquity_iE_zzfpn9OO70Jl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEU1HwtuXkm7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLmWdv8xsOKk" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,746,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,374</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,710,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,739,082</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,473,092</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_006"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_z2zfcMvZR8C4" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230331_zqzBZs0v6jYh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220331_zBnLvDW6n4wi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzYYU_zN1uEEYydmsb" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,367,659</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,656,918</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense included in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--GeneralAndAdministrativeStockBasedCompensationExpenses_i03_pp0p0_maNCPBUzYYU_zLSAdc6Ddkdc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:GeneralAndAdministrativeStockBasedCompensationExpenses" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">276,980</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:GeneralAndAdministrativeStockBasedCompensationExpenses" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">339,672</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i03B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i04B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Increase) decrease in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_i05N_pp0p0_di_msNCPBUzYYU_z4cOoVQv1sI" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Advances on research and development contract services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">15,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidInsurance_i05N_pp0p0_di_msNCPBUzYYU_zFRyPj6uGKQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,995</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidInsurance" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,072</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i05N_pp0p0_di_msNCPBUzYYU_zsx5yZn3ef5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Other prepaid expenses and current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,719</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,670</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i04B_zwO1OqwEFibd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase (decrease) in -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i05_pp0p0_maNCPBUzYYU_zU93qZZTpyAg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,133</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,525</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_i05_pp0p0_maNCPBUzYYU_ziGD7P6Mc2V5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development contract liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">138,666</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">198,142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzYYU_maCCERCzHds_zqWmAHqZkeBa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,271,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,035,097</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromStockOptionsExercised_i01_pp0p0_maNCPBUzKqe_zTyXW69Bqugl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of common stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--RepaymentOfDeferredOfferingCosts_i01N_pp0p0_di_msNCPBUzKqe_ztOg65Vc7Pf2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Payment of deferred offering costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="LIXT:RepaymentOfDeferredOfferingCosts" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,906</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUzKqe_maCCERCzHds_zfvyzWpB9sid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,906</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cash:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_i01T_pp0p0_mtCCERCzHds_zbUProuNface" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net decrease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,265,088</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,046,003</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_pp0p0_zmk1aLUqSMdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,353,392</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,823,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,088,304</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,777,742</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SupplementalCashFlowInformationRelatedText_i01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for -</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,861</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,494</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_007"></span>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months Ended March 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zezPRJOlrOk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_827_zGgFHkCjHt92">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#8220;Company&#8221;), at March 31, 2023, and for the three months
ended March 31, 2023 and 2022, are unaudited. In the opinion of management of the Company, all adjustments, including normal recurring
accruals, have been made that are necessary to present fairly the financial position of the Company as of March 31, 2023, and the results
of its operations for the three months ended March 31, 2023 and 2022, and its cash flows for the three months ended March 31, 2023 and
2022. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal
year. The consolidated balance sheet at December 31, 2022 has been derived from the Company&#8217;s audited consolidated financial statements
at such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notification of Failure to Satisfy a Continued Listing Rule</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2022, the Company received a written notice (the &#8220;Notice&#8221;) from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
that the Company had not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a
period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price
of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists
if the deficiency continues for a period of 30 consecutive business days. The Notice had no immediate effect on the listing of the Company&#8217;s
common stock on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days from the date of
the Notice, or until December 21, 2022, to regain compliance with the minimum closing bid price requirement. On December 22, 2022, the
Company received a written notice from Nasdaq that the Company was eligible for a second 180 calendar day compliance period, or until
June 19, 2023, in order to regain compliance with the $1.00 minimum bid price requirement. Nasdaq&#8217;s determination to grant the
second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares
and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price requirement,
and the Company&#8217;s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse
stock split, if necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company can generally achieve compliance with the minimum closing bid price requirement if the minimum closing bid price of the Company&#8217;s
common stock is at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period. However,
under certain circumstances, Nasdaq can extend this 10-day trading period up to a maximum of 20 days. The Company anticipates that its
shares of common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market during the compliance period ending
June 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to achieve compliance with the minimum closing bid price requirement, the Company filed a proxy statement with the SEC to hold
a special meeting of stockholders on May 26, 2023 to seek stockholder approval to approve an amendment to the Company&#8217;s Certificate
of Incorporation to effect a reverse stock split of the issued and outstanding shares of the Company&#8217;s common stock at a split
ratio of up to a maximum of a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230101__20230331_zHDO1NRZfbLf" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> split, as determined by the Board of Directors in its sole discretion. However, there can be no
assurance that the Company will be successful in obtaining stockholder approval and will thus be able to regain compliance with the minimum
closing bid price requirement by June 19, 2023, in which case the Company anticipates Nasdaq would provide a notice to the Company that
its shares of common stock and warrants are subject to delisting, and the Company&#8217;s common shares and warrants would then be delisted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the Company is able to achieve compliance with Nasdaq&#8217;s minimum closing bid price requirement, there can be no assurances that
the Company will be able to maintain compliance with Nasdaq&#8217;s other continued listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_801_eus-gaap--NatureOfOperations_ze7bVu1lJb45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_826_zrNbUJFvWJK3">Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company had cash of $<span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230331_zU28XjQtYbw"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,088,304</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">available
to fund its operations. Because the Company is currently engaged in various early-stage clinical trials, it is expected that it will
take a significant amount of time and resources to develop any product or intellectual property capable of generating sustainable
revenues. Accordingly, the Company&#8217;s business is unlikely to generate any sustainable operating revenues in the next several
years and may never do so. Even if the Company is able to generate revenues through licensing its technology, product sales or other
commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive earnings and
operating cash flows. At March 31, 2023, the Company&#8217;s unpaid remaining contractual commitments pursuant to clinical trial
agreements and clinical trial monitoring agreements aggregated $<span id="xdx_905_eus-gaap--ContractualObligation_iI_pp0p0_c20230331_zwnZkaDMOhL7" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,900,000</ix:nonFraction></span>, which are currently scheduled to be incurred through
December 31, 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the accompanying interim condensed consolidated financial statements are being issued. The Company&#8217;s
interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that existing cash resources will provide sufficient working capital to fund the current
clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound LB-100 through approximately
December 31, 2023. However, existing cash resources will not be sufficient to complete the development of and obtain regulatory approval
for the Company&#8217;s product candidate, as a result of which the Company will need to raise significant additional capital to do so.
The Company estimates that it will need to raise additional capital to fund its operations, including its various clinical trial commitments,
during the latter part of the fiscal year ending December 31, 2023. In addition, the Company&#8217;s operating plans may change as a
result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed sooner
than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zJFVPlsFE1Rb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_823_zSDkOQcpYvU3">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zVvzjHbKeJP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z1zpCyJUVz1h">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgckybU7JRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zF5yg8PBaMIg">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company&#8217;s President,
Chief Executive Officer and Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_847_eus-gaap--UseOfEstimates_zULEafopo5n" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z9mq2q1HzYq9">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBB7K77ynAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_ze77BMUmmZP2">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the
&#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically has cash
balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230331_zvTTGozSmfsg" title="Cash FDIC insurance"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230331_zHQpiHVDMvXi" title="Cash SIPC insurance"><ix:nonFraction name="LIXT:CashSIPCInsuredAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>, respectively. Morgan Stanley
Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not experienced
any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNBPSW0tlC8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zDRYAh1EmdGa">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="LIXT:PrepaidInsurancePolicyTextBlock"><p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zfhKOyLehoM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zaWragigvy2j">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zmEg5HhImiU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zDlpL0ZqcU0b">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20230101__20230331_zonfydgDVMWl"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">317,340</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20220331_zgo8N59zLuTj" title="Patent and licensing legal and filing fees and costs"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">315,237</ix:nonFraction></span> for the three months ended March 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zwrH3pMfgYac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zxRN2W9DqxN7">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zCZz7vU4SbUa" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zicZbxxY1gv2" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-03-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>% or more of general and administrative costs or research and development costs for the three months ended March 31,
2023 and 2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended March 31, 2023 and 2022 included charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMoFDdYcoM0d" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26.9</ix:nonFraction></span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp95C6OMtNkg" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-03-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">29.6</ix:nonFraction></span>% of total
general and administrative costs, respectively. General and administrative costs for the three months ended March 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zjozQ4A5x6Sb" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23.5</ix:nonFraction></span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zobcm3wt8HBe" title="Concentration of risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28.4</ix:nonFraction></span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended March 31, 2023 included charges from four vendors and consultants representing <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfirrZb1xwu1" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_VendorOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36.5</ix:nonFraction></span>%,
<span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmkSMS1gHTuf" title="Concentrtion percentage risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_VendorTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27.6</ix:nonFraction></span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbe7U3ng7dP" title="Concentrtion percentage risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_VendorThreeMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.9</ix:nonFraction></span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4ztDZaGzun6" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-03-31_custom_VendorFourMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14.4</ix:nonFraction></span>%, respectively, of total research and development costs. Research and development costs for the three months ended
March 31, 2022 included charges from two vendors and consultants representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumRnN3hjtGk" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-03-31_custom_VendorOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63.8</ix:nonFraction></span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrzCEiQcW7ye" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-03-31_custom_VendorTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.8</ix:nonFraction></span>%, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zk8Ql8VEDlab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zqNdZ8vhp4hj">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20230331_zOtcYNdMV08d" title="Unrecognized tax benefits"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zcsfv9vEdJi8" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> unrecognized tax benefits as of March 31, 2023 or December
31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of March 31, 2023 or December
31, 2022. Subsequent to March 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaJ3as2kuMCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zQPzBEuyWbd3">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting period
of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ynR6G1NOk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z71GVYS5YNRc">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS, but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zldWyJKMd9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zTcOwuFQCM09" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230331_z9Lo4bnMYCxb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220331_zhZhg32dVbG8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zxKb3SlDe8Ah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zwO39gcvi396" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,900,310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,110,310</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_z3QDuaYoZXDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_custom_CommonStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,882,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_custom_CommonStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,666,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqB8SHe3HNrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,511,769</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,506,144</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z7eA1fAOKw9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zx8zNb5i3uw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zxwt1rHZLexb">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMnGILblZs51" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zeSgDJXT8Xv5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statement presentation or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statement presentation or disclosures.</span></p>

</ix:nonNumeric><p id="xdx_854_zEZisUg2vYug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_801_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zstYRAaHetO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82D_zYhjGYinxWXc">Research and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="LIXT:ResearchDevelopmentTableTextBlock"><p id="xdx_899_ecustom--ResearchDevelopmentTableTextBlock_z8to79j4rsWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs, including costs associated with clinical trials involving the Company&#8217;s lead clinical compound LB-100, are
summarized below based on the respective geographical regions where such costs are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zenzdK84yMzl" style="display: none">Schedule
of Research and Development Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230331_zAI64C5cZFmk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220331_zRalxHNAElXd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zwaz8jWePPS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,907</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,531</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zEzaUW8bJ6F4" style="vertical-align: bottom; background-color: White">
    <td>Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_country_ES" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31_country_ES" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zWoMuWvwIlIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31_country_CN" format="ixt:numdotdecimal" decimals="0" unitRef="USD">860</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z875TLv8VRYg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Netherlands</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_country_NL" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31_country_NL" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,230</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_z0FW5y57kI5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">458,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_zHdW40dlmvJc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Research and development expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">458,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<!-- Field: Split-Segment; Name: 001 -->
</ix:nonNumeric><p id="xdx_8A7_zW7MnqNoBoe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z2sPVG6ul9sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82B_zKdZtjPVadK7">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230331_zNnqwhHJt3Xa" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230331_zvY7gs7W6y83" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total of <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUibnSNBah6l" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of <span id="xdx_901_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUIp53vnp2o3" title="Principal Cash Obligations and Commitments"><ix:nonFraction name="LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span> shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to <span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5ECfpZGE9s8" title="Preferred stock dividend, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% of the annual net revenue of the Company divided by <span id="xdx_906_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zA19qPj4lgXk" title="Annual net revenue"><ix:nonFraction name="LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares" contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span>, until converted or redeemed. As of March 31, 2023 and December 31,
2022, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zWAaGJRBnEv2" title="Preferred stock, shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zkivoHpRPzYf" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-03-31_custom_UndesignatedPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_UndesignatedPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,650,000</ix:nonFraction></ix:nonFraction></span></span> shares of undesignated preferred stock which may be issued with such rights and powers as the Board of
Directors may designate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3D6cgV8W529" title="Preferred stock, conversion description"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember" name="us-gaap:PreferredStockConversionBasis">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pp4d_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zldrTKtXjoF4" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="4" unitRef="Shares">2.0833</ix:nonFraction></span> shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zGV5RQdt3V6" title="Gross proceeds from sale of transaction"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember5713203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,875,000</ix:nonFraction></span></ix:nonNumeric></span>. The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have a cash liquidation preference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
fully converted, the <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zDYQFr2HmJ88" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zXCjOsD5QM17" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></ix:nonFraction></span></span> outstanding shares of Series A Convertible Preferred Stock would convert into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zSb94vYXBaN7" title="Preferred stock convertible into common stock"><span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zf0d4pg74ywa" title="Preferred stock convertible into common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember5713203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,167</ix:nonFraction></ix:nonFraction></span></span> shares of common stock
at March 31, 2023 and December 31, 2022. The Series A Convertible Preferred Stock has no right to cash, except with respect to the payment
of the aforementioned dividend based on the generation of revenues by the Company. The shares of Series A Convertible Preferred Stock
do not have any registration rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230331_ziaEH8adCnu3" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zJNHvDwDao42" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230331_z8rKObCphKkb" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zuppRRCLACab" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. As of March 31, 2023 and December
31, 2022, the Company had <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20230331_zeXWL6eLw9a6" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230331_zHMLLAG5qGEg" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,659,093</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_ziTbsV210921" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zjMKKCwvPaYl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,646,593</ix:nonFraction></ix:nonFraction></span></span> shares, respectively, of common stock issued, issuable and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 12, 2022, the Company completed the sale of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfR2tSuTIhx4" title="Number of common stock shares issued during period"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,900,000</ix:nonFraction></span> shares of common stock at a price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR9EQyFxQE9g" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span> per share in a registered direct
equity offering, generating gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaVfzQ4yMnZ4" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,800,000</ix:nonFraction></span>. The total cash costs of this offering were $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaXtp37xZGC7" title="Costs of public offering"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">658,616</ix:nonFraction></span>, resulting in net proceeds
of $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGp5TyHmXEof" title="Net proceeds from issuance of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,141,384</ix:nonFraction></span>. Pursuant to the placement agents&#8217; agreement, the Company granted warrants to the placement agents to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zOT9jawiuzJ4" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-12_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,000</ix:nonFraction></span>
shares of common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_z0bMeQ79mE9d" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-12_custom_PlacementAgentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span> per share exercisable through April 14, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 10, 2023, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHAR58ibB2k9" title="Stock issued new issue shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-092023-03-10_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span> shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5owQ7manCc" title="Stock issued new issue shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span> shares exercisable at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJK2NBygq5pc" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5025</ix:nonFraction></span> per share for total cash proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUlbKA53cRG4" title="Proceeds from warrant exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,281</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zWHHRASppmL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity during the three months ended March 31, 2023 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z5FIK2ZOXcC1" style="display: none">Schedule of Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYBpF6OJPfz3" title="Number of Shares, Warrants Outstanding, Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,900,310</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfahfJ3pFEL9" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning" style="width: 14%; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.016</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdAlOraAAbKe" title="Number of Shares, Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwJXs97qiP8k" title="Weighted Average Exercise Price, Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTdN3OT879F5" title="Number of Shares, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSdQ13mDDSi1" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwPl9OGmQZ4" title="Number of Shares, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBiCZ64EhOJ6" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za0FKoVFjKN" title="Number of Shares, Warrants Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,900,310</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zuRoGWSoKVg6" title="Weighted Average Exercise Price, Warrants Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.016</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYRR0XXV66lc" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468" format="ixt-sec:duryear" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">2.90</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbABWHjuhHSc" title="Number of Shares, Warrants exercisable, Beginning Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,900,310</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQl2PspOuIf6" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.016</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRx9ObsZhHMl" title="Number of Shares, Warrants exercisable, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,900,310</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqozfabtLFEj" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.016</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqam0IIlwgQe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468" format="ixt-sec:duryear" name="LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">2.90</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zqkvD14OM1Yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock"><p id="xdx_89F_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zgsX0KiSJiUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zErVmRl0DmTk" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXDiEWWp4yM9" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyF6tCGQ5dBg" title="Warrants Outstanding Shares" style="width: 47%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zTGcmYyiPujg" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.700</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3zC5HO0yIn4" title="Warrants Outstanding Shares" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">113,310</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFdwUhI9DUu3" title="Exercise Prices"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.700</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVDS5dzBbnb6" title="Warrants Outstanding Shares" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,497,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331_zWpd06WveR0i" title="Warrants Outstanding Shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,900,310</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zqr4CMNFqcY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zZu15BQk7cpk" title="Fair market value of stock"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-03-31_custom_CommonStockWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.83</ix:nonFraction></span> per share on March 31, 2023, there was no intrinsic value attributed to exercisable but unexercised common
stock warrants at March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z0jjqBsyvcOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82D_zYDN9y9cspp9">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. The employment agreements
are automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to the
end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically renewed
for additional one-year periods in July and August 2021 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, for Dr. Kovach to continue
to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_z6LbMc8Fflfe" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. During
the three months ended March 31, 2023 and 2022, the Company paid $<span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_ziWoGf2Z3qH6" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zk5EtyKoMmSj" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_DrKovachMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,500</ix:nonFraction></span>, respectively, to Dr. Kovach under this employment
agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90B_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zQTpBpFGf1pj" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_903_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zO3EvcOw4k7d" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMDMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>.
Dr. Miser is required to devote at least 50% of his business time to the Company&#8217;s activities. During the three months ended March
31, 2023 and 2022, the Company paid $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z85oM0dccP1j" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z2YK0jDd9Xn5" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span>, respectively, to Dr. Miser under this employment agreement, which costs are
included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_903_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zGtLO6XrAsli" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_900_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zSIJDbG7aiFh" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_ztlOJZmf1Tu6" title="Compensation"><span title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span></span>. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which Mr. Forman was paid $<span id="xdx_908_eus-gaap--PaymentsForRent_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FormanMember_zoXprCaTEeu7" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-03-31_custom_FormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,583</ix:nonFraction></span> for the three months ended March 31, 2023. During the three months ended March 31, 2023
and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zKfRL2lzgKC8" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zNoZ9E6dUgJ5" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_EricJFormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span>, respectively, to Mr. Forman under this employment agreement, which costs are included
in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_907_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zlGX31nkGZ85" title="Annual salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zIfZSsN4jhxa" title="Increase in annual salary"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span>. During the three months ended March 31, 2023 and 2022, the Company paid $<span id="xdx_909_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zeaY7sMG6He9" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zEF5Ov0zQ0R1" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,750</ix:nonFraction></span>, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Appointment
of Dr. Ren&#233; Bernards to the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $<span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20220615_z14zKa8Uw9La" title="Cash board fee payable"><ix:nonFraction name="us-gaap:ManagementFeePayable" contextRef="AsOf2022-06-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $<span id="xdx_902_ecustom--ManagementFeePayableQuarterly_iI_c20220615_zu0trpnAIT6g" title="Cash board fee payable"><ix:nonFraction name="LIXT:ManagementFeePayableQuarterly" contextRef="AsOf2022-06-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span>, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2021, the Company has previously entered into a Development Collaboration Agreement with the Netherlands Cancer Institute,
Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research
center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range
of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations, as described at Note 9.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the independent members of the
Board of Directors and committee members. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for independent directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zmeY5lCzWo8d" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee - additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zhvXfEl7bgV1" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees - additional $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zjM64qZpMoh5" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee - additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zpPYMt9v5wr3" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees - additional $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zfNZcItlRmlj" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500</ix:nonFraction></span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for independent directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new independent directors - The Company will grant options to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zuNKM3trb88b" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-03-31_custom_NewIndependentDirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of common stock, exercisable for a period of
five years, at the closing market price on the date of grant, vesting <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zRScVYoFZdB9" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-01-012023-03-31_custom_NewIndependentDirectorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% on the grant date and the remaining <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zR5JvlkEazy2" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-01-012023-03-31_custom_NewIndependentDirectorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% vesting <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230331_z1k5g1cBMfSb" title="Award vesting rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% on the
last day of each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject
to continued service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their
respective institution or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company
may elect to pay a one-time cash fee of $<span id="xdx_90E_eus-gaap--CostOfRevenue_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z7xZheQFScV4" title="One time cash"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-03-31_custom_NewIndependentDirectorMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to independent directors - Effective on the last business day of the month of June, the Company will grant options to
purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_z6M5CGhtMYP7" title="Options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting
<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zI7SoEkzOfD1" title="Share-based payment award, award vesting period"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested,
subject to continued service. If any director has served for less than 12 full calendar months at the grant date, the amount of such
stock option grant shall be prorated based on the length of service of such director. At the discretion of the Board of Directors, for
a nominee to the Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation,
in lieu of the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_905_eus-gaap--CostOfRevenue_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z8mCU1XvDv2g" title="Annual cash fee"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to independent directors was $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zFQYNl4gmim" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_IndependentDirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,500</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zwxvYeq51GPl" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_IndependentDirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,500</ix:nonFraction></span>, respectively, for the three months ended March 31, 2023 and
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zIaapNhijKDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months ended March 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zGq9IBIsvPSd" style="display: none">Summary of Related Party Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20230331_zrPvHzzbK4n2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zoenYFrgw2lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--CashBasedMember_zhqsl2hIf9Ql" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-03-31_custom_CashBasedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-03-31_custom_CashBasedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--StockBasedMember_zIvvdDw3Uiml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-03-31_custom_StockBasedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,980</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-03-31_custom_StockBasedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_zVPx2m1zwnb2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">519,480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">565,922</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_zLVSWL4Be6M2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Related party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">519,480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">565,922</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_zygDuHHkbNS6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zlx85rSHZnFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82B_z8QWitmOLsRl">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zqsGmZmFaZR4" title="Number of restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,333,333</ix:nonFraction></span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zd0Fcox30a17" title="Common shares avaliable for issuable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,800,000</ix:nonFraction></span> shares, to a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zkv3MXQmhtR6" title="Shares total"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,133,333</ix:nonFraction></span>
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, unexpired stock options for <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zwUO0BeNqqW1" title="Shares outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,603,125</ix:nonFraction></span> shares were issued and outstanding under the 2020 Plan and <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWPVtAljTKfe" title="Shares were available for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-03-31_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,530,208</ix:nonFraction></span> shares
were available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options requiring an assessment of value issued during the three months ended March 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zLTxKhMnGe66" title="Stock options description"><ix:nonNumeric contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zlGbwraY7wR2" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,333</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxL_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsbhhFkNX5hc" title="Stock option vested exercisable term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0701">five</span></span> years at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4itUxTf3ZEi" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">7.14</ix:nonFraction></span> per share, which was equal to the closing market
price of the Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90C_ecustom--FairValueOfStockOptions_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zj3y8XijbpV2" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,855</ix:nonFraction></span> ($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4DZdMErs893" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">6.8718</ix:nonFraction></span> per share), of which $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z40vRAub5I0a" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,214</ix:nonFraction></span> was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zikYZ5776hU1" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,710</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0elXYAyT83e" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_EricJFormanMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,710</ix:nonFraction></span>, respectively, with respect to these stock options</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2020, in connection with an employment agreement entered into with <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8t4ey3Gs745" title="Stock options description"><ix:nonNumeric contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgiC3QBpGR1g" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,334</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of five years at an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zqOuXVFQaYH8" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">7.14</ix:nonFraction></span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zo3V6BkEwHG5" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">572,650</ix:nonFraction></span> ($<span id="xdx_905_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zhNjUAEO79vg" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">6.8718</ix:nonFraction></span> per share), of which $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zlinjwNgPBb6" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,163</ix:nonFraction></span> was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8IzHyUH93K7" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,300</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRf5njdLExFf" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_DrJamesMiserMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,300</ix:nonFraction></span>, respectively, with respect to these stock options</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zBB3FWsB1Jk9" title="Stock options description"><ix:nonNumeric contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zt2BMBhQmeB1" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,333</ix:nonFraction></span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of five years at an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVCYsW7Uhfzc" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">7.14</ix:nonFraction></span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $<span id="xdx_90F_ecustom--FairValueOfStockOptions_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zT6QqmTpiKLa" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,855</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3XicVaSMw2b" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">6.8718</ix:nonFraction></span> per share), of which $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_za9nLHTwfxah" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,214</ix:nonFraction></span> was attributable to the portion of the stock
options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair
value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months
ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations
of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zErm9K9REoHc" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,710</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zdcf9cJX18Ak" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,710</ix:nonFraction></span>, respectively, with respect to these stock options</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zrvmRZBOvdZ2" title="Stock options description"><ix:nonNumeric contextRef="From2021-04-012021-04-09_custom_DrWinsonSzeChunHoMember_srt_DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#8217;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zWylQPsf99d" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-04-09_srt_DirectorMember_custom_DrWinsonSzeChunHoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zAWO1g2FcVo2" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-04-09_srt_DirectorMember_custom_DrWinsonSzeChunHoMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">3.20</ix:nonFraction></span> per share (the closing market price on the grant date),
vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zc6kHvPMLcB6" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-04-012021-04-09_custom_DrWinsonSzeChunHoMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">753,611</ix:nonFraction></span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z8VDv2m48mg1" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-04-09_srt_DirectorMember_custom_DrWinsonSzeChunHoMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">3.0144</ix:nonFraction></span> per share), of which $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjk2FIIFMn56" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2021-04-012021-04-09_custom_DrWinsonSzeChunHoMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">376,800</ix:nonFraction></span> was attributable to the portion of the stock options fully vested
on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock
options was being charged to operations ratably from April 9, 2021 through June 30, 2023. However, vesting of these stock options terminated
on October 30, 2022, the date that Mr. Schwartzberg died. During the three months ended March 31, 2023 and 2022, the Company recorded
charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zRD6RHW7oJCd" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_srt_DirectorMember_custom_DrWinsonSzeChunHoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zuciQZy1fcd" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_srt_DirectorMember_custom_DrWinsonSzeChunHoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,764</ix:nonFraction></span>, respectively, with respect
to these stock options</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zad7V0JUW1ni" title="Stock options description"><ix:nonNumeric contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zkOHzOPHoWZb" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of five
years at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zqf2w4989oV3" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">2.80</ix:nonFraction></span> per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90C_ecustom--FairValueOfStockOptions_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zp3ZJuW6vHp" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">658,363</ix:nonFraction></span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z5nwp5fFizVe" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">2.6335</ix:nonFraction></span> per
share), of which $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zMhT266vInO" title="Stock options fully vested amount, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">329,188</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from May 11, 2021 through June 30, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7IexJmAmKN1" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,983</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zPVSljrJX9Ni" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_MsReginaBrownMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,983</ix:nonFraction></span>, respectively, with respect to these stock
options</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zI6p2Y2OysFb" title="Stock options description"><ix:nonNumeric contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOueVA0wQ0ai" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zFbzYnPfXfOb" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_custom_NonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOXEiP2BSIt8" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">3.03</ix:nonFraction></span> per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90C_ecustom--FairValueOfStockOptions_c20210601__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z9K19CeHR6xa" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2021-06-012021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,421,095</ix:nonFraction></span> ($<span id="xdx_902_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z5Ohjr1O2Tpc" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">2.84225</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2021 through June 30,
2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the
consolidated statement of operations of $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zrYAhUOntEn8" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,123</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zKgMTJmcnpP" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,205</ix:nonFraction></span>, respectively, with respect to these stock options</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_ztcIETdO0ZXf" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zCXEfeY4t0l4" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zNSvzku9Wr41" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.74</ix:nonFraction></span> per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zNxgZpx8zQOg" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,525</ix:nonFraction></span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zLo2xH6GIDK6" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">0.6341</ix:nonFraction></span> per
share), of which $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zOHi15HNMCX3" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,263</ix:nonFraction></span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from June 17, 2022 through June 30, 2024. During the three months ended March 31, 2023, the Company recorded a total charge to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z1W12hLGNXo6" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_BasvanderBaanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,588</ix:nonFraction></span> with respect to these stock options</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220601__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_z7LBvkZ1DYpb" title="Stock options description"><ix:nonNumeric contextRef="From2022-06-012022-06-30_srt_DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220602__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_z9e73flIIqfc" title="Purchase of shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-06-022022-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares (a total
of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zd7v5tMI1yn1" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="5" unitRef="Shares">500,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zQEanGW1Zgnk" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.74</ix:nonFraction></span> per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90E_ecustom--FairValueOfStockOptions_c20220601__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zy5GNVxYWvL4" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-06-012022-06-30_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,700</ix:nonFraction></span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zgmO8srEOh1h" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">0.6334</ix:nonFraction></span> per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
During the three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__srt--DirectorMember_z0UUw35na8ee" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,394</ix:nonFraction></span> with respect to these stock options</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zJpyxciYa1Uj" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares
(a total of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zYp1VHeTP13l" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000</ix:nonFraction></span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxL_c20221106__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zKW4qRcL13wa" title="Stock option vested exercisable term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0827">five</span></span> years at an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zY2Bkw1ZDt87" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span>
per share, vesting <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNZX3C3ZcIPc" title="Share based compensation vesting rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service. The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zdtVs9fc8Eng" title="Stock options granted to purchase common stock, issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000</ix:nonFraction></span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zkgaTrPCwE0c" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-11-052022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,560</ix:nonFraction></span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zd5pRXQK47mk" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">0.3282</ix:nonFraction></span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated statement
of operations of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z4cvNTG6jTEi" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_FourOfficersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,172</ix:nonFraction></span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106_zcYl0u0JQlsk" title="Number of fully vested option exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-11-06" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock, which was fully vested upon issuance and is exercisable for a period of five years at $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zVol09Nf1Mck" title="Stock options are exercisable price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-11-06_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5025</ix:nonFraction></span> per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zTfkB7YQ5FPk" title="Fair value of stock options"><ix:nonFraction name="LIXT:FairValueOfStockOptions" contextRef="From2022-11-052022-11-06_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,264</ix:nonFraction></span> ($<span id="xdx_90C_eus-gaap--SharePrice_iI_pp5d_c20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zowLfN7cmHWg" title="Stock price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-06_custom_FiveNonOfficerDirectorsMember" format="ixt:numdotdecimal" decimals="5" unitRef="USDPShares">0.4326</ix:nonFraction></span> per share) and was charged to general and administrative costs in the consolidated statement of operations on
that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#8217;s Board of Directors at the
Company&#8217;s Annual Meeting of Stockholders held on October 7, 2022, and Gil Schwartzberg, a director of the Company, died on October
30, 2022. Accordingly, the unvested stock options for each such person ceased vesting effective as of the respective dates that their
service on the Company&#8217;s Board of Directors terminated. Furthermore, the expiration date of all vested stock options owned by such
persons are contractually scheduled to expire one year from the respective dates that their service on the Company&#8217;s Board of Directors
terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zUkPbHeRX7Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months ended March 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zuBc1L43seP" style="display: none">Summary of Stock-based Compensation Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230331_zSZh7j0mzpU4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220331_zeIGOCKaCUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zuFEZ9VFZ4Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,980</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,672</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zPBmOzJM8fld" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_zqzNOapDc172" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,980</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,672</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zO4kBW9JbnM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFbHoJbCUcD" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_zC1BLKG8RLVh" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331_zI3VBGN0CW9g" title="Number of shares, stock options outstanding, at the beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,894,792</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zI5mFDwxoStb" title="Weighted average exercise price, stock options outstanding, at the beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.9183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230331_zJxWLckPa9el" title="Number of shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_z9c0e6id6qMa" title="Weighted average exercise price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230331_z4bwHDiRcvJg" title="Number of shares, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zN72wDcIDXh7" title="Weighted average exercise price, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230331_z0VhiFm81I23" title="Number of shares, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zWGHOq5LjYh8" title="Weighted average exercise price, expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230331_zwEr2wT4jSKf" title="Number of shares, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,882,292</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zkiMipGUeKjc" title="Weighted average exercise price, stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.9260</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zYXAUwcsWQja" title="Weighted average remaining contractual life (in years), stock options outstanding"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.79</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCQIPksNcUE" title="Number of shares, stock options exercisable, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,819,792</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z61mfmRsYcd" title="Weighted average exercise price, stock options exercisable, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.2834</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230331_z6HQldkB2dr" title="Number of shares, stock options exercisable, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,913,542</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230331_zHj7mjfQG6x" title="Weighted average exercise price, stock options exercisable, at the end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.2431</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_z3TJtDZ276N8" title="Weighted average remaining contractual life (in years), stock options exercisable"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.28</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zWVnpF1wKIFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_902_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20230331_zIV4eIrlg2jf" title="Total deferred compensation expense for outstanding value of unvested stock options"><ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,000</ix:nonFraction></span> at March 31, 2023, which
will be recognized subsequent to March 31, 2023 over a weighted-average period of approximately <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20230331_zDxF02tpXrm6" title="Stock option vested exercisable term"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">15</ix:nonNumeric></span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z8Zbvsm0pQDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at March 31, 2023
are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zzNX2AxBd5o8" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zIt0gX5Bwdr2" title="Exercise Prices" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5025</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zkbYvjymyPB1" title="Options Outstanding (Shares)" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zO9kuVSjLadl" title="Options Exercisable (Shares)" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztpLw5PBn4X9" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.7400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zvyxXN8Whpvg" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">575,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxmNYagyKaq3" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">309,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zClDDRQs6NV2" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.6800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmpFB26ywZpk" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zI9bxUmLn6A5" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zBv0FSJ1oCw9" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.0000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zooXVbWkFGBj" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zIr6vOixStH" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zgNhR6kwcRKg" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.0600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuzOZz9BuKF9" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7DSWOFTHca" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zgYzBlBZvaq6" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zguXgay8hEa8" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztLIUhhVhDFc" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zSuxmGK9nMQ7" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.0000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWRSacMmGvV2" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">666,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXHT8PLGZtd4" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">666,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zR5GUdjSw1t2" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.0300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJkGCAYecpWa" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">425,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zXMtIq5inzi7" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">387,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z87ELwmJPxWh" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.2000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_znFYhgeqSkWg" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zKQV6zJri1N2" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,125</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMtmv8ArPDa" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.2100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z8WWZkHqOjqj" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z6f7uZNKweo8" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zq9fHiMX3wY5" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.0000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zLBvxdQ2qHcj" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zu7lbE10h0Ad" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zt1IzT7CU0Zc" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.6000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zBy6oHJCDvs2" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zM79bdnAnJ9j" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwYWnoEjoUp1" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.1400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zhXAHeT12fy" title="Options Outstanding (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z70h0X14xT58" title="Options Exercisable (Shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zubRnZBLyXu4" title="Exercise Prices" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-012023-03-31_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.0000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z427t7cWs6U3" title="Options Outstanding (Shares)" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPRX2edysUp1" title="Options Exercisable (Shares)" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,882,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331_zZN7lnr5V0kk" title="Options Exercisable (Shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,913,542</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_znbkrW7VZ6ll" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of exercisable but unexercised in-the-money stock options at March 31, 2023 was approximately $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20230331_znqCdrVy3NOj" title="Intrinsic value of exercisable but unexercised in-the-money stock options"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,500</ix:nonFraction></span>, based on a fair
market value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20230331_znioS8RrAiag" title="Fair market value, per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.83</ix:nonFraction></span> per share on March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20230331_zfAoknifgeLa" title="Outstanding stock options to acquire shares of common stock not vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">968,750</ix:nonFraction></span> shares of the Company&#8217;s common stock had not vested at March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zWMGNo1W8oQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_82A_zy0kSECwz3Dd">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company did not record any provision for income taxes as the Company incurred losses
during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount
of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has recorded a full
valuation allowance against its deferred tax assets for all periods presented as the Company believes it is more likely than not the
deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIqhr8JbhDm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_825_zXPqc4ca75w7">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of March 31, 2023 and December
31, 2022, the Company was not subject to any pending or threatened legal claims or actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company&#8217;s unpaid remaining contractual commitments pursuant to clinical trial agreements and
clinical trial monitoring agreements, as described below, aggregated $<span id="xdx_90B_eus-gaap--ContractualObligation_iI_c20230331_zvFayusOmba3" title="Contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,900,000</ix:nonFraction></span>,
which are currently scheduled to be incurred through December 31, 2025. The Company&#8217;s ability to conduct and fund these
contractual commitments is subject to the timely availability of sufficient capital to fund such expenditures, as well as any
changes in the allocation or reallocation of such funds to the Company&#8217;s current or future clinical trial programs. The
Company expects that the full amount of these expenditures will be incurred only if such clinical trial programs are conducted as
originally designed and their respective enrollments and duration are not modified or reduced. Clinical trial programs, such as the
types that the Company is engaged in, can be highly variable and can frequently involve a series of changes and modifications over
time as clinical data is obtained and analyzed, and are frequently modified, suspended or terminated before the clinical trial
endpoint. Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current
clinical assumptions and conditions, and are typically subject to significant revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida, effective for a term of five years, unless terminated earlier by the Company pursuant to 30
days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial
to evaluate the therapeutic benefit of the Company&#8217;s lead anti-cancer clinical compound LB-100 to be administered intravenously
in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application
(&#8220;IND&#8221;) to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of LB-100 in patients with low and intermediate-1
risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except
for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilizes LB-100 as a single agent in the treatment
of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line
therapy. The bone marrow cells of patients with del5qMDS are deficient in PP2A by virtue of an acquired mutation and are especially vulnerable
to further inhibition of PP2A by LB-100. The clinical trial began at a single site in April 2019 and the first patient was entered into
the clinical trial in July 2019. A total enrollment of 41 patients is planned. An interim analysis will be done after the first 21 patients
are entered. If there are 3 or more responders but fewer than 7, an additional 20 patients will be entered. If at any point there are
7 or more responders, this will be sufficient evidence to support continued development of LB-100 for the treatment of low and intermediate-1
risk MDS. Recruitment has been slow and the Covid-19 pandemic has further reduced recruitment of patients into the protocol. At the current
rate of accrual, the clinical trial is expected to be completed by June 30, 2025. However, with additional funds, the Company would consider
adding two additional MDS centers to the Phase 2 portion of the study to accelerate patient accrual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zZCZK3IPmuyb" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-03-31_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z4XJOgNO9yea" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-01-012022-03-31_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,332</ix:nonFraction></span>, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March
31, 2023, total costs of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zjfxH5kupvu8" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,074</ix:nonFraction></span> have been incurred pursuant to this agreement. <span id="xdx_903_eus-gaap--OtherCommitmentsDescription_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zcDayiVBFC5e" title="Aggregate commitments expected, description"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_ClinicalTrialResearchAgreementMember" name="us-gaap:OtherCommitmentsDescription">The Company&#8217;s aggregate commitment pursuant to
this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_906_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z0tlZzGxLIU2" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31_custom_ClinicalTrialResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">575,000</ix:nonFraction></span> as of March 31, 2023, which is expected to be incurred
through December 31, 2025</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival
(PFS, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS
of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression
or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required
for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--OtherClinicalAgreementsMember_zRpBkw5pl514" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_OtherClinicalAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,000</ix:nonFraction></span>. While the production of new inventory has
been completed, nominal amounts of trailing costs are expected to be incurred during the year ending December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, the GEIS clinical trial is currently scheduled to commence during the quarter ending June 30, 2023 and to be completed
by December 31, 2025. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n
Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The Phase 1b section
of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on both response and toxicity
from this portion of the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
Through March 31, 2023, the Company has paid GEIS an aggregate of $<span id="xdx_90D_ecustom--AmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z6silH3m84G8" title="Amount related to milestone payment"><ix:nonFraction name="LIXT:AmountRelatedToMilestonePayment" contextRef="From2023-01-012023-03-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,823</ix:nonFraction></span> for work done under this agreement through the third milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. Such costs, when incurred,
are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March 31, 2023, total
costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z0vSFGxU8Ee9" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,823</ix:nonFraction></span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $<span id="xdx_904_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zvQGUdIN1oNh" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,792,000</ix:nonFraction></span> as of March 31, 2023, which is expected to be incurred through
December 31, 2025. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations
between the United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign
currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with a standard
regimen for treatment of untreated extensive- stage disease small cell lung cancer (ED-SCLC). LB-100 will be given in combination with
carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously untreated ED-SCLC patients.
The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (RP2D).
Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the safety of the LB-100 combination
and to look for potential therapeutic activity as assessed by objective response rate, duration of overall response, progression-free-survival
and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add two additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, joined the City of Hope&#8217;s ongoing Phase
1b clinical trial. The Company is continuing its efforts to add a third site. The addition of SCRI is expected to expedite and expand
the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability and efficacy
of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company expects that this clinical trial will
be completed by December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_znIuv3ZWtK3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,001</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z95vrSSdqXZ2" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, pursuant to this agreement,
which are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March 31, 2023,
total costs of $<span id="xdx_909_eus-gaap--DeferredCosts_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zhSJuoqMJq5b" title="Total costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,512</ix:nonFraction></span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $<span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zN4X1W8vrpSj" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,433,000</ix:nonFraction></span> as of March 31, 2023, which is expected to be incurred through
December 31, 2024. If a significant number of patients fail during the dose-escalation process, an increase of up to 12 patients would
likely be necessary, at an estimated additional cost of approximately $<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z2dO8V88muv7" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31_custom_ClinicalResearchSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic
clinical trial. This study is being conducted and funded by the NCI under a Cooperative Research and Development Agreement, with the
Company being required to provide the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain is not known. Unfortunately,
many drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study is designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove one
or more tumors will receive one dose of LB-100 prior to surgery and have blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors show the biochemical changes expected to be present if LB-100 reaches its molecular
target. As a result of the innovative design of the NCI study, data from a few patients should be sufficient to provide a sound rationale
for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment regimen for GBMs. Five
patients have been entered and analysis of the blood and tissue will now proceed. If there is evidence in at least two of the patients
of penetration of LB 100 into tumor tissue, the study will be deemed as successful. Results of this study are currently being reviewed
by NCI and a report is expected by June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019. At the current rate of
accrual, the clinical trial is expected to be completed by June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20180910__20180912__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zt1udJ4abCR8" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2018-09-102018-09-12_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">954,000</ix:nonFraction></span>, with such payments expected to be allocated approximately
94% to Theradex for services and approximately 6% for payments for pass-through costs. The costs of the Phase 1b/2 clinical trial being
paid to or through Theradex are being recorded and charged to operations based on periodic documentation provided by the CRO. During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9kiArgfFVQc" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,287</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9nW8v9qP8Zk" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,281</ix:nonFraction></span>, respectively, and as of March 31, 2023,
total costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zMWQLYxPIMek" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,575</ix:nonFraction></span> have been incurred. The Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously
paid to date, totaled approximately $<span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zIsQDJnprjT7" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">826,000</ix:nonFraction></span> as of March 31, 2023, which is expected to be incurred through June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zhJJFVUpoYv3" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,000</ix:nonFraction></span>. During the three months ended March 31, 2023 and 2022, the Company incurred
costs of $<span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zLiQjtVNBYLh" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,553</ix:nonFraction></span> and $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zvZyeq9WD866" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-01-012022-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500</ix:nonFraction></span>, respectively, and as of March 31, 2023, total costs of $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_pp0p0_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zDBYcR1gVe24" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,994</ix:nonFraction></span> have been incurred. The Company&#8217;s aggregate
commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_900_eus-gaap--OtherCommitment_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zQhOqz4F5PT5" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,000</ix:nonFraction></span> as of March 31, 2023, which
is expected to be incurred through June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $<span id="xdx_90F_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zEXYnfz8iRp6" title="Non refundable license issue fee"><ix:nonFraction name="LIXT:NonRefundableLicenseIssueFee" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company is also obligated to pay Moffitt an annual license
maintenance fee of $<span id="xdx_90F_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zwNxECXRbpkf" title="Maintenance fee"><ix:nonFraction name="LIXT:AnnualLicenseMaintenanceFee" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> commencing on the first anniversary of the Effective Date and every anniversary thereafter until the Company
commences payment of minimum royalty payments. The Company has also agreed to pay non-refundable milestone payments to Moffitt, which
cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones aggregating
$<span id="xdx_908_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zgREugkczKsb" title="Payment on non refundable milestone"><ix:nonFraction name="LIXT:PaymentsOnNonrefundableMilestone" contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,897,000</ix:nonFraction></span>, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in
the License Agreement. During the three months ended March 31, 2023 and 2022, the Company recorded charges to operations of $<span id="xdx_906_eus-gaap--OperatingCostsAndExpenses_c20230101__20230331__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zk1uIhSK4Zf1" title="Operating costs and expenses"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2023-01-012023-03-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,165</ix:nonFraction></span> and
$<span id="xdx_902_eus-gaap--OperatingCostsAndExpenses_c20220101__20220331__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsmWPcFPAcq2" title="Operating costs and expenses"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2022-01-012022-03-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,165</ix:nonFraction></span>, respectively, in connection with its obligations under the License Agreement. As of March 31, 2023, no milestones had yet been
attained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject
to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $<span id="xdx_90A_eus-gaap--PaymentsForRoyalties_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__us-gaap--VestingAxis__custom--FirstFourYearsMember_zBUAbOZGmk05" title="Minimum payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2023-01-012023-03-31_custom_ExclusiveLicenseAgreementMember_custom_FirstFourYearsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> in the first four years
after sales commence, and $<span id="xdx_908_eus-gaap--PaymentsForRoyalties_pp0p0_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__us-gaap--VestingAxis__custom--FiveYearsAndThereafterMember_zOn47z2x1Cfi" title="Minimum payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2023-01-012023-03-31_custom_ExclusiveLicenseAgreementMember_custom_FiveYearsAndThereafterMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating
to the status of Valid Claims, as such term is defined in the License Agreement. The Company&#8217;s obligation to pay earned royalties
under the License Agreement commences on the date of the first sale of a royalty-bearing product, and shall automatically expire on a
country-by-country basis on the date on which the last valid claim of the Licensed Patents expires, lapses or is declared invalid, and
the obligation to pay any earned royalties under the License Agreement shall terminate on the date on which the last valid claim of the
Licensed Patents expires, lapses, or is declared to be invalid in all countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual compensation of $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zvT95vuoCo92" title="Salary and compensation"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">640,000</ix:nonFraction></span>, payable
monthly (see Note 6). The employment agreements are automatically renewable for additional <span id="xdx_902_ecustom--AgreementTermDescription_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zX41iREGNv2" title="Agreement term description"><ix:nonNumeric contextRef="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember" name="LIXT:AgreementTermDescription">one-year periods</ix:nonNumeric></span> unless terminated by either
party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination for cause. These
employment agreements were automatically renewed for additional one-year periods in July and August 2021 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the total aggregate annual compensation of all officers increased to $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210408__20210409__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--Dr.JamesMember_zJTCDSpFDpI6" title="Annual compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2021-04-082021-04-09_custom_EmploymentAgreementMember_custom_Dr.JamesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">775,000</ix:nonFraction></span>, effective May
1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zaWa8BkYwF27" title="Annual salary per year"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_custom_FormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>. Accordingly,
the total aggregate annual compensation of all officers increased to $<span id="xdx_906_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__srt--OfficerMember_zVgydyHEjtZf" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_srt_OfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span>, effective November 6, 2022. In addition, effective October
1, 2022, Mr. Forman is being paid an office rent allowance of $<span id="xdx_907_eus-gaap--PaymentsForRent_c20220929__20221001__srt--TitleOfIndividualAxis__custom--FormanMember_zPnJriJdKolb" title="Paid office rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-09-292022-10-01_custom_FormanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600</ix:nonFraction></span> per month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total aggregate annual compensation of all officers increased to $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__srt--OfficerMember_zkqYsYIWBkId" title="Compensation"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2022-11-052022-11-06_srt_OfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span>, effective November 6, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $<span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYQ3C6jeybc6" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span>. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $<span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_z1YtMf3uXA3d" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2023-01-012023-03-31_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zjHgw7SNwwec" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2022-01-012022-03-31_custom_NDAConsultingCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> for the three months
ended March 31, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zDUdEzalikd1" title="Consulting and advisory fee"><ix:nonFraction name="LIXT:ConsultingAndAdvisoryCashFee" contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment, and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 7). The Company recorded
charges to operations pursuant to this agreement of $<span id="xdx_902_ecustom--ReimbursementExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPeNH63cve56" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2023-01-012023-03-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--ReimbursementExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zLN6tNjtDYh4" title="Reimbursed expense"><ix:nonFraction name="LIXT:ReimbursementExpense" contextRef="From2022-01-012022-03-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> for the three months ended March 31, 2023 and 2022, respectively,
which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (see Note 6), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major
independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues,
to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.
The Company has agreed to fund the study and provide a sufficient supply of LB-100 to conduct the study. The study is expected to take
approximately two years to conduct. During the three months ended March 31, 2023 and 2022, the Company incurred charges in the amount
of $<span id="xdx_901_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zWBQ47kasDXj" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,203</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zmd0enjlXU9c" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-01-012022-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,230</ix:nonFraction></span>, respectively, with respect to this agreement, which amounts are included in research and development costs in
the Company&#8217;s consolidated statements of operations. As of March 31, 2023, total costs of $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zAVcJcMJ0Pk8" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,518</ix:nonFraction></span> have been incurred pursuant
to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_908_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zdf5xgiWAoq7" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></span> as of March 31, 2023, which is expected to be incurred through June 30, 2025. As the work is being conducted in
Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $<span id="xdx_909_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zP5Nosi6JMdk" title="Contract price"><ix:nonFraction name="LIXT:ContractPrice" contextRef="From2022-06-092022-06-10_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,980</ix:nonFraction></span> for services to be
rendered through April 30, 2023. During the three months ended March 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_90A_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zkEOu8Lvn6r3" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2023-01-012023-03-31_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,173</ix:nonFraction></span> and $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zVY3RwdB77vb" title="Advance amount related to milestone payment"><ix:nonFraction name="LIXT:AdvanceAmountRelatedToMilestonePayment" contextRef="From2022-01-012022-03-31_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">756</ix:nonFraction></span>,
respectively, pursuant to this contract. As of March 31, 2023, total costs of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zJ8481wLxdYa" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,784</ix:nonFraction></span> have been incurred pursuant to this contract.
The Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_90D_eus-gaap--OtherCommitment_iI_c20230331_zhaLRFPnCvwj" title="Aggregate commitments expected"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></span>
as of March 31, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of $<span id="xdx_902_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zT3u8c1qQS37" title="Contract price"><ix:nonFraction name="LIXT:ContractPrice" contextRef="From2023-04-152023-04-17_custom_MRIGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,274</ix:nonFraction></span> for
services to be rendered through April 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may impact the Company&#8217;s business activities and capital raising efforts will depend on future developments, which are
uncertain and cannot be predicted. The Company is continuing to monitor this situation and will adjust its current business plans to
the extent additional information and guidance become available. The coronavirus pandemic has also presented a challenge to medical facilities
worldwide. Although the Company&#8217;s clinical trials are conducted on an outpatient basis, the coronavirus pandemic appears to have
caused some delays in the Company&#8217;s clinical trials, but the impact of the coronavirus pandemic appears to be subsiding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
Risk. </b>The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#8217;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zpy4Hi2NcUt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82A_zH1SDycSCnqi">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
There were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.</span></p>

</ix:nonNumeric><p id="xdx_815_zV71uYh6zT0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_008"></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward-Looking
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc. (the &#8220;Company&#8221;) contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These might
include statements regarding the Company&#8217;s financial position, business strategy and other plans and objectives for future operations,
and assumptions and predictions about future clinical trials and their timing and costs, product demand, supply, manufacturing costs,
marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as &#8220;intend&#8221;,
&#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;potential(ly)&#8221;, &#8220;continue&#8221;, &#8220;forecast&#8221;,
&#8220;predict&#8221;, &#8220;plan&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;,
&#8220;expect&#8221; or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations
reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company
cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action
that the Company may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties.
Actual results or experience may differ materially from those expected, anticipated or implied in the forward-looking statements. Factors
that could cause or contribute to such differences include, but are not limited to, regulatory policies or changes thereto, available
cash, research and development results, competition from other similar businesses, and market and general economic factors. This discussion
should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly
Report on Form 10-Q and the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, including the section
entitled &#8220;Item 1A. Risk Factors&#8221;. The Company does not intend to update or revise any forward-looking statements to reflect
new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments&#9;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>GEIS
Clinical Trial</i>. In April 2023, the Spanish Sarcoma Research Group (<span style="text-decoration: underline">Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas, or
GEIS</span>) completed its first site initiation visit in preparation for the advanced soft tissue sarcoma (ASTS) clinical trial at Fundaci&#243;n
Jim&#233;nez D&#237;az University Hospital (Madrid). Fundaci&#243;n Jim&#233;nez D&#237;az University Hospital is the home
base of Dr. Javier Mart&#237;n-Broto, Coordinating Investigator of the clinical trial, GEIS Co-Founder, and an internationally recognized
expert in sarcoma research and therapy. Three additional GEIS-associated cancer research centers, located in Valencia, Barcelona, and
Madrid, Spain, are expected to be activated in the near-term, with Phase 1b patient accrual planned to begin during May 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 1b portion of the clinical trial to determine the recommended Phase 2 dose (RP2D) is expected to be completed within approximately
nine months from commencement. Subsequently, up to ten more clinical sites are expected to join the international Phase 2 portion of
the study to enter up to 150 patients, randomized to standard cytotoxic chemotherapy with doxorubicin alone, versus doxorubicin plus
LB-100. Given the lack of effective first-line treatments for ASTS, this trial has been designed to provide data expected to be sufficient
to justify proceeding to a Phase 3 comparative study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Notification of Failure to Satisfy a Continued Listing Rule</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2022, the Company received a written notice (the &#8220;Notice&#8221;) from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
that the Company had not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a
period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price
of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists
if the deficiency continues for a period of 30 consecutive business days. The Notice had no immediate effect on the listing of the Company&#8217;s
common stock on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days from the date of
the Notice, or until December 21, 2022, to regain compliance with the minimum closing bid price requirement. On December 22, 2022, the
Company received a written notice from Nasdaq that the Company was eligible for a second 180 calendar day compliance period, or until
June 19, 2023, in order to regain compliance with the $1.00 minimum bid price requirement. Nasdaq&#8217;s determination to grant the
second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares
and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price requirement,
and the Company&#8217;s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse
stock split, if necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company can generally achieve compliance with the minimum closing bid price requirement if the minimum closing bid price of the Company&#8217;s
common stock is at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period. However,
under certain circumstances, Nasdaq can extend this 10-day trading period up to a maximum of 20 days. The Company anticipates that its
shares of common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market during the compliance period ending
June 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to achieve compliance with the minimum closing bid price requirement, the Company filed a proxy statement with the SEC to hold
a special meeting of stockholders on May 26, 2023 to seek stockholder approval to approve an amendment to the Company&#8217;s Certificate
of Incorporation to effect a reverse stock split of the issued and outstanding shares of the Company&#8217;s common stock at a split
ratio of up to a maximum of a 1-for-10 split, as determined by the Board of Directors in its sole discretion. However, there can be no
assurance that the Company will be successful in obtaining stockholder approval and will thus be able to regain compliance with the minimum
closing bid price requirement by June 19, 2023, in which case the Company anticipates Nasdaq would provide a notice to the Company that
its shares of common stock and warrants are subject to delisting, and the Company&#8217;s common shares and warrants would then be delisted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the Company is able to achieve compliance with Nasdaq&#8217;s minimum closing bid price requirement, there can be no assurances that
the Company will be able to maintain compliance with Nasdaq&#8217;s other continued listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company had cash of $4,088,304 available to fund its operations. Because the Company is currently engaged in
various early-stage clinical trials, it is expected that it will take a significant amount of time and resources to develop any
product or intellectual property capable of generating sustainable revenues. Accordingly, the Company&#8217;s business is unlikely
to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company is able to
generate revenues through licensing its technology, product sales or other commercial activities, there can be no assurance that the
Company will be able to achieve and maintain positive earnings and operating cash flows. </span>At March 31, 2023, the
Company&#8217;s unpaid remaining contractual commitments pursuant to clinical trial agreements and clinical trial monitoring
agreements aggregated $7,900,000, which are currently scheduled to be incurred through December 31, 2025.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the accompanying interim condensed consolidated financial statements are being issued. The Company&#8217;s
interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that existing cash resources will provide sufficient working capital to fund the current
clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound LB-100 through approximately
December 31, 2023. However, existing cash resources will not be sufficient to complete the development of and obtain regulatory approval
for the Company&#8217;s product candidate, as a result of which the Company will need to raise significant additional capital to do so.
The Company estimates that it will need to raise additional capital to fund its operations, including its various clinical trial commitments,
during the latter part of the fiscal year ending December 31, 2023. In addition, the Company&#8217;s operating plans may change as a
result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed sooner
than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to recent accounting pronouncements is provided at Note 3 to the condensed consolidated financial statements for the three
months ended March 31, 2023 and 2022 included elsewhere in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration
of Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to concentration of risk is provided at Note 3 to the condensed consolidated financial statements for the three months ended
March 31, 2023 and 2022 included elsewhere in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s consolidated financial statements in conformity with generally accepted accounting principles in the
United States (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments
can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions
or conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable
in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates
the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly.
Actual results could differ from those estimates. Significant estimates include those related to assumptions used in the calculation
of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services, and the realization
of deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following critical accounting policies affect the more significant judgements and estimates used in the preparation of the Company&#8217;s
consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the
&#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically has cash
balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. Morgan Stanley
Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not experienced
any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company&#8217;s President,
Chief Executive Officer and Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and Licensing Legal and Filing Fees and Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs are charged to operations
as incurred. Patent and licensing legal and filing fees and costs are included in general and administrative costs in the Company&#8217;s
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, patent and licensing legal and filing fees and costs related to the development and protection
of the Company&#8217;s intellectual property were $317,340 and $315,237, respectively, an increase of $2,103, or 0.7%, in 2023 as compared
to 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
late 2021, the Company engaged a new patent law firm that is highly regarded for its expertise in biotechnology. This firm conducted
a comprehensive analysis of the Company&#8217;s extensive patent portfolio in order to implement a program to maximize intellectual property
protection, both domestically and internationally. As a result, several patents were filed in 2022, reflecting potential new uses of
the Company&#8217;s lead clinical compound LB-100 in cancer therapy. The Company expects that patent and licensing legal and filing fees
and costs will continue to increase in 2023 as compared to 2022, as the Company continues to focus on efforts to expand clinical programs
to analyze various potential uses for LB-100 and to develop and expand its patent portfolio related to the clinical development of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
descriptive summary of the patent portfolio for the Company&#8217;s most important clinical programs involving the development of LB-100,
as well as a detailed listing of each domestic and international patent that has been issued, is presented at &#8220;ITEM 1. BUSINESS
&#8211; Intellectual Property&#8221; in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting period
of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Business Activities and Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s product pipeline is primarily focused on inhibitors of
protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses
two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is focusing its development activities on its LB-100 series of drugs. The Company believes that the mechanism by which compounds
of the LB-100 series affect cancer cell growth is different from cancer agents currently approved for clinical use. Lead compounds from
each series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, compounds
from both series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers
of neural tissue. Lead compounds of the LB-100 series also have activity against melanoma, breast cancer and sarcoma in animal models
and enhance the effectiveness of commonly used anti-cancer drugs in these animal models. The enhancement of anti-cancer activity of these
anti-cancer drugs occurs at doses of LB-100 that do not significantly increase toxicity in animals. It is therefore hoped that, when
combined with standard anti-cancer regimens against many tumor types, the Company&#8217;s compounds will improve therapeutic benefit
without enhancing toxicity in humans. The Company is not currently planning to allocate resources to further develop its LB-200 series
of drugs,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LB-100 series consists of novel structures which have the potential to be first in their class and may be useful in the treatment of
not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds which have the potential
to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher&#8217;s disease,
in addition to cancer and neurodegenerative diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has demonstrated that lead compounds of both the LB-100 series and the LB-200 are active against a broad spectrum of human cancers
in cell culture and against several types of human cancers in animal models. The research on these compounds was initiated in 2006 under
a Cooperative Research and Development Agreement, or CRADA, with the National Institute of Neurologic Disorders and Stroke, or NINDS,
of the National Institutes of Health, or NIH, dated March 22, 2006 that was subsequently extended through a series of amendments until
it terminated on April 1, 2013. As discussed below, the Company&#8217;s primary focus is on the clinical development of LB-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LB-200 series consists of histone deacetylase inhibitors (HDACi). Many pharmaceutical companies are also developing drugs of this type,
and at least two companies have HDACi approved for clinical use, in both cases for the treatment of a type of lymphoma. Despite this
significant competition, the Company has demonstrated that its HDACi have broad activity against many cancer types, have neuroprotective
activity, and have anti-fungal activity. In addition, these compounds have low toxicity. LB-200 has not yet advanced to the clinical
stage and would require additional capital to fund further development. Accordingly, because of the Company&#8217;s focus on the clinical
development of LB-100 and analogs for cancer therapy as described below in more detail, the Company has decided not to actively pursue
the pre-clinical development of the LB-200 series of compounds. At this time, the Company intends to only maintain composition and synthesis
patents on the LB-200 series of compounds in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
with leading academic research centers in the United States, Europe and Asia have established the breadth of activity of LB-100 in pre-clinical
models of several major cancers. There is considerable scientific interest in LB-100 because it exerts its activity by a novel mechanism
and is the first of its type to be evaluated so broadly in multiple animal models of cancer and now in human beings. LB-100 is one of
a series of serine/threonine phosphatase (s/t ptase) inhibitors designed by the Company. The s/t ptases are ubiquitous enzymes that regulate
many cell signaling networks important to cell growth, division and death. The s/t ptases have long been appreciated as potentially important
targets for anti-cancer drugs. However, because of the multi- functionality of these enzymes, it had been widely held that pharmacologic
inhibitors of s/t ptases would be too toxic to allow their development as anti-cancer treatments, but the Company has shown that this
is not the case. LB-100 was well tolerated at doses associated with objective regression (significant tumor shrinkage) and/or the arresting
of tumor progression in patients with progressive cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
studies showed that LB-100 itself inhibits a spectrum of human cancers and that combined with standard cytotoxic drugs and/or radiation,
LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity. Given at very low doses
in animal models of cancer, LB-100 markedly increased the effectiveness of a PD-1 blocker, one of the widely used new immunotherapy drugs.
This finding raises the possibility that LB-100 may further expand the value of the expanding field of cancer immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed a Phase 1 clinical trial of LB-100 to evaluate its safety that showed it is associated with antitumor activity in humans
at doses that are readily tolerable. Responses included objective regression (tumor shrinkage) lasting for 11 months of a pancreatic
cancer and cessation of growth (stabilization of disease) for 4 months or more of 9 other progressive solid tumors out of 20 patients
who had measurable disease. As Phase 1 clinical trials are fundamentally designed to determine safety of a new compound in humans, the
Company was encouraged by these results. The next step is to demonstrate in Phase 2 clinical trials the efficacy of LB-100 in one or
more specific tumor types, against which the compound has well documented activity in pre-clinical models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources
to expand the breadth and depth of its patent portfolio. The Company&#8217;s approach has been to operate with a minimum of overhead,
moving compounds forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain
milestones are reached. The Company&#8217;s longer-term objective is to secure one or more strategic partnerships or licensing agreements
with pharmaceutical companies with major programs in cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may impact the Company&#8217;s business activities and capital raising efforts will depend on future developments, which are
uncertain and cannot be predicted. The Company is continuing to monitor this situation and will adjust its current business plans to
the extent additional information and guidance become available. The coronavirus pandemic has also presented a challenge to medical facilities
worldwide. Although the Company&#8217;s clinical trials are conducted on an outpatient basis, the coronavirus pandemic appears to have
caused some delays in the Company&#8217;s clinical trials, but the impact of the coronavirus pandemic appears to be subsiding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
Risk. </b>The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#8217;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company had not yet commenced any revenue-generating operations, does not have any positive cash flows from operations,
and is dependent on its ability to raise equity capital to fund its operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s condensed consolidated statements of operations as discussed herein are presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Compensation to related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">519,480</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">565,922</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Patent and licensing legal and filing fees and costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">317,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Other costs and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">344,242</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,743</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">189,085</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">458,450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total costs and expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,370,147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,654,352</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,370,147</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,654,352</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,861</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,494</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency gain (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,334</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(181</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,367,659</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,656,918</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.08</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,649,510</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,746,593</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months Ended March 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues.
The Company did not have any revenues for the three months ended March 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and Administrative Costs. For the three months ended March 31, 2023, general and administrative costs were $1,181,062, which consisted
of the fair value of vested stock options issued to directors and officers of $276,980, patent and licensing legal and filing fees and
costs of $317,340, other consulting and professional fees of $170,585, insurance expense of $104,153, officer salaries and related costs
of $216,355, cash-based director and board committee fees of $42,500, licensing fees of $6,165, shareholder reporting costs of $3,546,
listing fees of $15,500, filing fees of $6,725, taxes and licenses of $3,769, investor relations of $12,972, and other operating costs
of $4,472.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2022, general and administrative costs were $1,195,902, which consisted of the fair value of vested
stock options issued to directors and officers of $339,672, patent and licensing legal and filing fees and costs of $315,237, other consulting
and professional fees of $137,715, insurance expense of $117,135, officer salaries and related costs of $210,867, cash-based director
and board committee fees of $32,500, licensing fees of $6,165, shareholder reporting costs of $2,954, listing fees of $14,875, filing
fees of $5,324, taxes and licenses of $4,069, investor relations of $2,397, and other operating costs of $6,992.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs decreased by $14,840, or 1.2%, in 2023 as compared to 2022, primarily as a result of a decrease in the fair
value of vested stock options issued to directors and officers of $62,692, a decrease in insurance expense of $12,982, offset by an increase
in other consulting and professional fees of $32,870, an increase in officer salaries and related costs of $5,488, an increase in cash-based
director and board committee fees of $10,000, and an increase in investor relations of $10,575.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development Costs. For the three months ended March 31, 2023, research and development costs were $189,085, which consisted of clinical
and related oversight costs of $96,130, regulatory service costs of $6,079 and pre-clinical research focused on development of additional
novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $86,876.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2022, research and development costs were $458,450, which consisted of contractor costs incurred in
connection with the synthesis work done to develop a new supply of LB-100 for the Spanish clinical trial of $332,713, clinical and related
oversight costs of $11,113, and pre-clinical research focused on development of additional novel anti-cancer compounds to add to the
Company&#8217;s clinical pipeline of $114,624.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in pre-clinical research costs for the three months ended March 31, 2023 and 2022 were $52,203 and $54,230, respectively, of costs paid
to the Netherlands Cancer Institute, which employs Dr. Ren&#233; Bernards, a director of the Company since June 15, 2022. On October
8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam, one of the
world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify
the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well
as to identify the specific molecular mechanisms underlying the identified combinations (see &#8220;Principal Commitments &#8211; Other
Significant Agreements and Contracts &#8211; Netherlands Cancer Institute&#8221; below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs decreased by $269,365, or 58.8%, in 2023 as compared to 2022, primarily as a result of a decrease in contractor
costs incurred in connection with the synthesis work done to develop a new supply of LB-100 of $332,713, and a decrease in pre-clinical
research focused on development of additional novel anti-cancer compounds to add to the Company&#8217;s clinical pipeline of $27,748,
offset by an increase in clinical and related oversight costs of $85,017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Income</span>. For the three months ended March 31, 2023, the Company had interest income of $5,015, as compared to interest income of $109
for the three months ended March 31, 2022, related to the investment of funds generated by the Company&#8217;s financing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
Expense</span>. For the three months ended March 31, 2023, the Company had interest expense of $3,861, as compared to interest expense of
$2,494 for the three months ended March 31, 2022, related to the financing of the premium for the Company&#8217;s directors and officers
liability insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Foreign
Currency Loss</span>. For the three months ended March 31, 2023, the Company had a foreign currency gain of $1,334, as compared to a foreign
currency loss of $181 for the three months ended March 31, 2022, from foreign currency transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss</span>. For the three months ended March 31, 2023, the Company incurred a net loss of $1,367,659, as compared to a net loss of $1,656,918
for the three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources &#8211; March 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated statements of cash flows as discussed herein are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,271,369</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,035,097</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,906</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net decrease in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,265,088</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,046,003</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company had working capital of $4,080,829, as compared to working capital of $5,165,227 at December 31, 2022, reflecting
an decrease in working capital of $1,084,398 for the three months ended March 31, 2023. The decrease in working capital during the three
months ended March 31, 2023 was primarily the result of funding of the Company&#8217;s ongoing research and development activities and
other ongoing operating expenses, including maintaining and developing its patent portfolio. At March 31, 2023, the Company had cash
of $4,088,304 available to fund its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that existing cash resources will provide sufficient working capital to fund the
current clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound LB-100
through approximately December 31, 2023. However, existing cash resources will not be sufficient to complete the development of and
obtain regulatory approval for the Company&#8217;s product candidate, as a result of which the Company will need to raise
significant additional capital to do so. The Company estimates that it will need to raise additional capital to fund its operations,
including its various clinical trial commitments, during the latter part of the fiscal year ending December 31, 2023. At March 31,
2023, the Company&#8217;s unpaid remaining contractual commitments pursuant to clinical trial agreements and clinical trial
monitoring agreements aggregated $7,900,000, which are currently scheduled to be incurred through December 31, 2025. In addition,
the Company&#8217;s operating plans may change as a result of many factors that are currently unknown and/or outside of the control
of the Company, and additional funds may be needed sooner than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
Activities. For the three months ended March 31, 2023, operating activities utilized cash of $1,271,369, as compared to utilizing cash
of $1,035,097 for the three months ended March 31, 2022, to fund the Company&#8217;s ongoing research and development activities and
to fund its other ongoing operating expenses, including maintaining and developing its patent portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
Activities. For the three months ended March 31, 2023 and 2022, the Company had no investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
Activities. For the three months ended March 31, 2023, financing activities consisted of $6,281 from the exercise of common stock options.
For the three months March 31, 2022, financing activities consisted of the payment of deferred offering costs of $10,906.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company&#8217;s unpaid remaining contractual commitments pursuant to clinical trial agreements and
clinical trial monitoring agreements, as described below, aggregated $7,900,000, which are currently scheduled to be incurred
through December 31, 2025. The Company&#8217;s ability to conduct and fund these contractual commitments is subject to the timely
availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds
to the Company&#8217;s current or future clinical trial programs. The Company expects that the full amount of these expenditures
will be incurred only if such clinical trial programs are conducted as originally designed and their respective enrollments and
duration are not modified or reduced. Clinical trial programs, such as the types that the Company is engaged in, can be highly
variable and can frequently involve a series of changes and modifications over time as clinical data is obtained and analyzed, and
are frequently modified, suspended or terminated before the clinical trial endpoint. Accordingly, such contractual commitments as
discussed herein should be considered as estimates only based on current clinical assumptions and conditions, and are typically
subject to significant revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida, effective for a term of five years, unless terminated earlier by the Company pursuant to 30
days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial
to evaluate the therapeutic benefit of the Company&#8217;s lead anti-cancer clinical compound LB-100 to be administered intravenously
in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application
(&#8220;IND&#8221;) to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of LB-100 in patients with low and intermediate-1
risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except
for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilizes LB-100 as a single agent in the treatment
of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line
therapy. The bone marrow cells of patients with del5qMDS are deficient in PP2A by virtue of an acquired mutation and are especially vulnerable
to further inhibition of PP2A by LB-100. The clinical trial began at a single site in April 2019 and the first patient was entered into
the clinical trial in July 2019. A total enrollment of 41 patients is planned. An interim analysis will be done after the first 21 patients
are entered. If there are 3 or more responders but fewer than 7, an additional 20 patients will be entered. If at any point there are
7 or more responders, this will be sufficient evidence to support continued development of LB-100 for the treatment of low and intermediate-1
risk MDS. Recruitment has been slow and the Covid-19 pandemic has further reduced recruitment of patients into the protocol. At the current
rate of accrual, the clinical trial is expected to be completed by June 30, 2025. However, with additional funds, the Company would consider
adding two additional MDS centers to the Phase 2 portion of the study to accelerate patient accrual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $6,000 and $3,332, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March
31, 2023, total costs of $137,074 have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to
this agreement, less amounts previously paid to date, totaled approximately $575,000 as of March 31, 2023, which is expected to be incurred
through December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival
(PFS, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS
of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression
or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required
for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $1,144,000. While the production of new inventory has
been completed, nominal amounts of trailing costs are expected to be incurred during the year ending December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, the GEIS clinical trial is currently scheduled to commence during the quarter ending June 30, 2023 and to be completed
by December 31, 2025. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n
Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The Phase 1b section
of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on both response and toxicity
from this portion of the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
Through March 31, 2023, the Company has paid GEIS an aggregate of $415,823 for work done under this agreement through the third milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. Such costs, when incurred,
are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March 31, 2023, total
costs of $415,823 have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $3,792,000 as of March 31, 2023, which is expected to be incurred through
December 31, 2025. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations
between the United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign
currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with a standard
regimen for treatment of untreated extensive- stage disease small cell lung cancer (ED-SCLC). LB-100 will be given in combination with
carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously untreated ED-SCLC patients.
The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (RP2D).
Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the safety of the LB-100 combination
and to look for potential therapeutic activity as assessed by objective response rate, duration of overall response, progression-free-survival
and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add two additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, joined the City of Hope&#8217;s ongoing Phase
1b clinical trial. The Company is continuing its efforts to add a third site. The addition of SCRI is expected to expedite and expand
the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability and efficacy
of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company expects that this clinical trial will
be completed by December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $69,001 and $0, respectively, pursuant to this agreement,
which are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March 31, 2023,
total costs of $447,512 have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $2,433,000 as of March 31, 2023, which is expected to be incurred through
December 31, 2024. If a significant number of patients fail during the dose-escalation process, an increase of up to 12 patients would
likely be necessary, at an estimated additional cost of approximately $800,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic
clinical trial. This study is being conducted and funded by the NCI under a Cooperative Research and Development Agreement, with the
Company being required to provide the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain is not known. Unfortunately,
many drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study is designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove one
or more tumors will receive one dose of LB-100 prior to surgery and have blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors show the biochemical changes expected to be present if LB-100 reaches its molecular
target. As a result of the innovative design of the NCI study, data from a few patients should be sufficient to provide a sound rationale
for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment regimen for GBMs. Five
patients have been entered and analysis of the blood and tissue will now proceed. If there is evidence in at least two of the patients
of penetration of LB 100 into tumor tissue, the study will be deemed as successful. Results of this study are currently being reviewed
by NCI and a report is expected by June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019. At the current rate of
accrual, the clinical trial is expected to be completed by June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $954,000, with such payments expected to be allocated approximately
94% to Theradex for services and approximately 6% for payments for pass-through costs. The costs of the Phase 1b/2 clinical trial being
paid to or through Theradex are being recorded and charged to operations based on periodic documentation provided by the CRO. During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $9,287 and $3,281, respectively, and as of March 31, 2023,
total costs of $136,575 have been incurred. The Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously
paid to date, totaled approximately $826,000 as of March 31, 2023, which is expected to be incurred through June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $335,000. During the three months ended March 31, 2023 and 2022, the Company incurred
costs of $5,553 and $4,500, respectively, and as of March 31, 2023, total costs of $63,994 have been incurred. The Company&#8217;s aggregate
commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $273,000 as of March 31, 2023, which
is expected to be incurred through June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $25,000 after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company is also obligated to pay Moffitt an annual license
maintenance fee of $25,000 commencing on the first anniversary of the Effective Date and every anniversary thereafter until the Company
commences payment of minimum royalty payments. The Company has also agreed to pay non-refundable milestone payments to Moffitt, which
cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones aggregating
$1,897,000, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in
the License Agreement. During the three months ended March 31, 2023 and 2022, the Company recorded charges to operations of $6,165 and
$6,165, respectively, in connection with its obligations under the License Agreement. As of March 31, 2023, no milestones had yet been
attained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject
to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years
after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating
to the status of Valid Claims, as such term is defined in the License Agreement. The Company&#8217;s obligation to pay earned royalties
under the License Agreement commences on the date of the first sale of a royalty-bearing product, and shall automatically expire on a
country-by-country basis on the date on which the last valid claim of the Licensed Patents expires, lapses or is declared invalid, and
the obligation to pay any earned royalties under the License Agreement shall terminate on the date on which the last valid claim of the
Licensed Patents expires, lapses, or is declared to be invalid in all countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual compensation of $640,000, payable
monthly. The employment agreements are automatically renewable for additional one-year periods unless terminated by either party upon
60 days written notice prior to the end of the applicable one-year period, or by death, or by termination for cause. These employment
agreements were automatically renewed for additional one-year periods in July and August 2021 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the total aggregate annual compensation of all officers increased to $775,000, effective May
1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $200,000. Accordingly,
the total aggregate annual compensation of all officers increased to $800,000, effective November 6, 2022. In addition, effective October
1, 2022, Mr. Forman is being paid an office rent allowance of $600 per month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total aggregate annual compensation of all officers increased to $800,000, effective November 6, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $4,000. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $4,000 and $4,000 for the three months
ended March 31, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment, and agreed to issue to BioPharmaWorks certain equity-based compensation. The Company recorded charges to
operations pursuant to this agreement of $30,000 and $30,000 for the three months ended March 31, 2023 and 2022, respectively, which
were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent
cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used
to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations. The Company
has agreed to fund the study and provide a sufficient supply of LB-100 to conduct the study. The study is expected to take approximately
two years to conduct. During the three months ended March 31, 2023 and 2022, the Company incurred charges in the amount of $52,203 and
$54,230, respectively, with respect to this agreement, which amounts are included in research and development costs in the Company&#8217;s
consolidated statements of operations. As of March 31, 2023, total costs of $416,518 have been incurred pursuant to this agreement. The
Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $53,000
as of March 31, 2023, which is expected to be incurred through June 30, 2025. As the work is being conducted in Europe and is paid for
in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global.</b> The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $273,980 for services to be
rendered through April 30, 2023. During the three months ended March 31, 2023 and 2022, the Company incurred costs of $3,173 and $756,
respectively, pursuant to this contract. As of March 31, 2023, total costs of $222,784 have been incurred pursuant to this contract.
The Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $53,000
as of March 31, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of $326,274 for
services to be rendered through April 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trends,
Events and Uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development of new pharmaceutical compounds is, by its nature, unpredictable. Although the Company undertakes research and development
efforts with commercially reasonable diligence, there can be no assurance that the Company&#8217;s cash position will be sufficient to
enable it to develop pharmaceutical compounds to the extent needed to create future revenues sufficient to sustain operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurances that the Company&#8217;s pharmaceutical compounds will obtain the regulatory approvals and market acceptance to
achieve sustainable revenues sufficient to support operations. Even if the Company is able to generate revenues, there can be no assurances
that it will be able to achieve operating profitability or positive operating cash flows. There can be no assurances that the Company
will be able to secure additional financing, to the extent required, on acceptable terms or at all. If cash resources are insufficient
to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to reduce or discontinue its research and development
programs, or attempt to obtain funds, if available (although there can be no assurances), through strategic alliances that may require
the Company to relinquish rights to certain of its pharmaceutical compounds, or to curtail or discontinue its operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as discussed above, the Company is not currently aware of any trends, events or uncertainties that are likely to have a material
effect on its financial condition in the near term, although it is possible that new trends or events may develop in the future that
could have a material effect on the Company&#8217;s financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Z_009"></span><b>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Z_010"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined
in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), that is designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized, and reported, within the time periods specified in the rules and forms. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the
reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its
principal executive officer and principal financial officer, or persons performing similar functions, as appropriate, to allow timely
decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Exchange Act Rules 13a-15 and 15d-15, an evaluation was completed under the supervision and with the participation of
the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design
and operation of the Company&#8217;s disclosure controls and procedures as of March 31, 2023, the end of the most recent fiscal period
covered by this report. Based on that evaluation, the Company&#8217;s management has concluded that the Company&#8217;s disclosure controls
and procedures were effective in providing reasonable assurance that information required to be disclosed in the Company&#8217;s reports
filed or submitted under the Exchange Act was recorded, processed, summarized, and reported within the time periods specified in the
rules and forms of the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on Effectiveness of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well
designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls
can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. In addition,
the design of disclosure controls and procedures must reflect that there are resource constraints and that management is required to
apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, has determined that no change in the Company&#8217;s
internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities Exchange Act
of 1934) occurred during the period ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect,
the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_011"></span>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Z_012"></span><b>ITEM
1. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not currently subject to any pending or threatened legal actions or claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_013"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business, financial condition, results of operations and cash flows may be impacted by a number of factors, many of which
are beyond the Company&#8217;s control, including those set forth in the Company&#8217;s Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, as filed with the Securities and Exchange Commission on March 29, 2023 (the &#8220;2022 Form 10-K&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Risk Factors set forth in the 2022 Form 10-K should be read carefully in connection with evaluating the Company&#8217;s business and
in connection with the forward-looking statements contained in this Quarterly Report on Form 10-Q. Any of the risks described in the
2022 Form 10-K could materially adversely affect the Company&#8217;s business, financial condition or future results and the actual outcome
of matters as to which forward-looking statements are made. These are not the only risks that the Company faces. Additional risks and
uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect
the Company&#8217;s business, financial condition and/or operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, except as disclosed in this document, there have been no material changes to the Risk Factors previously
disclosed in the Company&#8217;s 2022 Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notification of Failure to Satisfy a Continued Listing Rule</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2022, the Company received a written notice (the &#8220;Notice&#8221;) from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
that the Company had not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a
period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price
of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists
if the deficiency continues for a period of 30 consecutive business days. The Notice had no immediate effect on the listing of the Company&#8217;s
common stock on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days from the date of
the Notice, or until December 21, 2022, to regain compliance with the minimum closing bid price requirement. On December 22, 2022, the
Company received a written notice from Nasdaq that the Company was eligible for a second 180 calendar day compliance period, or until
June 19, 2023, in order to regain compliance with the $1.00 minimum bid price requirement. Nasdaq&#8217;s determination to grant the
second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares
and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price requirement,
and the Company&#8217;s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse
stock split, if necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company can generally achieve compliance with the minimum closing bid price requirement if the minimum closing bid price of the Company&#8217;s
common stock is at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period. However,
under certain circumstances, Nasdaq can extend this 10-day trading period up to a maximum of 20 days. The Company anticipates that its
shares of common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market during the compliance period ending
June 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to achieve compliance with the minimum closing bid price requirement, the Company filed a proxy statement with the SEC to hold
a special meeting of stockholders on May 26, 2023 to seek stockholder approval to approve an amendment to the Company&#8217;s Certificate
of Incorporation to effect a reverse stock split of the issued and outstanding shares of the Company&#8217;s common stock at a split
ratio of up to a maximum of a 1-for-10 split, as determined by the Board of Directors in its sole discretion. However, there can be no
assurance that the Company will be successful in obtaining stockholder approval and thus will be able to regain compliance with the minimum
closing bid price requirement by June 19, 2023, in which case the Company anticipates Nasdaq would provide a notice to the Company that
its shares of common stock and warrants are subject to delisting, and the Company&#8217;s common shares and warrants would then be delisted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the Company is able to achieve compliance with Nasdaq&#8217;s minimum closing bid price requirement, there can be no assurances that
the Company will be able to maintain compliance with Nasdaq&#8217;s other continued listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) has led to disruptions in general economic activities worldwide, as
businesses and governments have taken broad actions to mitigate this public health crisis. In light of the uncertain and continually
evolving situation relating to the spread of Covid-19, this pandemic could pose a risk to the Company. The extent to which the coronavirus
may impact the Company&#8217;s business activities and capital raising efforts will depend on future developments, which are highly uncertain
and cannot be predicted at this time. The Company intends to continue to monitor the situation and may adjust its current business plans
as more information and guidance become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
coronavirus pandemic presents a challenge to medical facilities worldwide. As the Company&#8217;s clinical trials are conducted on an
outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical trials, which
could include delays in and increased costs of such clinical trials. Current indications from the clinical research organizations conducting
the clinical trials for the Company are that such clinical trials are being delayed or extended for several months or more as a result
of the coronavirus pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
Risk. </b>The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#8217;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_014"></span>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Z_015"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3. DEFAULTS UPON SENIOR SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Z_016"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="Z_017"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
5. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Z_018"></span><b>ITEM
6. EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 96px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Number</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Contract between Lixte Biotechnology Holdings, Inc. and MRI Global effective April 17, 2022</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer&#8217;s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document (does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101.INS)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_019"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIXTE
    BIOTECHNOLOGY HOLDINGS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 10, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    JOHN S. KOVACH</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Kovach</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 10, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    ROBERT N. WEINGARTEN</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_001.jpg" ALT="" STYLE="height: 868px; width: 670px">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 868px; width: 670px"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<B>ERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
John S. Kovach, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to
    ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report my conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 10, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    JOHN S. KOVACH</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Kovach</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">C<B>ERTIFICATION OF CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Robert N. Weingarten, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: May 10, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>/s/ ROBERT N. WEINGARTEN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Robert N. Weingarten</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B></B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
John S. Kovach, the Chief Executive Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Company&rdquo;), certify, pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2023 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 10, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    JOHN S. KOVACH</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Kovach</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert N. Weingarten, the Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (the &ldquo;Company&rdquo;), certify, pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2023 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 10, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ROBERT N. WEINGARTEN</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    N. Weingarten</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" XK"N\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\R5F:E\%*3^7^9WU%<.GASQ5(/WNNE/]V5_\*E7PMX@'7Q'/G_KJU2Z%-?\
M+Q?B:K&5G_RXE]Z_S.SHKD!X?\31<Q^("Q'9\G^E*9O&&G#=)%;W\:]=A"G'
MZ4O8)_#-/\/S*^N27QTY+[G^3.NHK!T?Q5::G,;65'M;Q>L,HP3]*WJQG"4'
M:2.JE5A5CS0=T%%%%0:A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-=U1
M=SL%'J:S[G7+*WR!)YC#LO-5&+ELB)3C#63L:5%<I=^+74'R8D0?WG.:R'U'
M5=4;;%YTN>T:_+71'"S>KT.*IF%*+M'5G<7&I65J,S7,2^VX9_*LBZ\7V$)(
MB5Y3Z@8%8D'A75+HAIW2!3UW?,:U;;P38IS<S33MZ9 '\JOV="'Q2OZ&+K8R
MK_#ARKS_ *_0R;KQQ=N=MM'&A^FYJHFX\3ZJ<HEV5;OL\L?G@5WUMI-A9_ZB
MUC7WQFK@  P  /:G]9IP^"'WD?4*]7^-5?HCSN'P3JUTVZ[N5C!]6+'^9K5M
M?A]8(,W,\TK>@.T?I7845$L96>SMZ&M/*<+'5QN_-W,BV\+Z-:X,=C&2.[DM
M_,UI1VMO$/W<$:?[J 5+17/*<I;L[X4:</@BE\D%%%%0:A1110 444A( ))P
M!0!Q/Q!M(8;>UU*'$5VDNT.O!(/_ .JNLTNY:\TJTN7^_+$KM]2 :X[Q:IUC
M4+6S63<2VV").Y[LWL.,?6NWMH%M;6*!/NQH$'T Q796THPB]]?N/*PR;Q=6
M<=(Z??W):***XSU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW:C)MI,?2H6!0X=2I]"*] J.6"*=2LL:N/\ :&:UGDJM[D_O0'%6/_(0M_\
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M:DI*Z8&/XD_Y!H_WQ_.N6KJ?$G_(-'^^/YURU?)YM_O+]$ 'I7;Z9_R#;?\
MZYC^5<0>E=OIG_(-M_\ KF/Y5ODW\67I^H%JBBBOI@"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&U_,"?Q/]RW_ -[^AKG:Z+Q/]RW_ -[^AKG:\K,_]ZE\OR 1ONFN^B($"D]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'RIXS_Y'K7?^OV7_P!#-8J?ZZ+_ *Z+_,5M>,_^1ZUW
M_K]E_P#0S6*G^NB_ZZ+_ #%?10^!>A\_/XWZGT/\1-*_M3X9.57,MM DZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>O28+'5=>E$UPS10'D%N./85Y_\  ^VM;S4M6>15D:-(]HSD#.>WX5[F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^]_B'2BBBL#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+GY3NZ***Q-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH BNO^/2;_<;^5?,GA?\ Y*?9?]A&3_T)J^F[K_CTF_W&_E7S)X7_ .2G
MV7_81D_]":N_"?#/T.+$_%#U/J"O _CB=OBJP)_Y]F_F*]\KP+XY?\C38?\
M7LW\Q6>#_BFF*_AF]X<^#VG7^BP7^KWD\UW=1+)E'(" C('OBO/1I\GACXG6
MUC#,6:UOXU20<$JQ'!_!L&OHWPU_R*^E?]>D7_H(KP+Q1_R69_\ K_@_]DKH
MH593G)2>FISUZ<8PBXK70[_XR>)KC3=%MM*M)7BEO@?-9#@^7W&??D5RW@KP
MKX+?1H[OQ#J,#W,PW" .0(AZ'WK6^.&F3-%I6JHI,,:F&0@<+GH3^=8_@GPA
MX&\3Z2CWMRT.IIQ/&\Y3)]5YY'THIVC033:[V'.[K--7]3%\46>G^$?$=GJ?
MA;5!+%DLHC<[HL8RI/H1G\J^A]#U)=8T*QU%1C[1 DA'H2 2*\ND^'GPX@U*
M#33J9^U7!*QQI<L<GW(.!^->IZ/I5OHFDVVFVN[R+= B;CDX'O6&(G&48[W\
MS:A!QD^Q9N#(MK*T(S*$)0>IQQ7RWHTVDR>+9YO%HN)(&=O.QDMOSQN[XQ7U
M0S*BEF8*JC)). !7E5SIOPY\>7]Q)'<Q6U^CE'=9#$7]\' ;ZT8::BI73MW0
M8B'-:S^\H3>!_A]XH6-=!U..VF#!B@) 8>F#BNJ^(FKGP?X %OIQ,<C!+2W8
M'E!C&?\ OD&O(_''@ZT\&SVT^FZNMP96.T*X\R/'.<KVKK?%"ZCXD^"FDZI.
MKRW-L4DE;'++]S=[]<ULX)N#<KQOU,5-I225G8POAU\.D\713:GJ-PZV:R%<
M*3OF;N2?3-===? ^P;5[6:TOY([%6W31,3OXZ;6[?I5+X/\ C'2]/TF31=0N
MH[:02F2%Y#M5U;GKTSG-=_=?$'PS::M;:<^JP-+.<!D;<BGMN8<#/N:FM4KJ
MHU'8JE"BX)O<X3XZH(].T5!G"R.!GGL*V?"NK_V#\%8M2 RT%OE1_M$@#]36
M/\=R&L-&(((,LG(^@JYI.FRZM\!!:0*6E:W#*!WVL&_D*-'0A?N-W565NQYU
MX1T[3O%&OW.H^*=46*,MOD\QSNF8]L^@&!^%;WC;PMX*319+OP_J,*7,*[C;
M[RPE'H/>N9\$:;X;U?5&L?$LC0%AB%RY10PZJ3V/7K7H=_\ #?X<Z5:-=W>I
M".)!G(NB2?H <G\*Z*DU&HM7Z):&%./-#9&M\)?$5QK7A*ZM+N1Y9[ [/,<Y
M+(0=N3^!KQ_PWH4GB7Q>VDQW!MQ+)(9)!UV \C^5>]^#_"FB>'=-N[G0Y9)8
M+Y%8NTA8$ -C&3_M&O'_ (7?\E07_MM_.LJ<U^\E TJ1?N1D=/XN^$NE:+X5
MN=0TZXF%Q:1AR'8E7 (SWXXS2? >>0MK%ON/DY20)G@,1@G\@*]$\?\ _(AZ
MQ_U[FO-_@-_Q\ZQ_N1_UJ%.4\/+F=RG",*\>70Y;Q3?W_C[Q_P#887)03>1:
MQN?E0=VQZ]/RKT,_!#1_[-\L7MQ]LV_ZXDXS_NYZ5YKYLO@GXFM/=Q,1;7)=
MEQRT9[CUZ5[VWCCPTNFF_&LVAAVY $@W'VV]<_A5UY5(**I[$T8PDY.IN8/A
MWPW'\,_!VHW<MP9[E8VED*D[-W8 '\*\B\/6UIXQ\57&H>)M46"'/F2-(YW.
M.R*>P Q7MEYJNG^// 6I#1[@2F6!@(^CJPYP5/(Z5X1X0T_P_?:V=.\3L\$9
M_=QON*A) <$,>W;K10;:G*7Q?B%:W-&*V.R\7>$_ S:)+-H.I017D*EA&9"P
ME]OK71_!;Q'/J6CW.E7<KR/9;3$7.3L.>/PP*J7?PS^'6GVK75QJ*I$HSN^U
M9_( Y-=5X%\)>'=&C;5M GDGBO8EP[2,P*]1P>E9U*D72<6V_5&D(-5+JR.S
MKR3XF6[^&_&.A^,K==L:2I#=E>I7."3^!Q7K=87C+0D\1^$]0TUD#/)"QB]G
M ROZXKEHSY9J^QT5(\T=#6CO(9+%;S>HA9 ^[/ &*\I^&T3^*O&NM>,;A<P@
M^3:A^< DGCZ8'YUA+XWGB^#\VDF;_B;I.U@(OXRI ^;]?TKUKP7X?3PSX5L]
M-"@2*@,N.[D<FMI1]E"7=Z?(S4O:27D><7EJ_P 1OBS=:;>.QT?1]VZ'/#LI
MV]/J?RS7IDW@_P /3:>;%]'LO(*[=H@48'MQUKSCPY<IX6^-&N66H$0QZF7D
M@D<X#%F#@9^F?QKV$LJH79@% R23P!2KR<7%1VL@I)--O>YX[X/\[P-\3KKP
MIYSMIEXOG6ZD\*3QP.W(Q^ JS\4/^1[\(?\ 763_ -DJM:3KXL^.?VRQ/F6>
MF0A&F7[I()/7ZG'X5/\ %61(/&OA*:4[(UEDRQZ#[E;+^*F][:_<9/\ AOM<
M]<KRBW_Y.)NO^O5?_1(KU;<NW=D;<9SGBO(]-O+:^_:#NYK69)HA;["Z'(R(
ML$9^H-<]':7H;U=X^IZ[6;X@U5=$T"]U)AD6\1?'K6E6%XSTR35_".I64()E
MDA(0#N:QA;F5S25^5V//?AIH^E7]K)XH\1W%I=:K>L6 N75C$N<\!NG:NB\9
M^'/"^O:%<^7)I\%]$ADM[B)D5U=>1R.>V*X_X9^%O"/BGP_MO[1FU:W.VX0W
M$B-Z9VAA7:2_"SP3!$TLU@8XT&6=[R4 #W):NRI*,:EVW=>7_!.6"FX;+[_^
M ,^'6I#Q=X :UU51<-$TEG<;^?, _P#K$5RVC:G-\)_$-WHFK/(^@W ,UG,
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M;VZAMT9@BM*X4$GH.>]35G-5&73C%P1P7Q7T73(? 6HWR6,'VV..)$N2@,@
M91][KTXK8\!:)I=OX:TS4(=.M8[QX/FG6)0YSG^+&:J_%M@WPSU1@001&01W
M^=:V/ Y!\$Z2001Y Z?4T.3]BM>HE%>UVZ'045 ;RU%T+4W,(N",B+S!OQZX
MZU/7,;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>!_RQ3^0KS35_P#D?6_Z^8O_ &6NNC455SIN*LDSS,50GAE2KQJ-R;7Z'?\
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MQ%+EJT:46TM>NNQ7U;P[K&F64NH6VLW$LL*F1E;'(')P,5T_AO4WU?0X+N4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %&*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *1E5QAE##T(S2T4 (JJHPH 'H!2T44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$R.HRKD9HTGXV^']6\2VN@+I6MVM]<2B$+=6\:!&/][]X2/RJM^S]_R3%/\
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M)=P!_P!H"J/PH\>'QSX7\RZVC4[,B*Z"\;N.' [9_F#5KXL_\DMU_P#Z]_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEHI_=W%DQ8>ZLI'\S7MGQ9_Y);K_ /U[_P#LPKQ_]G'1I9_$NI:R5(@MK;R
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M-8LE"W"_\]5[2#^OO]:THVLZD=7_ %^1-:^D'M_7YGHM%%%(H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^$[\'_\ 0UZ'_P"#&'_XJIV5AZWN=!7Q]\9[ZVU#XHZK+:RK+&@CC+H<C<J
M'GV/%?2NI>)?A]K%NMOJFM^&+Z%6WB.ZNK>50WKAB1GDUE_\6@_ZD;_R4J'&
M\D^Q:E9-=S$_9ZO[6;X?R623H;F"[D:2+<-P!Q@X]/>O6ZX!6^$2,&5O ZLI
MR"#: @UO_P#"=^#Q_P S7H7_ (,8?_BJUD[NYE&/*K'045S_ /PG?@__ *&O
M0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q526</\8OA;)XP@36=&1?[8MTV-$3
MC[0@Z#/9AVSUZ>E>8_"/QP?A[XBO-%\0QS6EG=,!*)4(:WE'1F'7!!P?P-?0
MW_"=^#_^AKT/_P &,/\ \567K&K?#3Q#&J:OJWA>]"_=,UY S+]#NR*4+P>F
MSZ!*TUKN=79:A9ZG;+<V%W!=0-TDAD#J>_45SWB#Q[I6C,+.S)U;69/EATZQ
M(DE8^K8^XOJ37&#PC\#A+YGVG0-V[=C^VSC/T\W&/:NJT?6?AMX?A,.D:OX8
MLD/WO(O(%+?4[LG\:;5Q:HWO#BZPNAP'7FB.I.6DF6$Y2/<Q(0'OM! _"O'O
MVD[ZV.EZ+8"9#<B=Y3&#R%VXR1^->J2>-O!DT3Q2^*-!>-P59&OX2&!Z@C=R
M*P?^+0?]2-_Y*5,US-%1?*>,_L]WMM:?$">.XGCB:>R>.(.P&]MRG ]\ \5]
M35Y__P 6@_ZD;_R4JY)JWPRFTR+39=0\(O81-OCM6FMC$C<\A,X!Y/;N:TE*
MZ2[$1C9M]SYQ^,U_:ZC\4=5EM)DFB7RXRZ$$%E0 @$>AX_"O:/V>[VVE^'KV
MB3QFXANY&DB##<H.,''I6U_Q:#_J1O\ R4IR/\(HW5T;P0KJ0593: @^HJ:?
MN1Y?ZWN.I[\E+M_E8F^)_CVT\%>&+ADGC.K7"&.T@W?-N/\ &1UP.OY"KGPT
MCTZ'X?Z1'IUQ'.I@625T8,3*WS.6]\D]:HW=W\*;^ZDNKRX\&7%Q(<O+,]J[
MN?4D\FI-/U/X7Z3="ZTV^\'V=P 5\VVEMHWP>HRI!HCI>_7]/ZN$M6K=#MJ^
M/_C-HEKHGQ)OTLW0Q70%T44Y\MGSN!].03^-?3=SXQ\$7MM);7?B3P]/;RJ5
MDBEOH65P>Q!;!%8G_%H/^I&_\E*AQO)/L6G9-'&_ #QS;S:2_A6_N%CN;=B]
MGYC8\Q">4&>X/./0^U=G\8M:L=+^'6I0W-S&EQ<JL<,)8;G.X'@=>@)_"D_X
MM!_U(W_DI3YIOA)<3/--)X)DE=BSN[6I9B>I)/4UI4?-9]=/PM_D1!<AU>@Z
MQ8ZYHUK?Z?=17$$D:G=&P.#CD'T(]*TJXFPU+X7:5="ZTZ]\'V=P 0)K>6VC
M< ]1E2#6M_PG?@__ *&O0_\ P8P__%42:;NA132LSR#XX_# _O?%VBP=!NU"
M!!_Y% _]"_/UKU'X7?\ ),?#W_7HO\S5UO''@UT9'\4Z$RL,$'4(2"/^^JKZ
M?XK\"Z580V-CXDT&"UA&V.-=1BPHSG ^:IA[L7'II^HY>])2[7_0E\<>#;'Q
MQX<ETJ\/EOG?!.!DQ2#H?IV([BOFG3[?Q#\&/']K>ZI8R&!6,;21\QW$1Z[6
MZ9[X/((&:^FO^$[\'_\ 0UZ'_P"#&'_XJH;OQ?X&O[9[:\\1>';FWD&'BFO8
M'5A[@M@T*\9<T2G:4>61>\/^*M$\46:76CZC!<JRY**XWI[,O4'GO7F_[0][
M:_\ ""06?VF'[4;V-A#Y@WD!6R=O7'(_.K%WX9^"-[*));CPXK 8Q#JXB'7/
M1) *EL=!^"FG,#!-X7<AMW^D:DD_/_;1SQ[=*4XJ7D$6XZ[GC7P.L[J;XGZ;
M<Q6TSP0B3S950E4S&P&X]!SZU];LRHI9F"J!DDG  KF[;QCX'LX%@M?$GAZ"
M%?NQQ7T*J/H U5=3U_X<ZTL:ZKJWA6_$1)C%U<V\NS/7&XG'2M)2NDET(C&S
M;?4^5?B'>6]_\0]>N;6598'O'V.IR&P<9'MQ7OOP=\:>&K+X;:?8WVNZ=9W5
MNTBR175RD3<NQ! 8C(P:W/\ BT'_ %(W_DI1_P 6@_ZD;_R4J:?N0Y/3\"I^
M]+F)]8^*O@7P];S3C6;.ZE8[S%I["9I6QCJO&< #)(Z#VKF?A+XEO?'7C'Q)
MXENHQ%"D45K;0@Y\I,LV/KP"3ZFM_P#XM!_U(W_DI6EIGB'X=:+')'I6L>%K
M!)#N=;6YMX@Q]2%(S1&R=WV%+567<ZZBN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A
M._!__0UZ'_X,8?\ XJ@9QGQA^&#^,[%-4TE$&LVJ;=AX^T1]=N?[P[?7%>?_
M  5\;)X-U6]\*^)"]A'/*&C-R"@AEQ@JV?N@C')XX]Z]S_X3OP?_ -#7H?\
MX,8?_BJRM9U3X9^(55=7U7PO>[/NM->0,R_0[LBE"\&[;/H$_>2ONCKI+ZTA
MM#=RW4*6P&[SFD 3'KNZ5\P_%/Q-<?$[QI:Z+X9AEOK:T!2'RAQ*YQN?V48
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\P?\,X
M^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5?3]% 'S!_PSCXP_Z"6A_]
M_P";_P"-4?\ #./C#_H):'_W_F_^-5]/T4 ?,'_#./C#_H):'_W_ )O_ (U1
M_P ,X^,/^@EH?_?^;_XU7T_10!\P?\,X^,/^@EH?_?\ F_\ C5'_  SCXP_Z
M"6A_]_YO_C5?3]% 'S!_PSCXP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W_F_^
M-5]/T4 ?,'_#./C#_H):'_W_ )O_ (U1_P ,X^,/^@EH?_?^;_XU7T_10!\P
M?\,X^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5?3]% 'S!_PSCXP_Z"
M6A_]_P";_P"-4?\ #./C#_H):'_W_F_^-5]/T4 ?,'_#./C#_H):'_W_ )O_
M (U1_P ,X^,/^@EH?_?^;_XU7T_10!\P?\,X^,/^@EH?_?\ F_\ C5'_  SC
MXP_Z"6A_]_YO_C5?3]% 'S!_PSCXP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W
M_F_^-5]/T4 ?,'_#./C#_H):'_W_ )O_ (U1_P ,X^,/^@EH?_?^;_XU7T_1
M0!\P?\,X^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5?3]% 'S!_PSCX
MP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W_F_^-5]/T4 ?,'_#./C#_H):'_W_
M )O_ (U1_P ,X^,/^@EH?_?^;_XU7T_10!\P?\,X^,/^@EH?_?\ F_\ C5'_
M  SCXP_Z"6A_]_YO_C5?3]% 'S!_PSCXP_Z"6A_]_P";_P"-4?\ #./C#_H)
M:'_W_F_^-5]/T4 ?,'_#./C#_H):'_W_ )O_ (U1_P ,X^,/^@EH?_?^;_XU
M7T_10!\P?\,X^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5?3]% 'S!_
MPSCXP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W_F_^-5]/T4 ?,'_#./C#_H):
M'_W_ )O_ (U1_P ,X^,/^@EH?_?^;_XU7T_10!\P?\,X^,/^@EH?_?\ F_\
MC5'_  SCXP_Z"6A_]_YO_C5?3]% 'S!_PSCXP_Z"6A_]_P";_P"-4?\ #./C
M#_H):'_W_F_^-5]/T4 ?,'_#./C#_H):'_W_ )O_ (U1_P ,X^,/^@EH?_?^
M;_XU7T_10!\P?\,X^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5?3]%
M'S!_PSCXP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W_F_^-5]/T4 ?,'_#./C#
M_H):'_W_ )O_ (U1_P ,X^,/^@EH?_?^;_XU7T_10!\P?\,X^,/^@EH?_?\
MF_\ C5'_  SCXP_Z"6A_]_YO_C5?3]% 'S!_PSCXP_Z"6A_]_P";_P"-4?\
M#./C#_H):'_W_F_^-5]/T4 ?,'_#./C#_H):'_W_ )O_ (U1_P ,X^,/^@EH
M?_?^;_XU7T_10!\P?\,X^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5?
M3]% 'S!_PSCXP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W_F_^-5]/T4 ?,'_#
M./C#_H):'_W_ )O_ (U1_P ,X^,/^@EH?_?^;_XU7T_10!\P?\,X^,/^@EH?
M_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5?3]% 'S!_PSCXP_Z"6A_]_P";_P"-
M4?\ #./C#_H):'_W_F_^-5]/T4 ?,'_#./C#_H):'_W_ )O_ (U1_P ,X^,/
M^@EH?_?^;_XU7T_10!\P?\,X^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO
M_C5?3]% 'S!_PSCXP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W_F_^-5]/T4 ?
M,'_#./C#_H):'_W_ )O_ (U1_P ,X^,/^@EH?_?^;_XU7T_10!\P?\,X^,/^
M@EH?_?\ F_\ C5'_  SCXP_Z"6A_]_YO_C5?3]% 'S!_PSCXP_Z"6A_]_P";
M_P"-4?\ #./C#_H):'_W_F_^-5]/T4 ?,'_#./C#_H):'_W_ )O_ (U1_P ,
MX^,/^@EH?_?^;_XU7T_10!\P?\,X^,/^@EH?_?\ F_\ C5'_  SCXP_Z"6A_
M]_YO_C5?3]% 'S!_PSCXP_Z"6A_]_P";_P"-4?\ #./C#_H):'_W_F_^-5]/
MT4 ?,'_#./C#_H):'_W_ )O_ (U1_P ,X^,/^@EH?_?^;_XU7T_10!XW\)OA
M-KW@/Q5=:IJEWILT$MD]NJVLCLP8NC9.Y%&,(>_I7LE%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^\/]H?\ UJ^PM/U"UU73X+^QG2>UG0/'(AR&!K:<4U=;?E_70RA)I\KW_/\
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MVKJ-%UJP\0Z1;ZIIEP)[2==R.!CZ@@]"#VH6JNAO1V9?HHHH **** "BBB@
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M/H#C-.\/>*M(\4V[W&CSSSP+C]Z]I+$C?[K.H#?AG%"UV!Z&O)(D4;22,%1
M69CT %1VEW!?V4%Y;/O@GC62-L$;E(R#@\CCUKQ+XR?%JRBTVZ\,:!<+/=39
MAO+B,_+$O1D![L>A].>_3K/!7Q/\'7>G:'H4&L;]2:"*W$/V:8?O H!&XIMZ
MCKG%*#YDVOEYBD^5I/\ K8]'HJ"\O+;3[26[O)X[>WB4M)+*P55'J2:X6_\
MB_HUE ;N+1/$=YIH&[^T+?36^SXSUWN5R.^:+HJQZ#16'X8\7Z'XPL&N]%O5
MN$0XD0@J\9]&4\C^5;E4TUN2FGL,F1I89(TE>)F4@2( 60^HR",CW!%>(?%O
M7_&_@!]/GTSQ9<W%I=[T(N;.U+HRX/58@"#GT[5[E7AG[2O_ "!=!_Z^)/\
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M]M,H>.6-MRL#W!HA[L&H[?UH*?O23>_](GHHHH&%%%% !1110 4444 %%%%
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MO^12TC_K^/\ Z+:O4O"?_(GZ+_UXP_\ H KRW]I+_D4M(_Z_C_Z+:O4O"?\
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M.CZE*<[GE\S[4P[%R 0W^SC'I7KNM:5I^IZ?<"^LK>X_<2(#+&&(4CD GIG
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M2I"/*HK:R_K[R*<GS2;WN_Z^XY#X:^%-0\&>#H=(U*]CNITD=\Q$E$!_A4D
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M?['^T?9SY7]E^;LV[OXO,YSGTKZCTS_D$V?_ %P3_P!!%?._[2/_ "-.B_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB*U\+-;I&8_(CDOK<D!.F<2=SS7TA122M)2ZH'K%Q[GGL?BSXCB)1+\,E:0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%9VI^(-%T5XTU75["P:4$QBZN4B+@=<;B,T :-%<__ ,)WX/\
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M#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJMY'26-9(V5T8!E93D$'H0:
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M (J@#H**PH?&OA2XE6*'Q-HTDC'"HE_$23[ -6W'(DT:R1.KQL,JRG((]0:
M'4444 %%%% !1110 451UC5K/0='NM4OY#':VL9DD8#)P/0=S6/X+\=:/X\T
MZ:\TD7"""3RY8KA KJ>HZ$C!]C0M;I= >EK]3IJ*** "BBB@ HHHH **** "
MBBJ.I:SI6BQ)+JNI6=C'(=J-=3K$&/H"Q&30!>HK&L_%WAK4;I+6Q\0Z3=7,
MG"0P7L;NWT ;)K9H **;))'#$\LKJD: LSL<!0.I)["L'_A._!__ $->A_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:;5!!*2O+QX!VGU'%=EX)\8V'C?P[#JED0K_ '+B GYH9.X/MW![BN<^)O\
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M3^=?1%E_QXV__7)?Y5X'^TI_Q_>&_P#<G_FE>^67_'C;_P#7)?Y4Z?\ "?\
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MGSW\??"-CI>CZ=K,=S?3WLER8))+JY:7<"I;@'A<;1PH ]J]?^'G_).O#O\
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M_P!U00BC\%0#\*<FIRE;;_-B@G"$4]]ON6I\F^)[22P\5:M:3*5DBO)5(/\
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M=JEBFIZ3>6$APES"\+'V8$?UKYU^"]^_@OXE:GX7U?\ <277[@;N 94)*_\
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M<M='^'>IQ3.#<7\1M+:$<M([\<#O@'-,^$7A.?PCX#M[:\39>W3FYG0]4+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*XG4?B[X&TG4KC3[[7/*NK:0QRQ_9)VVL.",A"#^%5?^%V_#S_H8?_)*X_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@9&X;1R<8P>#G-3)I)/>_P"I4+MV[?H>CVMI;6-K';6EO%;V\8VI%$@1%'H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA&2Q'3[W7Z5[OKNOZ7I6CO<75Y&J31D0*AWM,2. BC)8GVS6<M:#GWO9??\
MB_ZN7_R]4?37^NB/&OV:O^9C^L'_ +/7<_'+_DE&J?\ 72'_ -&+7GW[.=_;
M68\3O<S1PQQI#*[R,%"J-^2<UWOQPFC;X2W[AQB5X-F>,_O%/\JUQ/PKTC^:
M)H_&_5_D2? W_DE&E_\ 72;_ -&-73^-/#</BWPEJ&C2A0T\9\IR/N2#E6_/
M%<M\"W5_A3IP5@2DLRM['S"?ZBO1ZO$14I-?ULB*+LDUY_FSP_X ^))H4U'P
M7J68[JQD>2%&/(&<.OX-S^)KK;O_ (JKXO6UH/FT_P -0_:)>>#=2#"#ZJO/
MXUYU\6;"Z\ ?$O3?'&E1GRKE]TJYPID PRD^C+_6O5/ACI=Q:^%SJM^I&I:S
M,U_<[NHW\HOT"XJ8R<TJCW6_KLOPN_N"4>5N"V>WIN_QT^;#XH>"I/'/A!]/
MMI$CO89!/;E^%+ $;2>V02,UXWHGQ3\:?#:>+0_%6ERW-K%A$6?Y)548^Y)R
M' 'U^HKW7Q;XLM_"2Z5<7K(EE=7HMIY6S^[#(Q#?]] 9]LUHZKH^D^)=+-IJ
M5I;WUG*N0' 8<]&4]CZ$5"O&\H[/=>9H[.RE\C-\'>+]"\::>^IZ.X\PX6XC
M=0LL9'0/Z]\'D5SWQR_Y)1JG_72'_P!&+7 _"C1#H?QL\0Z?I4SS:59Q21N^
M<C!9=JD]R#D?@:[SXZ.J_"G4@S %I80H)ZGS%/\ 2E5LZ:DNMG^*"E=3<7T_
MR'? W_DE&E_]=)O_ $8U<?\ %+P/XHTWQB?'7A!I7F*@SQV_,B,JX)V_QJ0!
MD<_2NN^!<BO\*=."D$I+,K>Q\PG^HKHM*\7VE]XPUGPU-)%'?6+HT4><&6)H
MU;(SU().<=L5M65ZMXO5:_@KF=-_N]=O^"SR[PG^T%#/*NF^,-.%M(3Y;W4*
MG8#T.^,\K[XS]!7N%J]O+:0O:-&ULR Q&+&TKCC&.,8KS+XT^#= U'P=J.NS
MP16VIVD>^.Z4;6D.1\C?WL]!GI6G\%HKV+X6:4+W?D[VB#=?++';^'I[5,7S
M*5U9JWXC:Y6K;._X'H%8WBC2]"U;0+B#Q)% ^F(/-E,SE%3'\6X$$?4&MFO$
M?VD;V]A\/Z/:Q,RV4]PYGVDC<R@;0?;DG\*SF[+U-8*[.DTWQE>ZU;+IOPYT
M"-]-M0($U*_+16J <81?OOC\*\XT"'4+?]IL1ZK>1W=\&8RS11>6I)M\X"Y.
M !@>^*]G\&:OH2?#W2[RSNK6#38;1 [%PJQ$#Y@Q['.<YKQC2]5M;[]I];ZW
M9C;SRE8W=2F[]Q@$!L'![>N1CK6R5L0H[OWOR_4PO>@WMMI\_P!#Z&U0 Z3>
M C(,#Y!_W37B7[-/_(/\0?\ 76'^35[)?:C9SZ!J5S#<))##%,KNAR 5!W#/
ML>/K7C'[-,J?9?$$.X>9OA;'MAA6=/\ B2_P_J54^&/^+]#T+XQ?\DIUW_KF
MG_HQ:R/@.VSX50-Z7$Q_6M7XR,J_"G7-S 92,#)ZGS%K)^ ;I+\+HD# E;J9
M6'IR#_(TH7M4MOH54_Y=^K_(X3X'WAUOXK>(-6NLO<2PR2*7.2NZ0<?E@5]&
M5\K:;<S?!WXR3?VA"_\ 9\C.A91]ZW<Y5QZXP./8BOIF+7=*GT?^UX]1MFT[
M9O-SYHV!>O)[52:]E%K9*WH)_P 62[NZ/!_ @Q^TIKN/^>EW_.OHBOF?P)KF
MGC]H34K^2X6&UNY+GRI)_P!WG=R,[L8SCO7TI#/#<PK-!*DL3?=>-@P/T(HA
M_!AZ!)_O9^OZ$E1K/"UP\"RH9D4.T88;E4YP2.H!P?R-25Y5XB\;6GA#XU6\
M6I2^5I^H:7'%)*?NQN)'*L?;DC\:%K)1[_Y7&_A;[?YG2>,_AGX<\;1L]]:^
M1?XPE[;@+(/3/9A['\,5\Y^)?!WBGX0Z[;:E;7A\HOBWO[?(5O\ 8=>Q(_A.
M0?>OKJ*:.>))89$DC<95T8$,/4$5YE\=]2L+?X=S:=,ZM>WLL:VL(&79@X)(
M'L >??'>LY7@[QWN4K3TEL=;X$\3KXP\'6&L[ DLJ%9D'19%.&Q[9&?QKR#Q
M[_R<GX=^EK_Z&U>G?"GP[=>&/AYIUA?*4NGW3RQGJA<YVGW Q^->5_$FYBL/
MVA_#]W<MY<""U+.W  WL,_2MY)+$0MW_ $,-7AY>GZ_Y'T17F<VM>$/ WB"[
MTOPMHC7_ (COWWS65@23GK\[,=L:\]!TSG%=AXAUE;73=0M[&8/JJV$UQ!$H
M+$;5X)P..2,9Z]NE>-_LYZCI[W>N1W,R'6;AED5I&^>5.=V">3SR?PK./O3:
M71?KM_F:R=HI^?\ 3_R]2M\;5\7S^%+"\\1/IUK;M>A8M.LU+LAV-\SRGJ>"
M, 8Y]J]J\#_\B'H'_8/@_P#0!7E/[1&MZ==^'K+3+:Y6>Z@O0TRQ981?(V S
M#@,<]"<XR:]+\":E:/X*\-6_GQ^?-IT;)%NRQ"J QQZ \?4TZ3O3E;^;]"9Z
M3C?L_P SR+7/^3I['_KK#_Z*KZ'KYR\37=O8_M/VES=3QP0)+!NDD8*JYB Y
M)Z5]%EU";RPV8SNSQCUI4_X,?G^94_XTO2/Y'SE\8+86'QLT"]ML)+.+:1BO
M4LLI7)_ #\J]J^(?_).?$7_8/F_]!->7PZ?_ ,+.^-YUNV!?0-#V1_:,?)-(
MA+ *>_S'/T'N*].^(SK'\./$3.P4?8)1DGN5(%9RTPUGYOY-Z%1UKW[67SZG
M _LX?\B3J?\ V$#_ .BTKT#XA_\ ).?$7_8/F_\ 037GO[-\BGP;JL8(W+?Y
M(]BBX_D:] ^(SK'\./$3.P4?8)1DGN5(%:XOX7Z+\D1A_B^;_,X']G#_ )$G
M4_\ L('_ -%I70?'+_DE&J?]=(?_ $8M<[^S>ZGP;JD88;UO\D>@*+C^1KH/
MCHZK\*=2#, 6EA"@GJ?,4_THQ6W_ (#_ .VA0W^;_4=\#?\ DE&E_P#72;_T
M8U<)^T+_ ,C3X4_X'_Z&E=S\"Y%?X4Z<%()2696]CYA/]17"?M%.(?$/A>=P
M?+19"3CT=":NK_'C_B7Y$05Z4DNS_-GT GW%^@KB/BSX1_X2[P+=P0QAKZU_
MTFV..2RCE?Q&1^5=2NL:?C3T%TC-? &V5,L9!MW9X[8'4\?G6A652/,FOZNC
M2G*UF>5? CQ=_;O@[^R+E\WNE$18)Y:(_=/X<C\!6EX?_P"*H^*&L:^WS6.C
MI_9ED<Y!DZRL/T6O)_%B:E\)?BS/?Z- 7MM5C=H8LD!B_!7_ ("^"/PKWKP/
MX?\ ^$9\(6&G.=UR$\VY<\EYF^9R3WY/Z5HI<]JOE_Y-L_P_,S<>5^S\[_+?
M\_R.AHHHJ30*\L_:!_Y)DW_7Y%_6O4Z\J_:#D1/AKL9@&>]B"@GD]3Q657X?
MFOS1=/XOO_)D_P !/^276W_7S-_.O3J\O^ 3HWPPA56!*74P8 ]#D&O4*Z:O
MQ?=^2.>E\/W_ )L\#^-DYNOB;X1TR:[GM+8;&,T$FQXR\NTLI[$!1@UWG_"K
M/^I]\<_^#C_["N._:(\,7=W8:=XDLT9A8YBN-@Y1205?Z Y'XU)X&^/FC2Z1
M#:>*I);.]A4(;I8FD28 =2%!(/KQ6-*S@X]4W^)K4NI)]&E^!MS_  )T&\U.
M/4KW7_$EY>(RL)KF\CD8[>F6,>?UK=^)_@J3QQX/?3K:1$O89!/;M(?E+ $8
M)[9!/-8=W\1=/\>:A!X7\(O/=?:'5KV],31I!;@@OC=@[C]T<=ZZ[Q;XLMO"
M*Z5<7K(EE=7HM9Y6S^[#(Q#?]] 9]LTVN:*B]-=/7O\ ?IY@G:3:W2_I?=J>
M%:)\4_&GPVGBT/Q5I<MS:Q81%G^255&/N2<AP!]?J*]T\'>+]"\::>^IZ.X\
MPX6XC=0LL9'0/Z]\'D5I:KH^D^)=+-IJ5I;WUG*N0' 8<]&4]CZ$5X=\*-$.
MA_&SQ#I^E3/-I5G%)&[YR,%EVJ3W(.1^!JHR<I<L][-W].Y$DHQYH[76GKV'
M_M"_\C3X4_X'_P"AI7OR?<7Z"OG_ /:*<0^(?"\[@^6BR$G'HZ$U[DNL:?C3
MT%TC-? &V5,L9!MW9X[8'4\?G4T_X?\ V\QS_B_]NK\SPS]I3_C^\-_[D_\
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M;:4EO(IELH_LTZ \HR],_48->>_&NQE\6?$;P[X>TI3->I$3,$Y\I68<MZ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?>9 2[?[S'+'\36Q115-WW$DEL1S017,#P3Q)+%(I5XW4,K ]B#U%<C#\)_
MMOJ7]H1^&[7S\YPS.T8/M&3L'3TKLJ*2T=^HWJK,155$"(H55&  , "EHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<U[%3MHGW"^K78****0PHKQ[QW\=K+0KV32O#ELFIZ@C;'F8GR4;T&.7.?3
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M<A)4]5!).1W&?>O3*MIHE23"BLG68O$+KOT2]TR$JA_=WMG)+O;M\RRKM'_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^28^'O^O1?YFLZ'\!?]N_D:5_X_W_H<Q\>O#,.K^!'U9(Q]LTQA(K@#)C)
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MO5)=E^MC&/NQCYM_J=7X*\.GPOI5YIP0)!]OGE@ QCRW;*].F,X_"LKXQ?\
M)*==_P"N:?\ HQ:[FN&^,7_)*==_ZYI_Z,6N>K\'W?H=%)>^O7_-GS-\,/\
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M#Q+EX4:>&[C$<A'S*#D$ ^]=-\)_^26>'_\ KV_]F-*#YE+RM^)4G:45WO\
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M444 %%%% !1110!1OM+AO[W3KF5CFQF,Z+V+%&3GZ!B:O444 ?+UO_R<\?\
ML*M_Z":^H:^7K?\ Y.>/_85;_P!!-?4-*G_ @*7\:?R_4QBFE^&GU/4[W4(+
M."]N%ED>YD6.-7V*F,D@<[142>./"4CJB>*=$9V("JNH1$D^@^:MJ>"&Z@>"
M>))8G&&1U#*P]P:^<=*T^U^&_P"T,EG)"JZ?>,5M68<(LOW<?1AM^E..LU!]
M=OET">D'-=/ZN?0&I>(M$T:5(M4UG3[&1UW(EU=)$6'J Q&15:V\9>%[RYCM
MK7Q)H\\\K!8XHKZ)F<GL &R34GB;0;'Q+X>O-*OXT>&:-@&89\ML<,/0@\YK
MQ+]G;5;6RU?6O#\OE&Y<^;%,I!WA#M8 ]QT/YT0]Z3B^UPG[L5)=['NVI:SI
M6BQ)+JNI6=C'(=J-=3K$&/H"Q&33-,U_1M:,@TK5K"_,6#(+6Y279GIG:3CH
M:P_B5>_9? ]];)&DMUJ %C;1,,[I)3M''MDG\*DMK33?AQ\/Y/(A1(-.M#+)
MM&#*X7))/<D_SJ>9)2E+9?\ #_UZH=KM16[_ *_KT-/7?%&A^&;83ZUJ=O9(
MV=HD;YGQUVJ.3^ K)T3XF^#?$5V+33->MY+ACA8Y5>%G/HH<#/X5YCX ^(O@
MJVCG\0>*M81O$]Y(QD=[2:0V\><+'&0A"KCG@]^:Q?C'XH\!>*M-MM0T#4%D
MUV"8#?':RQ,\?.<LR '!P1SGK3=XVOKZ=/\ ,%[U[:'TI7SK\5_^2^>&_P#M
MT_\ 1S5Z?\(?$MUXH^'MG=7TADNX':VDD/5]O0GWP1FO,/BO_P E\\-_]NG_
M *.:K4>7$07G^A'-S49OR9[[J6L:7HT*3:IJ5G8Q.VU'NIUB#'K@%B,FLT>.
MO"!( \5:&2>@&H1?_%5LW5K;WMM);74$<\$@VO'(H96'H0:^<_#EA:_#7]H%
MM.N8E6QN]T=G(_\  LG*$$^A&RIAK-0?7^K%RT@Y+H?1TL\4$#SS2I'"BEWD
M=@%50,DDG@#WK'@\9^%KJXCM[?Q+HTTTC!(XX[^)F=CT  ;)-;4CK%&TCL%1
M069B> !7#?#W3;6^FU7QD;2-+C6;EG@?:,BW7Y4^FX#<?K0M96Z?U_7R$]%Y
MG;SSPVT#SW$J10QC<\DC!54>I)Z5QDGQ@\ QWOV1O$<!DR!N6*1D_P"^PNW]
M:X7QIXWT*]^*BZ%XFOO(\-Z4GF2P>6[K=7. 0'" Y49Z'C(-;NL?$SX3ZYHD
MNDWVJ0R6;Q[!'_9\XV<<%?W?RD=B*B[Y>=?=_7X%6][E9Z;9WMKJ-I'=V5S%
M<V\@W)+$X96'L14]?-7P"\2W%EXRN?#:7#3:9=+(\0;/#KR& [97.?PKZ5K5
MK1-;,A/5I[H****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM$-CI\Q)/N655'XFI-(TOQ'KGB"W\0>(F&G6MJ6:QTB%]Q4LI7?,W0M@G '
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M[DNO_ _R,*<7RI/I_P '_,[\ZXC>+ET*((S)9M=3G/*98*@_'YOR%<[\8O\
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M6C(. !GG(/3M7K-9K6*DMC1Z2Y>H4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1GO7H/@KQWHWCK3#=:9*5FCP)[63B2(GU]1Z$<4+WE=";L[,Z>BBB@84444
M%%5[6^MKR2YCMY1(UM+Y,V ?E? ;'OPPZ58H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BO*OCCXXN?"N@65EIER\&HWDP</&Q
M5EC0@GD>IP/<$UWOA;7H?$WAC3]8@(VW4(9@/X6Z,/P((HC[R;71V_K\@>C2
M?4V**** "BBB@ HHHH ***RO$FEW&M^&]0TRTO7LI[F%HTN$ZH3WXYJ9-I70
MTKO4U:*X+X5>!]4\">'[FQU348[J2:;S$CA9C'$,?PE@#D]3P*Q_C6OB*Q\(
M7>JZ?XCGL[:*2-3:V\8C+(Q"G,@.[.3GC P<8[TZC4=M103EN>JT5YW\$':3
MX5Z:[L6=I)RS$Y)/F-S7HE7./+*Q,9<RN%%%9&N76N00!-"TVWNKAE)\RZN/
M*B0CUP"Q)]  /<5#=D4:]%>$?"_QMXJ\2_%:^L_$%ZP6VM9D-G$-D4;JZ@_*
M.I'/)R>>M>[U5O=4N^HKZM=@HKS'XR>-M5\+:9IUEX>F9-8OICL"0K*WEJ.<
M*00<D@=/6O+O^$R^.?\ SZZY_P"")?\ XS4)WN4U8^GZ*^5;WXC?&+33 -0F
MU&S\^01Q&YTB*(.Q[ M$,FOI[2H[N+2+--0G\^\6%!/+M"[WQ\QP  .<]!5V
MTN3?6Q<HHHI#"BBO._'7B?Q++JJ^%O!%JLNK&+S;N[DQLM$/W>3QN/7G/T.>
M$WT6X_-GHE%?.NL^$/C/H4,FLCQ-/?M&#(\-I?2/@8Y_=,H4_0 ].E=C\(?B
MO-XS:31M:6-=6AC\Q)4&T7"CKQV8>W!]JJ*YKI;HF3Y=7L>LT4A(4$D@ <DF
MO(XO%.M?$_Q9?:/X;U.72?#VG_+<ZA;@>=<$Y ",?N@D'!'.!GVJ;W?*MQO1
M79Z[17DGB5?$7PIMH-=LM=U/7M$64)?6FJRB650QP'23 (YXQTY%>F:)K%GX
M@T:UU73Y/,M;F,.A[CU!]"#P::U5UT%>SLR_17EOB[Q#XS\1:[<^'? 4<<$=
MF0E]JLN J2'!\M20>0.N 3]*\^UW1/C#X%@?7)/$=QJ%O%\TQAO)+A(QG.6C
MD X]P.!4J2M=Z(JW1:L^DZ*\]^%7Q)7Q]I,T=W$D&K6F//1/NR*>CJ.WN.WX
MUV&O:S#H&CSZA,CRE %CAC&7FD/"HH]2<"KFN7<F+YMC2HKPW6/#'QG\3AM0
M.MV^D(WS1Z=;7KPM&.RDHN"?JW7TK)^'OQ,\4:%XTC\)>,I)IA)*+?=<D&6"
M0\+\W\0/'))ZY!I17,^7J$G9<W0^B****!A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV8)IJZ"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJU]<RZ?9![33;B^9<*L%LT:MCZR.JX'UJ.EW_7]="OM61X1JO_)U=G_O1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+^N@WHKL]=LKRWU"SCN[63S()1E'VD;AZC/;W[UA^(/'GA;PO)Y6LZU;6TV
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+')K[4\ V:Z?\/\ 0;90!ML8B<#N5!/ZFOB:6)X)GAE4K)&Q5E/4$<$5]O\
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M6>%8_/1LAXP25QSC&6//O7QMXP^'7B/P3+G5+/=:,<)>0'?$WX_PGV(%=_\
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MV^C:1=ZE=,%@M8FE<GT S1)J*;8TKZ(\[\<:6/B)XN7PB)F2PTVU:[O'0_\
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M("4=6 )4E3G!'!%.IK22EV*>L6NX4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4U_N-]#3JQM<T&?6T:)-?U73H7CV/'8F%=WO
MN:-F!^A%3--Q:0UOJ?$-]_R$+G_KJW\S7W!H4,5UX0TV"9%EAEL(D=&&0RE
M"#7FY_9Q\($Y.I:[G_KO%_\ &J[SPYX2?PS!;VMOXAUBZLH%V):W9@=0,8 W
M"(/@=ANJU;DY'_6EB9W=3G7G^=SY@^*OP_E\#>(V\A&;2;LE[63'W?6,GU'Z
MC'O7J7P*^)']HVJ>$]6GS=P+_H4KGF1!_!]1V]OI7JWBKPKIGC'0Y=)U6-C
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MN9-=QP]VWD?#D4E[X?UQ9%)AO;"X[=5=&_Q%?;/A;Q!:^*/#=CK%HX*7$8+
M'[C_ ,2GW!R*\\N?V>?"MY=2W-QJVO23S.9)':>'+,3DD_NO6NF\'_#:S\$2
M$:3KNM-:LQ9[2>6)XG.,9QY8(/3D$=*N+]SEEO\ U<F2]_FB<=\._'UM9>//
M$GA/4IEB$FJ7$ME(YP"Q<[D^IZC\:]FKBH?A9X6:'4AJ.F6U]<ZA<RW$MS)%
MB1=[$@(V<K@$#@C.,U6;P+XIL0(-"^(>H6EF.%BO;**\91V =L' _'M4+2,4
M]TE^2*?QMK9MGF_[2%CIPO\ 1+B!%&JSATD"#YI(QC:3Z\D@?C7JGPL\/W/A
MKX=Z787JE+DJTTB'JA<EMI]P"*K:'\+=+T_7/[?UB^N]=UGC;<WQ&V/'3:@X
M'ZX[8KNZ<%R0<>[_ *0I7E)/L?+OQN^'<^@Z[-XBT^!FTN^??+M'$$IZY] Q
MY!]21Z5Z=\"/%<&M>"(](>5?MVEYC9">3$3E6^G./PKT^XMX+NWDM[F&.:&1
M2KQR*&5@>Q!ZUYM=?!/1H-6&K>&M3U#P_>C)!M7W(,_[+<XSVSC'&*5/W$X=
M/R_K\AS7,U);H].KY2^-_B2/Q1X^CT_3C]HBL$^S)Y?S>9*3\P&.O.!^%>S7
M/@'QKJ-N;34?B9=26C*5=+;2XK=V&,8WJV:T?"'PK\+^#)5N;&U>XOP,?:[I
MM[C_ '1@!?P&?>CE3DG+9!S-)I+5F=\'? #^"O#;37Z!=5O]KSKWB4?=3ZC)
M)]S[5K?%61(OAGK3NP5?*7D_[ZUV-<5XI^'$'C"-H-6\2:\UH9-XM8I((XUY
MX&!%DXSQN)/O3J-R>GE^#7^04TH[G86KK):0NARK(I!'<8I\D:31/%*BO&X*
MLK#((/4&N=\->$F\,0PVT'B'6;RSA7:EM>O#(H';YA&'X[#=BNDIRLV^Q,+I
M)/H?)WQ?^&C^#-6_M'3HF.B7;_)CG[._]P^WI^7:OH/X7?\ ),?#W_7HO\S7
M0:QI%CKVDW.F:C LUI<(4D0_S'H1U!J#PWHB>'/#MCH\4S31VD?EK(RX+#)Q
MD4H>[%P?E;\1S5Y*7K^A\[?M%::]OXYLK_'[N[LPH/\ M(Q!_0K7M_PMF$_P
MP\/N#G%H%_(D?TK+^,7@J3QCX.8V:;M1L&,\  Y<8^9/Q'Z@5D_L_:TM]X#D
MTMCB?3;AD*GKM8[@?S+#\*5'2,H=M?E=_P"85?BC+Y?.W_ +7QMUFX\/:!HF
MKVO^NM-6CE4'HV$?(_$9%=OX9\2Z=XLT.WU73)EDBE4;ES\T;=U8=B*A\4>%
M+'Q9'IT&I 26EI=BY>!ER)L*P"GGIE@>^<8[UD7OPUTM+LWWARZN/#=\0%9]
M,VK%(!V>(C8?R%$=$T^_Z(<M6FNWZLZC5[6QO=(N[;4HXWLI(F$RR_=VXYS7
MS#\$_#DVI_$Q-0M YTW3&>0S$<'(*HOU.<_@:]DN_AQXCUZ!K/Q+\0+Z^T]_
MOV]I8Q6F\=PS+G(]B*[/0/#VE>&-*CTW2+1+:V3G"\ECZL3R3[FG!<LW/R_I
MBG[T>0U*^,=7MGU[XOWMK&#(UUK+QC'<&7';VK[!UC4H-'T:]U*Y<)#:PM*Q
M/H!FOG[X$^$9]9\2W/C+4(F\B!W^SEAQ),V=S#U"@G\3[4J?\9/^57_'_@#J
M.U)I;O3\/^"?1JJ%4*.@&!2T44P2L<A\4CCX8>(?^O1OZ5\H> _^1_\ #_\
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M0):Z5XDUT62R>8;69[>2,\\CF+*@]]I%%+W*?(_(53WI\R\S8\8,%\%:Z6(
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MG\+^*=/UB$G-M,&=1_$G1E_$9K[=L+ZVU/3[>^M)5EM[B,21NIR"I&17E/\
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MOYDX09^SR'KD?W2><^IQZ5]/4UT26-HY%5T8$,K#((]"*F4;NZW1:=M&>/?
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M=#.-U3UW_4],HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2*6=W. H'4DT/178>0^BO*O"'CF'QK\7=3^PONTRPT\PV[8^^3(N]Q[' Q[
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MA01]:X3QSKOQ*^',L&L2ZW::YI$DFR2-M/2%8B3D [<L!V!W'WK/\&74E_\
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M?;@N[1<=GZ'OUL[26D+L<LR*2??%2U!9?\>-O_UR7^53U<MV8TW>"]%^2 G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&?Z40NU.';5>5Q3LG&7?1D?PJ.@_$&^US5_$=O:ZEK;7)"6]ZJR"&W_A"(W
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MJ7P)T*Z\166L66HWUH\4JRW"LYF:=@<[M['*L3U/(] *Y+2/^3JK_P#WI/\
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M:+J!N'86%A+\UO;Q@XR$/!)([^E5?CA+8P_"FS@T6."+3FU!8@EO'LC 7?D
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MZ&:,BV\[$&TD*1L  /KDY.:Y;]GG_D;O$W_7,?\ HPUZ#\<O^24:I_UTA_\
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MAW_L'P_^@BO.]8UB?XE_%-_!<-S+#X=TY6:_$+[3=,N 5)'\.XA<?4^F/0O
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MOY-5\,Z7J$W^MN;2*5_JR@FO#_VE/^/[PW_N3_S2O9/ _P#R(>@?]@^#_P!
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M\&>'_!\=Q'H-A]D6X(:4>=))N(SC[[''4]*WJ**5[C22"BBB@84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CZWXJT'PZC
M?VOJ]E9R>69!%+,JR.OJJ9R?P%?,'PI\2Z7I'Q5.IZC<+:V=P)U$LO"H7Y&X
M]J^MZ*4?=GS^5@E[T>4JZ?J=AJUK]JTV^MKVWW%?-MI5D3(ZC*DC-1:OK6F:
M#9&\U:_M[*WS@//(%#'&<#/4\'@<U?HH?D"\SY@^$?BW2-.^*6M7M_>PV=GJ
M(F,4T[;%!,@8 D\#C/6O;?'WBO0=-\&ZFEUJUFLMU82&WB$REY@ZD*44'+ G
MN.*[*BE**=-4^RM\AQ?+-S\[GSW^SQXETC3K35-*OK^WM;JXN(W@6>0)YN1M
MPN>ISCCKS4?QN\"ZGIWB$>-M#24QMM>Y: '=!(O23CL0!SV(]Z^B*.M5/WFI
M+1HF"44T]4SYOT;]I'5+2P2'5="AU"X4 >?'<>1N]RNUAGZ8KTKP WB#Q7J/
M_"8>(K46,8A,.F6*@C8C8+2'/)+8 !QT%=@OA;P\E]]N30=+6\SG[0+.,29Q
MC[V,]*UJJZW>XN7HM@HHHJ2CY=TS73X<_:!UK4WMII[6*ZN1=>2A9HXB<%\#
MDA>"?:O=+WXH>"K+2FU ^(]/F0+N6&"=7E;V" [L_4"O)? O/[2FO?\ 72[_
M )U[E'X7\/PWQOHM"TQ+LG)G6TC$A/KNQFIA?V,%Y!+^-/U_1'F_PO\ #&HZ
MGXKU3XA:[:-:SW[-]AMY!ADC.!N(_P!T #\371?&+0KK7_AMJ%O91--<PE+A
M(U&68*<D >N,UWE%$XJ45!:);?((:2YGJWN>%_"[XO>&=)\$V>C:U<S6M[9
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MH":8LR[6FVY"OCTR2?J1Z5ZI-X8\/W-_]NGT+3);S.?M#VD;29_WB,UJ !0
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MKQ1XCTCPYH\\^JZA;VH:)_+220!I2!T1>K'D<#UK;HJ)QYHN*ZE1=G=GS+\
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MQC;.TSRA"^.2%!Y8^PK1HI[148]!):N3W9\L^ ?&>E6WQNU#7+VX6VL-0DN
MDTORJH=LJ6].@_.OIO3M4T_5[;[3IE_:WL 8KYMM,LBY';*DC-6Z*:T@H]M
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MNYS$4CA=5 V98?,3_LY '4C@'R;]H'Q)I&M:SHUOI=_;WIM(Y#,]O('52Q7
MW#C/RGBOI*UM+:QMDMK2WBMX$&$BB0(JCT ' J:JF^::GYW^8J:Y(V^1A>%?
M$^C>)-)@ETK4;:Y984,L4<@+Q9'1UZKT/4=JW:**).[N**Y4D<_XZ_Y$'Q!_
MV#Y__0#7G?P_^*"Z1X?L=(\;V=]H\\,:QV]Y=VTB13H!\N21P<#Z'%>P3017
M,$D$\22PR*5>.10RL#U!!ZBEDABFB,4L:/&>"C*"#^%2M&WWM^%_\RGJDNU_
MT.9O?B3X+L+-[F7Q/I<B*,[8+E)7/&>%4D_I7GG@7PY>^,/B=>?$6_L9;+3M
MW^@13+AY<+L5\>FT9^IXZ5ZG;^$/#-I<BXMO#ND0SCI+%91JP_$+FMFG'27-
MU_S%*[7+T.(^*G@M_&_@V6SM=HO[=Q/:[N S $%<^X)'UQ7@O@OXJ>(/AIY^
MAW^FFZMHG.;.X8Q20MW ;!P#UP0?:OK&L[4M T;665M4TBPOBGW3=6R2[?IN
M!J8IQ;:V>Y3M))/H>3:)XX\1_%RY72[30QI6@%A_:%T93*70<F)6VJ,MT(P>
M":[CXE^"5\;^#Y=-A\M+V$B:T=N ' ^[GL",BNN@@AMH5A@B2*)1A4C4*H^@
M%24YQ37*OZ8HMI\S/"OA-X_A\+VLG@SQBYTJZLY#]GDN_D7:3RI8\#!R0>A!
MZUT/Q%\76?B30I?"?A*>+6=5U,")OL3B6."/(W,[KE0,<=>]>C:CHVE:Q&L>
MIZ99WR*<A;F!90/P8&GV&EZ?I4'D:=8VUG#_ ,\[>%8U_)0!3E[_ ,?_  XD
MN3X?^&,CP-X5A\&^$K+1HV5Y(UW3R*,;Y#RQ_H/8"OG_ $S73X<_:!UK4WMI
MI[6*ZN1=>2A9HXB<%\#DA>"?:OJ*OG?P+S^TIKW_ %TN_P"=";E73\F#2C1:
M\U^9ZU>_%#P59:4VH'Q'I\R!=RPP3J\K>P0'=GZ@5Q_PO\,:CJ?BO5/B%KMH
MUK/?LWV&WD&&2,X&XC_=  _$UZ1'X7\/PWQOHM"TQ+LG)G6TC$A/KNQFM:A:
M/FZ[>G<&FUR]/S/+_C5X N/&'A^&]TR/S-3T_<R1#K+&?O*/?@$?EWKR?P?\
M;M?\'60T?4]/&I06WR(DTAAFBQ_"6P>!Z$9%?5%9>H>&]"U:<3ZEHNG7DJ])
M+FU21A^+ ^@_*IBG%NVS*E:5K[H\M\-^*?$'Q>U*W#:4-*\,6DRS7+"0R-<N
MA!6/?A01N ) ';FO9J9%%'!$L44:QQJ,*J# 'T%/J]+61"3O=A7@GQA\$ZKI
M7BB#Q]X=@:0Q.DETD2DLCKT? ZJ0 #Z?C7O=%0T[J2W1>EFGLSA_#OQ8\(Z[
MHL5[-K5C83[!YUM=SK$Z-W #$;A[C-<=/IA^+7Q,L=8A@?\ X1;1@ EQ*A47
MD@;)" ]5R!D^@]Z]2F\*>'+B]^VS:!I4EUD-Y[V<9?(Z'<1FM955%"JH55&
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M *6BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_'?@W
M6/&NFS:2NOVUAIDI5FC73S)*=I!P7,H&,C/"BJO@'P%K/@2T&GQ>)+:]TTRF
M5H9=-*N,CG8XEXS@=0:[ZBB/NWMU"7O6OT"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KSSQY\/-;\>VRV-UXGM;33XYO-CA@TPECU"[F,W) /8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJ<6I36H32[R
MUM)\\R7-JTZXQV4.G/3G)^E>6Z5\&=9TCQ@WBBW\:(VI/(\DADTK*N7SN!'F
M]#GM7K]%"T?,MP>JY7L0VBW*6L:WDT,UP!\\D,1C1C[*68C\S4U%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!=WMII\!GO;J&VA! \R:0(N?J:AU#5],TE(WU'4;2S65ML9N)UC#GT&XC)H
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MYD$-HWEW>ILN](W[QQC^-QW)^5?<\5SOQC\9S^&O#L.F:8Y75]6?R("O6->
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MF6-2?JQ%36MW;7ULES:7$5Q XRDL3AU8>H(X- $U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPJ^*9\':A=-/I5U,L:YX7Y_N2*#TYP#^/I7J/Q6\:3>&K#3],L+N*TU#5IQ
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M\1?M(Z7ITA+065Q!"%)XX_>-^I_2OHZOF4_N?VI/G4<ZB,9]X^/YU]-4J?\
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MZ6W<I-<';PFX?=3N<<G@<#.?=/%__(EZY_UX3_\ H!KRO]FS_D6M:_Z^T_\
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M-!2ZWM]Q%N6?+T:O]Y3UNT2^T+4+210R36TD9!&<Y4BO#?V;=7D$FMZ([?(
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MA'F95BN[)!&<#KBO%?%>D7.A?'[2[>QNKB]F>6"6%M0G9\%B>"W)VYR:]?\
M@K_R2C1OI+_Z,:O//'O_ "<GX=^EK_Z&U=$TOK,?5_D<Z?\ L\O3]3T2]^$G
MA_73)=>)'N]6U.4'==27#Q^7[1HI"JH[ @^^:\W^"]S>>&_B?KG@XSM)9*9L
M*W]^-L!O8E>OX5]#5\\>!/\ DY37?^NEW_.HIZ5;+9IFM1?NF^J:_,^AZ***
M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8\]>,C/N3Z9]8U'1;/4O#]QHLL86SFMS;E%_A4C Q]*OQQI%&L<:*B*,*JC
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M7Z*:25/D?G^(WK/F_K0^;#I^H?!#XF'5&MI9O#5XS1F6)20(V.=I]&4XP#U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 8]MX=M]/UF34--E:T6X8M=6J &*9C_'M_A?W'
M7N#U&Q111TL 4444 %%%% !1110 4444 %%%% !1110 4444 9.KZ&NN%8+V
MYD.FX'F6D?R"8YZ.P.2O3Y1C/?(.*TXHHX(4AAC6.-%"HB# 4#H .PI]% >8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 R:&*XA>&:-)(I%*NCJ"K ]00>HI8XTBC6.-%
M1%&%51@ >PIU% !1110 5CZIX=M]0OH=2@D>SU2$;8[N$#<5SG8X/#H?0_@0
M>:V**/, &<#/6BBB@ J&[CGFM7CMK@6\K<"4IOV\\X![XSC/Y'I4U% &;I&A
M66BI-]F5WGN&WW%S,V^6=O5F[^PX Z  5I444!8**** "BBB@ HHHH YSQ9H
M>M^(-.N=.L-;M=-M+F$Q2EK S2\Y!PWFJ "#C[I/O7)^!?A;K7@"6X_LWQ7;
M3V]R5,T%QI1()'<$3 @X)_PKT^BB/NNZ"7O*S"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO''BZU\$^%[C6+A/-92$AA!QYDAZ#/IW/L#7*WG@[Q1XG\,Q:G)XTU:RUF:
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MAM85C&.^!R?Q.36C5M):)_U_70B+;U9Y!\2OBQX@\+6L7]G>&IK6*Y)6*^U
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M[PL@;6M6MK,L"RQNV78>H098_@*H:'\2?!WB.Z6UTO7K:6X8X6*0-$SGT4.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAM574JU-_+UT9E)<M*:_KH>L1_#GPIY$HO-'MM0N)\F>[O8Q--(QZG>W(_#
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M).<UH+\,/#%EX,;0?LTUQ:11RLIGF8DNPR7(&%W9 P<<8XKH/"?_ ")^B_\
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M7YHQ<P)*%SW&X'%>#_M(Q"36_#BQC=,\4J[0.3\RX_4FO?M,A>WTJSAD^_'
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M.0HQ@$$9 ]/>O;K3P#H$I>]UBQM]:U&X ::ZU"%92?9%;(11V _6O)?VCO\
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M>)? ;0$\0Z?K=K?3O_98EB,]I&2OV@X; =@<[/51U[\<5]#:G_R"KS_K@_\
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M[]9V%OJ7A6QM;M&>![:+<JNRYPH.,J0<>W>O'?VEO^//P[_UUF_DE>U:)_R
M-._Z]8O_ $$44U^Z:_O?H%3^)%_W?U/G;1](LM"_:<CT[3H1#:17#&.,=%W0
M%B![9)KW[Q'H6CZOI\TNI:58WLD,#^4]S;I(4X_A+ XZ#I7A_P#S=?\ ]M__
M &VKZ U/_D%7G_7!_P#T$U$_]UB_*7ZEK^._D> ?L^:!HVM6.N-JND6%^T<L
M00W5LDI0$-G&X'%>Z7?AK1KW2H]*FT^$:?']VUBS'$!@C&U< CD\'BO'/V:?
M^0?X@_ZZP_R:O>*WJ).R\D8T^K\V?-OP9LH=.^->N6-N"(;>.YBC!.2%650/
MT%>L?%CQE)X+\%RW5HP%_<N+>V)_A8@DM^ !_'%>7_"C_DO?B7_M[_\ 1PK2
M_:6BF.G^'YAGR%EF5O\ >(4C] :QFVZ-._5(VBE[6?E_D=W\*?"]KHW@^RU*
M2,2ZMJ40NKJ[E^:5R_(!8\X /\ZY/XX^#((-*3QEHT?V/5+&56GEMQL+J3@,
M<?Q XY],UZ/X!O4U#P!H-RA!#640..Q"@']0:K_$M4;X:>(@_ ^PR'IWQQ^M
M7B?=;:^SM\G_ )$4/>BK]=_F9_PV\3CX@> $FOSNN5S;7@C<H68=\J01D$'C
MWKQWQ;X>M]#^/^E66A(E@)Y()8SMWJCL2"V"?49QZUVO[.%M+'X0U2X=2(YK
MW"$]]J#/\ZQ/'O\ R<GX=^EK_P"AM522]O#S_P KF5W["?E?\SUB/X<^%/(E
M%YH]MJ%Q/DSW=[&)II&/4[VY'X8 [8KQ_P"$0D\.?&C7?#EM*_V']^FPG(_=
MM\A/N!D?C7T57SQX$_Y.4UW_ *Z7?\ZFG_%2\F:S7[IOLU^9UOQWTSQ-K&A:
M98:%97-W:R7!^UQVREF)XV;@/X<Y.>@P,UZ!I^AZ;8>$H-(N+*UCLDME2:%D
M'E_=^;.>.N>:Y[XE?$>+P+96\%M;"\UB].VUMR<*.<;F]LD<=_;K5?3?A[=:
M[%%?^/M2GU6Z;$G]G*YCLX#U"[%QO(]3Z=ZF*O&26S>K^6WG8<G:47U2T^_?
MR/._@5-]@^)'B32+.<2:?LD*;7W*VR4*K#UX/6O8OB'_ ,DY\1?]@^;_ -!-
M>._!V&*V^-?BB""-(H8UN42-% 55$P   Z"O8OB'_P DY\1?]@^;_P!!-*J[
MX>+_ +J*IJU:2_O'G_[.'_(DZG_V$#_Z+2O9:\:_9P_Y$G4_^P@?_1:5[+71
M5^+Y+\D8T]GZO\Q&570HZAE88((R"*^</CIH6CZ1XD\,Q:9I5C91S;_-2VMT
MC#_.GW@H&>IZU](5\_\ [0O_ "-/A3_@?_H:5BOXD/5%R^"7HSV?3_"GAS39
M5N+'0-*M9]A7S(+.-&P1R,@9P:\$\=:19_#SXU:1KB6D:Z3=RK<%-HV(<[9
M![9#?C7TDGW%^@KS?XX>&?[?^'T]U$FZZTQOM*8')4<./RY_"E*7))5.S_#J
M.,5.+@^J_$] O+.SU;3I;6ZACN+2XCVNCC<K*17SM\)I;+PA\9=6\/2-%*DK
M26MO/D'#*Q*C/J1D'WXKM_"/Q":3X+0WD;>=J\&-,BC8Y,DYPL?N>"I_ UQ7
MQ4\%2^!]/\,>(=-9OM=H5CNYP>7GR9 Y^K%_TJM*=:[VV^_;[E;[[$7=2GR]
M=_N_S9[WXHU>'0O#&HZE<*KI! S!#_&V,*OXD@?C6/\ #?PI!X4\'V<'V>..
M^G03W;JO+2-SC/H,XQ[5@WFM0?$&X\(Z=:'=:W2C5K]!VCC^ZA^LO'_ 37I;
M?=./2AIP4GUV^[_-_D._-;MO\W_DOS/!9/B#X6U;XG:G<>+[]4TO2'\G2[1X
M))8VD!(>4JJD%N.,^HQ6KXZ^('PO\7>%;S3YM6CEN1$QM7^PSAHY /EVL8^.
M>/3!KG?@/K$6G>./$.B7;A+B[8LFX_>>-FW+]<,3^%?1%2X7I17=)_/J_6_Z
M%\UJLK='^'^7_!/!OV=/$]Y=1ZCX=N96D@MD%Q;;B24!.&4>W(./K57]I3_C
M^\-_[D_\TKW?^T[?^V!I8+&Y\@W! '"IN"C/U/3Z&O"/VE/^/[PW_N3_ ,TJ
MW+FJ4WYK]14X\O,O7]/Z^9[W;(DFG0I(JLC1*"K#((Q7SGXKT>Q^&WQQTG5_
MLB+HUU*)U4* D1/RO@=MI(8?45]&V7_'C;_]<E_E7GWQM\+_ /"1> )[B&/=
M>::?M46!R5'WQ_WSS^ J9RY*GM.SU].I-*//2Y'U7XV1Z.K*Z!U(*D9!'0BN
M#\-V-GXA\>ZWXK:VB=;9AIME+M!SY?\ K''ON)7/HM<QX/\ B++<_!@RH_F:
MW:E=,A0G)DE;Y8C^1!/^Z:]0\.:-'X?\.V.E1DL+>(*SGJ[]68^Y))_&K<>6
M;?;;Y_\  _,E2YHI/KO\O^#^1Y_\:/&)T.STO0X[YK$:I-B[ND!+0VX(#E<9
M.3GMSP:?I?Q.^$^C:0FEV&I00V2KM,0T^?#>I;]WR3W)ZUQOQQO6T;XG^%=6
MD!,%NB28]=DN6_3%>^VEU!?6D-U;2+)!,@>-U.0RD9!J(*]-ONW?Y;?UZFD]
M)I>2_P""?**^*-*\,?&%=4\%W1;1IYHP\:QNB%'QO3:P!P#DCCCC%?6@.0".
M]4]4U*WTC3IKZZ+"&(#(49)).  .Y)(%7*:T@H]A/XW+O_5PKYM\27/]N_M-
M6-M*0T5I=00J#TPBAS_X\37TE7S-)NM?VI1OX+:B,?1HQC^=*'\>'S_(*G\&
M9],T444QGC7[1_\ R).F?]A ?^BWKT#X>?\ ).O#O_8/A_\ 017G_P"T?_R)
M.F?]A ?^BWKT#X>?\DZ\._\ 8/A_]!%%+X)_XE^0JGQ0]&=+116'XF\21>'K
M.,)"UWJ5TWE65E&?GGD_HHZD] *3=AG'?%NZN=9@L/ NDDMJ.KR!IB.D-NIR
MSMZ#('UP:[O0-%M?#N@V6D62X@M8A&I[L>Y/N3D_C65X3\+/H[76JZI*EWK^
MH$/=W('"CM$GHB]/?&373TTN56ZO5_Y?+\[OL3\3OT6W^?S_ "^85\W?%BZ?
MP_\ '?2-5A.QMEO*3Z@.5/Z#%?2-?,WQ\0W'Q0TJ!#EVM(5Q[F1Z4?XU/U*D
MDZ<[]CZ8!! (Z&EIL:E8D4]0H%.IL2U6I\_?M"^&=*T[2]-U:UMBE[/=M'+*
M9&8N"I;G)/0CCTS7H/@[P;I6J>%-#O\ 7;>+5I_L$(A2[C#PP)L'RI&<KGU8
MY)/?& .5_:2_Y%+2/^OX_P#HMJ]+\#_\B'H'_8/@_P#0!127[N7^+]!3^./H
MSP7XP:!9>!_'VA:IX=B33VG_ 'OEPKA$=&'(48P"",@>GO7MUIX!T"4O>ZQ8
MV^M:C< --=:A"LI/LBMD(H[ ?K7DO[1W_(?\,_\ 7.7_ -"2OH*'_41_[H_E
M13_A?-H)_P 3Y(^<IM/M_ O[1VGVFB*;>TNGC#0J?E"R##*/;(SCM7M_CCQ,
MGA#P?J&LE5:2%,0HW1I&.%'YFO&O'/\ R<MH7^]:_P S77?M"Q32?#B-X\^7
M'?1M)],,!^I%9-OZO'U:_&Q<4O;OT3_!C_@QHB7NA/XRU8?;-;U25W-S,-S(
M@; 5<_='!Z>P[58^,?@6SU_PK=ZQ:VZQZQIZ&>.>)</(J\E21R>,D>AJW\$K
MU+SX5Z6JD;K=I(6 [$.3_(BNWU14?2+U9,;# X;/IM-:8E<J=OLK3Y*Y-!WL
MWU>OWV/-/@UXOD\;^#[K2M8E::[LL12.)"KRQ,/E)((.>"":\Y\6^'K?0_C_
M *59:$B6 GD@EC.W>J.Q(+8)]1G'K6K^S5;2_P!HZ_= 'R1%%'N]6))_D*E\
M>_\ )R?AWZ6O_H;5I)+VU-]]_N9EM1J+M_P#UB/X<^%/(E%YH]MJ%Q/DSW=[
M&)II&/4[VY'X8 [8KQ_X1"3PY\:-=\.6TK_8?WZ;"<C]VWR$^X&1^-?15?/'
M@3_DY37?^NEW_.HI_P 5+R9K-?NF^S7YGIOQ2T+1[KP/KVIW&E6,U_%8OY=U
M);HTJ8!QAR,C'UKC/@7X8T#5_ +W.IZ'IE[.+R1?-N;2.1L +QE@3BO0_B7_
M ,DT\1_]>,G\JY']GK_DG$G_ %_2?R6E3WGZ+\V*I]CU?Y%SXYQQP_"6\BB1
M4C26!511@* XP .PJE\+?"-AK?P^T2\UY4U**.-A:VDR9@A&]LG8>&<_WCVX
M&.<W_CQ_R2J__P"N\/\ Z&*TO@__ ,DJT+_KDW_H;44_MOS7Y!/>"]3RCXX^
M'=.\(:WH&M^'[2'3II';<ELGEKO0J58*.!U.<5[CKFJ74'@.^U6S7==+ISW$
M0'][R\BO)/VEO^//P[_UUF_DE>TZ.BR>'M/1U#*UI&"",@C8*E)RHRCYO\BV
MU&K%^7ZGF7P(US0;KPM]BCFA77C+))>"0_OIR6)#Y/+#&/I76/X(L[3XBV/B
M?3;2*!F@EAO!& H<D#:^/7@@X]1Z5YWXR^ &^[DU3P=>"UG#>8+.5BJANO[M
MQROL#^8K.\ _$[Q/X<\50^$O&R7#K)(L"27(_?0L>%);^-3Z\^N:U34Y*VDN
MWRMH9R3A%WU7_!N?0U%%%26%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>PVJ0<G@<UZ)10NJ!ZV9Y!\.?"M]>?$+6O'EWITFFVEYN%E;3+MD8-C+LO\
M#G'YDU1^.TE_XCTRRT;1=!UN]EM[HRS2Q:;/Y:X4K@,4PV<]5R..M>VT5,HI
MJ,>B_0<79N75G$_##4Y)?!VF:7>:9JEA?65LL4L=Y8RPJ=O&5=E"G/IG/M7G
MWQ$\ ZYX>\;Q>//"-L]T1*)[FUB7+*W\1"CEE89SCD9/X>[T5<VY3YUHR8I*
M/(]4><:=\:_"EY;*DW]H0:J 0^F?8I7F#@<J-JD'\2/?%5/"'A+4]:\>W?Q
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M3:EX2\0165])/O(TV9FB5SD$@+SC SBOHO3M1@U2V^T6Z72)N*XN;66W;/\
MNR*IQ[XQ5NBFM(J/8'K)R[A7#?&+_DE.N_\ 7-/_ $8M=S7#?&+_ ))3KO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!2U.QGU"U$,&IW>G-G)EM1$7(QT_>(XQ]!G
MCK7G]C\$=%TW7!K=IX@\11:EYC2?:!<0EBS=2<Q8.<G.:]-HH6CNMP>JL]B&
MT@DMK6.&6ZFNG08,\P0._N0BJOY 5-110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7)^+/ D7C*"6TU'7]8BL)&5C9VS
M0)'D8[F(L>1GECS7644FD]QIM;'%>$OAO:^"OW>D:_K8M&D\R2UF>!XW/_?K
M(S_LD&NUHHJFV]R4DM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S]4T6RU<0
MM<QLL\#;X+B)MDD3>JL.GN.AZ$$5H#@ 9S[T44 %%%% !1110 4444 9T.B6
M<6J/J<BM<7QRJ33'<8D)^X@Z*/H,G')-:-%%'D 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5O-*R:,(MW<7_5_ZL4-7CU>2T_XDUS907(.<WEN\J,,=/E=2.<<\_2O =?\
MCCX_\-:U<Z3J>CZ'%=6[88>1,0P[,#YO((Y!KZ-KPSQW\/?^$Z\7^*C:MMU6
MQM[1[7+?+)E7W(?K@8/8CTK"3:EY:_A8V5K:^1U?PL^*<7CRUEM+](+;6H,L
MT,60DB?WD!)/'<9KT.Y6X>VD6TEBBN"I\MY8S(JGU*AE)'MD?6OA?3=1U/PO
MKT=Y:O)::A9R]",%6!P58?H17V)X!\;67CKPY%J-OMCN4PEU;YR8G_P/4&MV
ME*/-'^O/^OU,DW&7++^O(Y?5?$?Q(T_QQIWAR%/#=PE^CR1W9M9D"HGWMR^:
M>1QP">M>CZ<E^EDBZG/;3W?\;VT+1)] K,Q_'//M7+:Q_P E:\,?]>%[_P"T
MZZZYN(K2UEN9F"11(7=CV &2:S3M"[\_P95FYM+R_%&/XJ\7Z/X-TDZAK%SY
M:9Q'$O,DK>BKW_D.]>5:3\3/'?Q&U>6T\(:;9:98P_ZV[N@9"@/ )/3/<* >
MG7%>,>._&%YXU\3W&IW,C>0&*6L)Z11 \ #U/4^]?57PP\/1>&_A_I5JJ*LT
MT(N)V'5G<9.?H"!^%$(MQ<Y?=_F$Y6:A'[S.@\,?$B%%E?XB6\\H',$FBQ",
MGTW*0V/?%96I_%+6O SBW\<>'68/D07^DMOAF..FUR"I^IS[5ZK65XD\/V7B
M?0+O2-0C#P7"%<]T;LP]P>:4G)*Z*23>ID^ M>OO%7@6WUB5T2ZNFF:,O'N6
M,>8P0$ KD  #J"<=>]<5\2?'OCGX>?8I6/A^_MKHLJR"SFB96 !P5\X^O7-=
MA\,-(NM!\!6.EWL3QSVTDT;!U*YQ*V& /8C!'L:\\_:5_P"0+H/_ %\2?^@B
MBLU&2Y=KH*5VGS>?ZE?P5\6/B%X[U>73=+M/#$,T4)F9KJ.X5=H('&UV.>1V
MKM;J?XQV\#216O@RY8=(HC<!C]-S*/UKR?\ 9S_Y'R^_[![?^AI7T3?ZM]DU
MS2=-786O6EW!NH5$)R/QV_G6DTDHVZ_\'_(SC+65^G_ _P SS+P%\3O%VN_$
M%_#'B/2;"P>**1Y$CAD20,N,<LY&#GKCFO8JYJ_\-^;\0-(\1PQKNAMIK:X8
M8!*L 4]S@Y'XUTM2G>*OOK^?^17VGVT_+_,*YCQ;<>*M.TZ]U+0[G2'CMX3*
M+6[LY"S;1D_O%E [<#;^-=/69XD_Y%?5O^O.7_T UG5;4')=$:05Y),^=%_:
M-\8NP4:;H9).!^XE_P#CM>^Z1'XNEL1-JFH:*D\D&5BM]/EQ%(>F6,WS@=QA
M<^HKXEM_^/F+_?'\Z^^(?]1'_NC^5=%ER7\_T,;OGMY?J>)>/_B7\0_ &IQV
M]W8:#<VDX)M[N.VF57QU!'F\,/2CX=_':;Q!X@72O$L%C9_:,+;3VRLB[_[K
M;F;KV/K73_%#P[:>*]:\+:+>EUAN9;D;T."C"$E6'T(!Q7S)XI\,ZCX.\0SZ
M3J"E9H3NCD7A9%_A=3Z']*QIRL[2\_P_7^NYI-77N^7]>A]R5YQX_P#$'COP
MAIW]IV!T'4+0SK%Y;V<T<B;VPO/G$-R0">.O2LKX+_$W_A)]/&A:M,/[7M4_
M=R,>;F,=_P#>'?UZ^M=3\4?^1,_[?[3_ -'I5RC:2UW:^YM(A3O%OJD_P39M
M>'U\2?9O,\13Z6TK*"(;"WD01GOEFD;=^ %;-%%#=QI605Y-J/Q+UGQ+XS?P
MIX#AM2\!/VK4[H%HT"G#;0.HSQD]3T'>O1O$4EQ%X9U62US]H6TE,6.N[8<?
MK7R7\+O'2>!/%1OKJ%IK*YC\FY"<NHR"&'J01T[U$;2J<KVM_P ,.5U#F6_]
M7/HJ'0_B3IJ?:%\9:?J\HP3:7FEK C<<@21G(^N/\*S[+XG76H^/-(\*S:/>
M:5J/F2&_BFV/&RB)BNQ^K G!S@=/K7<Z#XCT?Q-IZWNCW\-W <9V-\R'T9>J
MGV-9>O>&OMWB[PYK]M$OVFPF=)GR 3 \;#OUPVW\S5ZJ:4MO^ R79Q?+N=17
M#>/?BEH?@2/R)R;S4V7='90M@X[%S_"/U] :UO'7BB/P?X/O]88!I8DVP(?X
MI&X4?3//T%?(VA6=WXX\>V=O?3O-<:E=@SRL>2"<L?R!J%><^2);:A'G9[CX
M=\1?%3XBJ;W37L/#ND$_N[AK<2,^,\*'SN]S@#CCO79Q:3\1-*A,B>)],UUQ
MD^1>:<+7=TX#QL<'ZJ>OY=E:6D%A9PVEK$L5O"@CCC48"J!@ 5-5NVT2%=ZR
M/*3\7I;KQ3I7A=]$OM*UB6]CCNTGV,B)U(5A][/3.!QR#7JU</XS\)KJ7BCP
MOXAMK<M=Z??HLS(N286SUQV4X/L":F^*'BYO!O@B[U" J+V4B"VSV=N_X $_
MA6;E:%WO=_I;^O4I1O.RVLOUN8?Q"^,^E>#9WTVQA&I:LOWXP^(X3Z.WK[#\
M<50\-#XK^,K"/5[GQ#9^'+29=T,,6G),[*>C%7R0/3YNG;U\#\#:5_PE'Q!T
MJQO&,RW-T'G+G)<#+-D^X!K[85510J@*JC  Z 5HH6CS2W9+E>7+'9'CWBC4
M/BE\/[,ZLVJV/B33(VS.7L5A>-?4JF./?)QWXKHOA[\6-(\=K]DV&QU9%W-:
MR-D..Y1NX]NH_6NZN[6&^LYK2XC62&9#&Z,,@J1@BOAZ[%UX4\7W"V<S1W.F
MWCK%(#SE&(!_2IA+W^26Q4HOEYH[GW%<K</;2+:2Q17!4^6\L9D53ZE0RDCV
MR/K7B_Q&^)GCGX>ZK;6DL?A^]AN8S)%,MI-&>#@@KYQQV[GK7J'@WQ%'XK\(
MZ=K* *UQ$#(HZ*XX8?F#7B7[2W_(5\/_ /7";_T):51.$DO.WYC@U*-S>\$_
M$'XE>/;.\N=)MO"D2VCA'6Y2X4L2,C&&([=\57O_ (V>*?!^MC3/&'A>U5QR
M7LY60.O9DW%@P_$?A3OV:O\ D":]_P!?,7_H)J/]I6" Z7H-P0/M FD0'')4
MJ"?U IU'R.-NMOQ)I^^G?I?\#UCPYXIT[QEH!U+0;I3N!3]]&289,='3(/'L
M>>QKSWXD^/?'/P\^Q2L?#]_;7195D%G-$RL #@KYQ]>N:XO]FZYNE\4:M:J6
M-J]H'D'8.& 4_7!:NA_:5_Y N@_]?$G_ *"**WN\KCUM^H4GS73Z7*_@KXL?
M$+QWJ\NFZ7:>&(9HH3,S74=PJ[00.-KL<\CM7:W4_P 8[>!I(K7P9<L.D41N
M Q^FYE'ZUY/^SG_R/E]_V#V_]#2OHF_U;[)KFDZ:NPM>M+N#=0J(3D?CM_.K
MFDE&W7_@_P"1,9:ROT_X'^9YEX"^)WB[7?B"_ACQ'I-A8/%%(\B1PR)(&7&.
M6<C!SUQS7L5<U?\ AOS?B!I'B.&-=T-M-;7## )5@"GN<'(_&NEJ4[Q5]]?S
M_P BOM/MI^7^8445YA\</&<WA?P@MG8R^7?:FS0JX.&2,#YV'OR!^-1.7*BX
MJ[,WQW\=K+0KV32O#ELFIZ@C;'F8GR4;T&.7.?3 ]ZO:+I/Q7URR2_U+Q=;:
M$9E#)9PZ7%.4&/XMV,'VR:\5^"NAPZY\2[$7"!X;16NF5NA*_=_\>(/X5]>U
MHH<L4WJV9\UY-+9'B?BCQ3\3/AHT-YJD]AXAT=VV-<?9A"RD] P3 4^AP1^-
M=[X$^(NC>/;%I+%F@O(AF>SE(WI[C^\ON/QQ6OXJT:'Q!X5U/2IU!2XMW49&
M=K8RI'N#@U\8>&O$%[X3\1VNK63E9K:3YESPZ]&4^Q%33E>3A+[QSBU'GC]Q
M]NZA'?R6I73KFVM[C(Q)<6[3)CO\JNA_6O"_&WQA\<^"?$T^BW-KX?N&15=)
M4MY@'5AP<&7@^U>YZ7J$&K:5::C;',%U"LR'V89%?+GQ_P#^2GR?]></]:F=
MXS2]?R*BU*-T>E^"_&OQ.\=:/+J>F0>$888YC"5N4N5;< #_  LPQR.]:NJ:
MA\9=.MFFATOPGJ&T9,=IY^[\ [KG\/2L[]G3_D0+S_L(/_Z E>C3:T4\8V>A
MH(R);*6ZD)^\NUT5<<]#N;MVK:I&TN5?UI<SA*Z;?]:V.,^$_P 0=<\;RZS#
MKEE:6DM@T:!((G1@3NR&#,>1M]J],KG-*\/_ -F>-M=U2*!8[?48+=BRD?-*
MN\-QUZ;/S^M='4MW2]"DFF_7_(Y7QWJ'B?1M!N-5\.C39OLD1DFMKN"1F=1R
M2K*ZXP,\$'/K7A0_:.\8$@?V=H7_ 'XF_P#CM?3S*KHR, 588(/<5\5?$3PT
M?"?CG4M+5<0"3S;?_KFW*_ET_"LT[3L]G_3-+7C?L?7VD?VY-HOF7][IKWLT
M8>)[:T=8H\KQD&0EQGT*Y]NM>3_$'XG>/_A_J\5I=6F@75M<*7M[E+:90X'4
M$>:<$<<9/45UOP8\3_\ "2?#ZU25]UWI_P#HLN3R0!\A_%<?D:I_'C1;?4_A
MQ/>2NB3Z?*DT3,<9R=I7\0?S JJ_N2NMOT_IHSH>]&SW_7^D8/PX^)_C/X@Z
MS<V"GP_8+;P^:SM9S2,PSCA?.'KZU[6@<1J'96? W,JX!/L,G'YU\7?#7Q)_
MPBOCS3-1=MMNTGDW'.!Y;\$GZ<'\*^T@0P!!!!Y!%:22Y4T1%OF:?]?TSS#Q
M+XG^(&B^,='T"R'AZ]_M7>8I6M)HS&%QN+#SCP >H/->E6BW2VD2WLL,MR%_
M>/#&40GV4LQ _$UQ7A]1XA^(^M^(&!-MIBC2K,GH6!W3,/Q(7\*L_%#Q<W@W
MP1=ZA 5%[*1!;9[.W?\   G\*RYN6FF^OZO1?=;[S5+FFTO3_/\ KR,/XA?&
M?2O!L[Z;8PC4M67[\8?$<)]';U]A^.*H>&A\5_&5A'J]SXAL_#EI,NZ&&+3D
MF=E/1BKY('I\W3MZ^!^!M*_X2CX@Z58WC&9;FZ#SESDN!EFR?< U]L*JHH50
M%51@ = *M0M'FENR'*\N6.R/'O%&H?%+X?V9U9M5L?$FF1MF<O8K"\:^I5,<
M>^3COQ71?#WXL:1X[7[)L-CJR+N:UD;(<=RC=Q[=1^M=U=VL-]9S6EQ&LD,R
M&-T89!4C!%?#UV+KPIXON%LYFCN=-O'6*0'G*,0#^E3"7O\ )+8J47R\T=S[
M@O$NWM)%L9H8;DCY))X3*B_50RD_]]"O$OB!\5?'/@'7TTRX@\/W:2Q":*9+
M69-RDD<KYIP<CU->K^#?$4?BOPCIVLH K7$0,BCHKCAA^8->!_M(?\CII?\
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M5MP33V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/XU?# ^'[V3Q'HT'_$JN'S<1(.+>0]Q_LD_D>/2LXR=*6FW]?@RY152-GO\
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MQ)_Z"*VO@?X2T*'P/IVO'3;>35)FD<W4J!G3#%1M)^[P.WJ:Q?VE?^0+H/\
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MK:1<LP<@_=VH<C@\]N,XR*XC0?%^J0_$S7-2O/"'B6'2=02**&;^RYF9/+!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !16?K.MZ;X>TR74=6O([6TC^])(>_H!U)]AS7G*?M">"FOOL
MY35$BSC[2ULOE_7 ;=_X[233=D#T5SU:BJFF:G8ZSI\-_IUU'<VLPW)+&<@_
MY]*MU35MQ)IZH****0PHHHH **** "BBH;NZALK.:ZN'"0PHTDC$X 4#)-)M
M)78TKZ(\?^,?Q)N?"WB/0=/TV=U>&5;R\5&(WQYP(SZ@C<<>PKU^QO(-1L+>
M]MG#P7$:RQL#U4C(KYUU[P?<>,_A[KGCZ:)_[2N;LW=LA'*VB97;_P!\\_\
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M7&EW[;--U.3[RO\ \\9CW/HW?OSDU9^%FM2:]\-]&O)G+S+%Y,C'J2A*Y/X
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M>/\ PO\ $-?#</BQY()FB\J:2PMBP5\#D! "0<^F:^C*^8_B]_R7/3_I:?\
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M):W-E#%&+.)65(R&;) )/)R.<\C':L/X]'Q)I6D6M['XEN%LKBY:%K.W3R5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MME;/<I:%Q,T8W@KR/FZ\5Y5\4+%]5_: T6RM5+2NMMNQVP[,3^"\U['\2_\
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M]#@D9]S5)VDI=O\ @_Y@U=-=R2O)/#G@+Q%:_&[5?$^JK%)I[B0V\YD5BP;
M50N<KM7CI]*]*M]:M+K6KS2H=[S6<:/.X V(7SA,Y^]@9QCH1ZUY+#XHU?XK
M^.;W0-+U";2O#=@";F6V;;/<@-C ?^$$^G;KGI4Q^-..]G]W<<K<C3VNOOW2
M+?Q\U?0)O!,VF2:A:-JT<\<D-LKAI%.<$D#[ORENM=+\')Y)_A3HC2L6*HZ
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MC)7/H0"*Y3X#>)W\2>%KWP_JNVZ-AM""9=P:%NBG/7!'ZBO6M4*+I%ZTGW!
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M[@3B $ R+M((&>_.:I_#O5_'.IZ/IND7OAZ71K>Q1(YM1NLK),B?PI$Z\$@
M%CD=2.<5ZK11'W;^>OS"2YK>1X_\9-$\6>-;*UTG1?#-PT%M<&5[F:ZMT$A
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MBDU>*BM$O\[_ (@M).3U;.4^'5]XFU'P?;W'BRV,&IEF&&C$;LG9F0?=/7C
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M4]_X^UG5]-N--TOP%XCCU*>-H@U_:K#;H3P29"V"!G/3FO2:*GE3CR/;^O\
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M'E@#L<DGTQSWM%%7*7,[DQCRJP5Y%X]^$%Q?ZZOBGP=>+IVM+()7C)VI(_\
M>4C[K'N",'VYSZ[14-:IK=%WTMT9Y9I7Q%\8:9%':^*_ &M2W"C!N=)@\]7Q
MW*@X'_?6#VKHK7Q=KFM*JZ3X.U.TW#F?6MMJB<XR5!9V[\8'U&<UV-%5ON3:
MVQEZ/I!T[SKBYN&N]1N2#<7++MSCHJK_  H,G ]R3DDD^9_&31/%GC6RM=)T
M7PS<-!;7!E>YFNK=!(0"HV#S,XY)Y /M7L%%3)<UKE1=CC/ATVO6/AK3M%US
MP]<V$UE;B+[1]H@DB<+P/N.6!(_V<<=:Y+XR:)XL\:V5KI.B^&;AH+:X,KW,
MUU;H)" 5&P>9G')/(!]J]@HIS]]W?J*'N*R..^'(URQ\+6&C:YH-QI\]C (O
M.-Q#+'(%X&-CE@<>HQ[UYY\7/@]?:OJLGB3PQ&)+J7#75H&"LS#^-">,^H_*
MO=**)^_+FZA#W5R]#YBT:^^.3%='M4UB-%^3S+RT0!1T_P!;(O/X,?45[=X,
M\+W'@_0+F6[DGU;6[HFXO9E<%YY,<(I<@8 X&2!]*Z^BG?3S[D\NOEV/G[Q3
MX7^(&M?%*V\6VGA.5+>TDA,4,M];!V1#GG$A )Y]:]I_MC4?[)^U_P#"-:E]
MIW;?L7G6WF=/O;O-V;>WWL^U;%%):0Y$4]9<Q\_>&O"WC[1_BK<^+KCPE(UO
M=2S-)!%?6Q=5?/3,F"1QZ5Z;\1O#]]XS^'-YI]I \%]*J31V\S+NW*P;82I*
MYXQP2,]Z[2BI<4X*'1#3M-S[GB/PROOB!::%'X2;PQ-8K;NZ_P!K7F46%"Q)
MVHRXD(R<8..F>*]M4%5 +%B!@D]32T5HY7W(4;;!1114E!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %5K?3K.TNKBYM[=(I;DAIF08\PCN1T)]^O3T
MJS10 4444 %%%% !1110!#=VD-]:O;7"EX7P&4,5R,YP<'IZCOTIT,$5M D,
M$2111@*B(H55 [ #H*DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
MO7O GA_Q/(S:S;W=VK$-Y3:A<+$"!C(C5PH_ 5TE%*R87.6T/X=>&/#5P)]&
ML[JR;<&*Q:A<;'(_O(9-K?0@UU-%%5<5D%%%%(84444 %%%% !1110 4444
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MUO79;=REP='LC.D3>C-D#/TS2OK8#MJYSQ#I6I1^9J_AV;R]4C&Y[:0_N;P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPZ5X L;LC?>ZFOVRZG;EY&?D9/4X!_G67\5_A9=^/+K3K_2[RWM;VV!C<SY
M9,YR"H)R#G ]^U6_@KXCMM<^'=C;)(/M6G+]FFCSR /NGZ$8_(UZ%--';PR3
M2NJ1QJ6=F. H'))K:LESWZ+5>G3\#*DWR^;W*,&DP-I5E::C'#?/;1JOF31A
MLL%VE@#G!//YUX#\'[>*T^.7B"VMT$<,2W2(B]%42J !7T'I5^-5TJVOUB:)
M+B,2(K]=IY&?0XP<5X#\*/\ DO?B7_M[_P#1PHA?V[OVD.22HV7='T57SYX
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M[B5_*M9)XF(Y1T4L&'ITKAOV<]0BF\$WUB&'G6]X69<\[648/Z'\J])\7_\
M(EZY_P!>$_\ Z :K$I1@TMDM/NO^9.'=YW>[>OWV_(\K_9L_Y%K6O^OM/_0*
M]NKQ']FS_D6M:_Z^T_\ 0*]NK:INO1?D94]GZO\ ,AN;6WO(O*NK>*>,$-LE
M0,,CH<&OF_3="M9/VD=0TJ+=:VC22EDMCLRICW%<CH#G!QCJ:^EJ^?=(_P"3
MJK__ 'I/_1 K**7MH^C_ "+J?PG\OS/;YM TI] ET8:?;)I[Q&/[.L0" 8QT
MKP_]G*62#6O$>GAR8%5& )XR&*YQ]*^@G^XWTKYZ_9Y_Y&[Q-_US'_HPTZ;_
M 'LO\+_,=1)4U_B1V7[02*WPT+%02MY%@D=.M=#\)_\ DEGA_P#Z]O\ V8U@
M?M  GX9.0#@7D6?;K6_\)_\ DEGA_P#Z]O\ V8U-+:IZK\@J?%#T?Z'F/[2J
M+YWAR3:-Y$XW8YQ\G%>W6UA9W^CV"WEI!<*D*%1-&'VG;C(STX)KQ/\ :6^]
MX;_[;_\ LE>Z:9_R";/_ *X)_P"@BG!?NG_B?Y#J?Q(_X?U/G#X4:'97WQ8\
M1:;*K"PC6=6MT.U9$68 (V.J],CH<8.1D5[]XCT'3-3\)7VE7%G#]D^SN$C"
M ",@'!4=B#R,5XE\&_\ DM7BCZ7/_H\5[_J?_(*O/^N#_P#H)J*G^[1_P_HQ
MP_CR]3Y^_9]TFTUN#58=25[FVLYHIXK60YA\PAAO*_Q$;1C/ ],UZ?\ %[2+
M&_\ AEJ[7%M&SVD'G0-MYC92/NGMZ5Y[^S1]WQ%]8/\ V>O4/BC_ ,DP\0_]
M>;?TK3%?!\D10^-^K.<^ -U+<?#...5RP@NY8TR<X7@X_,FN%^.L0G^*/AN%
MF=0\,2ED;:PS,>A[&NS_ &>O^2<2?]?TG\EKD/C?_P E8\+_ /7.'_T<:N>M
M>%^Z_(B#M0J>DOS9[OIVB:9I.G#3[*RABM<89 N=^>I;/WB>Y.2:^<_B=HJ_
M##XD:7K_ (>7[+!<'SUA3A593AT _ND$<>YKZ<KP/]HS-[J'A?3($WW4K2[5
M'4[BB@?B:RN_:0DM[I&R4>247M9GHWQ'\62>'OAM=ZS9.4N)XD2V;NK28P?P
M!)_"N0\!>-+;P[X/L+2#P/XQN))(Q-<74&E;UN)&Y9PV_P"8'/!],59^..G2
MQ_"&WC'S?8IK?S"!V *9_,BMWX/>)K7Q#\/]/B21?M>GQBVN(\\KMX4X]" /
MUJXI7J6Z-?<9W?+3YNJ?WZ?\$\L^++WOCFXTV^T7P/XKM=0MMRRS7&E.A9."
MN"I;)!S^=>MZ59MXA^&-O+XETO.I-ISQ3B\M\2@@$$D,,C. :[621(HVDD8*
MB LS,<  =36-;:M'KGA&34X8RD-Q!(T8)SN3Y@K?B #^-8U+*C.*\W^#-%K4
MBWZ?D>)?LYZ5'>R:K=W#EX[62-HH"!M$I##S/J!D#TR:]KL?!OAW3->GURRT
MBW@U*<%9)T!&<]<#H">Y !/>O)/V:?\ D'^(/^NL/\FKWBNF>C5NQC3U3OW"
MN3^)/BAO"'@;4-4A(%UM$5OG_GHW /X<G\*ZRO*OV@K*:Z^&_G1!BMM>1RR
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M+]-N]-U@^9J.GA?WY&#*AR/F']X$8/K4QM)MQT=M5Y"=XVYMK[^9ZK4%[/\
M9;"XN#_RRB9_R&:GJKJ<+7&DWD*_>D@=1]2I%956U3DUV?Y,UA;F5SY\_9VW
M7WC'7]1F^:5K<$L1W>3)Y_"OHVOG']FU_+\1Z[;MPQMD.WZ/C^M?1U;R22BE
MV7ZF4;\TK[W_ ,CY_P#VA?\ D:?"G_ __0TKWY/N+]!7@/[0O_(T^%/^!_\
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M_P#R3F'_ *_X_P#T%ZBHG&"3WNF_5M?EHODRZ3YIM]-5\DG^MV:_PBT&RM/
M^D:J5,]_<6JYN)<,R(,XC3^ZH]!U)).:X_X_^"[(:-'XKL84M[R"54N6C7;Y
MJL<!CC^(''/H?I7HGPN.?ACX>_Z]%_F:R_C;+'%\*-6#_P 9B5?KYBUIB=)-
MKH_U1&&UBD^O_!+WPUUK_A+_ (;:=<Z@JW$C1M;W(E 82%3M.0>N1@_C7D'Q
M,L+2P^/?A\6=M% LKVCNL:A06\TC.![ ?E7I_P $+":Q^%NF^<I4SO).H/\
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MKCH3SR.><]:^B8="TJWT?^R8M.MET_9L-MY0*$>X[_C7@^NG'[4]C_UU@_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!P?Q1MO$D^G:-+X5MGGU2
MVU%9D ("A1&^=Q8@!2#CDC.<=35>V^)6L10I#JGP]\3)J! RMG;": G_ *Z9
M  SZ]*]$HI+16!ZV9YEX \%:I%XPU;QOX@@CL[[4<B"Q1]Q@0X^\1QNP /SK
MSWX^PRW'Q)T"&"3RY9+:-4<_PL96 /YU]'U\Z_'*6./XK>&F9U 2*$MS]T><
M>M"M[2G'HFD#TIU)=;,]'B\>>(-'@2QUWP1KMUJ*#9Y^E0"XMYB.-V[(V ]<
M$<5G:#X/UKQ1XZ7QMXOM5LEMAMTW2]^\Q =&<CC/)./7TQ7J@.1D=**:WYGO
M_70EJZY5M_7X&'XN\+V7C#PW=:-?95)AE)%',;C[K#Z&OFS_ (0[XH?#?5I6
MT2#4'1FP)].C,\<PZ@L@!]/XAQ^//U?14I6ES(MNZLSP_P )>&/B'XTO[:[\
M?WMQ%H]NZRK8R(D1N&'*AD0# !Z[N>V*]AUG2+/7=&N]*OH]]K=1&-P." >X
M]".HJ_152M)<MM"8W3YKZGRK?_#OXA_#G7I+OPVE]<PYQ'=:>OF%USP'C&3]
M00179^&_#_Q/\=31#QIJ-U9Z""&FMGC2"2X'78410<'ONKW>BB+MOK8)*^VA
M1U"YGTS3PUCI5Q?LN$2WMGB0@8XYD90!QCKGVKPOP1X4\?>&OB/=>)KWPG))
M;WC3>=%#?6VY1(V[Y<R '!QU(KZ"HH6DN;J-I./+T,O4M3O[.QCFL]!O;Z>1
M<_9XY8$,9QT<O(![?+NKPWPCX5^(N@_$J?Q5>>%&ECNY)3<117UON"R'/RYD
MYP<=?2OH:BA:2YD#UCRLHVE_<W%A)<RZ3>VLJ9Q:S/"9'P.,%)&3GH,L/?%>
M%^.?"GCWQ-\1K3Q+8^$Y8H+/R1#'->VP=@C;OFQ(0,DGH37T%10M)*2Z!O%Q
M?4S[&:;5M+8:CI,]BT@*26UR\;D@CGF-F!')'4'V%?./BSX1>*_!WB%M6\(+
M=7-HK&2![-CY\'?:5'+>G&<]Z^GJ*37O<RT8+;E>J/G30X?C3XQ9=.U"^U#3
M--;Y)[BYMDMG"]\8578D'_$U[M8>'M-T_P -1:!% &T](/(,;<[U(P<^YR2?
MK6K15.S5K;[B2:=[GS?<>!O&_P *?%KZOX2M9M5TQSCRXD,C-&3_ *N1!\Q(
M_O#TSQR*[BXUSQYXU\*ZC WA:7P];&TD\R25S)/<':?W<<14%2QXR0>#QS7K
M%%0U>'(]?Z_$I:2YEH>&_!;PQX[\-P70GTZTLM/O&61OMQ;SE(&,A%YZ'HV.
ME>Y445I*5R(QL5K^YFM+1YH+&>]D7&(+=HP[<]B[*OYFO!]/\+_$&U^+LGC2
M3PG(8)9W9K=;^WWB-EVXSYF,@8/X5] T5*TES=2I:Q<68FH:OJD.DI/9^&=0
MN;N56Q;&:W0Q'MO8RXP?]DM7CWPM\+>.? _B2_OM1\*3S6M['M<6]Y;%T;=D
M$!I0".O>O?**(Z2YOD#UCROU.6^('A=_&7@B^TB)A%<R*LD)<\"12" <>N,?
MC7E_@'7_ (B^$]/3PI+X#N[[R&(@N'<PQQ@G/,FTHP!/8BO>:*25FWT8/5)=
M4?/_ ,6O!/C+Q%-H3B&74]2E\XRQVJ[;:T'R;4!; '?+,<MCL!@>I:1<>+]*
M\.0?VMI-O?WB1)$MMILJAL@'YG>5U4#@<+G!/>NNHIK2+BNK!ZM-]%8^?_ '
MA7QYX5^(%[XAOO"DLEO?"42QP7ML67>X;C,@!P1ZBO7O$6I:PFANFE^&[R]N
M[FW8"/S[>-86(QB0M)[_ ,.X<=:Z*BE)*4%#I:WR!:2<NIX7\(O#?C3P!=:B
MNI^$[F:VO0GSV]Y;%D*Y[&4 CYO6N[^)0U_5?"^H:%HGARYO9;R$1_:&N((X
ME!Z_>D#$C_=Q[UW-%.?OJS%%<KNCR;X.Z3XL\'Z5)H>N>&YXX)+@RQW45U;N
MJ9 !# 2;L<=@>O2H_BY\.=>\2ZSIWB+0'@FNK"-5^R2G:6*L6!#$X/)Z''UK
MUVBB3<FI=4$4DFNC_4\VTWXE:\8!;:I\/?$:ZH!@_9;8-;LV,Y\QB H_/'3F
ME\.>"-4U3Q@?&OC%8DU!5"V.G1.'2S7MENC-R>G&3GZ>D44[Z\W45M.7H4M7
MTJTUS2+K3+Z/S+6ZC,<B^Q]/>OF+5/AKX_\ A[KTEYX;6^N8!D176G@N[*3]
MUXQDY]1@CO7U5146M+F6Y=[JS/G_ ,/Z-\5O'\D=MXLO[VPT$G-PDD*6TDRY
MY3:JJW./XN,>M>N^(Y=1TSP^UAX?\/SW\K6[0PK%-#%'%\NU=Q=P<?0'IVKH
MZ*<TI1Y>C)CI+F/"/A)X;\<_#^]OUU'PG<7%G>*F3;WML71ES@X,@!!R>XKW
M922H)!!(Z'M2T5;E?<2C;8*J:IIMKK&EW.G7L0DM;F,Q2(>X(JW14-)JS+3L
M[H\&T/PYXR^#WB*\?3M+N/$'ANZ.62UYF7'0[.N\9QP""/3MUNL:_P")O&^C
M3:/X>\,:KI(NU,-Q?ZU&+<0H>&VH"68D' KTRBBUURRU_KJ+9WCH87@_PK8^
M#?#EOH]CEDCRTDK?>D<]6/\ GIBN1^*L/BOQ)X;NO#VA>&+F59I%$EW+=6Z(
M44AOD'F;CD@=0*]+HHFN?<(>YL>4_"RV\7>#O#(T36/"5ZZI,SQ36UU:L &.
M2&!E'0YZ9KU:BBKE*^K)C&VP4445)1XW\1/A=)XC^)VA:I!;LUC=,%U)E'""
M/D$_[P^7\!7L:JJ(J* %48 '84M%$?=CRK;7\0>LN9^AC>);W4[32Y4TG1;C
M4[J6-U18Y8HU1L<;S(Z\<]@>E>/_  C\+>-O 6KWSZGX5GEM+U%5F@O+8LC*
M3@X,@R.3W_.O>:*(^[)R[Z?()>\K'E_QK\":AXR\/V<^DQB6^L'9A 2 9$8#
M(!/?@5F^!?%'Q(N-'MM"E\'&">V00C4]19X(U4< F,KER!_=//M7L5%**Y;K
MHPEK9]4?.FI>&/&GA[XW0Z[;:3=Z_O<2"X"B*.3,>U@S ;8\9.,]@.M>RZA>
M>([3PX^-';4]5N$DQ%:2Q1Q0$CY59I'4D#/W@"3@\#@5TU%)J]/V;V_1A]OG
M_K0\%^$OACQOX U2_?4?"=Q/:WL:AC;WEL71E)(X,@!')[UV7Q$'B^#Q+X=U
M7PGIDE[+:Q7!NH2RJC1GR\HQ) R<< $G(R <5Z115MMV?;_@_P"8DDK^?]?H
M>>?\+*U5HC;CX>^*!J>,!#;#[/NQ_P ]LXQ[XI/A;X#O/"D6IZIJ[1?VMJLW
MFRQ0G*0KDD+GH3ECTKT2BDM&WU>@-7LN@4444#/ O#NG'P)^T3<V,FY+/5XY
M&MF/1MYW@?@RE?RKWVN0\?>#3XJTZWN+&5;;6].D%Q87)_A<<[6_V3@?I6EX
M8\1#7+-H[J!K/5K;"7ME)PT3^H]5/4,.#2A\"AUC^73[MG\NXI?&Y=_S_P"#
MNOF><_';P7K7B"#2M7T2VDNY;#>LD$0R^#@AE'4X*]!SS74>#-<\8^)%M9M7
MT)M!M+=?WOFMNENVQC 1E!C7/)[\  ]:[NBG'W4UYW"2YFG\@KPSXR>!8==\
M>>&GM'5;O5)/LUP@/S%$P3)^"Y!_"NLN?CAX+LM?NM)N[B\A:V=HWN3;EHBP
M."!MRW7_ &<4_P 'M)XR\7W7C:2"6+3(H/L>D+,I4NF<R2X[;CP/84HKFE&2
MV6O]>N@Y-Q3CU>G]>FYWUI:PV5G!:6Z!(88UC11V4# %>6?M#_\ ).8?^O\
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M7WBCQ%8:KJEHUEINF.9;.TE(,LLI&!)( 2% 'W5SGGG'2NOJK^ZK_P!=OU_
M2^)OI_7_   KYW\5>$_%_@CXIR>+_#FE3:G:W$S3;+>(R'Y_OHRKR.IP<>E?
M1%%3:TE);HO>+B]F>8ZB/'/CSPAJ4,^E1^'()K614MFE$UQ<MCA22H$:GH<C
M=].M<U\%K#QKHUA>:-+H+Z?:O=><]]>@J4& &5(R/G) X;.!G//2O<Z*J/NR
M;74AIN*3>QXQ\8M!\8>.8K+3M'\,7(MK29Y&GGN[9?,.-H*KYA.,9/.#ST%=
MUX*NM=M?"]I8:SX<O+6[L;18RPGMY$G*C "D29!./X@![UUM%3'W8M+KK\RG
MJT^QX#\1_"WCOQAXUL=:T[PG+!!8HBQ+/>VP=RKELD"0@=?4U[=I%]>7]D);
M[2;G3)P<-#/)$^3CJ#&[#'UP?:M"BG'W8\H/67-\@KC_ (B_VY>^%]0T;1-!
MN-0GO;=HO.$\,<48;@YWN&SCG@8]Z["BIE'F5F-.SN>/?!O0_%O@JUN])UKP
MS<+;W,XE2YBN[=Q&< '<OF9QP#QD^U:7Q>T_Q/XI\/OX?T+PY<SHTZ/)=O<V
M\<;*O/R@R;CSZ@=.]>GT54_?M?\ JPH^[>QY[\*X/$F@^%[/P_KOAVYMFMMX
M6Z6Y@DC*DEAD+)N!YQP#^%<C\7O#OC/Q]+IT.E^%+F*WLBY,EQ=VRL[-CH!*
M>./UKW"BB?ON["'N*R.#9M=O_A=J6FZAX?N[+48]*: )YD4JS/Y97Y/+=CV'
M! Z]ZQO#_C;QEX?TF"Q\7>"-;NIX5$:W6EQI<F0 <%E5L XZG/7TKU6BFVVV
M^_\ P?\ ,2245'M_P/\ (\BG\.:O\2?'>D>(-2TB?1M$TK#0Q7H"W-PV0PR@
M/R#('4]CZ\>E>(M'C\0>'-1TB5MBWEN\.[^Z2.#^!K3HJ6DX<G37\1JZES=?
M\CYY\#W7Q"^&4]UX=;P7=:Q:R3&2)X2RQANF1*%9<$ '!P:UOBIX:\9^)O"=
ME-=6KS:A)>H(]+T_+Q6R;&R7;^)LX!8X4=!UR?<**)>\ES;Z?@$?=;<?ZN<)
M\.[#Q?H?A.SL==M;)4L[<I'!;OOG?'*J22$!ZCJ0>.17G/CGPIX]\2_$:T\2
MV/A.2."R\GR8YKVV#N$;=\V)"!DD^M?0-%4VW-3ZHE12@X=&8FVX\2^'+VSU
M+2KG2VN87@>*=XI#\RX)!C=@1SWP>.E>$^#+7X@_"KQ#>Z=%X4NM8L[HC/D!
MA&Q&=KB4 A>.H:OI&BDM)<R]"GK'E9X?\5O#?CCQ5X-@OKFU7SH;@2+H]@/.
M,:%2"S/C,C^R@  G@]:[/X9-XH;PUIEOK.EKI5M96P@6.1BTUP0  Q! \L =
MCDD^F.>]HHC[J:77435[7Z'@'C#P]XK\*?&0>,M%T6YU>UG<-LMU+'E-C(VT
M$KTR&QCI7KOA]]<UFRGNO$5C'81W481-+#B7RUYR7? RQSC'0 #OFNBHI))0
MY'JO\QO67,M#YA\6?"+Q7X.\0MJWA!;JYM%8R0/9L?/@[[2HY;TXSGO6GH</
MQI\8LNG:A?:AIFFM\D]Q<VR6SA>^,*KL2#_B:^BZ*(JRL]5YA+5W6C*&C:/9
MZ%HMKI-E'MM;:,1J#R3ZD^I/)/UKP?Q7\,O$_@KQ?_PE/@2)[B#>9?L\(W/%
MG[R;/XT/H.>WH:^AZ*'=RYT]022CRVT/+]$\7?$#Q9;BS/A!] +#;/J5VS#8
M.YCA902WIDD9ZUQ'PD\(^/=!\17NHPZ7#;6=R&BD?5"T;, V0RH/FSQW !S7
MT/15*RES+M8EJ\>5]QL8<1J)"K/@;BHP">^!SBG444BCQ[1-9\<^$M8UH7?A
M/4-3\/SZA<36S6VTSQ@R'.V/.2IZ@$#.<@D&G>+I]>^*FDQ^'M+\,:II%G),
MKW5[K4 @V!3G")DEC_\ JKU^BE962EK:WX=_N!MW;6E_U.3U&VO_  WX,AT3
MP[HESJDL=F;:$K-%&J$+@%S(X/.<\ ].U><?"'PWXT\ W6H1:IX5N9;6]V'?
M;WEL6C9<\E3*,CGZ\=Z]SHJDVI.;W8G%<JCV//OBC#XAUWPM?^']$\-W5V]R
M$!NFN+>.(*"&. T@8GC'*BJ'P@T[Q1X5T%= USPY<0()WDCNX[FW=%##.& D
MW=1V!Z]J]0HI1]V_F.7O6\CQ_P",FB>+/&ME:Z3HOAFX:"VN#*]S-=6Z"0@%
M1L'F9QR3R ?:NO\ AR-<L?"UAHVN:#<:?/8P"+SC<0RQR!>!C8Y8''J,>]=C
M11'W4UWU"7O-/L?,WCN#4;G]HR./2)8XM0WP-;M+]W>(P0#['&/QKUAOB-K-
MNGV6Y^'WB,ZH!C;!"LEL6_Z[ XQ^%>:Z]-&G[4MDS.H G@4G/0F(#'ZBOHNI
MIK]S'Y_F$_XTO1?D>:>!? ^J#Q/>>-_%@C&MW8Q!:QMN6T3&,9Z$XP./?UJC
M^T/_ ,DYA_Z_X_\ T%Z]9KR7]HAE'PZ@!(!-_'@9Z_*]35^%);*WYETE[S;W
M=_R91^'?B/Q%X5\":7'?^'-1UG2I8O,M+G24$TL:L3^[>/(/!SR.,&K.MZ7X
MC^+6H65I=Z3>:!X6MI!-*+W"7%RW8; ?EXSUZ9SSTKK_ (5R))\+_#Y1@P%J
M%./4$@UV%;U%^\=];/\ KU.>GK35M+_U\B*VMH;.TBM;>-8X(4$<:#HJ@8 K
MYY^(_P &M:LO$$FO^#XGFBED\XP0/LEMY"<DIR,C//'(^E?1=%9M7ES7U-E9
M+EMH?->B7?QRUUETQ9=3LX#A7N+VT2#8/7>R!S^!)KV_0=#'@GPG'9V5M=:I
M<H?,F,;H);B5C\SDR,HZ^K=!WKI:*IO30A+6Y\]V_A;XB0?%M_&H\),8GN&=
MK87]ON\LKLQG?UQS]:][L+F:[LTFGL9[&1LY@G:-G7ZE&9?R-6:*2TBH]$-J
M\G+N%%%% RIJFGP:MI5WIUT@>"YB:*13W##%>6_!;X>7?A1]6O\ 58G6[,[V
MMN'7'[I3RXSV8@?4 5Z[11'W6Y+JK!+WDD^]SD/B;X8_X2SP'J.GQQ[[I$\^
MV &3YB<@#Z\C\:B^%?A=O"?@&PLYXC'>3#[1<@C!#MV/N!@?A7:441]V]NMO
MP_K\ >MK]+C)G:*&21(GE95)$:$!G/H,D#)]R!7@'CGPIX]\3?$:T\2V/A.6
M*"S\D0QS7ML'8(V[YL2$#))Z$U]!44EI)2[ ]8N/<I:7>75]9+->:9<:=-G#
M03O&Y'N#&S C\0?85X':Z/XS^&_Q7U+4M.\-76M66H/+L\C(1E=MPW. 0A!_
MO#UKZ)HI[3YEZ"M>/*SC+R\\7Q^&+EGT-[[5;Y'\NTMIX5AL@5 56=V4MZD@
M'G(X&*\_^$/AOQIX!NM0BU3PK<RVM[L.^WO+8M&RYY*F49'/UX[U[G11'W9.
M2ZZ?(&KQ2?J>??%&'Q#KOA:_\/Z)X;NKM[D(#=-<6\<04$,<!I Q/&.5%4/A
M!IWBCPKH*Z!KGARX@03O)'=QW-NZ*&&<,!)NZCL#U[5ZA11'W;^8Y>];R"D(
M!!!&0>HI:* /GCQ7\,O$_@KQ?_PE/@2)[B#>9?L\(W/%G[R;/XT/H.>WH:[?
M1/%WQ \66XLSX0?0"PVSZE=LPV#N8X64$MZ9)&>M>H44DO=Y'J@EJ^9:,^>/
MA)X1\>Z#XBO=1ATN&VL[D-%(^J%HV8!LAE0?-GCN #FM_P"+VA>,_'%I8:9I
MGAB8PVDK227,MU;H)6QM!1?-)"]3SSR.*]HHHDN9)/H"TDY=SC_A_-X@M_#U
MAI&O>'KFQGL[=8C<_:()8I-H 'W7+ D?[...M=A17.^,O&FD^!M'74M6\]HW
MD$4<<"!G=L$X&2!T!ZD54YW?,Q0C961HZ_I%KKV@7VEWH!M[F%HW/]WC@_@>
M?PKRCX >$ETO3M3UR4I(]Q,UM;RKT:)#@L/8M_Z#5_5?BMIGC#13H?@YKJ?6
M]37R%1H&3[*K<-([=.!GH3S7I.A:1;Z!H5EI5J,0VD*Q+[X')_$\THIQ<I=]
M/\_\A2:DE'Y_Y?CK\C0HHHH*(+RXEM;22:&TFNY%'$$!0._T+LJ_F17@;>%/
MB!_PM_\ X38>$G\C[3O^S_;[<-Y>W9U\S&<<_6OH.BA:24^J!ZQ<>YE7MA!X
MH\-SV&J6$UO#>1&.6WF9"Z9]T9ESW&":^:K_ .'?Q#^'.O27?AM+ZYASB.ZT
M]?,+KG@/&,GZ@@BOJJBE:TN9:#WCRO4\(\-^'_B?XZFB'C34;JST$$--;/&D
M$EP.NPHB@X/?=7N3VT#VC6K1*8&3RS'CC;C&,>F*EHJG9JUM"4FG>^I\P^+/
MA%XK\'>(6U;P@MU<VBL9('LV/GP=]I4<MZ<9SWK3T.'XT^,673M0OM0TS36^
M2>XN;9+9PO?&%5V)!_Q-?1=%3%65GJO,<M7=:,R+33%\-^%1I^BVP<V=L5MH
MF;'F. <9/N>I]Z\A\)>/OB/:>*;.+QCILR:7J-Y]C0S6@@,4AR5V8 ++QU.>
M.]>XSS"WMY)F61Q&I8K&A9C@9P .2?85RG]E7WBCQ%8:KJEHUEINF.9;.TE(
M,LLI&!)( 2% 'W5SGGG'2FF_:<SU[_UW)DK4^5?+^OS.OHHHH*/G?Q5X3\7^
M"/BG)XO\.:5-J=K<3--LMXC(?G^^C*O(ZG!QZ5W6HCQSX\\(:E#/I4?AR":U
MD5+9I1-<7+8X4DJ!&IZ'(W?3K7IU%3R_N_9O;H._O\_7KYGAGP6L/&NC6%YH
MTN@OI]J]UYSWUZ"I08 94C(^<D#ALX&<\]*N?&+0?&'CF*RT[1_#%R+:TF>1
MIY[NV7S#C:"J^83C&3S@\]!7L]%5/W[7Z?H3%<M[=3DO!5UKMKX7M+#6?#EY
M:W=C:+&6$]O(DY48 4B3()Q_$ />O+OB/X6\=^,/&MCK6G>$Y8(+%$6)9[VV
M#N5<MD@2$#KZFO?J*;;<U/JM?F"24'#H]/D<]/9?\)EX6N]-U[1KG3UN$\N2
M&:2)R#@'<K1NPX/3.#QTKP[2]"^(GP?\0W!TK2I];TF=L,MM&TBRCG!*KED8
M>N,?6OI*BIVES1T'O'E>IXSXPN/'7C?X?ZD9?#<VC6PC0I8JQN+J[;<N!@*"
MBCJ1C/'89J_\'= \:^&]!73]5M+&TL#,9E65R]P-W484[1T[G(STKU>BJC:+
M=NHI+F23Z!6!XV\/'Q5X.U/15=8Y+F+$;,. X(9<^V0*WZ*B45)692;3NCYZ
M^'5[\1? +W'AMO!-WJ,#REXV+&*.-C@$B;:4*G@XI_QB\'^-M:@TC5I8&U"X
M0NKV6FPETM02I4#C<_3ECQP. *^@J*IW=F]U;\!17+>VS.=\)7/B&^T^.ZUV
MPATS,2HEDLGFN".KNV!C/91T[D]NBHHIMW=R8QY58****104444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'/"MS;R0.
M9 DBE28Y&1@#Z,I!!]P0:XN]^$/@C4KIKJ_TF>ZN&^]+/J-R[GZDR9KM998X
M8FEE=8XU&69S@ >YIEK=6]]:QW-I<17%O(-R2Q.'1QZ@C@TK*]POT*>CZ'8Z
M#;&VL/M0AXPD]Y+.% Z!?,9MH]ABM*BBFW<226P4444#"BBB@ HHJ&ZN[:QM
M9+F[N(K>WC&YY97"(H]23P* )J*AM;NVOK6.YL[B*XMY!E)87#HP]01P:FH
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M>XK)"T444#"BJ]MJ%E>R31VMW;SO VR58I QC;&<, >#CUJQ0 4444 %%%%
M!1110 4444 5M0TZSU:PFL;^VCN;69=LD4BY5A6-X>\!^%_"DK2Z+H\%K,PP
M926D?'H&<D@>V:Z*BA:.Z!ZZ,**** "BBB@ HHJG!JVFW5]/8V^H6LUW;_ZZ
M".96DC_WE!R/QH N4444 %%91\3^'QJ']GG7-,%[G'V;[7'YF>N-N<U9N-6T
MVTO8+*YU"UAN[C_4P23*KR_[JDY/X4;@7**** "BBB@ HHHH **KVU_9WDD\
M=K=P3O VR98I QC;&<, >#CL:L4 %%%% !1110 444R66.&-I)9%CC499G.
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MHHH **** "BBB@ HHJO>7]GIT'GWUW!;0Y"^9/($7)Z#)H L44=:* "BBB@
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MCE6'K7U#3IJU)>K%/^+\E^H4444#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9KR+]GC29K'P+<WTRE5OKHO'GNJ@+G\\_E7KM:U?B^[\B*7P_-_F>&?M*_\
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ML\;.!W+0_-^=?0&I_P#(*O/^N#_^@FO M<_Y.GL?^NL/_HJO?=3_ .05>?\
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MA);F621H^BL?*#8('49Z@\'O7T3/!%-9R6[QJ87C*%,<;2,8KP/2/^3JK_\
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MBF_<Q0\CGD#!KZ,M[>"TMX[>VA2&&-0J1QJ%50.P Z5\]_$C_DXOP[_O6?\
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MLXQ=-[[?+?\ *R.XHHHJ30\%N?$FL:E\?-0ETO0?[=?2+=H+:U-XEN(ONAY
M7!&<DCU_*NXD\4_$&:)XY/A<&1U*LIUZW((/;[M>4?VZ/A]^T/J=WJ 9+*ZG
M<2L1TCEPP;W ./R-?2EO<07=O'<6TJ30R*&22-@RL#W!'6I@N:C'TU]=;A)V
MJR7I]UD>$_"7P)XU\*>/)+V_T8V6E7,4B2@7<3A>Z#"L2<'CI5/]H]%/B#PV
MV,,T4@)'7&Y?\37MESKZ)XLLM!M@DL\D3W%SU)AB PI/H2Q &>P->*_M'?\
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MQJ%50.@ '2OG"QTJP?\ ::O=-DME:REGD+P9PC9BWD$#J-W.#Q7TI7SM8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWW9BR@Z= U;E%"TCRK8'J^8\/\0?#+Q]KOQ A\6BY\/6\]O)&T, N9F"A#D
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M5#,H],D\>E>_VFFV=EID6FV]NB6<40A6$#Y0@&,8JU15-W5B$K.YX#K?P?\
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M1] ,G\S^5:=%-:1Y4)J[YF%%%% PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *%
M[H>D:E=175]I=E=7$/\ JI9[='=/]TD9'X5?    & **P-,\;>&]8UVYT73]
M6@N-1ML^;"H;MUP2,-CO@G%"[('W9OT444 %%%% !1110 4444 %%%96N^)M
M%\,VHN=:U*WLHSG;YC?,^/[JCEOP%)M+<$KFK17,^'OB#X4\4W!M]&UJ"XG&
M<0LK1.<>BN 3^%=-56:%=,****0PHHHH **** "BBB@ HHHH **** "L>]\)
M^&]3NWN[_P /Z5=7+XWS3V4;NV!@98C)XK8HH Q;7P=X8L;J.ZM/#FD6]Q$V
MZ.6*QB1T/J"%R#6U16-K?BW0/#>P:OJMM:O(0$B9MTC9]$&6/4=J+] \S9HH
M!R,BB@ HHHH **** "BBL5?%N@/K\>A1ZK;2ZI(&(MXFWL,#)W8R%X]<4=;!
MTN;5%%% !14%[>VVFV4U[>SI!;0(7DE<X55'4FL[P[XIT3Q98O>:'?I>0(^Q
MRJLI4^A5@"/RH6H;&Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ%%X7\-:?%J&N21&>0SR%(+6/LTA')YQP.:TG=2Y7N9QMRW6QV=%>7ZYXO\
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M<\8R" 2#TZ5ZM#;PVR%((8XD+,Y5%"@LQR3QW)))]S2PPQ6\2Q0QI'&O1$4
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M#5\_? W_ )*9XN_[:?\ HXU[[.[QV\DD41FD525C4@%SC@9/ S[TU+]U!O\
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M*.R@8 KR/Q_\:KOPM=1V-EX;N4FF3?'/J2F-&'J$'S'\2I'I7KEO(9;:*1L
MN@8X]Q1'X;K:_P"(W\2OO;\"2BN,USQT\'B$>&O#NG?VMK>S?,AE\N&V7UD?
M!P?8#-<SXE\<?$'P)!'J?B'2- O=*>41L=-EF5XR>F2_L#VZ^E)26_0/+J>L
MT5D>&?$FG^+-!M]8TUV:WF'W6&&1AU4^XK'U7QE<MKLGA_PSIRZIJL(#73R2
M^7;V@/3S'P26/]U033=T[=1)IJ_0Z^BO(_$/CWXA> _)OO$NAZ)?:2[A&FTJ
M253&3ZE\_AQCWKTCP[XAT_Q1H=OJ^F2^9;3CC/#*1U4CL0:%JKH&[.S-2J6I
MZ59:S:?9=0A\ZW)RT9=@K<$88 C<.>AXKG_&OCVR\(+;6J6\FH:Q>-MM-/@/
MSR$\ D_PKGOBLA]9^*-C#_:=YX?T&XLE&]]/M+B3[6J]\,?D8CG@=:FZ:UV_
M K5/3<\Q^&.G6^D_M!:KI]HFRVMS=1Q+G.U0>!7TE7S9\+]2@UCX_:GJ5L'$
M%T+F5 ZX8 D'D=C7TG5QO[*%][?J0[>UG;O^@44R8RK#(8$1Y0IV*[E5)[ D
M X'O@_2O+/$WQ=U;PCXDM-%U;PG 'NBACG@U0NC*S;<C,(/![$"DM9*/5E/1
M.3V1ZM15>^>\CLW>PMX)[D8V1SS&)#SSE@K$<?[)KS33OB]>S_$6+P;J/A=;
M*[:8Q/*NH>:%^7<"!Y8R",=QUH6LN5;@](\SV/4Z*XKQW\0AX*T^6Y&A:C?"
M,A6E1-D"L1D;G/;G&0",\=:P?#OQ5U+7_"L-S9Z&-0U^YDE\K3[1MJ11J<*\
MKL<*.V3C)Z#KA)WO;H#TM?J>IT5X;=_&+QIX2UN*#QKX3M[6RF;Y6M2<A?9]
M[(Y'' Q^%>SZ9J5IK&F6^HV$RS6MP@DCD7N#5+5<R%>SY66Z*Y'QAX\M?#%S
M:Z9;6DNIZY>G%KI\# ,WNS?PK[_7T-8FI:O\6-.M7U'^Q/#=U;(-[65M-,UP
M!CGYCA21[ U/,K7Z=RK:VZGI-%<7X ^).E>/;6001M::C ,SV<C99?=3QN'O
M@?2J?Q"^)C>"+-I(_#]_=_/Y8N'7RK</C.-QR3WZ#!QUHD^7<4?>V/0**\WT
MGXE:CJWA+3[G3M#.J^(+R)I&L[1O+A@&X@&21CA>G )R?85SD/QB\3^'O%D&
MD^._#MMIT%RPV2V[']VI.-Q.YE<#O@C'Z527O<O4GF7+S'M=%("&4$'(/((I
M:1044UW6-&=V"HHRS$X 'K7"+XO\1>*//;P1IE@]C$Q1=3U:5TAF8'!\M$!9
MAU^8X%*^M@.]HKR!OBSKOA/Q-#HOC_1K2VCGYCO]/9C%MSC=M8DD ]>01Z5Z
MT;B$6IN3*GD!/,\S/R[<9SGTQ3TY>;H*^O+U):*\MT_XB^)/'%_>Q>!-*TX6
M5FX1]0U>1PDAYX5(^>>H_7%55^*NO>&?%]KX>\<Z18P?:B/*OM.=C&0QP&VM
MDXSP>01Z4+5I=]@;LF^VYZY117"W?CN]U37KK0O!NFPZE=6G%W>W,ICM;=O[
MI(!+M["E?6P^ESNJS]8T/3M?L_LFJ6WVBWY)B+L%/&.0",_C7F.N_$GQEX O
MK/\ X3+1](N=/NF*K<:0\@*XZC$G4\@XXZ'FO4],U*TUG2[;4;&42VMS&)(W
M'<&AI2C?="O9V/ /@3:)8?$[Q+9Q#$=O%)$HSGA90!_*OHJOG#X6ZM9Z+\3_
M !C>7LA6-3,JJBEGD8S\*JCEF)Z 5UOBCXC?$;1(6U=/!$-MH<;9=KJ423;,
M]6"/\GXJ0,T*7[N%^R$E[\[=V>Q45SO@CQ=:>-O#,&L6L9B+$I+"3DQN.HSW
M['/O715333LQIIJZ"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_
M=/TKY7^%>FW>I_%/58;+5KG2YU2=Q/;HC$XE7Y2'!!!KZH;[I^E?-'P.(;XP
M:L0008+@@CO^\6E37[[_ +=85/X7S1Z1K/PQ\4^)(?L>M?$:[N-/).^WATV.
M N.P8HP!_$$5U/@WP%H7@:R>#28&,LN/.N9CNDDQZGL/88%=/136FPFK[GBG
M[20'_")Z.V.1?$9_X U>F>"+.WL/ VB6]M$L<0LHFVCU*@D_B237FG[27_(I
M:1_U_'_T6U>H^$6#^#-$93D&QAP?^ "E3^"?^+]!3_B1]'^9LU\Z_"?CX]^)
M,?\ 3W_Z.%?15?.OPH/_ !?OQ)_V]_\ HX4Z?\;_ +=D.I_"?JCI/VBM:FL_
M"VG:3#(46_N"90#]Y$ ./IDC\J]6T&S@T_P_IUG;*%@AMHT0#T"BO)?VCM'E
MNO#.EZK$A9;*X9)2!]U7 P?S4#\:Z+X1_$'3_$_A>ST^>ZCCUBSC$,L#L T@
M7@.H[@C&<=#12UC)=;_A8*FDHOI;\;FMXH^&/AWQ=KMEK&I)<+=6N!^XD"B4
M Y ?@D@>Q!YKCOVA]6EM/"NF:5"VT7]U^\!SAE09P?;)7\J]#\4^*+7P_I[*
MLT3ZI.1%96F[+RRMPHV]<9.2>PKS3]H?1[JX\':3J(S*;&?;.X[!U W8_P!X
M#\ZS;22[*2_/_ABX_%YV?]?F=-;1_%N*TACA7P,L2(JH/]+X4#BN,\:_"OXA
M^.]3MM0U.Y\+03V\7E+]DDN%!&<\[D;GFNQ^%GQ)TSQ5X?M+&YNXH=9MXUBE
M@D;:9<8 =<]<\=.AKI_%OBNQ\+Z3)--,C7L@V6EJ&'F3RGA55>IY[UK47+*^
M_;S]#.D[QMMW_KL:VF0W%OI5G!>.CW,<*)*R$E6<  D9YQFK55[$7(T^V%XP
M:Z$2^<P& 7P-W'US5BG+XF$+<JL8OB__ )$O7/\ KPG_ /0#7F'[-W_(I:O_
M -?P_P#0!7IWC%@G@G768X L)\G_ ( :\P_9N/\ Q26KC_I^'_H J:?Q3]%^
M953X(_XOT+'[0^ORZ=X0L])@<H=1G/FX.,QH 2/Q)7\J]!\!V46G^ M"MHE
M5;*(G ZDJ"3^9-><_M%Z'/?>%M/U:%"RV$Y67'9' &?S _.NO^$>NPZ[\-]*
M:-P9;2(6LR]U9.!^8P?QI4OAGWO^%M!5/BAVL_O*OQIT2'6/AIJ,CJ/.L0+J
M)L<@J?F_-2:Q_P!GS6I]2\!S6,Y+?V?<F.-B<_(PW ?@<UU?Q2NH[3X8^())
M2H#6C1C=W9OE'ZFN:^ >@3:1\/S>7"E7U*<SJI_YY@!5_/!/XTZ6]3MI]X5/
ML>K^XXKXCV5O??M$Z%;7,2R0S"U$B'HPWMP?RKZ) P,#I7SYX_8)^TCX=+'
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MNL?\'Z,J'\:7^(\(_9ICB9O$$ABC,J^2%DVC< =V1GTX%>I?%-5?X8>(0P!
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M?!GQS!X(UO4/#WB!_LEM<2X,DG2"9?E(;T!Z9]A7TJ;^S%G]L^UP?9<;O/\
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M\Z?#Z&.W_:/UN*)0J+)=X [?-7T77SMX$=3^TIKA# AI+O&._-?1-3#^#3]
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MY\#7UI,Q,=E=GRR>RLH;'YY_.NY^).HQ:7\.=>N)75,V;Q)D]6<;0/S-<E\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBF3316\32S2)'&@RSNP  ]R:-@'T5QEM\4_"E_XI
MM?#VFWS7]Y<,5#VR;HDPI;ES@'@?PYKLZ.EPZV"BBB@ HHHH ***XO0/BCX<
M\2>*[KP[I[W)O(-V'DBQ'+M^]M.<\>X'M0M79;@]%=G:4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/L/B!<C/FPG'X-2I_P 27^']0J?#'_%^@?M+?\>?AW_KI-_)*]JT, >']-
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M)."<[68%BOT&<?A7DG[-,J?9?$$6X>9OA;;WQAAFE&[JSOOR_J*5O9PMM?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 9-#%<P203QK)%(I5T<9# \$$5XSKW[.>BW]Z]QH^KSZ9&[;C \(G1
M?9?F4@?4FO::*5E>X[NUCA_ OPKT#P*S7-J)+O467:UW/C('HH'"C]?>NV=%
MD1D=0R,,,K#((]*=15-\VY*26QYC-\'(=-UN35_!WB"\\.W,A^>..,3PD9R1
ML)''L20/2M6V^'+7U]:WWB[7KKQ%/:MOABEB2"W1O[WE)P3TZDUW-%):6MT!
MJ^Y7O;:2[LW@AO)[)VQB>W"%UY[;U9?;D&O.8_@AHL6O_P!NIX@\1#5/-,WV
MG[1"6W^O^J_2O3J*%H[K<;U5GL8]SHMW<Z5'9?\ "1:K%(I.^[B6W$L@.>#^
MZVCKU50>.M<7HWP4T?P]JW]JZ5XA\0V]]SF43PL6SR<AHB#GWKTRBA:.ZW!Z
MJQ@:YX8EU[2QI\WB#5K>!H3%/]F,"-.#U+$Q$@G_ &=HYZ5S?A?X0Z9X.OFN
M]$U_7;=Y !*AE@9) #T8&+Z^_/!KT.@G )]*%HVT#5U9G@W[2W_'GX=_ZZ3?
MR2NOTSP!JUCI-H_A/QA=Z);SPI+):26J7<2L5!)0/]S)YX-<3\<'U'Q@VDVV
MA>'=?NEM#(\DQTJX1<MM  #(">A[5ZWX,UP:IH=G!+IVIV-W!;(LT5[8RPA2
M  <,RA6Y]"32IKW)>OX!4?OQ]/QN4O#7P[L=#UB77+^]N=9UR48-]>8R@QC"
M*.%%=7>6\EU:20PW<UI(PXG@"%T^@=67\P:GHIO56$E;4\P/P/T1M>.N'Q!X
MB_M0R^=]I%Q"'W^O^J_3I7HUC:RVEFL$][<7SC.9[A8P[?78JK^E6:*%HN7H
M-ZN_4\E\6_ /0/$%_+?Z;>2Z1<3'=(B1"2(MGDA,@C//0X]JL^"?@?H7A+4(
MM2N[J35;^(YB:2,1QQM_>"9//U)KU&BB/N_"$O>W$(#*5(R",$&O)(O@3;6/
MB674=(\4:II=E,3YEK:$HY!.2HD##Y?8J?K7KE%*ROS ]58R7T)(]$ATK3;Z
M[TN&(!5DM/++XYR,R(XYSDG&<]ZXC2?@CHNA:RNKZ;X@\0V]^I)\X3PL3GKD
M&(@Y]\UZ;13Z\W4+:<O0B2$?9A!,YG&S8[2A<R<8)(  Y]@!7FTWP<ATW6Y-
M7\'>(+SP[<R'YXXXQ/"1G)&PD<>Q) ]*].HI6UYNH=+=#AK;X<M?7UK?>+M>
MNO$4]JV^&*6)(+=&_O>4G!/3J3787UK+=V;P07MQ8NV,3VXC+K]-ZLOMTJS1
M3Z6$E9W/,8/@AHMMKPUR+Q!XB75!*9OM/VB$MO/4_P"J]^G2NSO] NM0TJ.Q
M;Q'JT.%99;B 6ZRS _WCY6!C_9"UMT4K)QY>@^O-U/-O#_P7TCPKJ)U#1?$&
MOVMRRE&82P,&4]B&A(/XBNA\=^"X?'/ADZ//?36I#K*DZ+NPPS]Y<@,.>G%=
M113E[RLP6CNCFO G@^#P-X9BT:&[DN]KM(\KKMW,>N%R<#CIDUTM%%-MMW8D
MDE9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]G]O%A]K@^V%#(+?S!YFT8RVW.<<CGWH L4444 %%%% !1110 4444 %%%%
M!1110 4444 %%4[[5=.TORO[0U"UM/.?9%]HF6/>WHN2,GV%7.M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1137=(HVDD94102S,< #U)H =156PU*PU6V%SIU[;7EN20)
M;>59%R.HRI(JU0 4457O+^ST^-9+V[@MD9@BM-($!8G  )/4GM0!8HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BLW4?$6B:/(L>IZQI]B[_=6YNDB+?0,15^*:.>)989$DC895T8$$
M>Q%'F ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJNU_9I?)8M=P+>.I=+<R 2,HZD+G) ]:L4 %%%0W=Y:V%L]S>7,-O @R\LS
MA%4>Y/ H FHIJ.DL:R1LKHP#*RG((/0@U5N-6TVTO8+*YU"UAN[C_4P23*KR
M_P"ZI.3^%'D'2Y<HHHH ***IP:MIMU?3V-OJ%K-=V_\ KH(YE:2/_>4'(_&@
M"Y1110 4444 %%%% !1110 4444 %%%5X;^SN+N:TANX)+F  RPI("\8.<;E
M!R,X/7TH L4444 %%%% !1110 4444 %%%% !1110 45!>7UIIULUS?74%K
MOWI9Y BCZD\5,K!E#*001D$=Z %HHHH **** "BBB@ HHHH ***9+-%;PO--
M(D<2#+.[ !1ZDGI0 ^B@$$ @Y!HH **** "BBB@ HHID4T4X8Q2I(%8HQ1@<
M,.H/N/2@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444=* "B
MJ]I?6=^CO9W<%RD;F-VAD#A6'53CH1Z58H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF?\ 80'_ *+>O0/AY_R3KP[_ -@^'_T$44OX<U_>_0=3XX^C.EHHK'\2:_\
M\(WIC:@^E:CJ$*9,@L41VC4#.XAF7(^F:3:2NQI7V-BBN \(_%G2O&VI-9:-
MHVLL8P#--+'"J1*>A8^;G\@3[5H^,?']MX(C%QJ>B:Q+9$A1=VL<3Q[CV.9
MP_$ >E-Z6N):['745R7A#Q[;^-85NM-T35H[$LR_:[E84C!'; D+'\%-6_%O
MBZ+P=IS:C>:5J-U9( 99[01,(LG W!G5N_8$42]W<(^]L=%7G)^$=B?B>/&G
M]J7&?,\_[)L'^LQC._/W?]G'XUU&F>*[6^\/#6[NRO=*LVP4^WHJNX.,$*C,
M><X ."?2N3T[XS:-K?CBS\-:58W<QFD:-[J8>2$*J3PA&X],8(6FE:HDOB0F
MTX.^QW>K:8-7LC:M>WEHC'YFM)?+=A@C&[&1USQ@\#FOGOX,6IL?C5K=H9I)
MC!%<Q>;(<L^V51DGN3BOI.OG7X4?\E[\2_\ ;W_Z.%*E_&_[=8ZG\+YH][U;
M3!J]D;5KV\M$8_,UI+Y;L,$8W8R.N>,'@<U\]_!BU-C\:M;M#-),8(KF+S9#
MEGVRJ,D]R<5])U\Z_"C_ )+WXE_[>_\ T<**7\;_ +=85/X7S1]%4444 %%4
M-9UK3O#^ES:EJETEM:0C+._Z #J2?05QDWQ \37%H-0T7X>ZA>::5WK-<7L5
MO(Z]BL1W,01R*5T!Z%17&^!OB7HGCM98K(2VU] ,RVEP ' SC((X(_EZ5TNK
MZO8:%IDVHZG=1VUI",O(YX^@]2?04Y>ZKL(^]HB[17G8^(GB+4[07_AWX?ZA
MJ&FL"4N+F\BM6D7LRH<L0>U6_!_Q2T7Q9?R:4\-QI>L1$AK&\7:Q(Z[3WQZ<
M'VII7=NHFTE?H=S16=K6NZ=X?LC=ZC.8X^=H5&=FP,X"J"37%>&?C'H?B?5M
M2@@@EM-.L+8W$E]=N$! 8#[O.!SW.?:INKV&]%<]&HKR37?C>^D2+<1>"]:D
MT@L%_M"X1K=&'J@*$'/;)%>A^&_$VG>*?#\.M::[O;2*25*_.C#JI SR/04U
MJK]A-ZI=RUK.K6NA:3<:E>,1! NY@N,L<X &2!DD@#ZU=!R ?6OFSXP?$#5M
M6U.QTE=(U/3M(2=90+NU>&2\96'(5@/E'8>IY[5[-X?\=C7-12Q/A;Q/IP*%
MC<ZCI_DPC S@MN/)[4HZQYO/] D[2MY?J9OQ%^%EK\0KO3[F74YK*2TRAV1A
MPZ$Y( )&T^_/T-=U:6R6=G!:QEC'#&L:ECDX P,_E7FWBWXX>'?#<HMK6WNM
M3NV4,H13%$0>AWL.1[J&'6O1GOH(-.^VW,BPPK&)'9CPHQFG'2%UM?\ $;^)
M7WM^!9HKS67XTZ')XOLO#FFV=W=3W%PL#S2*84CR<9PPW'UZ#ZU)XE^+":6\
MZ:#X<U3Q"+<D3W%K&PMHR.H\T*P)'.<#'O4\RM<.MCT:BN+^'WQ*TOX@6DQM
M89+2]MP#-:RL&(!_B4C[P[9P/I3?%GQ*M?!8$FL>'];6U:0QQW420/&Y]L2Y
M&<<;@#52]UV8HOFV.VHK,\/Z[;>)/#]IK-E',EO=1^9&DP <#)'(!([>M<9X
MC^,6F>$KV.TUSP]K]I+*NZ/,<#*X]0RS$&AZ/E>XUJKH]&HJ."9;BWBG0$+(
M@< ]<$9KGM=\9VFDZE'I%G9W6JZS(N\6-F 61?[SL2%1?<FAZ.S$FFKK8Z6B
MO+-2^+FJ>&+J >+O!%[I5G,VU+F&\2Z7/OM '3G&<^U>D:9J5GK&FP:AI]PE
MQ:SH'CD0\$4+570-V=F6Z**Y;QQXLNO"VDM+I^B:CJM\Z,8H[6U>2-,?Q2,H
MPH]NI_6IE)15V4E=V-JVU>UN]8OM,A+-/9+&TQXV@OD@=<YP,].XJ_7SC\(_
MB!=VESXAU"_T37]:NK^X26272[+SPAP>&Y&WV'H*^@=)U'^UM*M[[['=V?G+
MN^SWD7ERQ\]&7)P:NSLK]D0I7;7FR[17$:C\1XFUBXT;PSH]UXAU*W!\];9U
MC@A/]UY6X!SZ9Z'TK(D^+TFA:I#8^-/"U[H'GG$=P)EN8?J64#\<9QQ4IWMY
ME/2_D>G45%;W$-W;1W%O*DL,JATD0Y5@>A!J6F"=PHK)U[Q)I7AJS-UJER8D
M"LX5(VD=@N,D*H)P,C)Z#/-<;X=^,VA>(;C5Y%@FM-.TZ%9#<W!&Z0EMH54&
M>3QCG)SC%*ZU\@>BNSTBBO'M8^.L^C7:/=>!M9M],D;"7=WF!G_W59,'CG[U
M>D>'?%&D^*=#35],N0]JP._=PT9'4,.Q%-:KF$W9V-FBO,O$OQN\/:%?QZ?:
M6]UJ%X[*,*ABC )QG<PR1[J"/>G>./C%:>$)TBM]%O-202>5-<J3' CCJ@DV
MD,X[J.GK2YE:X^MCTNBLO0-=M?$/AVSUNW5XK>ZB$H$N 5'?/TP:Y5_B5+JM
MU<V_@WPY=^(OLS;);E9TMK?=W"R/]X_0>E-Z/EZB337,MCOJ*\ULOB_;6^NI
MHGBW1+OPY?2?<:>02PMZ?O !Q[XQ[UWVHWTECI[W4%C<WY4 B&TV;V'J-[*#
M^?TS0]N;H.^MNI<HKS&R^.&B:AKJ:);:!XA;4WD,0MF@A5@PZ@YE&,8/6O2H
M)'EMXY'ADA=E#&*0J60^AVDC/T)'O1TOT#K8DK,\0Z+!XC\/WVCW$DD<-W$8
MF>,X9<]Q7//\1 GB8>'O^$5\0'4C'YWEJEN5\O.-Y?SMH'U-7_%7CO0_!UH\
MVJ33%U4-Y$$1D?!R!G'"Y((RQ J96<==F-74K+=%'X<_#Z#X>Z3<V<>H27TE
MS+YDDK1^6.!@ +DXX]^:[.N1^'_CN'Q_I=YJ%O8R6D,%R8$$D@9G&T')P,#K
MTR?K71ZGJ=EHVG3ZAJ%PEO:P+NDD<\ ?Y[5<VUK(F*6T2>>,S021+*\3.I42
M1XW)D=1D$9'N#7S/\5M%&C?%G0PM_>W:W)AF_P!+G,I0^;@@$]!P..U>K6_Q
M)US6HOMOAOP'J&HZ5DXNY[N.V,@'\2(V2PZUY)\2?$UGXI^(WAF[M8YX)(O*
MAN+:X39+!()CE6'K2@OWT'YA-KV4UY,^H:**XN\\?37-U<VGA/0+KQ#-;-LF
MECF2"W5P>5\U^&8>B@TK]!G:45YEIWQCMXO$2Z#XKT*Z\.W[D!#-*)8CGI\X
M X/J 1[UZ;UI]+]!7UL%%%8WB?Q1IOA/23J&I.^TL(XH8EW23.>B(O<FDW8I
M*YLT5Y[)X]\5VD3WM[\.-1CTQ1O\V&^BEFV^IA'(XSQFN@\'^+K3QEX>.M6=
MM/!;&5T1)0#(0O<A<\^P)I]_(F^WF:FLZM:Z%I-QJ5XQ$$"[F"XRQS@ 9(&2
M2 /K5T'(!]:^;/C!\0-6U;4['25TC4].TA)UE N[5X9+QE8<A6 ^4=AZGGM7
MLWA[QU_;NI1V'_"*^)].W(6^T:AI_DPC Z%MQY/:B'O1OY_H$GRRMY?J==17
M/>*O&>D>$+:)]0>22XN&V6UG;IOFG;T5?ZGBN8U#XB>*]*MVU"\^'%^FEJ-S
M3+?Q/*JXZF)02/Q/%*Z*L>D45SOA'QMHGC;33>:1<%BF!+!(-LD1]&']1D5%
MXL\?:#X-MGEU2:9G4 ^3;PF1N>F3]U<]MQ%.7N[BC[VQT]%>=:7\7+#4_",N
MNII-\SF>2*WL+<>=/,$ ); 'R@;N3R!Z\U)\./BK:_$"6]M_[,ET^YM$$C*T
MHD0J3C.[ Y]L4=6NVHKJU_D>@T5YV_Q2?5M3NM/\&>'+KQ%):G$\ZSI;0*>>
M!(_4\>G/:H-.^+T4?B>+P[XIT"[\/ZC,P6/S)5FB8DX7YP!P>F0",]Z(^]:W
M4;=KWZ;^1Z7117-:_P"-M/T35K318XIK_6;PCR;&VP6"_P!]R2 J]>3Z4K]
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M ?*.P]3SVKU_2OB$^IS&WC\&>+8'6)I UUIZQ*VT9VAF<#)[9(S2B[Q<O/\
M04M)6\OU.UHKS*W^-VBW6OKH47A_Q$=4,AB^S-!"K;QU!S* *[37->DT/2AJ
M#:+J=Y&J%Y8[,1/)" ,G(+C/_ =W2AM*/-T'UY>ILT5YWX9^,&E^+[U[30]
MUVYEC4-)^[MT5%)ZDM,!7<:E>RV%B]S%I]U?,O\ RPMC'O([D;V4?KGTS3>B
MNQ)W=D7**Y/P=X]M?&PEDT_1M7M[6(E6N;N*-(RXZJ,.23]!CU-7?$?BVP\.
M-!;R1SWFHW61;6%HF^:;'<#LH[L< 4/3<??R-^@\CKBO,=:^*/B#PP!=Z_\
M#^]M-*+[?M45_%.R@]-RJ,+GW:NY\.^(M,\4Z/%JFDW FMI./1D;NK#L10M5
M<3=G8^>OC[H7]DZUHUQ_:6H7ANHWWB[FWA2I7E1@!<YY  '%?2=E_P >-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[78.F-X./SKM_P!H'_DF3?\ 7Y%_6N+\"?\ )RFN_P#72[_G7:_M *6^&,A
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M7@'P+NKG0?B/K?A>1V:$B12#_?B?&<>XS7T;7S[\)[-]5^-?B?7(5_T."2X
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M (3^*7QKXNE_M2Y-PT=I:R\P6P&,[4Z9_P ,\GFL7]HU534O"RJ JJ)0 !@
M9CHU]I3YM[H<;.,N7;4]_A),,9/4J/Y5\]?#Z^GO?VC-;EU!LW&;J- QZ!6
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MAS(YQT  Z^I%;=-/W%%;+03^-M[NWZA7@_[2O_'IX=_ZZS?R2O>*\&_:5/\
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MD4;T!^:)NZL.Q%)XGU]- TU)%"27MS,EO:0-G,LC$ # YP.I]A56Y9IO=/\
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M]^3[B_044_X3_P 3%/\ BKT1\[ZA$EA^U1;_ &8;/-GC9P.Y:'YOSKZ U/\
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MYZDL><9SQ7D/PD/_ !?/Q7_V]?\ H\5</XSOJ[2,I+]U9*RNCNOCQ_R2J_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(^8'>0&4\]\\U[M10[N2G?4:24>6VAYM<>&/&WC#PS>V_BG4;.Q>:W=(;#3
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M<@9ZJWJI_3K[5W%%5/W]Q1]UZ'AGA/2_C1X2C70[:STN[T^,[8I[V</'$/\
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M@^I^(+E-DD[NTGE+UVJS<G)ZG_)]#HHJF[DI6&R&01.8E5I #M5FV@GL"<'
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MI3W+$PY3Z -6Y10M(\JV&]9<S/#]0^&7CZ_^)">,Q<^'H[B.9)$@%Q,5"J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 55OM,L-4A,.H6-M=Q$$;+B)9%Q]"#5JBB
MP&58>&- TJ;SM.T/3+.7@[[>TCC/'NH%:M%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)8HYHFBE1
M9(W&&1AD$>A%/HH     !@"BBB@ HHHH **** "HXH(8 PAB2,.Q=@B@98\D
MG'<^M244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<EXX\<_\
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M)3$?[0CN?-)"Y'R ;<<=?6O7/#_B3QM.=-MKKX?_ &:R98T>\_MF%]B8'S[
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MF6FFKH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX&?Q/YUK?'J-'^%EXS*"4N(2I/8[P/Y$UF?LZ?\ (@7G_80?_P! 2M7X\?\
M)*K_ /Z[P_\ H8J\5_\ (_\ MI%#_/\ 4L_!2.)/A5I+QQ1HS^87*J!N/F,,
MGU. *Y']I15_X1W1'P-PNW /ML_^M78?!7_DE&C?27_T8U<A^TG_ ,BUHO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !1110 4457M;^SOC+]CNX+CR7\N7R9 ^QL9VM@\'!'!H
ML4444 %%%% !15>VU"RO9)H[6[MYW@;9*L4@8QMC.& /!QZU8H **** "BBB
M@ HJ.>>&VA>:>5(HD&6>1@JJ/<GI26]S!>6T=S;31SP2J'CEB8,KJ>A!'!%
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M@ HHHH **** "BBB@ HHHH **** "BH;J[MK&UDN;NXBM[>,;GEE<(BCU)/
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MVFDZE'I%G9W6JZS(N\6-F 61?[SL2%1?<FAZ.S$FFKK8Z6BO+-2^+FJ>&+J
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M&*0J60^AVDC/T)'O1TOT#K8DK,\0Z+!XC\/WVCW$DD<-W$8F>,X9<]Q7//\
M$0)XF'A[_A%?$!U(Q^=Y:I;E?+SC>7\[:!]35_Q5X[T/P=:/-JDTQ=5#>1!$
M9'P<@9QPN2",L0*F5G'79C5U*RW11^'/P^@^'NDW-G'J$E])<R^9)*T?EC@8
M "Y../?FNSKD?A_X[A\?Z7>:A;V,EI#!<F!!)(&9QM!R<# Z],GZUT>IZG9:
M-IT^H:A<);VL"[I)'/ '^>U7-M:R)BEM$GGC,T$D2RO$SJ5$D>-R9'49!&1[
M@U\S_%;11HWQ9T,+?WMVMR89O]+G,I0^;@@$]!P..U>K6_Q)US6HOMOAOP'J
M&HZ5DXNY[N.V,@'\2(V2PZUY)\2?$UGXI^(WAF[M8YX)(O*AN+:X39+!()CE
M6'K2@OWT'YA-KV4UY,^H:**XN\\?37-U<VGA/0+KQ#-;-LFECF2"W5P>5\U^
M&8>B@TK]!G:45YEIWQCMXO$2Z#XKT*Z\.W[D!#-*)8CGI\X X/J 1[UZ;UI]
M+]!7UL%%%<7XQ^*'A[P6C+>M<7%R#M$-M$6^;T+G"@^V<^U)R2W*2N=I17G%
MQ\7+2#P1:Z^FC7ES<W,+3BQMLR&*,,5WR.%PBY'4CKTS@UK?#OX@VOQ!TBXO
M(;&6REMI!'+$[AP"1D%6P,C\!5)7;78FZLGW.QHKD]6\<)!JDVCZ#I5UKNJP
M#,T-LRI' <<"25B%4GTY/M7,R?&.70M9AT[QGX5O-!\__5SBX6YC([DLH P.
M^,XJ4T]NHWH>I45C:QXJT70],74;Z] MWC,L9B1I3(@ )90H)(Y'/09KD/#O
MQFT+Q#<:O(L$UIIVG0K(;FX(W2$MM"J@SR>,<Y.<8HOJUV#HGW/2**\>UCXZ
MSZ-=H]UX&UFWTR1L)=W>8&?_ '59,'CG[U>E>&O$VE^+-&BU329_-MWX((PT
M;=U8=C36JNA-I.QKT5D>(_$^D^%-*;4=7NA!"#M50,O(W957J37(S_$'Q7]E
M&HVGPVU*73-H?S);V*.?;Z^2 6SCM2NAV/1:*Y'P5\1M"\<12)8/);WT/^NL
MK@!9$]QV(SW'XXKJ+N[M["SFN[J9(;>%#))(YP%4#))IR]W5B3OL345Y[#\0
M]?U=!>^'/ E]J.D$G;>37L5LT@!^\D;<L/3IFK_A'XAV_BS6[[25TB_T^[L(
M@US'>JJE6)QM !.1WR<?2A:Z VD:/C?PE!XV\,3Z+/=26HD9725!NVLIR,CC
M(]J3P-X1@\$>%X-%ANI+K8S2/,Z[=S-UPN3@>V35#QA\3?#W@N-Q?/<7%PK;
M/(MHBQW8S@L<*IP<X)SCM6CX)\4KXS\+6^N):&T2=Y%6(R;R K%<YP.N,T0V
MDX^5QRZ7^1MW5S#96DUU<.(X84,DCD\*H&2:9IU]'J>F6M_"KK%<Q+*BN &
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M=$NM#U&1]D:3ON!;LK952I/;C^=>I4[:)BOK8**Y/5O'"0:I-H^@Z5=:[JL
MS-#;,J1P'' DE8A5)].3[5S,GQCET+68=.\9^%;S0?/_ -7.+A;F,CN2R@#
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M0LH82-G[ZK_#QUSCGUZUZS61XC\3Z3X4TIM1U>Z$$(.U5 R\C=E5>I-<C/\
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M_P"NL/\ )JQI?'/R2*J_#'S9ZG\0_P#DG/B+_L'S?^@FO/\ ]G#_ )$G4_\
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M)OC?PW/X2US0H+HZC?O:2 PV49G\H@?>=A\J@'DY/&*H?L[.S?#ZZ4DD+?N
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MI8<\22;2_([\ #\37N   P!@>E?,_P 3[J?P=\=[7Q#Y9:-O)N1_M*!L8?\
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M>I^%]7'B#PKIFJE<&[MDD9?1B.?US7@WP>TFSNOBUXC2YA65+1IGB0_<#";
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M\1&6;\LK7OE:U-UZ+^OR(I]>UW_7YC9 &B=6&05((-?-_P  M+LKSQKK4UQ
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MG^C/4=' \4_%G4M8)#V.@1?V?:G@@SMS*P^@PM>B5S/@'0'\.>#K*SN#NO9
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MD+;0%]"3GGMCCUKN/"7@;1_"-FHM8%FOW&;B_F&Z:9SU)8\XSGBE#6+MM?\
M'J5/XEWM^%SQGX(S*_Q<\1^3%+!#)%.PAE38R#SA@,O8C.,=J[_X]Q+)\+;I
MR!F.XA89'3YL?UKB/A(?^+Y^*_\ MZ_]'BNZ^/'_ "2J_P#^N\/_ *&*FI_
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M?P]X(U75D($MO;,T>?[Y&%_4BO&OV@_^1Q\+_P"X?_1BUZK\3K";4_AAKEM
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M\5_]O7_H\5Z_\0_^2<^(O^P?-_Z":FI_N\?\**A_'E_B//\ ]G#_ )$G4_\
ML('_ -%I7LM>-?LX?\B3J?\ V$#_ .BTKV6NFK\7R7Y(QI[/U?YA7S5\,97U
M3]H+5+R7+,'NWR3T^;:/T-?2M?-'PTA;2OVA-2LY@5<R7: 'C/)8?H*QI_QE
MZ,NI_"?JOS/I>BBBF,^?/VE/^/[PW_N3_P TKWRR_P"/&W_ZY+_*O _VE/\
MC^\-_P"Y/_-*]\LO^/&W_P"N2_RHI_PG_B8I_P 1>GZD]%%<CXC\0W<^H_\
M",>&V5M9E3=/<$;H["(_QO\ [1_A7N>>E)OHMQ^;.=\;12?$/Q-;>"[%C_9=
ME*MQK5PO1<<I"#_>/7VX]*]+MK>&SM8K:WC6.&) D:*.%4#  K/\/>'['PUI
M*6%BK%<EY99#N>:0\L[GN2:MMJ-HNIIIIF'VQXC,(@"2$! ))Z#DCKUYQT--
M:+E7_#O_ ("V\O46[YG_ ,,OZW_X!:KYGU><Z3^U"DL9P'OX0<?]-(U4_P#H
M5?3%?-&LV_\ :G[4,<48+;+Z!FQVV1JQ_E1#^/#Y_D%3^#,^EZ***!A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHQ23NK!=N3;5CD?#<OQ&\ >*M+L/%-__ &KI&J7/V43&X,Y20C*D,P##Z'C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=W$5O @R\LSA%4>Y/ J#3M9TO6(FDTO4K.^C4X9K6=90#[E2: +M%%% !15
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% #)8HYE"RQI(H(8!E!&0<@_@:?110 4444 %%%% !1110!'#!#;0
MI#!$D42#"I&H55'L!4E%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD^#%U:T2*TG^TWK>< SD @0Q_P!YB"<XZ?7BO6+>"*UMXK>! D42!$4=%4#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <K\2QGX9^(O^O&3^5</^SG#$O@:^F$:B5[]
ME9P.2 BX&?Q/YUW'Q+_Y)IXC_P"O&3^5<5^SI_R(%Y_V$'_] 2BE\53T7YDU
M-H>K_(T_CU&C_"R\9E!*7$)4GL=X'\B:M_!2.)/A5I+QQ1HS^87*J!N/F,,G
MU. *K?'C_DE5_P#]=X?_ $,5;^"O_)*-&^DO_HQJ*6U3UC^05-X?,X_]I15_
MX1W1'P-PNW /ML_^M7::KK\OA[X+#5T8_:(M*B$;9_C9%53^9%<9^TG_ ,BU
MHO\ U^-_Z :Z[6=$E\0_ \:;;KNGDTJ%HE]6558#\<8K%_P:GK^BO^%RU_&A
M?M^IS_[.]JB^";^^;YI[F^;>YZD*JXR?J2?QKU74]/@U;2[K3[I \%S$T3J1
MU!&*\3_9PUR+[#JWA^5MMPDHNHT/!*D!6_(@?G7NS$*I8G  R2:Z*R36NUOT
M,Z3:OWN_S/F_X"W]SHWQ!U?PT[EH9$D##L)(FQG'TS73?M)J#X5T9^XO2/S0
M_P"%9/P4TE]4^)/B3Q.@'V..6:.)AT9I'SQ]%'ZBM?\ :2(_X1/1QGG[<>/^
MV;5E4;=.FY;^Z7!6J3MM=GIO@NV@M/!.BQ6\211_8HFVHN!DJ"3^).:\3^-:
MK%\7O#,T8VR-' 2PZG$QQ7N/A(@^#M%(Y'V&'_T 5XA\;_\ DK'A?_KG#_Z.
M-;3_ -YC_B_S,H?[M+_#^A[[J?\ R"KS_K@__H)KQ']FG_D'^(/^NL/\FKV[
M4_\ D%7G_7!__037B'[-+#[#X@7(SYL)Q^#5G3_B2_P_J74^&/\ B_0]OU/_
M )!5Y_UP?_T$UX9^S5;0&#7KDQ(9U>)%D*_,%(8D ^G KW/4_P#D%7G_ %P?
M_P!!->(?LTL/L/B!<C/FPG'X-13_ (DO\/ZA4^&/K^AWOQFC23X4ZWO4-M6-
MAGL1(O-9_P !I&?X66@/1+B91]-V?ZUI_&+_ ))3KO\ US3_ -&+65\!/^27
M6W_7S-_.G2_Y>?\ ;I53:GZO\CSJ?Q+K/P?^*>N2WM@]UIFJSM-DG!D0L6#(
MW3*[B"/Y=:]<TCQEX0^)>F/I]K? ROM=K24!)D*D," <@X('(R*VRFA^-=)N
M(+JTAO;5)Y+>2*= =LD;%3]#D9!ZX(KP7XH_"N/P'%%XI\,WD\-M%.H,+.2]
MNQ/RLC]2,X&#SSU-3&7+%1GLK6?W6_0)1YFW'=WNOS/I:BL/P;JEQK?@S1]3
MNQBXN;5)),=V(Y/X]:W*TE'E;3Z$QES),X?XC?#>U^(4&GI-J$MD]G(S!TCW
MAE;&X8R.>!@]O0T^Z^(.A:7(FB:.EUKNH0((A:Z9'YI3''SO]U>G.37!_';Q
M9J$&I:7X3M+I[.UOE5[N9,@LC/M"Y]."2._%>N>'?#NE^&-'ATW2K9(8(U&2
MHYD/=F/<GUJ(:Q;6BO\ CU]"IZ22ZV_ \)^"KRO\8O$C36YMI&CN"\&\-Y;>
M<N5R.#CIFO8?B7_R33Q'_P!>,G\J\C^$;J?CEXJPP.[[5MQW_?BO7/B7_P D
MT\1_]>,G\JBI_N\?\*''^-+U_0Y']GK_ ))Q)_U_2?R6O6*\F_9Y8'X<R@$$
MB^DR/3A:]9KHJ?%]WY(QI?#\W^;"O/=5^'.EI\1D\?W>KFVCME$DL,H CW*N
MT,7)^48[8_&O0J^?;S46^(_QT_X1S6)G&AZ=+(([+)596C')8=R2#^'2LE?V
MD5'?7Y::FLK*$F]M/ST.J\<_$"QU[P;KMCX?TR^U> VDJSWT4?EVL( Y/F-C
M<1UPH.<5#^SJ2?A_=C/34'Q_WPE=IX]A@L_ACK\,,<<,*:=*J(@"JHVG  KB
M?V<V!\ WJ@\C4'R/^ )3IVO4]%^9,[V@WW?Y'L%%%%!1\ZV%E;7?[4]VD\2N
ML<S2J#T#B$$'\#S7T57SYI+!?VJK[)QEI /<^0*^@Z4/X,/3]27_ !9_+\CS
MW5?ASI:?$9/']WJYMH[91)+#* (]RKM#%R?E&.V/QK)\<_$"QU[P;KMCX?TR
M^U> VDJSWT4?EVL( Y/F-C<1UPH.<5RMYJ+?$?XZ?\(YK$SC0].ED$=EDJLK
M1CDL.Y)!_#I7K'CV&"S^&.OPPQQPPIITJHB *JC:< "LY?P+]-;+YFB_C6ZZ
M7_KT.+_9U)/P_NQGIJ#X_P"^$KG?VA?^1I\*?\#_ /0TKH/V<V!\ WJ@\C4'
MR/\ @"5SW[0Q"^*/"A)  #DD_P"^E=%3^-3]8_D81_A3])'OZG$8/H*^>OA]
MJ7C'7O&OB[6/#?\ 83333J)6U;SLK'E@BIY?; &<^@KZ%7#1#T*U\N>#/$G_
M  JWXKZO8:NKQV,TSP3M@G8-V4D]Q@_D:SC_ !;/L[?>C1_PKKNON/7=0LOB
MUJ6FW-C<?\(1Y-S$T3[?M>=K#!QGZUG?"/X9^(? &J:C+J=YITUK=0JH2UDD
M8[P<@G<BCH37I]IJ=C?V(O;.\@GM2NX31R!DQC/4>U8>C>)T\0^*M0M],F2?
M2]/B$<LZ897N&.=JMWVJ.<=V]J:]V3MO;\/Z_$4K.*[77WG353U?4$TK1KW4
M9!E+6!YB/4*I/]*N50UO3QJV@ZAIQ./M5O)#D]MRD?UJ*E^1VWL:0MS*^QXO
M^SV\FK:KXHUZ\;S+V>1 SMR?F+,?Z?E7NKHLB,CJ&5A@@]"*^</@#J)T'QMJ
M_AS4/W-S<+M"-Q^]B)ROY$_E7TC6LE%QC;:R,HWYI7WN?,O@EG\%?M!76B6Q
M/V2>XDMB@X&QAO3\N*^@/%__ ")>N?\ 7A/_ .@&O%] TMO$?[2VK:E  ;33
M9FDD=>FY4$8'UW9_(U[/XQ8)X)UUF. +"?)_X :PF[X6-][/_@&U/_>7ZK[]
M+GF/[-W_ "*6K_\ 7\/_ $ 5[37BO[-Q_P"*2U<?]/P_] %>U5U5?B^2_(PI
M[/U?YA117*_\)0MO\3'\-W-PJI/IT=Q:QL ,N'<. <9)(V\9_AK):NW]=S3H
MW_78X;XL_#C2=?UK1/L<45AJ>IW3PRW2)P^(G<%E'!.5'/7%<9X5\8^)?A%X
MD3PQXIC>3268!<MN$2D_ZR)NZ^J_R->S^+O^1J\%_P#82D_])Y*\Z_:(6WU!
MO#NE6J";6)9V\N-.7V-@8_%L?D:F#<.6W5M6^X))2O?HKW[;GN:,KHKH0589
M!'<5FZYH%AXBLOL>HBX:#DE8;J6'/UV,-P]CD5+81C2]#M8[J5$%M;(LLCMA
M1M4 DD]N*FLK^SU*U6ZL+N"ZMW^[+!('0_0CBJE%-M;HF$G9-Z,^;_BA\&(_
M">FOX@\/7,[V<+ S6\IR\()X96'4 XZ\CKDUZU\'?$]WXI^']O<7\AEN[:1K
M:20GE]N""??!%:7Q,OK2P^'.N-=L-LUJ\$:GDO(XVJ .YR15#X0>&+CPM\/K
M2VO$,=W<LUS*A&"A;& ?< "BFW:<7MI;U_X8*BUBUOK]W_#_ (G=U0UC1=.U
M_3)=.U2TCNK6489)!G'N#V(]14_]H60OOL/VN#[7MW_9_,'F;?7;G.*G=UC1
MG=@JJ,EB< "DTFM=BT[/0^<O!VDW?PW^/B>'XYGDLKY&5"3]^(J60GW!7'X'
MUKN?V@H'E^&GF*.(KV)F^AW+_,BET*UB\:_%^Y\7VP#Z1I-O]BM)\?+<3<[F
M4]P-Q&?I7;^,O#Z^*?"&IZ,Q :YA(C8C[KCE3^8%14NZ,;[K7Y7NOP_,<+*K
M)K;];6?]?Y')_ EPWPJL  ,K-,#CUWD_UKMO$DH@\+ZM*3@)9RMG'HAKRG]G
MS4I+?3-9\,7BF*]L+HR&)^" ?E8?@R_K78_%W6HM%^&FKL[[9+J+[+$,\LS\
M<?AD_A5XI\T6UU7YI(G#JTDGT?ZW/+?V:H6.JZ_/@[%@B3..Y8G^E>I>)?\
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M[3X18-X-T0J00;&'!'^X*\7_ &AB%\4>%"2  '))_P!]*NK_ !X_XOU9%/\
M@/\ P_H>^6T,5O:Q0PQK'%&@5$08"@#@ 5\^:L!;_M4VC1*%+RQ;L=\PX-?0
MR<QK]!7SUKG_ "=/8_\ 76'_ -%5$?X\/G^1;_@2]%^:/H>BBB@H**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML2P:652, Y& 9B>ISR:]=HH>LN9[B2LN5;&;I=GJ46G-;:S?6U_(1M\V&U,
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M6["ZO%55AN3IS(!CJ703?,3[%?QKSR^^#.LW_C,>*Y?&D:ZFLRRH4TK"*5P
M /-Z8&*]?HH^US=0LN7EZ&8]EJ5QH$]E=:C&+Z6)X_M=K 8@A((#!6=L$<=_
MRK@_A5\-M;\"WVJ7&J:S%=1W7"0P,[*QSGS&W 8;MQGKUKT^BA:2<EU5@:ND
MGZA1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ"\OK33K9KF^NH+6
M!?O2SR!%'U)XJ96#*&4@@C(([T +1110 444R66.")I9I$CC499W. ![DT;
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MVVNFP%@FNXT<Y.!A2<]:TU8,H92"I&01T-'2X>0M%%% !1110 4444 %%%%
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M.[U 9U75=0DOKUCUWNA('X#'ZU[?\)_^26>'_P#KV_\ 9C3IIQC)/=/\>O\
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M'P=!K6I>.O%T<LLCH([;5&51M8C^(-FMW]H'_DF3?]?D7]:M? C_ ))78_\
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MOC)9+>_"O6@PR8D29>.A5P?\:JK^Z^'I;Y[7OWW_ ,K$TOWB][K^&]K=MO\
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M3=6[8ZC(17!]ME2FM/,?Z'>45R>@?$SPAXHU1=,T?5_M-XREQ']FE3('7EE
M_6L7XA_%NT\ :M9:=)I,][).@E=EE$:HF2..#N;CIQ]:;T:3Z@M;VZ'HU%0V
MERE[907488)-&LBAA@@$9&??FIJ;5G9B335T%%%%(84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF%>0_!;1?%6I>&=3E\/>+!HZ)<X:!M.CG$C[!@[FY7L. :]>^+/_ "2W7_\
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M^R0^AN) &D/X+M'XUX]X0UX_"+X@^(]#U!F^Q&.0Q Y.YE!:(_5@<?4BO=?
M6C3:-X2MDNQ_I]T6O+L^LLAW-^6<?A6EU-JJMK7^;T_#5_,CE<5[-]_P6O\
MDOD)\1D63X<>(E=0P^P2G!'<*2*X']G#_D2=3_["!_\ 1:5Z!\0_^2<^(O\
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M_P#U_#_T 5N^/_AE?^,/&NAZU;ZE##:V143PRYR K[LI@8)/3G'05A?LW?\
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MJ?'#T9UU%%9-]K(@U_3='@V/<W(>:53D[(4'+<=RQ4#/J?2GY%=+G!?M _\
M),F_Z_(OZUS7PE\ KKG@&VU >*O$^G&260&#3M0\F(8;&0NT\\5TO[0/_),F
M_P"OR+^M6O@1_P DKL?^NTW_ *&:5)?Q/5!4?P?,P_%OP/OM8L7%GXSUF[E4
M92'5[@SHQ';<,;>>^#7*?#GXBKX#UMO">OZ#9Z>!,(9;JW0K(K] 9.3O'OV!
MSS7TA7R7\:Y(-3^+-S!IJ^;-LA@<1C.Z7&,<=3R!^%$&XU%%:I]/Z_K8)14H
MMO==3ZS!! (.0>A%<W\0_P#DG/B+_L'S?^@FMG2H);71[&WF.98K>-'/^T%
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M?A7D/QLDT@>,;#Q/X<UG3[J:4+YWV2ZCE:.6,C:Q"D]1C_OFOH'_ (03P?\
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M'XKJ6^%WB *,D6V?R(KGOV?B#\,E (R+R7/MTK.G\53TB.I]CU?Y%+]HP?\
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M[#6+34-"@UB*0?9)H!<!\]%QG]*YCX;V[W=AJ'BBX4BXUVY-RF[JL ^6)?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;UQ[9S7H=%&NS865[H\6UKX8>+OB/K,%[XQOM.TVTMMRPVVGJ9'"D\Y9N,G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#-U'P]HFKL&U/1]/O6!R#<VR2$'I_$#4NGZ/I>D1^7INFV=DG3
M;;0+&/7HH%7:*%IL#U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^+^G^%KVSM=+MQ<A)H8B)FD4J2,R$=#P> IH6LE%;L'I%R?0]NHHHH ****
M"BBHKIIUM)FMD5[@(QC5C@%L< ^V:3=E<:5W8EHKS/X6:O\ $'4[[5E\963P
MV\;#R&EMA"0V>57 &Y<?Q<_4UZ95-6L2GJUV"BBBD,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HJ.=WB@DDCB:9U4E8U(!<XZ D@<^YKQ+QQ\
M4?&>C>-+#01I]KI4,\L3"0,+AY(V?'4C:.A!&,CU[T+62CU8/2+EV/<:***
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !3)98X(VDED2.->K.< ?C4.H7]OI>FW-_=R".WMHVED8]E R:\ZT
M3PW+\153Q+XP61["8[].T<N5BBC_ (7D /S.1SSTI:MV0-V.XL_%/A[4;G[-
M8Z]I=U/_ ,\H+R-VZXZ YZUK5RU[\-O!=_:-;R>&=,C4C[]O;+"X]PR ']:Q
MM"OM1\'>+8/".K7DM[IM\C/I%[.V9%*_>@<_Q$#H?\AK5VZB=UKT/0J***!A
M1110 4444 %%%4M7U.WT71[S4[MML%K"TKGV S2DU%78TKNR/)OBC8WGQ"\3
M-X2TR7$6DV;WUR1R#.5Q$A_ST:L;]G7Q,T<FH^%;IBK FYMU8\@CAU_D<?6O
M0OA5I=PF@7/B'45/]I:].;V7=U5#_JU^@7^=>->.[:;X9_&J#7+-"MI<2B\0
M*, JQQ*G\_S%."]G-0E]I:^N_P"&B^3(G[\'*/3;TV_'5_-'U%14-K<PWMI#
M=6[AX9D$B,.A4C(-9WB'0_[>T][5M2U"R0HRDV4WE$D]"2!GC'3.#DY!I3;B
MGY%1M*VI?2^M)+V2SCNH&NHU#O L@+JIZ$KU ]ZIS>)=!M]0&GS:WIL=Z3@6
M[W2+)G_=)S7SG\%=,U+5/$&OZ=;Z@]K!)&%O+I&/GE YR$/9F/5NPSCGIZ)X
MK^ WAF]T*<Z%;S6>J(A>.0W#R"9\='WD]?48HE[J4GM:X+63CU3L>N57N[ZT
ML(EEO+J"VC9@@::0("Q. ,GN37BWP+\8:AJMKJ/A#5;J9;FTB)MI21YL:YVL
MO(/*DC&0:Y'XMZ-+HGQ2T?R+Z\OFN/*F1;ZX,FU_,Q@$]%.!P.GZ537OQCTD
M2G[DGUC?\#Z3U'5M-TB$3:GJ%I91$X#W,RQJ3]6(J2RO[/4K9;FQNX+J!ONR
MP2!U/T(XKB+CX4:)K^^]\6&?5=5F&6F%Q)&D/^S$BD *.V<DXR:\@8:A\#_B
MC#;0W4LNA7A5B)#Q)"3@Y[;U/<?UI1UDH2W>W^0Y:1<ET/IZJE_JFGZ5!Y^H
MWUM9P_\ /2XF6-?S8@=ZS/%_B:#PKX1OM=<"001;HDS@2.>%'XDBO//"<G@?
M4],AUSQEKN@:IKM\GF2IJ%W"ZVP/(B2-FPF!CMG-+5MI=!Z63[GJ>G:SI>L1
MM)IFI6=\BG!:VG64#\5)J]7S#\2_^$>\)>(]+\1_#[6+".=V836^G7*2(A&"
M#M4G"D<$=.*]AU3QCJ%Y\&I/%&CVY-]+9"14C&[RV)VL1Z[>3^%)R7LW/MN"
M3YU#OL=7J/B'1-'=4U36-/L6;[HNKE(B?IN(JQ8ZE8ZI )]/O;:[A/22WE61
M?S!(KR?X.^#-(U;P8-<\0:1!J.I7\SN\^HQ"9F4' (WYQTZ]ZY2_LT^'G[0>
MFVVA;K6PU!H=]LC'9MD)5EQZ9&1Z=JOE:FJ<MW^=KD.7N.:V7^=CZ-JO#?6E
MQ//!!=02S0$":-) S1YZ;@.G0]:Q/&>@'7=!NX_[3U"SVV[E1:3^4"V,@M@9
M(XZ9Q7AWP(TF;7['7-,G+II#O&UV8I2CS<,!%D<A3R200> .YJ(MRDX]E<N3
MY4GW=CZ'L=9TO4Y9HK#4K.[D@.V5()UD,9]& /'XU/=7=M96[3W=Q%;PJ,M)
M*X11]2>*\]\(_![3/!OC*;7M/U&Z,)C:.*S<#";NN7SEAZ#'XFN,@M[SQW\?
M+[3_ !)9S3:3I@D,-I)GR5 X1B.AW9S[_04UJXQ6[3?I83=E*3V5OG<]EL/%
M'A_59_(T[7=,O)O^>=O=QR-^2DUK5XI\;/ N@:?X*.N:1I=KIU[931X>SB$(
M96;&"%P,Y(.>O%=O\.=2O/$WPOTNYN[N9;J6!HGN$(\S*L5W9((S@=<4U[R;
M73]0>C2[_H=9<7UI:/"ES=00O,P2)99 I=CT"YZGV%1ZCJVFZ1")M3U"TLHB
M<![F98U)^K$5\V^*](N="^/VEV]C=7%[,\L$L+:A.SX+$\%N3MSDU[!>_"3P
M_KIDNO$CW>K:G*#NNI+AX_+]HT4A54=@0??-2FW!37G^']>@VTIN/H=Q:W=M
M?6R7-I<17$#C*2Q.'5AZ@C@U-7SS\%[F\\-_$_7/!QG:2R4S85O[\;8#>Q*]
M?PKT'XL^-[OPOI=GINCD?VUJTGDV[=?*&0"^/7) 'U]JIM6BXZ\UK?,2O>2E
MI;?\SM-2\0:+H[*NJ:O86);[HNKE(L_3<15JTO+6_MUN+.YAN(&Y62%PZGZ$
M<5R6B?#'PU8:8L>I:5:ZK?R+NNKV_B$\LKGJ=S9(_"O-]$\*^*O!'QJ:#0]/
MNQX;O)MSE QMQ">NX] RG.,\_G0OBY'UZ]!-^[SK[NO]>1[Y5#4M;TG1U5M4
MU2RL58X4W5PD0/TW$>AKG/B;XR;P3X/EOX C7TSB"U#] [?Q'V !/X5SNB6?
MPSBT]9==USPWK.K7"A[N\U"\@F=G(Y"[F.T#H ,4DV[VZ%/2U^IZ58ZE8ZI;
MBXT^]MKN ])+>59%/X@D5:KY8\4:GIOPX^)%OJW@75;6?3[A!)/;6MRLL0Y(
M:,X)X/49Z9XKZ@L;N._L+>\B_P!7/$LJ_1AD?SJEK'F0F[2Y7ZD]<=\3/&2^
M"?!MS?QD&]F_<6BGG]X1U^@&3^%=C7SI\?;Y]2\>:#H 8^5&BL5SU:1]O\E_
M6LY)R<8+[3M_F6FHIS?17/6?AAH)T3P19O<$OJ%^/MMY*WWGDD^;D^P(%=E3
M(8EA@CB0 *BA0!V &*XWXA_#W2O&>B79:RA&KK"?LUV%Q(&'*J2.2O;!]:NK
M.UY):?I_PQ%*+LD]_P!?^'.UHKP']G6#1V.K07-A#_;MI,'666(&1(R-I"D\
MK@Y!QZUZYXX.DQ>$-0N=9L(+ZV@C+I!-&'W28PH4$'#$D $<\T5/<5UKI?\
MK\O4(>\[>=CHJ@O+ZTTZV:YOKJ"U@7[TL\@11]2>*Y+X>> ]-\'^';41V<2:
MK+"#=76P>86;DKN/( ...G%>,?'W0?[(UK1KC^T]0O#=1ON%W/YFTJ5Y4<!<
MYZ  <4Y*TU#N[#A[RN?32L&4,I!!&01WJGJ6LZ7H\2RZIJ5G8QL<*]U.L0)]
MBQ%26[^7ID3X)VP@X'?"UXU\*CH/Q!OM<U?Q';VNI:VUR0EO>JL@AM_X0B-P
M #D9 I6;DXKIK^-B5+W%)];?BKGL5MJVG7ENEQ:ZA:SP2,$22*965F/0 @X)
M-7*\UU?X8:38^,_#_B/0-.2TDM[U1=0VR;8S&01NVC@8..F!@^U=!X[\+Z)K
MOAO4IM1TRVGN(K.3RKAHAYL>%)&U\9'/.*F4N6#EVO\ @7%-RY?3\3JJ*\-_
M9J_Y FO?]?,7_H)K;^.7AC19O >I:V=.MDU2%HF%VD861OG5<,PY88..:=3W
M%?T_$5/WW;U_ ]7J&ZN[:RMVGN[B*WA49:25PBCZD\5YY\"/^25V/_7:;_T,
MUQL%O>>._CY?:?XDLYIM)TP2&&TDSY*@<(Q'0[LY]_H*J46JGLU_5E<E2]QS
M?]:V/9;#Q1X?U6?R-.UW3+R;_GG;W<<C?DI-:U>*?&SP+H&G^"CKFD:7:Z=>
MV4T>'LXA"&5FQ@A<#.2#GKQ7>_##6+K7?ASH]_>R-+<M$4>1NKE6*Y/OQ2C[
MR;[?J.6C2[_H>5?M*?\ ']X;_P!R?^:5[Y9?\>-O_P!<E_E7@?[2G_']X;_W
M)_YI7OEE_P >-O\ ]<E_E13_ (3_ ,3"?\1>GZG.?$3PZOB7P5?VB B[B3[1
M:2*<,DR<J0>WI^-9WPG\;'QKX/CFN2/[1LR(+K_:('#_ (C]<UW1 92#R#Q7
MSE\&KUM%^+^O:"N%M[AIT"=,-&Y*X_#=13^-P[J_S7^:"II%2[.WR?\ P3Z.
MHHHH&%%%<U\0-4U'1? NK:AI,327T4/[O:,E<D MCV!)_"IG+EBV5%<SL:>H
M^(=$T=U35-8T^Q9ONBZN4B)^FXBK%CJ5CJD GT^]MKN$])+>59%_,$BO)_@[
MX,TC5O!@USQ!I$&HZE?S.[SZC$)F90< C?G'3KWKE+^S3X>?M!Z;;:%NM;#4
M&AWVR,=FV0E67'ID9'IVJ^5J:IRW?YVN9.7N.:V7^=CZ-K.U+Q!HNC,BZIJ]
MA8L_W1=7*1%OIN(S3/$NIOHOAC5-3B3?):6LDRKC.2JDBO,OA'I'ACQ9X7DU
M?5K2RUC79YW:_DOHUG=&R=H 8':NW&,5*NVTNGZENR2;ZGK,5]9SK$T-U!(L
MV?+*2 [\=<8ZX]JL$@ DG %><V7PXT_PW\3[#7=#M/L]E/;S17,,8.R-\ JP
M_N@\C'3('K65\;/$'V%_#VAW%Q+;:7J5U_Q,)8VVDPJ5#+D= =V3]*+WM;=N
MWX_TQ+=WV6OX7_X!Z-#XH\/W-Z;*#7=,ENU.# EW&S@YQC:#GK6E'-%+O\N1
M'V,4;:P.UO0^AKDY/AOX%U/1UMX_#VE_9I(QLGMX55R".&$B_,?KFF_#7PY-
MX3\,SZ-+O*V]]-Y3L,;XR<JWY8_'-/JT_P"M17V:Z_Y'7R2QPQM)*ZHB\EF.
M /QK(MO%WAJ\N1;6OB'29YSTBBO8V;\@V:\B\='4_%7QOTGPKJ$%RV@1E)#
MI(29=NYG;'7!^7VQ[UTGQ.^'/AAOA_JEU8Z)8V5W8P&>&:U@6)OEY(.W&X$
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M%_F:=/X9^J_(52_-"_9_FCKJ***!A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<<1JPW.<XR<  =\\5;^"'BNTN/!>G:#;13W%];/(+G;$5C@C+,P9G(VG.<
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MJ6V:,[H6F4NRXY'EGYC],5P_P)\,76G/KFO/:2V=CJ$FVQAE!#&(,2&P>W(
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M43W;1/##$NTY&74%GQT4#ZD5B]://U?X?Y>IHM*O*]M/G_78I?LZ?\B!>?\
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MX7[V/^ EJQJ_#?LU^9M#>QJ_"]P_PR\/%0 /L:CCVR*ZQ_N-]*\[^!^HB_\
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MH'FNK6/R[F*($NR Y5U ZD9.?;Z5BWR3C)K1;_-6-TN>$HI[GIG_  @G@_\
MZ%30_P#P70__ !--/AGP?HT]O=KH&C6DWG(D,L=C&K"0G"[2%R#FO!O#/[0N
MM:-IL=EJ^EQZJ8EVI-YYADP.FX[6!^N!7HO@K5O$'Q*UFU\0ZIIXTS0=/8R6
M5L&+&XF((#ECC<%!.. ,FM+.^FW<S;TUW['JU%%%26?/G[2G_']X;_W)_P":
M5[Y9?\>-O_UR7^5?-W[0/B32-:UC1K?2[^WO3:1R&9[>0.JEBN!D<9^4\5[G
MHGC3PY?^&8M4BUNP6UBBC\]WN%3R6(P%?)^4YXP:*;_=/_$PJ?Q%Z'D6D?\
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MFO;8OB;X*ETW[=_PDFGHFW<8I)@LH]O+/S9]L5--KV,?*_YCFOWS]%^1X_\
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M/M[N0Y>>&V1';ZL!DUI44>8%*^TC3-3>%[_3K2[>!MT37$"R&,^JY'!^E70
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M6KVM[:P7-LXPT,T8=&'N#P:GHHMI8.MR&UM+:QMDMK2WBMX$&$BB0(JCT '
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M(X/H0#4H    P!0M'?\ K^M6$E=6"BBB@92U+1],UB)8M4TVSOHU.52Z@64
M^H# U8@M;>UMEMK>"**!1A8HT"J!Z #BI:* *=AI&FZ4)!IVG6EF)6W2"WA6
M/>?4[0,FKE%% !1110 5FZCX=T35Y4EU/1M/O9$^Z]S:I(5^A8'%:5% %2XT
MO3KNWBM[FPM9H(6#Q1R0JRHPZ$ C (]15L    8 HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKZBG>*4NFWH>D_%G_DENO_\ 7O\ ^S"N)_9N_P"12U?_ *_A_P"@"NV^+/\
MR2W7_P#KW_\ 9A7D?P2UOQ1IGAW48]"\(_VU UT&>;^THK;8VT?+AP2>.<TJ
M3]ZIZ(=1>[#U9]'UX9^TK_R!=!_Z^)/_ $$5V?\ PEOQ#_Z)A_Y7[?\ PKRG
MXX:SXEU32])77?"G]B1I,YB?^T8[GS#M&1A ,8]ZBHKV]47#KZ,]M^&O_)-?
M#O\ UXQ_RKJ:Y;X:_P#)-?#O_7C'_*NIKIK?Q)>IA2^!!11161H%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 454U&SGO;816^I76GON!\ZV6)F(]/
MWB.,?AFOGSQ1XT^(>A?$K_A%(/%A=))XHXIY+"WR%DQ@D!.<9[>E):R4>K&]
M(N78^CJ*\YG\,_$ZV@\ZT^(-K>SJ,BWN-(BBC<XZ%ER1S[5@>$OC+>KXG;PM
MXVL8;'4%E\@7,650OV# YQGC# XYZ"FM7RK<ENRYGL>RT444#"BBB@ HHHH
M**KW%];6MS:V\TH6:Z<I"F"2Y"ECTZ< \G^M6* "BO+O&GPSUSQ)\1-*\0V6
MO"VM+79NC9F#Q;3D^6!P=W?)'XUZC0M8W>X/XK!1110 4444 %%%% !17E7Q
MK7Q%8^$+O5=/\1SV=M%)&IM;>,1ED8A3F0'=G)SQ@8.,=ZT?@@[2?"O37=BS
MM).68G))\QN:(>\I/M;\0E[MO,]$HHHH ***KWU];:;8S7MY*(K>%"\CD$X
M]AR?PH L44 Y&110 4444 %%%5[VWEN[1X8;V>SD;&)X A=>>P=67VY!H L4
M5\Z_$[QI\0/ 7BA-.M_%3W-K-")X7ELK8.!D@@XCP>1UXZU['\/_ !4GC'P;
M8ZMD?:&7R[E0,;95X;\^OXT1]Z/,A2]V2B^IT]%%!( R>E PHKYD\5?&?Q7=
M>.+JS\-ZNEKIOV@6]N/LT3AL';O)92>3D_3%?0>B:5J=@@?4O$-[JDI0!EEA
M@CC#>JB.-6_-C1'WH\W04G:7+U-BBBB@84457O+ZVT^..2ZE$:R2I"G!.7<A
M5''J30!8HHJO<7UM:W-K;S2A9KIRD*8)+D*6/3IP#R?ZT 6**** "BBB@ HH
MHH ***RO$]]-IGA35K^W<I/;V<LL;!0<,%)!P>#SZU,GRILJ,>9I+J:M%>4^
M'-#^*NK:-!?:GX\3399T#K;C2()64'IN.%P?;FN,^)/BOXA_#W5+*R_X37[?
M]IA,N_\ LNWBVX.,8PV:J7NOE>Y,?>5T?1-%><67AOXB7FGV]U_PLS9YT2R;
M?[!MSC(!QG/O4?@^Y\=:=\0KG0O%FK)J-H]B;BTFBMXXU;#J#]U0<C/(YZT[
M>]RO?7\">9<O,MM/Q/2Z***104444 %%%% !15=KZV748]/,H^U21-,L>#]Q
M2 3GH.6'^0:L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %8'B+QGH7A;RDU.\VW$W^JMH4,DTGT
M1<G'OTJUXFUN/PYX9U'6)5W+:0-(%_O-V'XG KG_ (?^&#8V \0:N1=>(=34
M3W-RXR8PW*QI_=4 @8%)7;?D#=K>96'Q9TR',FI^'O%&E6@ZW=]I;+$/Q4D]
M.>E=K8:A9ZK8Q7MA<Q7-K*-T<L3!E8?45890RE6 *D8(/>O-WM1\/_B'IXT\
M>7H'B*5H9;5>$@NL95T'8,,@@>GTIIZJ/?\ K\1.Z7,>DT444#"BBB@ HHHH
M *^9_B3_ ,G$:9_UWLO_ $):^F*^8OBD9U^/UD;5(WN!):&)9&*J6R, D X&
M:4-*]/U_0)?PI^A].U\L_M!+"GQ+B:WXG-E$9-O7=N;'XXQ7LFH^)/B7' T-
MGX M'N"@VW UB-HPW^XP1C],_C7)>&O@WK.I^+3XH\>7L,]QYOFBTB.X.P^[
MN/0*,#Y1GIUH4;SB]DOZT&Y<L7U;/8=*>1="L7NSME%M&92W&#M&<UR-Q\6M
M"-W-;Z/I^M:^T!VS/H]B9TC/NV0#^&:V/'NE:GK?@?5=-T:01WUQ#LCRVW<,
MC*Y[9&1^-9'PM\/7/@GX>PVFMB"TN!))-/F1<(">-S XZ8[TV^:4F]$OU_R(
M2Y8QBM>GW+]2UX5^)OAOQ=?/I]E-/;:B@):SO(O+E&.H[@D=P#71:MK>EZ%:
M&ZU74+:R@_OSR!<^PSU/L*^=_$^KZ5>_M#:+J/A^]@N$DGMEFFMSE2^[:W/0
M_+CD5] >(M)T_5-&OEO;*WG)MI$#21AB 0>A/2HE)JC[1>?X%17[SD?E^)BZ
M1\4/"VLV&JZA;7KII^F;?.NIHRB-NSC:#\QZ=, ^E9.E?'+P1JDUU&U[/9"W
M4N'O(P@E _N8))/H#@^U>??LYZ5'>R:K=W#EX[62-HH"!M$I##S/J!D#TR:]
MKL?!OAW3->GURRTBW@U*<%9)T!&<]<#H">Y !/>M'%I_(B,KI^IX;#\8+#6/
MC!8ZQJ,[6/A^PBFBM]T;.?F7&]E4$Y)QVX&*]Q\.>,_#_BVVN;G1-0%S#;$+
M,YB>,(2,_P :CL*\;TC_ ).JO_\ >D_]$"O?IH(KF!X)XDEBD4J\;J&5@>H(
M/44H?PHOO?\ ,;_B2^7Y'&ZC\5_"-AK5MI$>H_;KZXG2 1V:^8$9FV_,V0HP
M>HSGVKMJ^;/B986EA\>_#XL[:*!97M'=8U"@MYI&<#V _*O>_%>N+X;\*:GK
M!4,;2!I%4_Q-_"/SQ4\R5%5'Y_@79^TY%V7XE77_ !MHOAVZCLKF6:XU&4;H
M[&RA:>=QZ[%Z#W.*P+?XP^'?[3CT_5[+6-!GEQY?]KV?DAO?()P/<X'-9?P.
ML#=>';OQ7?O]HU;5[EVEN'&6V*<!1Z#(/'T]*U_BM\/9?'^A6T%G<0P7]I+O
MA:?(1@1AE) )'8\#M524H6OKM?\ KR)34KVT['5ZMX@T_1+5+F]-T8&!;S+>
MSFN%4#G+&-6VCW.*S?#7C_PQXONIK;0M3^US0())%\B2/:N<9RZCO5GPEHMS
MX?\ "&G:1?70NY[6#RWE&<-UX&><#I^%>*_ -0OQ!\4*H 41L  . /-H5O:.
M'2S9+;]FI=;I?>>T^(/&&B^%UWZQ-=6\6T,9EL9Y(ADXY=$*@^Q.:?X;\6Z'
MXOM)KK0K[[7!"_ENWE/'AL9QAP#T-5_'J+)\/O$*NH9?[/F."/\ 8-><?LW?
M\BEJ_P#U_#_T 40U<D^B3+GHHM=7;\#I/CE_R2C5/^ND/_HQ:/@;_P DHTO_
M *Z3?^C&H^.7_)*-4_ZZ0_\ HQ:/@;_R2C2_^NDW_HQJ*6U3_MT53['S.H\3
M>,="\(V\<NL7RPM*<10JI>20_P"RHY/6N5G^,^BV#1MJV@^)M*MY3A+F^T[9
M&WT(8D_@*R]9\!>(M3^.FG^(Y%BFT.W",KM(O[H*OW-A.<ELG(&.:V_B[J^@
M0^ ]7TS4]0M([N>W)M[=W!D:0<J0HYZXYZ5FY.,.=[]OG^9:5Y\JVTU.UL-4
ML=4TR+4K*ZBGLI4WI,K?*5]?:O /BU\7++69H/#^AS^9IZ3H]Y=KG;)M8':O
MJHQDGO@8KK_V>)Y)?AW/&[$K%?2*@] 54_S)KFOVA?\ D:?"G_ __0TK6<;5
M8+I=?YF497IR;WL_U1ZEX>^)?A#Q-J4>EZ/J_P!IO&0L(_LTJ9 &3RR ?K70
MZMK&G:%ITE_JEY%:6L?WI)6P/H/4^PYJVGW%^@KPS7?&"7OQO>&[TC5=8L-"
MB(M[+3K;SR)^,RLN1TSC/8@5+=Y**ZW_  *6D>;T.QO_ (Q:/IFV:[T'Q-#8
M,0%OY--*0$'OEB#^E=CH7B#2_$NEIJ.D7D=U:OQN7(*GT(/(/L:XN]^(]OJ%
MC/9W7P]\;2V\Z&.2-]&R&4C!!^>O//@GI_B?P_XZN+:?0]9L]&O(WW&ZLY(T
M4KRA)(P#C(Z]ZJ&K<7]_Z"F[+F_ ^BJ***11Y%XVT*W\2_%^VT>Z'[NZ\/S)
MG^ZVX[6'N#@UQ7P0UVX\*>.M0\':H?+%S(R*K<!9TR./]X _D*]*U#_DX+1_
M^P++_P"AFO.?CSX>FT#Q7IWC#308_/=1(RC[LZ<JWX@?^.U--J'*WL[I_P#@
M3L$TY\R6ZLU_X"?1U<3\3]<N-+\+_P!GZ=DZMK$HL;15Z@OPS?@,\_2MOPCX
MB@\5>%;#68",7$0,B@_<<<,OX'-<?HN/&OQ5OM<)\S2_#P-C9=U:X/\ K''T
MZ?E52A>7(_GZ+_/1?,2G[O.OEZO_ "U?R/%?B%H=OX:^(^BZ/:C]W:V]HF?[
MS;N6_$Y-?6O:OE[XS_\ ):K3_<M?_0J^H>U%-MTKON_U):4:MEV1S7B7QYH/
MA6>*UO[B26_F_P!58VL9EGD],*.F<<9Q7/'XS^'[2]BMM:TO7]",OW'U2P,2
MM^1)Q[XK*\.> O$5K\;M5\3ZJL4FGN)#;SF16+!L!5"YRNU>.GTJ+X^:OH$W
M@F;3)-0M&U:.>.2&V5PTBG."2!]WY2W6HYG&,9/=]/G^9I:\G%;+K\CU:74K
M*#3&U*6[A2Q6+SC<%QL"8SNSTQBOGKQ9\7['7OB%H*03-#X=TR]2>2<HV96'
M5]H&< 9P,9Y->J?!N>2?X5:(TC%BJ.@)] [ ?I7G'CW_ ).3\._2U_\ 0VK1
MQY:\8^?Z7,N:]&4GV_X!Z?9?%?P1J%K>7-MKL;16<8DG9X)8]H)P,;E&23Q@
M9->1P_&"PUCXP6.L:C.UCX?L(IHK?=&SGYEQO95!.2<=N!BOH^OGW2/^3JK_
M /WI/_1 J8ZU8KU_+_@E3TIOY?FCV7PUXQT'QA!<3:#?_:X[=@DI\F2/:2,C
M[ZC/X4[7_%FD>&S#'?W#&YN#B"T@C:6:4_[**"3]>E:MU<1V=G-<RG$<,;2,
M?8#)KP7X=>//,U#6_$M]X8\2:QJ-[<E$N=.L//C@A &V(-N&,9Y'THO>7*NU
M_P!"M4K^9W7_  NCP];:A'9ZSINNZ&TOW'U2Q,2M^1)Q[XQ7?&_LQ8B^:ZA%
MH4$GGF0!-I[[NF*\<^(OB0>-?!]UI4?@'QB+S*O:RSZ00L;@]<AB1QD=.]7_
M ((6FL?\(C=Z-XFTB[BAM+@-:IJ%JRC:1G"AQS@@GVS3C=I]U^(I.S3Z/\#K
M+#XG^%=5\41>'],OS>W3JS&6%<PH%&3ES@'C^[FLM_C9X,7Q*FBK=7$C-((O
MM<<68 Y.,;LY//< CWKRRQT&VF_:2O\ 28,6UDTLADBB4 /&8MS)[!LD''8F
MO>=2\$^&M7U&SO[_ $:UFNK/'D2%<;0.@(& P'8'(%*&L83>SW%)OFE%;K8W
MJK:A8P:GI]Q8W2EH+A#'(H.,J>HJS13*    #H*^;?VDO^1IT;_KS;_T.OI*
MOFW]I+_D:=&_Z\V_]#K.7QP]?T9<=GZ?Y'T'HG_( T[_ *]8O_014LNGV\VI
M6^H.I^T6\;QQG/ 5]I;_ -!%1:)_R -._P"O6+_T$5?K>I\;]7^IA2_AQ]%^
M2*6K:QIVA:=)?ZI>16EK']Z25L#Z#U/L.:XB_P#C%H^F;9KO0?$T-@Q 6_DT
MTI 0>^6(/Z5QVN^,$O?C>\-WI&JZQ8:%$1;V6G6WGD3\9E9<CIG&>Q KKKWX
MCV^H6,]G=?#WQM+;SH8Y(WT;(92,$'YZQ3;CSKKT_KN:_:Y6=IH7B#2_$NEI
MJ.D7D=U:OQN7(*GT(/(/L:I^)?&.D>%5@6_DEDNK@D6]G;1&6>8C^Z@_F<"O
M%/@GI_B?P_XZN+:?0]9L]&O(WW&ZLY(T4KRA)(P#C(Z]ZOZQXOA\(?M#WM[X
MAC;[%):)!!,%W>2A53N ZXW!@<>IK1V<HI:7O^'0A-I2OK;^KG=/\8?#]DN=
M;T[7M#W9\L:EIKIYF.R[=W^171ZYXQT7PYX>CUK5+G[/;2H&B1AF20D9"JHZ
MG%1ZG:Z+\0/"%U:07-M>V=W$52:-@X1\?*P]"#^-;.G6[VFF6EM(5+PPI&Q7
MH2% .*EWLUL_Z_$:>J>Z/GSP=\7=.NOB9JWB'Q+=_P!GV<MH+>TC\MY-BAP0
MOR \]23ZU[OX?\1Z3XITP:EHUW]JM"YC\SRW3YAU&& /Z5XE\%_^2O>+OK/_
M .CZ^@J<;>SB^Z7^8OMR]?T04444%!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]TY^M1#64K[Z6_KN.>T;;:W_ $^1E_$2V@L_C[X4M[6"."!!:!(XD"JH\UN
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MU^U_XAOE"RR,^X0QCI&O;KR<<9JK7UZ$MO;J=U115>]N);2T>:&RGO)%QB"
MH';GL795]^2*19Y_J'_)P6C_ /8%E_\ 0S73>.?#,?B[P?J&CO@22Q[H&/\
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ"0<$<X&?:IO=\JW&]%=GKM%>2>)5\1?"FV@UVRUW4]>T190E]::K*)95#'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M],UG?L_VZP_#)) ,&:[E<G'7&!_2HIZRG+LK??O^ ZFT8]W^7_!/1-8UG3]
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MOB!X=\:QO_8]X6GC&9+:9=DB#UQW'N"16#;?$N&SMHK:V^'OC:*")0B1IHV
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MKJ:,HC;LXV@_,>G3 /I5F0:5XQ\#KJ<]E;S)>:<7!DB#%0R9(!/(P?Y5X_\
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M$****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYUZ9%X\\0:/ ECKO@C7;K44&SS]*@%Q;S$<;MV1L!ZX(XI4W^ZMYL*G\6_\
M=1PO[1R_:K[PQ8PKON9&E"J.IR4 'YUT/QPTZ9/A#;1@9^QS6_F<=@I3^9%6
M-!\'ZUXH\=+XV\7VJV2VPVZ;I>_>8@.C.1QGDG'KZ8KT?5]*M-<TBZTR^C\R
MUNHS'(OL?3WJ7%^RY>K=_P#)?UW&I7J<W1*W^9QOP>\36OB'X?Z?$DB_:]/C
M%M<1YY7;PIQZ$ ?K7>R2)%&TDC!40%F9C@ #J:^5]4^&OC_X>Z])>>&UOKF
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M?(J,G%-M:VV\_P#+S.D\)Z?-I?PKTZSN%*S1Z9\ZGJ"4)Q^M>:?LT_\ (/\
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MPMX\\*>/;_Q!?^$I98+X2B6."^MBZ;W#Y&9 #C'M1#2K=]F@GK3T[H]QUO\
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MO\3T[Q[<QVGP_P!?FE *"PF&#W)4@#\S7G_[.FGS6W@J_O)%*QW=X?*SW"J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJIJ.FP:I;""XDND0,&S;7
M4MNV?]Z-E./;.*^9_&L_B+0OBJ/#EIXN\0I8SSPB,G4I69%DQD9+<XR:2=YJ
M'<'I%R['U'17GH^%<GE 'Q_XW,F.6&K<9]<;>GXUQOBX_$3X6Q1ZO9^))==T
M565)4OXP[Q]AN/4@GC<".V:&TMPLWL>Z45RW@'QM9^._#B:G;1F"9&\NX@)S
MY;_7N#U!KJ:IIIV8DTU=!1112&%%%% !1110!'//#;0O-/*D42#+/(P55'N3
MTI+>Y@O+:.YMIHYX)5#QRQ,&5U/0@C@BO"/VAM!^RZ/8:L=3U"=I+PQM!--F
M)00S#:@  QC&>N.N:]7^'G_).O#O_8/A_P#011#WHN79V"6C2[G2T444 %%%
M% !1110 4444 %%%% !1110 4452U/3_ .T[3[,;R[M5)^9K63RW88(QNQD=
M<\8/ YI/R E:_LTODL6NX%O'4NEN9 )&4=2%SD@>M6*^;/A?8G3/V@-3L?M$
MMQ]G^TQB69MSL < L>YKZ3IK6$9=U<3TG*/;_(****!A117CM_KNI_$KXB7G
MA'2]2FTW0M,!-_/;-MFN"#@J&[#/'X'.>E*]Y**W!Z+F9[%17GX^#'@R,&2U
MM;ZUO2#F]@OYA-D]3DL1G//2N36U\8^'_BOX8T35]>N-5T-YI);269%WEEB<
M8=@,E@#W/.<TXZR4>_\ P?\ (3T3EV/;***H6VKVMWK%]ID)9I[)8VF/&T%\
MD#KG.!GIW% R_1110 444V2-98GC8L%<%258J>?0CD'W% #J*\#^-UKJ7@^V
MTR_T+Q'K]K'<2-%+"=6N)%R!D$%G)]>]=C\-/#;:AX,TO6-6UW7[Z\NXQ,?,
MU>X5$Y. %5P"/KFB'O)OMH*3Y6EW/2Z***!A1110 4444 %%%% !5.^U73M+
M\K^T-0M;3SGV1?:)ECWMZ+DC)]A5RO/_ (B_"RU^(5WI]S+J<UE):90[(PX=
M"<D $C:??GZ&EK=#[GH'6BH;2V2SLX+6,L8X8UC4L<G &!G\JFJGOH2KVU"B
MBBD,**** "BHYX5N;>2!S($D4J3'(R, ?1E((/N"#7@'QIM-:\(W>ES^'_$?
MB*.&\$BO;?VI<2;2F#D$L3C!.<GM4N5FKE)7V/H.BO+_ ((>-9O%/A-[/4+E
MY]3T]]DDDK[GD0\JQ)Y)ZC/M7J%:2CRNQG&7,@HHKY;^+7Q'URZ\:W$.B:OJ
M-CIMH3;1M:7#Q+,ZGYVRI&[!./P]ZS<K-(M+1L^I**Y+P5X=2QT33+^XU36+
M^^DMDDDEN]2GD5BR@G]V7V8YXXK:\0:_IWAG1;C5M4G$5K N2>['LJCN3Z5<
M[0O?H3!\Z374TZ*\8\/77BCXP3W%_<W]SH?A1)#'';V3[)KG'4-)UQZ]N< =
MZZAO@OX'8^:=.NOMF0WVO[?/YN[^]G?C/X4K-:M?YA=/8[^BO$=<U'Q1\&;^
MTF^WW6O>$YW\LI>-NFMS_=#_ $Z=N,8'6O7M$UJP\0Z/;:KILXFM;A=R,.H]
M01V(/!%-6:YD#=G9FA1112&%%97B+Q%IOA;19M5U6<16T0[<L[=E4=R:\ZT)
MO%7Q39M4OKNZT'PLQ(M[2S?9/=KZM(.0OTQGI[TEJ[+I^']=@>BNSUJBL/1_
M!WA[0;DW6G:5!%=L,-<L#),1WS(Q+<]^>:A\6ZQJ%A916.APQS:Y?$I:)(?D
MCQ]Z5_\ 94$?B0.]#=M@7F=%17@FN? 3Q'K4<E_?^,_M^J$%@EQ VS=Z!]QV
MCIT7\*J?!_QIXATGQL_@CQ#+/*K,\:+.Q=X)5!. Q_A(!]NA%5'WGR]12=ES
M=#Z&HHKF?%L'BJYT^Y7P_J-CI^V$LLLD)ED9L=!G"H/?#?2HE+E5RDKNQTU%
M>#?L]ZIJ&L:SXEO-3O)[NY9(-TDTA=NK\<]![=*]YK24;6OU1*=V_(**X3QW
MJWB&[O;?PKX19(M4N8_.N;U_NVD&<9_WF.0.,\'ZCSC4_P!GO79HSJ">+_MN
MK* P\^)URPY&)=Y/7OBL[]>A7EU/H*BOGKX5?$;7]*\6KX+\5232[I#;Q-<'
M,D$HZ*6[J>@Z]L<5[OJ^J0:+I5QJ%QN*0KD(HRSL3A5 [DD@#W-7*R2DM4R4
M[MQ>Z+U%>*ZQ\*_&/C_??^)/%*Z?YGS1:7#"TL4"]0I^=1NZ9.#SWKSZWO?%
M?P2\:6]A>733:8Y#&)79H9XB>64'[K#GW!]0>5'62C+1L);<T=;'U73(9HKB
M%9H)4EB<95T8,"/8BEC=9(UD7[K $?0UQ'BRVOO"8F\4^'T+0Q?O-3TT']W<
M1_Q2(/X9!UR.HZYI-V>HUJO=U.YHJAHNLV7B#1K75=/E$MK<H'1NX]CZ$=#5
M^J::=F)--704444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG#_Z *\!_:+\12W/B"P\.Q.1!:Q">1>S2-D#\E'_ (]7OWAS_D6-)_Z\X?\
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M/UKZ0IZ.*E'9@F[N+W0R66."%YII%CB12SNQP% ZDFO*?!'A:/7/B/J_Q#D
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M(_,$?I4GP^\&^(-$U75];\5ZE;ZCJU]LC62!V94C&3M&57')Z 8XIK5^7]:
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MX@^-=77['J^E6>DVSA[6#[1*C[AT=\1GYO3GCM7._P#"K/B__P!#[_Y6+O\
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M(?'<ZDV_VB6*S8]&+'J/HN!^->Z4HJU*$7O:_P!XY.]64OE]P4444#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "LW5Y]6CC2+2+.&::7(,UQ+LCAZ<D#+,>3
M@ <XY(K2HI-7 QO#?AZ+P_9S+YS7-[=2FXO+IU ::4]3@= .@'85LT44Q)6"
MBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !5>]FN+>T>2UM6NIAC;"'";LG'4\ #K^'>K%% '.:1X?N?[;D\0ZW)#+J
MCQ>1#%#DQ6D6<E%) +$GJQ SZ 5T=%%'D)(****!A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<9XI
MNKSQ,DWA?0'*^=^ZU'45'[NUC/WE4_Q2$<;1TSDXXKLZCA@AMH4A@B2*)!A4
MC4*JCV I-)[[!=K8IZ'HECX=T:UTK3H1%:VZ;5'<^I/J2>2:T***IMMW8DDE
M9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7QY<-RP>.3/0+(, Y^F#ZUM?#W2[?2/ &B6MNBJOV1)&(&-S,-S$_4FN+_:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPP_X1B^;7](B_P")1<O^]C4?\>TA[?[I[>AX]*SOA#\2I/!FL#3]0E9M$NW
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M6V>S:)7\IWRVY3C"@GH#7I^B?$BW\=?&;2[?3%E72[*UN"C2#:97*\MCL,#
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MO_/5>T@_K[_6O1:UGI[O0BGK[SW/FS]I+_D:-&_Z\V_]#-:O[-'W?$7U@_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(@;<IP6/ Z'K7T3=>//!$2K<3>)M$<Q'*%;N.1E)&,@ D]"1QVJ?_A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:N4FTEV)4;-ON>1>+/BG;^.?$
MFC^%/#GF-IUQ?P_:;EU*>< X.U0>0O&3G!..GK[[6+:^#_#%C=1W5GX<TBWN
M(CNCEAL8T=#Z@A<BMJI5E&WS&[N5_(*Q/&%];:?X/U>XNYDAB%I*-SG&25.
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MM$L:9/4X4 4HV5V]]OZ^X):V2_K^KGE/QZ\8:YX:TK3;31YY;07K2>;=1'#
M*!A0W\).<Y'/%4_@'XSU[Q"-3TW5[J:^BM422*YG8LZDG&TL>3TSS[UZUKGA
M_2O$FG-I^L6,5Y:L<[),\'U!'(/N"#3- \-:-X6L#9:+816=N6W,J9)8^I8D
MDGZFBG[O-?K_ %^ 5/>Y;=/Z_$U:***!A1110 4444 %%%% !1110 4444 %
M%%% !1110 444UT26-HY%5T8$,K#((/8B@#Q#]I*]MO[ T>Q\]#=&Z,OE!OF
M"A",X],D5V/P7O[6[^&&E0P7$<DMNK),BL"T;;V.".W%=!_P@G@__H5-#_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1N-&TZ[U*'4+F
MT2:Z@ $+R981]>5!X5N3R!GWJ]110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM'_#1W@__H&ZY_WXA_\ CM>P44 >/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\
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M^.U[!10!X_\ \-'>#_\ H&ZY_P!^(?\ X[1_PT=X/_Z!NN?]^(?_ ([7L%%
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M_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM>P44 >/_ /#1W@__ *!NN?\
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MKG_?B'_X[7L%% 'C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
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MM'_#1W@__H&ZY_WXA_\ CM>P44 >/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\
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M^.U[!10!X_\ \-'>#_\ H&ZY_P!^(?\ X[1_PT=X/_Z!NN?]^(?_ ([7L%%
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M_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM>P44 >/_ /#1W@__ *!NN?\
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MKG_?B'_X[7L%% 'C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
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M.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P!
MW7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\
M=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&
MCO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_
M +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\
M':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'
M_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_
M /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^
M_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X
M:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!_
M_0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0
M_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@
MHH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#A
MH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-
MUS_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_
M ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'
M_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-U
MS_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#Q
MVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \
M?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?
M_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_O
MQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H
M_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=KL/ OQ'T?X@
M?;_[)MKZ'[#Y?F?:T1<[]V,;6;^X>N.U=A7C_P (/^2A_$[_ +"H_P#1MQ0!
M[!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDT[3[,F21<$2S;P"0?11D>^3[5WE0M4GW'?5KL%%%% PHHHH **** "BBB@
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MI[]"1Y2[AN(Z[6(PW_ 2:Z6OFWP3\$O%FE^/+*\U%8+>PL+A9OM,<ZMYP4Y
M51R,]#N KZ2J[+E3ZD7?,UT"BBBD4%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/\ P@_Y*'\3O^PJ
M/_1MQ7L%>/\ P@_Y*'\3O^PJ/_1MQ0![!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRFO O@(2/BE:@$\VTV?^^:5%ISE#I_P&_P!"JMU!2Z_\%?YGUE11104%%%%
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MECI#,4AU2:UW?:6'4QEP4V_@3]*[70O&GBG6_A&/$]I_9RZC;1S-.ES;NR7
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M%FN#_P #%=U^T-;1R_#J*9A\\-[&5/U# _SJJON<LEY?B[$4O?<HO^M+G8>
M?&]GX[\.IJ5NGDSH?+N;<MDQO]>X/4&E\=^.-.\":"=0O099I#LM[93AI7_H
M!W->(?LXZC)#XNU+3LDQ7%GYA&> R,,'\F-4/VA-2GNOB%'9,Q\BSM$"+V!;
M+,?QX_*G6T<5'3F_IA2Z\W3^D>C^'[WXF>./#[>)+77K'1HG+M9V"6"RB90>
M-SODKDC&1]>*N?"WXKOXONIM#UNWCM=;@!(\OA)@O#<'HP[C_P#55/P/XF\;
M6W@?1H--^'@O+-+5%BN1K4$?FC'WMI&5SZ&N)\,_#CQ_IWQ+M/$4GA\VMN;\
MS2@7L#^7&['<.'R< GMS5VM5</L_J0VW3YNO]:'TK1114&@4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/_  @_Y*'\
M3O\ L*C_ -&W%>P5X_\ "#_DH?Q._P"PJ/\ T;<4 >P4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%]_)J4$\NEZA+DR20H'CD;^\R''/T(S6+X?_ &=-$TZ]2XUC59]45&W"!81
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M7_AC _:0O;*75=#L;>>)IK6*7S8D/,88KMR!TZ'BND_9N(_X1/5QGG[:./\
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MHJMI]K)96,5O+>W%ZZ#!GN-GF/\ 78JC]*LU#+05\*^)R#XLUD@Y!OI\$?\
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MAKT/_P &,/\ \57/_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4
M=!_PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5<__P *2^'G_0O?
M^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY0!T'_"=^#_ /H:]#_\&,/_ ,51_P )
MWX/_ .AKT/\ \&,/_P 57/\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_
M (Y0!T'_  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\57/_ /"D
MOAY_T+W_ ).W'_QRC_A27P\_Z%[_ ,G;C_XY0!T'_"=^#_\ H:]#_P#!C#_\
M51_PG?@__H:]#_\ !C#_ /%5S_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_
M "=N/_CE '0?\)WX/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57/_\
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M_P#%5S__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE '0?\)WX/\
M^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5<_P#\*2^'G_0O?^3MQ_\
M'*/^%)?#S_H7O_)VX_\ CE '0?\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"A
MKT/_ ,&,/_Q5<_\ \*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE '0?\
M)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \57/_P#"DOAY_P!"]_Y.
MW'_QRC_A27P\_P"A>_\ )VX_^.4 =!_PG?@__H:]#_\ !C#_ /%4?\)WX/\
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M /PI+X>?]"]_Y.W'_P <H_X4E\//^A>_\G;C_P".4 =!_P )WX/_ .AKT/\
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M_P#PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4 =!_PG?@__ *&O0_\
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M0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%5S_\ PI+X>?\
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M .%)?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<H Z#_A._!__ $->A_\
M@QA_^*H_X3OP?_T->A_^#&'_ .*KG_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\
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M_P 57/\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y0!T'_  G?@_\
MZ&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\57/_ /"DOAY_T+W_ ).W'_QR
MC_A27P\_Z%[_ ,G;C_XY0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\
M!C#_ /%5S_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE '0?\)WX
M/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57/_\ "DOAY_T+W_D[<?\
MQRC_ (4E\//^A>_\G;C_ ..4 =!_PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H
M:]#_ /!C#_\ %5S_ /PI+X>?]"]_Y.W'_P <H_X4E\//^A>_\G;C_P".4 =!
M_P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%5S_P#PI+X>?]"]
M_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4 =!_PG?@__ *&O0_\ P8P__%4?\)WX
M/_Z&O0__  8P_P#Q5<__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_X
MY0!T'_"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%5S__  I+X>?]
M"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE '0?\)WX/\ ^AKT/_P8P_\ Q5'_
M  G?@_\ Z&O0_P#P8P__ !5<_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)V
MX_\ CE '0?\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5<_\
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MC#_\57/_ /"DOAY_T+W_ ).W'_QRC_A27P\_Z%[_ ,G;C_XY0!T'_"=^#_\
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MG_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE '0?\ "=^#_P#H:]#_ /!C#_\
M%4?\)WX/_P"AKT/_ ,&,/_Q5<_\ \*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\
MR=N/_CE '0?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \57/_P#"
MDOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4 =!_PG?@__H:]#_\ !C#_
M /%4?\)WX/\ ^AKT/_P8P_\ Q5<__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%
M[_R=N/\ XY0!T'_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 5
M7/\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y0!T'_  G?@_\ Z&O0
M_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\57/_ /"DOAY_T+W_ ).W'_QRC_A2
M7P\_Z%[_ ,G;C_XY0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_
M /%5S_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE '0?\)WX/_Z&
MO0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57/_\ "DOAY_T+W_D[<?\ QRC_
M (4E\//^A>_\G;C_ ..4 =!_PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_
M /!C#_\ %5S_ /PI+X>?]"]_Y.W'_P <H_X4E\//^A>_\G;C_P".4 =!_P )
MWX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P__%5S_P#PI+X>?]"]_P"3
MMQ_\<H_X4E\//^A>_P#)VX_^.4 =!_PG?@__ *&O0_\ P8P__%4?\)WX/_Z&
MO0__  8P_P#Q5<__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY0!T
M'_"=^#_^AKT/_P &,/\ \57#_%_Q9X;U/X6ZS9V'B#2KNZD\C9#!>QR.V)XR
M<*#DX )_"MC_ (4E\//^A>_\G;C_ ..5Q_Q2^%O@WPY\.-6U;2=&^SWT'D^7
M+]JF?;NF13PSD'@D<B@#M/!?C3PK:^!?#UO<>)=&AGBTRV22.2_B5D81*"""
MV00>,5N?\)WX/_Z&O0__  8P_P#Q5</X3^$'@34_!NAW]YH7F75UI]O-,_VN
M<;G:-2QP'P,DGI6Q_P *2^'G_0O?^3MQ_P#'* .@_P"$[\'_ /0UZ'_X,8?_
M (JC_A._!_\ T->A_P#@QA_^*KG_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_
MY.W'_P <H Z#_A._!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8?_BJY_\
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MX/\ ^AKT/_P8P_\ Q5<__P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\
MXY0!T'_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 57/\ _"DO
MAY_T+W_D[<?_ !RC_A27P\_Z%[_R=N/_ (Y0!T'_  G?@_\ Z&O0_P#P8P__
M !5'_"=^#_\ H:]#_P#!C#_\57/_ /"DOAY_T+W_ ).W'_QRC_A27P\_Z%[_
M ,G;C_XY0!T'_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%5S_\
MPI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_ "=N/_CE '0?\)WX/_Z&O0__  8P
M_P#Q5'_"=^#_ /H:]#_\&,/_ ,57/_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^
MA>_\G;C_ ..4 =!_PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
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M_P#P8P__ !5<_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE '0?\
M"=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5<_\ \*2^'G_0O?\
MD[<?_'*/^%)?#S_H7O\ R=N/_CE '0?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^
MAKT/_P &,/\ \57/_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4
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M "=N/_CE '0?\)WX/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57/_\
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M_P#%5S__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE '0?\)WX/\
M^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5<_P#\*2^'G_0O?^3MQ_\
M'*/^%)?#S_H7O_)VX_\ CE '0?\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"A
MKT/_ ,&,/_Q5<_\ \*2^'G_0O?\ D[<?_'*/^%)?#S_H7O\ R=N/_CE '0?\
M)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \57/_P#"DOAY_P!"]_Y.
MW'_QRC_A27P\_P"A>_\ )VX_^.4 =!_PG?@__H:]#_\ !C#_ /%4?\)WX/\
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M /PI+X>?]"]_Y.W'_P <H_X4E\//^A>_\G;C_P".4 =!_P )WX/_ .AKT/\
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M<L>!6-_PG?@__H:]#_\ !C#_ /%54^(^E2Z[X,GTB$LK7L]O 65<[5:5-Q_
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MAB)2 <#V 'X5](T0UI\SWNU]PI:3Y?)/[PHHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%9GB'6[7PYX?O=7O& AM8BY']X]E'N3@?C4FAWLNI:!IU].$
M66YMHY7" A064$XR3QS0M;^0/2QD^-/'6C^!--AO=6^T.)I/+BBMT#.YZGJ0
M, >IK7T;5[/7M'M=5L'+VMU&)(V9<''N/6J_B'PQHWBJP%CK=A'>6ZN'569E
M*MZAE((_ U?LK*VTZRALK.!(+:! D<2#"JHZ 4+9W^7H#W5B>BBB@ HHHH *
M*** "LC7O%.A^&+;S]9U.WLU(RJR-\[?[JCEOP%:]<1\5-(T^[^'GB"XFL[=
M[A+0NLS1 N"O(^;KQ_6HJ2<8W145=V-GPGXNTWQGI4FI:4)_LR3-"&F0*6(Q
MR!D\<]\'VK>KR?\ 9Z_Y)Q)_U_2?R6O6*UFK.WI^2,H2<E=^?YA7%^(/BCX;
M\->*;7P]?O<_;)]N7CBW1Q;CA=YSGGV!]Z[2L'5/!?AS6=;M=9U'28+C4+7'
ME3-GC'(R <-CMD'%2OB5]NI;^%VWZ&]1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%<]XU\41>$O#<VHL4,[,L-M&_(>1C@# () ZGV!KH%.5!]
M10M?Z^8=;"T444 %%%% !1110 4444 >/_%__DH?PQ_["I_]&V]>P5X_\7_^
M2A_#'_L*G_T;;U[!0 4444 4]2U73]&LGO-3O8+.V3K+/($7Z9/?VKS^V^-7
MA63Q7>V$VLVB::D4?V>X$,OSRY;S 6QC  7!X!SU-<E9WL/CC]H2[T_70)[#
M2Q*ME9R',>]"!DKT)^\>?0>E>B:?:V\GQ-\0VSV\36_]F62^4R K@-+QCI2A
M=I2[IO\ K^M!3=FX]FOQ.KT_4K'5K1;O3KR"[MW^[+!('4_B*M$@ DG %>:Z
M)X.L?"?Q@DFTF(6UAJ6ER2&WCX1)$D0' Z 88<=LG%:OCNSU+Q++9^$]/N7L
MX+Q6FU&ZC^\D"D#8ONY./H#0WHFMW_P?\K@M&^;I_7_ ':G\6/ ND7;6MWXB
MM_-4D,((Y)@".H)12 :Z/1]=TK7[/[7I.H6][!G!>%PV#Z'T/UKAE^!'@(6/
MV<Z;<-+C'VDW<F_ZXSM_\=KQNYM-4^"GQ1MTMKJ26QE*L">!<0,<%6'3<.?Q
M -.-G)0>[V"5^5R73H?5M%(K!E##H1D4M UJ4=8UG3] TJ?4]4NEMK. 9DE8
M$XYP.!DD^PI=)U:RUS2K?4]-G\^SN%WQ2;&7<,XZ, 1T[BO!_C)J][XLT2_N
M[*1H_#VD726ZN.EY<$X8C_909'U->I?"?_DEGA__ *]O_9C2@^9-^GX_U_5Q
M2=I**\_PL=G1113&%84WC7PI;S/#-XGT6.6-BKH]_$&4C@@@MP:J^/-?FT'P
MV_V$;]4O76SL(QU:9^ ?H!EOPKR;_AFB27]Y-XO_ 'K?,_\ Q+]W)Z\^;S4I
MMM]OU'I\SVK3_%/A[5KH6NG:]I=Y<$%A%;7D<CD#J<*2:UJ\X^&WPEM_A]?W
ME\VI_P!HW,\8B1S;>5Y:YR?XFSGCTZ5U_B4:M-I7V31OW=U=.(?M/&+9"#ND
MQW( X [D54M%IJ3&[;N9VO?$CPAX:NS::KKEO#<J<-$BM*Z'_:" D?C6EH/B
MC1/$]J;C1=3@O(UQN$;?,F>FY3@K^(KC8?@7X&%F8[JRNKNZ89>\ENY/,9CU
M; (7.>>E>1VNBZA\+_CCIVEZ;<RSP7$T03/!E@D."' X)'/Y9XHAK)0>[";:
MBYKH?4M%%<7\1_B%9^ M%64HMQJ5QE;2VS]X]V/HHS^/2IE*R*2N=/J>KZ;H
MMHUWJE];V=N/^6D\@0?09ZGVJAH_B_1=?N6@TN>XN=HSYJV<PA_"4H$/MSS7
M%>!_ 5UJ<T?BWQTQU'6K@"2"VF&8K-#R $Z!NGT^O->H]*NS7Q;D*7-K'8**
M**104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_\;?\ DD.N_P#;
MO_Z41UZ!7G_QM_Y)#KO_ &[_ /I1'0!T'@3_ ))YX:_[!5K_ .BEKH*Y_P "
M?\D\\-?]@JU_]%+704 %%%9/B7Q#9>%?#]WK.H,1!;IG:O5VZ!1[D\4FU%78
MTFW9&A=7=M8VSW-W<16\$8R\LKA%4>I)X%<9=?&+P!9S>5+XCA9L9S#!+*O_
M 'TBD?K7G'@W3=3^-&OW'B#Q3+)_8-G+MMM.1B(F?KCW !&3U.<=.*]VT_3+
M#2K5;;3[."T@48$<$81?R%.S2O+[B;INR,[1?&/ASQ$=ND:U97<G7RTE&_U^
MZ>?TK1L-1L]4MVN+&=9X5D>(NG3<C%6'X$$5R7CCX8:!XSTZ8-:0VNI[28;V
M) K!NV['WAZ@_A5/X+6ESIO@'^S+Q/+N;*^N()%]"&Y_G1%IW3W7^8.ZMY_Y
M7/0Z***!A1110 4444 %%<[XH\4Q>'[G1K-3&UWJE]';1HW/R$_.V 1T''U(
MKHJ%JK_U_6H=;!1110 4444 %%%% !7(>,_B3H'@6XL[?5C<M+=Y*K;QAMB@
MX+-DCCZ9/M77UA^(/!WA_P 5-;-K>F17C6S;HBY8%?;@C(]CQ[4M;H>FIL6\
M\5U;17$+;HI4#HWJI&0:DIJ(L:*B*%10 J@8 'I3JIVOH2KVU"BBBD,****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ
M_P /?\G0^+/^P5'_ .@VM>P5X_X>_P"3H?%G_8*C_P#0;6@#V"BBB@ HHHH
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M_,U] U\SNQN/VI096'RZ@ ,C^['Q_*ICK6@OG]PYNU*;\K?>?2ZJ%4*!@ 8
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M+]]Y[\*N/\^]>LW5M%>6DUM.@>*9#&ZGN",$54XN"]W>WW]?^ 3"2FVWM?\
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MTEX>RP^4VH/L=S?XBOH6O,M1^".BZMKC:U?>(/$,NHEU?[1Y\*D,O3&(@!C
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M''(_ Y'X5IU<DXMIBC)22:/&OVC_ /D2=,_[" _]%O7H'P\.?ASX=_[!\/\
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M\.^&]+\*Z1'IFD6RP6Z<GNSMW9CW)IQTES]KV^82NX\O?<\K_:2/_%):./\
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MMX[>VA7;'%$NU5'L*J.DN?[OF)W<>7[RQ1112*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O/_C;_P DAUW_ +=__2B.O0*\_P#C;_R2'7?^W?\
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M13O))=4[GBGQ!E2']H_P[)(P5!]ER3_OL*^@6N($N([=IHUFD!9(RP#,!C)
MZD#(S]17!_$3X56'CV>VO1?RZ=J5NNQ;A(]X*YR 5R.G."".M;7A'P='X7@9
MY]4OM6U&10DE[?2L[[1T502=J^V:5/2'*^C?XCDO?YEU2_ Z:JFJ$#2;PDX
M@?)/^Z:MUB^(_#S>([%K)M9U+3[>1&25+%HE,H/JS(Q'_ 2.M34BY0<5U+B[
M239X]^S3*GV7Q#%GYP\+8]L,*][(R"*\W\._!K2O"=ZUYH?B'Q!:3.NURLL#
M*X]"K1$'\17HZ@A0"22!U/>MIM22]+&44XW]3Y5TW6KOX/\ Q=U)+N!WL9)&
M25%'+P,VY'7/4CC]17T#:?$KP5>V(NX_$VF(A7=LFN%CD'&<;&(;/X4WQO\
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M^>/@A(EE\5/$]A,VV=EE55/!)67FO7?B/J-II_@+65NIUC>XLYHH4ZM(Y0\
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M'15!)VK[9KIJ3*3;W"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O'_ (0?\E#^)W_85'_HVXKV"O'_
M (0?\E#^)W_85'_HVXH ]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?\
M#W_)T/BS_L%1_P#H-K7L%?/FJ>"M-\>?M$>)M+U2>[A@BLHKA6M756+".W7!
MW*PQASV]* /H.BO'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /
M_P :H ]@HKQ__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\ O_#_ /&J /8*
M*\?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_  __ !J@#V"BO'_^
M&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:H ]@HKQ_\ X9Q\'_\
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M[!17C_\ PSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z"6N?]_X?_C5 'L%%>/\
M_#./@_\ Z"6N?]_X?_C5'_#./@__ *"6N?\ ?^'_ .-4 >P45X__ ,,X^#_^
M@EKG_?\ A_\ C5'_  SCX/\ ^@EKG_?^'_XU0![!17C_ /PSCX/_ .@EKG_?
M^'_XU1_PSCX/_P"@EKG_ '_A_P#C5 'L%%>/_P##./@__H):Y_W_ (?_ (U1
M_P ,X^#_ /H):Y_W_A_^-4 >P45X_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\
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M_02US_O_  __ !JC_AG'P?\ ]!+7/^_\/_QJ@#V"BO'_ /AG'P?_ -!+7/\
MO_#_ /&J/^&<?!__ $$M<_[_ ,/_ ,:H ]@HKQ__ (9Q\'_]!+7/^_\ #_\
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M (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T$M<_[_P__&J /8**\?\ ^&<?!_\
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M_02US_O_  __ !JC_AG'P?\ ]!+7/^_\/_QJ@#V"BO'_ /AG'P?_ -!+7/\
MO_#_ /&J/^&<?!__ $$M<_[_ ,/_ ,:H ]@HKQ__ (9Q\'_]!+7/^_\ #_\
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M (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T$M<_[_P__&J /8**\?\ ^&<?!_\
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M:H_X9Q\'_P#02US_ +_P_P#QJ@#V"BO'_P#AG'P?_P!!+7/^_P##_P#&J/\
MAG'P?_T$M<_[_P /_P :H ]@HKQ__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+
M7/\ O_#_ /&J /8**\?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_
M  __ !J@#V"BO'_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:H
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M:H_X9Q\'_P#02US_ +_P_P#QJ@#V"BO'_P#AG'P?_P!!+7/^_P##_P#&J/\
MAG'P?_T$M<_[_P /_P :H ]@HKQ__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+
M7/\ O_#_ /&J /8**\?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_
M  __ !J@#V"BO'_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:H
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M4$X &<#T% 'ME%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW:W)AF_TN<RE#YN" 3T' X[5].41UAS>;7W"EI/E\D_O"BBB@84444 %%%%
M!14-U<PV5I-=7#B.&%#)(Y/"J!DFF:=?1ZGIEK?PJZQ7,2RHK@!@&&1G!(SS
M0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?,DE:/RQP, !<G''OS0MW?Y ^ECLZ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\?^$'_)0_B=_P!A4?\ HVXKV"O'_A!_R4/XG?\ 85'_ *-N* /8
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "O'_#W_ "=#XL_[!4?_ *#:U[!7
MC_A[_DZ'Q9_V"H__ $&UH ]@HHHH BNH?M%I-!G'F(R9],C%?*7@OQ?J7P?\
M7ZCI6JV;R6K2".ZA'##;G;(G8\'\0:^LJY#QO\.-"\=VH&H1&&]C&(KR' D3
MV/\ >7V/X8J=8RYUZ,;2E'E9K^'?%.B^*]/%[HU_%<Q<;U!P\9]&4\@_6I9]
M&CG\1V6L[PLMM;RV^W;]]7*'KGC&S]:^6O$7P_\ &?PNU$:K8S3-;1GY-1L2
M0 /1UZJ/4'*^YKU;X5_&4^*KN/0M>2.+5&!\FXC&U)\#H1V;Z<'VK2-I:QW(
M;<=);'<^./%EUX6TEI=/T34=5OG1C%':VKR1IC^*1E&%'MU/ZUXU\(_B!=VE
MSXAU"_T37]:NK^X26272[+SPAP>&Y&WV'H*^A-3_ .05>?\ 7!__ $$UXC^S
M3_R#_$'_ %UA_DU13^.7I^HZC]V/K^C/:M+U-=3TB#46M+JQ65-Y@O8_*EC'
M^VN>#Q7'O\2I=5NKFW\&^'+OQ%]F;9+<K.EM;[NX61_O'Z#TK'^/GB:;0_!,
M>GVLC1SZG*8F9>"(@,M^? ^A-=?\.M+AT?X>Z':PHJYM$E? ^\[C<Q_,T1][
MF?1:?/\ X /W>5=7K\CG++XOVUOKJ:)XMT2[\.7TGW&GD$L+>G[P <>^,>]>
M@7VI6>FV37EW.L< Q\V"V<]  ,DGV%>>_'/PY#K7P]N;[RU^UZ:1/&^.=N<.
M/ICG\!3/@3XDGUWP%]FNY&DGTZ8V^]CDE, K^0./PIQ]Y275?D$O=:?1_F3:
M7\:-!UOQ>NAV%M<"!4E>:]N?W*($4L2%//;OMQ6?>?'2QLO%T&CS>'M2CM)F
M54NYP8G8,<!UB9<E#U!R#[5Q-II=M??M07MM,#Y G>5D4X#D1!L-Z@GJ.]?0
MMSIMC>3P3W5E;3S6[;H9)8E9HCZJ2,@_2E#6,)OKN*3?-.*^7W&-XP\;Z/X)
MT^.YU1Y&DF)6WMH5W23-Z ?ER>.:Y:_^)/BK2[!M5O/AQ>QZ2HWM.-0C:54_
MO-$%)7WR>/6CQ_\ #*_\8>-=#UJWU*&&ULBHGAESD!7W93 P2>G..@K=\5>.
M/#>FPW.DW%W]LOIHGC^P6<9GF;(/!5<X_P"!8J')J#EUUT]/\S2UY)=--?Z[
M%_P?XRTKQOHHU/2G?:&V2Q2C#Q-Z$?UK1UG6M/\ #^E3ZGJETEM:0C+R/^@
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M\KLSC+W92?2_YV1U\WQ \37%H-0T7X>ZA>::5WK-<7L5O(Z]BL1W,01R*T/
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MSL:/1I=]23PQ\7-.UG7SX>UC3;G0M:#;!;W+!E9O[H; Y],@9[9KT4D $DX
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M@,<AAG('/%5'XU%[/\!2OR-]5^)]&T4#H,\&BD4%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X
M_P#"#_DH?Q._["H_]&W%>P5X_P#"#_DH?Q._["H_]&W% 'L%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN$<,T=NL$G/(=/E(/Y9_&M-_#4&H>%I=$UN9]26X0_:9)"<LS')*_P!T _=
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M3R1*S?9;F.9P!GY>5)_\>I/@IXULM?\ !UII$DZ+J>G1^2\+-\SQC[K =QC
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M?=W_ "^XP?V;O^12U?\ Z_A_Z *X_P")]U/X.^.]KXA\LM&WDW(_VE V,/\
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MW2[ (JB!]UU.%^ZK.CE0O SC!(X[FHI[2B^]_E8=3>,O*WXGJ5%%%,H****
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M@;2,D9,>8L$^N<9]16]6TZC[.[_X'J]O+?L8PO&GYK^OZ[['G7CWP!K7@/\
ML[QOI=]/<ZC%)YNIS=A,QR7 '\!)*D>F/6O;O!'BZS\:^&;?5K3"N?DGASS%
M(.H_J/8U>\16MW?:#=V=G:6=U+<1F(Q7LK1Q%6&#DJK'\,?B*\@\!_##XA^
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MNF:?^]D)WS3OPTTGJ?0=@.PIQTDYOM9?,4M8\B[J_P CR+]H7CQ1X4)]'_\
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M]#GH?_?E?_D>@#V"BO'_ /A'OCG_ -#GH?\ WY7_ .1Z/^$>^.?_ $.>A_\
M?E?_ )'H ]@HKQ__ (1[XY_]#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z /8**
M\?\ ^$>^.?\ T.>A_P#?E?\ Y'H_X1[XY_\ 0YZ'_P!^5_\ D>@#V"BO'_\
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M  CWQS_Z'/0_^_*__(] 'L%-?<8VV$!\':3TS7D/_"/?'/\ Z'/0_P#ORO\
M\CT?\(]\<_\ H<]#_P"_*_\ R/2:NK <?X4\:ZE\+?%NLVOC;3+MFU.?S7O$
M&XE@3\RYX=.>QX].U>G)\</AZ\2NVN,C$9*-9SY'MPA'ZUS=SX2^-5["8;OQ
M5X=GB/5);9&7\C;5F6GPO^)UA.)K/4?!EO*.CPZ9 C?F+6FKV2?0&E=M=3NA
M>S?$IK6.WT^ZM/#4<J7$UQ=IY;WA4AE2-.NS< 2QQG&!ZUW]>/\ _"/?'/\
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MRO\ \CTAGL%%>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\
MR/0![!17C_\ PCWQS_Z'/0_^_*__ "/1_P (]\<_^AST/_ORO_R/0![!17C_
M /PCWQS_ .AST/\ [\K_ /(]'_"/?'/_ *'/0_\ ORO_ ,CT >P45X__ ,(]
M\<_^AST/_ORO_P CT?\ "/?'/_H<]#_[\K_\CT >P45X_P#\(]\<_P#H<]#_
M ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\
M(]'_  CWQS_Z'/0_^_*__(] 'L%%>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\
M<_\ H<]#_P"_*_\ R/0![!17C_\ PCWQS_Z'/0_^_*__ "/1_P (]\<_^AST
M/_ORO_R/0![!17C_ /PCWQS_ .AST/\ [\K_ /(]'_"/?'/_ *'/0_\ ORO_
M ,CT >P45X__ ,(]\<_^AST/_ORO_P CT?\ "/?'/_H<]#_[\K_\CT >P45X
M_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(] 'L%%>/_P#"
M/?'/_H<]#_[\K_\ (]'_  CWQS_Z'/0_^_*__(] 'L%%>/\ _"/?'/\ Z'/0
M_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\ R/0![!17C_\ PCWQS_Z'/0_^_*__
M "/1_P (]\<_^AST/_ORO_R/0![!17C_ /PCWQS_ .AST/\ [\K_ /(]'_"/
M?'/_ *'/0_\ ORO_ ,CT >P45X__ ,(]\<_^AST/_ORO_P CT?\ "/?'/_H<
M]#_[\K_\CT >P45X_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS_P"AST/_ +\K
M_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\ (]'_  CWQS_Z'/0_^_*__(] !\7_
M /DH?PQ_["I_]&V]>P5\R>.]*^)%MXJ\'1>(/$&FW>H37I72I88P%@EWQ?,^
M(ER-QC/1NAX]>[_X1[XY_P#0YZ'_ -^5_P#D>@#V"BO'_P#A'OCG_P!#GH?_
M 'Y7_P"1Z/\ A'OCG_T.>A_]^5_^1Z /8**\?_X1[XY_]#GH?_?E?_D>C_A'
MOCG_ -#GH?\ WY7_ .1Z /8**\?_ .$>^.?_ $.>A_\ ?E?_ )'H_P"$>^.?
M_0YZ'_WY7_Y'H ]@HKQ__A'OCG_T.>A_]^5_^1Z/^$>^.?\ T.>A_P#?E?\
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M#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z /8**\?\ ^$>^.?\ T.>A_P#?E?\
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M]#GH?_?E?_D>@#V"BO'_ /A'OCG_ -#GH?\ WY7_ .1Z/^$>^.?_ $.>A_\
M?E?_ )'H ]@HKQ__ (1[XY_]#GH?_?E?_D>C_A'OCG_T.>A_]^5_^1Z /8**
M\?\ ^$>^.?\ T.>A_P#?E?\ Y'H_X1[XY_\ 0YZ'_P!^5_\ D>@#V"BO'_\
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MS_Z'/0_^_*__ "/1_P (]\<_^AST/_ORO_R/0![!17C_ /PCWQS_ .AST/\
M[\K_ /(]'_"/?'/_ *'/0_\ ORO_ ,CT >P45X__ ,(]\<_^AST/_ORO_P C
MT?\ "/?'/_H<]#_[\K_\CT >P45X_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS
M_P"AST/_ +\K_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\ (]'_  CWQS_Z'/0_
M^_*__(] 'L%%>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\
MR/0![!17C_\ PCWQS_Z'/0_^_*__ "/1_P (]\<_^AST/_ORO_R/0![!17C_
M /PCWQS_ .AST/\ [\K_ /(]'_"/?'/_ *'/0_\ ORO_ ,CT >P45X__ ,(]
M\<_^AST/_ORO_P CT?\ "/?'/_H<]#_[\K_\CT >P45X_P#\(]\<_P#H<]#_
M ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\
M(]'_  CWQS_Z'/0_^_*__(] 'L%%>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\
M<_\ H<]#_P"_*_\ R/0![!17C_\ PCWQS_Z'/0_^_*__ "/1_P (]\<_^AST
M/_ORO_R/0![!17C_ /PCWQS_ .AST/\ [\K_ /(]'_"/?'/_ *'/0_\ ORO_
M ,CT >P45X__ ,(]\<_^AST/_ORO_P CT?\ "/?'/_H<]#_[\K_\CT >P45X
M_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(] 'L%%>/_P#"
M/?'/_H<]#_[\K_\ (]'_  CWQS_Z'/0_^_*__(] 'L%%>/\ _"/?'/\ Z'/0
M_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\ R/0![!17C_\ PCWQS_Z'/0_^_*__
M "/1_P (]\<_^AST/_ORO_R/0![!17C_ /PCWQS_ .AST/\ [\K_ /(]'_"/
M?'/_ *'/0_\ ORO_ ,CT >P45X__ ,(]\<_^AST/_ORO_P CT?\ "/?'/_H<
M]#_[\K_\CT >P45X_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS_P"AST/_ +\K
M_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\ (]'_  CWQS_Z'/0_^_*__(] 'L%%
M>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_*_\ R/0![!17C_\
MPCWQS_Z'/0_^_*__ "/1_P (]\<_^AST/_ORO_R/0![!17C_ /PCWQS_ .AS
MT/\ [\K_ /(]'_"/?'/_ *'/0_\ ORO_ ,CT >P45X__ ,(]\<_^AST/_ORO
M_P CT?\ "/?'/_H<]#_[\K_\CT >P45X_P#\(]\<_P#H<]#_ ._*_P#R/1_P
MCWQS_P"AST/_ +\K_P#(] 'L%%>/_P#"/?'/_H<]#_[\K_\ (]'_  CWQS_Z
M'/0_^_*__(] 'L%%>/\ _"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\ H<]#_P"_
M*_\ R/0![!17C_\ PCWQS_Z'/0_^_*__ "/1_P (]\<_^AST/_ORO_R/0![!
M17C_ /PCWQS_ .AST/\ [\K_ /(]'_"/?'/_ *'/0_\ ORO_ ,CT >P5X_\
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M* "BBB@ HHHH **** /'_B__ ,E#^&/_ &%3_P"C;>O8*\?^+_\ R4/X8_\
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_XV_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7C_A[_DZ'Q9_V"H__ $&UKV"O'_#W_)T/BS_L%1_^@VM
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M^T'&=H&3VI)I4E)]F_Q_K\!6;JR2\OR+.M>(M&\.6PN-8U*VLHF.%,S@%CZ
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M2_%_\#4=2WN^K_(]KCDCFB26)U>-U#*ZG(8'H0>XIU-CCCAB2*)%2-%"JBC
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M[3Q+X O0IVB2<10O$@DSR-K*O##&0..M>Z>/_B"/#7PXBUNUVB^U")%LU(R
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M\1D0*$AOH],F<E1T#C;GCU&?I71?$_P,OQ%\)P2V&8]1MQYUH9XVB+ CE&#
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M-I6G2&,RH"1F23[Q!]!C.,\5H?%K1+OQM\-F.CP7$D\4RW*020O%(X7((V.
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M=Q?E_2.GL? VI^*_BF?&NNVC6%A:%186<I!EDV?=9P"0HSEL=>E2_M!QR/\
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MFVL(SF4Z5.@9BP. &0'L.HHVJ0OT:;_$7Q0E;JG8^B4^XOT%?/6N?\G3V/\
MUUA_]%5[5IOB:VO-&:^>QU:W,**98)M,N%E4GLJ;,O\ \ S7A6L-K=S\<H?%
MEOX3\0OID-Q%\QTR8,R*H4L%VY]3BFM*T?*_Y">M"7FE^A[1\2_^2:>(_P#K
MQD_E7(_L]?\ ).)/^OZ3^2UV7B6%_%GP^U:VTZ.=9;RTECB2YMW@?=@@ JX#
M#GU%>-_!_P ;W?A>SO/",_AW5+O5/M)DAAAB V$@ B0L1L'&<X/6E#2<UU:7
MX!4VC+HF_P CZ*HJ"R^U?8H/MQB-UL'F^2"$W8YVY).*GILI:A1110 4444
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M_E.R"&U@>15./O/M!P!^M>&Z)XM^*6AW-[>1^!Y[J_O7WW%Y=:3=-*X[+D,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "3KP[_V#X?_ $$5I>(-:L?#^AW6I:BP%M$G*XR9"> @'<D\ >]<S\-M89?
M^GV%]I>KV-YI]H$FBN=.F3(08RAVX8GLHRWM7.Q:U>>+?B9:_P!L>'=?M= L
M#NT\3:9,(Y;C.!)+\OR@<[<\#J<5O6]^JXKK?[OZV\S&F^6G=]/S_K?R/,Y;
M;7_A-XLT[Q>^GQ6]AJ9=GLXR2(48Y,+9Z,%P1[CVKZ;TG5;/6]*MM2L)EFM;
MA \;CN/\>U8WCW3M.U7P;?V6I6MU<PR)A%M+9YY5D_A950$Y![]/6O&_A%K7
MBWP9+)I6L>%O$+Z+,Q=6739F-N_<@;<E3W ^M1!WO3?3;T[?U^HYIJT^^_\
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M !1110 4444 %%%% !1110 4444 %>/_  @_Y*'\3O\ L*C_ -&W%>P5X_\
M"#_DH?Q._P"PJ/\ T;<4 >P4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/^
M'O\ DZ'Q9_V"H_\ T&UKV"OGS5/$FI>%_P!HCQ->Z7X>N]=G>RBB:VM2VY%,
M=N=YVHQP"H'3^(<T ?0=%>/_ /"W_&'_ $2;7/SF_P#C%'_"W_&'_1)M<_.;
M_P",4 >P45X__P +?\8?]$FUS\YO_C%'_"W_ !A_T2;7/SF_^,4 >P45X_\
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M_1)M<_.;_P",4 >P45X__P +?\8?]$FUS\YO_C%'_"W_ !A_T2;7/SF_^,4
M>P45X_\ \+?\8?\ 1)M<_.;_ .,4?\+?\8?]$FUS\YO_ (Q0![!17C__  M_
MQA_T2;7/SF_^,4?\+?\ &'_1)M<_.;_XQ0![!17C_P#PM_QA_P!$FUS\YO\
MXQ1_PM_QA_T2;7/SF_\ C% 'L%%>/_\ "W_&'_1)M<_.;_XQ1_PM_P 8?]$F
MUS\YO_C% 'L%%>/_ /"W_&'_ $2;7/SF_P#C%'_"W_&'_1)M<_.;_P",4 >P
M5A^(_&'A_P )1P/KNI1V8G8K$&5F+8Z\*"<#(YZ5YW_PM_QA_P!$FUS\YO\
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M ,8H ]@HKQ__ (6_XP_Z)-KGYS?_ !BC_A;_ (P_Z)-KGYS?_&* /8**\?\
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M_&* /8**\?\ ^%O^,/\ HDVN?G-_\8H_X6_XP_Z)-KGYS?\ QB@#V"BO'_\
MA;_C#_HDVN?G-_\ &*/^%O\ C#_HDVN?G-_\8H ]@HKQ_P#X6_XP_P"B3:Y^
M<W_QBC_A;_C#_HDVN?G-_P#&* /8**\?_P"%O^,/^B3:Y^<W_P 8H_X6_P",
M/^B3:Y^<W_QB@#V"BO'_ /A;_C#_ *)-KGYS?_&*/^%O^,/^B3:Y^<W_ ,8H
M ]@HKQ__ (6_XP_Z)-KGYS?_ !BC_A;_ (P_Z)-KGYS?_&* /8**\?\ ^%O^
M,/\ HDVN?G-_\8H_X6_XP_Z)-KGYS?\ QB@#V"BO'_\ A;_C#_HDVN?G-_\
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MQ0![!17C_P#PM_QA_P!$FUS\YO\ XQ1_PM_QA_T2;7/SF_\ C% 'L%%>/_\
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M ,8H_P"%O^,/^B3:Y^<W_P 8H ]@HKQ__A;_ (P_Z)-KGYS?_&*/^%O^,/\
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MDVN?G-_\8H_X6_XP_P"B3:Y^<W_QB@#V"BO'_P#A;_C#_HDVN?G-_P#&*/\
MA;_C#_HDVN?G-_\ &* /8**\?_X6_P",/^B3:Y^<W_QBC_A;_C#_ *)-KGYS
M?_&* /8**\?_ .%O^,/^B3:Y^<W_ ,8H_P"%O^,/^B3:Y^<W_P 8H ]@HKQ_
M_A;_ (P_Z)-KGYS?_&*/^%O^,/\ HDVN?G-_\8H ]@HKQ_\ X6_XP_Z)-KGY
MS?\ QBC_ (6_XP_Z)-KGYS?_ !B@#V"BO'_^%O\ C#_HDVN?G-_\8H_X6_XP
M_P"B3:Y^<W_QB@#V"BO'_P#A;_C#_HDVN?G-_P#&*/\ A;_C#_HDVN?G-_\
M&* /8**\?_X6_P",/^B3:Y^<W_QBC_A;_C#_ *)-KGYS?_&* /8*\?\ A!_R
M4/XG?]A4?^C;BC_A;_C#_HDVN?G-_P#&*I_ J\FU'Q5\0+VXM)+.>XO8I9+:
M3.Z%F><E#D Y!..@Z=!0![91110 4444 %%%% !1110 4444 %%%% !1110
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M S_*2!Z?A71^#?&>E^-M&_M#3BR.AV3V\G#POZ'^A[T+4&['14444#"BBB@
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MENBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KQ_X0?\E#^)W_ &%1_P"C;BO8*\?^
M$'_)0_B=_P!A4?\ HVXH ]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWMLNBZOHC^&=,NVV2S,&EWKGE?, P1@<A1D_0TZZYKQ76YG0]V,6^B7Y(?\
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M@D$G))P.OUKUW3O"W@34K6*^TW0/#MS _P R3064+ _0A:XW6?V>_"-] _\
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M\K+];_=I]Y#?-:#]?^&_4OT445)84444 %%%% !1110 4444 %%%% !1110
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M"YST  XK22M.,>]OQ)@^9/R/II6#*&4@@C(([U!+?V<%Y#:2W<$=S/GRH7D
M>3 R=JYR> >E5WLS?Z+%;"ZN;7=&F9+9PK@8' .#C/MS7S?H^F7FE?M%RZ=I
M]X\T\<LJQ7%\[2LH,).6/5\ ],C..HI+^)R>OX"YOW?/Z?B?2.I:WI.C*C:I
MJEE8JYPINKA(@Q]MQ&:MP3PW,*302I+$XRKQL&5AZ@CK7 :G\&O"^M0SRZG]
MNO-5F4[M1FNG,@;U"@A !Z;<5Y?\'9/$"ZWKO@NSU7[+;H6,DX^9X=C[&,0/
M 9LCD\#K@FE'5N/6U_(<G9*738^@;WQ%HFG7:6E]K&GVMRYPD,]TB.Q]@3D]
M16BK!E#*05(R".AKRGQ/\$O",GAN_FM+>YBU-(7F%[)=22.[@$Y<,Q!SWX%5
M/V>->N]2\)WVFW4K2+I\RK 6.2J,"=N?0$''UIQUNNJU^02=K/H]#(_:6_X\
M_#O_ %UF_DE>Q66H66F>%]/N;^\M[2!;6+,L\HC4?(.Y.*\=_:6_X\_#O_72
M;^25V-C\,-(\1Z58WWBUY]7NVMH_+7SI(8;==HPL:(PQ[DDDFIIW]G*W\S_(
M<[>TC_A_4[W3]4T[5H//TV_M;V'IYEM,LB_FI(JW7S'XQ\/ZA\%/&%CK?AVZ
MF.F73$"*1L],%HG_ +P(/!Z_B,U[X]AH/CKP[97E_IMK>VUS;B6'SXE=HPZ@
MG:3RI]QZ4[WASQ%M+ED=!17SM^S[ EMXZ\201YV10E%SUP),"O4OB=X8T76/
M!FL7M[IUM)>VUC(\-T8QYJ%5+ !NN,]NG-*<N6"GY7*@N:;AV=CMZ@N[VTT^
M SWMU#;0@@>9-($7/U->-_LX MX/UA0Q4F]P&'4?(.>:X_XXZ(^B>+]$N([Z
M_OC<J7"7=P7PZL.%[*#D< 8JY+EG&/>WXD)WC)]K_@?1VH:OIFDI&^HZC:6:
MRMMC-Q.L8<^@W$9-6PZL@=6!0C(8'@CUKS+Q)\(+/QKIZ7FK7]Q!KSC<;E&,
MD<0/2(1D@;%SCC!/4GFN?^),L?@[0/!_@MKZY71YY!%?W.[:SP(5W*2.@.X\
M>@ J==GNVEY?TO\ ANX[WU6UF_Z]3UJ'Q1X?N;TV4&NZ9+=J<&!+N-G!SC&T
M'/6M*.:*7?Y<B/L8HVU@=K>A]#7)R?#?P+J>CK;Q^'M+^S21C9/;PJKD$<,)
M%^8_7--^&OAR;PGX9GT:7>5M[Z;RG88WQDY5ORQ^.:?5I_UJ*^S77_([&LB3
MQ7X<BO?L4GB#2DN\@>0UY&'R>@VYS7G?C#Q79:S\0T\&7NM0Z5HEK#YVI3/=
M" W#$ B$.2,#!!.#D\^E3ZQHWP>U31)=/2]\*6C&/;'<6UU DJ-C@[@<G\<Y
MJ>9\O-T_K^D7UY3U,$, 000>014%Y?6>G6YN+ZZ@M8!P9)Y BC\3Q7@/P'\8
MWT>MW/@ZZNS<6A1VM)-V?+9>H4_W2.0/;WK)^.VAG1O$NC2KJ6H7IN8V)%Y.
M9-K*P&5XPN<C@#'%6_BBEM*Q,7\5]T?2MU>VEC:M=7EU#;VZ#+2S2!$ ]23Q
M46G:MIVKP&?3-0M;V$'!DMIED4'ZJ37)W7PYTWQ2$N_%S2ZE+M_=6Z3O%!;#
ML$52"3CJS9)] , >--IUW\,?CC;:7X=N?W%Z46..X<["DF0%<CJ%;D=^!27Q
M\CZ["YO<YT?2.HZOIND0B;4]1M+*(\![F98U/XL14MI>VNH6R7-E<PW,#C*R
MPR!U;Z$<&N'N?A%X>UEI+OQ*UWK&J2CY[N2X>/9[1HI"JH[#!_&O-_A6UQX.
M^,VK>#HKIYM/<R*%?U4;E;'0''!HCK+E>_\ D.3M'F6W^9]#U0U+6])T=5;5
M-4LK%6.%-U<)$#]-Q'H:YSXF^,F\$^#Y;^ (U],X@M0_0.W\1]@ 3^%<[HEG
M\,XM/677=<\-ZSJUPH>[O-0O()G9R.0NYCM Z #%)-N]N@WI:_4]*L=2L=4M
MQ<:?>VUW >DEO*LBG\02*M=*^6/%&IZ;\./B1;ZMX%U6UGT^X023VUK<K+$.
M2&C.">#U&>F>*];^*6EIK_PWOM;BU/48D6R6XB@AGVQ,,9(90/FR#SDFE*5J
M?.O^&!?'R,]%M;ZTOD=[2Z@N%C<H[0R!PK#J#CH?:JEOXAT6\OVL+;6-/GO4
M^];Q7*-(/JH.:\7^#7AZY\3?#V2QO+R6WT47DGF0VLA22Z)"Y5V'*H..!R>Y
MQQ6;\8OAQHO@K2=.\0>&89;"2.Z6-U6=W&2"RL"Q)!!7U[U4O<:YMM/Q%!N:
M=M]?P/HRO)_&_C^UG\>^'?".FS+*_P#:4,E\RG*KM;*QY]<X)],"NU\+WA\5
M_#_3;F_+EKZS7SS%(T9)(PV&4@CG/0BO ?%_@OP_IOQOT;P_:6!CTNZ\@S0&
M>1M^YF#?,6+<X[&AIJM&#[_E^A+DG1<O(^H:*YKPUX \,>$+J:YT+3/LDTZ"
M.1O/DDW+G.,.Q[UTM!04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_P"$'_)0_B=_V%1_Z-N*]@KQ
M_P"$'_)0_B=_V%1_Z-N* /8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M,_3%13:]FH]8Z%S3]HY=&>Y6V@^%=#U.U>TT72;&^F+) \%G'&YPI+ %5R.
M:\8_:._Y#_AG_KG+_P"A)7?^ 7\0>*M0/C'Q';"PB$)ATVQ&1L1L%Y&SU+8
M!..!7E/Q\\2Z1K7B+1DTJ_M[X6<3F5[>0.@+,"!N'!/RT]54I\W=/T_KJ$=5
M)K:W]?\  /IF'_41_P"Z/Y5\\_$C_DXOP[_O6?\ Z,->UZ-XN\/ZMHO]H6FL
M6+V\,*R7#?:%_< C_EIS\G0]<=*^>_'_ (KT:]^.6EZO:WT<^GV;VRRW$1W)
M\KY8@CJ #VJEI7A?N_R9GO0=NQ]15\\Z#_R=-J'_ %TF_P#15>W1^*_#TNDG
M54US3CIZL$:Y^TIY:L?X2V<!N1P>:^=-'\7Z-!^T-<Z\]XBZ7-<2H+EN% *;
M0WTR.OO4P_C1]'^1536D[>7YG7_M)/(NG>'C@F$7$I8=B<+C],UZ/H_A7P3J
MVBV6H6_AC0GAN84E5AI\)SD9_NU1^(_A6#XC>!3'IEQ!/.A%S8S1N&1V (P&
M'&""1GZ5X1X0^*7B7X:22Z'?V!N+:%R&LKHF-X6SSM;!P#]".XI4VES0EO>Y
M4[OEG':UOQ/I"3P1X-BB>23PMH2H@+,QT^'@#_@-9_CU[63X2:T]D$%HVF,8
M1&NU0FWY<#L,8XKS_3/B#XD^+EQ_86E:-_9.E/@:C>B8RLL7\2*VU0"PX[GK
M76_%CQ#HNA_#W5=(DOK:.\FL_)M[/S 92&^4';UQP>>G%353]F[]=OZ_+YC@
MTYJW3^OZ^1F?L]?\DXD_Z_I/Y+2?M#_\DYA_Z_X__07K(_9]\4:/!X7FT2ZU
M"VM]0-X6BAFD"-*&"XVY^\<@C YI?V@?$VBW/A6+1;;4K:XU!;U6D@AD#M$%
M# [\'Y3DC@\U>)Z?+]"<-I>_G^IZ#\+O^28^'O\ KT7^9KROQ[_R<GX=^EK_
M .AM7??![Q+I&I^ ](TVWO[=M0M;<I+:>8/-7:<9V]<<CGIS7G/Q?GE\._&C
M0?$-S YL42%PX&=VQSO ]P#T]Q6E1VQ$6]KO\C**;P\DM[?J?15%<UX<\;:=
MXNN6.A)+=:?&A\V]>-XE#\810R@L>I)Z#CKFNEJ+&J:>P4444#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKQ_X0?\ )0_B=_V%1_Z-N*]@KQ_X0?\ )0_B=_V%1_Z-N* /8**** "BBB@
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M +\0_P#QV@#V"BO'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\
M': /8**\?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QV@#V"BO'
M_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ': /8**\?_X:.\'_
M /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QV@#V"LZ_T#1M5GCGU'2+"\FB
M_P!7)<6R2,GT+ D5YA_PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
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M_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM 'L%%>/_ /#1W@__ *!NN?\
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MKG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
MCM 'L%%>/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM 'KSQI+&
MT<B*Z,,,K#((]"*S;3PSH&GWC7EEH>FVUTQ),T-I&CG)R?F SUKS/_AH[P?_
M - W7/\ OQ#_ /':/^&CO!__ $#=<_[\0_\ QVCS#R/8*JZAIEAJUL;;4K&V
MO("<F*YB61<^N&!%>4_\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^(?\
MX[0!ZW;6UO9VZ6]K!%!"@PD<2!54>P' I[QI+&T<B*Z,,,K#((]"*\A_X:.\
M'_\ 0-US_OQ#_P#':/\ AH[P?_T#=<_[\0__ !VAZ[@M-CTRT\,Z!I]XUY9:
M'IMM=,23-#:1HYR<GY@,]:U*\?\ ^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\
M0-US_OQ#_P#': /4KC1M+N[8VUSIMG- 2Q,4D"LI+'+'!&.3R?6FZ;H6D:,&
M&EZ58V._[WV6W2+=]=H%>7_\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^
M(?\ X[1L![!5"]T/2=1NHKJ^TNRNKB'_ %4L]NCNG^Z2,C\*\N_X:.\'_P#0
M-US_ +\0_P#QVC_AH[P?_P! W7/^_$/_ ,=H ]@Z45X__P -'>#_ /H&ZY_W
MXA_^.T?\-'>#_P#H&ZY_WXA_^.T >P45X_\ \-'>#_\ H&ZY_P!^(?\ X[1_
MPT=X/_Z!NN?]^(?_ ([0![!17C__  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;
MKG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\
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M\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\
MOQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =
MH ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_
M .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\
M] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\
M0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH
M[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_]
M W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_
M /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@
MHKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&C
MO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7
M/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\
MQVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_
M - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/
M^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':
M /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ_
M_AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__
M $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$
M/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_
M (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W
M7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/
M_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8*
M*\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[
MP?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=
M<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QV
MC_AH[P?_ - W7/\ OQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.
M\'_] W7/^_$/_P =H ]@HKQ__AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\
MOQ#_ /': /8**\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =
MH ]@KS_XV_\ )(==_P"W?_THCKG_ /AH[P?_ - W7/\ OQ#_ /':YCXB?&OP
MWXN\":EH=A9:K'=77E;'GBC"#;*CG)$A/13VH ]G\"?\D\\-?]@JU_\ 12UT
M%>%^&OC[X5T;PKI&EW&GZRT]E90V\C1PQ%2R(%)&9 <9'H*U/^&CO!__ $#=
M<_[\0_\ QV@#V"BO'_\ AH[P?_T#=<_[\0__ !VC_AH[P?\ ] W7/^_$/_QV
M@#UYT61&1U#(PPRL,@CTK%F\&>%KB=IYO#6C2S,<M(]A$S$^Y*UYW_PT=X/_
M .@;KG_?B'_X[1_PT=X/_P"@;KG_ 'XA_P#CM'F!ZY!;PVT0BMX8XHQT2-0H
M'X"I*\?_ .&CO!__ $#=<_[\0_\ QVC_ (:.\'_] W7/^_$/_P =H ]>DBCF
MC:.5%=&X*L,@_A679>%_#VFW/VFQT+3+6X_YZP6D:-Z]0,UYK_PT=X/_ .@;
MKG_?B'_X[1_PT=X/_P"@;KG_ 'XA_P#CM'F'D>P5%):V\T@DE@B>0(T89D!.
MUL97/H<#([X%>2?\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^(?\ X[0!
MZ0/"?AL7OVT>']*%UG/GBSCWYZ9W8S6Q7C__  T=X/\ ^@;KG_?B'_X[1_PT
M=X/_ .@;KG_?B'_X[1Y!YGJVH:98:M;&VU*QMKR G)BN8ED7/KA@14MM;6]G
M;I;VL$4$*#"1Q(%51[ <"O)/^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US
M_OQ#_P#': /8**\?_P"&CO!__0-US_OQ#_\ ':/^&CO!_P#T#=<_[\0__':
M/8**\?\ ^&CO!_\ T#=<_P"_$/\ \=H_X:.\'_\ 0-US_OQ#_P#': /7GC26
M-HY$5T8896&01Z$5FVGAG0-/O&O++0]-MKIB29H;2-'.3D_,!GK7F?\ PT=X
M/_Z!NN?]^(?_ ([1_P -'>#_ /H&ZY_WXA_^.T>8>1[!17C_ /PT=X/_ .@;
MKG_?B'_X[1_PT=X/_P"@;KG_ 'XA_P#CM 'L%%>/_P##1W@__H&ZY_WXA_\
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M997RH<HMU;K*%/MN!Q4WV"S^PM8_9(/L;(8S;^6/+*GJNWICVKR?_AH[P?\
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MP45X_P#\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^(?\ X[0![!17C_\
MPT=X/_Z!NN?]^(?_ ([1_P -'>#_ /H&ZY_WXA_^.T >P5GZEH.CZSM_M32;
M&^V_=^U6Z2X^FX'U->7_ /#1W@__ *!NN?\ ?B'_ ..T?\-'>#_^@;KG_?B'
M_P".T >M6MG;6%NMO9VT-O @PL<*!%7Z <5-7C__  T=X/\ ^@;KG_?B'_X[
M1_PT=X/_ .@;KG_?B'_X[0![!17C_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@_
M_H&ZY_WXA_\ CM 'L%5=0TRPU:V-MJ5C;7D!.3%<Q+(N?7# BO*?^&CO!_\
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M >P45X__ ,-'>#_^@;KG_?B'_P".T?\ #1W@_P#Z!NN?]^(?_CM 'L%%>/\
M_#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\ ?B'_ ..T >P45X__ ,-'>#_^
M@;KG_?B'_P".T?\ #1W@_P#Z!NN?]^(?_CM 'L%%>/\ _#1W@_\ Z!NN?]^(
M?_CM'_#1W@__ *!NN?\ ?B'_ ..T >P45X__ ,-'>#_^@;KG_?B'_P".T?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_P"$'_)0_B=_V%1_Z-N*
M]@KQ_P"$'_)0_B=_V%1_Z-N* /8**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>)-/\'6MOXJN3/JBEMQ:02,J_P *LP^\1ZY/U-=34R5G8J+NKA1112&%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X_P#"
M#_DH?Q._["H_]&W%>P5X_P#"#_DH?Q._["H_]&W% 'L%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4-'UK3O$&F1:EI5W'=6DOW)$S^((/(/L>:OU#5M&4G?8****0PHHHH ****
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MW_LQJ:=O?]5^05-X][/]#LZ***904444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5X_\(/\ DH?Q._["H_\ 1MQ7L%>/_"#_ )*'\3O^PJ/_ $;<4 >P
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>/^'O^3H?%G_8*C_\ 0;6O8*\'
M;Q3HWA']I#Q1?ZY>?9+633XH5?RGDRYCMR!A 3T4_E0![Q17G_\ PNWX>?\
M0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C= 'H%5-1TV#5+807#W2(&#9MKJ6W;
M/^]&RG'MG%<5_P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW0!)/\
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M\+M^'G_0P_\ DE<?_&Z25KVZ@]=PT;X,^#]$\0-K$-K//-YGF117$@>*%O\
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MT,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW0!Z!17G_ /PNWX>?]##_ .25Q_\
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M=OP\_P"AA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\
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MA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C=
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MT >@45Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW0!Z!17G_\
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M_P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW0!Z!17G_\ PNWX>?\
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MV_#S_H8?_)*X_P#C= 'H%%>?_P#"[?AY_P!##_Y)7'_QNC_A=OP\_P"AA_\
M)*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C= 'H%%
M>?\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-T >@45Y__P +M^'G
M_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW0!Z!17G_\ PNWX>?\ 0P_^25Q_
M\;H_X7;\//\ H8?_ "2N/_C= 'H%%>?_ /"[?AY_T,/_ ))7'_QNC_A=OP\_
MZ&'_ ,DKC_XW0!Z!17G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\
MC= 'H%%>?_\ "[?AY_T,/_DE<?\ QNC_ (7;\//^AA_\DKC_ .-T >@45Y__
M ,+M^'G_ $,/_DE<?_&Z/^%V_#S_ *&'_P DKC_XW0!Z!17G_P#PNWX>?]##
M_P"25Q_\;H_X7;\//^AA_P#)*X_^-T >@45Y_P#\+M^'G_0P_P#DE<?_ !NC
M_A=OP\_Z&'_R2N/_ (W0!Z!17G__  NWX>?]##_Y)7'_ ,;H_P"%V_#S_H8?
M_)*X_P#C= 'H%%>?_P#"[?AY_P!##_Y)7'_QNC_A=OP\_P"AA_\ )*X_^-T
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M= 'H%%>?_P#"[?AY_P!##_Y)7'_QNC_A=OP\_P"AA_\ )*X_^-T >@45Y_\
M\+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C= 'H%%>?\ _"[?AY_T,/\
MY)7'_P ;H_X7;\//^AA_\DKC_P"-T >@45Y__P +M^'G_0P_^25Q_P#&Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Q^M_"WP;XCUB?5M6T;[1?3[?,E^U3)NVJ%'"N . !P*["B@#
MS_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_
MZ%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".
M4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\
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M/_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\
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M]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\
MQRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\
MX4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_
M ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\
M"DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^
M3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0**
M //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//
M^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\
MXY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_
MT+W_ ).W'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <
MKT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0** //_\
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M4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\
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M/_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\
MH7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY
M1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+
MW_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT
M"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A2
M7P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C
M_P".4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X
M>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W
M'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_
M /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%
M[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE
M'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_
MY.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0
M** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\
M//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_ ,G;
MC_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOA
MY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_
M\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_
M /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_
M\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_
MPI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_
M ).W'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B
M@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P
M\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N
M/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?
M]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\
MQRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\
MX4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_
M ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\
M"DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^
M3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0**
M //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <KT"B@#S_ /X4E\//
M^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\
MXY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_
MT+W_ ).W'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY1_PI+X>?]"]_Y.W'_P <
MKT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QRO0** //_\
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M4?\ "DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\
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M/_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\ X4E\//\
MH7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_ ,G;C_XY
M70>&/!/AWP=]J_L#3_L?VK9YW[Z23=MSM^^QQC<W3UKH** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-1_002.jpg
<TEXT>
begin 644 ex10-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" XK"N\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\R5F:E\%*3^7^9WU%<.GASQ5(/WNNE/]V5_\*E7PMX@'7Q'/G_KJU2Z%-?\
M+Q?B:K&5G_RXE]Z_S.SHKD!X?\31<Q^("Q'9\G^E*9O&&G#=)%;W\:]=A"G'
MZ4O8)_#-/\/S*^N27QTY+[G^3.NHK!T?Q5::G,;65'M;Q>L,HP3]*WJQG"4'
M:2.JE5A5CS0=T%%%%0:A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-=U1
M=SL%'J:S[G7+*WR!)YC#LO-5&+ELB)3C#63L:5%<I=^+74'R8D0?WG.:R'U'
M5=4;;%YTN>T:_+71'"S>KT.*IF%*+M'5G<7&I65J,S7,2^VX9_*LBZ\7V$)(
MB5Y3Z@8%8D'A75+HAIW2!3UW?,:U;;P38IS<S33MZ9 '\JOV="'Q2OZ&+K8R
MK_#ARKS_ *_0R;KQQ=N=MM'&A^FYJHFX\3ZJ<HEV5;OL\L?G@5WUMI-A9_ZB
MUC7WQFK@  P  /:G]9IP^"'WD?4*]7^-5?HCSN'P3JUTVZ[N5C!]6+'^9K5M
M?A]8(,W,\TK>@.T?I7845$L96>SMZ&M/*<+'5QN_-W,BV\+Z-:X,=C&2.[DM
M_,UI1VMO$/W<$:?[J 5+17/*<I;L[X4:</@BE\D%%%%0:A1110 444A( ))P
M!0!Q/Q!M(8;>UU*'$5VDNT.O!(/_ .JNLTNY:\TJTN7^_+$KM]2 :X[Q:IUC
M4+6S63<2VV").Y[LWL.,?6NWMH%M;6*!/NQH$'T Q796THPB]]?N/*PR;Q=6
M<=(Z??W):***XSU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW:C)MI,?2H6!0X=2I]"*] J.6"*=2LL:N/\ :&:UGDJM[D_O0'%6/_(0M_\
M?%=S6*^@)'=Q3VK; K E#T_"MJNO+<-4H*<:BZ_H!@>)_N6_^]_0USM=%XG^
MY;_[W]#7.UX>9_[U+Y?D C?=-=_#_J4^E< WW37?P_ZE/I7=DOQ3^7Z@/IKN
MJ*6=@JCDDU3U;5;71M/DO+M]J+T ZL>P%>3:YXCU#Q#,WF.\-G_!;JV,C_:Q
MU-?64,-*L]-CS\9CZ>%6NK['H>H>.M"T]S&UR9I!_#$,UC-\4].#8&GW17UX
MKS];8*N%3 ]A4,D6.U>BL#32UU/ EG5>3TLCU6Q^)'A^[D6.2:2V<_\ /90!
M^>:ZJ"XANHEE@D62-AD,IR#7SG-&""" 14NCZ_J?AN[$VGSL(P<O;LQV.._'
M0?6N>K@U]AG=A\VDW:JON/HND/0UA>%O%-EXITW[1;DI,AVS0M]Y#_A6Z>AK
MSI)Q=F>_&2FN:.QP,O\ KY?]\_SIM.E_U\O^^?YTVOSY[LHW/#/_ !\3_P"Z
M*Z6N7\/S1V[W,LTBH@4$LQQ535_'UM 6ATV,W$G0R,,(/ZG\J^RR:C.KAHJ"
M[_F<V(Q5'#J]25OS^XZZXN8;2%I9Y%C1>I8UQ.L^/U&^#2HMQZ>>YX_ =ZX^
M_P!1O=6FWWD[S-GY4_A'T%;>@^$)=4*RW<Z0P?\ /)3\Y_PKZ-8>AA[.O)7>
MR_X&[/ J9CB<7+V>%C9=_P#@[+\S$ O];O\ CS+JZ<]?3_ 5W&A^!8;8K<:F
MPGE'(B ^5?\ &NGT[3+/2[<0VD"1J.I Y;ZGO5RLJV-E)<M/1'9A,HA3?M*S
MYI?A_P 'YB*H4 *  .PI:1F5%+,0%'4FLV37[",X$C/_ +JUY52M3I?Q))'N
M&G16/_PDME_<F_[Y'^-/3Q%8.<%G3_>6L%CL,].= :M%10W,-PNZ&17'M4M=
M:DI*Z8&/XD_Y!H_WQ_.N6KJ?$G_(-'^^/YURU?)YM_O+]$ 'I7;Z9_R#;?\
MZYC^5<0>E=OIG_(-M_\ KF/Y5ODW\67I^H%JBBBOI@"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&U_,"?Q/]RW_ -[^AKG:Z+Q/]RW_ -[^AKG:\K,_]ZE\OR 1ONFN^B($"D]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'RIXS_Y'K7?^OV7_P!#-8J?ZZ+_ *Z+_,5M>,_^1ZUW
M_K]E_P#0S6*G^NB_ZZ+_ #%?10^!>A\_/XWZGT/\1-*_M3X9.57,MM DZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>O28+'5=>E$UPS10'D%N./85Y_\  ^VM;S4M6>15D:-(]HSD#.>WX5[F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^]_B'2BBBL#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+GY3NZ***Q-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH BNO^/2;_<;^5?,GA?\ Y*?9?]A&3_T)J^F[K_CTF_W&_E7S)X7_ .2G
MV7_81D_]":N_"?#/T.+$_%#U/J"O _CB=OBJP)_Y]F_F*]\KP+XY?\C38?\
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M ,^'6I#Q=X :UU51<-$TEG<;^?, _P#K$5RVC:G-\)_$-WHFK/(^@W ,UG,
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M;VZAMT9@BM*X4$GH.>]35G-5&73C%P1P7Q7T73(? 6HWR6,'VV..)$N2@,@
M91][KTXK8\!:)I=OX:TS4(=.M8[QX/FG6)0YSG^+&:J_%M@WPSU1@001&01W
M^=:V/ Y!\$Z2001Y Z?4T.3]BM>HE%>UVZ'045 ;RU%T+4W,(N",B+S!OQZX
MZU/7,;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>!_RQ3^0KS35_P#D?6_Z^8O_ &6NNC455SIN*LDSS,50GAE2KQJ-R;7Z'?\
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MQ%+EJT:46TM>NNQ7U;P[K&F64NH6VLW$LL*F1E;'(')P,5T_AO4WU?0X+N4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ,E&87 Z[37EFDZ9?Q^*H)7LYEC%RS%B!C&3S7JU%=%&NZ2DDMSAQ6"CB)
M0DW;E=PKSOQ]87EUJUN]O;22J(B"5'N*]$HJ:%9TI\Z5R\9A5B:7LI.Q4TM6
M32K174JPA4$'L<5YYJNG7S^-VG2TE:+[1&=X QCBO3J*JE7=.3DEN1B<%'$0
MC!NW*T_N,7Q'H0UW2Q"&"3Q_-$QZ ^A]JX6SN_$?AAGMDMG,9.=A&Y<^HKU2
MBJI8EPCR25T9XG+U5J*K"3C+NCSRPU+Q9JNJP2K$8X8VRR-\J$>_K^5>ACIS
M116=:JJC5HI6[&^%P[H)\TW)ON%>.26TMYXGFMH)/+F><A'SC!XKV.O+K"RN
MU\<I*UK,(_M.=Y0XQQWKKP,N7G?D>;G$.=THVTYO\AE[JWBD1-87*S _=8HO
M+?CFMCP7X9N+:Z&IWL?E;5(AC/7GN?PS7>45G/&-P<(Q2OO8VI96HU55J3<K
M;7.-\8^%I=2?^T+$!IPNV2,\;Q[>]8=KXD\3:="+4VKR%> 9$R17IU%*&*M!
M0G%22*K9=S575I3<&][=3C_"LOB*XOYKC401:R+P'.,'_9%2^,/#,FKQK=V>
MW[5&,%3QO7T^M=716?UB2J>TBK&WU&#H.A4;DGU>YY1;:KXETJ#[#'',JKPH
M9-Q7Z'-7- \+7^J:BM]J:LD(<.WF<M(?\*]+HK>6-=GR12;ZG)#*(J2]I-R2
MV3V./^(8QHUL/^FP_E7+Z4VNZ;IJZAIC%[:1BKQCG!'<BNL\?P37&D0+!"\K
M"8$A%R>E3^!H98/#X2:)XW\QOE<8/6M:=50PJ=D]=CEK8=ULQ:NX^[HT<.;3
M7/$NHJ9HY6<_+O<86,5Z')IHT_PE/80*7*6SJ .K,0?ZUM45S5<4ZEDE9+H>
MCALNC1YFY.4I:79Y_P" +&[M=1NVN+:2)3&H!8=>M2^+O"EQ/=G4].7>[',D
M8.#G^\*[NBF\7/VOM4)992^K?5Y.Z6M^IYE#XI\36\(MC:M(ZC:'=/FKI/"3
M:](;B750?)D.Y-Y^8'V'I74T4JF(C*+2@E<=# SIS4IU92ML@HHJCJ^III%@
MUU)%+*H(&V)<FN6,7)V1Z,YJ$7*6R.)\90W&E:U]NLSM^W1^0X'<GC^E=?X<
MTT:5H5M;8&_;N<^I//\ 6N8MA=^+/$UO>RVLL.FVN642C&X]N/K7>5VXB;5.
M-)[]?T/)P-*,JU3$1^%O3]6O5F!XJT!M<L$\A@EU"2T3'^7Z5D6_B[5+"(6^
MI:/</<)QOCP0U=M16,*R4>2:NCJJ81NHZM*7*WOU3^1PMKI^J>*-:AU'4X/L
MUC =T4+')/I72^(].?5- NK.''F,N4![D<X_2M6BE*O)R4EI;9#IX.$:<H2;
M;EN^K_KH<#I/BC4-+LDT^[TBXDEB^563'(J#7(M=U.XT^[NK0I'YIV6Z'<4'
M'+'\J]%HK58F*ESQ@KG.\OG*G[*=1M+;1=._<****XSU3C]/M+A?B%?7#V[B
M$H LA'!X[5?\5>'AK-FLL&$O8,M$_K[5T-%;NO+G4UHUH<2P=/V4J4M5)M_?
M_D8'AO5+R_TYHK^VEANXEPQ8</[BL_P;:7%OJ&KM/ \:O<,5+#J,UU]%#K:2
M25N8:PKO3E*5W"_SNK:E'64>31+Y$4L[0. HZD[369X*@FMO#<4<\31N'.5;
MKVKH:*A5+4W#SN:N@G65:^R:^\X:^TW4O#6MRZKI4/VBUN,^= #@CG-/N/%^
MI7L)M]/T>X2Y<;0SX 7WKMJ*V^L)V<XW:Z_YG)]2E&ZI5'&+Z:==[=CG_"N@
MR:/:22W3A[VX8O*P[>U,\9Z=)?:+OMT+SP-YB =:Z.BL_;2]I[1[F[PE/V'U
M=;6_I^IS'@JQN+?3Y[N\5A<W4F]]W7VS^=4O'&GWADM[_3XW:7!A?9UVD&NT
MHJEB&JOM;$2P4'AOJ]_GUOW,KPWI_P#9F@6EL5PX3<P]R<_UK,T36-9O-?N[
M6\M!':Q_=;'3TY[YKJ**GVM^9R5V_P #3ZNTH*$FE'IWTZA1116)U!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %&*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *1E5QAE##T(S2T4 (JJHPH 'H!2T44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6=J^O:1H%L+C5]2M;*
M(G"M/(%W'T /)/TKD_BG\1(_ 6A*8%675;O*VL;=%QU=O89''<US?PU^'@UF
MVC\8^-=VK:K? 2P1W?SI#'U4[3QD]0.@'04HWE>VR_JR"7NV[LZ9?C+\/WN?
MLX\11[]Q7)MY@N?]XIMQ[YQ720^*=!N-'GU>WU>SFL($,DL\4H<(/?'(/MUK
M2%M +?[.(8Q!MV^7M&W'ICIBO&OB[\)-,NM&N?$'A^SCM+^U4RSP0+M2=!RQ
MVC@,.3QUI.2COL.*N['M*.LB*ZG*L,@^HI:HZ++Y^@Z=+_?MHV_-15ZM)*TF
MB(2YHJ7=!1114E!1110 4444 %%%% !1110 4444 %%%<]XU\41>$O#<VHL4
M,[,L-M&_(>1C@# () ZGV!H Z&BD4Y4'U%+0"U"BBO%OBQ\2M1AUF+P5X4=E
MU2X98Y[B,_,A;HB'L><D]NWLF]4EJV.VC;V1Z5KOC?PSX:<QZOK5I:RA=QB+
M[I,?[BY;].:R++XO> ;^;RH?$ENK<<SQR0CGW=0*;X)^&.B^$[*.6>WBO]9?
MY[B^N%WN7/)VY^Z,_B>]=??:=9:I:M;7]I!=0,,&.>,.I_ TVK>9*=_(A;6M
M,!L@+Z!_MSF.U*/N$K!2QP1[*>>E7Z\.U#X;6_@OXL>&M<T5"FE7=[Y,D.21
M!(RMC'^R><>F/I7N-"LXI^H;2MZ?J%%%% PHHHH **** "BLSQ#K=KX<\/WN
MKWC 0VL1<C^\>RCW)P/QJ30[V74M TZ^G"++<VT<KA 0H+*"<9)XYH6M_('I
M8OT444 %%%% !1110 4444 %%(2 "2< =37/>$?%$?BNWU*[M]AM(+Z2V@=1
M]]4"_,>><G=CIQBA:NP/0Z*BBB@# ;QSX15BK>*M$# X(.H19!_[ZI/^$[\'
M_P#0UZ'_ .#&'_XJN!_:'T^WF\!07S11_:+>\15DV_,%8,",^G3\J/@UX1\-
MZE\-;"]O] TR[NI7EWS7-JDC'#L!RP/:E#WE)]OU"5HV\SU.QU33M4C\S3[^
MUNX\ [K>99!@]#D$U;KY_P#BY\/K;P=:P^,/")DTN6"54N$MY&4#. K+Z<X!
M'0YKT7X3^-Y?''A$7-X%&H6K^1<E1@.<9#8[9'ZYIQM)-KIN*3<6D^IW=%%%
M RCK&K6>@Z/=:I?R&.UM8S)(P&3@>@[FL?P7XZT?QYITUYI(N$$$GERQ7"!7
M4]1T)&#[&M^\L[;4+*:SO(4GMID*21.,JRGJ#6?X>\+Z+X4L6LM$L([.!W+L
MJLS%F]2S$D_G0MW?Y ^EC7HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *YKQ-X[\.>%8I5U+6+2"[6,LEN6+R
M$]LHN6P3_6CX@:Y<>&_ FKZK:8^TP0_NB1]UF(4'\,YKA/@]INGS_#F[\02(
MMSK-V;C[5=R_/+D9 &X\CC!_&LY-\LVOLK_/;_,I:.-^K.D\'_%7PUXBTRQ6
MXUJQAU:2)?/MVW0@2XY5=_7GT)KO.M>?Z%X3T;Q9\)]"LM5LHIMVFQ!)2H\R
M([."K=01FKWPLLYM.^']E83N7EM)KBW8G_8F=?RXKHFK3DNW^;1C%OEB^YV5
M%%9^N:D=(T.]U!8C*\$3,D8ZNW\*_B<"LF[*YHBGX@\8^'O"R*VMZM;V98;E
MC8EG8>H1<L?P%4]!^(OA'Q-<BVTG7+>>X)PL3AHG;Z*X!/X5RFE?!C2=1+ZM
MXT:?5M9O#YEP#.\<<1/\"[2#@=.OX5POQ7^#]CX8TD^)/##300VSJ9[9I"WE
M@GAT8\\'&<D^M%^3X_PZ?Y@O>^'\3Z-JKJ&IV&DVINM2OK:SMP0IEN95C3)Z
M#+$"N,^#_BJ[\6> H+F_<R7EM(UM+*>LFT AC[X(S61\4O#NL?$'5;'POICQ
MV]G:C[7>W4N=JL<JB@#[S8W''TIS3C+E7]=;_<*$DUS/^OZ9VG_"=^#_ /H:
M]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 57C__  S+_P!3=_Y3?_MM<EXL
M^#Z^&=>T+1[?7#J-[JL^P1+:>5Y: @%R=[>OZ&A:M+OH#=DWV/JBWN8+RVCN
M;::.>"50\<L3!E=3T((X(K#\0^.O#'A5Q'K6L6]K*0"(OF>3![[%!;'OBKEY
M%<Z3X;^S:+:B:XAA6"VC) 4'A03[#J?8&N,MO@GX4F22XUZ.YUC5)R7N+R>Y
MD0LYZD!&  ] <]!2EN^78(O17W.I\.^-?#?BL-_8FKP7;J,M&,I(!TR48!L>
M^*WZ^4_'?A.?X4>/=+O?#]U.89V\VU#-\ZD, T9(^\#D?4'FOJF)F>%'9=K,
MH)7T-4K2AS+T%JI<K]1]%%-DD6*-I'.$4%F)[ 5+:2NRBIJFKZ=HEDUYJE]!
M9VRG!DG<*,^G/4^U<SI_Q8\"ZI?"SM?$5MYQ.T"5'B4G.,!G4 _G7!>!9T^*
MOQ$U7Q%JR>?IFE%8].LY.8T))PY7H6PN?J1Z"O3O&'@_3/&'A^?3;ZVC+^6?
ML\VT;H7QP5/;Z=Q2;<8J37G;R_S\OD&CDXKII?S_ ,CH@00"#D&D)"@DD #D
MDUXG\#/&5_+<7W@S69&>YL QMV<Y8*IVM'[X.,>V?2KWQ[\0W-AI&DZ'!.]M
M#JLY6ZE0X/E+MRN?0[AGZ8JI:6Y=>:UOF*+O?FTM>_R.KU+XM>!-*NC;77B*
MW,JD@B".28 CJ"44BNAT3Q%H_B.T-SH^HV][$IPQA?)4^A'4?C3?#^@:5X=T
MB"PTFTBAME0#**,R?[3'^(GU/K7D/Q!1/ OQ7\-:OH$8MGU1_)O+>$;4F&]0
M<J.YW?F ::^)0[NWS]!-OD<^RO\ (]SJEJFKZ=HEBU[JE[!9VRG!EF<*,^G/
M4^U6Y)$BB>21@J("S$]@*\(\)77_  MSXJWVK:DOG:%HXS9VC\IDG",5[DX+
M'/L.U2KN7*O7T13TCS/^F>G:'\2O!WB.]%GI>NV\MRQPL4BO$SGT4.!N_#-=
M77'_ !&\)6OB?P=>0K @OK:(S64RC#1R*,@ ]@<8K$^"_CN;QAX8>VU&7S-4
MT\B.5SUD0_=8^_!!^GO3C[UUU7Y?UN)W5F]G^9Z71110,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;>?]EB^U>7]HV#S?*SLW8YVYYQGIFI:**;!*R/+/V@?^29-_U^1?UJ]\#?\
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MTP/H*ZFBE'2_F4];>04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!G:[HUMXAT*]TB\SY%W$T3%>HSW'N#S7S&S^,?@CK%U:2Q"XTF]#(-V
M?)N!C 93_"X'^2*^K:S?$%A::EH%];7MM%<0-"Q,<J!ER 2#@]ZRJ>ZI27;7
MS6I<?>M%]_N.1^$GBS1M<\%Z;IUE=JU[86L<-Q;O\KJ5 &0.Z^XKT"OE>]^&
M^L>'/"FC^//"]]-D6D=S<(IQ) 2H+,O]Y/4'I[BO<?A;XY;QUX4%Y<HD=_;R
M>3<J@PI;&0P'8$'\\UU3]Z4GU3U_KL81]U)='L=O11161H%<)\8M1@T[X7ZQ
MYW6X06\:^K,1_P#7/X5W3,%4LQ  &23VKS069^)WBVWU&5<^%-&E)M0>E_<#
M@OC^XO0'O]#42CS^Y]_I_6B\QJ7+[W]7_K?R-'X0>&I?#/P\LH+E-EU=$W4J
MD<J6Q@'W"@5W*HBLS*JAF.6(')[<TZBM92YG<B$>56"O(_#8/B[XZ:WKI&^Q
MT*(6-LV,CS.0V/?[_P"8KOO&FNKX:\&ZKJQ(#6\#&/)ZN>%'YD5SWP<T%]$^
M'EG).I%WJ#&\F+#YB7^[G_@(%1#XW+LOQ?\ P+_>.?PJ/=_@M?SLCOZJW^I6
M.E6K76H7D%K;J,M)/($4?B:M5EZOX;T/7MO]KZ18WS*I5&N(%=D!ZA21D?A0
M[VT*5NIY1!XF\(?$7XK6<MUJ,8@TH%--MY4*B[F)!+Y/&.!M7J<9KVNOFCXP
M_"FR\(VD7B'P]YL5GYH2:W+EO))^ZRD\XSQSGDBO;/AKK5QK_P /-&U"Z<O<
M/#LD<]6925S^.*<+.GITW^?4B5U4UZ_IT_KS.KJEK$$EUHE_;Q$B26WD1,>I
M4@5=HJ9QYHN/<N+LTSYX_9PU)+75]<T6<^7<2(DJ(W!RA(8?49%?0]>3^*?@
M_<2^*1XJ\':JFDZMO,CQR*?*=SU.1G&>XP0<UK73^.;#P]=7OB;7]&T^VM(6
MDEDTJU=I7 '9I3M4GV0^U5*I>'-+1I:_(E1M)I;-GDGA*;;^TO<FUQY;ZA=J
MV/3#Y_45Z_\ %GP&_CGPN([,@:E9L9;;<<!^/F0GMD?J!7EGP T2XU;QEJ7B
MBX#M%;JZAW.2TLAR>3U(&<_45['\0O'5MX&T-;CROM&H7+>59VV?]8_J?]D<
M9^H'>IE'EI0@]TE]_0<97JSDMO\ @:GDWP_^,\WAF-O#GC6&Y7[&#'%<;"94
MV](W7J?0'Z9]:[G0_"]_XO\ &$'CGQ+$MO! @_LG30X8QKU$DA'&XYS@>WI5
M'5?@Q'XLT,WVMZA,?%5PHDDNP?W2''$0CZ;!TXY[YKAO _C#Q!\+?%J>$?%"
MO_9CR!!N.1%N/$D;=T/<?R(-:1?-.TOBZ=K]?GT_X>YFU:%X_#U[V_R\O^&/
M:?B=?-IWPUU^X1BK_9&C5AU!;Y?ZUYY^S9;JOAW6[C W/=(F?8+G_P!FKO?B
MM;->?"[7XX^2+;S./12&/Z"N'_9NE#>$]7AR,I>AL?5!_A4TOBJ>B+J?##U/
M:6 9"IZ$8KYI^!\[:?\ %O5M.0XBDBGC*CI\C@C^1KZ68[4)/0#-?,OP/C>^
M^+VI7J M&D-Q(6_WG '\Z5/^-_VZPJ?POFCZ;HHHIC"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBG[JDGUM^ 5->6W2YVM%%17$3SVTD4<\EN[J0LT04LA]1N!&?J"/:@#Y_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!AZGX<
M&MWN=4O9)]-5@R:>BA(V(QS(>K\C.,A?4'&:VP JA5   P .U+11MH'6X444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !116+XMU^'POX5U'6)L'[-$2BD_><\*OXDBIE+E5QI7=D)I7BK2]9UW5M
M'LY6:[TMU2<'&"6&?EYY Z'IS6W7R=X&UC5? GQ:@;7=T3:CM%YN/!$P#!C]
M&()].:^L:NWN)_?Z]2.;WFON] HHHI%!1110 4444 %%%% !1110 4444 %%
M%% !1110 445Q]CXQ35?B;>>';*97M]/L2]P5P09BZC&>ORCWZL<]*.MOZT!
MZ*_]:G84444 %%%% !1110!#=W=O8VDMU=3)#;PJ7DDD.%51U)-<!J_Q+U:#
M23K6B>"K_4]&"E_MCW*0;D_OK'AG*]>2HK _:)UF:R\):?I<+E5O[D^;C^)$
M&<?F5_*O5M(A2/0;" *"BVT:8(XQM J5>47)=';\+C;M))]5?\;'/>!/B-HW
MCZUF;3Q+!=08,UK,!N4'H01P1[UU]<GX8^'/A_PAK.H:II,,T<U[PR-)E(ES
MDJ@QP,^N?RKK*MV=K$*ZO<.E<3JWQ6\*Z9?MI\-S/JE^N<VVF0FX?([9'RYS
MQC/UQ7F_Q5\<ZGXD\5Q?#_PU,8TDF6"ZFC;!D<]4R.BKW]>1VY]=\'^#=)\%
MZ-%8:; H<*/.N"O[R9NY8_TZ"IC>4>;IT\_^ 5)V?+U_(P?^%M:9;H9=5\.^
M*=(MAUN+[2F6,?BI;IUK7M?B'X5U"\TZTT_6+:]N+^0QQ1P.&9<*6)=<Y4?+
MCD=2*Z<@,"" 0>"#7DGB+X?6>A?$SPYXKT>W6W@EOEAO88QA%9P0' Z#).#[
MD>M-/WDGLQ2TBVNAT_C'XH>'O!:LEXUQ<W(.T0V\1/S8S@N<*#@YQG/M6UX0
M\1#Q7X6L=;%J;472EA"7W[<,1UP,]/2N-^/4:O\ "R[9ADI<0LOL=X'\B:U?
M@_\ \DJT+_KDW_H;4J>JE?I;\0F[2BEUN=Q1113&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !5#5]<TO0+$WNK7\%G;CC?,^,GT ZD^PJ'Q+K]IX7\/
M7NLWI_<VT9;:#@NW0*/<G KQ+X<6%U\6/%][XL\4?Z196#A+6S)S$KGD*!Z
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M6M:_Z^T_] KVZMII)I+LC&#;O?NPHHHJ"PHHHH **** "BBB@ HHHH ****
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M"[BV]T[?A_7Y="7+WTEM;];?U]YIT444%!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M4U+4[+1["2]U"X2"WCZNY[GH .I)/  Y-67=8HVD=@J*"68G  '>O+O".HO\
M2?&U[K\I)T'1I?(TR$_=DF[S$=SCIZ9I;OE7K\OZT7_ !NRN>C:9>SZA;&XF
ML9;-6;]TDQ&]E[,RC[N?3.?7!X%VBBF)!1110,**** "BBB@ HHHH **X_QC
MXQ30]8T#1;:91?ZG?1H5&"4AW?,2#Z_=_$XZ5V%"U5PZV"BBB@ HHHH ****
M "O.?%GQ;M/"OC>R\-R:1<W!GV>9<*X79O.%VKCY_?D?C7HU5+C2].N[V"]N
M;"UFNK?_ %,\D*L\7^ZQ&1^%"^)/IU!_"TMRW1110 4444 %1SSQ6T$D\\BQ
MQ1J7=V. J@9))J2B@#S#7/C=H.F:Y!H]C9W=]=RS)$S,A@C3<P&<L,GKGA<'
MUKT^OG7XVQHOQ<\-2*H#O'!N/KB8XKZ*HAK3YGO=_@*6E3E\D_O"BBB@8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117'
MZGXQ2/XCZ+X4M)E,LJ2SW@7!VJ$.Q3Z$GYNQX'8T=4NX/1-]CJ;R6>"TDEMK
M?[1*HR(MX0MZ@$\9QZ_F.M4]&UZPUV&5K21A+ _EW%O*NV6!_P"ZZ]0?T/49
MK3KS7XG0W7AE[;Q[HR[;NR98M0B'2ZMB<88>H)&#VS[4KI/7;\O^!W^\+-[;
M_G_70]*HJAHFL6FOZ+::K82;[:ZC$B'N,]C[@\5?JFFG9B335T%%%%(84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUNU_D/EO54%MI_7_  #*TJ^UGXG"YOK/5KK1/#2R/#;M9!5NKO'!<NP.Q<]
M!GWKDO'$7C#X4/::YI7BG4M6TF241SV^JR^>5/) R>Q /(P0?6I/A9X&CU_X
M?V%\GC#Q59$M(C6UAJ7E0QD.> NTX['\:ZC4/@QI^K6OV;4O%_B^]M\AO*N=
M261,CH<,A&:N<7!VCT_'U%%J2][S_4Z_PEXEM?%WAFSUJS!5)U^:,]8W'#*?
MH:VZY_P=X0L/!.A_V3IL]W-;^:TH-TZLP)QD?*H&./2N@JI6OH*-[:GB?[2&
MI2P>&M)TY&(CN;EI),=PB\#\VS^%=%\";1;;X6V4@7#7$TLK'U^8K_)17/?M
M(:=+/X8TG4$4E+:Z9'([!UX/YKC\:W_@->+=?"ZTB#9:VGEB89Z?-N_DU31^
M&IWO_D.KO#^NYZ91110,^2=5E;PW^T!-+:Y7R]75\#T=@6'XAC7OOQ,U/Q9H
MWAB_U+P_-I\$5K%YCO*C/*1W*@_*,=><YKP76(&\1_M"RP6WS;]61<CL(R Q
M_ *:^B?B7_R33Q'_ ->,G\JRVPL7_70?_,0_Z[GG/PUUSQ?XU\%7EI::W)#J
M'VB1KC5+F,RF($+LCC4X&3SG'"CMDBNE^%^C>/M#NM4B\8:BUU8C'V9Y;GSF
M9L\L&/S!<=FQ]*I?L] ?\*XD_P"OZ3^2UT_Q5U2;2/AGKEU S+*8/*5E."N]
M@F?UK6J_9WDNR_3^O^"127M$D^[_ #9RL7BG7?B;XIO-+\+ZDVD^'M..VYU&
M) TUPW. A/0''!]!GOBD\7^&/$7A#PKJ=_I'B;5=8L_LTB7EEK$XG)C92"\;
MX!4KG..^#1^SO#$GP^N954"22^?>>YPJXKT+Q@,^"]<!_P"?"?\ ] -16CR0
M:7;7STO]Q=%\\T_/3RUM]YY7^S9_R+6M?]?:?^@5W_C7Q?-H=QIVBZ3#'<:]
MJLGEVL<I.R,#[TCX[#T[UP'[-G_(M:U_U]I_Z!63XO0Z[^T?::7/J=]I\:P)
M!%<6,_E2IF,M\K8.,EL5M4UJ1CW_ $5S*GI"<NU_SL>@ZA\.=;U"T,\GQ!\1
M1ZKMX>WF$-L&Z_ZI .,_[6<5S'PT^)>L_P#"6W'@GQ?*LU_'(\4%T  6=<Y5
ML#!R!D'\ZZK_ (59_P!3[XY_\''_ -A573?@GH.F^);?Q -8UZYU"&83^9<W
M,;^8P_O'R\G\ZF&DM=OZV*FKQTW*_P 8-?\ &GAOP]+J6D75A:V(E6)F1"]P
M W .6&T<\8QD9ZUE>&I_&?CKX7VL>CZ[)8SQQ.)K^<,TMS-N;Y%?JB@8^<9.
M>!T-;OQX_P"257__ %WA_P#0Q6E\'P!\*M"Q_P \F_\ 0VK.$;J:?=#F[2A;
MS&?"_3?&FF:!=6_C"Z,UP)L6QDF$T@3'5F&<@GD9)/TK#\!Z'\3+#Q[?W7B;
M4FFTAE;AKD/'(?X3&G\&._"_C7J]%:7][F\K"Y?=Y?.X4444B@HHHH ****
M"BBB@ HHHH JZEIUKJ^F7.G7L0EMKF-HI4/=2,&OF/7_  GXO^#FJW&I:-.\
M^CS@QM.J;D*'HLR]CSP?R(Z5]354U55?2+U6 93 X((R#\IK*I[J<UV?S6NA
M<=;19YO\(/B+H>M^'M.\/>:;75+*W2'R9B!YP48W(>_TZUZG7S1J_P )=WP[
MTGQAX;EEAOHK"*YN8 Q^8A03(AZAN^/RQW]2^#7C6[\9>$';4G\R_L9?(EEQ
M@R#&58^_4'Z5U3]Z4K[K?_,YX^ZH]GM_D>BT445D:A1110 5B>*O$EMX6T*7
M4)P9)21';6Z_>GE;A44>I-;=> ZS\5]!B^*%U<>(+/49K?17:WT^WMXT=1*#
MAYFW./FXP.N![U+U:C?_ (;_ #Z+_@#U2<K?U_7]:GJG@CPW<:-8W&H:M()]
M=U-_/OI?[I_AC7_94<"O*/@;_P E,\7?]M/_ $<:Z'_AH[P?_P! W7/^_$/_
M ,=KR_X<?$?1_!_C#7=7U"VOI;?4-WE+;HC.N9-WS L!T]":J/\ $OLN5K\K
M(SDO<MN[I_YL^L*P_$7C#0/"D EUK5(+0LI9(V.9' _NH.3^56?#VN6WB70+
M/6;..:.WNTWHLP <#)'(!([>M:,D:31M'(BNC#!5AD$?2E)-:=2XM/4\%TCX
MF^$_%?Q2AU+6EGMDM1Y&D&91Y2$GEW.<AF[=A@<YKWP$$ @Y!KY^^./PTTK3
M-'_X2?1+..S:.55NX81MC8,<!@O0'.!Q@<UZ?\*M0N-3^&6AW%TS-+Y!C+-U
M8*Q4'\@*<+.%OY?UZ_U^A,O=G?I+]/Z_JYV5%%%!05SOCO68= \#ZQJ$Q&$M
MG5 3C<[#:H_$D5T)(4$D@ <DGM7F\]J?B?XBA=P?^$1TJ;<N00-1N%XR/6-?
M7N<]JB4>?W.^_IU_R7F-2Y?>_J_]?@1? [PG-X;\#BZNXREWJ;BX9&&"J8P@
M/X9/XUYW\8A/X;^,ND>(G1OLS""96'?RVPR_EC\Z^D0   !@#H!6'XL\(:1X
MST=M-U> O'G='*AQ)$W]Y3V/Z'O5SD^=5(]/RV(A%<CA+J:]K=0WMI#=6\BR
M03()(W4\,I&0:\'_ &EYDV>'8?X\SO\ A\@KL] ^&?B+PTGV+3?B#?1:2,[+
M4V,3L@]G?<!SZ**\A\8Z0OB_XP6_AO2KF\OO)98+B[N9C*[,#F1B>@"CC
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M0"I'Y9/YU[)?2/+\/KB20DN^ELS$^IBYJ9R;H.?577W(<4E64>CL_P ;'$?
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M^B^[]1/65^EO^'^\NU\Q_&VQ;PG\4+#Q#IKB.:Y5;K"G&)4.">.Q 'ZU]-L
MRD'.",<'%<5?_"3P5JMT;K4=+N+RX(P9;C4KF1L>F3(34V?/&2Z%:.+B^IT'
MAK7[/Q/X?L]7L9%>*XC#$ YV-_$I]P>*\._:/D0>(/#8+#*Q2,P]!N7_  ->
MOZ#\//#/ABX\_1;.YLVSDK'?W!1N,?,A<JWX@U2U#X2^"]6NC=:EI=Q>7!&#
M+<:E<R-CTR9,XJI?'&4>CN3&ZBT_0["V=9+2%T(9612".XQ7SS\2)$_X:*T
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MUU%')(UYZPQE%.%_O-WZ"NBM?C'\-+*TBM;76TA@A0)'&EC<!54= !Y=2_\
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M/M2@N6,D^KO^ I*\D^RM^)+1113&%%%% !1110 4444 %%%% !1110 4444
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MH/BCC68+JZCP/W)OYTBXZ'8KA<^^,U6T+X<>%_#-V+G1;&XLI,Y81W]QM?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K#\1>&+7Q MM,9'M=2LW\RSOH?]9"W?\
MWE/0J>#6Y12: HZ2^I-9[-5BA2ZC;:7@;,<H[. >5SZ'H>Y'-7J**;!:!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEX<T>#0/#FGZ5;J%CMH%CX[G')_$Y->+?&*:;P3\2] \8:<"DDR%9U7@2["
M0?7*MC\!5:1FHO9Z7\^_H2N:4.9;[V_3U/?:Y;Q9X\TOPI+;6<D<]]JMV0+;
M3[1=TLF3C..P]S6S+K%I%X?;6F<?9%MOM.[/\&W=_*O%/@JT_C#Q]XA\9:F"
M\Z )#GD1[R>!]%4#\:FS<^3:VK&Y)0YUUV^9V[?$O4=&>!_&/A"\T*QG<(EX
MMTEU&A/3S-F"GY&O08I8YX4FAD62)U#(ZG(8'H0:RO%6BP^(?"VI:5.H9;FW
M91D9VMCY2/<'!KRO]GKQ3/>Z5?>&;QRTFGGS+<L<D1DX*_@W\Z<7S-QZK7Y?
M\ )7C:71Z?,]LHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;K>NV6@V:SW;.S2
MN(H((EW23R'HB+W/\NIP*NW5S#96DUU<2+'!"ADD=NBJ!DFO+?AQ=S>/O%>J
M>-KT'[):N;+286SB)>K/C^\01D^Y%):RY5ZO^O/I]X-V5_D>E:9+J$UL9=1@
MAMY';*01N7,:]@S="WKC@=.>I36-7L=!TFXU/4IU@M+=-\CG^0'<GH!5ZO%/
MVC]2F@\.:1IR,1%=7+/(!_$$ P#^+9_"E-O1+JTBH*^YT6I^)_B'=Z"->\.Z
M!I*6!C\Y+:^DD>ZDCQD-L7:JG'.-Q-<3<_M$WLWASS=/T!5U:.0"?S=TD"1_
MWOEP<D\8)'U->YZ2@31K%%'RK;Q@?]\BJ6D^$]!T+4[W4=,TR"UN[TYN)$S\
MW?@9PHSS@8YJG&TG'I^.C_4SC+FC&77_ #_R'^&=4NM:\,Z=J=[9M97-S"LD
MENV<H3]>??\ &M:BBFVF[H<4TK,****0PHHHH **** "O./B%\5)/!-N&A\.
MWUR7<Q)<SKY,&X=@>6/0GH 1T->CUY+^T./^+<P_]?\ '_Z"]9U&TM/(N"3=
MCO?!NM7'B+P=I>KW:1)<7< D=8@0@)] 23^M;M<C\+O^28^'O^O1?YFNNK>H
MDIM(PIMN";"BBBH- HHHH **** ,KQ)J=SHWAO4-2L[)KVYMH6DCMUZN1VXY
M_*N7^%7C?5O'/A^YO]5TV*T>*;RTDA5ECE&.<!B3QT/)KO:*%HW?_A@>MK!1
M110 4444 %%%% &!K?B&7PY/]JU*VW:*Q :[A!)MCZRK_<S_ !#IW'>MR*6.
M>%)H9%DB=0R.IR&!Z$&DGABN8)()XUDBD4HZ.,A@>""*\G\#ZR_@_P"(.H_#
MN^D<V3,;C2'<_=1AN\OZ=<>ZGUHCJ^7KT_5?JA2T7-TZ_P"?^?WGKE%%% PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"*YMX;NVEMKB-9894*2(PR&4C!!KYN\:?"CQ#X$U"77_!L]S+8
MX;<D)_?0(>JD?QI_DCO7TE-<0VR!YYHXD+*@9V"@LQP!SW)( 'J:AU/_ )!5
MY_UP?_T$UE4TBYKHG^6Q<=6HO9GCWPC^+FE76F:?X8U8+87=O&EO;3%OW<X
MP 2?NM^A_2O:Z^?M7^$^GZ_\*=*\0:5$+;6(=,CFD"#"W(" G(_O8[]^]=;\
M"/%-]XB\&SVNH3///ITPA65SEFC(RH)[D<CZ8KIE[TI)_$M_/7<YX^ZHM;/\
M/(]4HHHK,U"BBB@ HHHH **** ."^,>A7.O_  VU""T0R7%N5N50<E@ARP'O
MC-<]^S]XFMM0\&G0FE47NGR,1&3RT;'(8?0DC\J]>KS_ %;X.>%]1U@ZM9OJ
M&C7Q;>TVEW'DDMW.""!^&*4;Q<NS_-!)<R7=&[X^OH=.\ Z[//(B+]BE1=S
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M;1@?8UI4OAF_-(53XH+R9U%S#]IM98/-DB\Q"GF1-M=<C&5/8BOFKXX>$_\
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M[_L$.<_[@K<K:HN6;2Z,RIMN";[!1114%A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH5% "JHP /2G4W_=)5^IYOX2^+5KXQ\8)H=GIEW9^7;227(O$"NLBE0% !/
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M3QIIO@C1Q?7X>625_+M[:+EYG]!_4U?\,Z=-H_A?2M-N)/,FM;6.*1LYRP4
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MFE'KK_7Y$4Y:.^MM#R__ (::_P"I1_\ *E_]JI?^&FL_\RA_Y4O_ +57K_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.EG)-P7 X\IL_P 0[>O3M2G)SIRB_B2^]:?U_6M17)--?"_P?]?UN?0WA/\
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M24N9W(C'E5ALDB0Q/)(P5$4LQ/8"O)_A-&WB/Q-XF\=S [;VX-K9[ATB7']
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^%7:7+>FH/I_G<+M3<^_^5CY.\%_%3Q!\-//T._TTW5M$YS9W#&*2%NX#8.
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M0 <"ICI>_P BWTM\R6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO'RVDAF>)8'TB!P=N.2V!Z^E8%Y\7O'O@/Q(VD>*K:RU#R@"S*GEF1#T=&7
MY]U[=!7<?L_?\DQ3_K\E_I7GO[2)@/BO2 N//%F=_P!-YV_^S5I4?)-6V?\
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M5AK&K:D'#RZC)&[?)@HJ1J@7/?H3_P "KFOC%_R2G7?^N:?^C%J)MQIZ;_\
M!-8KFJ:[?\ \/\+_ !2^(?B3Q/IVC?\ "4_9_MDPB\[^S[=]F>^-@S^=>KZY
MX>^*UAIDMSI7CV+4;B-2WV=])@A+X[*<,,_7%?/_ ,,/^2G>'?\ K\2OM*MI
M1]Q6WU_0QC+WVGMI^IP?PB\0:QXE\$_;M=N#/?+=2Q,S1+&0%QP0H XY[5WE
M9>B:)#H:WR6Y'EW5Y)=; NT(7QD>_()_&M2DW?7T_)#BFE9^?YLP?$.E:O>0
M33:3XDO-,G6(^7&D$$L6X9.6#QEC^#"OE]OC7\1%<J?$/(.#_H5O_P#&Z^NI
M_P#CWD_W#_*O@B;_ (^)/]\_SK./\2W2WZFMO<OY_H?5L?A_XG3Z5;WMG\1(
M)998EE$$^CPQKRN<%E!/7CI7'CXU^*_!_B"31_&VBV\IC/S/:_(^T]&7DJX]
M.GN<U[?HG_( T[_KUB_]!%>2_M%Z!%=>%['7$0?:+.<0NWK&_;_OH#\S5U7[
M.>FU[?B94ESP5][?I<]5\/\ B+2_%&D1:GI-RL]M)QD<,A[JP[$>E1:]I>J7
M\#/I?B"\TN=8R$$4,$D;-V+"2-C^3"OFCX'>+)]!\<0:8\C?8=4/DNA/ D_@
M;ZYX_&OJ]_N-]**JM#F79A3D[V?0^0Y?C3\18I7C;Q#\R,5/^A6_4?\ ;.OH
M_P &66O7&BZ7JNK^*+Z\FG@6:2W%O;1PG<N<?+%OXSU##I7QM??\A"Y_ZZM_
M,U]O^$_^1/T7_KQA_P#0!50UI\W73\@J:5>5;:_F3ZMI]YJ$"I9:S=Z9(N3O
MMXX7W?[PD1N/ICZUYEX+;Q]K?BG7].U;QE,EII$X@+6MC;!YF.2#EHR%&,'H
M>M>O5Y]X _Y';Q]_V$H__1=1'X_D_P!/\QS?NKU7Z_Y'2:QH^K75H/[.\3W]
MA<1P[0P@MY$=A_$X:,G)_P!DJ/:OF";XT_$2&:2)O$.2C%3_ *%;]C_USKZ[
M?[C?2O@F^_Y"%S_UU;^9J+OVEO+]32RY+^?Z'U79^'OB1?:/;7T/Q)027$*2
MB-]$@ &X XW#/KUQ7GVK?%CXB^ /$7]D^)(]/OS&H8MY6P3(3PZLN,=Q]WMT
MKWKPY_R+&D_]></_ * *\&_:5\C^V=!VD>?]GEW^NW<NW]=U:57R5++:]OS_
M ,C*E[]--[V3_(]I\%>,]-\<:"FIZ<2A!V3P.?FA?T/K['O71U\\?LT_:/M^
MOXW?9O*BS_=WY;'XXS7T/5S235NHH-NZ?0*\7^(OQ4E\._$_1=,MKAEL;-@V
MI*IX?S.,'UVJ=WU->LZWJUOH6AWNJW1Q#:0M*WO@=/QZ5\7>,[;68?$DUUKL
M1CO=05;W!/\ #(-P_+ICMBL>;]XNR_JWYLT:O!^?]7_(^WHW26-9$8,C ,K
M\$'O3J\X^"?BG_A(_ ,$$TA>\TT_9I<GDJ/N'\N/PKT>M9QY96,X2YHW9Y)\
M1M<\=CXAZ5X=\'7XMS=6?G2!H(W5<,P+LS(Q   Z5;U+0_B1I>@7FI3?$A&D
MM;=YFA31("&VJ3@,?IUQ7>)HL2^*)=<9PTKV:6BIL^X [,3GWW#C_9J'Q?\
M\B7KG_7A/_Z :QFW"D[;ZO\ ,VBN:HETT7Y7/F"S^,OQ#N[ZWMO^$CV>=(L>
M[[#;G&3C.-E>X7WA;XGQ6<DEA\1HKFX )2*71H(E8^FX;L?E7RMHW_(<T_\
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MH6MVN@WI9/J;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_7Q)_Z"*ZOX':=9VOPRTZZAMHDN+DR--*%&YR'(&3U/ %<I^TK_ ,@70?\
MKXD_]!%.O'E:7FA49<UWY,\[^"__  DG_"67?_"+_P!E?;?L;;_[2\SR]FY>
MFSG=G'7CK7;>$7\6-^T!"/&'%\+27RPG^J\O;QY>.-O7WSUYK"_9S_Y'R^_[
M![?^AI7T#J>B?:?%FAZQ'$"]F)XI'R 0CI^OS ?G6LM)0EY?GS&.ZFO-?H;M
M%8'C+Q"OAOP[+=JZB[E9;>T5N=TSG"\=\9S] :WER%&XY..34+4U\A:S/$G_
M "*^K?\ 7G+_ .@&M.LSQ)_R*^K?]><O_H!K*M_#EZ/\BZ?QKU7YGPO;_P#'
MS%_OC^=??$/^HC_W1_*O@>W_ ./F+_?'\Z^^(?\ 41_[H_E75_R[^?Z&'_+S
MY?J<AXI_Y'WP5_U\7/\ Z)-7?'/@RP\<>'9=-O%"S#+VT^.8I.Q^GJ.XJEXI
M_P"1]\%?]?%S_P"B3795ARJ4+/N_S1I>T[KLOU/A35])U3PIX@EL+U'M;^SD
M!#*<8(Y5E/IT(->XVWQ(C\;_  R^RWKJNM6=Y9B=>GG+YZ 2#^OH?K7:?%GX
M;1>.-&^U62JFM6BDP/T\U>IC8_R/8_4U\N:+!+:^+-/@GC:.:.]C1T<8*L'
M((JZ,G*2IR[K\UK_ )_\,16C:+G'L_R>G^7_  Y]TT444BPKY5_:$_Y*6/\
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M[1]*C<%K6!YI%!Z%R ,_@OZUA4WBO/\ S-H=7Y'.? 82'XI6FSH+>;=]-O\
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MT)5N9XX1!+:M(J' 8D,I8@?Q'(R*Z3X/^!+_ ,#>&KB+5)$-[>3"5XHVW+&
M, 9Z$^N*ZKQ%XMT'PG:QW&N:E%9I(<(&#,S^N%4%CU[#BKNDZQIVNZ='J&EW
M<5W:2?=EC.1[CV/L:B'NIJ/]=2Y^\US%VBBB@84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!XM\1/@1!KMY-JWAF:&SO)27EM)>(I&[E2!\I/IC!]J;X3\4>/_  581:-X
ME\&ZKJEM;GRH;K3U\Z14&, A<AACH21Z?3VNBE'W59;!*TM7N<+'X_U;4DV:
M1X"\1&<G _M.-+.,>Y9F)Q]!5C1/"FISZ['XD\4WZ7.I1!A:6=ME;>R##!"]
MW8C@L?RKLJ*:LG<35]&9.M:IJ-@NW3_#][J<C(2IAF@C0-V#&213^0-?+EY\
M&_B->WUQ=/X= >:1I& O;?J3G_GI[U]<T5/*K\Q5]+'&^!+G7[/0-+T?6O#%
MY936T"P-<K<V\D.%7 /RR;^<= IK(^)R^*?$GA:]T#1/"EXYN'"/<SW5LB%%
M8'*CS2QSCN%ZUZ3155/?=Y"A[FQ\K>&/A9\1/#OB?3=8_P"$9\[['.LIC^W6
MXW =1G?7T:-;U5M*FN1X5U);I" MH\]L&D)ZD,)2H ]R#Z UN44VVU82BE+F
M/%?#UM\1[3XD7_BG6?"#W$5W!]G6*&_MMUO&""H7,@STYZ9)S7LEK-)<6L<L
MMM+;.XR89BI=/8[69?R)J:BDM(J/8+:M]SB_B+#J6L>&-3T*P\-7>HO=6^V.
M<36\<2OV)WR!L@@'[OXU\\VOP;^)5E=PW5MH1CGA<21NM[;Y5@<@_P"LKZZH
MI17++F6Y3=U9[')Z3K_B?^PD?5O!U^NIH%5X[>ZM620X.6!,HP,CD'D9&,\X
MX_19/B'9?$+5]=O/!<C:?J*QQ^3%J%L9(ECX4C,@!/)R..O7BO7**J_O<W]:
MDV]WE(;2>2YM8YI;6:U=QDP3%"Z>Q*,R_D34DD:2QM'(JNC JRL,@@]C3J*3
MU&CR+P_\,G\'?&)-4TR%CH=U;S;0!G[,Y ^0^Q['\/KZ[110M(J/85O><NYQ
M/Q ^&>D>/K-3<$VNI1+B"\C7)'^RP_B7V_(UYUX6TSXD?">XFLET3^W]#D8R
M%;.7)4]R@/S X'W=N#V.:][HI17*WR]1NTEJ>>+\4KAXE"?#_P 9_:&P-KZ;
MM3/^^6X'N17CMW\)?''C3Q1J&K2:1'I$%[<O-_IEPOR G.,+EC^0KZEHHLK\
MP7=K'->#/#LO@SP3::.TAOY;1'.8E"&0EBV%#''?')'X5YI\7-!\:^/QIUMI
MGA*Y@MK1G=GN;RU#LQ '192 !@]Z]PHHG[[O((^ZK(^:_A]X)^)7@+Q$=5B\
M)+>*\+0R0MJ,"9!(/#;S@Y [&O4)_%GQ*:(BW^&D<<G9I-<@<#\!C^=>B453
M;:LQ)).Y\_'PI\4?%GC_ $74_%FF+%IUI=)(8HKF'RH5!!.%#DG..O)KZ!HH
MH6D>5!;WN8*Y7QE?:ZVD:AINB^&KN_GGMVCCG^T6\<(+*1SND#\9_N_C7545
M$HJ2LRD[.Z/D%/@I\1$=7'A[E2"/]-M__CE?3FBZSK4]@JZGX5U"SNHX-S@7
M%M(CN!]U")<Y/;< /4BNBHK3F=N4FRO<\D\5R?$'5/%^A:II7@R5+/29'D\N
MXO[97F+#:0=LA"_+]>37I6D:A>:A SWNC7>F2+@>7<20ON]=IC=N/KCZ5HT5
M*T5OZU!J[N%>0?$WX7?VEK]AXJT.WS>1W41O8(QS*H8?O /[P[^H^G/K]%&T
ME+J@>L7'NK!1110,K7]U-9VC306%Q?2 @""W:,.?<&1E7CZU\[?$CP'X_P#'
M'B^75X/"KV\'E)#$DE];%MJYY.),9R37TE14N*;NQWTL>2_"BR\7>#/#[:)K
M'A*[:/[0TL<]M=VK8#8SN!E'3!/&?I7K5%%6W?<B,>78@O+B2UM))H;2:[D4
M<00% [_0NRK^9%?/_P 4O!GCOQ[XFBU"S\*2V]M! (8Q->VV]N222!(0.O3)
MKZ'HJ'&[3?0T3LK(\/\ A)H7C7P NH6VI^$;F>VNV1P]M>6I=64$=&E (.1W
MKUS6-'L_$_A^?3=4M6\BZBP\4F"T9ZCD$C<#W!/(K4HJI>^K,B*Y7='R9??
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MZ%)(G&0RGM5BBB7O*SVV!*SO\SYV\2_ ?7-$U==7\$W@F6*3S8H)) DT3 Y
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M]R3G_C]M_P#XY7U]14J.MQWTL>8:=K_Q-L=#M+#_ (5W"UQ!"D7VAM8AV':
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ;("^@?[<YCM2C[A*P4L<$>RGGI568KHOT444AA1110 4444 %%%% !1110
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MU-];#L=C15#2=:TS7K(7FE7T%Y;DX\R%PP!]#Z'V-7Z;5A)I[!1110,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMT,:7<0?83DH>A'X$&O$_P!I3_C^\-_[D_\ -*IIJK!/^9#IM2BVNQ[Y9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKRC]HB18_$WA9F( 179O8;TK:;7M::71I?F813]G-]TSZ B54A1% 554  =
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MM?\ T8U<I^TD!_PB>CG'/VX\_P#;-JZKX*$'X4:/@@X\T''_ %T:N5_:2/\
MQ26CC_I^/_HMJ,5\?S1-#X?O_4],\$L6\":"Q.2=/@_] %>,?M!\>,O"Y'78
M>?\ MHM>S>!_^1#T#_L'P?\ H KQG]H0A?&'A@D@ (22?^NBU=7_ 'B/^/\
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M#^J'1--.H>3O^UFU3S=VX\[\9S[YJWXD)UWXD^'M 4[K:P5M5NU[97Y8@?\
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M@C->ET4FDW=C3ML>/^%OV?=#T34([W5=0EU=XFW)$81%%GMN7+%OSQ[5Z^
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M]"#'D4KK8+'=T5Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW3
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2&%%<G;?$30[SQY)X/MA<RZA$C,\JJODJ0,E=V[.1]*ZRA:I-;,.K78****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOU9-K5)KS7Y!1113*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWSZ?=^2/>/#VCP^'_#UAI,'W+6%8\^IQR?Q.36G115-MN["*Y59!7S'\7O\
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M=C_[ISU]#FE"_M6I;N/_  Z"5O9)QV3O\N_ZGU$_W&^AKY[_ &>/^1M\3?\
M7,?^C#7NFH:YIFGZ.VIW%]"MGMRLH<,'ST"X^\3V Y-?/WP"U:QLO&.O+=W4
M5N9X<Q^<X3.'Y'/?GI4T_P"*_P#"RJG\)?XD?2=(1D$>M(CI+&LD;*Z, RLI
MR"#T(-.IM7T8SY&\#Q'0?CM:6MR"IAU&6 [AW.Y1^>17US7@?QM^']]!JB>-
M]!B=I(RKWB1#+(RXVR@>G SZ8!]:]&^'?Q&TOQSH\.V>.+5HT N;1CA@PZLH
M[J>O'3O13;E24>L=_P#,532HY=)?U;\3MJ**Q-3UIOM@TC22LVJ.,N?O):I_
MSTD_HO5C[9(/(9Q'Q^U&:Q^&KPPD@7EU'#(1_=Y;_P!E%:OP8$0^%.B^5C!6
M0MC^]YC9JU\3?"DWBSX?WFFP$RWL:K- 2!EY$[>G(R./6N#_ &?O%,0TRZ\(
MWS>1?6LK20QR?*S*?O+@]U.>/>BEO./71_)"J;0EZ_B>M^)+"+5/#.IV,R;H
MY[61"/JIKPW]FJ[G%]KUEN/D>7%+M]&R1G\OY5[3XRUNU\/>$=3U&[E6-8X'
M"9/+.00JCU).*X/X"^$+CP_X5GU6^B:*[U1E=4<8*Q+G;GZY)^F**?QS?2UO
MG<*GPQ7G^6YQ_P 2/^3B_#O^]9_^C#7T37SE\2YXD_:(T%V<!8VLPY_N_O#U
M_,5]&T4_X,?67YBE_%?HCYWT\D?M67&#UF?_ -)Z^B.U?.FGR(?VJYV#K@SR
M+G/?R,8_.OHL\ TH_P "'H_S8W_%E\OR/GGX(?\ )5O%7^[-_P"CJZW]H?\
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MJBH+*]MM1LH;RSG2>VF0/'+&<JRGN#4]#5@3OJ@HHHH&%%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCAGAN(R\$J2H&9=R,&&02"..X((/N*DH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;2+*"5=LD<"(ZYS@A0"*E=;CZJVQ;KCOB=XM/@WP1=ZA"P%Y)B"US_ST;O\
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M?H:ZZO!?CSX+T/2/#5CK.D:9::=<QW0A?[)$(@ZLI/(7 R"HYKU?P#J,^K>
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M(;)5VF(:?/AO4M^[Y)[D]:\<7Q1I7ACXPKJG@NZ+:-/-&'C6-T0H^-Z;6 .
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MD4M7%VT:_JX]I);IGG'@_P"*&G>(OBKJNIW^H6VFZ7%8_9[(7DZQ C>"3\Q
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M220RW* D"8O)M /J  ?Q/M7NJVT"6@M5A06X3RQ%M&W;C&,>F*2NX\Z[M+Y
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MA23=-*.]OO/?KJ[MK&UDNKNXBM[>(;I)9G"(@]23P!6+_P )WX/_ .AKT/\
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MKIV1SOQ#_P"2<^(O^P?-_P"@FO/_ -G#_D2=3_["!_\ 1:5Z!\0_^2<^(O\
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MP4?YE7+=1D>U>[:!]B^(GP^TF\UJV%PMS &EBW,J,_*L2 1GD'KTHU<')+5
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MZ*K:7PQ]$3O.?J_T"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/TKY@^#'
M_):KO_=NO_0J^B-;\16^BHRR66J74QC+I'9:=-/N]MR*5!]B17SI\-K7Q!X:
M^)']N:GX3\0)9S>:LA339F,>_D' 7)P:5/\ C7\F*JOW5O-'U'1573]0AU.U
M^T0)<HFXKBYM9('R/]F15;'OBHM7U:'1[(W,UO>W SA8[.TDN'8XSC:@..G4
MX'O0W9:C6NQX9\%_^2O>+OK/_P"CZ]H\7_\ (EZY_P!>$_\ Z :\*^&#ZWX>
M^(^J:OJWA?Q!;V.HB7+C2YG\LM('&0%)QU'&:]@\<:ZD7A._M;;3=7O;J]LG
M6"&VTV=\EU(&XA,(>>0Q!'I45$_J\8]>6WS'2TKM_P!Z_P M#@/V;/\ D6M:
M_P"OM/\ T"K/[1__ ").F?\ 80'_ *+>L[X%/J7A>#4=+UOP_KEF;N9'AF?3
M)RA.-I#$*=O;DX'O5GX[27_B/3++1M%T'6[V6WNC+-+%IL_EKA2N Q3#9SU7
M(XZUIB->6WE^!-#3FOYGI'P\_P"2=>'?^P?#_P"@BLCXA?"S2/'J+<22-9ZI
M$FR.ZC&<CLKK_$,_0^]3?##4Y)?!VF:7>:9JEA?65LL4L=Y8RPJ=O&5=E"G/
MIG/M7-2^.[_PG\2?$5O>Z/J5UX?EFB;[7:VS2""7R4R"0,$$ $C.1U[U5;EE
M5=_-K^OG^@J5U3NNAYK/%\1?@I>HXG:XT8R8&&,EK)[$'F-C^'U.*^BO"/B6
MV\7^&+/6K5#&EPIW1L<E&!PR_F*\]\8_$+0O&_A.^\/>%8KG7-1OD$2Q16DB
MK$2<[W9U &,9^HKL_AUX6D\'>";#2+AU>Y0-).5.1O8Y(![@=/PHBVXOFZ6L
M_P Q.RDN7SN=57E/Q^\/S:OX"2^MT+2:;.)G &3Y9&UORR#^%>K4R6*.>%X9
M45XY%*NK#(8'J#64X\RTW-8NSU/)/V>=:AO? TVE[Q]HL+AB5[['Y!_/=7KU
M> ZE\//%/PS\5MXD\#0MJ.G/GS; ?,ZH>2A7JX]"/F'IW/8Z?\<_"K1JFN)?
MZ'>!<O!=6KM^14$D>Y Z5JYJ?O=>J,U%P=NG1GIM,\V/SO)\Q/-V[MF?FQTS
MCTKE+;QW#K@">&=,O]29@,7$MN]M;)D9RSR $CIPH8\BMO2-+?3HI9[N?[5J
M%P0US<;< XZ*B_PHO.![DG)))GU'>^QXE^T+_P C3X4_X'_Z&E>_)]Q?H*^=
M_C,=8\6>)-*ET/PUK]Q!I\9S,=+G0,Q8' #(#QM'4=Z]MTSQ-;7NC&^DL=7M
MC"B^;!/IEPLH)[*FS+_\ S2I_P )^K%)?O?DCQ77/^3I['_KK#_Z*KUWQ_XY
MLO 7A\ZC<QF>>1O+MK=3CS'QGD]@.YKQC6&UJX^.4/BRW\*>(7TR&XB^8Z9,
M&9%4*6"E<^I KJ?C?H5]XP\):9K.C6EY*+*20R6\EM)%+L; +>6X#<%?3H<]
M*B[5"/KKY79IHZTO1?@C9T/PKK/CK3H=7\<ZE.;:Z42PZ+9N8;=$/(\S!W.2
M.Q/&:X'1]/L]*_:@^PZ?;16UK"2L<42A54?9_2NI\!?%RZUG0[32+;PQJ5]K
M-O$(6:+:MO\ *  SR$Y3MG@^V:XC4;C6?"_[0<6JZOI\UW/*XD\O3H2?-5HM
MN(PQ^;;G!)(SC/%;)*->-MM?GIIZF.KI2YM]+^6OX'N/Q+_Y)IXC_P"O&3^5
M<C^SU_R3B3_K^D_DM7_B!K>I7/P_U+3O[ U235=0@*16MI92SB-&.!OD52F[
M )(!.,XYZUA_ ZZOM T"70M:T/6K*=[LR0R2Z9/Y;!@!RP3"X(ZM@>]337O3
M]$54V@_-_D7/VA_^2<P_]?\ '_Z"]=7\+O\ DF/A[_KT7^9KB?CA=7GB#P['
MH6C:'K=]<I=B25XM,G\M0H8<,4PV2>JY'O73?"C4IAX,TS1;_2M5L+^SA*.M
MW831(0#P0[+MY!'&<]>*5+X9^J_(=3XH>2?YG(?%/P=?:7XUTWQWH#1RWWVB
M)'L6;#SR#@;!_%E1@@=AGUKT'_A-_,TPO#X>UXZD4.+)]-F3YP.AE*B/&>^[
M%>:_$ZZ\;:%\5-.UG1[3^T8A;E+"U6-IL<?O<QJ=V>>6'8CFJO\ PM/XO_\
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M$<G.W)Z<44TU4=_Y?U+FTZ:M_,C<_:6_X\_#O_76;^25[5HG_( T[_KUB_\
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M3VZCXIZI*O@[5-&L=*U74+^\MC'&EI82RH W&2X7:,<\9STXJ:L7R-/=_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%\7_\
M(EZY_P!>$_\ Z :VJY_Q-X6/BBUELY]<U6SLIH_+EM[,PJKCOEFC9N>A ;'M
M45(N47%=2X-1DF^AYC^S81_PCFMC(R+M./\ @%>W5Y]X8^$NG^#KB2;0_$.O
M6WFX\V,R0.DF.F0T1]^1SSUKT&MIM.S,8)QNO,****@L**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ9-^>7/TZ'*_$O\ Y)IXC_Z\9/Y5YC^S3_R#_$'_ %UA_DU>G?$O_DFGB/\
MZ\9/Y5YC^S3_ ,@_Q!_UUA_DU32^.?H@J_##U.A^/'B^7P]X1CTNSE,=WJC-
M&64X*Q#[^/KD#\35GX&>&H-%\ 6^H&,?;-3)GD?'.S)"+],<_C7FW[2#RGQ?
MI2-GRA8Y3ZEVS_(5[C\.V1OASX>,?W?L$0ZY_A&:='X)3ZMV^6O^0ZOQ0CY7
M.FHHKA/B,GB/2O#>IZ[H?B>[M9+6/SOLKVUO)%M&,@$Q[@>IY8U,I**NRDKZ
M&_H?AV/0]7UNYM]BP:E<+<[%ZJ^W#_F0#^)JM\0_^2<^(O\ L'S?^@FO,_A#
MXB\:>/I]0GU3Q7<16EF4'EV]G;!I&;)Y)B.!Q^O:O3/B'_R3GQ%_V#YO_032
MK1Y:=O(*33J:=SS_ /9P_P"1)U/_ +"!_P#1:5[!<7,%G;27%S,D,$:EGDD8
M*J@=22>E>/\ [.'_ ").I_\ 80/_ *+2J/QBUR;7/'&@^ H)F6TGFB>]"'&_
M<W"GZ $_B*WK7<U%;NR_!&=.RC*3V5V=I/\ %S1MKS:9HWB+6;1"0UWIVG,\
M(QU^9BOYCTK:\*^/O#GC-'_L>_#SQ\R6\JE)5'KM/4>XR*W[2TM["SAM+6%(
M;>% D<:# 51T %?/7QITJ7P3XVTKQAH7^BR7+$R>7P/-7&<C_:4\_0UE=*23
MV?4JTG&ZW['T4_W&^E?.7P'O[33/$'BN]OKB.WMH80TDLK;54>8>IKWS1-6B
MUWPY8ZK",)=VZR@>F1DC\Z^>_@7HFGZQXRUQM0@%PEL!)'$YS'OWG#,O1B.V
M>E.*:K27]U_F*4DZ*?FCT.3]H'P0FH_90VHO%G'VI;8>5^18/_X[7I&F:G8Z
MSI\-_IUU'<VLPW)+&<@_Y]*SO%'A/2?%NB2Z9J5K&Z%2(I-HW0MV93VQ7BGP
M&U2^T7QIK'@^ZD+0CS&"]EEC;:Q'U'\A1#5N#WM?U'.Z2DMMCVKQ-XQT+PC;
MQRZQ?+"TIQ%"JEY)#_LJ.3UKE9_C/HM@T;:MH/B;2K>4X2YOM.V1M]"&)/X"
MLO6? 7B+4_CII_B.18IM#MPC*[2+^Z"K]S83G);)R!CFMOXNZOH$/@/5],U/
M4+2.[GMR;>W=P9&D'*D*.>N.>E9N3C#G>_;Y_F6E>?*MM-3MM.U*SU?3X;_3
M[B.XM)UW1RQG(85PGQR_Y)1JG_72'_T8M9/[/$\DOP[GC=B5BOI%0>@*J?YD
MUK?'+_DE&J?]=(?_ $8M5B(\JMZ?FA4)-O7S_4/@;_R2C2_^NDW_ *,:O1:\
MZ^!O_)*-+_ZZ3?\ HQJ]%K>M\;_KHC*G\/W_ )L*Q-?\6:1X;,,=_<,;FX.(
M+2"-I9I3_LHH)/UZ5JW5Q'9V<US*<1PQM(Q]@,FO!?AUX\\S4-;\2WWACQ)K
M&HWMR42YTZP\^."$ ;8@VX8QGD?2L=Y<OE?]#1Z*_P CNO\ A='AZVU".SUG
M3==T-I?N/JEB8E;\B3CWQBN^-_9BQ%\UU"+0H)//,@";3WW=,5XY\1?$@\:^
M#[K2H_ /C$7F5>UEGT@A8W!ZY#$CC(Z=ZO\ P0L]8_X1&[T;Q-H]U'#:7"O:
MIJ-JRC:1G"AQS@C/MFG&[3[K\12=FGT?X'6:?\3O"VL>*8?#VEWK7UW(&/F0
M)F)=HR<N<9_X#FLKQ%\;?!WAS4&L7GN;^>-ML@L8U=8SZ%F90?P)KR[3="M9
M/VD=0TJ+=:VC22EDMCLRICW%<CH#G!QCJ:^@YM TI] ET8:?;)I[Q&/[.L0"
M 8QTJ+OV2J>5QW_>2CVL,\.>)=*\5Z0FIZ/<B>V8E3E2K(PZA@>0:X'XK?%F
MQ\*V%SH^E3K/KLB["%Y%L"/O,?[V#P/Q-<A^SE+)!K7B/3PY,"JC $\9#%<X
M^E=S\>/^257_ /UWA_\ 0Q3KI<J:V=OQ'3OS-/=-K[C#^&7Q1\'Z5X(T;1]0
MUDQZDH*/$;:9OF9SCY@A'<=Z]?O+RVT^SEN[R>.WMHE+22RL%51ZDFN.^#__
M "2K0O\ KDW_ *&U<5\3_$ZS_$W0O#<]C?ZCIEJ!>75A8P^;)<R8)0;,C<!@
M''N:TJOW^7JW^AE2^#FZ)?J=9?\ Q?T:R@-W%HGB.\TT#=_:%OIK?9\9Z[W*
MY'?-=+X8\7Z'XPL&N]%O5N$0XD0@J\9]&4\C^5<R?B@AC\L^ /&^S&W;_8W&
M/3&^O*?!%AXAT;XPKJ.E^&->T_0[RZ:-X[BPD14A<]&X( !P>O&*4-9<K^__
M #*F[1YNW0]X\1^-_#?A.(MK.K06\F,B '?*WT1<G\<8K*O/BIX8L/"-GXCN
MIYXK:]#?9H"@,\N"0<*#CMU) Y&2*YWX\Z3I_P#PKB[O196ZW27,3B98P'R6
MVGGKR#5GX/:!9R_#*RGOXTO6O86C<3("%A#MB,#^[G)]R:B/-)2[JQ4FE*/G
M<ZOP;XWT;QSIDE]I#3 1/LEBG3:\9(R,X)'Y$U!K/Q T?2;Z73X(-0U?4(1F
M6TTFU:XDC_WL<+]"16%XQ32OA7\-M6N/#5E'833L%C*$D^:YQNRQ)X&2!T&*
MP? 7C2V\.^#["T@\#^,;B22,37%U!I6];B1N6<-O^8'/!],55U)NW2WWBU25
M^M_N.KT#XM>&==U?^R&-[I>IEMBVNI0>2Y/IP2,^Q.:[JOFWXLO>^.;C3;[1
M? _BNUU"VW++-<:4Z%DX*X*ELD'/YUZ5=^,]3\.?!2'7=5MYXM9%LL/EW,11
M_.)V!F4X/^U2<K4W)K5?CVL.SYU%;/\  W?$7Q#T'PYJ":9*US?:HXRMAI\!
MGF/X#@?B17#?$'Q_I/B#X<Z_IIMM0TO4Q CBRU2V,$K+YB\J"2#^!S6C\#M#
M6+PD_B2\S/JNKRO)+<R'<Y0,0!GZ@G_]56?CGHUIJ/PUO;R:)3<V+)+!)CYE
MRP4C/H0?Y5-:+C&TO*_X;?\ !*I2YI)Q^7XD?P$_Y)=;?]?,W\Z].KS'X"?\
MDNMO^OF;^=>G5O5^+[OR1A2^'[_S8R::*WA::>5(HE&6=V"@#W)KC[;XI^%+
M_P 4VOA[3;YK^\N&*A[9-T284MRYP#P/X<UUUS:V]Y"8;J"*>(D'9*@9<@Y!
MP?0U\YVEG;V'[4_D6L*0PBY9@B# !: DX'U)-9PUJ*+V=_P1K+2#DNA]!:MK
M>EZ#:&ZU74+>S@_OSR!<GT&>I]A6%X?^(_AOQ+;ZG=V-VR66F[?/NKA?*CP0
M3D;CG''<"M3Q)I%AJFBWRW=E;3L;61 TL88@%3P#U'->&?L^:%9ZQ!J\FH*;
MB"WFB=;5\&(OAL.R_P 1';/ Z]:F-W*4>RO^(IOE2:ZNQW;_ !^\#KJ@LQ+?
MM%G!O%MOW0_7?_X[7I4-W;W%FEY#,CVSH)%E#?*5(SG/IBO/OC=I-G>_##4)
MY((_-LO+D@?:,I\X! ] 02*3X%W4MS\++ 2L6\F66-23G"AL@?K51]Y2756_
M$)73B^CO^!Y[\6OBY9:S-!X?T.?S-/2='O+M<[9-K [5]5&,D]\#%>N>'OB7
MX0\3:E'I>CZO]IO&0L(_LTJ9 &3RR ?K7EO[0O\ R-/A3_@?_H:5[\G^K7Z4
MJ?\ #;?=_D*?\2R[+\S.UWQ#I/AG3FO]8OHK2W7@,_)8^B@<L?8"N.NOC%H]
MBHGO- \3V^GDC%_-II2 YZ').?;I7%>'M07XC_'F[N+S$^F:*DALX6Y0%6"A
ML=R3EOP'I7NMQ;PW5O);W$22PR*5='&0P/4$4*_(I]];>7_!_ IVYG'M^91T
M/7]*\2::FH:/>Q7=J_&].H/H0>0?8BM*OF?1[F;X5_'.71H9'71[V=8S$3D&
M.3[A^JDXS[&OIBJ5I14ULR=5)Q?0*X;XQ?\ )*==_P"N:?\ HQ:[FN&^,7_)
M*==_ZYI_Z,6L:OP/^NJ-J7QHX_\ 9N_Y%+5_^OX?^@"O7=5U.WT?3)[^ZW>3
M" 6"XR<D  9(YR17SY\$M$\4:GX=U&30O%W]BP+=!7A_LV*YWMM'S9<@CCC%
M=/XZ\&^.O['ANK[QJ=8LK6XBEGM?L*6N5#CGY"=V.N#Z5TU'[R^7Z'-'2,FO
M/]3V!;*V74'OUB NGB6%I,GE 20,=."3^=4M>\1Z5X:LA=:K=K CMLC3!9Y6
M_NHHY8^P%:O:O M$\=)?_%'7]<N]!UW6A9'[)IRZ;9_:%M4!(+'YAM+8SGZU
MEO+E7K_7S9J]%S>AV]W\9=#TRY2/5M$\2:9;R,52ZO=.,<3>XYW'\LUWFG:E
M9:OI\-_I]S'<VLR[HY8SD,*\R\4>-H/$OAG4-(G^'WC5Q<PLJ>9H_"OCY6^]
MQ@X-8GP MO$VCS:II6KZ5J=G8,BSPF[M7C029PP!8#DC''M50UNGT)D[6:,K
MXW_\E8\+_P#7.'_T<:]+\5_&#PEX2O7LKJYFN[R,XD@LD#M'_O$D*#[9S[5Y
MA\=8A/\ %'PW"S.H>&)2R-M89F/0]C7O>G:)IFDZ<-/LK*&*UQAD"YWYZEL_
M>)[DY)J(7]EIW94[>U_[=7ZF+X0^(?AWQO&_]D7;"XC&Y[6==DJCUQR"/<$B
MM/7?%&A^&;;S]9U2VLTQE5D?YV_W5'S-^ -?/7Q.T5?AA\2-+U_P\OV6"X/G
MK"G"JRG#H!_=((X]S7L'Q*L--U7X8ZUJ#V5N\K6'GI*T8+@@;EYZ\42E^[]I
M'T8)6J<C]46;;XI>%[CPK/XD:ZE@TV*<VZM-'AI7 !PBC).<^W?.*HZ%\9O"
M6OP7$D']J1&W&^5&T^64HG]X^4' 'N2*Y?\ 9\TB&;PA/J-R1.PN)(8(W4%8
ME(7?CW;C/L *]-T7P?X>\-SWEQH^E6]G+=\S-&#\WL 3A1[# JYIQ;]/QL1&
M7,OG^!6\->/_  QXONIK;0M3^US0())%\B2/:N<9RZCO5CQ!XPT7PNN_6)KJ
MWBVAC,MC/)$,G'+HA4'V)S7BWP#4+\0?%"J %$;  #@#S:]D\>HLGP^\0JZA
ME_L^8X(_V#43E:FIKM<T@N:HX/O;\BQX;\6Z'XOM)KK0K[[7!"_ENWE/'AL9
MQAP#T-2^(/$FD>%]-;4-9O8[6W!P"W)<^B@<D^PKRO\ 9N_Y%+5_^OX?^@"K
MWQ/\!^(_%GC?P[=V(CFTFV9?.5Y !"=^68J3\V0 .,]*TG&THQ76VO:Z(C*\
M92?2_P [&I<?&71[2);JY\/>)X-.8@+J$NF[8&!Z$,6S@_2NTT'Q!I?B;2H]
M2TB[2YM7XW+D%3W!!Y!]C5'QAJ^@:9X>O+?7;^TMK>X@>/RYG +@J1A5ZG\*
M\F_9IGD-KXAM]Q,2O"X'N0P)_05,/><H]E<<KQ2?=V/3_$WQ(\*^$@R:GJL1
MN5_Y=8/WDN?0J/N_\"P*I^(OBKX9\,:78WE_+<-)>PK/#:0H&FV, <D9"CKW
M/KC->?\ [1>DZ?:^'M'N[:RMX9_M;(7BC"D@J2<XZ\C->A^$_"NF7/P]L;/5
M+>+4/MUK%)=-.@)D.P;?IM& ,=,5$>:4&^J=AMI32[HG@^)/AB;PM#XD-W<)
MILC%#)]DE<QL.H<(K;?J>/>H--^+'@S6;Q;33-3N+RY89$4&G7+MCUP(^GO7
M0:9X;T?1M#_L73["*'3MK*8!E@P;KDG).?4UX%X>B7X4?':32YOETO4!Y4+L
M>D<ARAS[,-IK16=7EZ/;_(EW5/FZK?\ S/HZ218HFE8,552Q"J6.!Z <D^PK
ME;3XE^%;[6O[&MKV[?4MVUK4Z;<AT/\ M Q_*.>2< 5U4TT=O!)-*P6.-2[,
M>P R37 ?"^T;4!K/C*XB"SZY=,\/RX*VZ?+&/QQFE'65GLE_P%^OW#EHM-W_
M $_Z\ST*J>J:;!J^EW&GW)<07";)-AP2IZC\>E7**!C8XTBC6.-0B( JJHP
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MC\_2NH\*^'+3PGX;L]&L^8[=,,Y',CGEF/U-*GHY2[Z?Y_=L*>O+'Y_Y??\
MD;-%%%,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!HMXX<L,<[I _&?[OXTJ]G"48];_>U_P ,OD315I)OI9?)/_AV>*?LV?\
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M9;2\V$/;WELS1LN>H,HR,'U[44_XDO2WXDU-8QMWN=S\8O\ DE.N_P#7-/\
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M'._L]?\ ).)/^OZ3^2UZN>AKR#X0:5XQ\%:=/H^L^%KDVTUP)4N(+NV;R\@
M[E\P''&>,GKQ7L%;U==NWZ&5-65GW?YGSU\!@1\1/%0(((1L@_\ 76O9?'7_
M "('B#_L'S_^@&O&KSP_XP^&'Q,OM?T'0I]9TN_=R8[=&<[7.XJ0H)4@C@X(
M_E7:ZL?&?C'P;JTNH:4^AVOV.7RM.@D,UU=/M.T,0!M7/\(&X].G7"7O4$ET
M5F;0]VNV^LKK\#&_9N_Y%+5_^OX?^@"M'XB_$#5H_%MCX&\+NEOJ=XR+->N
MWDAN@4>N.2?R]1E_!?PQX[\-65S%=6%G96%U*LI%XQ,PQP<(I[C^\1@CH:H_
M%?P1XFL_'MOXV\,V<EZRF-WC@CWNDB<#Y!RRD =/>MJK3G'FVTO]W^9E3OR2
MY=];?>>D:1\/=#\/VLUX\3:CJYB8R:E?,99F;'4%L[?PKS3]FKKXD_WH/_9Z
M[C2-8\=^,].,4^A+X7MV0K+<SN9)WR.D<;*-GU;./0UYY\)-$\<^$]>U?3D\
M..BW.V-KZ\)2&$J3AUX_>]>BD?44H7522?\ +I]_X!*S@K=U_7F;W[27_(I:
M1_U_'_T6U>I>$_\ D3]%_P"O&'_T 5Y?\7M!\9>-[2QTO2O#-PT%G*TCW4]U
M;)YS8V@JHD. >3S@\]!7<?#^;Q!;^'K#2->\/7-C/9VZQ&Y^T02Q2;0 /NN6
M!(_V<<=:5/X9>M_E8<_CB_(["O)/CWX3.K^$X]=M4/VW2FWL5ZF$_>_(X;\#
M7K=1W$$5U;2V\Z!XI4*.IZ%2,$5$TVM-UL:1=GKL>*KXZE\9_"G2M'M9,ZWJ
MTZZ5.!U4 9DD/L4YS[U[+I]C!IFG6UC;($@MXEBC4=@!@5XG\'_ 4&F?$'Q'
MJ"NL]KI<[V=I(#D%C][\57 /N37NM:MIKF7VM?PT_5_,QC&SY?Y=/Z_!?(**
M*R/$MYK-CH4\N@:8-1U+&V&!I5C4$_Q,6(&!Z9R:ANRN:I791\4>)9--DATC
M2(DN]?O0?LUN3\L:]Y9#V1?UZ"I_"WAB#PW92@S-=:A=/YU[>R#YYY#W/H!T
M ["O#;/0OCGI^IWVHVEH([N^8-/*TEE(S8Z*"Q)"CLHXK0_XR'_S_9]$=%?J
M_P"K?UOZ61+5WY+^K_UMZGOC7$"W"6[31B=U+I$6&YE&,D#J0,C/U%25YU\+
M] \56AU'6?&TDDFL7++%&))4?RX5YP-A*J"3T'I6'\1?$7Q0T_QC%;>%],E;
M2DB#B1+594F.,MO<CY,=,94_6B346D^OX=1K6[['L-%87@WQ#_PE7A'3M:,(
MA>YBR\8Z*P)#8]L@UNU4DT[,46I*Z"N1\2:_>76H?\(OX;=3J\JAKFYZK81'
M^-O5S_"OX]*L>.+SQ3:Z$4\):4M]J4Q*!WFC18!C[V'8;CZ#\Z\4TC0OCIH4
M4Z:=;>5Y\IFF=GL7>1SU+,Q+$_4U'Q.SV_/_ ('?[N[*=TKK?^OZ_$]\\/>'
M['PUI$6G6"'8I+22.<O*Y^\[GNQ/>M$7$#7+VRS1F=%#M$&&Y5.0"1U .#S[
M&O R/VAB"/\ Y KTSX::#K6C^'I;CQ+(\NNWTQENGDE$C #A%R"1@ =!P,U>
M]VR/ALD>2Z+9GP1^TF]M./+MK^63R6)X*R@E?_'N/PKZ.KB?B'\/8?&MK;7-
MK<"RUJQ826=WC(!!SM;VR ?8_B#G'5/BI<6?]E_\(UIEK>%=C:P;]6A]V6(#
M?GZ]Q41;5-0ZK3U73_@E27ON71_F><+I[>,_VE[F2("2TTZX625QT A51CZ[
MQBOHZN0\ ^ ;/P/ITP$QO-3NV\R\O7&#(W7 '8<G^==?5I<L(P[?GU%K*3F^
MOY(\Z^.7_)*-4_ZZ0_\ HQ:/@;_R2C2_^NDW_HQJA^*MKXE\3^&+OP_HWA>[
MF,LJ9NI;FV2,JK!LJ#+N.<=P*3X56WB;POX8M?#^L^%KN+RI6VW45U;.@5F)
MRP\S<,9[!J5+:?G;\ J?9\KGIE8?B;Q+!X=M(P(S=:C=-Y5E91GYYY.P'H!U
M)Z 5HZI<7=KIEQ/8637MVB$Q6PD5/,;L-S$ ?6OGZ?1OCA)XGN/$$.G1PWLR
M^6I$MG((8_[B;V;:/7'7OFIO=V_K^OR^XKI<]F\*^&9=,EN-8U>5;K7[\ W,
MX^[$O:*/T1?U/)KHI;B"%XDEFCC>9MD:NP!=L$X'J< G ]#7@?\ QD/_ )_L
M^NK^'&@>.Y?$=SK?CZ21I8(?*LHVEB95+??8+$=JG  SUYJTKZ;+^OZ^]D?"
MN[/5:*\P^)FC?$34M?TF7PAJ#06,>/.5+@1;7S]YP3\ZXQQS]*],B#B)!*P:
M0*-Q P">]):QOYE/1V'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%<_P")?#D.L6=S,-1U:RNA 1'+9:C-"$(!(.Q6
M"$^Y6IE+E3?8:5W8Z"BOBN^\4^.=.%L;CQ1KBK<PB>(_VC-AD)(S][U!'X5]
M!_ [QG/XG\)RV>HW4EQJ.GR;7DE<L\D;<JQ)Y/<9]JT2NFUT(<K->9ZC117"
M?$_5[^WTBTT+1;E[?5]8F\F&6-RK0QJ-TDF1R, 8R/6LY2Y5?^OZ_P BTKG=
MT5\0_P#"<^,-^W_A*]<ZX_Y",W_Q5?77A[PM!IVEP^=J6L7MS);!)IKG5+A]
MVX#)"E]JGT*@$=C6G+[O,2W:7*=)17S[\;XM2\&MI-SH7B/Q!;1W9D22$ZM<
M2*"NT@@LY/<]ZQ_A&NM^/M7U&TU7QEXIACMH%D0VNJ.I)+8YW;N*F/O7MT'+
MW;7ZGTU17CGB_P ">*_#FD7&M^&?'7B&YDLXVDDM=0NC/O0#G;VR!DX*GZBN
M5^'GQWU1=6M],\5RI=6D["-;P($>(G@;MN 5]3C/?FG'WG9;A+W5=['T;13)
M$6:)HV+;74@E&*G!]".1]17@OQO@U#P=!I5[H7B+Q!:K<N\4D)U:XD7@ @@L
MY([]ZANPTKGOM%?,7P<N]<\9>,9;/6/%'B"2TM[5IS$FJ3IYA#*H!(;./FSQ
MBOI6QLHM/M$MH7G>-,X-Q<23/R<\NY+'\36CC9)OJ2G=V+%%>2_%#XRP>$9G
MT?14BNM8 _>N_,=OD=\?>;V[=_2L'P/X'U_XB:>-?\<Z[J<MA=<P6"3&-94_
MO,HX5<]  ,XS4Q][5;#>FY[Q17!1?!SP99AGTRSO=-N2NT7-GJ$Z2+]"7(ZX
M/([5Q'CO6OB+\-=->./4H=8T:XS%%?W4&;BV)'"L5(!/HQ!R?3@4FTAI7/=*
M*YOPM:QZA\.M$MYWG"2:=;[FAG>)_N*>'0AA^!KPWXSRZWX+\3VD6C>*-?BM
M+NW\WR7U2=]C!B#@ELXZ=2>]5/W)\K[V%'WHW1]+45\^?!"+5/&4NJW6N^(_
M$%S#:>6D<(U:=%);<225<'C []Z]^M;9+2UCMXFE9(UVJ996D<CW9B6)]R33
M<;"3OL2T44A(52S$  9)/:I&+17SO\1?CG?W&HR:-X.?RH5;RVOE7=)*V<8C
M[ =LXR>V._6>&O@K87>G0WWCFXO=9U:5 76>[DVPYYV@A@Q//)SC/ZBNU?H#
MT=NIZY17C7C'X3GP]H\^K^ +[4=*N[4><]G#=2%)PHYQDD[L9ZY!Z5G_  M^
M-TVJ7T&A>*G3[1*0EO?!0H=CT5P. 3V(Q_6G'WG9;@]%=['NM%0W=K'>VLEM
M*TRI(,$PS/$X^CH0P_ BOF_XSS:UX+\36<.C>)]?AM+JW\SR6U2=]C!B#@EB
M<=.I-0W9V&E<^EJ*^>_A)H^J^/M$U"\U/QMXLAEM[@1(+;5&52"N>0P/\Z@^
M(-AX]^&7EZIIWC/5K_3)W$1:ZE,K1-U 8/N7G!Y 'I]:E[KU$O>V/HNBO)?A
M#\6)_&<DFC:RD:ZK%'YB31KM6=1UR.@89'3@^V*]:IM6$G<***\,^._CRYT?
M5-&TC3)REQ;2I?SE3W4_(I_(DCZ5-U=+N4E=,]SHK.T'6+?Q!H%CJUJ<PW<*
MRJ/3(Y'X'(_"M&J::=F2G=7045R/C;PX+[0]4OK75=8L+]+9Y(Y;74IXT#*I
M(_=AMF#CG"Y_&OE&#QMXQGN(XAXKUS+L%'_$QE[G']ZIC[TN7J4U:/-T/MRB
ML/0O#%OHJ0R"_P!7O+A8]CRWNI3S!SW)1G*9^BUN53)3N%%%%(84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/%FLZGH=]>+&/M%Y(<-C)1UW8.>HIVM)1?4GF]QR70]UHHHI%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5!>?\>-Q_US;^53U!>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1V5$9V("
MJ,DGL*6L_71(WA_4A%GS#:R!<>NTXJ*DN6#DNB945>21\;>/_%$WB[QG?ZI(
MY:$R&.V7LL2G"X^O7ZDU]1?"/1HM%^&FCHB;9+F+[5*<<EGYY_# _"OC>ON/
MP9*DW@C0I(_N-80D?]\"M81Y:32\OU,IOFJJ_G^AN5'<01W5M+;S('BE0HZD
M9!!&"*DHJ&DU9EIVU,7PEH;>&_#%EH[.K_959%923E=Q*]>^"*\&_:2_Y&C1
MO^O-O_0S7TG7S9^TE_R-&C?]>;?^AFLZCO*-^_Z,JFDDTNWZFW^S3_R#_$'_
M %UA_DU>\5X/^S3_ ,@_Q!_UUA_DU>\5TU-UZ(PI]?5A2'[I^E+2'[I^E8RV
M9J?!VL_\AS4/^OF3_P!"-?:?@?\ Y$/0/^P?!_Z *^+-9_Y#FH?]?,G_ *$:
M^T_ _P#R(>@?]@^#_P! %72_@+Y?D*K_ !OO_,XO]H'_ ))DW_7Y%_6O%/@G
M_P E7TCZ2_\ HMJ]K_:!_P"29-_U^1?UKP3X76FHWWQ!TVWTK5/[+O6$GEW?
MV=9]GR-GY&X.1D?C4X?^)+^OLCK?PU_74^J?%FMKIEUH-BL[1W&H:E%$JJV"
MR [F_#  /UK2U?18=7FTV:1MLEA=K=1-MSR 01^(8UX5J/ACQ9HWQF\+7OB+
M5FU>&>[5(+P+L48R2FP<(>^!P:^B*(ZQ4O-_A8E_&X^2_&X5Y9JWA#3_ !KX
MO\9Z5?K@FWLF@F ^:&3:^&']1W%>IUQNA?\ )4/%O_7O9?\ H+TN52E9]G^A
M3;2NNZ_,^2-?T+4O">OSZ9?HT-W;/D,O 8?PNI]#U!KZ8^#WQ+3QAI(TO4I1
M_;=HGS$\?:$'&\>_3/Y]ZTOBI\.H?'6A%[94CUBU4M;2GC>.\;'T/;T-?*5C
M>ZIX5\01W,!DM-2L9NC#!5@<%2/S!%52G]B?]>?^?_#"J0O[\?Z\O\O^'/KG
M6/\ DK7AC_KPO?\ VG73:KI=OK%C]CNM_E&6.4[" 24=7 ^F5&?:O+O"_CBR
M\=>-_"E_ 5CNX["\2[M@<F)_W?\ XZ>H/^!KUZG9Q23[O\Q*5Y-KR_(*^1OC
MG_R5;4O^N</_ *+6OKFOD;XY_P#)5M2_ZYP_^BUK&7QQ^?Y&T?AE\OS/9OV?
MO^28I_U^2_TKT;4=+M]3%L+C=FVN$N8RI&0ZGC\.H_&O.?V?O^28I_U^2_TK
MU.NBI\7W?DCFI?!;U_-A1114&H4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(/[M8B#C_>_"G7UBXQ[6_#^ON%25I<S[_P!?UYGQ)_RV_P"!5]ZV7_'C;_\
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MSP*)NT;(45>5V<SI7AD_$?6M2\8/KNM:9 TK66FMI=T(2]O&<%B=I)#."?\
M(K;/PK!&#X\\<$'_ *B__P!A4GP]T3QAX4T2RT+4X=$N+*WW*+BWNY1(JDD_
M<,6&.3ZK7=MN"G: 6QP"< GZT-):+;^O^"";>K/BWXC^#V\$^,;G2U>:6U8"
M6VFF(+.C>I  R#D=.U?0?P+\5?V_X%33YY-UWI;>0P)Y,?5#^65_X#63\2OA
MOXQ^(EY83F/0-/%HC( +V:5GW$'D^2O QTQW-9?@?X3?$#P+KZZG8:AH,J,O
MESV[W$P65/0XBX(Z@]J*;M%QE_78*FK4E_7<]H\1?\BSJO\ UYR_^@&OAO3R
M%U*U)( $R$D_45]D^)8/&6JZ)=Z=IMEHEN]U;^4UQ+J$K&,LN&PH@YQDX.1Z
MX'2O#1^SEXQ5@1J6A@CD'SYO_C53#W:G,_+\&5-7I\OK^1]/+]T?2D=TBC:2
M1@J*"S,3@ #O7GMO%\8(+:.%I?!4Q10OF2?:MS8[G  S]!6'XJ\*?%SQ;ISZ
M?<ZQX:L[.08EBLGG3S!Z,60G'MGFG+R%'S.E^'&NKXINO$VN1,6MI=1^SVY/
M_/*.-0"/J23^-=W7&_##PA=^"/!T>D7\MO+=>>\KM;L60Y/&"0#T [5V55*R
MT7E^0DV[MA1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "D8!E*D9!&"*6BAZ@?&'Q+\'S^#?&
M5W9F,BRG<S6CXX:,G./JO3\/>OH7X'>(HM;^'=K:%U-SII-M(G<+U0_D<?@:
MZ[Q5X1T?QEI+:=K%MYD>=T<BG#Q-_>4]C^A[UY!8_"3QQX UTZGX,U:TO8FR
MKP7.8S(O4*Z]#]00<^E*F^6+A+;OZ;!47,U.._\ 5SWNHYYXK:"2>>1(H8U+
M.[G 4#J2:X*T\4?$ET2*Y^'5NDISF;^VHE0'UV@,?YU+)X2U_P 621MXRO[>
M/3D8.-(TPL(Y#V$TAY<>P %-I]!71VEA>P:EI]O?6K[[>XC66-L8RI&0:^=/
MVDO^1HT;_KS;_P!#-?1,R36FG>7I=K;-)$H6&"20PQX'&-RJVT >BFO%_B%\
M+/'/C_7H]1FGT"TBAB$44"W<S[1DDDMY(R3GT%1-7DK;)_HRX.R=^Q!^S2P^
MP^(%R,^;"<?@U>\UX7X(^&?Q)\ W%U+I-_X9E6Z55EBN9)V4XS@_*@.>3WKL
MI$^,+QLJR>"8R>CK]JR/S!'Z5M-IVMV,H1:O?N.^*/B".RM](\/QR?Z9K%_#
M#L4\B(2*7/T/3\:[\_=/TKP[2?A+XWE^(NG^*/$NLZ9>F"=99/+FD+87HJJ8
MP ,]N*];UN3Q$L9CT*STR5F0_O;V[DCV-V^18FW#_@0K)JU/S=_RLBMY^22_
M/4^)-9_Y#FH?]?,G_H1K[3\#_P#(AZ!_V#X/_0!7@4W[.WC.XGDFDU/0S)(Q
M=CY\O))R?^65>V>"['Q?HFCZ?I&L6^BSPVL8A^U6MY*'V*,+^[:+!/0'YA5T
M]*7(]]/P05-:G,MM3G/V@?\ DF3?]?D7]:\4^"?_ "5?2/I+_P"BVKV[XC>%
M/&_CS1X])BBT&PM5F$KDWTTK2$9Q_P L!@<Y[_6N#\/? [Q[X9UVUUC3M3T
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MHN( 0/*E..5']UO3L?;IZ/6G-S1C_74S4;3E\OR"OD;XY_\ )5M2_P"N</\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=7'^R<TN6PR0TTD8]Z7-,?"JS'M0B3(UO45M;1DW8=@5'UKF_#WAG[5)]OO
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M5PB DLF!BM'':FLH*%<<54&!X5X:L;4^,;B/4(P2 ,;N.>:]LM8+>WMU^SH
MOM7-:EX.M9]1-] FVX8Y9JZ73[>6WMU20@XK6;3V M]12CI29SQ3ATK( HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *0TM(30#.=\73>3I3G/)!KG/ MMOTV6Y(Y96&?P-:WCPG^
MSHU'<XI_@JV$/AU01U)KI@[0),SPE#Y&JNO3+L<?C7>@@\^E<7:$6WC*. <!
ME)KM,8K&H[R 8\@C4NYPHKBIA+K6N21<F&)LBKOB/56,L5E"?GD^7BM71-.%
MI:*77]\1\V:T4>6-P.!\7VZ0ZC;P*.%F7^8KTRU&+>%1TV+_ "KSSQHF=7A]
M?-7^=>BVQ'V:$=]B_P J)NZ0T6.U**3M0*YGN,6BBBJ **** $S2]*3(H(R*
M (IIHT0L[  <\FN:N_%'F7'V6P^:;W'%7]9T;^U8TC:>2(*<Y0]:;IOAVVTX
M#!+G^\PYJUL!>TX7+0[[O D/3'I5U".<4T)\N >*>O Q4L!U%%%2 4444P"B
MBB@ J*9=\3IZ@BI::: . O? B7ET9))IQDY^5S_C73Z1HJZ5 $B9V_WSFM<#
MCD49;/2JG4N(;W&[K5+5;D0:?<-G!V\5H$9%<AXKO2L]K;@\.VTTX1NQ%CPM
M;B2T6^D'SRC!KHN(U(';FJ>DVX@T^.$<!:GNY!%;R2$_PG^5$M[".,OI'U+Q
M? !S$%(/Z5W,$8CB1?05RGA.%;MI[MN664@'\377'C"TY/H,</6EI!P*6LV4
M%%%%)@%%%%" #TI <BDSUH7[M,""[F$-N[D]C7$Z"IO-5DO),;8Y",FM_P 5
MW7V727<&O-++4M0OHYK"QCR)6Y8'!%==!-J5C.9T>KZI<:_J8TZTSY"MLE/2
MNST;3(]+L8X5'08SWJIX>T1+&T1Y$'G$98D<YK;YW?-P.U85&KV141]+24M9
MLL*6D'6EJ8L044450!1110 C=*3L*4T=J2>H%>\XM9&]%-</X=_TCQ;,[<C9
M_C7:ZD^S3K@^B&N5\'P[F-[W;(K:.Q)V8'-./ IH/S 4I.>*RD4C+UJZ%OI\
MK9P^WY:R/#=D8D;491EIADYJ#5KAM1UBWMT.4C;:^*Z,QBVT]T4855XK=*R(
M./@S>^/;E#RBH"/UKOD&% ]!7$>&U$OB6>?N4_QKN*FK+H"%HHH[U@M2Q:**
M*H HHHH **** "BBB@ HHHH *2EI.] "TE H-(!C<*:X7Q#/]LUJS@4YC#8D
MKN)I5CC+$]*\R2[#7VH!C\Y?]W712W,V:=E:?;=9>W4?NK=LK7=J!'&% K#\
M.68AM5F8?O''S5O@#-*M/6Q403[M X%+[4A]*QW*'4W/-*#2'FC8 (]!2CWI
M.1THW>M"=P%S0,]Z,=Q0#FI 6@T4&F 4444P"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPM%4#YR/F^M:6<KD5!"ZRQ[E.0:FY  KEFW<J(J].:=2"EJ44%%%%, HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*
M6D/2A@(!QZTTJ2<YQ020,"FF01J6D8 >]*+N%QV] <%N:0DLO3%8U]KEK;@E
M%$K^BGFL>#5M2U*4A$DMUS@;A5\EQ7.Q8#&W=@FN,\<WB6]FB'&X@CZU#J"Z
MOI]O)=2Z@2%Y"UPVIW>H:E=0R73L4#956_B^E=N%I\LU(F;]T[;P/I"R6J7D
MB#YQQFN["C 0G)%<SX7U&)--BMGC^SE1P&KI5P1G//K7-7NZC'#8<_W&^E<?
MH"_9]3N(SQYDA-=B_*&N1?\ T;Q3;(.-YS54;*,T^J&]SKP.*6@4'C%<T=K%
M$%]_QY3#_8;^5<GX,?RXY8CU\QC^IKK[D V\@/\ =/\ *N*T&18-9>'V8UK%
M7BT2R3Q1=?:[I=,'/FCI74:9;_9]-AB]%Q7&VL;:CXOAN.J1DJ?SKOL;0 .E
M75TLD"8#@8KG?%U]]DTY54_-*=GYUT? &37%Z\AU/5DM5.1$X;]:RHKWK@RU
MX.TDV.G;G&'9B>?>I_$^K_8+5H8SF=AE0.M;#.EG9[R0%5/UQ7%64<GB'7UN
MI03#&2A!^O\ ]:M8ZR<@-30M(/V5YIAEIOFY[5D>$?\ 1/$VL(Y^4M@$_A7>
M(@CB"*,;1@5YKJMT='U"^D'$DQ^7ZUK#]XW<AFM?*=:\0-9GYD@8,#7:VT"P
M1*H["N9\%VC26*:C,/WTH^8GK75=ZYZD^@UL5;^80VSRGMQ7.>#[?8]](1P\
MN:TO%4_V?1I,'G(J/0=MKIQF<@!ADYJX_ ,K>*-3\M8[&(Y:?Y>.U11V7V#0
M$C88<J0U9^EV\FK^(KB:;)C@DS'FNB\1_+;QA>,GFE2?O6 =X5B$.BH@Z;C6
MM(ZQJ1T&,U1T( :8@'3-0>)KS[%I;R*?G/'%1;]XRNAPOB*Z?6M3$<63$F5;
M'2MWX?Q"'[8G]TX_E5/0M*:WTF[N)ES)(^]2:O\ @<G[3?C_ &O\*WJ/W;$G
M:TG\5*.M'<URE(:1FD(&<]Z.0O-(Q"C<QP*25V2SSWQ[.T=[:NAY45>\)Z;Y
MX%W(.6YYK#U^;^TO$EM:@Y4M@UZ+IMJME91Q*/NC%=U5^SIV(6Y<)QQ3A2?>
M&:%.37GK6[-EL/%%%%4A#6&2*IZFOF6$X]$-734,Z>9;NI_B7%6A&!X2DSHZ
MQG[P<UT9'(KF=&'V75WL^P4G%=,O--@A<<4TBGT8K!1M*Y3."\8Z(5>/4+=<
M.K;F*UEWFM?VIHMHG67S@#Z]17HVH0"XLY8B,[E(KR 1#3/$YLI.45@1]<UZ
M,'SQUZ&;/7--MQ!9Q@=U!_2K]5;8%88^>-H_E5JN26XXA1114%!1110 UP67
M .*0$8QGFG$@#FFX ^:CJ!GZGJ*Z=%N8Y)Z"N?2XOM<;Y0]O&.0X[UJ>(-/:
M]@#IR4YQ6-I&O"S;[%=0M$J=';@&NB))J0: 'Q]HD\W_ 'JTX])LHEP+9/RI
M\&H6LR QRJ?H:LHP;D&IE)L13;2;%N3;)FL'7M("6$[Q/Y>%R *ZHG&21FN;
M\4W#A88ER _!%53OS WH9/A[49;'3X!*AVGC<:M>(M32Y2*"W8.?,7./J*OV
MMC VB1K*H^4=37)031V_B)@R;X!T;MFNEI2=S)GHMA;B&T1 <$J#5H],=ZS4
MU6S,2L+A!@#C-4;KQ/%'$QBC,I7^[7%*%S6+-T8 .3GVKA]6U*&+6 )&"A'S
MS3QJ.J:GN\E)8!ZD5C66BS7>MRB^D\_!Y!KHHTTHMB.IF\4ED M(!,3_ ':J
M+8ZGK+;YI)+=#_#6_9Z+9VA!BB"5JJ!C&*R;2V&<ZNC66FVQ=HD=Q_&1S67X
M9MEN=1N9F/\ JW^45I>,[EK70YV0[6QUIWA6T%O8).2&:4!B:T<GR>HF=%UI
MDCB-3WQU]J4#J<]:Y7Q)K3P$6EKEYF;:VWL#7/&)0FL:XT\YL+,;B>KK4EKH
M?V32I"WS3N=VX]14OA_0A:QBXG >9N<UONF8BIZ]JUO;0#E/",K9O5!\PJ^,
M>E2Z]K>[;86PS++\C%>JUS:RZCX<OKM(HI)#<.67:.E='H&BEG.HWBYDD^;#
M=5-.Z3N!8T?11IFG,[_/.R$,QZFN>T @>.)F/RCR_P#&O0)1NC;'((KS^%TL
M/'4AF&V(I@$],TKN5V!Z'VX&/>H+JYCLX&EE8!1W-$EW%#!YCN F,UQ&H:C/
MX@U$6-L2(&.UV'2H2 ?<ZA=^)+S[/;HR0(<,Z]"*ZG2-'ATR ;<%\8)I=,TV
M'2K9(HX_F(PS#O6F ,"B<]+#0B9/)K \8.$T4X'\8KH"#T%8/BY-VCD8R=PI
M1W)98T",I8H2>H!K7Q[UB^'I?.L1S]T 5K9ZDG %$EJ"',=H&!Q61KFLQZ9;
MY4AI&.T"JFM>)%L_W$2EI&X!%4M-T6?4]MY?MN!Y"-U!I*-BF)I.DRZE<_VE
M>Y'81M4OBW1FGL3<6HQ.@PNWK73Q1^7"%Z 4H*RJ585?.TQ&%X:U>*ZLUMF8
M":(;6]2:Z%23Q7"ZEI<NBWS7]KG9G<Z+_%71Z1K,>HVZL#B3'*GJ*4E?8#8
MQ3L4Q#QUS3JQ>FA2%Q1BDHIW 6C-)13L*XM%)1188M%)2T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(L;*:X)P57(K-(HLM<PHVUI45O0FI X_^O7EVD7%SXGUQII"XA&&&,BO2XT
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M76FZVEHX)A(SZU+2Z%([(-\N:44Q&#IE:>.E0 M%%%2 4444P"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV41L7V_* 6IJQ*3YDD:[_7%38YII3+[L_A1J *% XIXI,"EI@%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%_\ %4YL$=#G^*G9R*YU?'/A <'Q5H?_ (,8O_BJ=_PG7A#/_(UZ'_X,8O\
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M?_A._"&,GQ1HF3_U$(O_ (JC_A./!X *^*M#!_["$7_Q5/F Z/&116 /'7A
M#_D:]#_\&,/_ ,51_P )WX0_Z&K0_P#P8Q?_ !59H3(/%MNTEKYBG!4=:P;B
M9KRVTF"*3)5L/BM?5/%_A&]L981XJT/<PP/^)A%_\57.:'JOA>TNW>X\5Z&5
M!RN=0B_^*KJC)<IG;4](M(!;PB)>@JR*YU?'/A <_P#"5Z'_ .#&+_XJE7QY
MX0/_ #-6AC_N(1?_ !5<\G=FIT5%<_\ \)WX/_Z&O0__  8P_P#Q5'_"=^#_
M /H:]#_\&,/_ ,50!OFE%<^?'7@__H:]#_\ !C%_\51_PG?A#_H:]#_\&,7_
M ,50!OD9KF?%5M)';F[@4M*N %'6I_\ A._!_P#T->A_^#&'_P"*J&?QMX.D
M!W>*=#(QC']H1?\ Q55%V9,MB;1]7ANK18WE"R  $'J#5+7+YKJ2*QMLR"3Y
M79?X:YNXO_"ZSM-9^+]!BW')']H1?_%5JZ1XA\'V0=Y?%6A&5NK?VA%U_P"^
MJMM;DI'5:/IJ:?9)%PS 8+>M:&.<USR>.O" Z^*]#_\ !C%_\52GQWX1SQXK
MT/\ \&,7_P 56;9:-UQG</45Q%JLFG^+(H "$E8L:VSXZ\'G_F:M#_\ !C%_
M\567<>)_!TNL07G_  E.A_NQC_D(1?\ Q55"5KC.S!I0.<USW_"=>#_^AKT/
M_P &,7_Q5._X3OPA_P!#7H?_ (,8O_BJA@;]+7/_ /"=^#_^AKT/_P &,/\
M\51_PG?A#_H:]#_\&,/_ ,522 WZ*Y__ (3OPA_T->A_^#&'_P"*H_X3OPA_
MT->A_P#@QA_^*I@=#17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\
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MX*L)K#1H4F!WA><U+_PG7A!\AO%.AX_["$7_ ,51'XY\'J2!XJT,#_L(1?\
MQ5:<WNV Z$'=3ZYW_A._!_;Q5H?_ (,8O_BJ</'?A#_H:]#_ /!C#_\ %5F!
MT%)WK _X3OP?_P!#7H?_ (,8?_BJ3_A._"'_ $->A_\ @QA_^*I@=#17/_\
M"=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\
MZ&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\
M\&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\
M%4?\)WX/_P"AKT/_ ,&,/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^
M#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O
M0_\ P8P__%4 =!17/_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,
M/_Q5 '045S__  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T
M%%<__P )WX/_ .AKT/\ \&,/_P 52?\ "=^$/^AKT/\ \&,/_P 52N!T!H/O
M7/\ _"=^$/\ H:]#_P#!C#_\52'QUX/(_P"1JT/_ ,&,7_Q5-"->XN$MX'DE
M("KZUQY6XUC4MQW?9U;*^A%4M=\=>';Z=+2'Q%I(A;AF^VQ[?SW5KZ;XM\'6
MEG'"?%&AY48)_M"+_P"*K1/E).E@MX[>VVHH  KEK$[O&SL.GEU;N/'7A);>
M4)XHT0G:< :A%S_X]7-Z!XM\,G4FN[CQ%I$9.1^\O8U_FU-.Z;8STP4HKGAX
MZ\(?]#7H?_@QB_\ BJ</'?@__H:]#_\ !C#_ /%5F,Z"BN?_ .$[\'_]#7H?
M_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*I#.@HKG_ /A._!__ $->A_\ @QA_
M^*H_X3OP?_T->A_^#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!_
M_0UZ'_X,8?\ XJ@#H**Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA
M_P#BJ .@HKG_ /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*H Z"B
MN?\ ^$[\'_\ 0UZ'_P"#&'_XJMR">&ZMXKBWECF@E0/')&P974C(((X((YS0
M!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%Y:1WUI
M);3-,L;C!,$[PN/HZ$,/P- 'SA^T?/&_C#2858&2.SRP],N<?RKZ'T6X@N='
MM&@FCE58D4F-@P!"C(X[URMY\'_ VHW3W5[I$US</R\L^HW+NWU)DR:@_P"%
M)?#S_H7O_)VX_P#CE*'NPY?.X2UDI>5C6\8^/]"\&Z9//>WL+7:J?*LT<&61
MNPV]0.G)X%>%_!?PIJ/B7QU_PEEW$R6-M,]P92N!+,V?E7UP3D_2O:++X1>
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M:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\
M\&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__
M !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =
M!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__
M ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@
M_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:
M]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8
MP_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%
M4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )
MWX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\
MZ&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_
M /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/
M_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5
M'045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/
M_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)W
MX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z
M&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\
M&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\
MQ5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\
M"=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_
M .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0
M_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C
M#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 5
M0!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045
MS_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"
M=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\
M^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0_
M_!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_
M ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_
M  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#
M_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AK
MT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P
M8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
M%4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%
M%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\
MPG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_
M /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT
M/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#
M_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51
M_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?
M@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H
M:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\
M\&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__
M !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =
M!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__
M ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@
M_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:
M]#_\&,/_ ,56AIFNZ/K?F_V3JMC?^3CS/LEPDNS.<9VDXS@]?0T :%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU[I\5Q/J&LJ[KDA)H@/UCKH/'#>;XAL8U[CFN]T=2FF0*>RUM)+E)3U/+_\
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MPSCX0_Z"6N?]_P"+_P"-5[!11J!X_P#\,X^#_P#H):Y_W_A_^-4?\,X^$/\
MH):Y_P!_X?\ XU7K]!I,#R#_ (9Q\(?]!+7/^_\ #_\ &J/^&<?"'_02US_O
M_%_\:KU^BJ3 \@_X9Q\(?]!+7/\ O_#_ /&J/^&<?"'_ $$M<_[_ ,/_ ,:K
MV"D%)[@>0?\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44P/'_
M /AG'P?_ -!+7/\ O_#_ /&J/^&<?!__ $$M<_[_ ,/_ ,:KV"B@#Q__ (9Q
M\'_]!+7/^_\ #_\ &J/^&<?"'_02US_O_#_\:KV"B@#Q_P#X9Q\(?]!+7/\
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M[_P__&J]@HH \?\ ^&<?!_\ T$M<_P"_\/\ \:H_X9Q\'_\ 02US_O\ P_\
MQJO8** /'_\ AG'P?_T$M<_[_P /_P :I/\ AG+PAG_D(ZYC_KO%_P#&J]@/
M0TT'Y032 \@;]G/P@/\ F(ZY_P!_XO\ XU6;J_P(\':9:-*=1ULN.@,\7_QN
MO<),!"Q[#-<+J4K:UK*6Z9,0RIQ6L4F(X?2?@#X<OH_,FOM75#RNV6,''XQU
MJ?\ #.?A'_H(ZY_W_B_^-5ZM9Q"VM$C ^ZN*E:51&7)P *4EV$>)ZM\!/".G
M6P==0UHNW"AIXL9_[]TNB_L^^&[VQ$M[?ZNDA/2.:(#'XQFNZU*Y?6=56UBY
M6)PU=C$FQ50#  '2DE9687/)/^&<O");C4=<Q_UWB_\ C5.'[./@\_\ ,2US
M_O\ P_\ QJO73\HXI5Z5(SR'_AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
MO_#_ /&J]@HH&>/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\
MC5>P44 >/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_
M /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5>P44 >/_\ #./@
M_P#Z"6N?]_X?_C5'_#./@_\ Z"6N?]_X?_C5>P44 >/_ /#./@__ *"6N?\
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M5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\
M\,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_
M /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_
MX?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\
M,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"
M6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_
M^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!1
M0!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^
M#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H)
M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#
M_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]
M_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[
M!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X_
M_P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\
MH):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W
M_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_
MPSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H
M):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'
M_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!
MX_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,
MX^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y
M_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^
M-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX
M/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_
MW_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-
M5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\
M\,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_
M /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_
MX?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\
M,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"
M6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_
M^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!1
M0!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^
M#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H)
M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#
M_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]
M_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[
M!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X_
M_P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\
MH):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W
M_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\ XU1_
MPSCX/_Z"6N?]_P"'_P"-5[!10!X__P ,X^#_ /H):Y_W_A_^-5V'@7X<:/\
M#_[?_9-S?3?;O+\S[6Z-C9NQC:J_WSUSVKL** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/
M2H]JGD\M4IZ5&$&[)ZT >;^+!<?V^)?+8Q "M)]5N[Y(K:W1U&P#(KK;O3[>
M];;,FX4EKIEM:G,,>TBM5(AF9IFA+; 3RD.YYK=7 7*C'M3@,4!0.1U-0Y7&
M@4@_6G4T* <]Z=4E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(*6D%  :#G'%!HI(#D_&,)-L)0I)5>U9_AV8ZL(D=6_T?U&*
M[2>&.X0I* 0?:H++3[>R=S$,%NO%;J=E8DO(,?2G4U00:=6(T%%%% PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDI %%!HIB"EI
M*7M2&%%(*6F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4F*6BE8!I'M2$'G"T^BF*PQ-Q&6&#3Z**25AA1113 **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ I*6B@ I*6
MB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;7+[7K&-I=)T>RU
M&-(RS)+?M!(6'\*CRF4_4L*V:1ONGZ5,KV=AH\6T'XZZQXFU0Z;H_@-KJ\"E
MC&-55< '!)+1@#J.];FI?%'Q#X<A^T^)?A[?V5D,9GM;V.Z"Y]=H 'XFO-?@
M<H7XOZLJC %O< #_ +:+7TG=6T-[:RVMS&LL$R%)$89#*1@@U3OR1E'=JXM.
M>47LF8WA7QCHGC/3C>Z-=^:J'$L3C;)$?1E_KTK>KY0^'L\WA7XY#2[*1OLS
M7TMBZ@Y#Q[B!GZ8!_"OJYW6-&=V"JHR6)P *=TXJ:V9.JDX/="T54_M73O[.
M.H_;[7[" 2;GSE\H '!.[..M/LK^SU*U6ZL+N"ZMW^[+!('0_0CBD4>;>#M9
M^(]W\1]4L_$&GF+0H]_EL;<)&G/R>7)C+Y'7D_A7J-5_M]G]O%A]K@^V%#(+
M?S!YFT8RVW.<<CGWJQTH7PI=OQ#[3?<**@M;ZTOD=[2Z@N%C<H[0R!PK#J#C
MH?:JEOXAT6\OVL+;6-/GO4^];Q7*-(/JH.: -*BBO)_&_C^UG\>^'?".FS+*
M_P#:4,E\RG*KM;*QY]<X)],"A?$H]Q-VBY=CUBBBF2S1P1-+-(D<:]6=@ /Q
M- Q]%95AXG\/ZI<?9]/UW3+N?_GG;W<<C?D"36K0 52U.YO;6TWZ?I_VVX)P
ML9F6)1P>68]!QC@$\]*ND@ DG %9<'B70;G4/L$&MZ;+>]/L\=TC2?\ ?(.:
M6^@;:GE?@?XE^*/$OQ6ET+58;>QMK>.99+.% QWK@<N<DX.>F![5[17SQX$_
MY.4UW_KI=_SKZ'IQUI0?=">E2:[/]"&Z:Y2UD:TBBEN /W<<TIC1CZ%@K$#W
MP:\K\7_%[7O!%W'#K/@=5BE)$5Q#JF^.3'7!\H<^Q ->M5YQ\<;9+KX:SQ,%
MW&[MU5BN=I,@&1^!-1*ZLUW7XM+]2E;6YV'AGQ)I_BO0K?5M-E#P3#E3]Z-N
MZMZ$5KU\K^'-9UGX)^/9=+U8/)I<Y'G!0=LD9^[,@]1Z?45]0V5[;:C90WEG
M,DUM.@>.1#D,IZ$5J[-<T=C.+:?++?\ ,Y/QEXM\0^$M,N]5'ANSOM.MSDO%
MJ;+*$R!N9##@=>S&K/A/Q#XA\1V%GJ5WX>M--L;E/,&[46DF"D94[!"!SQU8
M&H_BC_R3#Q#_ ->;?TK6\)_\B?HO_7C#_P"@"HA]J_2WXI_Y%2>J2ZW_ $_S
M-BBH;J[MK*W:>[N(K>%1EI)7"*/J3Q6?8>*/#^JS^1IVNZ9>3?\ /.WNXY&_
M)2:>^@]C6HHJO>7UGIUN;B^NH+6 <&2>0(H_$\4 6**@NKVTL;5KJ\NH;>W0
M9:6:0(@'J2>*BT[5M.U> SZ9J%K>P@X,EM,LB@_52: +E%4]1U?3=(A$VIZC
M:641X#W,RQJ?Q8BI;2]M=0MDN;*YAN8'&5EAD#JWT(X- $]%%9FH^(M#T>18
M]3UG3K)V^ZMS=)$3] Q'J* -.BH;:ZM[VW6XM;B*>%QE9(G#*?H1Q4Q( ))P
M!0]-P6H453L-6TW51*=.U"TO!"^R7[/,LFQO0[2<'V-7* "BBB@ HHHH H:W
MJUOH.AWNJW1Q!:0M*WO@=/QZ5@?#CQF/'/A*+5)$BCNU=HKF*+[J.#V!).""
M#S7/?%/SO%&I:1X!L9O+?4&-S>NO)C@3D9^K?RKSCX(:S<>%/B%?^%-1)C%T
MS0[2>!/&3C'U&1[\4J?O2:?R^6_^7R%4]U)KIO\ /;_,^EJR/$.H:OI]@\FC
MZ0-1N C-M>X6%%QV).22>P [<D5KTC_<;Z5,[\KL4MSR'X0_$;7_ !UXCUA=
M5:".W@@5HK>&(*J$L1G)RQ...3CVKU^OGG]GG_D;O$W_ %S'_HPU[E)XDT*+
M4/[/DUK3DO<X^S-=()/^^<YK5VM&W5(C:4T^C?Z&I7+_ !!O/$EAX.N[CPK;
M^?JBE=H6,2,JY^8JI^\P';GZ&NHI&944LS!5 R23@ 5G)75KEIV9R_P\O?$F
MH>#K6X\56Y@U1BVY6C$;E<_*64?=)],#Z"NIJ"TO;34+<7%E=0W,))420R!U
MR#@C(XR",5/6DG=W(BK*P45D2^*O#L%[]BEU_2X[O('D/>1B3)[;<YK65@RA
ME(*D9!'0U/2Y76PM%%9NH^(=$T=U35-8T^Q9ONBZN4B)^FXBBX&E156QU*QU
M2 3Z?>VUW">DEO*LB_F"15JA@>7>#M9^(]W\1]4L_$&GF+0H]_EL;<)&G/R>
M7)C+Y'7D_A7;>)M4UC2],DGT;1AJ4ZQL^U[A8E7';G))/. !VY(K3^WV?V\6
M'VN#[84,@M_,'F;1C+;<YQR.?>EO/^/&X_ZYM_*LYMJEIT7WVN5%7GZL\K^#
MGQ!U[QWJ>N/J\D BMTB,,$$058\EL\G+'H.I/2O6Z^>_V:O^/[Q)_N0?S>OH
M2NB:2M;LC.+=Y>O^05Q7C3Q?X@\'Z9=:K_PC=G?:; PR\6ILL@4D ,R&' Y/
M9C7:UR'Q2&?AAXA_Z]&_I7/4;C%R1I!)NS.;\%?%77O'DEQ_9/@^W2&W($L]
MSJQ5%)Z#B$DGCL*]-M&N7M8VO(88;@CYXX93(BGV8JI/Y"O%_P!FS_D6M:_Z
M^T_] KVZMYI+3T,H-N[?=A1114%A1110!!>/=I:2-8PPS7('R1SS&)&^K!6(
M_P"^37DWB[XTZMX)U@:9J_@Z+S6021O#JNY)%)(R#Y(/4'J!7L%?-O[2('_"
M5:*>_P!C;_T,U#;YHKN[%))IGN'AK6/$.LVUO>:CH-IIMK/&)% U$S3#(R,I
MY07O_>X]*T=6GUBWB5M(T^SO6YWI<WC6_P!-I$;YS[XJ?3/^039_]<$_]!%6
MJUFM6D94VW%-]4>+1?'759O% \.+X'/]J&X-MY)U0<.#@\^5C'O7K6E3ZM/"
MS:M86=G)QL2VNVN,CODF-,'Z9^M?.-@,_M0M_P!A.3_T U].U,-:49O=E2_B
M2CT045%<7,%I"TUS-'#$OWGD8*H^I-4-/\2Z#J\QATW6]-O91U2VNTD;\E)]
M#1N,U**** "BLF]\4>'M-NOLM]KNF6MQ_P \I[N-'ZXZ$YK4CDCFC62)U=&&
M593D$>QHWU#R//?B?XV\2>#]&FOM*T."2V1UC:\N)@0N[&"(U.2,G&21SV(K
M2^%FOZCXG\ V6K:K.)KR:27<X14& Y &  .  *S/CE_R2C5/^ND/_HQ:/@;_
M ,DHTO\ ZZ3?^C&HIZJ=^E@J?8MUN>BT5Y3\8O']KI%A'X:LYE?4[]T295.?
M)A+#=N]V' 'H2:]43[B_041U5UWL)NTN7RN<+\5=2\9:7X=@F\&VTDUR9@)V
MA@$TB)CC:A!SD]3@X_6NF\,SZM<^&=.FUR%8=4>%3<QJ,!6^G;Z5I3SPVT+S
M3RI%$@RSR,%51[D]*2WN8+RVCN;::.>"50\<L3!E=3T((X(HCHFAO5IDM%5[
MB^M+1X4N;J"%YF"1++(%+L>@7/4^PJ/4=6TW2(1-J>H6EE$3@/<S+&I/U8BE
M<"Y14-K=VU];)<VEQ%<0.,I+$X=6'J".#4U, HJCJ.LZ5H\:R:GJ=G8HQP&N
M9UB!_%B*DL-2L-4MQ<:?>VUW">DEO*LB_F"11N!:HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+Q[M+21K&&&:Y ^2
M.>8Q(WU8*Q'_ 'R:GHH \?\ %_QIU7P3K0TO5O!\)F9!(DD.J[D=22,@F$'J
M#U K:7QQX\-JMT?AA-Y# -\FL1,^#Z)MR3[5YE^T>H'BW16QR;0@G_@9KZ,L
MO^/&W_ZY+_*E#6GS=;M?<$])J*[7.$\+?&'P_P"(]5_LBYBNM(U7>4%M?)MW
M-_=!]?8X/UKT*OF[]HS2+>Q\1:1K%LHBN;N-UE*\%FC*[6^N&QGV%>W> =5N
M-;\!:+J-VQ:XFM5,C'JS#@G\<9IP?-#FZIV8I7C-1Z-71T=%0"^M&O6LENH#
M=JF\P"0;POKMZX]Z@AUG2[C49=/@U*SEOHO]9;).K2)]5!R*!G!?%/5_B!IE
MUI*^#;)YK>1C]H:*W$S%LC"L"#M3'\7'U%>BVC3M90-=(J7!C4RJIR ^.0/;
M-)>7UIIULUS?74%K OWI9Y BCZD\5,K!E#*001D$=Z(Z*WG_ $@>K3\A:*KW
M%]:6CPI<W4$+S,$B660*78] N>I]A4>HZMIND0B;4]0M+*(G >YF6-2?JQ%*
MX%RBH;6[MKZV2YM+B*X@<926)PZL/4$<&N?\<^--/\$>'IM0O)%,[*5MK?/S
M2R=@!Z>I["B3Y5=CBN;8Z:BN.^%=W-?_  XTJ\N&WSW EED;^\S2,2?S)KL:
MJ2L[,B,N97045DWOBCP]IMU]EOM=TRUN/^>4]W&C]<="<UJ1R1S1K)$ZNC#*
MLIR"/8TM]2O(=116=J6OZ-HY4:IJUA8EON_:KE(L_3<10!Y-\5/B=XR\)M;0
M6ND6^FQ7:GRKJ619Y,C&1M'RJ1D==PKU_2YI+G2+*>5MTDD".[8QDE02:\-_
M:/GAN=-\-302I+$\DQ5XV#*PPG((ZU[=HG_( T[_ *]8O_0113^!WWO;\!3^
M.-MFK_B7ZX_Q9XF\3^&[:XOK7PG!JMC#EBT&I%90@'+-&8OT4M784'D8-3*]
MM"E;J><_#KXNZ=X]NI[&2S_LW4$&Z.!I_,$J]RIVKR/3%>C5\?:MX<UG2GOO
M&VCN4@M-9N(281@VS*_RG_=.<?IWKZ,^&OQ M/'GA]9LI'J=N MW;CL>S#_9
M/_UJN+4X*2WTNO5)_J9MN,K/;6WY6_ Z;5)M6AB1M)L;.[?G>MS=M!@=L$1O
MD_7%<)X>^(WB;Q'K^I:/;^#+>WGTU]ES)<ZL5C1LG RL))SC(P*]*KSGX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^KR&74K%0RS-]Z6/..?<' SWR*N?$KQAY'B/2/!T6K1Z3'?_ +W4+]IEB,,
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M&%9Y8"^G1+YD1 9?E'(R",_A7"?M'_\ (DZ9_P!A ?\ HMZ] ^'G_).O#O\
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M=8?!#1=(\<6OB'2[^[M8;=C(+/[_ ,^,<2,2<=<@YSZUQOP7_P"2O>+OK/\
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M$KU_"NA^.WA'1!X2OO$GV61M6$D2+.]S*P52P! 0MM QV KG? G_ "<IKO\
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MX:T.X&Z"SL/^/J5#T+2G[N?]D"HBOB2UV^7E^II+[-_/Y^?R.$\"+)X,^/\
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M/"IFL6,Q7RA*SA749!!8D\\@@FO5O@K_ ,DHT;Z2_P#HQJY#]I/_ )%K1?\
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ML3<:+J,%UA SQJP\R//0.O5>_7TKF?\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\
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M)J\^;^M#QWP9XLT:U^/6H:S<7D<.FW<UPL=S*=J#<?E))Z XZGUKZ \5:EJ
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MA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C=
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MTFW:6\MHA'=0PY9B@Y#+W.TD^^/I7K]CHFDZ7-+-I^EV5I+,<RO;VZ1LY]R
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MT,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW0!Z!17G_ /PNWX>?]##_ .25Q_\
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M=OP\_P"AA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\
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MA_\ )*X_^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C=
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M^-T >@45Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C= 'H%%>?\
M_"[?AY_T,/\ Y)7'_P ;KH/#'C;P[XQ^U?V!J'VS[+L\[]S)'MW9V_?49SM;
MIZ4 =!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*] HH \_\ ^%)?#S_H7O\
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M/^A>_P#)VX_^.5Z!10!Y_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\
MCE>@44 >?_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^A>_\G;C_ ..5Z!10!Y__
M ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_XY7H%% 'G_P#PI+X>?]"]
M_P"3MQ_\<H_X4E\//^A>_P#)VX_^.5Z!10!Y_P#\*2^'G_0O?^3MQ_\ '*[B
MPL;?3-.MK"SC\NUM8DAA3<3M10 HR>3@ =:L44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<?K?PM\&^(]8GU;5M&^T7T^WS)?M4R;MJA1PK@#@
M <"NPHH \_\ ^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !RO0** //\
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MRO0** //_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*] HH \_\
M^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !RO0** //\ _A27P\_Z%[_R
M=N/_ (Y1_P *2^'G_0O?^3MQ_P#'*] HH \__P"%)?#S_H7O_)VX_P#CE'_"
MDOAY_P!"]_Y.W'_QRO0** //_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\
MD[<?_'*] HH \_\ ^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !RO0**
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M27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*] HH \_\ ^%)?#S_H7O\
MR=N/_CE'_"DOAY_T+W_D[<?_ !RO0** //\ _A27P\_Z%[_R=N/_ (Y1_P *
M2^'G_0O?^3MQ_P#'*] HH \__P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.
MW'_QRO0** //_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*] HH
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M)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QRO0** //_P#A27P\_P"A>_\
M)VX_^.4?\*2^'G_0O?\ D[<?_'*] HH \_\ ^%)?#S_H7O\ R=N/_CE'_"DO
MAY_T+W_D[<?_ !RO0** //\ _A27P\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ
M_P#'*] HH \__P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QRO0** //
M_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*] HH \_\ ^%)?#S_H
M7O\ R=N/_CE=!X8\$^'?!WVK^P-/^Q_:MGG?OI)-VW.W[['&-S=/6N@HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@OB'XK\2Z%J>A:
M7X6L+.]OM2>0&.Y1R%"A><JRX R<DUWM49=+AEURWU5F)EM[>2!%[ .RDGZ_
M(!2MJ@O9,XQ6^,!0,5\#J2,E3]KR/;BN$\,?%GX@^*_%$GA^QM/#$=W&)"7G
MCN GR'!Y#D_I7O9^Z?I7S!\&/^2U7?\ NW7_ *%3AK5Y7M9L4_=I\RWNCU74
MKWXQZ?8R7,=CX0O3&"QAMOM&\@>@9E!_.NG\!>(+OQ3X,T_6+Z***ZG#B6.)
M2JJRL5P 22.GK7250TC2HM'M9;>%BR/<2S@$8VF1RY ]@6-"ZW!K9H\].A_$
M;_A<0U'^TV_X1?=G9]H'E>7C[GE9SOS_ !8_'M7J-8DGB_P]'KT&A_VM;/JD
M[%4MHVWN" 20VW.W@'[V*E\1^)=*\*Z3+J6K7200H#M!/S2'^ZH[FE=1@NR'
M:\WW-)9X6G>!94,R*&>,,-R@YP2.H!P<?0UC^*'\1)I4K>'3IZ7"Q.V^\#-@
M@9 "KZ\\D\<<&O,?A?\ $C3M7UOQ1K&NZK8Z:;J:(6\-W=)'MC4, HW$9QWQ
MW->NF\MK_1Y+JSN8;FWDA8I-"X='&#R".#4U;JFWY7_!C@TYV\[?D>0_ GQ7
MKWBK5/$$VMZG/>,B0[%<X1,E\[5&%'X#M7M=?/?[-7_']XD_W(/YO7T)6\TE
MRV[(SCO+U_R"BN9U_P"(?A/PQ<?9]7UNW@G&,PJ&E=<^JH"1^-6O#_C'P[XJ
M1FT35K>[*C+1J2KJ/4HP##\JS6NQ;TW-RBF3316T$D\\BQQ1J6=W. H'))-8
MGAWQGX=\5O<IH>J17CVQQ*JJRD>^& R/<9%"U=D#T-ZBBB@ HHHH **** "B
MBB@ K/UK6].\.Z3/J>J7*6]I",L[=_0 =23V K0KYC^*>O77CWXH6GA2SE;[
M#;72VJJIX:4G#N1[<C\#ZU+NY*$=V/1)RELCT73/&_C7X@S/+X0TZTTK18W*
M_P!HZD"[RX_N(./Y_4=*UU\-?$BV4RI\0K6[D XAN-%B2,G_ 'D.:[72]-M=
M'TNVTZRB$5M;1B.-0.@ JW5M):1)5WK(\7UGXI>,O#^LZ=X?UW0+2TN[JZA7
M^T;:4M#)%O4-L5@><9')R,].E>T5S'COPPGB?P\84B#WUK*EU:'(!$B'. 3T
MR,C\:Z<=!GK23]VSWO\ H#^+3:WXW"BL37_&'A[PL@;6M6MK,L"RQNV78>H0
M98_@*H:'\2?!WB.Z6UTO7K:6X8X6*0-$SGT4. 3^%"UV&]-SJJ**QK[Q9H&F
MZK;:7=ZK;)J%S((XK8-ND+'@949('N<"CK8.ES9HKFM8^(/A/0-5CTS5-<MK
M>\?CRCN;9_OD A/^!$5K:EK>E:/8_;=2U&UM;8C(EFE"JWTSU_"E=6YN@=;%
M^BL23Q?X?A\/0:]-JL$.F3J&BGERF\'T! )/MC-4_#_Q$\)>*+K[+H^M03W'
M:)D>)V^@< G\*?6W45U:YT]%%9FM>(M&\.6PN-8U*VLHF.%,S@%CZ =3^%)M
M+<9IT5QNE_%;P-K-TMM9^(K;SF("K.CP[B>@!D50379=:JS%=;!169K7B+1_
M#MK]IUC4K:RB[&:0 M[*.K'V%4M7\;^&]"TFVU/4]6AMK6Z0/ 65B\BD @A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[<V<)^T+P\"A!L6(]5 &,CH3DG.:YW]I+_D4M(_Z_C_Z+:O4O"?_ ")^B_\
M7C#_ .@"E32Y)+S_ $";?M(^GZGGGCKP;?>&OA"_A[P5;7EPK3C[2JDR3R1G
M.XX YR0H( Z9XKK?AUX>30?A]IEA<V$5M.UN&NXR@RSGD[_4\\YJ3Q_XYLO
M7A\ZC<QF>>1O+MK=3CS'QGD]@.YKFM#\*ZSXZTZ'5_'.I3FVNE$L.BV;F&W1
M#R/,P=SDCL3QFG%M\UNMKOY;?\ ))+E\KV7Z_P#!. \'FWT3]I&\T_1I(QIT
M[RIL@8&/:8]^T8XX88QVQ7JGQ2T+1[KP/KVIW&E6,U_%8OY=U);HTJ8!QAR,
MC'UKRS1]/L]*_:@^PZ?;16UK"2L<42A54?9_2O8_B7_R33Q'_P!>,G\JB?\
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MJ5L9REO)Y0,C (V,@@9QG('.*\9^,?\ R6SPS_N6W_HYJ]_U/_D%7G_7!_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<<"_8$M_LWE'H4Q@@_6O!]-TG7_@CXVN+L6%UJ?A>[&V2:V3<53J"P[,O/7
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M^&FO^I1_\J7_ -JH_P"&FO\ J4?_ "I?_:J:?5ZL3BMEHCZ HKY__P"&FO\
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MX],5X!INDZ_\$?&UQ=BPNM3\+W8VR36R;BJ=06'9EYZX!&>?2Q_PTU_U*/\
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M>[.H QC/U%=9X(\%)H'PZ@\-:D$G,L3B[4<J3)G<!Z@9QGVKS#_AIK_J4?\
MRI?_ &JC_AIK_J4?_*E_]JI65FN^X];I]MCCM:\+^,OA#XGDU'1S<FR!)BO(
MDWQO'UVRCH..H/ID5TVA_$_XH^.RNF:-I]C#O^234(;5P(ACEBS,5!YSTSZ5
M;_X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J([<LM4$M[QT9['H^FVG@SPK!:
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M_P#^&FO^I1_\J7_VJC_AIK_J4?\ RI?_ &J@#Z HKY__ .&FO^I1_P#*E_\
M:J/^&FO^I1_\J7_VJ@#Z HKY_P#^&FO^I1_\J7_VJC_AIK_J4?\ RI?_ &J@
M#Z HKY__ .&FO^I1_P#*E_\ :J/^&FO^I1_\J7_VJ@#Z HKY_P#^&FO^I1_\
MJ7_VJC_AIK_J4?\ RI?_ &J@#Z HKY__ .&FO^I1_P#*E_\ :J/^&FO^I1_\
MJ7_VJ@#Z HKY_P#^&FO^I1_\J7_VJC_AIK_J4?\ RI?_ &J@#Z HKY__ .&F
MO^I1_P#*E_\ :J/^&FO^I1_\J7_VJ@#Z HKY_P#^&FO^I1_\J7_VJC_AIK_J
M4?\ RI?_ &J@#Z HKY__ .&FO^I1_P#*E_\ :J/^&FO^I1_\J7_VJ@#Z HKY
M_P#^&FO^I1_\J7_VJC_AIK_J4?\ RI?_ &J@#Z HKY__ .&FO^I1_P#*E_\
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M5RJLCDE6/;(/&:]6\,^,;CQ3$VJ0:/>V.C1PEM]Y ?/G?_IFB$DJ #S@EB0
M*ZZBE'W8\OK;YBDKRYOO^1\V?$3^V];^*UAK^E^%?$$]C8>0 YTN=3+L<L2
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M1_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5
M'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y
M4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2
M_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--
M?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_
MU*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S
M_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[5
M1_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5
M'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y
M4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2
M_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--
M?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_
MU*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S
M_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[5
M1_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5
M'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y
M4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2
M_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--
M?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_
MU*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S
M_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[5
M1_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5
M'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y
M4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2
M_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--
M?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_
MU*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S
M_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[5
M1_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5
M'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y
M4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2
M_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--
M?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_
MU*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[57H'PR^)O_"QO[4_XE']G_8/*
M_P"7GS=^_?\ ["XQL]^M 'H%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$=ZY$&N.7@5OX&0?(/\ O@8_"OH2OF'XP^&/^$$\7Z/KVBQ^1;LL?E[>B2Q
M#]0%_6OHSP]K,'B'P]8:O;']U=PK(!Z$CD?@<C\*N-G35NFGW;$.ZF[]=?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M],HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3Z5KVA>!+?2_$-NT%U;2NL:-,LG[O.5Y4D=R,9KJY](TVZOX+^XTZTFO(/\
M4W$D*M)'_NL1D?A5+PUKH\16$^H1*OV,W,D=K( ?WL:G;OY]2&Q[8K9HDW)\
MS_K0<4DK+S_,****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;79/$GEO%H-GI<A:,@3
M7MW)'L;_ '%B;</^!"MFBDU=68T['S]X9^$'Q%\)ZY)K&F:IX>^V.C(S2R2N
M"&()X\OVKOWC^+\J^69_!<()&9(UN691WP&X->A44^EA=6^K/)%^#%SK^J)J
M?CKQ/<ZS*GW;>%/)B4>G'0'C[H7ZUZE8:?::78Q65A;1VUK"NV.*)<*HJS13
MO966PK:W9Y_\6/A]+X]\/P1V4R1:A9N9(/,.$<$892>V<#GVKG_!.F_%RWTR
M'0M1;3=-L+=?+6]EVSW(0= @5RIP.A8?G7L%%3%<M^S'+6WD>"ZE\,/&6D_%
MB'Q#X;$-Y#N$@NM1N-^UBFU_,&0QSR?E]>V*];O?#T^J^#[[1=2OVN+B^@D2
M6X"[0K,/X5[*.PY.!R2>:WZ*+7AR/8/M<YX7X!\(?%'P=-=Z%;)I<&E3R[VO
MYF$NWC!:-0P.< <,N.*]-\2^!].\4^$1H&H2S2!%'E74C;Y4D X?)ZGU]<FN
MGHIR]Y6D)+E=T?+<GP;^)7AK4G/A^5I%8D"YL+\6Y*]MP9E/<\<]Z]/^'?PP
MU32=57Q#XPU235-812MNDD[3" '@G<W5L<<<#WKU6BG%M!**93U:.]FTB\CT
MV5(;YH7%O(XRJOCY2?QKS[X4Z-\0-*GU,^,KV6:WD(\B.>Y$[;L\LI!.U<=L
MCZ"O3:*2T;?=6&]4D%%%9^NW5Y8^'M3O-.M_M%]!:2RV\.POYDBH2J[1R<D
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M_P#T(7_E'N__ (NC_A:?Q?\ ^A"_\H]W_P#%T ?0%%?/_P#PM/XO_P#0A?\
ME'N__BZ/^%I_%_\ Z$+_ ,H]W_\ %T ?0%%?/_\ PM/XO_\ 0A?^4>[_ /BZ
M/^%I_%__ *$+_P H]W_\70!] 45\_P#_  M/XO\ _0A?^4>[_P#BZ/\ A:?Q
M?_Z$+_RCW?\ \70!] 45\_\ _"T_B_\ ]"%_Y1[O_P"+H_X6G\7_ /H0O_*/
M=_\ Q= 'T!17S_\ \+3^+_\ T(7_ )1[O_XNC_A:?Q?_ .A"_P#*/=__ !=
M'T!17S__ ,+3^+__ $(7_E'N_P#XNC_A:?Q?_P"A"_\ */=__%T ?0%%?/\
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M  M/XO\ _0A?^4>[_P#BZ/\ A:?Q?_Z$+_RCW?\ \70!] 45\_\ _"T_B_\
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M//X?M(XHA%# MU,^U<D\MY0R<GT%=58VGQ@L;5+?[3X,G5 %5I1<Y  P!\H
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M_P H]W_\70!] 45\_P#_  M/XO\ _0A?^4>[_P#BZ/\ A:?Q?_Z$+_RCW?\
M\70!] 45\_\ _"T_B_\ ]"%_Y1[O_P"+H_X6G\7_ /H0O_*/=_\ Q= 'T!17
MS_\ \+3^+_\ T(7_ )1[O_XNC_A:?Q?_ .A"_P#*/=__ != 'T!17S__ ,+3
M^+__ $(7_E'N_P#XNC_A:?Q?_P"A"_\ */=__%T ?0%%?/\ _P +3^+_ /T(
M7_E'N_\ XNC_ (6G\7_^A"_\H]W_ /%T ?0%%?/_ /PM/XO_ /0A?^4>[_\
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M .A"_P#*/=__ != 'T!17S__ ,+3^+__ $(7_E'N_P#XNC_A:?Q?_P"A"_\
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M_A:?Q?\ ^A"_\H]W_P#%T ?0%%?/_P#PM/XO_P#0A?\ E'N__BZ/^%I_%_\
MZ$+_ ,H]W_\ %T ?0%%?/_\ PM/XO_\ 0A?^4>[_ /BZ/^%I_%__ *$+_P H
M]W_\70!] 45\_P#_  M/XO\ _0A?^4>[_P#BZ/\ A:?Q?_Z$+_RCW?\ \70!
M] 45\_\ _"T_B_\ ]"%_Y1[O_P"+H_X6G\7_ /H0O_*/=_\ Q= 'T!17S_\
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MM/XO_P#0A?\ E'N__BZ/^%I_%_\ Z$+_ ,H]W_\ %T ?0%%?/_\ PM/XO_\
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M"2$%UM;=8@Q'0G:!FKU%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%0SW=M:M"MQ<11&9Q'$)'"[W/(5<]3P>!Z4 3
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M15#5M;TO0K0W6JZA;64']^>0+GV&>I]A2;2W"UR_1532]3L]:TRWU+3YO.M+
MA-\4FTKN7UP0"/Q%6ZIJVC$G?5!14=Q<06D#SW,T<,*#+R2,%51ZDGI6;H?B
M?1?$HNFT;4(KU+5Q'*\0.T,1G ;&&X[C-+R&:U%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/$DJ-(GWU# E?K4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAV"+\PY^]C/^-:EKX4^(OB%3->ZO=6.8R8WCN3C?VX#DXKVR&&.")8XD"(O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ7MOAGX;:#X9(E@A,]UDMY\I^;)&.W'_ .NNDTS2[+1[*.SL(%A@C4*J@D\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!C^(=,DU.R6*/!P3D5Q6EZYJGA.X.EWEG*]JG*2!3M
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MPVUK+$K*#'^\'&0&7(P>F:]<\/?#KPWX<A5+2P21U.X//^\8-UR"V<<UU8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGJ36A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %>8_&36K[2M)M8+>XDAANEE\QHV*MA=O&1V.
M3Q7IU8GB?PKIOBS3A9:DC% <JZ8#*>.A(/H* /FSPEK6B>'K]]0U*PBO)MBR
M6ZN@8*6SDG@\X/UXKVGP/\4+?Q1*;62R:VF:9HH!SB3:N?3CC/6KVE?"GPKI
MEF+=]/CNR)"_F7"([<]L[>@KHK7PUHUC+%)::=;P-%(TJ&.,+AB,$]/2@#4!
M) )&#Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A. 2 3CL.] "T5Y_
MXE^*]GX0\DZ[X9\0VBS$B-_+MW1B.VY9B,^W6KWA?XA1^+[>.[TKPWKALGD\
MO[5,MO'&.<$\R[F [[0:%KL#TW.RHHHH **** "BBB@ HHHH **** "BBD8A
M5+'. ,\#)H 6BO(?&_QFO/#FKVVDV?ARXBFG*E;C41L5D) RJ*<GOU(([BO7
M1R :%JKB;L["T444#"BBB@ HHHH **** "BBJ&K:A-IEIY\&EWNHG/S16?E[
MP,=<.Z@_0$GGI0!?HKRJU^/GAV]U2/3+?1/$+WTDODK!]FB#%\XVX,O!S7HJ
MZC<MI)O3HU\L_P#SXEX?./..OF>7[_?Z>_%'2X=;&A17E>J?'KP]HNHS:?J6
MA^(+:[A.V2*2WA!'_D7D>]=[H&N2Z[:K='1=2T^!XUDB:]\H&0'T5)&(_P"!
M =:%JKH'H[,UZ*H:KJ$^FVPF@TJ]U$Y^:.S,6Y1C.?WCKG\,GVKD/#GQ6LO%
M6I36.E>&_$$DMNVVX:2&&-83G'S%I>#P>.O!XH6KL@>BNSOJ*\O^(WQ;G\%*
MD5MX=O)9)BRQ7-VOEP$CK@?>;MQ\N0<YKT'1+V34M!T^^F5%EN;:.9P@(4%E
M!.,]N:%JKH'H[,OT444 %%>8>#OB1KWB'XCZMX=OM 6UL[3?MD"L'BVG \PG
M@[NHP!^/6O3Z.B?<'HVNP4444 %%%% !1110 445!>3R6MI)-#:37<BCB" H
M'?GL795_,B@">BO,]>^-NB^&=3;3M9T#Q!:704-L:& Y!Z$$2D$>X-6!\7+8
M0"X?P9XS2W(!,S:5\@'KG?THZ7!Z'HE%<MX9^(OA;Q=,8-(U6.2Y S]GD4QR
M$>H# 9_#-;.L:HVDV+7"6%Y?2<[8+2/<[8&>Y 'XFAZ:L%KL:%%>8?#SXJW7
MCSQ=J.G?V6EC96MN9$#L6F+!POS'@#@],<'O7I].VB?<5]6NP4444AA14%Y/
M):VDDT-I-=R*.(("@=^>Q=E7\R*\YUWXVZ+X9U-M.UG0/$%I=!0VQX8#D'H0
M1*01[@TK]!VZGIM%>=P?%N"YC\RW\$>-94_O1Z4&'YAZ<OQG\)0S1P:K_:>C
M7#_\L=1L71EY(YV@C''7\\4Q'H5%5--U2PUBR2\TV\@N[9_NRP2!U/MD=ZMT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR^[5_BU]PY;I?/\ 1?J>+_M)*/\ A$M(;'(OB/\ R&U>I^%/^1/T7_KQ@_\
M0!7EG[27_(HZ0/\ I_\ _:;5NZ;X8U;QIX0TJ/4]6OM'TI;.)8K33I%264!
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M0/PSBE3?-!I[Q8YVC--=3T>BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCO\ Q?Y'F/[-G_(M:U_U]I_Z!79^,_&7A_POK5JBZ4FJ^*9U\NTM[>)3/@]
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M ..E3^!J5=5%;[6G^02LZ;OTU^[<]7^&L;:E'K/BN93OUJ\9X"1S]GC^2/\
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M<I*C0%=XD##:5ZYSZ44_X-_-E3_B_P#;J/GGX4?\E[\2_P#;W_Z.%>P?$O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYU5H=*NH_F4YPP1#P0>X'0\UZ=X,U27XE_#BTN+R^O+.X^:"Z:QF\IG=>,Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#]T_2EK%U
MWQ9H/AN)SJVKV=I((S(L,LRB1Q_LI]YN?05,W:+&E=GS[\%/^2S:C_URN?\
MT,5].5\A_#'QCI7AGXAW6N:J\D=K-',!Y:%SEV!' KWI_C=X V_NM9DGD) 6
M*.RGW,3V&4 _6K6E."[(E_Q)OS.^GGBM;>2XGD6.*)2[NQP% &237R;X<MY?
MB'\;OMD<>;>2_-Y(<<+"C9&?J H_&O0/%.N^-_BG"=%\,^'KW3-$E.)[N_7R
M3*,]"?[O'(7<3^E>A?#KX=6'@#2GBB<7.H7 !N;HKC=C^%1V44J::G[27385
M1WC[-==SK;S_ (\;C_KFW\J\"_9J_P"/[Q)_N0?S>O:?%'B/2/#FCSSZKJ%O
M:AHG\M)) &E('1%ZL>1P/6O ?V?O$FDZ+K6KVVIW\%F;R./R6G<(K%2<C<>,
M_-T[T4OXDO\ #^HZFE->J/3_ (\?\DJO_P#KO#_Z&*TO@_\ \DJT+_KDW_H;
M5RWQZ\3Z,/!-QH::A;RZG+/%FVCD#.@!#$L!]WC'7'6K?P1\7Z-=^!]-T-M1
MMH]4MR\?V5Y KN-Q8%0?O<'MGH:5+53MW7Y"J:.#]0_:#,H^&H"9VF]BWX],
M-_7%7OAUX>\':_X T:__ .$<T6>4VZQS.]C$S&1?E;<2N2<C//K74^-/#,/B
M_P )W^BRL$,Z9BD(^Y(#E3^8KYE\/^+_ !;\'M;NM)N;3,6[,ME<9",>@=&'
MKZC(-*FTG*+ZV:^ZQ4TVHR72]_F?3/\ P@G@_P#Z%30__!=#_P#$UYQ\;S9)
M\)K6/1(H(M-6_5-EO&$10-X(   'S"L^R^,?B?X@7 T+PQX=2QN9QMEO6N#,
M+=#P7^ZH&!G&<\UZ3KO@6UU7X;OX2B?:J6ZI!*_)$B\JQ^K#GZFE4C+D;]/G
M9_U\QPDN=+U^5U_7R(OA1J4.I_#+0Y(6!\FW$#@?PLGRD?IG\:[.OD?PSXS\
M4?!_6[O2KNQWQ%LS65P2H)Z!T;WQUY!%>BZ;\6/%'Q(N/[$\-^'UTT3#9<Z@
MTYF%NAZL#M4!L=,YYK:3]H^:&M_Z^XSBN1<L^A[=;7,-Y;K<6\@DB?.UQT/.
M.*\"^"__ "5[Q=]9_P#T?7O.GV,.FZ=;6-LNV&WB6)![*,"OF[P?XBL_AY\9
M?$?_  D9>T@N'G0R^6S[<R;U.%!)!'H.XK.-E6^3_0<TW2VZH]"_:%:<?#B,
M19\MKZ,2X_NX;'ZXK9^"US'<_"K2/+QF(21L!ZAVJ]J-K;_$SP1J%H]M);65
MV,64\RD.^,%9=A *C=T!Y(YXS7E7PR\3S_"[6;WPAXR1[&VDD\RWN'!,8;H2
M#W1ACGL>N.Q3T<H/=V:_R'-W49KI?\>I[UJT23Z-?0R %'MY%;/3!4UX%^S4
MDO\ :NON,^4(8E)[;MQQ^F:](\8_$71AH-Q8>'[Z#6=9O8V@M;73I!.VYAC<
MVS. ,YYI_P ,_!\7P[\%,-3F@BNI<W-],SA4CXX!8\84=^G6G3TE*;VM;YW_
M $">JC%;WO\ UZGG?CW_ ).3\._2U_\ 0VKZ"KY<\?>,=)G^..G:Y97:7-A8
M-;K)/$=RG:Q+%2.N >WI7TII.MZ7KUI]KTG4+:]@S@O!('"G&<''0X(X/-%-
M?N5ZO\Q2TJOT1?HKBOB/\1;;X>:9:W$MA)?3W4A2*)9/+7CDDM@XZ^AJUX"\
M>:=X^T5[ZRBDMY87\N>WD()C;&1@CJ#V-$?>O;H4]+7ZG5T454U'5=.T>V%S
MJ=_:V4!8*);F98USZ98@9XH ^<OB3_R<1IG_ %WLO_0EKZ8KY+\=^*],U'XU
M1:W:W"SZ=:W-M^^C!(98RI8CU[U]0Z1XCT77T9](U:ROMBAG%O,KL@/3< <K
MWZT4_P"!'U8I_P 5^B-.JNI_\@J\_P"N#_\ H)JU7/\ C#Q+H_AO0;J75+^"
MW9X)/*B=P'E..B+U;J.GK65;^'+T?Y,TA\2/)_V:?^0?X@_ZZP_R:N_^,7_)
M*==_ZYI_Z,6O*/V>_%&D:--K%AJFH6UD]R8GA-Q($5R-P(#$XSR.*]!^-7B;
M1;;P#JVD/J=J=2F6-$M%E#2\LK9*@Y P,Y-:8GX5Z+]#/#Z3=^[%^ G_ "2Z
MV_Z^9OYU)K7Q'O=1\5MX1\$VD%YJ<>?M5]<$_9[4#[W Y8C^?'-8GP#\2:0W
M@I-"?4+>+4UN9=ML\@5Y >05!^]WZ9Z5P/@'Q(GPO^)FL6OB>.:*.XW12SE"
MQ4[MRO@<E3[>M7/WJUGM:_KHM"(75)M;W^[5ZG8_%7P7/9?#J_UC6]>U#6-4
M1XMID?RK>(EP#LA7Y1P2,G-=G\%?^24:-])?_1C5RGQ2\7)XN^&>I-X?L+FY
MTI&B:;498VA0X<<1JPW.<XR<  =\\5;^"/BVSF\$Z=H=O'//>VKR?:<1E8[>
M,LS!V<_+WP "3GMCFE3VFO0J=O<?J<]^T+_R-/A3_@?_ *&E>_)]Q?H*^9OC
MOXJTC6/$^B_V1?V]\+&-FDD@<.@)8$#<.#]WMZU] >&O%6B^*-/CN-)U&WNB
M(U:2..0%XLCHR]5Z'J.U*DOW3_Q,)Z55Z(Y#X\?\DJO_ /KO#_Z&*M_!7_DE
M&C?27_T8U<_\>_$FCIX'N=#&H6[ZG)/%_HJ2!I$ (;+*.5&/7UJS\#O$^CS^
M ]-T7^T;9-3A:53:/*!(WS,V54\D8/:BEJJENZ_(=31POYF7^TE_R*6D?]?Q
M_P#1;5Z7X'_Y$/0/^P?!_P"@"O'OVA?$VBZEI6FZ58:E;7=W#=M),D$@?RP%
M*D,1P#D].O%>D_#?Q5H6J>"])MK75;1[FUL(Q<0&4"2+8H#%E)R #WZ44OX<
M_7] J?''T/,?V@_^1Q\+_P"X?_1BU[[<7=O86$EW=3)#;PQF221S@*H&237S
M5\=/%&CZOXNT5]*OX+Y+*+,KV[ATR7!P&'!.!VKUSQ=>VWCOX4:NOAF^BO97
MMU.RWD#,""&*,.H) (P<&LTW&@VN['9.LD^R,S3O&/B3XE7MS%X3*:-H-N_E
MR:M/%YDTI](D/ X]<XR.AXKS;XU^%[?PYJ/A]EO;^_N[GS#/=7UP9'<ADQCL
MH&3P .M:OP;^*&@>%_#DV@Z_+)9RQ3M)$X@=Q)NQE2%!(8$=Q6?\==6O=8E\
M/ZDVE7%EI^)1;/<_+)+RI)9/X >, G)YR!6EE"<&MKK7^OR%%N2E??73^OS/
M6_BVTR_"/6##][R(PW^[O7/Z9K)^ .I0W?PVCM$8>;9W$B2+W&X[@?U_2NDT
MW5=,^(GA>ZM+>&XDTNYM/)>ZDB,:L[#!5 P!.WUQC.,$\X^=+2]\5?!+QC/$
MT(:-_E9) ?)NXP>&4^O/7J,X-"?+4E&7VK?A?^OG<E>]2@X_9_5(^NJQ/$-T
MMQX2UQK*3?)%:SQY7LX0\?@:\BL?CIXC\67":3X:\)(NHS?*)GN3*D6?XR B
MX Z\FO8M!T1=(\.P:7-)]H<(?M$K#_72.278_5B3^-34@Y0:[K^OD7&:4UY'
MBWP!TSPUKOA_4[34]&TR]O[>X$FZZM8Y7\ME &"P)QD'\Z]?_P"$$\'_ /0J
M:'_X+H?_ (FOFWQ#H_B3X,^.&U'2BZV,CG[-.5W12QGGRW]QZ=>,BNPM?VC=
M4OECLK3PBDVI2D)'Y=TS!F/H@3/X;JOG4TI1W[$\K@VGMW/;-(T_0=*NKJRT
M>PL+*90CW$=I;K%USM+;0,]#7A_A/_DY_5_]^Y_]!KU[P/H^I:=I,M[KLHDU
MK4I?M-YM^[&< +&OLJ@#\Z\8\17<GPW_ &@'\0:A;RG3+TEQ)&F<HZ!6QZE6
MZC_&I6E:/-V:^=@?O4I675/Y7/HN?_CWD_W#_*OGW]G#_D-^)/\ KG'_ .A-
M7I<'Q(T_Q.CV?@^.74[@K^\GD@DBM[88ZR,P!)]%7)/MU'CGP'UXZ-XDUB%M
M.O[TW,0 -G 9-K*Q.&[*#D\DXXIT_P"(_P##^HYM>S7^)':?M)?\BEI'_7\?
M_1;5ZEX3_P"1/T7_ *\8?_0!7FO[1%E<W?@6PNHH7,=M>!YN,E 48 G'N0/Q
MK4\ _$O2M9T#1='TN*:[UA((HKBV$;HD 4 ,[2%2N, D8R2<"E2^&2Z\WZ"G
MI*,NEG^99^.7_)*-4_ZZ0_\ HQ:/@;_R2C2_^NDW_HQJROCQXCTB'P)>Z*=0
MMVU.:6("U20&10&#991R!@=3ZTGP'\2:3/X%M-$%_;KJ<$LN;5G"R,"Q;*J>
M6&#VZ4Z6JJ?(=33DOYG'>"]3%E^TGK*7S!7NYKFW0GUSE1^(4"OHROG3XW^!
MM3TWQ&/&NC)(87*O<-"#NMY5QA^.Q '/8CWIND_M(ZG!816^H>'H;Z[ "^?%
M<F+>?4KL;GZ$5--WIQCUCH.::J.71ZGT1)<PQ7$-N\@$LV[RT[M@9/Y?U%<;
MX[^(]IX/DMM-MK5]2UR\(%M8QMCJ<!F/89_$_K47@(>(->N9/%?B6T6QEEB\
MBPL0"#!"2"S-GG<Q"_@HXKRGXI2WOA'XWV'BBYMY)K',,L1[$*-K(#V(Y/XT
MVK2C&6E]_P#(2=XRE'6VWF>F'P9K_B"PDNO&FO3D&,L=)TQC!;IQ]UV!W2?G
M7#_LU#'_  D8]X/_ &>O0(?B=I?B>TDM?"=M=:O>O$=R>2\,4&1UED88'T7<
M3VKR/X$^)[3P[J>M:?=QW$E[=B,6UK!"SO*ZELKQPO7JQ '<U5/2I)6^S^OX
MBGK!._5?UY'JOQR_Y)1JG_72'_T8M'P-_P"24:7_ -=)O_1C5D?'3Q+I4?@"
MZT:2]M_[6G>'_0TE#2)A@Y+ <@8'4]:/@3XHT:3P-9:&=1MH]4BEE7[+)(%D
M?+%@5!^]P>V>E%+:I\AU/L?,]<HHHI#*-EJMM?WNH6D.\2V$PAF#8ZE%<$<]
M,,/3D&HM=\.Z3XETYK'6+&*[@;H''*GU4]5/N*\DN/%FJ^$?C+XDN?['U"^T
M&<P)=RVMNT@@<1+M;(&,\\CN#7HMA\2O!6HVJW$/B?2XU/\ #<7*PN/^ N0:
M5E*"?]?UV&VXS:_KH?/'Q.^'%Q\-M4M-6T>ZF;3Y9?W$I/[R"0<A21UZ<'V.
M??USQCK5UKW[/,VK;0)[JQB>4#W=0_\ 6L#XBZLOQ7O-/\)>$5-]##<">\U%
M5/D0C! &[OPQ/Y 9KU<>%K >"AX7()LOL?V3/?&W&?KWJ6FZ$EYZ>G]: FE6
MBUVU_K\3B/@#J4-W\-H[1&'FV=Q(DB]QN.X']?TKU.OD6TO?%7P2\8SQ-"&C
M?Y620'R;N,'AE/KSUZC.#7H5C\=/$?BRX32?#7A)%U&;Y1,]R94BS_&0$7 '
M7DUK*7M/>CK?^OZ[&:3A=2/<X+F&Y\SR9 XCD,;D=F'4?A7SU\5_^2^>&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>lixt-20230331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCEObP9z5Z82ekhvWBxbTkqLyoshJfFsylz8mM2UekB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:LIXT="http://lixte.com/20230331" elementFormDefault="qualified" targetNamespace="http://lixte.com/20230331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://lixte.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
	  <link:definition>00000008 - Disclosure - Organization and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/Business" id="Business">
	  <link:definition>00000009 - Disclosure - Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" id="ResearchAndDevelopmentCosts">
	  <link:definition>00000011 - Disclosure - Research and Development Costs</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000012 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000013 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000014 - Disclosure - Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000015 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000016 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000017 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" id="ResearchAndDevelopmentCostsTables">
	  <link:definition>00000020 - Disclosure - Research and Development Costs (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000021 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
	  <link:definition>00000022 - Disclosure - Related Party Transactions (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000023 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" id="OrganizationAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000024 - Disclosure - Organization and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/BusinessDetailsNarrative" id="BusinessDetailsNarrative">
	  <link:definition>00000025 - Disclosure - Business (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
	  <link:definition>00000026 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" id="ScheduleOfResearchAndDevelopmentCostsDetails">
	  <link:definition>00000028 - Disclosure - Schedule of Research and Development Costs (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" id="ScheduleOfWarrantsOutstandingDetails">
	  <link:definition>00000029 - Disclosure - Schedule of Warrants Outstanding (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" id="SummaryOfRelatedPartyCostsDetails">
	  <link:definition>00000032 - Disclosure - Summary of Related Party Costs (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" id="SummaryOfStock-basedCompensationCostsDetails">
	  <link:definition>00000034 - Disclosure - Summary of Stock-based Compensation Costs (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" id="SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails">
	  <link:definition>00000035 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" id="ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails">
	  <link:definition>00000036 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000037 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000038 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="lixt-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lixt-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lixt-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lixt-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="LIXT_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" name="WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" name="StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorOneMember" name="VendorOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorTwoMember" name="VendorTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorThreeMember" name="VendorThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_VendorFourMember" name="VendorFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockOptionsMember" name="CommonStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PlacementAgentsMember" name="PlacementAgentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CommonStockWarrantMember" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EmploymentAgreementMember" name="EmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrKovachMember" name="DrKovachMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrJamesSMiserMDMember" name="DrJamesSMiserMDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_EricJFormanMember" name="EricJFormanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FormanMember" name="FormanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RobertNWeingartenMember" name="RobertNWeingartenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfAuditCommitteeMember" name="ChairmanOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ChairmanOfOtherCommitteesMember" name="ChairmanOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfAuditCommitteeMember" name="MemberOfAuditCommitteeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MemberOfOtherCommitteesMember" name="MemberOfOtherCommitteesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NewIndependentDirectorMember" name="NewIndependentDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualGrantOfOptionsMember" name="AnnualGrantOfOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IndependentDirectorMember" name="IndependentDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CashBasedMember" name="CashBasedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_StockBasedMember" name="StockBasedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrJamesMiserMember" name="DrJamesMiserMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DrWinsonSzeChunHoMember" name="DrWinsonSzeChunHoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MsReginaBrownMember" name="MsReginaBrownMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FiveNonOfficerDirectorsMember" name="FiveNonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NonOfficerDirectorsMember" name="NonOfficerDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BasvanderBaanMember" name="BasvanderBaanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FourOfficersMember" name="FourOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RelatedPartiesMember" name="RelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NonRelatedPartiesMember" name="NonRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceNineMember" name="ExercisePriceNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTenMember" name="ExercisePriceTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceThirteenMember" name="ExercisePriceThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExercisePriceFourteenMember" name="ExercisePriceFourteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalTrialResearchAgreementMember" name="ClinicalTrialResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_OtherClinicalAgreementsMember" name="OtherClinicalAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" name="GrupoEspanolDeInvestigacionEnSarcomasMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CityOfHopeNationalMedicalCenterMember" name="CityOfHopeNationalMedicalCenterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ClinicalResearchSupportAgreementMember" name="ClinicalResearchSupportAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_WorkOrderAgreementMember" name="WorkOrderAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_TheradexSystemsIncMember" name="TheradexSystemsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" name="MoffittCancerCenterandResearchInstituteHospitalIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FirstFourYearsMember" name="FirstFourYearsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FiveYearsAndThereafterMember" name="FiveYearsAndThereafterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ExecutiveOfficersMember" name="ExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_Dr.JamesMember" name="Dr.JamesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NDAConsultingCorpMember" name="NDAConsultingCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_BioPharmaWorksLLCMember" name="BioPharmaWorksLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_DevelopmentCollaborationAgreementMember" name="DevelopmentCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NetherlandsCancerInstituteMember" name="NetherlandsCancerInstituteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_MRIGlobalMember" name="MRIGlobalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvancesOnResearchAndDevelopmentContractServices" name="AdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" name="ResearchAndDevelopmentContractLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses" name="GeneralAndAdministrativeStockBasedCompensationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" name="IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" name="IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_RepaymentOfDeferredOfferingCosts" name="RepaymentOfDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PrepaidInsurancePolicyTextBlock" name="PrepaidInsurancePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ResearchDevelopmentTableTextBlock" name="ResearchDevelopmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_CashSIPCInsuredAmount" name="CashSIPCInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" name="NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" name="AnnualNetRevenueDividedByConvertedOrRedeemedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ManagementFeePayableQuarterly" name="ManagementFeePayableQuarterly" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_FairValueOfStockOptions" name="FairValueOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AdvanceAmountRelatedToMilestonePayment" name="AdvanceAmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AmountRelatedToMilestonePayment" name="AmountRelatedToMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_NonRefundableLicenseIssueFee" name="NonRefundableLicenseIssueFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AnnualLicenseMaintenanceFee" name="AnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_PaymentsOnNonrefundableMilestone" name="PaymentsOnNonrefundableMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_AgreementTermDescription" name="AgreementTermDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ConsultingAndAdvisoryCashFee" name="ConsultingAndAdvisoryCashFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ReimbursementExpense" name="ReimbursementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LIXT_ContractPrice" name="ContractPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>lixt-20230331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20230331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20230331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20230331.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Business" xlink:href="lixt-20230331.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20230331.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20230331.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20230331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20230331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20230331.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BusinessDetailsNarrative" xlink:href="lixt-20230331.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20230331.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20230331.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20230331.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20230331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20230331.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20230331.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230331.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230331.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses" xlink:label="loc_LIXTGeneralAndAdministrativeStockBasedCompensationExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTGeneralAndAdministrativeStockBasedCompensationExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RepaymentOfDeferredOfferingCosts" xlink:label="loc_LIXTRepaymentOfDeferredOfferingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_LIXTRepaymentOfDeferredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Organization and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Business" xlink:title="00000009 - Disclosure - Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="00000011 - Disclosure - Research and Development Costs" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="00000014 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="00000020 - Disclosure - Research and Development Costs (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="00000021 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="00000022 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="00000023 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="00000024 - Disclosure - Organization and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/BusinessDetailsNarrative" xlink:title="00000025 - Disclosure - Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000026 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="00000028 - Disclosure - Schedule of Research and Development Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="00000029 - Disclosure - Schedule of Warrants Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000030 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000031 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="00000032 - Disclosure - Summary of Related Party Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="00000034 - Disclosure - Summary of Stock-based Compensation Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="00000035 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="00000036 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000038 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>lixt-20230331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20230331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20230331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20230331.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Business" xlink:href="lixt-20230331.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20230331.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20230331.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20230331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20230331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20230331.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BusinessDetailsNarrative" xlink:href="lixt-20230331.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20230331.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20230331.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20230331.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20230331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20230331.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20230331.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230331.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230331.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:label="loc_us-gaapAccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Organization and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Business" xlink:title="00000009 - Disclosure - Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="00000011 - Disclosure - Research and Development Costs" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="00000014 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="00000020 - Disclosure - Research and Development Costs (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="00000021 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="00000022 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="00000023 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="00000024 - Disclosure - Organization and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/BusinessDetailsNarrative" xlink:title="00000025 - Disclosure - Business (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000026 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_90" xlink:type="arc" order="94" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTStockOptionsGrantedtoDirectorsAndCorporateOfficersMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTStockOptionsGrantedtoDirectorsAndCorporateOfficersMember_70" xlink:type="arc" order="74" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorOneMember" xlink:label="loc_LIXTVendorOneMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorOneMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorTwoMember" xlink:label="loc_LIXTVendorTwoMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorTwoMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorThreeMember" xlink:label="loc_LIXTVendorThreeMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorThreeMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorFourMember" xlink:label="loc_LIXTVendorFourMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorFourMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_170" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="00000028 - Disclosure - Schedule of Research and Development Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="loc_countryES_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="loc_countryCN_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="loc_countryNL_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="00000029 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000030 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000031 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="loc_LIXTUndesignatedPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTUndesignatedPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockWarrantMember" xlink:label="loc_LIXTCommonStockWarrantMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_190" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_190" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_190" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="00000032 - Disclosure - Summary of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CashBasedMember" xlink:label="loc_LIXTCashBasedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:to="loc_LIXTCashBasedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_StockBasedMember" xlink:label="loc_LIXTStockBasedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:to="loc_LIXTStockBasedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrJamesSMiserMDMember" xlink:label="loc_LIXTDrJamesSMiserMDMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMDMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FormanMember" xlink:label="loc_LIXTFormanMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFormanMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NewIndependentDirectorMember" xlink:label="loc_LIXTNewIndependentDirectorMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTNewIndependentDirectorMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:to="loc_us-gaapRelatedPartyMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IndependentDirectorMember" xlink:label="loc_LIXTIndependentDirectorMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTIndependentDirectorMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="loc_LIXTManagementFeePayableQuarterly_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_LIXTManagementFeePayableQuarterly_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation_310" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="00000034 - Disclosure - Summary of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RelatedPartiesMember" xlink:label="loc_LIXTRelatedPartiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRelatedPartiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonRelatedPartiesMember" xlink:label="loc_LIXTNonRelatedPartiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNonRelatedPartiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="00000035 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="00000036 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="loc_LIXTExercisePriceFourteenMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourteenMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_300" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_300" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTEricJFormanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrJamesMiserMember" xlink:label="loc_LIXTDrJamesMiserMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrJamesMiserMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRobertNWeingartenMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrWinsonSzeChunHoMember" xlink:label="loc_LIXTDrWinsonSzeChunHoMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrWinsonSzeChunHoMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MsReginaBrownMember" xlink:label="loc_LIXTMsReginaBrownMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMsReginaBrownMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="loc_LIXTNonOfficerDirectorsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTNonOfficerDirectorsMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_500" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_500" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_500" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_500" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_500" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_500" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_500" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_500" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions_500" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_500" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_500" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_500" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_500" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_500" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_500" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_500" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_500" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_500" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_500" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_500" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_500" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000038 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="loc_LIXTClinicalTrialResearchAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_OtherClinicalAgreementsMember" xlink:label="loc_LIXTOtherClinicalAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTOtherClinicalAgreementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="loc_LIXTExclusiveLicenseAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTExclusiveLicenseAgreementMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember_380" xlink:type="arc" order="382" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FirstFourYearsMember" xlink:label="loc_LIXTFirstFourYearsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_LIXTFirstFourYearsMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FiveYearsAndThereafterMember" xlink:label="loc_LIXTFiveYearsAndThereafterMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_LIXTFiveYearsAndThereafterMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExecutiveOfficersMember" xlink:label="loc_LIXTExecutiveOfficersMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTExecutiveOfficersMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_Dr.JamesMember" xlink:label="loc_LIXTDr.JamesMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDr.JamesMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FormanMember" xlink:label="loc_LIXTFormanMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFormanMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation_460" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="loc_LIXTAdvanceAmountRelatedToMilestonePayment_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAdvanceAmountRelatedToMilestonePayment_460" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_460" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription_460" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherCommitment_460" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment_460" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDeferredCosts_460" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="loc_LIXTNonRefundableLicenseIssueFee_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTNonRefundableLicenseIssueFee_460" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="loc_LIXTAnnualLicenseMaintenanceFee_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAnnualLicenseMaintenanceFee_460" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="loc_LIXTPaymentsOnNonrefundableMilestone_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTPaymentsOnNonrefundableMilestone_460" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses_460" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_460" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_460" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AgreementTermDescription" xlink:label="loc_LIXTAgreementTermDescription_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAgreementTermDescription_460" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_460" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOfficersCompensation_460" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent_460" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee_460" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTReimbursementExpense_460" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ContractPrice" xlink:label="loc_LIXTContractPrice_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTContractPrice_460" xlink:type="arc" order="19" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>lixt-20230331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockParValue0.0001PerShareMember" xlink:to="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:to="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Warrants to Purchase Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:label="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:to="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_lbl" xml:lang="en-US">Stock Options Granted to Directors and Corporate Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorOneMember" xlink:label="LIXT_VendorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorOneMember" xlink:to="LIXT_VendorOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorOneMember_lbl" xml:lang="en-US">Vendor One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorTwoMember" xlink:label="LIXT_VendorTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorTwoMember" xlink:to="LIXT_VendorTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorTwoMember_lbl" xml:lang="en-US">Vendor Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorThreeMember" xlink:label="LIXT_VendorThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorThreeMember" xlink:to="LIXT_VendorThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorThreeMember_lbl" xml:lang="en-US">Vendor Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorFourMember" xlink:label="LIXT_VendorFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorFourMember" xlink:to="LIXT_VendorFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_VendorFourMember_lbl" xml:lang="en-US">Vendor Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockWarrantsMember" xlink:label="LIXT_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockOptionsMember" xlink:label="LIXT_CommonStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockOptionsMember" xlink:to="LIXT_CommonStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockOptionsMember_lbl" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="country_ES" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_ES" xlink:to="country_ES_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_ES_lbl" xml:lang="en-US">SPAIN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="country_CN" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="country_NL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US">NETHERLANDS</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="LIXT_UndesignatedPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_UndesignatedPreferredStockMember" xlink:to="LIXT_UndesignatedPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_UndesignatedPreferredStockMember_lbl" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_PlacementAgentsMember" xlink:label="LIXT_PlacementAgentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PlacementAgentsMember_lbl" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockWarrantMember" xlink:label="LIXT_CommonStockWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantMember" xlink:to="LIXT_CommonStockWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CommonStockWarrantMember_lbl" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceOneMember" xlink:label="LIXT_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTwoMember" xlink:label="LIXT_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceThreeMember" xlink:label="LIXT_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EmploymentAgreementMember" xlink:label="LIXT_EmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EmploymentAgreementMember_lbl" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrKovachMember" xlink:label="LIXT_DrKovachMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrKovachMember_lbl" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrJamesSMiserMDMember" xlink:label="LIXT_DrJamesSMiserMDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMDMember" xlink:to="LIXT_DrJamesSMiserMDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrJamesSMiserMDMember_lbl" xml:lang="en-US">Dr. James S. Miser, M.D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EricJFormanMember" xlink:label="LIXT_EricJFormanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_EricJFormanMember_lbl" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FormanMember" xlink:label="LIXT_FormanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FormanMember" xlink:to="LIXT_FormanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FormanMember_lbl" xml:lang="en-US">Forman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RobertNWeingartenMember" xlink:label="LIXT_RobertNWeingartenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RobertNWeingartenMember_lbl" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="LIXT_ChairmanOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_lbl" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="LIXT_ChairmanOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_lbl" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="LIXT_MemberOfAuditCommitteeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfAuditCommitteeMember_lbl" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="LIXT_MemberOfOtherCommitteesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MemberOfOtherCommitteesMember_lbl" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NewIndependentDirectorMember" xlink:label="LIXT_NewIndependentDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NewIndependentDirectorMember" xlink:to="LIXT_NewIndependentDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NewIndependentDirectorMember_lbl" xml:lang="en-US">New Independent Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis_lbl" xml:lang="en-US">Related and Nonrelated Party Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="LIXT_AnnualGrantOfOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualGrantOfOptionsMember_lbl" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IndependentDirectorMember" xlink:label="LIXT_IndependentDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IndependentDirectorMember" xlink:to="LIXT_IndependentDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IndependentDirectorMember_lbl" xml:lang="en-US">Independent Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CashBasedMember" xlink:label="LIXT_CashBasedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashBasedMember" xlink:to="LIXT_CashBasedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CashBasedMember_lbl" xml:lang="en-US">Cash Based [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_StockBasedMember" xlink:label="LIXT_StockBasedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockBasedMember" xlink:to="LIXT_StockBasedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_StockBasedMember_lbl" xml:lang="en-US">Stock Based [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrJamesMiserMember" xlink:label="LIXT_DrJamesMiserMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesMiserMember" xlink:to="LIXT_DrJamesMiserMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrJamesMiserMember_lbl" xml:lang="en-US">Dr. James Miser [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrWinsonSzeChunHoMember" xlink:label="LIXT_DrWinsonSzeChunHoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrWinsonSzeChunHoMember" xlink:to="LIXT_DrWinsonSzeChunHoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DrWinsonSzeChunHoMember_lbl" xml:lang="en-US">Dr Winson SzeChun Ho [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MsReginaBrownMember" xlink:label="LIXT_MsReginaBrownMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MsReginaBrownMember" xlink:to="LIXT_MsReginaBrownMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MsReginaBrownMember_lbl" xml:lang="en-US">Ms.Regina Brown [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="LIXT_FiveNonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsMember" xlink:to="LIXT_FiveNonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FiveNonOfficerDirectorsMember_lbl" xml:lang="en-US">Five Non Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="LIXT_NonOfficerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonOfficerDirectorsMember" xlink:to="LIXT_NonOfficerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NonOfficerDirectorsMember_lbl" xml:lang="en-US">Non Officer Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_BasvanderBaanMember" xlink:label="LIXT_BasvanderBaanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BasvanderBaanMember_lbl" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FourOfficersMember" xlink:label="LIXT_FourOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FourOfficersMember_lbl" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RelatedPartiesMember" xlink:label="LIXT_RelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RelatedPartiesMember" xlink:to="LIXT_RelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RelatedPartiesMember_lbl" xml:lang="en-US">Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonRelatedPartiesMember" xlink:label="LIXT_NonRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRelatedPartiesMember" xlink:to="LIXT_NonRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NonRelatedPartiesMember_lbl" xml:lang="en-US">Non Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFourMember" xlink:label="LIXT_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFiveMember" xlink:label="LIXT_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceSixMember" xlink:label="LIXT_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceSevenMember" xlink:label="LIXT_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceEightMember" xlink:label="LIXT_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceNineMember" xlink:label="LIXT_ExercisePriceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTenMember" xlink:label="LIXT_ExercisePriceTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceElevenMember" xlink:label="LIXT_ExercisePriceElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="LIXT_ExercisePriceTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="LIXT_ExercisePriceThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceThirteenMember_lbl" xml:lang="en-US">ExercisePriceThirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="LIXT_ExercisePriceFourteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourteenMember" xlink:to="LIXT_ExercisePriceFourteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExercisePriceFourteenMember_lbl" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="LIXT_ClinicalTrialResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchAgreementMember" xlink:to="LIXT_ClinicalTrialResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalTrialResearchAgreementMember_lbl" xml:lang="en-US">Clinical Trial Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_OtherClinicalAgreementsMember" xlink:label="LIXT_OtherClinicalAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherClinicalAgreementsMember" xlink:to="LIXT_OtherClinicalAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_OtherClinicalAgreementsMember_lbl" xml:lang="en-US">Other Clinical Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_lbl" xml:lang="en-US">GEIS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CollaborationAgreementMember" xlink:label="LIXT_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_lbl" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="LIXT_ClinicalResearchSupportAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_lbl" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_WorkOrderAgreementMember" xlink:label="LIXT_WorkOrderAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_WorkOrderAgreementMember_lbl" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_TheradexSystemsIncMember" xlink:label="LIXT_TheradexSystemsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_TheradexSystemsIncMember_lbl" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:to="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_lbl" xml:lang="en-US">Moffitt Cancer Center and Research Institute Hospital Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="LIXT_ExclusiveLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExclusiveLicenseAgreementMember" xlink:to="LIXT_ExclusiveLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExclusiveLicenseAgreementMember_lbl" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FirstFourYearsMember" xlink:label="LIXT_FirstFourYearsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FirstFourYearsMember" xlink:to="LIXT_FirstFourYearsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FirstFourYearsMember_lbl" xml:lang="en-US">First Four Years [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FiveYearsAndThereafterMember" xlink:label="LIXT_FiveYearsAndThereafterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveYearsAndThereafterMember" xlink:to="LIXT_FiveYearsAndThereafterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FiveYearsAndThereafterMember_lbl" xml:lang="en-US">Five Years And Thereafter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExecutiveOfficersMember" xlink:label="LIXT_ExecutiveOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExecutiveOfficersMember" xlink:to="LIXT_ExecutiveOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ExecutiveOfficersMember_lbl" xml:lang="en-US">Executive Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_Dr.JamesMember" xlink:label="LIXT_Dr.JamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_Dr.JamesMember" xlink:to="LIXT_Dr.JamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_Dr.JamesMember_lbl" xml:lang="en-US">Dr.James [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NDAConsultingCorpMember" xlink:label="LIXT_NDAConsultingCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NDAConsultingCorpMember_lbl" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="LIXT_BioPharmaWorksLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_BioPharmaWorksLLCMember_lbl" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="LIXT_DevelopmentCollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_lbl" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="LIXT_NetherlandsCancerInstituteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NetherlandsCancerInstituteMember_lbl" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MRIGlobalMember" xlink:label="LIXT_MRIGlobalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_MRIGlobalMember_lbl" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other prepaid expenses and current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses, including $44,972 and $46,982 to related parties at March 31, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued and outstanding &#8211; 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares &#8211; 729,167 shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 16,659,093 shares and 16,646,593 shares at March 31, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Related parties accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:label="us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:to="us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_lbl" xml:lang="en-US">Accounts Payable, Current, Related and Nonrelated Party Status [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Preferred stock, issuable upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and administrative costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Compensation to related parties, including stock-based compensation of $276,980 and $339,672 for the three months ended March 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Patent and licensing legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Other costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated share based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract_lbl" xml:lang="en-US">Stock-based compensation expense included in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses" xlink:label="LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses" xlink:to="LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses_lbl" xml:lang="en-US">General and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase) decrease in -</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_lbl" xml:lang="en-US">Advances on research and development contract services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Other prepaid expenses and current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase (decrease) in -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_lbl" xml:lang="en-US">Research and development contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RepaymentOfDeferredOfferingCosts" xlink:label="LIXT_RepaymentOfDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RepaymentOfDeferredOfferingCosts" xlink:to="LIXT_RepaymentOfDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LIXT_RepaymentOfDeferredOfferingCosts_lbl" xml:lang="en-US">Payment of deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xml:lang="en-US">Cash:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Balance at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Balance at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid for -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_lbl" xml:lang="en-US">Prepaid Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patent and Licensing Legal and Filing Fees and Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ResearchDevelopmentTableTextBlock" xlink:label="LIXT_ResearchDevelopmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchDevelopmentTableTextBlock" xlink:to="LIXT_ResearchDevelopmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ResearchDevelopmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Summary of Related Party Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Summary of Stock-based Compensation Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="LIXT_CashSIPCInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_CashSIPCInsuredAmount_lbl" xml:lang="en-US">Cash SIPC insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Shares, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants exercisable, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants exercisable, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:to="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_lbl" xml:lang="en-US">Principal Cash Obligations and Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock dividend, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:to="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_lbl" xml:lang="en-US">Annual net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US">Preferred stock, conversion description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Preferred stock convertible into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Gross proceeds from sale of transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock shares issued during period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs of public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued new issue shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair market value of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Related party costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Increase in annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Paid office rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="us-gaap_ManagementFeePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeePayable_lbl" xml:lang="en-US">Cash board fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="LIXT_ManagementFeePayableQuarterly" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ManagementFeePayableQuarterly" xlink:to="LIXT_ManagementFeePayableQuarterly_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LIXT_ManagementFeePayableQuarterly_lbl" xml:lang="en-US">Cash board fee payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, grants in period, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based payment award, award vesting period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Annual cash fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding, at the beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, stock options outstanding, at the end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, stock options outstanding, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, stock options exercisable, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options exercisable, at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable (Shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common shares avaliable for issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares were available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Stock options description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Stock option vested exercisable term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock options are exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FairValueOfStockOptions" xlink:label="LIXT_FairValueOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_FairValueOfStockOptions_lbl" xml:lang="en-US">Fair value of stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Stock options fully vested amount, fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of fully vested option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Purchase of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2_lbl" xml:lang="en-US">Share based compensation vesting rights, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xml:lang="en-US">Stock options granted to purchase common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Total deferred compensation expense for outstanding value of unvested stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value of exercisable but unexercised in-the-money stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair market value, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Outstanding stock options to acquire shares of common stock not vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:to="LIXT_AdvanceAmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Advance amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Aggregate commitments expected, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Aggregate commitments expected</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="LIXT_AmountRelatedToMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AmountRelatedToMilestonePayment_lbl" xml:lang="en-US">Amount related to milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Total costs</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="LIXT_NonRefundableLicenseIssueFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRefundableLicenseIssueFee" xlink:to="LIXT_NonRefundableLicenseIssueFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_NonRefundableLicenseIssueFee_lbl" xml:lang="en-US">Non refundable license issue fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="LIXT_AnnualLicenseMaintenanceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualLicenseMaintenanceFee" xlink:to="LIXT_AnnualLicenseMaintenanceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US">Maintenance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="LIXT_PaymentsOnNonrefundableMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PaymentsOnNonrefundableMilestone" xlink:to="LIXT_PaymentsOnNonrefundableMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_PaymentsOnNonrefundableMilestone_lbl" xml:lang="en-US">Payment on non refundable milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Operating costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Minimum payments for royalties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_2_lbl" xml:lang="en-US">Salary and compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AgreementTermDescription" xlink:label="LIXT_AgreementTermDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AgreementTermDescription" xlink:to="LIXT_AgreementTermDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_AgreementTermDescription_lbl" xml:lang="en-US">Agreement term description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Annual compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="LIXT_ConsultingAndAdvisoryCashFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_lbl" xml:lang="en-US">Consulting and advisory fee</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ReimbursementExpense" xlink:label="LIXT_ReimbursementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ReimbursementExpense_lbl" xml:lang="en-US">Reimbursed expense</link:label>
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ContractPrice" xlink:label="LIXT_ContractPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractPrice" xlink:to="LIXT_ContractPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ContractPrice_lbl" xml:lang="en-US">Contract price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Advances on research and development contract services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SeriesAConvertiblePreferredStockMember" xlink:to="LIXT_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:to="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_doc" xml:lang="en-US">Number of share tranche of the series a convertible preferred stock receive a per share dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:to="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares_doc" xml:lang="en-US">Annual net revenue divided by converted or redeemed shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_UndesignatedPreferredStockMember" xlink:to="LIXT_UndesignatedPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_UndesignatedPreferredStockMember_doc" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:to="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent_doc" xml:lang="en-US">Research and development contract liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PlacementAgentsMember" xlink:to="LIXT_PlacementAgentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PlacementAgentsMember_doc" xml:lang="en-US">Placement Agents [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantsMember" xlink:to="LIXT_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average number of share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule Of Warrants Outstanding And Exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceOneMember" xlink:to="LIXT_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwoMember" xlink:to="LIXT_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThreeMember" xlink:to="LIXT_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CommonStockWarrantMember" xlink:to="LIXT_CommonStockWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CommonStockWarrantMember_doc" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EmploymentAgreementMember" xlink:to="LIXT_EmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EmploymentAgreementMember_doc" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrKovachMember" xlink:to="LIXT_DrKovachMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrKovachMember_doc" xml:lang="en-US">Dr. Kovach [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesSMiserMDMember" xlink:to="LIXT_DrJamesSMiserMDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrJamesSMiserMDMember_doc" xml:lang="en-US">Dr. James S. Miser, M.D [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_EricJFormanMember" xlink:to="LIXT_EricJFormanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_EricJFormanMember_doc" xml:lang="en-US">Eric J. Forman [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FormanMember" xlink:to="LIXT_FormanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FormanMember_doc" xml:lang="en-US">Forman [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RobertNWeingartenMember" xlink:to="LIXT_RobertNWeingartenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RobertNWeingartenMember_doc" xml:lang="en-US">Robert N. Weingarten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ManagementFeePayableQuarterly" xlink:to="LIXT_ManagementFeePayableQuarterly_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ManagementFeePayableQuarterly_doc" xml:lang="en-US">Management fee payable quarterly.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfAuditCommitteeMember" xlink:to="LIXT_ChairmanOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfAuditCommitteeMember_doc" xml:lang="en-US">Chairman of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ChairmanOfOtherCommitteesMember" xlink:to="LIXT_ChairmanOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ChairmanOfOtherCommitteesMember_doc" xml:lang="en-US">Chairman of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfAuditCommitteeMember" xlink:to="LIXT_MemberOfAuditCommitteeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfAuditCommitteeMember_doc" xml:lang="en-US">Member of Audit Committee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MemberOfOtherCommitteesMember" xlink:to="LIXT_MemberOfOtherCommitteesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MemberOfOtherCommitteesMember_doc" xml:lang="en-US">Member of Other Committees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NewIndependentDirectorMember" xlink:to="LIXT_NewIndependentDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NewIndependentDirectorMember_doc" xml:lang="en-US">New Independent Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualGrantOfOptionsMember" xlink:to="LIXT_AnnualGrantOfOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualGrantOfOptionsMember_doc" xml:lang="en-US">Annual Grant of Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IndependentDirectorMember" xlink:to="LIXT_IndependentDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IndependentDirectorMember_doc" xml:lang="en-US">Independent Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses" xlink:to="LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses_doc" xml:lang="en-US">General and administrative stock based compensation expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_doc" xml:lang="en-US">Increase decrease in advances on research and development contract services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:to="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_doc" xml:lang="en-US">Increase decrease in research and development contract liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RepaymentOfDeferredOfferingCosts" xlink:to="LIXT_RepaymentOfDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RepaymentOfDeferredOfferingCosts_doc" xml:lang="en-US">Repayment of deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FairValueOfStockOptions" xlink:to="LIXT_FairValueOfStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FairValueOfStockOptions_doc" xml:lang="en-US">Fair value of stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrJamesMiserMember" xlink:to="LIXT_DrJamesMiserMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrJamesMiserMember_doc" xml:lang="en-US">Dr. James Miser [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DrWinsonSzeChunHoMember" xlink:to="LIXT_DrWinsonSzeChunHoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DrWinsonSzeChunHoMember_doc" xml:lang="en-US">Dr Winson SzeChun Ho [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashSIPCInsuredAmount" xlink:to="LIXT_CashSIPCInsuredAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CashSIPCInsuredAmount_doc" xml:lang="en-US">Cash SIPC insured amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MsReginaBrownMember" xlink:to="LIXT_MsReginaBrownMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MsReginaBrownMember_doc" xml:lang="en-US">Ms.Regina Brown [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveNonOfficerDirectorsMember" xlink:to="LIXT_FiveNonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FiveNonOfficerDirectorsMember_doc" xml:lang="en-US">Five Non Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonOfficerDirectorsMember" xlink:to="LIXT_NonOfficerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NonOfficerDirectorsMember_doc" xml:lang="en-US">Non Officer Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BasvanderBaanMember" xlink:to="LIXT_BasvanderBaanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BasvanderBaanMember_doc" xml:lang="en-US">BasvanderBaan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:to="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_doc" xml:lang="en-US">Stock Options Granted to Directors and Corporate Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorOneMember" xlink:to="LIXT_VendorOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorOneMember_doc" xml:lang="en-US">Vendor One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorTwoMember" xlink:to="LIXT_VendorTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorTwoMember_doc" xml:lang="en-US">Vendor Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorThreeMember" xlink:to="LIXT_VendorThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorThreeMember_doc" xml:lang="en-US">Vendor Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FourOfficersMember" xlink:to="LIXT_FourOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FourOfficersMember_doc" xml:lang="en-US">Four Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ResearchDevelopmentTableTextBlock" xlink:to="LIXT_ResearchDevelopmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ResearchDevelopmentTableTextBlock_doc" xml:lang="en-US">Research Development [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourMember" xlink:to="LIXT_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFiveMember" xlink:to="LIXT_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSixMember" xlink:to="LIXT_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceSevenMember" xlink:to="LIXT_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceEightMember" xlink:to="LIXT_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceNineMember" xlink:to="LIXT_ExercisePriceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceNineMember_doc" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTenMember" xlink:to="LIXT_ExercisePriceTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTenMember_doc" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceElevenMember" xlink:to="LIXT_ExercisePriceElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceElevenMember_doc" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceTwelveMember" xlink:to="LIXT_ExercisePriceTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceTwelveMember_doc" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceFourteenMember" xlink:to="LIXT_ExercisePriceFourteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceFourteenMember_doc" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:to="LIXT_AdvanceAmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AdvanceAmountRelatedToMilestonePayment_doc" xml:lang="en-US">Advance amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_OtherClinicalAgreementsMember" xlink:to="LIXT_OtherClinicalAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_OtherClinicalAgreementsMember_doc" xml:lang="en-US">Other Clinical Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AmountRelatedToMilestonePayment" xlink:to="LIXT_AmountRelatedToMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AmountRelatedToMilestonePayment_doc" xml:lang="en-US">Amount related to milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:to="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember_doc" xml:lang="en-US">GEIS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CollaborationAgreementMember" xlink:to="LIXT_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CityOfHopeNationalMedicalCenterMember" xlink:to="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CityOfHopeNationalMedicalCenterMember_doc" xml:lang="en-US">City of Hope [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalResearchSupportAgreementMember" xlink:to="LIXT_ClinicalResearchSupportAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalResearchSupportAgreementMember_doc" xml:lang="en-US">Clinical Research Support Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_CashBasedMember" xlink:to="LIXT_CashBasedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_CashBasedMember_doc" xml:lang="en-US">Cash Based [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_StockBasedMember" xlink:to="LIXT_StockBasedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_StockBasedMember_doc" xml:lang="en-US">Stock Based [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PrepaidInsurancePolicyTextBlock" xlink:to="LIXT_PrepaidInsurancePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PrepaidInsurancePolicyTextBlock_doc" xml:lang="en-US">Prepaid Insurance [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RelatedPartiesMember" xlink:to="LIXT_RelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_RelatedPartiesMember_doc" xml:lang="en-US">Related Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRelatedPartiesMember" xlink:to="LIXT_NonRelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NonRelatedPartiesMember_doc" xml:lang="en-US">Non Related Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExercisePriceThirteenMember" xlink:to="LIXT_ExercisePriceThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExercisePriceThirteenMember_doc" xml:lang="en-US">Exercise PriceThirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ClinicalTrialResearchAgreementMember" xlink:to="LIXT_ClinicalTrialResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ClinicalTrialResearchAgreementMember_doc" xml:lang="en-US">Clinical Trial Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_WorkOrderAgreementMember" xlink:to="LIXT_WorkOrderAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_WorkOrderAgreementMember_doc" xml:lang="en-US">Work Order Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_TheradexSystemsIncMember" xlink:to="LIXT_TheradexSystemsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_TheradexSystemsIncMember_doc" xml:lang="en-US">Theradex Systems, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NonRefundableLicenseIssueFee" xlink:to="LIXT_NonRefundableLicenseIssueFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NonRefundableLicenseIssueFee_doc" xml:lang="en-US">Company is obligated to pay non refundable license issue fee..</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:to="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember_doc" xml:lang="en-US">Moffitt Cancer Center and Research Institute Hospital Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExclusiveLicenseAgreementMember" xlink:to="LIXT_ExclusiveLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExclusiveLicenseAgreementMember_doc" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AnnualLicenseMaintenanceFee" xlink:to="LIXT_AnnualLicenseMaintenanceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AnnualLicenseMaintenanceFee_doc" xml:lang="en-US">Company is obligated to pay annual license maintenance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_PaymentsOnNonrefundableMilestone" xlink:to="LIXT_PaymentsOnNonrefundableMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_PaymentsOnNonrefundableMilestone_doc" xml:lang="en-US">Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FirstFourYearsMember" xlink:to="LIXT_FirstFourYearsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FirstFourYearsMember_doc" xml:lang="en-US">First Four Years [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_FiveYearsAndThereafterMember" xlink:to="LIXT_FiveYearsAndThereafterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_FiveYearsAndThereafterMember_doc" xml:lang="en-US">Five Years And Thereafter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ExecutiveOfficersMember" xlink:to="LIXT_ExecutiveOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ExecutiveOfficersMember_doc" xml:lang="en-US">Executive Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_AgreementTermDescription" xlink:to="LIXT_AgreementTermDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_AgreementTermDescription_doc" xml:lang="en-US">Agreement term description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_Dr.JamesMember" xlink:to="LIXT_Dr.JamesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_Dr.JamesMember_doc" xml:lang="en-US">Dr.James [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ConsultingAndAdvisoryCashFee" xlink:to="LIXT_ConsultingAndAdvisoryCashFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ConsultingAndAdvisoryCashFee_doc" xml:lang="en-US">Consulting and advisory quarterly cash fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NDAConsultingCorpMember" xlink:to="LIXT_NDAConsultingCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NDAConsultingCorpMember_doc" xml:lang="en-US">NDA Consulting Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_BioPharmaWorksLLCMember" xlink:to="LIXT_BioPharmaWorksLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_BioPharmaWorksLLCMember_doc" xml:lang="en-US">Bio Pharma Works LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ReimbursementExpense" xlink:to="LIXT_ReimbursementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ReimbursementExpense_doc" xml:lang="en-US">Reimbursement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_DevelopmentCollaborationAgreementMember" xlink:to="LIXT_DevelopmentCollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_DevelopmentCollaborationAgreementMember_doc" xml:lang="en-US">Development Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_NetherlandsCancerInstituteMember" xlink:to="LIXT_NetherlandsCancerInstituteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_NetherlandsCancerInstituteMember_doc" xml:lang="en-US">Netherlands Cancer Institute [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ContractPrice" xlink:to="LIXT_ContractPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_ContractPrice_doc" xml:lang="en-US">Contract price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_MRIGlobalMember" xlink:to="LIXT_MRIGlobalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_MRIGlobalMember_doc" xml:lang="en-US">MRI Global [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_VendorFourMember" xlink:to="LIXT_VendorFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LIXT_VendorFourMember_doc" xml:lang="en-US">Vendor Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:to="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices_3_lbl" xml:lang="en-US">IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:to="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidInsurance_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:to="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities_3_lbl" xml:lang="en-US">IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_RepaymentOfDeferredOfferingCosts" xlink:to="LIXT_RepaymentOfDeferredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_RepaymentOfDeferredOfferingCosts_3_lbl" xml:lang="en-US">RepaymentOfDeferredOfferingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:to="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_4_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average number of share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LIXT_ManagementFeePayableQuarterly" xlink:to="LIXT_ManagementFeePayableQuarterly_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LIXT_ManagementFeePayableQuarterly_3_lbl" xml:lang="en-US">ManagementFeePayableQuarterly</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>lixt-20230331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lixte.com/role/Cover" xlink:href="lixt-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheets" xlink:href="lixt-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BalanceSheetsParenthetical" xlink:href="lixt-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperations" xlink:href="lixt-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:href="lixt-20230331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:href="lixt-20230331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StatementsOfCashFlows" xlink:href="lixt-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:href="lixt-20230331.xsd#OrganizationAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Business" xlink:href="lixt-20230331.xsd#Business" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:href="lixt-20230331.xsd#ResearchAndDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquity" xlink:href="lixt-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactions" xlink:href="lixt-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensation" xlink:href="lixt-20230331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/IncomeTaxes" xlink:href="lixt-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingencies" xlink:href="lixt-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SubsequentEvents" xlink:href="lixt-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:href="lixt-20230331.xsd#ResearchAndDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityTables" xlink:href="lixt-20230331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:href="lixt-20230331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationTables" xlink:href="lixt-20230331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:href="lixt-20230331.xsd#OrganizationAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/BusinessDetailsNarrative" xlink:href="lixt-20230331.xsd#BusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lixt-20230331.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="lixt-20230331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:href="lixt-20230331.xsd#ScheduleOfResearchAndDevelopmentCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="lixt-20230331.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="lixt-20230331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:href="lixt-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:href="lixt-20230331.xsd#SummaryOfRelatedPartyCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="lixt-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:href="lixt-20230331.xsd#SummaryOfStock-basedCompensationCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230331.xsd#SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:href="lixt-20230331.xsd#ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="lixt-20230331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lixt-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:label="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTWarrantsToPurchaseCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_LIXTAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent" xlink:label="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_LIXTResearchAndDevelopmentContractLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:label="loc_us-gaapAccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses" xlink:label="loc_LIXTGeneralAndAdministrativeStockBasedCompensationExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract" xlink:to="loc_LIXTGeneralAndAdministrativeStockBasedCompensationExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:label="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_LIXTIncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidInsurance" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidInsurance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:label="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_LIXTIncreaseDecreaseInResearchAndDevelopmentContractLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RepaymentOfDeferredOfferingCosts" xlink:label="loc_LIXTRepaymentOfDeferredOfferingCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_LIXTRepaymentOfDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Organization and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Business" xlink:title="00000009 - Disclosure - Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCosts" xlink:title="00000011 - Disclosure - Research and Development Costs">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensation" xlink:title="00000014 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_PrepaidInsurancePolicyTextBlock" xlink:label="loc_LIXTPrepaidInsurancePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LIXTPrepaidInsurancePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ResearchAndDevelopmentCostsTables" xlink:title="00000020 - Disclosure - Research and Development Costs (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ResearchDevelopmentTableTextBlock" xlink:label="loc_LIXTResearchDevelopmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_LIXTResearchDevelopmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityTables" xlink:title="00000021 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_LIXTScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsTables" xlink:title="00000022 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationTables" xlink:title="00000023 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" xlink:title="00000024 - Disclosure - Organization and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/BusinessDetailsNarrative" xlink:title="00000025 - Disclosure - Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000026 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockOptionsMember" xlink:label="loc_LIXTCommonStockOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_LIXTCommonStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:label="loc_LIXTStockOptionsGrantedtoDirectorsAndCorporateOfficersMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTStockOptionsGrantedtoDirectorsAndCorporateOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorOneMember" xlink:label="loc_LIXTVendorOneMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorTwoMember" xlink:label="loc_LIXTVendorTwoMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorThreeMember" xlink:label="loc_LIXTVendorThreeMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_VendorFourMember" xlink:label="loc_LIXTVendorFourMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_LIXTVendorFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CashSIPCInsuredAmount" xlink:label="loc_LIXTCashSIPCInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_LIXTCashSIPCInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails" xlink:title="00000028 - Disclosure - Schedule of Research and Development Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_ES" xlink:label="loc_countryES" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryES" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="loc_countryCN" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_NL" xlink:label="loc_countryNL" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="00000029 - Disclosure - Schedule of Warrants Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockWarrantsMember" xlink:label="loc_LIXTCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LIXTSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000030 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000031 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_SeriesAConvertiblePreferredStockMember" xlink:label="loc_LIXTSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_UndesignatedPreferredStockMember" xlink:label="loc_LIXTUndesignatedPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LIXTUndesignatedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CommonStockWarrantMember" xlink:label="loc_LIXTCommonStockWarrantMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LIXTCommonStockWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_PlacementAgentsMember" xlink:label="loc_LIXTPlacementAgentsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LIXTPlacementAgentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:label="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTNumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:label="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LIXTAnnualNetRevenueDividedByConvertedOrRedeemedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaapPreferredStockConversionBasis" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConversionBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfRelatedPartyCostsDetails" xlink:title="00000032 - Disclosure - Summary of Related Party Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CashBasedMember" xlink:label="loc_LIXTCashBasedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:to="loc_LIXTCashBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_StockBasedMember" xlink:label="loc_LIXTStockBasedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:to="loc_LIXTStockBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrKovachMember" xlink:label="loc_LIXTDrKovachMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrKovachMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrJamesSMiserMDMember" xlink:label="loc_LIXTDrJamesSMiserMDMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDrJamesSMiserMDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FormanMember" xlink:label="loc_LIXTFormanMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ChairmanOfAuditCommitteeMember" xlink:label="loc_LIXTChairmanOfAuditCommitteeMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ChairmanOfOtherCommitteesMember" xlink:label="loc_LIXTChairmanOfOtherCommitteesMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTChairmanOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MemberOfAuditCommitteeMember" xlink:label="loc_LIXTMemberOfAuditCommitteeMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfAuditCommitteeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MemberOfOtherCommitteesMember" xlink:label="loc_LIXTMemberOfOtherCommitteesMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTMemberOfOtherCommitteesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NewIndependentDirectorMember" xlink:label="loc_LIXTNewIndependentDirectorMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTNewIndependentDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualGrantOfOptionsMember" xlink:label="loc_LIXTAnnualGrantOfOptionsMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LIXTAnnualGrantOfOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusAxis" xlink:to="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedAndNonrelatedPartyStatusDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_IndependentDirectorMember" xlink:label="loc_LIXTIndependentDirectorMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTIndependentDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeePayable" xlink:label="loc_us-gaapManagementFeePayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapManagementFeePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ManagementFeePayableQuarterly" xlink:label="loc_LIXTManagementFeePayableQuarterly" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_LIXTManagementFeePayableQuarterly" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails" xlink:title="00000034 - Disclosure - Summary of Stock-based Compensation Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RelatedPartiesMember" xlink:label="loc_LIXTRelatedPartiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonRelatedPartiesMember" xlink:label="loc_LIXTNonRelatedPartiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNonRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails" xlink:title="00000035 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails" xlink:title="00000036 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceOneMember" xlink:label="loc_LIXTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTwoMember" xlink:label="loc_LIXTExercisePriceTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceThreeMember" xlink:label="loc_LIXTExercisePriceThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFourMember" xlink:label="loc_LIXTExercisePriceFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFiveMember" xlink:label="loc_LIXTExercisePriceFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceSixMember" xlink:label="loc_LIXTExercisePriceSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceSevenMember" xlink:label="loc_LIXTExercisePriceSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceEightMember" xlink:label="loc_LIXTExercisePriceEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceNineMember" xlink:label="loc_LIXTExercisePriceNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTenMember" xlink:label="loc_LIXTExercisePriceTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceElevenMember" xlink:label="loc_LIXTExercisePriceElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceTwelveMember" xlink:label="loc_LIXTExercisePriceTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceThirteenMember" xlink:label="loc_LIXTExercisePriceThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExercisePriceFourteenMember" xlink:label="loc_LIXTExercisePriceFourteenMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_LIXTExercisePriceFourteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LIXTTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EricJFormanMember" xlink:label="loc_LIXTEricJFormanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTEricJFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrJamesMiserMember" xlink:label="loc_LIXTDrJamesMiserMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrJamesMiserMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_RobertNWeingartenMember" xlink:label="loc_LIXTRobertNWeingartenMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTRobertNWeingartenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DrWinsonSzeChunHoMember" xlink:label="loc_LIXTDrWinsonSzeChunHoMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTDrWinsonSzeChunHoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MsReginaBrownMember" xlink:label="loc_LIXTMsReginaBrownMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTMsReginaBrownMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FiveNonOfficerDirectorsMember" xlink:label="loc_LIXTFiveNonOfficerDirectorsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFiveNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonOfficerDirectorsMember" xlink:label="loc_LIXTNonOfficerDirectorsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTNonOfficerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_BasvanderBaanMember" xlink:label="loc_LIXTBasvanderBaanMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTBasvanderBaanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FourOfficersMember" xlink:label="loc_LIXTFourOfficersMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFourOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FairValueOfStockOptions" xlink:label="loc_LIXTFairValueOfStockOptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTFairValueOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:label="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_LIXTShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000038 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ClinicalTrialResearchAgreementMember" xlink:label="loc_LIXTClinicalTrialResearchAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalTrialResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_OtherClinicalAgreementsMember" xlink:label="loc_LIXTOtherClinicalAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTOtherClinicalAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CollaborationAgreementMember" xlink:label="loc_LIXTCollaborationAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ClinicalResearchSupportAgreementMember" xlink:label="loc_LIXTClinicalResearchSupportAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTClinicalResearchSupportAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_WorkOrderAgreementMember" xlink:label="loc_LIXTWorkOrderAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTWorkOrderAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExclusiveLicenseAgreementMember" xlink:label="loc_LIXTExclusiveLicenseAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTExclusiveLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_EmploymentAgreementMember" xlink:label="loc_LIXTEmploymentAgreementMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_DevelopmentCollaborationAgreementMember" xlink:label="loc_LIXTDevelopmentCollaborationAgreementMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTDevelopmentCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MRIGlobalMember" xlink:label="loc_LIXTMRIGlobalMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LIXTMRIGlobalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember" xlink:label="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTGrupoEspanolDeInvestigacionEnSarcomasMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NDAConsultingCorpMember" xlink:label="loc_LIXTNDAConsultingCorpMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTNDAConsultingCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_BioPharmaWorksLLCMember" xlink:label="loc_LIXTBioPharmaWorksLLCMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_LIXTBioPharmaWorksLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_LIXTCityOfHopeNationalMedicalCenterMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTCityOfHopeNationalMedicalCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_TheradexSystemsIncMember" xlink:label="loc_LIXTTheradexSystemsIncMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTTheradexSystemsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:label="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTMoffittCancerCenterandResearchInstituteHospitalIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NetherlandsCancerInstituteMember" xlink:label="loc_LIXTNetherlandsCancerInstituteMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LIXTNetherlandsCancerInstituteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FirstFourYearsMember" xlink:label="loc_LIXTFirstFourYearsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_LIXTFirstFourYearsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FiveYearsAndThereafterMember" xlink:label="loc_LIXTFiveYearsAndThereafterMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_LIXTFiveYearsAndThereafterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ExecutiveOfficersMember" xlink:label="loc_LIXTExecutiveOfficersMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTExecutiveOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_Dr.JamesMember" xlink:label="loc_LIXTDr.JamesMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTDr.JamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_FormanMember" xlink:label="loc_LIXTFormanMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LIXTFormanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AdvanceAmountRelatedToMilestonePayment" xlink:label="loc_LIXTAdvanceAmountRelatedToMilestonePayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAdvanceAmountRelatedToMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AmountRelatedToMilestonePayment" xlink:label="loc_LIXTAmountRelatedToMilestonePayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAmountRelatedToMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_NonRefundableLicenseIssueFee" xlink:label="loc_LIXTNonRefundableLicenseIssueFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTNonRefundableLicenseIssueFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AnnualLicenseMaintenanceFee" xlink:label="loc_LIXTAnnualLicenseMaintenanceFee" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAnnualLicenseMaintenanceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_PaymentsOnNonrefundableMilestone" xlink:label="loc_LIXTPaymentsOnNonrefundableMilestone" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTPaymentsOnNonrefundableMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_AgreementTermDescription" xlink:label="loc_LIXTAgreementTermDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTAgreementTermDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ConsultingAndAdvisoryCashFee" xlink:label="loc_LIXTConsultingAndAdvisoryCashFee" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTConsultingAndAdvisoryCashFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ReimbursementExpense" xlink:label="loc_LIXTReimbursementExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTReimbursementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lixt-20230331.xsd#LIXT_ContractPrice" xlink:label="loc_LIXTContractPrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LIXTContractPrice" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217585208032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIXTE
BIOTECHNOLOGY HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001335105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2903526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680
East Colorado Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">830-7092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,659,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember', window );">Warrants to Purchase Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to Purchase Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LIXTW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217585458096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 4,088,304<span></span>
</td>
<td class="nump">$ 5,353,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="nump">131,194<span></span>
</td>
<td class="nump">147,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">55,219<span></span>
</td>
<td class="nump">49,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other prepaid expenses and current assets</a></td>
<td class="nump">56,099<span></span>
</td>
<td class="nump">10,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,330,816<span></span>
</td>
<td class="nump">5,560,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,330,816<span></span>
</td>
<td class="nump">5,560,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, including $44,972 and $46,982 to related parties at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">223,631<span></span>
</td>
<td class="nump">229,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent', window );">Research and development contract liabilities</a></td>
<td class="nump">26,356<span></span>
</td>
<td class="nump">165,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">249,987<span></span>
</td>
<td class="nump">394,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value; authorized &#8211; 10,000,000 shares; issued and outstanding &#8211; 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares &#8211; 729,167 shares</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; authorized &#8211; 100,000,000 shares; issued and outstanding &#8211; 16,659,093 shares and 16,646,593 shares at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">45,341,522<span></span>
</td>
<td class="nump">45,058,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(44,762,358)<span></span>
</td>
<td class="num">(43,394,699)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,080,829<span></span>
</td>
<td class="nump">5,165,227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 4,330,816<span></span>
</td>
<td class="nump">$ 5,560,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances on research and development contract services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217584029744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Related parties accounts payable and accrued expenses</a></td>
<td class="nump">$ 44,972<span></span>
</td>
<td class="nump">$ 46,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration', window );">Accounts Payable, Current, Related and Nonrelated Party Status [Extensible Enumeration]</a></td>
<td class="text">Related Party [Member]<span></span>
</td>
<td class="text">Related Party [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,659,093<span></span>
</td>
<td class="nump">16,646,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,659,093<span></span>
</td>
<td class="nump">16,646,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock, issuable upon conversion</a></td>
<td class="nump">729,167<span></span>
</td>
<td class="nump">729,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates related and nonrelated party status for accounts payable classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217583974848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Compensation to related parties, including stock-based compensation of $276,980 and $339,672 for the three months ended March 31, 2023 and 2022, respectively</a></td>
<td class="nump">519,480<span></span>
</td>
<td class="nump">565,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Patent and licensing legal and filing fees and costs</a></td>
<td class="nump">317,340<span></span>
</td>
<td class="nump">315,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other costs and expenses</a></td>
<td class="nump">344,242<span></span>
</td>
<td class="nump">314,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">189,085<span></span>
</td>
<td class="nump">458,450<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">1,370,147<span></span>
</td>
<td class="nump">1,654,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,370,147)<span></span>
</td>
<td class="num">(1,654,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">5,015<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,861)<span></span>
</td>
<td class="num">(2,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gain (loss)</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,367,659)<span></span>
</td>
<td class="num">$ (1,656,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share &#8211; basic and diluted</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8211; basic and diluted</a></td>
<td class="nump">16,649,510<span></span>
</td>
<td class="nump">13,746,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217584052624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 276,980<span></span>
</td>
<td class="nump">$ 339,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217583911280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 1,374<span></span>
</td>
<td class="nump">$ 38,371,128<span></span>
</td>
<td class="num">$ (37,082,164)<span></span>
</td>
<td class="nump">$ 4,790,338<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">13,746,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">339,672<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">339,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,656,918)<span></span>
</td>
<td class="num">(1,656,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 1,374<span></span>
</td>
<td class="nump">38,710,800<span></span>
</td>
<td class="num">(38,739,082)<span></span>
</td>
<td class="nump">3,473,092<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">13,746,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 1,664<span></span>
</td>
<td class="nump">45,058,262<span></span>
</td>
<td class="num">(43,394,699)<span></span>
</td>
<td class="nump">5,165,227<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">16,646,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,280<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">276,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 276,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,367,659)<span></span>
</td>
<td class="num">(1,367,659)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 1,665<span></span>
</td>
<td class="nump">$ 45,341,522<span></span>
</td>
<td class="num">$ (44,762,358)<span></span>
</td>
<td class="nump">$ 4,080,829<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">16,659,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217583253280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,367,659)<span></span>
</td>
<td class="num">$ (1,656,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract', window );"><strong>Stock-based compensation expense included in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses', window );">General and administrative costs</a></td>
<td class="nump">276,980<span></span>
</td>
<td class="nump">339,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices', window );">Advances on research and development contract services</a></td>
<td class="nump">15,823<span></span>
</td>
<td class="nump">3,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="num">(5,995)<span></span>
</td>
<td class="num">(21,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other prepaid expenses and current assets</a></td>
<td class="num">(45,719)<span></span>
</td>
<td class="num">(41,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(6,133)<span></span>
</td>
<td class="nump">143,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities', window );">Research and development contract liabilities</a></td>
<td class="num">(138,666)<span></span>
</td>
<td class="nump">198,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,271,369)<span></span>
</td>
<td class="num">(1,035,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_RepaymentOfDeferredOfferingCosts', window );">Payment of deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,906)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="num">(10,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>Cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease</a></td>
<td class="num">(1,265,088)<span></span>
</td>
<td class="num">(1,046,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at beginning of period</a></td>
<td class="nump">5,353,392<span></span>
</td>
<td class="nump">4,823,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Balance at end of period</a></td>
<td class="nump">4,088,304<span></span>
</td>
<td class="nump">3,777,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">3,861<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative stock based compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in advances on research and development contract services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in research and development contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_RepaymentOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_RepaymentOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217586609424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zezPRJOlrOk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_827_zGgFHkCjHt92">Organization and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#8220;Company&#8221;), at March 31, 2023, and for the three months
ended March 31, 2023 and 2022, are unaudited. In the opinion of management of the Company, all adjustments, including normal recurring
accruals, have been made that are necessary to present fairly the financial position of the Company as of March 31, 2023, and the results
of its operations for the three months ended March 31, 2023 and 2022, and its cash flows for the three months ended March 31, 2023 and
2022. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal
year. The consolidated balance sheet at December 31, 2022 has been derived from the Company&#8217;s audited consolidated financial statements
at such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notification of Failure to Satisfy a Continued Listing Rule</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#8220;LIXT&#8221; and &#8220;LIXTW&#8221;,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2022, the Company received a written notice (the &#8220;Notice&#8221;) from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
that the Company had not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a
period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price
of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists
if the deficiency continues for a period of 30 consecutive business days. The Notice had no immediate effect on the listing of the Company&#8217;s
common stock on The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days from the date of
the Notice, or until December 21, 2022, to regain compliance with the minimum closing bid price requirement. On December 22, 2022, the
Company received a written notice from Nasdaq that the Company was eligible for a second 180 calendar day compliance period, or until
June 19, 2023, in order to regain compliance with the $1.00 minimum bid price requirement. Nasdaq&#8217;s determination to grant the
second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares
and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price requirement,
and the Company&#8217;s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse
stock split, if necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company can generally achieve compliance with the minimum closing bid price requirement if the minimum closing bid price of the Company&#8217;s
common stock is at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period. However,
under certain circumstances, Nasdaq can extend this 10-day trading period up to a maximum of 20 days. The Company anticipates that its
shares of common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market during the compliance period ending
June 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to achieve compliance with the minimum closing bid price requirement, the Company filed a proxy statement with the SEC to hold
a special meeting of stockholders on May 26, 2023 to seek stockholder approval to approve an amendment to the Company&#8217;s Certificate
of Incorporation to effect a reverse stock split of the issued and outstanding shares of the Company&#8217;s common stock at a split
ratio of up to a maximum of a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230101__20230331_zHDO1NRZfbLf" title="Reverse stock split">1-for-10</span> split, as determined by the Board of Directors in its sole discretion. However, there can be no
assurance that the Company will be successful in obtaining stockholder approval and will thus be able to regain compliance with the minimum
closing bid price requirement by June 19, 2023, in which case the Company anticipates Nasdaq would provide a notice to the Company that
its shares of common stock and warrants are subject to delisting, and the Company&#8217;s common shares and warrants would then be delisted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the Company is able to achieve compliance with Nasdaq&#8217;s minimum closing bid price requirement, there can be no assurances that
the Company will be able to maintain compliance with Nasdaq&#8217;s other continued listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588150288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business</a></td>
<td class="text"><p id="xdx_801_eus-gaap--NatureOfOperations_ze7bVu1lJb45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_826_zrNbUJFvWJK3">Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#8217;s corporate office is located in Pasadena, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company had cash of $<span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230331_zU28XjQtYbw">4,088,304 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">available
to fund its operations. Because the Company is currently engaged in various early-stage clinical trials, it is expected that it will
take a significant amount of time and resources to develop any product or intellectual property capable of generating sustainable
revenues. Accordingly, the Company&#8217;s business is unlikely to generate any sustainable operating revenues in the next several
years and may never do so. Even if the Company is able to generate revenues through licensing its technology, product sales or other
commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive earnings and
operating cash flows. At March 31, 2023, the Company&#8217;s unpaid remaining contractual commitments pursuant to clinical trial
agreements and clinical trial monitoring agreements aggregated $<span id="xdx_905_eus-gaap--ContractualObligation_iI_pp0p0_c20230331_zwnZkaDMOhL7" title="Contractual commitment">7,900,000</span>, which are currently scheduled to be incurred through
December 31, 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the accompanying interim condensed consolidated financial statements are being issued. The Company&#8217;s
interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#8217;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on current operating plans, the Company estimates that existing cash resources will provide sufficient working capital to fund the current
clinical trial program with respect to the development of the Company&#8217;s lead anti-cancer clinical compound LB-100 through approximately
December 31, 2023. However, existing cash resources will not be sufficient to complete the development of and obtain regulatory approval
for the Company&#8217;s product candidate, as a result of which the Company will need to raise significant additional capital to do so.
The Company estimates that it will need to raise additional capital to fund its operations, including its various clinical trial commitments,
during the latter part of the fiscal year ending December 31, 2023. In addition, the Company&#8217;s operating plans may change as a
result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed sooner
than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
market conditions present uncertainty as to the Company&#8217;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cash resources are insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588084464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zJFVPlsFE1Rb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_823_zSDkOQcpYvU3">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zVvzjHbKeJP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z1zpCyJUVz1h">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgckybU7JRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zF5yg8PBaMIg">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company&#8217;s President,
Chief Executive Officer and Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--UseOfEstimates_zULEafopo5n" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z9mq2q1HzYq9">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBB7K77ynAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_ze77BMUmmZP2">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the
&#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically has cash
balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230331_zvTTGozSmfsg" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_90E_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230331_zHQpiHVDMvXi" title="Cash SIPC insurance">500,000</span>, respectively. Morgan Stanley
Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not experienced
any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNBPSW0tlC8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zDRYAh1EmdGa">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zfhKOyLehoM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zaWragigvy2j">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zmEg5HhImiU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zDlpL0ZqcU0b">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20230101__20230331_zonfydgDVMWl">317,340</span> and $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20220331_zgo8N59zLuTj" title="Patent and licensing legal and filing fees and costs">315,237</span> for the three months ended March 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zwrH3pMfgYac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zxRN2W9DqxN7">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zCZz7vU4SbUa" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zicZbxxY1gv2" title="Concentration of risk, percentage">10</span></span>% or more of general and administrative costs or research and development costs for the three months ended March 31,
2023 and 2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended March 31, 2023 and 2022 included charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMoFDdYcoM0d" title="Concentration risk percentage">26.9</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp95C6OMtNkg" title="Concentration of risk, percentage">29.6</span>% of total
general and administrative costs, respectively. General and administrative costs for the three months ended March 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zjozQ4A5x6Sb" title="Concentration of risk, percentage">23.5</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zobcm3wt8HBe" title="Concentration of risk, percentage">28.4</span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended March 31, 2023 included charges from four vendors and consultants representing <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfirrZb1xwu1" title="Concentration risk percentage">36.5</span>%,
<span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmkSMS1gHTuf" title="Concentrtion percentage risk">27.6</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbe7U3ng7dP" title="Concentrtion percentage risk">15.9</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4ztDZaGzun6" title="Concentration risk percentage">14.4</span>%, respectively, of total research and development costs. Research and development costs for the three months ended
March 31, 2022 included charges from two vendors and consultants representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumRnN3hjtGk" title="Concentration risk percentage">63.8</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrzCEiQcW7ye" title="Concentration risk percentage">11.8</span>%, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zk8Ql8VEDlab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zqNdZ8vhp4hj">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20230331_zOtcYNdMV08d" title="Unrecognized tax benefits"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zcsfv9vEdJi8" title="Unrecognized tax benefits">no</span></span> unrecognized tax benefits as of March 31, 2023 or December
31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of March 31, 2023 or December
31, 2022. Subsequent to March 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaJ3as2kuMCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zQPzBEuyWbd3">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting period
of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ynR6G1NOk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z71GVYS5YNRc">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS, but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zldWyJKMd9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zTcOwuFQCM09" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230331_z9Lo4bnMYCxb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220331_zhZhg32dVbG8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zxKb3SlDe8Ah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">729,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">729,167</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zwO39gcvi396" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,900,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,110,310</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_z3QDuaYoZXDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,882,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,666,667</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqB8SHe3HNrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,511,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,506,144</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z7eA1fAOKw9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zx8zNb5i3uw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zxwt1rHZLexb">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMnGILblZs51" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zeSgDJXT8Xv5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statement presentation or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statement presentation or disclosures.</span></p>

<p id="xdx_854_zEZisUg2vYug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217587984064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Costs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_801_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zstYRAaHetO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82D_zYhjGYinxWXc">Research and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ResearchDevelopmentTableTextBlock_z8to79j4rsWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs, including costs associated with clinical trials involving the Company&#8217;s lead clinical compound LB-100, are
summarized below based on the respective geographical regions where such costs are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zenzdK84yMzl" style="display: none">Schedule
of Research and Development Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230331_zAI64C5cZFmk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220331_zRalxHNAElXd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zwaz8jWePPS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">135,907</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">74,531</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zEzaUW8bJ6F4" style="vertical-align: bottom; background-color: White">
    <td>Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,829</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zWoMuWvwIlIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">860</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z875TLv8VRYg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Netherlands</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_z0FW5y57kI5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">189,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_zHdW40dlmvJc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Research and development expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">189,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A7_zW7MnqNoBoe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588003440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z2sPVG6ul9sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82B_zKdZtjPVadK7">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230331_zNnqwhHJt3Xa" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230331_zvY7gs7W6y83" title="Preferred stock, par value">0.0001</span> per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#8217;s certificate of incorporation. The Company has designated a total of <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUibnSNBah6l" title="Preferred stock, shares authorized">350,000</span> shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of <span id="xdx_901_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUIp53vnp2o3" title="Principal Cash Obligations and Commitments">175,000</span> shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to <span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5ECfpZGE9s8" title="Preferred stock dividend, percentage">1</span>% of the annual net revenue of the Company divided by <span id="xdx_906_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zA19qPj4lgXk" title="Annual net revenue">175,000</span>, until converted or redeemed. As of March 31, 2023 and December 31,
2022, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zWAaGJRBnEv2" title="Preferred stock, shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zkivoHpRPzYf" title="Preferred stock, shares authorized">9,650,000</span></span> shares of undesignated preferred stock which may be issued with such rights and powers as the Board of
Directors may designate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3D6cgV8W529" title="Preferred stock, conversion description">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pp4d_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zldrTKtXjoF4" title="Preferred stock convertible into common stock">2.0833</span> shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zGV5RQdt3V6" title="Gross proceeds from sale of transaction">21,875,000</span></span>. The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have a cash liquidation preference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
fully converted, the <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zDYQFr2HmJ88" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zXCjOsD5QM17" title="Preferred stock, shares outstanding">350,000</span></span> outstanding shares of Series A Convertible Preferred Stock would convert into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zSb94vYXBaN7" title="Preferred stock convertible into common stock"><span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zf0d4pg74ywa" title="Preferred stock convertible into common stock">729,167</span></span> shares of common stock
at March 31, 2023 and December 31, 2022. The Series A Convertible Preferred Stock has no right to cash, except with respect to the payment
of the aforementioned dividend based on the generation of revenues by the Company. The shares of Series A Convertible Preferred Stock
do not have any registration rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue a total of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230331_ziaEH8adCnu3" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zJNHvDwDao42" title="Common stock, shares authorized">100,000,000</span></span> shares of common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230331_z8rKObCphKkb" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zuppRRCLACab" title="Common Stock, Par or Stated Value Per Share">0.0001</span></span> per share. As of March 31, 2023 and December
31, 2022, the Company had <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20230331_zeXWL6eLw9a6" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230331_zHMLLAG5qGEg" title="Common stock, shares outstanding">16,659,093</span></span> shares and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_ziTbsV210921" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zjMKKCwvPaYl" title="Common stock, shares outstanding">16,646,593</span></span> shares, respectively, of common stock issued, issuable and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 12, 2022, the Company completed the sale of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfR2tSuTIhx4" title="Number of common stock shares issued during period">2,900,000</span> shares of common stock at a price of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR9EQyFxQE9g" title="Sale of stock price per share">2.00</span> per share in a registered direct
equity offering, generating gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaVfzQ4yMnZ4" title="Proceeds from issuance initial public offering">5,800,000</span>. The total cash costs of this offering were $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaXtp37xZGC7" title="Costs of public offering">658,616</span>, resulting in net proceeds
of $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGp5TyHmXEof" title="Net proceeds from issuance of stock">5,141,384</span>. Pursuant to the placement agents&#8217; agreement, the Company granted warrants to the placement agents to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zOT9jawiuzJ4" title="Warrants to purchase shares">290,000</span>
shares of common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_z0bMeQ79mE9d" title="Warrant exercise price">2.00</span> per share exercisable through April 14, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 10, 2023, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHAR58ibB2k9" title="Stock issued new issue shares">12,500</span> shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5owQ7manCc" title="Stock issued new issue shares">12,500</span> shares exercisable at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJK2NBygq5pc" title="Warrant exercise price">0.5025</span> per share for total cash proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUlbKA53cRG4" title="Proceeds from warrant exercises">6,281</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zWHHRASppmL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity during the three months ended March 31, 2023 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z5FIK2ZOXcC1" style="display: none">Schedule of Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYBpF6OJPfz3" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">1,900,310</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfahfJ3pFEL9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">5.016</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdAlOraAAbKe" style="text-align: right" title="Number of Shares, Issued"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwJXs97qiP8k" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTdN3OT879F5" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSdQ13mDDSi1" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwPl9OGmQZ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBiCZ64EhOJ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za0FKoVFjKN" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">1,900,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zuRoGWSoKVg6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">5.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYRR0XXV66lc" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">2.90</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbABWHjuhHSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Beginning Balance">1,900,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQl2PspOuIf6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance">5.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRx9ObsZhHMl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Ending Balance">1,900,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqozfabtLFEj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance">5.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqam0IIlwgQe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">2.90</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zqkvD14OM1Yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zgsX0KiSJiUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zErVmRl0DmTk" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXDiEWWp4yM9" title="Exercise Prices">2.000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyF6tCGQ5dBg" style="width: 47%; text-align: right" title="Warrants Outstanding Shares">290,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zTGcmYyiPujg" title="Exercise Prices">3.700</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3zC5HO0yIn4" style="text-align: right" title="Warrants Outstanding Shares">113,310</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFdwUhI9DUu3" title="Exercise Prices">5.700</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVDS5dzBbnb6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares">1,497,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331_zWpd06WveR0i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares">1,900,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zqr4CMNFqcY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a fair market value of $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zZu15BQk7cpk" title="Fair market value of stock">0.83</span> per share on March 31, 2023, there was no intrinsic value attributed to exercisable but unexercised common
stock warrants at March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588094224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z0jjqBsyvcOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82D_zYDN9y9cspp9">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
party transactions include transactions with the Company&#8217;s officers, directors and affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. The employment agreements
are automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to the
end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically renewed
for additional one-year periods in July and August 2021 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, for Dr. Kovach to continue
to act as the Company&#8217;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $<span id="xdx_901_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_z6LbMc8Fflfe" title="Annual salary">250,000</span>. During
the three months ended March 31, 2023 and 2022, the Company paid $<span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_ziWoGf2Z3qH6" title="Compensation">62,500</span> and $<span id="xdx_903_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zk5EtyKoMmSj" title="Compensation">62,500</span>, respectively, to Dr. Kovach under this employment
agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#8217;s Chief
Medical Officer, with an annual salary of $<span id="xdx_90B_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zQTpBpFGf1pj" title="Annual salary">150,000</span>. Effective May 1, 2021, Dr. Miser&#8217;s annual salary was increased to $<span id="xdx_903_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zO3EvcOw4k7d" title="Increase in annual salary">175,000</span>.
Dr. Miser is required to devote at least 50% of his business time to the Company&#8217;s activities. During the three months ended March
31, 2023 and 2022, the Company paid $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z85oM0dccP1j" title="Compensation">43,750</span> and $<span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z2YK0jDd9Xn5" title="Compensation">43,750</span>, respectively, to Dr. Miser under this employment agreement, which costs are
included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#8217;s Chief Administrative Officer, with an annual salary of $<span id="xdx_903_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zGtLO6XrAsli" title="Annual salary">120,000</span>. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#8217;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#8217;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#8217;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#8217;s
annual salary was increased to $<span id="xdx_900_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zSIJDbG7aiFh" title="Increase in annual salary">175,000</span>. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $<span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_ztlOJZmf1Tu6" title="Compensation"><span title="Compensation">200,000</span></span>. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which Mr. Forman was paid $<span id="xdx_908_eus-gaap--PaymentsForRent_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FormanMember_zoXprCaTEeu7" title="Paid office rent">2,583</span> for the three months ended March 31, 2023. During the three months ended March 31, 2023
and 2022, the Company paid $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zKfRL2lzgKC8" title="Compensation">50,000</span> and $<span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zNoZ9E6dUgJ5" title="Compensation">43,750</span>, respectively, to Mr. Forman under this employment agreement, which costs are included
in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#8217;s Vice President
and Chief Financial Officer, with an annual salary of $<span id="xdx_907_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zlGX31nkGZ85" title="Annual salary">120,000</span>. Effective May 1, 2021, Mr. Weingarten&#8217;s annual salary was increased
to $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zIfZSsN4jhxa" title="Increase in annual salary">175,000</span>. During the three months ended March 31, 2023 and 2022, the Company paid $<span id="xdx_909_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zeaY7sMG6He9" title="Compensation">43,750</span> and $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zEF5Ov0zQ0R1" title="Compensation">43,750</span>, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#8217;s consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Appointment
of Dr. Ren&#233; Bernards to the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&#233; Bernards was appointed to the Company&#8217;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $<span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20220615_z14zKa8Uw9La" title="Cash board fee payable">100,000</span>, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $<span id="xdx_902_ecustom--ManagementFeePayableQuarterly_iI_c20220615_zu0trpnAIT6g" title="Cash board fee payable">40,000</span>, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2021, the Company has previously entered into a Development Collaboration Agreement with the Netherlands Cancer Institute,
Amsterdam, one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research
center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range
of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations, as described at Note 9.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensatory
Arrangements for Members of the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the independent members of the
Board of Directors and committee members. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
compensation for independent directors, payable quarterly, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
director compensation - $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zmeY5lCzWo8d" title="Compensation">20,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of audit committee - additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zhvXfEl7bgV1" title="Compensation">10,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
of any other committees - additional $<span id="xdx_90B_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zjM64qZpMoh5" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of audit committee - additional $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zpPYMt9v5wr3" title="Compensation">5,000</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
of any other committees - additional $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zfNZcItlRmlj" title="Compensation">2,500</span> per year</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
compensation for independent directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
of new independent directors - The Company will grant options to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zuNKM3trb88b" title="Options, grants in period, gross">250,000</span> shares of common stock, exercisable for a period of
five years, at the closing market price on the date of grant, vesting <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zRScVYoFZdB9" title="Share-based payment award, award vesting period">50</span>% on the grant date and the remaining <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zR5JvlkEazy2" title="Share-based payment award, award vesting period">50</span>% vesting <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230331_z1k5g1cBMfSb" title="Award vesting rights, percentage">12.5</span>% on the
last day of each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject
to continued service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their
respective institution or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company
may elect to pay a one-time cash fee of $<span id="xdx_90E_eus-gaap--CostOfRevenue_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z7xZheQFScV4" title="One time cash">100,000</span> to such director, payable upfront.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
grant of options to independent directors - Effective on the last business day of the month of June, the Company will grant options to
purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_z6M5CGhtMYP7" title="Options, grants in period, gross">100,000</span> shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting
<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zI7SoEkzOfD1" title="Share-based payment award, award vesting period">12.5</span>% on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested,
subject to continued service. If any director has served for less than 12 full calendar months at the grant date, the amount of such
stock option grant shall be prorated based on the length of service of such director. At the discretion of the Board of Directors, for
a nominee to the Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation,
in lieu of the grant of such stock options, the Company may elect to pay an annual cash fee of $<span id="xdx_905_eus-gaap--CostOfRevenue_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z8mCU1XvDv2g" title="Annual cash fee">40,000</span> to such director, payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
cash compensation paid to independent directors was $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zFQYNl4gmim" title="Stock based compensation">42,500</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zwxvYeq51GPl" title="Stock based compensation">32,500</span>, respectively, for the three months ended March 31, 2023 and
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation granted to members of the Company&#8217;s Board of Directors, officers and affiliates is described at Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zIaapNhijKDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months ended March 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zGq9IBIsvPSd" style="display: none">Summary of Related Party Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20230331_zrPvHzzbK4n2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zoenYFrgw2lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--CashBasedMember_zhqsl2hIf9Ql" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">242,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">226,250</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--StockBasedMember_zIvvdDw3Uiml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">276,980</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">339,672</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_zVPx2m1zwnb2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">519,480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">565,922</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_zLVSWL4Be6M2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Related party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">519,480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">565,922</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A2_zygDuHHkbNS6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588083648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zlx85rSHZnFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82B_z8QWitmOLsRl">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zqsGmZmFaZR4" title="Number of restricted stock issued">2,333,333</span> shares of the Company&#8217;s common stock, under terms
and conditions as determined by the Company&#8217;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zd0Fcox30a17" title="Common shares avaliable for issuable">1,800,000</span> shares, to a total of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zkv3MXQmhtR6" title="Shares total">4,133,333</span>
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, unexpired stock options for <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zwUO0BeNqqW1" title="Shares outstanding">2,603,125</span> shares were issued and outstanding under the 2020 Plan and <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWPVtAljTKfe" title="Shares were available for issuance">1,530,208</span> shares
were available for issuance under the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#8217;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#8220;simplified method&#8221;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options requiring an assessment of value issued during the three months ended March 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zLTxKhMnGe66" title="Stock options description">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zlGbwraY7wR2" title="Stock options granted to purchase common stock, issued">58,333</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxL_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsbhhFkNX5hc" title="Stock option vested exercisable term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0701">five</span></span> years at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4itUxTf3ZEi" title="Stock options are exercisable price per share">7.14</span> per share, which was equal to the closing market
price of the Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90C_ecustom--FairValueOfStockOptions_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zj3y8XijbpV2" title="Fair value of stock options">400,855</span> ($<span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4DZdMErs893" title="Stock price per share">6.8718</span> per share), of which $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z40vRAub5I0a" title="Stock options fully vested amount, fair value">100,214</span> was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zikYZ5776hU1" title="Stock based compensation">24,710</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0elXYAyT83e" title="Stock based compensation">24,710</span>, respectively, with respect to these stock options</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2020, in connection with an employment agreement entered into with <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8t4ey3Gs745" title="Stock options description">Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgiC3QBpGR1g" title="Stock options granted to purchase common stock, issued">83,334</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of five years at an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zqOuXVFQaYH8" title="Stock options are exercisable price per share">7.14</span> per share, which was equal to the closing market price of the Company&#8217;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zo3V6BkEwHG5" title="Fair value of stock options">572,650</span> ($<span id="xdx_905_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zhNjUAEO79vg" title="Stock price per share">6.8718</span> per share), of which $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zlinjwNgPBb6" title="Stock options fully vested amount, fair value">143,163</span> was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8IzHyUH93K7" title="Stock based compensation">35,300</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRf5njdLExFf" title="Stock based compensation">35,300</span>, respectively, with respect to these stock options</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zBB3FWsB1Jk9" title="Stock options description">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zt2BMBhQmeB1" title="Stock options granted to purchase common stock, issued">58,333</span> shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of five years at an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVCYsW7Uhfzc" title="Stock options are exercisable price per share">7.14</span> per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $<span id="xdx_90F_ecustom--FairValueOfStockOptions_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zT6QqmTpiKLa" title="Fair value of stock options">400,855</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3XicVaSMw2b" title="Stock price per share">6.8718</span> per share), of which $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_za9nLHTwfxah" title="Stock options fully vested amount, fair value">100,214</span> was attributable to the portion of the stock
options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair
value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months
ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations
of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zErm9K9REoHc" title="Stock based compensation">24,710</span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zdcf9cJX18Ak" title="Stock based compensation">24,710</span>, respectively, with respect to these stock options</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zrvmRZBOvdZ2" title="Stock options description">the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#8217;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zWylQPsf99d" title="Number of fully vested option exercisable">250,000</span> shares of the Company&#8217;s
common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zAWO1g2FcVo2" title="Stock options are exercisable price per share">3.20</span> per share (the closing market price on the grant date),
vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_906_ecustom--FairValueOfStockOptions_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zc6kHvPMLcB6" title="Fair value of stock options">753,611</span> ($<span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z8VDv2m48mg1" title="Stock price per share">3.0144</span> per share), of which $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjk2FIIFMn56" title="Stock options fully vested amount, fair value">376,800</span> was attributable to the portion of the stock options fully vested
on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock
options was being charged to operations ratably from April 9, 2021 through June 30, 2023. However, vesting of these stock options terminated
on October 30, 2022, the date that Mr. Schwartzberg died. During the three months ended March 31, 2023 and 2022, the Company recorded
charges to general and administrative costs in the consolidated statement of operations of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zRD6RHW7oJCd" title="Stock based compensation">0</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zuciQZy1fcd" title="Stock based compensation">41,764</span>, respectively, with respect
to these stock options</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 11, 2021, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zad7V0JUW1ni" title="Stock options description">the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zkOHzOPHoWZb" title="Number of fully vested option exercisable">250,000</span> shares of the Company&#8217;s common stock, exercisable for a period of five
years at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zqf2w4989oV3" title="Stock options are exercisable price per share">2.80</span> per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90C_ecustom--FairValueOfStockOptions_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zp3ZJuW6vHp" title="Fair value of stock options">658,363</span> ($<span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z5nwp5fFizVe" title="Stock price per share">2.6335</span> per
share), of which $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zMhT266vInO" title="Stock options fully vested amount, fair value">329,188</span> was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from May 11, 2021 through June 30, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7IexJmAmKN1" title="Stock based compensation">37,983</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zPVSljrJX9Ni" title="Stock based compensation">37,983</span>, respectively, with respect to these stock
options</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2021, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zI6p2Y2OysFb" title="Stock options description">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOueVA0wQ0ai" title="Number of fully vested option exercisable">100,000</span> shares (a total
of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zFbzYnPfXfOb" title="Number of fully vested option exercisable">500,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOXEiP2BSIt8" title="Stock options are exercisable price per share">3.03</span> per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90C_ecustom--FairValueOfStockOptions_c20210601__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z9K19CeHR6xa" title="Fair value of stock options">1,421,095</span> ($<span id="xdx_902_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z5Ohjr1O2Tpc" title="Stock price per share">2.84225</span> per share), which is being charged to operations ratably from July 1, 2021 through June 30,
2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the
consolidated statement of operations of $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zrYAhUOntEn8" title="Stock based compensation">105,123</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zKgMTJmcnpP" title="Stock based compensation">175,205</span>, respectively, with respect to these stock options</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2022, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_ztcIETdO0ZXf" title="Stock options description">the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zCXEfeY4t0l4" title="Number of fully vested option exercisable">250,000</span> shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zNSvzku9Wr41" title="Stock options are exercisable price per share">0.74</span> per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $<span id="xdx_90B_ecustom--FairValueOfStockOptions_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zNxgZpx8zQOg" title="Fair value of stock options">158,525</span> ($<span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zLo2xH6GIDK6" title="Stock price per share">0.6341</span> per
share), of which $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zOHi15HNMCX3" title="Stock options granted to purchase common stock, issued">79,263</span> was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from June 17, 2022 through June 30, 2024. During the three months ended March 31, 2023, the Company recorded a total charge to general
and administrative costs in the consolidated statement of operations of $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z1W12hLGNXo6" title="Stock based compensation">9,588</span> with respect to these stock options</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220601__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_z7LBvkZ1DYpb" title="Stock options description">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220602__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_z9e73flIIqfc" title="Purchase of shares">100,000</span> shares (a total
of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zd7v5tMI1yn1" title="Number of fully vested option exercisable">500,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zQEanGW1Zgnk" title="Stock options are exercisable price per share">0.74</span> per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $<span id="xdx_90E_ecustom--FairValueOfStockOptions_c20220601__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zy5GNVxYWvL4" title="Fair value of stock options">316,700</span> ($<span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zgmO8srEOh1h" title="Stock price per share">0.6334</span> per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
During the three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated
statement of operations of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__srt--DirectorMember_z0UUw35na8ee" title="Stock based compensation">23,394</span> with respect to these stock options</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zJpyxciYa1Uj" title="Number of fully vested option exercisable">200,000</span> shares
(a total of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zYp1VHeTP13l" title="Number of fully vested option exercisable">800,000</span> shares) of the Company&#8217;s common stock, exercisable for a period of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxL_c20221106__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zKW4qRcL13wa" title="Stock option vested exercisable term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0827">five</span></span> years at an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zY2Bkw1ZDt87" title="Share price">2.00</span>
per share, vesting <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNZX3C3ZcIPc" title="Share based compensation vesting rights, percentage">25</span>% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service. The
total fair value of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zdtVs9fc8Eng" title="Stock options granted to purchase common stock, issued">800,000</span> stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$<span id="xdx_90E_ecustom--FairValueOfStockOptions_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zkgaTrPCwE0c" title="Fair value of stock options">262,560</span> ($<span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zd5pRXQK47mk" title="Stock price per share">0.3282</span> per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated statement
of operations of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z4cvNTG6jTEi" title="Stock based compensation">16,172</span> with respect to these stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106_zcYl0u0JQlsk" title="Number of fully vested option exercisable">100,000</span> shares of the Company&#8217;s
common stock, which was fully vested upon issuance and is exercisable for a period of five years at $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zVol09Nf1Mck" title="Stock options are exercisable price per share">0.5025</span> per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $<span id="xdx_908_ecustom--FairValueOfStockOptions_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zTfkB7YQ5FPk" title="Fair value of stock options">43,264</span> ($<span id="xdx_90C_eus-gaap--SharePrice_iI_pp5d_c20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zowLfN7cmHWg" title="Stock price per share">0.4326</span> per share) and was charged to general and administrative costs in the consolidated statement of operations on
that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#8217;s Board of Directors at the
Company&#8217;s Annual Meeting of Stockholders held on October 7, 2022, and Gil Schwartzberg, a director of the Company, died on October
30, 2022. Accordingly, the unvested stock options for each such person ceased vesting effective as of the respective dates that their
service on the Company&#8217;s Board of Directors terminated. Furthermore, the expiration date of all vested stock options owned by such
persons are contractually scheduled to expire one year from the respective dates that their service on the Company&#8217;s Board of Directors
terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zUkPbHeRX7Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months ended March 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zuBc1L43seP" style="display: none">Summary of Stock-based Compensation Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230331_zSZh7j0mzpU4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220331_zeIGOCKaCUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zuFEZ9VFZ4Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">276,980</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">339,672</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zPBmOzJM8fld" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_zqzNOapDc172" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">276,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339,672</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zO4kBW9JbnM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFbHoJbCUcD" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_zC1BLKG8RLVh" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331_zI3VBGN0CW9g" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning">3,894,792</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zI5mFDwxoStb" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">2.9183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230331_zJxWLckPa9el" style="text-align: right" title="Number of shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0866">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_z9c0e6id6qMa" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230331_z4bwHDiRcvJg" style="text-align: right" title="Number of shares, Exercised">(12,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zN72wDcIDXh7" style="text-align: right" title="Weighted average exercise price, exercised">0.5025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230331_z0VhiFm81I23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zWGHOq5LjYh8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl0876">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230331_zwEr2wT4jSKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end">3,882,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zkiMipGUeKjc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">2.9260</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zYXAUwcsWQja" title="Weighted average remaining contractual life (in years), stock options outstanding">2.79</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCQIPksNcUE" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end">2,819,792</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z61mfmRsYcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end">3.2834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230331_z6HQldkB2dr" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end">2,913,542</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230331_zHj7mjfQG6x" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end">3.2431</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_z3TJtDZ276N8" title="Weighted average remaining contractual life (in years), stock options exercisable">2.28</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zWVnpF1wKIFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $<span id="xdx_902_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20230331_zIV4eIrlg2jf" title="Total deferred compensation expense for outstanding value of unvested stock options">605,000</span> at March 31, 2023, which
will be recognized subsequent to March 31, 2023 over a weighted-average period of approximately <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20230331_zDxF02tpXrm6" title="Stock option vested exercisable term">15</span> months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z8Zbvsm0pQDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at March 31, 2023
are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zzNX2AxBd5o8" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zIt0gX5Bwdr2" style="width: 30%; text-align: right" title="Exercise Prices">0.5025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zkbYvjymyPB1" style="width: 30%; text-align: right" title="Options Outstanding (Shares)">87,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zO9kuVSjLadl" style="width: 30%; text-align: right" title="Options Exercisable (Shares)">87,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztpLw5PBn4X9" style="text-align: right" title="Exercise Prices">0.7400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zvyxXN8Whpvg" style="text-align: right" title="Options Outstanding (Shares)">575,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxmNYagyKaq3" style="text-align: right" title="Options Exercisable (Shares)">309,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zClDDRQs6NV2" style="text-align: right" title="Exercise Prices">1.6800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmpFB26ywZpk" style="text-align: right" title="Options Outstanding (Shares)">33,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zI9bxUmLn6A5" style="text-align: right" title="Options Exercisable (Shares)">33,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zBv0FSJ1oCw9" style="text-align: right" title="Exercise Prices">2.0000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zooXVbWkFGBj" style="text-align: right" title="Options Outstanding (Shares)">800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zIr6vOixStH" style="text-align: right" title="Options Exercisable (Shares)">200,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zgNhR6kwcRKg" style="text-align: right" title="Exercise Prices">2.0600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuzOZz9BuKF9" style="text-align: right" title="Options Outstanding (Shares)">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7DSWOFTHca" style="text-align: right" title="Options Exercisable (Shares)">200,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zgYzBlBZvaq6" style="text-align: right" title="Exercise Prices">2.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zguXgay8hEa8" style="text-align: right" title="Options Outstanding (Shares)">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztLIUhhVhDFc" style="text-align: right" title="Options Exercisable (Shares)">234,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zSuxmGK9nMQ7" style="text-align: right" title="Exercise Prices">3.0000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWRSacMmGvV2" style="text-align: right" title="Options Outstanding (Shares)">666,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXHT8PLGZtd4" style="text-align: right" title="Options Exercisable (Shares)">666,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zR5GUdjSw1t2" style="text-align: right" title="Exercise Prices">3.0300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJkGCAYecpWa" style="text-align: right" title="Options Outstanding (Shares)">425,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zXMtIq5inzi7" style="text-align: right" title="Options Exercisable (Shares)">387,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z87ELwmJPxWh" style="text-align: right" title="Exercise Prices">3.2000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_znFYhgeqSkWg" style="text-align: right" title="Options Outstanding (Shares)">203,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zKQV6zJri1N2" style="text-align: right" title="Options Exercisable (Shares)">203,125</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMtmv8ArPDa" style="text-align: right" title="Exercise Prices">3.2100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z8WWZkHqOjqj" style="text-align: right" title="Options Outstanding (Shares)">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z6f7uZNKweo8" style="text-align: right" title="Options Exercisable (Shares)">150,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zq9fHiMX3wY5" style="text-align: right" title="Exercise Prices">6.0000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zLBvxdQ2qHcj" style="text-align: right" title="Options Outstanding (Shares)">166,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zu7lbE10h0Ad" style="text-align: right" title="Options Exercisable (Shares)">166,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zt1IzT7CU0Zc" style="text-align: right" title="Exercise Prices">6.6000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zBy6oHJCDvs2" style="text-align: right" title="Options Outstanding (Shares)">41,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zM79bdnAnJ9j" style="text-align: right" title="Options Exercisable (Shares)">41,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwYWnoEjoUp1" style="text-align: right" title="Exercise Prices">7.1400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zhXAHeT12fy" style="text-align: right" title="Options Outstanding (Shares)">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z70h0X14xT58" style="text-align: right" title="Options Exercisable (Shares)">150,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zubRnZBLyXu4" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices">12.0000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z427t7cWs6U3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)">83,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPRX2edysUp1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)">83,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,882,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331_zZN7lnr5V0kk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)">2,913,542</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_znbkrW7VZ6ll" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of exercisable but unexercised in-the-money stock options at March 31, 2023 was approximately $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20230331_znqCdrVy3NOj" title="Intrinsic value of exercisable but unexercised in-the-money stock options">56,500</span>, based on a fair
market value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20230331_znioS8RrAiag" title="Fair market value, per share">0.83</span> per share on March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
stock options to acquire <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20230331_zfAoknifgeLa" title="Outstanding stock options to acquire shares of common stock not vested">968,750</span> shares of the Company&#8217;s common stock had not vested at March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588086128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zWMGNo1W8oQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_82A_zy0kSECwz3Dd">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company did not record any provision for income taxes as the Company incurred losses
during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount
of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has recorded a full
valuation allowance against its deferred tax assets for all periods presented as the Company believes it is more likely than not the
deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588029968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIqhr8JbhDm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_825_zXPqc4ca75w7">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Claims</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of March 31, 2023 and December
31, 2022, the Company was not subject to any pending or threatened legal claims or actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company&#8217;s unpaid remaining contractual commitments pursuant to clinical trial agreements and
clinical trial monitoring agreements, as described below, aggregated $<span id="xdx_90B_eus-gaap--ContractualObligation_iI_c20230331_zvFayusOmba3" title="Contractual commitment">7,900,000</span>,
which are currently scheduled to be incurred through December 31, 2025. The Company&#8217;s ability to conduct and fund these
contractual commitments is subject to the timely availability of sufficient capital to fund such expenditures, as well as any
changes in the allocation or reallocation of such funds to the Company&#8217;s current or future clinical trial programs. The
Company expects that the full amount of these expenditures will be incurred only if such clinical trial programs are conducted as
originally designed and their respective enrollments and duration are not modified or reduced. Clinical trial programs, such as the
types that the Company is engaged in, can be highly variable and can frequently involve a series of changes and modifications over
time as clinical data is obtained and analyzed, and are frequently modified, suspended or terminated before the clinical trial
endpoint. Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current
clinical assumptions and conditions, and are typically subject to significant revisions over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida, effective for a term of five years, unless terminated earlier by the Company pursuant to 30
days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial
to evaluate the therapeutic benefit of the Company&#8217;s lead anti-cancer clinical compound LB-100 to be administered intravenously
in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application
(&#8220;IND&#8221;) to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of LB-100 in patients with low and intermediate-1
risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except
for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilizes LB-100 as a single agent in the treatment
of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line
therapy. The bone marrow cells of patients with del5qMDS are deficient in PP2A by virtue of an acquired mutation and are especially vulnerable
to further inhibition of PP2A by LB-100. The clinical trial began at a single site in April 2019 and the first patient was entered into
the clinical trial in July 2019. A total enrollment of 41 patients is planned. An interim analysis will be done after the first 21 patients
are entered. If there are 3 or more responders but fewer than 7, an additional 20 patients will be entered. If at any point there are
7 or more responders, this will be sufficient evidence to support continued development of LB-100 for the treatment of low and intermediate-1
risk MDS. Recruitment has been slow and the Covid-19 pandemic has further reduced recruitment of patients into the protocol. At the current
rate of accrual, the clinical trial is expected to be completed by June 30, 2025. However, with additional funds, the Company would consider
adding two additional MDS centers to the Phase 2 portion of the study to accelerate patient accrual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zZCZK3IPmuyb" title="Advance amount related to milestone payment">6,000</span> and $<span id="xdx_90E_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z4XJOgNO9yea" title="Advance amount related to milestone payment">3,332</span>, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March
31, 2023, total costs of $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zjfxH5kupvu8" title="Research and development costs">137,074</span> have been incurred pursuant to this agreement. <span id="xdx_903_eus-gaap--OtherCommitmentsDescription_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zcDayiVBFC5e" title="Aggregate commitments expected, description">The Company&#8217;s aggregate commitment pursuant to
this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_906_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z0tlZzGxLIU2" title="Aggregate commitments expected">575,000</span> as of March 31, 2023, which is expected to be incurred
through December 31, 2025</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GEIS.
</b>Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#241;ol de Investigaci&#243;n en Sarcomas or &#8220;GEIS&#8221;), Madrid, Spain, to carry out a
study entitled &#8220;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#8221;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#8220;ASTS&#8221;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival
(PFS, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS
of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression
or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required
for final analysis is reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#8217;s existing LB-100 inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--OtherClinicalAgreementsMember_zRpBkw5pl514" title="Research and development costs">1,144,000</span>. While the production of new inventory has
been completed, nominal amounts of trailing costs are expected to be incurred during the year ending December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#241;ola de Medicamentos
y Productos Sanitarios or &#8220;AEMPS&#8221;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#8217;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, the GEIS clinical trial is currently scheduled to commence during the quarter ending June 30, 2023 and to be completed
by December 31, 2025. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#243;n
Jim&#233;nez D&#237;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The Phase 1b section
of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on both response and toxicity
from this portion of the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
Through March 31, 2023, the Company has paid GEIS an aggregate of $<span id="xdx_90D_ecustom--AmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z6silH3m84G8" title="Amount related to milestone payment">415,823</span> for work done under this agreement through the third milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. Such costs, when incurred,
are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March 31, 2023, total
costs of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z0vSFGxU8Ee9" title="Research and development costs">415,823</span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $<span id="xdx_904_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zvQGUdIN1oNh" title="Aggregate commitments expected">3,792,000</span> as of March 31, 2023, which is expected to be incurred through
December 31, 2025. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations
between the United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign
currency gain or loss, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#8220;City of Hope&#8221;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#8217;s first-in-class protein phosphatase inhibitor, combined with a standard
regimen for treatment of untreated extensive- stage disease small cell lung cancer (ED-SCLC). LB-100 will be given in combination with
carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously untreated ED-SCLC patients.
The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (RP2D).
Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the safety of the LB-100 combination
and to look for potential therapeutic activity as assessed by objective response rate, duration of overall response, progression-free-survival
and overall survival.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add two additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, joined the City of Hope&#8217;s ongoing Phase
1b clinical trial. The Company is continuing its efforts to add a third site. The addition of SCRI is expected to expedite and expand
the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability and efficacy
of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company expects that this clinical trial will
be completed by December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_znIuv3ZWtK3" title="Research and development expense">69,001</span> and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z95vrSSdqXZ2" title="Research and development expense">0</span>, respectively, pursuant to this agreement,
which are included in research and development costs in the Company&#8217;s consolidated statements of operations. As of March 31, 2023,
total costs of $<span id="xdx_909_eus-gaap--DeferredCosts_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zhSJuoqMJq5b" title="Total costs">447,512</span> have been incurred pursuant to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $<span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zN4X1W8vrpSj" title="Aggregate commitments expected">2,433,000</span> as of March 31, 2023, which is expected to be incurred through
December 31, 2024. If a significant number of patients fail during the dose-escalation process, an increase of up to 12 patients would
likely be necessary, at an estimated additional cost of approximately $<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z2dO8V88muv7" title="Aggregate commitments expected">800,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>National
Cancer Institute Pharmacologic Clinical Trial. </b>In May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic
clinical trial. This study is being conducted and funded by the NCI under a Cooperative Research and Development Agreement, with the
Company being required to provide the LB-100 clinical compound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#8217;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain is not known. Unfortunately,
many drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study is designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove one
or more tumors will receive one dose of LB-100 prior to surgery and have blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors show the biochemical changes expected to be present if LB-100 reaches its molecular
target. As a result of the innovative design of the NCI study, data from a few patients should be sufficient to provide a sound rationale
for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment regimen for GBMs. Five
patients have been entered and analysis of the blood and tissue will now proceed. If there is evidence in at least two of the patients
of penetration of LB 100 into tumor tissue, the study will be deemed as successful. Results of this study are currently being reviewed
by NCI and a report is expected by June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trial Monitoring Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>On September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc. (&#8220;Theradex&#8221;), an international
contract research organization (&#8220;CRO&#8221;), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019. At the current rate of
accrual, the clinical trial is expected to be completed by June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
under this work order agreement are estimated to be approximately $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20180910__20180912__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zt1udJ4abCR8" title="Research and development costs">954,000</span>, with such payments expected to be allocated approximately
94% to Theradex for services and approximately 6% for payments for pass-through costs. The costs of the Phase 1b/2 clinical trial being
paid to or through Theradex are being recorded and charged to operations based on periodic documentation provided by the CRO. During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9kiArgfFVQc" title="Research and development costs">9,287</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9nW8v9qP8Zk" title="Research and development costs">3,281</span>, respectively, and as of March 31, 2023,
total costs of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zMWQLYxPIMek" title="Research and development costs">136,575</span> have been incurred. The Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously
paid to date, totaled approximately $<span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zIsQDJnprjT7" title="Aggregate commitments expected">826,000</span> as of March 31, 2023, which is expected to be incurred through June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>City
of Hope. </b>On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zhJJFVUpoYv3" title="Research and development costs">335,000</span>. During the three months ended March 31, 2023 and 2022, the Company incurred
costs of $<span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zLiQjtVNBYLh" title="Advance amount related to milestone payment">5,553</span> and $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zvZyeq9WD866" title="Advance amount related to milestone payment">4,500</span>, respectively, and as of March 31, 2023, total costs of $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_pp0p0_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zDBYcR1gVe24" title="Aggregate commitments expected">63,994</span> have been incurred. The Company&#8217;s aggregate
commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $<span id="xdx_900_eus-gaap--OtherCommitment_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zQhOqz4F5PT5" title="Aggregate commitments expected">273,000</span> as of March 31, 2023, which
is expected to be incurred through June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
and License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moffitt.
</b>Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#8220;Licensed Patents&#8221;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $<span id="xdx_90F_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zEXYnfz8iRp6" title="Non refundable license issue fee">25,000</span> after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company is also obligated to pay Moffitt an annual license
maintenance fee of $<span id="xdx_90F_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zwNxECXRbpkf" title="Maintenance fee">25,000</span> commencing on the first anniversary of the Effective Date and every anniversary thereafter until the Company
commences payment of minimum royalty payments. The Company has also agreed to pay non-refundable milestone payments to Moffitt, which
cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones aggregating
$<span id="xdx_908_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zgREugkczKsb" title="Payment on non refundable milestone">1,897,000</span>, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in
the License Agreement. During the three months ended March 31, 2023 and 2022, the Company recorded charges to operations of $<span id="xdx_906_eus-gaap--OperatingCostsAndExpenses_c20230101__20230331__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zk1uIhSK4Zf1" title="Operating costs and expenses">6,165</span> and
$<span id="xdx_902_eus-gaap--OperatingCostsAndExpenses_c20220101__20220331__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsmWPcFPAcq2" title="Operating costs and expenses">6,165</span>, respectively, in connection with its obligations under the License Agreement. As of March 31, 2023, no milestones had yet been
attained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject
to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $<span id="xdx_90A_eus-gaap--PaymentsForRoyalties_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__us-gaap--VestingAxis__custom--FirstFourYearsMember_zBUAbOZGmk05" title="Minimum payments for royalties">50,000</span> in the first four years
after sales commence, and $<span id="xdx_908_eus-gaap--PaymentsForRoyalties_pp0p0_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__us-gaap--VestingAxis__custom--FiveYearsAndThereafterMember_zOn47z2x1Cfi" title="Minimum payments for royalties">100,000</span> in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating
to the status of Valid Claims, as such term is defined in the License Agreement. The Company&#8217;s obligation to pay earned royalties
under the License Agreement commences on the date of the first sale of a royalty-bearing product, and shall automatically expire on a
country-by-country basis on the date on which the last valid claim of the Licensed Patents expires, lapses or is declared invalid, and
the obligation to pay any earned royalties under the License Agreement shall terminate on the date on which the last valid claim of the
Licensed Patents expires, lapses, or is declared to be invalid in all countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements with Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual compensation of $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zvT95vuoCo92" title="Salary and compensation">640,000</span>, payable
monthly (see Note 6). The employment agreements are automatically renewable for additional <span id="xdx_902_ecustom--AgreementTermDescription_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zX41iREGNv2" title="Agreement term description">one-year periods</span> unless terminated by either
party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination for cause. These
employment agreements were automatically renewed for additional one-year periods in July and August 2021 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2021, the Board of Directors increased the annual compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the total aggregate annual compensation of all officers increased to $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210408__20210409__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--Dr.JamesMember_zJTCDSpFDpI6" title="Annual compensation">775,000</span>, effective May
1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zaWa8BkYwF27" title="Annual salary per year">200,000</span>. Accordingly,
the total aggregate annual compensation of all officers increased to $<span id="xdx_906_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__srt--OfficerMember_zVgydyHEjtZf" title="Compensation">800,000</span>, effective November 6, 2022. In addition, effective October
1, 2022, Mr. Forman is being paid an office rent allowance of $<span id="xdx_907_eus-gaap--PaymentsForRent_c20220929__20221001__srt--TitleOfIndividualAxis__custom--FormanMember_zPnJriJdKolb" title="Paid office rent">600</span> per month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total aggregate annual compensation of all officers increased to $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__srt--OfficerMember_zkqYsYIWBkId" title="Compensation">800,000</span>, effective November 6, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Significant Agreements and Contracts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA
Consulting Corp.</b> On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#8217;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $<span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYQ3C6jeybc6" title="Consulting and advisory fee">4,000</span>. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $<span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_z1YtMf3uXA3d" title="Consulting and advisory fee">4,000</span> and $<span id="xdx_90A_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zjHgw7SNwwec" title="Consulting and advisory fee">4,000</span> for the three months
ended March 31, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioPharmaWorks</b>.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#8217;s
product pipeline; assisting in preparing technical presentations concerning the Company&#8217;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $<span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zDUdEzalikd1" title="Consulting and advisory fee">10,000</span>, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment, and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 7). The Company recorded
charges to operations pursuant to this agreement of $<span id="xdx_902_ecustom--ReimbursementExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPeNH63cve56" title="Reimbursed expense">30,000</span> and $<span id="xdx_90D_ecustom--ReimbursementExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zLN6tNjtDYh4" title="Reimbursed expense">30,000</span> for the three months ended March 31, 2023 and 2022, respectively,
which were included in research and development costs in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Netherlands
Cancer Institute</b>. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (see Note 6), one of the world&#8217;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major
independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues,
to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.
The Company has agreed to fund the study and provide a sufficient supply of LB-100 to conduct the study. The study is expected to take
approximately two years to conduct. During the three months ended March 31, 2023 and 2022, the Company incurred charges in the amount
of $<span id="xdx_901_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zWBQ47kasDXj" title="Advance amount related to milestone payment">52,203</span> and $<span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zmd0enjlXU9c" title="Advance amount related to milestone payment">54,230</span>, respectively, with respect to this agreement, which amounts are included in research and development costs in
the Company&#8217;s consolidated statements of operations. As of March 31, 2023, total costs of $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zAVcJcMJ0Pk8" title="Research and development costs">416,518</span> have been incurred pursuant
to this agreement. The Company&#8217;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled
approximately $<span id="xdx_908_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zdf5xgiWAoq7" title="Aggregate commitments expected">53,000</span> as of March 31, 2023, which is expected to be incurred through June 30, 2025. As the work is being conducted in
Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MRI
Global. </b>The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $<span id="xdx_909_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zP5Nosi6JMdk" title="Contract price">273,980</span> for services to be
rendered through April 30, 2023. During the three months ended March 31, 2023 and 2022, the Company incurred costs of $<span id="xdx_90A_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zkEOu8Lvn6r3" title="Advance amount related to milestone payment">3,173</span> and $<span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zVY3RwdB77vb" title="Advance amount related to milestone payment">756</span>,
respectively, pursuant to this contract. As of March 31, 2023, total costs of $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zJ8481wLxdYa" title="Research and development costs">222,784</span> have been incurred pursuant to this contract.
The Company&#8217;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $<span id="xdx_90D_eus-gaap--OtherCommitment_iI_c20230331_zhaLRFPnCvwj" title="Aggregate commitments expected">53,000</span>
as of March 31, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of $<span id="xdx_902_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zT3u8c1qQS37" title="Contract price">326,274</span> for
services to be rendered through April 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Risks Associated with the Company&#8217;s Business Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covid-19
Virus</b>. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may impact the Company&#8217;s business activities and capital raising efforts will depend on future developments, which are
uncertain and cannot be predicted. The Company is continuing to monitor this situation and will adjust its current business plans to
the extent additional information and guidance become available. The coronavirus pandemic has also presented a challenge to medical facilities
worldwide. Although the Company&#8217;s clinical trials are conducted on an outpatient basis, the coronavirus pandemic appears to have
caused some delays in the Company&#8217;s clinical trials, but the impact of the coronavirus pandemic appears to be subsiding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation
Risk. </b>The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#8217;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Chain Issues. </b>The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Recession. </b>There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588003440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zpy4Hi2NcUt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82A_zH1SDycSCnqi">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
There were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217583229440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zVvzjHbKeJP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_z1zpCyJUVz1h">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#8220;GAAP&#8221;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgckybU7JRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zF5yg8PBaMIg">Segment
Information</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#8217;s operating segment is reported
in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company&#8217;s President,
Chief Executive Officer and Chief Scientific Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_zULEafopo5n" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z9mq2q1HzYq9">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBB7K77ynAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_ze77BMUmmZP2">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#8220;Morgan Stanley&#8221;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#8217;s policy is to maintain its cash
balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the
&#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;). The Company periodically has cash
balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230331_zvTTGozSmfsg" title="Cash FDIC insurance">250,000</span> and $<span id="xdx_90E_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230331_zHQpiHVDMvXi" title="Cash SIPC insurance">500,000</span>, respectively. Morgan Stanley
Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not experienced
any losses to date resulting from this policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNBPSW0tlC8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zDRYAh1EmdGa">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#8217;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#8217;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#8217;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#8217;s consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#8217;s consolidated
balance sheet and are then charged to research and development costs in the Company&#8217;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#8217;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#8217;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_PrepaidInsurancePolicyTextBlock', window );">Prepaid Insurance</a></td>
<td class="text"><p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zfhKOyLehoM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zaWragigvy2j">Prepaid
Insurance</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#8217;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#8217;s consolidated statement of operations for each
reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent and Licensing Legal and Filing Fees and Costs</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zmEg5HhImiU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zDlpL0ZqcU0b">Patent
and Licensing Legal and Filing Fees and Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#8217;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#8217;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $<span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20230101__20230331_zonfydgDVMWl">317,340</span> and $<span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20220331_zgo8N59zLuTj" title="Patent and licensing legal and filing fees and costs">315,237</span> for the three months ended March 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zwrH3pMfgYac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zxRN2W9DqxN7">Concentration
of Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically contracts with vendors and consultants to provide services related to the Company&#8217;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zCZz7vU4SbUa" title="Concentration of risk, percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zicZbxxY1gv2" title="Concentration of risk, percentage">10</span></span>% or more of general and administrative costs or research and development costs for the three months ended March 31,
2023 and 2022 are described as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs for the three months ended March 31, 2023 and 2022 included charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#8217;s intellectual properties representing <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMoFDdYcoM0d" title="Concentration risk percentage">26.9</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp95C6OMtNkg" title="Concentration of risk, percentage">29.6</span>% of total
general and administrative costs, respectively. General and administrative costs for the three months ended March 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zjozQ4A5x6Sb" title="Concentration of risk, percentage">23.5</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zobcm3wt8HBe" title="Concentration of risk, percentage">28.4</span>%, respectively,
of total general and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs for the three months ended March 31, 2023 included charges from four vendors and consultants representing <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfirrZb1xwu1" title="Concentration risk percentage">36.5</span>%,
<span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmkSMS1gHTuf" title="Concentrtion percentage risk">27.6</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbe7U3ng7dP" title="Concentrtion percentage risk">15.9</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4ztDZaGzun6" title="Concentration risk percentage">14.4</span>%, respectively, of total research and development costs. Research and development costs for the three months ended
March 31, 2022 included charges from two vendors and consultants representing <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumRnN3hjtGk" title="Concentration risk percentage">63.8</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrzCEiQcW7ye" title="Concentration risk percentage">11.8</span>%, respectively, of total research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zk8Ql8VEDlab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zqNdZ8vhp4hj">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#8217;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20230331_zOtcYNdMV08d" title="Unrecognized tax benefits"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zcsfv9vEdJi8" title="Unrecognized tax benefits">no</span></span> unrecognized tax benefits as of March 31, 2023 or December
31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#8220;more-likely-than-not&#8221; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#8220;more-likely-than-not&#8221; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of March 31, 2023 or December
31, 2022. Subsequent to March 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaJ3as2kuMCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zQPzBEuyWbd3">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#8217;s financial statements over the vesting period
of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#8220;simplified method&#8221;). The estimated volatility is based on the historical
volatility of the Company&#8217;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#8217;s common stock on
the grant date. The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#8217;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ynR6G1NOk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z71GVYS5YNRc">Earnings
(Loss) Per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s computation of earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS, but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zldWyJKMd9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zTcOwuFQCM09" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230331_z9Lo4bnMYCxb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220331_zhZhg32dVbG8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zxKb3SlDe8Ah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">729,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">729,167</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zwO39gcvi396" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,900,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,110,310</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_z3QDuaYoZXDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,882,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,666,667</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqB8SHe3HNrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,511,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,506,144</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z7eA1fAOKw9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zx8zNb5i3uw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zxwt1rHZLexb">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMnGILblZs51" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zeSgDJXT8Xv5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2021-04,
Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation
(Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#8217;s
consolidated financial statement presentation or disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#8217;s financial statement presentation or disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_PrepaidInsurancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Insurance [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_PrepaidInsurancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588019376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zldWyJKMd9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zTcOwuFQCM09" style="display: none">Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230331_z9Lo4bnMYCxb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220331_zhZhg32dVbG8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zxKb3SlDe8Ah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series A Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">729,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">729,167</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zwO39gcvi396" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,900,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,110,310</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_z3QDuaYoZXDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Common stock options, including options issued in the form of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,882,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,666,667</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqB8SHe3HNrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,511,769</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,506,144</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217587965696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ResearchDevelopmentTableTextBlock', window );">Schedule of Research and Development Costs</a></td>
<td class="text"><p id="xdx_899_ecustom--ResearchDevelopmentTableTextBlock_z8to79j4rsWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs, including costs associated with clinical trials involving the Company&#8217;s lead clinical compound LB-100, are
summarized below based on the respective geographical regions where such costs are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zenzdK84yMzl" style="display: none">Schedule
of Research and Development Costs</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230331_zAI64C5cZFmk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220331_zRalxHNAElXd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zwaz8jWePPS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">135,907</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">74,531</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zEzaUW8bJ6F4" style="vertical-align: bottom; background-color: White">
    <td>Spain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,829</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zWoMuWvwIlIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>China</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">860</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z875TLv8VRYg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Netherlands</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_z0FW5y57kI5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">189,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_zHdW40dlmvJc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Research and development expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">189,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ResearchDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Development [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ResearchDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217588105712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zWHHRASppmL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of common stock warrant activity during the three months ended March 31, 2023 is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z5FIK2ZOXcC1" style="display: none">Schedule of Warrants Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (in Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Warrants outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYBpF6OJPfz3" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance">1,900,310</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfahfJ3pFEL9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning">5.016</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdAlOraAAbKe" style="text-align: right" title="Number of Shares, Issued"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwJXs97qiP8k" style="text-align: right" title="Weighted Average Exercise Price, Issued"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTdN3OT879F5" style="text-align: right" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSdQ13mDDSi1" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwPl9OGmQZ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBiCZ64EhOJ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za0FKoVFjKN" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance">1,900,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zuRoGWSoKVg6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending">5.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYRR0XXV66lc" title="Weighted Average Remaining Contractual Life (in Years), Outstanding">2.90</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbABWHjuhHSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Beginning Balance">1,900,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQl2PspOuIf6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance">5.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRx9ObsZhHMl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Ending Balance">1,900,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqozfabtLFEj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance">5.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqam0IIlwgQe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable">2.90</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zgsX0KiSJiUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the outstanding warrants are exercisable at the following prices per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zErVmRl0DmTk" style="display: none">Schedule of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXDiEWWp4yM9" title="Exercise Prices">2.000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyF6tCGQ5dBg" style="width: 47%; text-align: right" title="Warrants Outstanding Shares">290,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zTGcmYyiPujg" title="Exercise Prices">3.700</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3zC5HO0yIn4" style="text-align: right" title="Warrants Outstanding Shares">113,310</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFdwUhI9DUu3" title="Exercise Prices">5.700</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVDS5dzBbnb6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares">1,497,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331_zWpd06WveR0i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares">1,900,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrants Outstanding And Exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217584020144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Related Party Costs</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zIaapNhijKDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months ended March 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zGq9IBIsvPSd" style="display: none">Summary of Related Party Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20230331_zrPvHzzbK4n2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220331_zoenYFrgw2lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related party costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--CashBasedMember_zhqsl2hIf9Ql" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Cash-based</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">242,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">226,250</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--StockBasedMember_zIvvdDw3Uiml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Stock-based</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">276,980</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">339,672</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostOfRevenue_zVPx2m1zwnb2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">519,480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">565,922</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_zLVSWL4Be6M2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Related party costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">519,480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">565,922</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217585222272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock-based Compensation Costs</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zUkPbHeRX7Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock-based compensation costs for the three months ended March 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zuBc1L43seP" style="display: none">Summary of Stock-based Compensation Costs</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230331_zSZh7j0mzpU4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220331_zeIGOCKaCUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zuFEZ9VFZ4Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Related parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">276,980</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">339,672</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zPBmOzJM8fld" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_zqzNOapDc172" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">276,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339,672</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFbHoJbCUcD" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_zC1BLKG8RLVh" style="display: none">Summary of Stock Option Activity Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock options outstanding at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331_zI3VBGN0CW9g" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning">3,894,792</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zI5mFDwxoStb" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning">2.9183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230331_zJxWLckPa9el" style="text-align: right" title="Number of shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0866">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_z9c0e6id6qMa" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230331_z4bwHDiRcvJg" style="text-align: right" title="Number of shares, Exercised">(12,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zN72wDcIDXh7" style="text-align: right" title="Weighted average exercise price, exercised">0.5025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230331_z0VhiFm81I23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zWGHOq5LjYh8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl0876">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options outstanding at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230331_zwEr2wT4jSKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end">3,882,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zkiMipGUeKjc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end">2.9260</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zYXAUwcsWQja" title="Weighted average remaining contractual life (in years), stock options outstanding">2.79</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCQIPksNcUE" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end">2,819,792</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z61mfmRsYcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end">3.2834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230331_z6HQldkB2dr" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end">2,913,542</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230331_zHj7mjfQG6x" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end">3.2431</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_z3TJtDZ276N8" title="Weighted average remaining contractual life (in years), stock options exercisable">2.28</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z8Zbvsm0pQDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at March 31, 2023
are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zzNX2AxBd5o8" style="display: none">Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prices</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Shares)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zIt0gX5Bwdr2" style="width: 30%; text-align: right" title="Exercise Prices">0.5025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zkbYvjymyPB1" style="width: 30%; text-align: right" title="Options Outstanding (Shares)">87,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zO9kuVSjLadl" style="width: 30%; text-align: right" title="Options Exercisable (Shares)">87,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztpLw5PBn4X9" style="text-align: right" title="Exercise Prices">0.7400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zvyxXN8Whpvg" style="text-align: right" title="Options Outstanding (Shares)">575,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxmNYagyKaq3" style="text-align: right" title="Options Exercisable (Shares)">309,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zClDDRQs6NV2" style="text-align: right" title="Exercise Prices">1.6800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmpFB26ywZpk" style="text-align: right" title="Options Outstanding (Shares)">33,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zI9bxUmLn6A5" style="text-align: right" title="Options Exercisable (Shares)">33,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zBv0FSJ1oCw9" style="text-align: right" title="Exercise Prices">2.0000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zooXVbWkFGBj" style="text-align: right" title="Options Outstanding (Shares)">800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zIr6vOixStH" style="text-align: right" title="Options Exercisable (Shares)">200,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zgNhR6kwcRKg" style="text-align: right" title="Exercise Prices">2.0600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuzOZz9BuKF9" style="text-align: right" title="Options Outstanding (Shares)">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7DSWOFTHca" style="text-align: right" title="Options Exercisable (Shares)">200,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zgYzBlBZvaq6" style="text-align: right" title="Exercise Prices">2.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zguXgay8hEa8" style="text-align: right" title="Options Outstanding (Shares)">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztLIUhhVhDFc" style="text-align: right" title="Options Exercisable (Shares)">234,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zSuxmGK9nMQ7" style="text-align: right" title="Exercise Prices">3.0000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWRSacMmGvV2" style="text-align: right" title="Options Outstanding (Shares)">666,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXHT8PLGZtd4" style="text-align: right" title="Options Exercisable (Shares)">666,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zR5GUdjSw1t2" style="text-align: right" title="Exercise Prices">3.0300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJkGCAYecpWa" style="text-align: right" title="Options Outstanding (Shares)">425,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zXMtIq5inzi7" style="text-align: right" title="Options Exercisable (Shares)">387,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z87ELwmJPxWh" style="text-align: right" title="Exercise Prices">3.2000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_znFYhgeqSkWg" style="text-align: right" title="Options Outstanding (Shares)">203,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zKQV6zJri1N2" style="text-align: right" title="Options Exercisable (Shares)">203,125</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMtmv8ArPDa" style="text-align: right" title="Exercise Prices">3.2100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z8WWZkHqOjqj" style="text-align: right" title="Options Outstanding (Shares)">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z6f7uZNKweo8" style="text-align: right" title="Options Exercisable (Shares)">150,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zq9fHiMX3wY5" style="text-align: right" title="Exercise Prices">6.0000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zLBvxdQ2qHcj" style="text-align: right" title="Options Outstanding (Shares)">166,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zu7lbE10h0Ad" style="text-align: right" title="Options Exercisable (Shares)">166,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zt1IzT7CU0Zc" style="text-align: right" title="Exercise Prices">6.6000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zBy6oHJCDvs2" style="text-align: right" title="Options Outstanding (Shares)">41,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zM79bdnAnJ9j" style="text-align: right" title="Options Exercisable (Shares)">41,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwYWnoEjoUp1" style="text-align: right" title="Exercise Prices">7.1400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zhXAHeT12fy" style="text-align: right" title="Options Outstanding (Shares)">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z70h0X14xT58" style="text-align: right" title="Options Exercisable (Shares)">150,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zubRnZBLyXu4" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices">12.0000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z427t7cWs6U3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)">83,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPRX2edysUp1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)">83,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,882,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331_zZN7lnr5V0kk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)">2,913,542</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217587924384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217583211968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">$ 4,088,304<span></span>
</td>
<td class="nump">$ 5,353,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217582090592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">6,511,769<span></span>
</td>
<td class="nump">6,506,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">729,167<span></span>
</td>
<td class="nump">729,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,900,310<span></span>
</td>
<td class="nump">3,110,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,882,292<span></span>
</td>
<td class="nump">2,666,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=LIXT_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217584569024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insurance</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_CashSIPCInsuredAmount', window );">Cash SIPC insurance</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Patent and licensing legal and filing fees and costs</a></td>
<td class="nump">317,340<span></span>
</td>
<td class="nump">$ 315,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">29.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member] | Stock Options Granted to Directors and Corporate Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">23.50%<span></span>
</td>
<td class="nump">28.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">36.50%<span></span>
</td>
<td class="nump">63.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">27.60%<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">15.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_CashSIPCInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash SIPC insured amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_CashSIPCInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=LIXT_VendorFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=LIXT_VendorFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217585216832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Research and Development Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 189,085<span></span>
</td>
<td class="nump">$ 458,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">135,907<span></span>
</td>
<td class="nump">74,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">SPAIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">328,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">NETHERLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 52,203<span></span>
</td>
<td class="nump">$ 54,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217580660896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding (Details) - Common Stock Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">1,900,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare', window );">Weighted Average Exercise Price, Warrants Outstanding, Beginning</a></td>
<td class="nump">$ 5.016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Shares, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding, Ending Balance</a></td>
<td class="nump">1,900,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare', window );">Weighted Average Exercise Price, Warrants Outstanding, Ending</a></td>
<td class="nump">$ 5.016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Outstanding</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants exercisable, Ending Balance</a></td>
<td class="nump">1,900,310<span></span>
</td>
<td class="nump">1,900,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants exercisable, Beginning Balance</a></td>
<td class="nump">$ 5.016<span></span>
</td>
<td class="nump">$ 5.016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life (in Years), Exercisable</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option outstanding weighted average number of share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217584484048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">1,900,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">290,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 3.700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">113,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 5.700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding Shares</a></td>
<td class="nump">1,497,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217581825248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Apr. 12, 2022</div></th>
<th class="th"><div>Mar. 17, 2015</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,659,093<span></span>
</td>
<td class="nump">16,646,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,659,093<span></span>
</td>
<td class="nump">16,646,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember', window );">Placement Agents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,141,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new issue shares</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.5025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new issue shares</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantMember', window );">Common Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair market value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend', window );">Principal Cash Obligations and Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares', window );">Annual net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,167<span></span>
</td>
<td class="nump">729,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from sale of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 2.0833 shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
<td class="nump">9,650,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual net revenue divided by converted or redeemed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share tranche of the series a convertible preferred stock receive a per share dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LIXT_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LIXT_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LIXT_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217583903600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Related Party Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Related party costs</a></td>
<td class="nump">$ 519,480<span></span>
</td>
<td class="nump">$ 565,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedAndNonrelatedPartyStatusAxis=LIXT_CashBasedMember', window );">Cash Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Related party costs</a></td>
<td class="nump">242,500<span></span>
</td>
<td class="nump">226,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedAndNonrelatedPartyStatusAxis=LIXT_StockBasedMember', window );">Stock Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Related party costs</a></td>
<td class="nump">$ 276,980<span></span>
</td>
<td class="nump">$ 339,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedAndNonrelatedPartyStatusAxis=LIXT_CashBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedAndNonrelatedPartyStatusAxis=LIXT_CashBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedAndNonrelatedPartyStatusAxis=LIXT_StockBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedAndNonrelatedPartyStatusAxis=LIXT_StockBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217577251072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Cash board fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ManagementFeePayableQuarterly', window );">Cash board fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,480<span></span>
</td>
<td class="nump">$ 565,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,980<span></span>
</td>
<td class="nump">339,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember', window );">Independent Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,500<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember', window );">New Independent Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember', window );">New Independent Director [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember', window );">Annual Grant of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember', window );">Annual Grant of Options [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Annual cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FormanMember', window );">Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Paid office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember', window );">Chairman of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember', window );">Chairman of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember', window );">Member of Audit Committee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember', window );">Member of Other Committees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. Kovach [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr. James S. Miser, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Increase in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Eric J. Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">43,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Increase in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Robert N. Weingarten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,750<span></span>
</td>
<td class="nump">$ 43,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Increase in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ManagementFeePayableQuarterly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Management fee payable quarterly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ManagementFeePayableQuarterly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fee payable for management of fund or trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_IndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LIXT_NewIndependentDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedAndNonrelatedPartyStatusAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedAndNonrelatedPartyStatusAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LIXT_AnnualGrantOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ChairmanOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfAuditCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_MemberOfOtherCommitteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrKovachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrKovachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_DrJamesSMiserMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217582362880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-based Compensation Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation costs</a></td>
<td class="nump">$ 276,980<span></span>
</td>
<td class="nump">$ 339,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RelatedPartiesMember', window );">Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation costs</a></td>
<td class="nump">276,980<span></span>
</td>
<td class="nump">339,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonRelatedPartiesMember', window );">Non Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NonRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217583876000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity Including Options Form of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the beginning</a></td>
<td class="nump">3,894,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding, at the beginning</a></td>
<td class="nump">$ 2.9183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(12,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 0.5025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, stock options outstanding, at the end</a></td>
<td class="nump">3,882,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options outstanding, at the end</a></td>
<td class="nump">$ 2.9260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), stock options outstanding</a></td>
<td class="text">2 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, stock options exercisable, at the end</a></td>
<td class="nump">2,913,542<span></span>
</td>
<td class="nump">2,819,792<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options exercisable, at the end</a></td>
<td class="nump">$ 3.2431<span></span>
</td>
<td class="nump">$ 3.2834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), stock options exercisable</a></td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217585302528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">2,913,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 0.5025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">87,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">87,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 0.7400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">575,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">309,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.6800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">33,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">33,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.0000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.0600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 2.8000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">234,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 3.0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">666,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">666,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember', window );">Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 3.0300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">387,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember', window );">Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 3.2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">203,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">203,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember', window );">Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 3.2100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember', window );">Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">166,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">166,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember', window );">Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 6.6000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">41,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">41,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember', window );">ExercisePriceThirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 7.1400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember', window );">Exercise Price Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 12.0000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding (Shares)</a></td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable (Shares)</a></td>
<td class="nump">83,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=LIXT_ExercisePriceFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217571986064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th"><div>Jun. 17, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Jul. 15, 2020</div></th>
<th class="th"><div>Jul. 14, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,882,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,894,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,980<span></span>
</td>
<td class="nump">$ 339,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,913,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,819,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Total deferred compensation expense for outstanding value of unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 605,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of exercisable but unexercised in-the-money stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair market value, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding stock options to acquire shares of common stock not vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 100,000 shares (a total
of 500,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $0.74 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $316,700 ($0.6334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
During the three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated
statement of operations of $23,394 with respect to these stock options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="nump">$ 0.5025<span></span>
</td>
<td class="nump">$ 0.5025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6334<span></span>
</td>
<td class="nump">$ 0.6334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember', window );">Five Non Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board of Directors, in accordance with the Company&#8217;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 100,000 shares (a total
of 500,000 shares) of the Company&#8217;s common stock, exercisable for a period of five years at an exercise price of $3.03 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $1,421,095 ($2.84225 per share), which is being charged to operations ratably from July 1, 2021 through June 30,
2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the
consolidated statement of operations of $105,123 and $175,205, respectively, with respect to these stock options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="nump">$ 43,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,700<span></span>
</td>
<td class="nump">$ 1,421,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="nump">$ 0.4326<span></span>
</td>
<td class="nump">$ 0.4326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.84225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.84225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,123<span></span>
</td>
<td class="nump">175,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_NonOfficerDirectorsMember', window );">Non Officer Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember', window );">BasvanderBaan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase 250,000 shares of the Company&#8217;s common stock, exercisable for a period of five years
at an exercise price of $0.74 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($0.6341 per
share), of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from June 17, 2022 through June 30, 2024. During the three months ended March 31, 2023, the Company recorded a total charge to general
and administrative costs in the consolidated statement of operations of $9,588 with respect to these stock options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember', window );">Four Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="nump">$ 262,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="nump">$ 0.3282<span></span>
</td>
<td class="nump">$ 0.3282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation vesting rights, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember', window );">Eric J. Forman [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase 58,333 shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market
price of the Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $24,710 and $24,710, respectively, with respect to these stock options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option vested exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,710<span></span>
</td>
<td class="nump">24,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesMiserMember', window );">Dr. James Miser [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase 83,334 shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the Company&#8217;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $572,650 ($6.8718 per share), of which $143,163 was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $35,300 and $35,300, respectively, with respect to these stock options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,300<span></span>
</td>
<td class="nump">35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember', window );">Robert N. Weingarten [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase 58,333 shares of the Company&#8217;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the
Company&#8217;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the portion of the stock
options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair
value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months
ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations
of $24,710 and $24,710, respectively, with respect to these stock options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,710<span></span>
</td>
<td class="nump">24,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrWinsonSzeChunHoMember', window );">Dr Winson SzeChun Ho [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#8217;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#8217;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase 250,000 shares of the Company&#8217;s
common stock, exercisable for a period of five years at an exercise price of $3.20 per share (the closing market price on the grant date),
vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $753,611 ($3.0144 per share), of which $376,800 was attributable to the portion of the stock options fully vested
on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock
options was being charged to operations ratably from April 9, 2021 through June 30, 2023. However, vesting of these stock options terminated
on October 30, 2022, the date that Mr. Schwartzberg died. During the three months ended March 31, 2023 and 2022, the Company recorded
charges to general and administrative costs in the consolidated statement of operations of $0 and $41,764, respectively, with respect
to these stock options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 753,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember', window );">Ms.Regina Brown [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#8217;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase 250,000 shares of the Company&#8217;s common stock, exercisable for a period of five
years at an exercise price of $2.80 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($2.6335 per
share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from May 11, 2021 through June 30, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general
and administrative costs in the consolidated statement of operations of $37,983 and $37,983, respectively, with respect to these stock
options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options are exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_FairValueOfStockOptions', window );">Fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 658,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock options fully vested amount, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,983<span></span>
</td>
<td class="nump">$ 37,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of fully vested option exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares avaliable for issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to purchase common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,133,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,603,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares were available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Stock Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_FairValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_FairValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding period increase decrease value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FiveNonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_NonOfficerDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_NonOfficerDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_BasvanderBaanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FourOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FourOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_EricJFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesMiserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrJamesMiserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_RobertNWeingartenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrWinsonSzeChunHoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_DrWinsonSzeChunHoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_MsReginaBrownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LIXT_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140217568005456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>Nov. 06, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>Jun. 10, 2022</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Feb. 05, 2021</div></th>
<th class="th"><div>Sep. 12, 2018</div></th>
<th class="th"><div>Aug. 20, 2018</div></th>
<th class="th"><div>Sep. 14, 2015</div></th>
<th class="th"><div>Dec. 24, 2013</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,085<span></span>
</td>
<td class="nump">$ 458,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=LIXT_FormanMember', window );">Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Paid office rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember', window );">City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember', window );">GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AmountRelatedToMilestonePayment', window );">Amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember', window );">NDA Consulting Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember', window );">Clinical Trial Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Aggregate commitments expected, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s aggregate commitment pursuant to
this agreement, less amounts previously paid to date, totaled approximately $575,000 as of March 31, 2023, which is expected to be incurred
through December 31, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember', window );">Other Clinical Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | GEIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,792,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bio Pharma Works LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ConsultingAndAdvisoryCashFee', window );">Consulting and advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ReimbursementExpense', window );">Reimbursed expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember', window );">Clinical Research Support Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember', window );">Clinical Research Support Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,001<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Total costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | City of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,553<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember', window );">Work Order Agreement [Member] | Theradex Systems, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,287<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | First Four Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Minimum payments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Five Years And Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Minimum payments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_NonRefundableLicenseIssueFee', window );">Non refundable license issue fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AnnualLicenseMaintenanceFee', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_PaymentsOnNonrefundableMilestone', window );">Payment on non refundable milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Operating costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,165<span></span>
</td>
<td class="nump">6,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salary and compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AgreementTermDescription', window );">Agreement term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-year periods<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember', window );">Employment Agreement [Member] | Dr.James [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Annual compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember', window );">Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,203<span></span>
</td>
<td class="nump">54,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Aggregate commitments expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember', window );">MRI Global [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_AdvanceAmountRelatedToMilestonePayment', window );">Advance amount related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LIXT_ContractPrice', window );">Contract price</a></td>
<td class="nump">$ 326,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AdvanceAmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AdvanceAmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AgreementTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement term description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AgreementTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AmountRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AmountRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company is obligated to pay annual license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ConsultingAndAdvisoryCashFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting and advisory quarterly cash fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ConsultingAndAdvisoryCashFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ContractPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ContractPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_NonRefundableLicenseIssueFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company is obligated to pay non refundable license issue fee..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_NonRefundableLicenseIssueFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_PaymentsOnNonrefundableMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_PaymentsOnNonrefundableMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LIXT_ReimbursementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LIXT_ReimbursementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LIXT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_FormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_FormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=LIXT_FirstFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=LIXT_FirstFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=LIXT_FiveYearsAndThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=LIXT_FiveYearsAndThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LIXT="http://lixte.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lixt-20230331.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:StockOptionsGrantedtoDirectorsAndCorporateOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_VendorOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_VendorTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_VendorThreeMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_VendorFourMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_VendorOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_VendorTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">LIXT:VendorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CommonStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">LIXT:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_country_ES">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_country_CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-17</instant>
        </period>
    </context>
    <context id="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-16</startDate>
            <endDate>2015-03-17</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UndesignatedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember5713203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LIXT:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-112022-04-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-11</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="AsOf2022-04-12_custom_PlacementAgentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LIXT:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="From2023-03-092023-03-10_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="From2023-03-092023-03-10_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-10_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CommonStockWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LIXT:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_DrKovachMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrKovachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_DrJamesSMiserMDMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:DrJamesSMiserMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_FormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_EricJFormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ChairmanOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfAuditCommitteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:MemberOfOtherCommitteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_NewIndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_NewIndependentDirectorMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:NewIndependentDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LIXT:AnnualGrantOfOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_IndependentDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:IndependentDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CashBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">LIXT:CashBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CashBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">LIXT:CashBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_StockBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_StockBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedAndNonrelatedPartyStatusAxis">LIXT:StockBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-06</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LIXT:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EricJFormanMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:EricJFormanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrJamesMiserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-12</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RobertNWeingartenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-04-09_custom_DrWinsonSzeChunHoMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrWinsonSzeChunHoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-09_srt_DirectorMember_custom_DrWinsonSzeChunHoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrWinsonSzeChunHoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_srt_DirectorMember_custom_DrWinsonSzeChunHoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrWinsonSzeChunHoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_DirectorMember_custom_DrWinsonSzeChunHoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:DrWinsonSzeChunHoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-10</startDate>
            <endDate>2021-05-11</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_MsReginaBrownMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:MsReginaBrownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_NonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:NonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-06-012021-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-06-162022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-17_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_BasvanderBaanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:BasvanderBaanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-06-012022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-06-022022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-06-012022-06-30_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="AsOf2022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="From2022-11-062022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-06</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_FourOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FourOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-06_custom_FiveNonOfficerDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FiveNonOfficerDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_NonRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_NonRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NonRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">LIXT:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ClinicalTrialResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalTrialResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_OtherClinicalAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:OtherClinicalAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:GrupoEspanolDeInvestigacionEnSarcomasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ClinicalResearchSupportAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ClinicalResearchSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2018-09-102018-09-12_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-10</startDate>
            <endDate>2018-09-12</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:TheradexSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-04</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:WorkOrderAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-18</startDate>
            <endDate>2018-08-20</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:MoffittCancerCenterandResearchInstituteHospitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExclusiveLicenseAgreementMember_custom_FirstFourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">LIXT:FirstFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ExclusiveLicenseAgreementMember_custom_FiveYearsAndThereafterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">LIXT:FiveYearsAndThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:ExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="From2021-04-082021-04-09_custom_EmploymentAgreementMember_custom_Dr.JamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:Dr.JamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-08</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_custom_FormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2022-11-052022-11-06_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-05</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="From2022-09-292022-10-01_custom_FormanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LIXT:FormanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-29</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="From2013-12-232013-12-24_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-23</startDate>
            <endDate>2013-12-24</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_NDAConsultingCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:NDAConsultingCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-12</startDate>
            <endDate>2015-09-14</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">LIXT:BioPharmaWorksLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:DevelopmentCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LIXT:NetherlandsCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-06-092022-06-10_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-09</startDate>
            <endDate>2022-06-10</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-152023-04-17_custom_MRIGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001335105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LIXT:MRIGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-15</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-03-31">0001335105</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration contextRef="AsOf2023-03-31" id="xdx2ixbrl0079">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration>
    <us-gaap:AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration contextRef="AsOf2022-12-31" id="xdx2ixbrl0080">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <LIXT:RepaymentOfDeferredOfferingCosts
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_country_CN"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468"
      id="xdx2ixbrl0555"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468"
      id="xdx2ixbrl0557"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468"
      id="xdx2ixbrl0559"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468"
      id="xdx2ixbrl0561"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468"
      id="xdx2ixbrl0563"
      unitRef="Shares"
      xsi:nil="true"/>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468"
      id="xdx2ixbrl0565"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      id="xdx2ixbrl0701">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-11-062022-11-06_custom_FourOfficersMember"
      id="xdx2ixbrl0827">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_NonRelatedPartiesMember"
      id="xdx2ixbrl0854"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_NonRelatedPartiesMember"
      id="xdx2ixbrl0855"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0866"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0868"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0874"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0876"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-03-31">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-03-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-03-31">001-39717</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-03-31">LIXTE BIOTECHNOLOGY HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-03-31">20-2903526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-03-31">680 East Colorado Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-03-31">Suite 180</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-03-31">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-03-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-03-31">91101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-03-31">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-03-31">830-7092</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.0001PerShareMember">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.0001PerShareMember">LIXT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-012023-03-31_custom_CommonStockParValue0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-01-012023-03-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">Warrants     to Purchase Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-012023-03-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">LIXTW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-012023-03-31_custom_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-05-01" decimals="INF" unitRef="Shares">16659093</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4088304</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5353392</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">131194</LIXT:AdvancesOnResearchAndDevelopmentContractServices>
    <LIXT:AdvancesOnResearchAndDevelopmentContractServices contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">147017</LIXT:AdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:PrepaidInsurance contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">55219</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">49224</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">56099</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10380</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4330816</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5560013</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4330816</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5560013</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">44972</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">46982</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">223631</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">229764</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">26356</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">165022</LIXT:ResearchAndDevelopmentContractLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">249987</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">394786</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">10.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">729167</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">729167</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3500000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">16659093</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">16659093</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">16646593</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">16646593</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1665</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1664</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">45341522</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">45058262</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-44762358</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-43394699</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4080829</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5165227</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4330816</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5560013</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">276980</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">339672</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">519480</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">565922</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">317340</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">315237</us-gaap:LegalFees>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">344242</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">314743</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">189085</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">458450</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1370147</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">1654352</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1370147</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-1654352</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">5015</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">109</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">3861</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">2494</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1334</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-181</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1367659</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-1656918</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">16649510</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">13746593</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16646593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1664</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">45058262</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-43394699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5165227</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6280</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">6281</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">276980</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">276980</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1367659</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1367659</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16659093</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1665</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">45341522</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-44762358</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4080829</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13746593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1374</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38371128</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-37082164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4790338</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13746593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1374</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38371128</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-37082164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4790338</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">339672</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">339672</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1656918</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-1656918</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13746593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1374</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38710800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-38739082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">3473092</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13746593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1374</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38710800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-38739082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">3473092</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1367659</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-1656918</us-gaap:NetIncomeLoss>
    <LIXT:GeneralAndAdministrativeStockBasedCompensationExpenses
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">276980</LIXT:GeneralAndAdministrativeStockBasedCompensationExpenses>
    <LIXT:GeneralAndAdministrativeStockBasedCompensationExpenses
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">339672</LIXT:GeneralAndAdministrativeStockBasedCompensationExpenses>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-15823</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-3224</LIXT:IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">5995</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidInsurance
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">21072</us-gaap:IncreaseDecreaseInPrepaidInsurance>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">45719</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">41670</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-6133</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">143525</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-138666</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">198142</LIXT:IncreaseDecreaseInResearchAndDevelopmentContractLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1271369</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-1035097</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">6281</us-gaap:ProceedsFromStockOptionsExercised>
    <LIXT:RepaymentOfDeferredOfferingCosts
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">10906</LIXT:RepaymentOfDeferredOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">6281</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-10906</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1265088</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-1046003</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5353392</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4823745</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4088304</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">3777742</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">3861</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">2494</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zezPRJOlrOk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_827_zGgFHkCjHt92"&gt;Organization and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned
Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the &#x201c;Company&#x201d;), at March 31, 2023, and for the three months
ended March 31, 2023 and 2022, are unaudited. In the opinion of management of the Company, all adjustments, including normal recurring
accruals, have been made that are necessary to present fairly the financial position of the Company as of March 31, 2023, and the results
of its operations for the three months ended March 31, 2023 and 2022, and its cash flows for the three months ended March 31, 2023 and
2022. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal
year. The consolidated balance sheet at December 31, 2022 has been derived from the Company&#x2019;s audited consolidated financial statements
at such date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (the &#x201c;SEC&#x201d;). Accordingly, certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations.
These condensed consolidated financial statements should be read in conjunction with the financial statements and other information included
in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nasdaq
Notification of Failure to Satisfy a Continued Listing Rule&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s common stock and the warrants are traded on The Nasdaq Capital Market under the symbols &#x201c;LIXT&#x201d; and &#x201c;LIXTW&#x201d;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 24, 2022, the Company received a written notice (the &#x201c;Notice&#x201d;) from The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;)
that the Company had not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a
period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price
of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists
if the deficiency continues for a period of 30 consecutive business days. The Notice had no immediate effect on the listing of the Company&#x2019;s
common stock on The Nasdaq Capital Market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days from the date of
the Notice, or until December 21, 2022, to regain compliance with the minimum closing bid price requirement. On December 22, 2022, the
Company received a written notice from Nasdaq that the Company was eligible for a second 180 calendar day compliance period, or until
June 19, 2023, in order to regain compliance with the $1.00 minimum bid price requirement. Nasdaq&#x2019;s determination to grant the
second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares
and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price requirement,
and the Company&#x2019;s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse
stock split, if necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company can generally achieve compliance with the minimum closing bid price requirement if the minimum closing bid price of the Company&#x2019;s
common stock is at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period. However,
under certain circumstances, Nasdaq can extend this 10-day trading period up to a maximum of 20 days. The Company anticipates that its
shares of common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market during the compliance period ending
June 19, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to achieve compliance with the minimum closing bid price requirement, the Company filed a proxy statement with the SEC to hold
a special meeting of stockholders on May 26, 2023 to seek stockholder approval to approve an amendment to the Company&#x2019;s Certificate
of Incorporation to effect a reverse stock split of the issued and outstanding shares of the Company&#x2019;s common stock at a split
ratio of up to a maximum of a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230101__20230331_zHDO1NRZfbLf" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; split, as determined by the Board of Directors in its sole discretion. However, there can be no
assurance that the Company will be successful in obtaining stockholder approval and will thus be able to regain compliance with the minimum
closing bid price requirement by June 19, 2023, in which case the Company anticipates Nasdaq would provide a notice to the Company that
its shares of common stock and warrants are subject to delisting, and the Company&#x2019;s common shares and warrants would then be delisted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Even
if the Company is able to achieve compliance with Nasdaq&#x2019;s minimum closing bid price requirement, there can be no assurances that
the Company will be able to maintain compliance with Nasdaq&#x2019;s other continued listing requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-01-01to2023-03-31">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NatureOfOperations contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_801_eus-gaap--NatureOfOperations_ze7bVu1lJb45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_826_zrNbUJFvWJK3"&gt;Business&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases
and then designs novel compounds to attack those targets. The Company&#x2019;s corporate office is located in Pasadena, California.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic
agents and/or x-ray and immune checkpoint blockers. The Company believes that inhibitors of protein phosphatases have broad therapeutic
potential not only for cancer but also for other debilitating and life-threatening diseases. The Company is directing its efforts on
clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer
activity at doses that produce little or no toxicity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company
has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation
for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its
operating requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023, the Company had cash of $&lt;span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20230331_zU28XjQtYbw"&gt;4,088,304 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;available
to fund its operations. Because the Company is currently engaged in various early-stage clinical trials, it is expected that it will
take a significant amount of time and resources to develop any product or intellectual property capable of generating sustainable
revenues. Accordingly, the Company&#x2019;s business is unlikely to generate any sustainable operating revenues in the next several
years and may never do so. Even if the Company is able to generate revenues through licensing its technology, product sales or other
commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive earnings and
operating cash flows. At March 31, 2023, the Company&#x2019;s unpaid remaining contractual commitments pursuant to clinical trial
agreements and clinical trial monitoring agreements aggregated $&lt;span id="xdx_905_eus-gaap--ContractualObligation_iI_pp0p0_c20230331_zwnZkaDMOhL7" title="Contractual commitment"&gt;7,900,000&lt;/span&gt;, which are currently scheduled to be incurred through
December 31, 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business. The Company has no recurring source of revenue
and has experienced negative operating cash flows since inception. The Company has financed its working capital requirements through
the recurring sale of its equity securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the foregoing, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern
within one year after the date that the accompanying interim condensed consolidated financial statements are being issued. The Company&#x2019;s
interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research
and development activities and to ultimately achieve sustainable operating revenues and profitability. The amount and timing of future
cash requirements depends on the pace, design and results of the Company&#x2019;s clinical trial program, which, in turn, depends on the
availability of operating capital to fund such activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on current operating plans, the Company estimates that existing cash resources will provide sufficient working capital to fund the current
clinical trial program with respect to the development of the Company&#x2019;s lead anti-cancer clinical compound LB-100 through approximately
December 31, 2023. However, existing cash resources will not be sufficient to complete the development of and obtain regulatory approval
for the Company&#x2019;s product candidate, as a result of which the Company will need to raise significant additional capital to do so.
The Company estimates that it will need to raise additional capital to fund its operations, including its various clinical trial commitments,
during the latter part of the fiscal year ending December 31, 2023. In addition, the Company&#x2019;s operating plans may change as a
result of many factors that are currently unknown and/or outside of the control of the Company, and additional funds may be needed sooner
than planned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
market conditions present uncertainty as to the Company&#x2019;s ability to secure additional funds, there can be no assurance that the
Company will be able to secure additional financing on acceptable terms, as and when necessary, to continue to conduct operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
cash resources are insufficient to satisfy the Company&#x2019;s ongoing cash requirements, the Company would be required to scale back
or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and product development
efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights
to and/or control of LB-100, or to discontinue operations entirely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">4088304</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ContractualObligation contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">7900000</us-gaap:ContractualObligation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zJFVPlsFE1Rb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_823_zSDkOQcpYvU3"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zVvzjHbKeJP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z1zpCyJUVz1h"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgckybU7JRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zF5yg8PBaMIg"&gt;Segment
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#x2019;s operating segment is reported
in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company&#x2019;s President,
Chief Executive Officer and Chief Scientific Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zULEafopo5n" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z9mq2q1HzYq9"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBB7K77ynAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_ze77BMUmmZP2"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the
&#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically has cash
balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230331_zvTTGozSmfsg" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230331_zHQpiHVDMvXi" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan Stanley
Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not experienced
any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNBPSW0tlC8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zDRYAh1EmdGa"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zfhKOyLehoM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zaWragigvy2j"&gt;Prepaid
Insurance&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zmEg5HhImiU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zDlpL0ZqcU0b"&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20230101__20230331_zonfydgDVMWl"&gt;317,340&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20220331_zgo8N59zLuTj" title="Patent and licensing legal and filing fees and costs"&gt;315,237&lt;/span&gt; for the three months ended March 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zwrH3pMfgYac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zxRN2W9DqxN7"&gt;Concentration
of Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zCZz7vU4SbUa" title="Concentration of risk, percentage"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zicZbxxY1gv2" title="Concentration of risk, percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% or more of general and administrative costs or research and development costs for the three months ended March 31,
2023 and 2022 are described as follows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the three months ended March 31, 2023 and 2022 included charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMoFDdYcoM0d" title="Concentration risk percentage"&gt;26.9&lt;/span&gt;% and &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp95C6OMtNkg" title="Concentration of risk, percentage"&gt;29.6&lt;/span&gt;% of total
general and administrative costs, respectively. General and administrative costs for the three months ended March 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zjozQ4A5x6Sb" title="Concentration of risk, percentage"&gt;23.5&lt;/span&gt;% and &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zobcm3wt8HBe" title="Concentration of risk, percentage"&gt;28.4&lt;/span&gt;%, respectively,
of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the three months ended March 31, 2023 included charges from four vendors and consultants representing &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfirrZb1xwu1" title="Concentration risk percentage"&gt;36.5&lt;/span&gt;%,
&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmkSMS1gHTuf" title="Concentrtion percentage risk"&gt;27.6&lt;/span&gt;%, &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbe7U3ng7dP" title="Concentrtion percentage risk"&gt;15.9&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4ztDZaGzun6" title="Concentration risk percentage"&gt;14.4&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the three months ended
March 31, 2022 included charges from two vendors and consultants representing &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumRnN3hjtGk" title="Concentration risk percentage"&gt;63.8&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrzCEiQcW7ye" title="Concentration risk percentage"&gt;11.8&lt;/span&gt;%, respectively, of total research and development
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zk8Ql8VEDlab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zqNdZ8vhp4hj"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had &lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20230331_zOtcYNdMV08d" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zcsfv9vEdJi8" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits as of March 31, 2023 or December
31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of March 31, 2023 or December
31, 2022. Subsequent to March 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaJ3as2kuMCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zQPzBEuyWbd3"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#x2019;s financial statements over the vesting period
of the awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ynR6G1NOk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z71GVYS5YNRc"&gt;Earnings
(Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS, but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zldWyJKMd9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zTcOwuFQCM09" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230331_z9Lo4bnMYCxb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220331_zhZhg32dVbG8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zxKb3SlDe8Ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;729,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;729,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zwO39gcvi396" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,900,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,110,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_z3QDuaYoZXDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,882,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,666,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqB8SHe3HNrh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,511,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,506,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z7eA1fAOKw9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zx8zNb5i3uw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zxwt1rHZLexb"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMnGILblZs51" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zeSgDJXT8Xv5"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-04,
Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation
(Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#x2019;s
consolidated financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_854_zEZisUg2vYug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zVvzjHbKeJP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_z1zpCyJUVz1h"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally
accepted accounting principles (&#x201c;GAAP&#x201d;) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its
wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgckybU7JRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zF5yg8PBaMIg"&gt;Segment
Information&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and reports in one segment, which focuses on the utilization of biomarker technology to identify enzyme targets associated
with serious common diseases and then designing novel compounds to attack those targets. The Company&#x2019;s operating segment is reported
in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker, which is the Company&#x2019;s President,
Chief Executive Officer and Chief Scientific Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zULEafopo5n" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z9mq2q1HzYq9"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under
different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed
to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions
used in the calculation of accruals for clinical trial costs and other potential liabilities, valuing equity instruments issued for services,
and the realization of deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBB7K77ynAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_ze77BMUmmZP2"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC
(&#x201c;Morgan Stanley&#x201d;). Morgan Stanley is a FINRA-regulated broker-dealer. The Company&#x2019;s policy is to maintain its cash
balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the
&#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;). The Company periodically has cash
balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230331_zvTTGozSmfsg" title="Cash FDIC insurance"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--CashSIPCInsuredAmount_iI_pp0p0_c20230331_zHQpiHVDMvXi" title="Cash SIPC insurance"&gt;500,000&lt;/span&gt;, respectively. Morgan Stanley
Wealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not experienced
any losses to date resulting from this policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <LIXT:CashSIPCInsuredAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">500000</LIXT:CashSIPCInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zNBPSW0tlC8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zDRYAh1EmdGa"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation,
design, development and management of clinical trials with respect to the Company&#x2019;s clinical compound and product candidate. Research
and development costs also include the costs to manufacture the compounds used in research and clinical trials, which are charged to
operations as incurred. The Company&#x2019;s inventory of LB-100 for clinical use has been manufactured separately in the United States
and in the European Union in accordance with the laws and regulations of such jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of
milestones, the completion of contracted work, the termination of an agreement, or other information indicates that a different expensing
schedule is more appropriate. However, payments for research and development costs that are contractually defined as non-refundable are
charged to operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obligations
incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research
and development costs in the Company&#x2019;s consolidated statement of operations based on the achievement of such milestones, as specified
in the respective agreement. Obligations incurred with respect to mandatory scheduled payments under agreements without milestone provisions
are accounted for when due, are recognized ratably over the appropriate period, as specified in the respective agreement, and are recorded
as liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs in the
Company&#x2019;s consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made pursuant to contracts are initially recorded as advances on research and development contract services in the Company&#x2019;s consolidated
balance sheet and are then charged to research and development costs in the Company&#x2019;s consolidated statement of operations as those
contract services are performed. Expenses incurred under contracts in excess of amounts advanced are recorded as research and development
contract liabilities in the Company&#x2019;s consolidated balance sheet, with a corresponding charge to research and development costs
in the Company&#x2019;s consolidated statement of operations. The Company reviews the status of its various clinical trial and research
and development contracts on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <LIXT:PrepaidInsurancePolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_848_ecustom--PrepaidInsurancePolicyTextBlock_zfhKOyLehoM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zaWragigvy2j"&gt;Prepaid
Insurance&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in
excess of the amortization of the total policy premium charged to operations at each balance sheet date. Such amount is determined by
amortizing the total policy premium charged on a straight-line basis over the respective policy period. As the policy premiums incurred
are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the Company&#x2019;s consolidated
balance sheet at each reporting date and appropriately amortized to the Company&#x2019;s consolidated statement of operations for each
reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</LIXT:PrepaidInsurancePolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zmEg5HhImiU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zDlpL0ZqcU0b"&gt;Patent
and Licensing Legal and Filing Fees and Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company&#x2019;s
research efforts and related patent applications, all patent and licensing legal and filing fees and costs related to the development
and protection of the Company&#x2019;s intellectual property are charged to operations as incurred. Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_90D_eus-gaap--LegalFees_pp0p0_c20230101__20230331_zonfydgDVMWl"&gt;317,340&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--LegalFees_pp0p0_c20220101__20220331_zgo8N59zLuTj" title="Patent and licensing legal and filing fees and costs"&gt;315,237&lt;/span&gt; for the three months ended March 31, 2023 and 2022, respectively. Patent and licensing legal
and filing fees and costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">317340</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">315237</us-gaap:LegalFees>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zwrH3pMfgYac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zxRN2W9DqxN7"&gt;Concentration
of Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically contracts with vendors and consultants to provide services related to the Company&#x2019;s operations. Charges incurred
for these services can be for a specific time period (typically one year) or for a specific project or task. Costs and expenses incurred
that represented &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zCZz7vU4SbUa" title="Concentration of risk, percentage"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zicZbxxY1gv2" title="Concentration of risk, percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% or more of general and administrative costs or research and development costs for the three months ended March 31,
2023 and 2022 are described as follows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative costs for the three months ended March 31, 2023 and 2022 included charges from legal firms and other vendors for general
licensing and patent prosecution costs relating to the Company&#x2019;s intellectual properties representing &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMoFDdYcoM0d" title="Concentration risk percentage"&gt;26.9&lt;/span&gt;% and &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp95C6OMtNkg" title="Concentration of risk, percentage"&gt;29.6&lt;/span&gt;% of total
general and administrative costs, respectively. General and administrative costs for the three months ended March 31, 2023 and 2022 also
included charges for the fair value of stock options granted to directors and corporate officers representing &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zjozQ4A5x6Sb" title="Concentration of risk, percentage"&gt;23.5&lt;/span&gt;% and &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--TitleOfIndividualAxis__custom--StockOptionsGrantedtoDirectorsAndCorporateOfficersMember_zobcm3wt8HBe" title="Concentration of risk, percentage"&gt;28.4&lt;/span&gt;%, respectively,
of total general and administrative costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs for the three months ended March 31, 2023 included charges from four vendors and consultants representing &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfirrZb1xwu1" title="Concentration risk percentage"&gt;36.5&lt;/span&gt;%,
&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmkSMS1gHTuf" title="Concentrtion percentage risk"&gt;27.6&lt;/span&gt;%, &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbe7U3ng7dP" title="Concentrtion percentage risk"&gt;15.9&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4ztDZaGzun6" title="Concentration risk percentage"&gt;14.4&lt;/span&gt;%, respectively, of total research and development costs. Research and development costs for the three months ended
March 31, 2022 included charges from two vendors and consultants representing &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zumRnN3hjtGk" title="Concentration risk percentage"&gt;63.8&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrzCEiQcW7ye" title="Concentration risk percentage"&gt;11.8&lt;/span&gt;%, respectively, of total research and development
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-03-31_us-gaap_CostOfSalesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      unitRef="Pure">0.269</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-03-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      unitRef="Pure">0.296</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember"
      decimals="INF"
      unitRef="Pure">0.235</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-03-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember"
      decimals="INF"
      unitRef="Pure">0.284</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_VendorOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      unitRef="Pure">0.365</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_VendorTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      unitRef="Pure">0.276</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_VendorThreeMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      unitRef="Pure">0.159</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-03-31_custom_VendorFourMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      unitRef="Pure">0.144</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-03-31_custom_VendorOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      unitRef="Pure">0.638</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-03-31_custom_VendorTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      unitRef="Pure">0.118</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zk8Ql8VEDlab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zqNdZ8vhp4hj"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly,
the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and
the tax basis of assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In
the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded
amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Should the
Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred
tax assets would be charged to operations in the period such determination was made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company&#x2019;s net operating
losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which
the Company currently operates or has operated in the past. The Company had &lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20230331_zOtcYNdMV08d" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pp0p0_do_c20221231_zcsfv9vEdJi8" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits as of March 31, 2023 or December
31, 2022 and does not anticipate any material amount of unrecognized tax benefits through December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The
tax effects of a position are recognized only if it is &#x201c;more-likely-than-not&#x201d; to be sustained by the taxing authority as
of the reporting date. If the tax position is not considered &#x201c;more-likely-than-not&#x201d; to be sustained, then no benefits of
the position are recognized. The Company had not recorded any liability for uncertain tax positions as of March 31, 2023 or December
31, 2022. Subsequent to March 31, 2023, any interest and penalties related to uncertain tax positions will be recognized as a component
of income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaJ3as2kuMCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zQPzBEuyWbd3"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,
contractors and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each
grant. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over
the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors and consultants
by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the
cost recognized as compensation expense on the straight-line basis in the Company&#x2019;s financial statements over the vesting period
of the awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is
affected by several variables, the most significant of which are the expected life of the stock option, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock.
Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point between
the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The estimated volatility is based on the historical
volatility of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of
the stock option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
The fair market value of the common stock is determined by reference to the quoted market price of the Company&#x2019;s common stock on
the grant date. The expected dividend yield is based on the Company&#x2019;s expectation of dividend payouts and is assumed to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development
costs, as appropriate, in the Company&#x2019;s consolidated statements of operations. The Company issues new shares of common stock to
satisfy stock option exercises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ynR6G1NOk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z71GVYS5YNRc"&gt;Earnings
(Loss) Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s computation of earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted
EPS is similar to basic EPS, but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares,
warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance date, if
later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share)
are excluded from the calculation of diluted EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods.
Basic and diluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options
outstanding were anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zldWyJKMd9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zTcOwuFQCM09" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230331_z9Lo4bnMYCxb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220331_zhZhg32dVbG8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zxKb3SlDe8Ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;729,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;729,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zwO39gcvi396" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,900,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,110,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_z3QDuaYoZXDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,882,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,666,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqB8SHe3HNrh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,511,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,506,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z7eA1fAOKw9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zldWyJKMd9s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023 and 2022, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire
shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zTcOwuFQCM09" style="display: none"&gt;Schedule
of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230331_z9Lo4bnMYCxb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220331_zhZhg32dVbG8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zxKb3SlDe8Ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series A Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;729,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;729,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zwO39gcvi396" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,900,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,110,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_z3QDuaYoZXDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Common stock options, including options issued in the form of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,882,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,666,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqB8SHe3HNrh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,511,769&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,506,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">729167</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">729167</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">1900310</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">3110310</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_custom_CommonStockOptionsMember"
      decimals="INF"
      unitRef="Shares">3882292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_custom_CommonStockOptionsMember"
      decimals="INF"
      unitRef="Shares">2666667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">6511769</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">6506144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zx8zNb5i3uw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zxwt1rHZLexb"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed
in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair
value measurements, is also required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to
access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities
and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable
through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop
its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives
and commingled investment funds and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of financial instruments (consisting of accounts payable and accrued expenses) is considered to be representative of their
respective fair values due to the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMnGILblZs51" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zeSgDJXT8Xv5"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2021-04,
Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation
(Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04
provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified
written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument
for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the
modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition
model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt
origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is
effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An
entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective
date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company&#x2019;s
consolidated financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company&#x2019;s financial statement presentation or disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_801_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zstYRAaHetO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_82D_zYhjGYinxWXc"&gt;Research and Development Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ResearchDevelopmentTableTextBlock_z8to79j4rsWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs, including costs associated with clinical trials involving the Company&#x2019;s lead clinical compound LB-100, are
summarized below based on the respective geographical regions where such costs are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zenzdK84yMzl" style="display: none"&gt;Schedule
of Research and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20230331_zAI64C5cZFmk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20220331_zRalxHNAElXd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zwaz8jWePPS2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;135,907&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;74,531&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zEzaUW8bJ6F4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Spain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;328,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zWoMuWvwIlIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0467"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z875TLv8VRYg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_z0FW5y57kI5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;189,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_zHdW40dlmvJc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Research and development expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;189,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_zW7MnqNoBoe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <LIXT:ResearchDevelopmentTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_899_ecustom--ResearchDevelopmentTableTextBlock_z8to79j4rsWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs, including costs associated with clinical trials involving the Company&#x2019;s lead clinical compound LB-100, are
summarized below based on the respective geographical regions where such costs are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zenzdK84yMzl" style="display: none"&gt;Schedule
of Research and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20230331_zAI64C5cZFmk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20220331_zRalxHNAElXd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--US_zwaz8jWePPS2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;135,907&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;74,531&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--ES_zEzaUW8bJ6F4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Spain&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;328,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--CN_zWoMuWvwIlIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0467"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--StatementGeographicalAxis__country--NL_z875TLv8VRYg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Netherlands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_z0FW5y57kI5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;189,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_zHdW40dlmvJc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Research and development expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;189,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</LIXT:ResearchDevelopmentTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_country_US"
      decimals="0"
      unitRef="USD">135907</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31_country_US"
      decimals="0"
      unitRef="USD">74531</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_country_ES"
      decimals="0"
      unitRef="USD">975</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31_country_ES"
      decimals="0"
      unitRef="USD">328829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31_country_CN"
      decimals="0"
      unitRef="USD">860</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_country_NL"
      decimals="0"
      unitRef="USD">52203</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31_country_NL"
      decimals="0"
      unitRef="USD">54230</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">189085</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">458450</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">189085</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">458450</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z2sPVG6ul9sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_82B_zKdZtjPVadK7"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230331_zNnqwhHJt3Xa" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230331_zvY7gs7W6y83" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share. On March 17, 2015, the Company
filed a Certificate of Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware
Secretary of State to amend the Company&#x2019;s certificate of incorporation. The Company has designated a total of &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUibnSNBah6l" title="Preferred stock, shares authorized"&gt;350,000&lt;/span&gt; shares as
Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority
of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The
holders of each tranche of &lt;span id="xdx_901_ecustom--NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUIp53vnp2o3" title="Principal Cash Obligations and Commitments"&gt;175,000&lt;/span&gt; shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal
to &lt;span id="xdx_90B_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20150316__20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5ECfpZGE9s8" title="Preferred stock dividend, percentage"&gt;1&lt;/span&gt;% of the annual net revenue of the Company divided by &lt;span id="xdx_906_ecustom--AnnualNetRevenueDividedByConvertedOrRedeemedShares_iI_pid_c20150317__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zA19qPj4lgXk" title="Annual net revenue"&gt;175,000&lt;/span&gt;, until converted or redeemed. As of March 31, 2023 and December 31,
2022, the Company had &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zWAaGJRBnEv2" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_zkivoHpRPzYf" title="Preferred stock, shares authorized"&gt;9,650,000&lt;/span&gt;&lt;/span&gt; shares of undesignated preferred stock which may be issued with such rights and powers as the Board of
Directors may designate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3D6cgV8W529" title="Preferred stock, conversion description"&gt;Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pp4d_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zldrTKtXjoF4" title="Preferred stock convertible into common stock"&gt;2.0833&lt;/span&gt; shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zGV5RQdt3V6" title="Gross proceeds from sale of transaction"&gt;21,875,000&lt;/span&gt;&lt;/span&gt;. The Series A Convertible
Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. The Series A Convertible Preferred
Stock does not have a cash liquidation preference.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
fully converted, the &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zDYQFr2HmJ88" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zXCjOsD5QM17" title="Preferred stock, shares outstanding"&gt;350,000&lt;/span&gt;&lt;/span&gt; outstanding shares of Series A Convertible Preferred Stock would convert into &lt;span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zSb94vYXBaN7" title="Preferred stock convertible into common stock"&gt;&lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zf0d4pg74ywa" title="Preferred stock convertible into common stock"&gt;729,167&lt;/span&gt;&lt;/span&gt; shares of common stock
at March 31, 2023 and December 31, 2022. The Series A Convertible Preferred Stock has no right to cash, except with respect to the payment
of the aforementioned dividend based on the generation of revenues by the Company. The shares of Series A Convertible Preferred Stock
do not have any registration rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible
Preferred Stock as a permanent component of stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue a total of &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230331_ziaEH8adCnu3" title="Common stock, shares authorized"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zJNHvDwDao42" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230331_z8rKObCphKkb" title="Common Stock, Par or Stated Value Per Share"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zuppRRCLACab" title="Common Stock, Par or Stated Value Per Share"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. As of March 31, 2023 and December
31, 2022, the Company had &lt;span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20230331_zeXWL6eLw9a6" title="Common stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230331_zHMLLAG5qGEg" title="Common stock, shares outstanding"&gt;16,659,093&lt;/span&gt;&lt;/span&gt; shares and &lt;span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_ziTbsV210921" title="Common stock, shares issued"&gt;&lt;span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zjMKKCwvPaYl" title="Common stock, shares outstanding"&gt;16,646,593&lt;/span&gt;&lt;/span&gt; shares, respectively, of common stock issued, issuable and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 12, 2022, the Company completed the sale of &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfR2tSuTIhx4" title="Number of common stock shares issued during period"&gt;2,900,000&lt;/span&gt; shares of common stock at a price of $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR9EQyFxQE9g" title="Sale of stock price per share"&gt;2.00&lt;/span&gt; per share in a registered direct
equity offering, generating gross proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaVfzQ4yMnZ4" title="Proceeds from issuance initial public offering"&gt;5,800,000&lt;/span&gt;. The total cash costs of this offering were $&lt;span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaXtp37xZGC7" title="Costs of public offering"&gt;658,616&lt;/span&gt;, resulting in net proceeds
of $&lt;span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220411__20220412__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGp5TyHmXEof" title="Net proceeds from issuance of stock"&gt;5,141,384&lt;/span&gt;. Pursuant to the placement agents&#x2019; agreement, the Company granted warrants to the placement agents to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_zOT9jawiuzJ4" title="Warrants to purchase shares"&gt;290,000&lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220412__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsMember_z0bMeQ79mE9d" title="Warrant exercise price"&gt;2.00&lt;/span&gt; per share exercisable through April 14, 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 10, 2023, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHAR58ibB2k9" title="Stock issued new issue shares"&gt;12,500&lt;/span&gt; shares of common stock upon the exercise of a stock option in the form of a warrant held by
a consultant to the Company for &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5owQ7manCc" title="Stock issued new issue shares"&gt;12,500&lt;/span&gt; shares exercisable at $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJK2NBygq5pc" title="Warrant exercise price"&gt;0.5025&lt;/span&gt; per share for total cash proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20230309__20230310__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUlbKA53cRG4" title="Proceeds from warrant exercises"&gt;6,281&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zWHHRASppmL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity during the three months ended March 31, 2023 is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z5FIK2ZOXcC1" style="display: none"&gt;Schedule of Warrants Outstanding&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYBpF6OJPfz3" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;1,900,310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfahfJ3pFEL9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;5.016&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdAlOraAAbKe" style="text-align: right" title="Number of Shares, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0555"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwJXs97qiP8k" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0557"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTdN3OT879F5" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSdQ13mDDSi1" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0561"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwPl9OGmQZ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0563"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBiCZ64EhOJ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0565"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za0FKoVFjKN" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;1,900,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zuRoGWSoKVg6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;5.016&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYRR0XXV66lc" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;2.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbABWHjuhHSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Beginning Balance"&gt;1,900,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQl2PspOuIf6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"&gt;5.016&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRx9ObsZhHMl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Ending Balance"&gt;1,900,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqozfabtLFEj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"&gt;5.016&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqam0IIlwgQe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;2.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zqkvD14OM1Yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zgsX0KiSJiUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zErVmRl0DmTk" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 47%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXDiEWWp4yM9" title="Exercise Prices"&gt;2.000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyF6tCGQ5dBg" style="width: 47%; text-align: right" title="Warrants Outstanding Shares"&gt;290,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zTGcmYyiPujg" title="Exercise Prices"&gt;3.700&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3zC5HO0yIn4" style="text-align: right" title="Warrants Outstanding Shares"&gt;113,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFdwUhI9DUu3" title="Exercise Prices"&gt;5.700&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVDS5dzBbnb6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;1,497,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331_zWpd06WveR0i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;1,900,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zqr4CMNFqcY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on a fair market value of $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zZu15BQk7cpk" title="Fair market value of stock"&gt;0.83&lt;/span&gt; per share on March 31, 2023, there was no intrinsic value attributed to exercisable but unexercised common
stock warrants at March 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Information
with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesAuthorized>
    <LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">175000</LIXT:NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2015-03-162015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.01</us-gaap:PreferredStockDividendRatePercentage>
    <LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares
      contextRef="AsOf2015-03-17_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">175000</LIXT:AnnualNetRevenueDividedByConvertedOrRedeemedShares>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-03-31_custom_UndesignatedPreferredStockMember"
      decimals="INF"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_UndesignatedPreferredStockMember"
      decimals="INF"
      unitRef="Shares">9650000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockConversionBasis contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember">Each
share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 2.0833 shares of common stock (subject
to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion
rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000</us-gaap:PreferredStockConversionBasis>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember_us-gaap_CommonStockMember"
      decimals="4"
      unitRef="Shares">2.0833</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember5713203"
      decimals="0"
      unitRef="USD">21875000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-03-31_custom_SeriesAConvertiblePreferredStockMember5713203"
      decimals="INF"
      unitRef="Shares">729167</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-01-012022-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">729167</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">16659093</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">16659093</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">16646593</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">16646593</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-04-12_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">2.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">658616</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-04-112022-04-12_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5141384</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-12_custom_PlacementAgentsMember"
      decimals="INF"
      unitRef="Shares">290000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-12_custom_PlacementAgentsMember"
      decimals="INF"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-092023-03-10_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-10_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.5025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-03-092023-03-10_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">6281</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zWHHRASppmL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of common stock warrant activity during the three months ended March 31, 2023 is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z5FIK2ZOXcC1" style="display: none"&gt;Schedule of Warrants Outstanding&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Warrants outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYBpF6OJPfz3" style="width: 14%; text-align: right" title="Number of Shares, Warrants Outstanding, Beginning Balance"&gt;1,900,310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfahfJ3pFEL9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning"&gt;5.016&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zdAlOraAAbKe" style="text-align: right" title="Number of Shares, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0555"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwJXs97qiP8k" style="text-align: right" title="Weighted Average Exercise Price, Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0557"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTdN3OT879F5" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSdQ13mDDSi1" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0561"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPwPl9OGmQZ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0563"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zBiCZ64EhOJ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0565"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_za0FKoVFjKN" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding, Ending Balance"&gt;1,900,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zuRoGWSoKVg6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending"&gt;5.016&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYRR0XXV66lc" title="Weighted Average Remaining Contractual Life (in Years), Outstanding"&gt;2.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbABWHjuhHSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Beginning Balance"&gt;1,900,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQl2PspOuIf6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"&gt;5.016&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRx9ObsZhHMl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants exercisable, Ending Balance"&gt;1,900,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice_iI_c20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqozfabtLFEj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"&gt;5.016&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqam0IIlwgQe" title="Weighted Average Remaining Contractual Life (in Years), Exercisable"&gt;2.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">1900310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.016</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">1900310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare
      contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.016</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468">P2Y10M24D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">1900310</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.016</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="Shares">1900310</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_custom_CommonStockWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.016</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice>
    <LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-03-31_custom_CommonStockWarrantsMember5713468">P2Y10M24D</LIXT:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm>
    <LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_89F_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zgsX0KiSJiUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023, the outstanding warrants are exercisable at the following prices per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zErVmRl0DmTk" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 47%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zXDiEWWp4yM9" title="Exercise Prices"&gt;2.000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zyF6tCGQ5dBg" style="width: 47%; text-align: right" title="Warrants Outstanding Shares"&gt;290,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zTGcmYyiPujg" title="Exercise Prices"&gt;3.700&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3zC5HO0yIn4" style="text-align: right" title="Warrants Outstanding Shares"&gt;113,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFdwUhI9DUu3" title="Exercise Prices"&gt;5.700&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVDS5dzBbnb6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding Shares"&gt;1,497,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230331_zWpd06WveR0i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding Shares"&gt;1,900,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">2.000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">290000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">3.700</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">113310</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">5.700</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">1497000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">1900310</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-03-31_custom_CommonStockWarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.83</us-gaap:SharePrice>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z0jjqBsyvcOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_82D_zYDN9y9cspp9"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
party transactions include transactions with the Company&#x2019;s officers, directors and affiliates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
Agreements with Officers&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. The employment agreements
are automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to the
end of the applicable one-year period, or by death, or by termination for cause. These employment agreements were automatically renewed
for additional one-year periods in July and August 2021 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, for Dr. Kovach to continue
to act as the Company&#x2019;s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $&lt;span id="xdx_901_eus-gaap--SalariesAndWages_c20201001__20201001__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_z6LbMc8Fflfe" title="Annual salary"&gt;250,000&lt;/span&gt;. During
the three months ended March 31, 2023 and 2022, the Company paid $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_ziWoGf2Z3qH6" title="Compensation"&gt;62,500&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrKovachMember_zk5EtyKoMmSj" title="Compensation"&gt;62,500&lt;/span&gt;, respectively, to Dr. Kovach under this employment
agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020 to act as the Company&#x2019;s Chief
Medical Officer, with an annual salary of $&lt;span id="xdx_90B_eus-gaap--SalariesAndWages_c20200730__20200801__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_zQTpBpFGf1pj" title="Annual salary"&gt;150,000&lt;/span&gt;. Effective May 1, 2021, Dr. Miser&#x2019;s annual salary was increased to $&lt;span id="xdx_903_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zO3EvcOw4k7d" title="Increase in annual salary"&gt;175,000&lt;/span&gt;.
Dr. Miser is required to devote at least 50% of his business time to the Company&#x2019;s activities. During the three months ended March
31, 2023 and 2022, the Company paid $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z85oM0dccP1j" title="Compensation"&gt;43,750&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrJamesSMiserMDMember_z2YK0jDd9Xn5" title="Compensation"&gt;43,750&lt;/span&gt;, respectively, to Dr. Miser under this employment agreement, which costs are
included in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the
Company&#x2019;s Chief Administrative Officer, with an annual salary of $&lt;span id="xdx_903_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zGtLO6XrAsli" title="Annual salary"&gt;120,000&lt;/span&gt;. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased),
a former member of the Company&#x2019;s Board of Directors who died on October 30, 2022 and was a significant stockholder of and consultant
to the Company, and is the son of Dr. Stephen Forman, a member of the Company&#x2019;s Board of Directors. Julie Forman, the wife of Mr.
Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which firm the Company&#x2019;s
cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman&#x2019;s
annual salary was increased to $&lt;span id="xdx_900_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zSIJDbG7aiFh" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief
Operating Officer with an annual salary of $&lt;span id="xdx_90D_eus-gaap--OfficersCompensation_c20221105__20221106__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_ztlOJZmf1Tu6" title="Compensation"&gt;&lt;span title="Compensation"&gt;200,000&lt;/span&gt;&lt;/span&gt;. Effective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance,
pursuant to which Mr. Forman was paid $&lt;span id="xdx_908_eus-gaap--PaymentsForRent_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FormanMember_zoXprCaTEeu7" title="Paid office rent"&gt;2,583&lt;/span&gt; for the three months ended March 31, 2023. During the three months ended March 31, 2023
and 2022, the Company paid $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zKfRL2lzgKC8" title="Compensation"&gt;50,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--EricJFormanMember_zNoZ9E6dUgJ5" title="Compensation"&gt;43,750&lt;/span&gt;, respectively, to Mr. Forman under this employment agreement, which costs are included
in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company&#x2019;s Vice President
and Chief Financial Officer, with an annual salary of $&lt;span id="xdx_907_eus-gaap--SalariesAndWages_c20200811__20200812__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zlGX31nkGZ85" title="Annual salary"&gt;120,000&lt;/span&gt;. Effective May 1, 2021, Mr. Weingarten&#x2019;s annual salary was increased
to $&lt;span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20210429__20210501__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zIfZSsN4jhxa" title="Increase in annual salary"&gt;175,000&lt;/span&gt;. During the three months ended March 31, 2023 and 2022, the Company paid $&lt;span id="xdx_909_eus-gaap--OfficersCompensation_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zeaY7sMG6He9" title="Compensation"&gt;43,750&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--RobertNWeingartenMember_zEF5Ov0zQ0R1" title="Compensation"&gt;43,750&lt;/span&gt;, respectively, to Mr. Weingarten
under this employment agreement, which costs are included in general and administrative costs in the Company&#x2019;s consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Appointment
of Dr. Ren&#xe9; Bernards to the Board of Directors&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
as of June 15, 2022, Dr. Ren&#xe9; Bernards was appointed to the Company&#x2019;s Board of Directors as an independent director. Dr.
Bernards is a leader in the field of molecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. As a
new director, in lieu of a grant of stock options, Dr. Bernards received a one-time cash board fee of $&lt;span id="xdx_90E_eus-gaap--ManagementFeePayable_iI_c20220615_z14zKa8Uw9La" title="Cash board fee payable"&gt;100,000&lt;/span&gt;, which was paid upon his
appointment to the Board of Directors, and an annual cash board fee of $&lt;span id="xdx_902_ecustom--ManagementFeePayableQuarterly_iI_c20220615_zu0trpnAIT6g" title="Cash board fee payable"&gt;40,000&lt;/span&gt;, payable quarterly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 8, 2021, the Company has previously entered into a Development Collaboration Agreement with the Netherlands Cancer Institute,
Amsterdam, one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research
center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range
of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations, as described at Note 9.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Compensatory
Arrangements for Members of the Board of Directors&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the independent members of the
Board of Directors and committee members. Effective May 25, 2022, the Board of Directors approved an amendment to the program. Officers
who also serve on the Board of Directors are not compensated separately for their service on the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
compensation for independent directors, payable quarterly, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Base
director compensation - $&lt;span id="xdx_90A_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__srt--DirectorMember_zmeY5lCzWo8d" title="Compensation"&gt;20,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of audit committee - additional $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfAuditCommitteeMember_zhvXfEl7bgV1" title="Compensation"&gt;10,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman
of any other committees - additional $&lt;span id="xdx_90B_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--ChairmanOfOtherCommitteesMember_zjM64qZpMoh5" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of audit committee - additional $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfAuditCommitteeMember_zpPYMt9v5wr3" title="Compensation"&gt;5,000&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Member
of any other committees - additional $&lt;span id="xdx_90F_eus-gaap--OfficersCompensation_c20210408__20210409__srt--TitleOfIndividualAxis__custom--MemberOfOtherCommitteesMember_zfNZcItlRmlj" title="Compensation"&gt;2,500&lt;/span&gt; per year&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
compensation for independent directors is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Appointment
of new independent directors - The Company will grant options to purchase &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zuNKM3trb88b" title="Options, grants in period, gross"&gt;250,000&lt;/span&gt; shares of common stock, exercisable for a period of
five years, at the closing market price on the date of grant, vesting &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zRScVYoFZdB9" title="Share-based payment award, award vesting period"&gt;50&lt;/span&gt;% on the grant date and the remaining &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember_zR5JvlkEazy2" title="Share-based payment award, award vesting period"&gt;50&lt;/span&gt;% vesting &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230331_z1k5g1cBMfSb" title="Award vesting rights, percentage"&gt;12.5&lt;/span&gt;% on the
last day of each calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject
to continued service. At the discretion of the Board of Directors, for a nominee to the Board of Directors who is restricted by their
respective institution or employer from receiving equity-based compensation, in lieu of the grant of such stock options, the Company
may elect to pay a one-time cash fee of $&lt;span id="xdx_90E_eus-gaap--CostOfRevenue_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--NewIndependentDirectorMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z7xZheQFScV4" title="One time cash"&gt;100,000&lt;/span&gt; to such director, payable upfront.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
grant of options to independent directors - Effective on the last business day of the month of June, the Company will grant options to
purchase &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_z6M5CGhtMYP7" title="Options, grants in period, gross"&gt;100,000&lt;/span&gt; shares of common stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting
&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_uPure_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember_zI7SoEkzOfD1" title="Share-based payment award, award vesting period"&gt;12.5&lt;/span&gt;% on the last day of each calendar quarter beginning in the quarter immediately subsequent to the date of grant until fully vested,
subject to continued service. If any director has served for less than 12 full calendar months at the grant date, the amount of such
stock option grant shall be prorated based on the length of service of such director. At the discretion of the Board of Directors, for
a nominee to the Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation,
in lieu of the grant of such stock options, the Company may elect to pay an annual cash fee of $&lt;span id="xdx_905_eus-gaap--CostOfRevenue_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--AnnualGrantOfOptionsMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_z8mCU1XvDv2g" title="Annual cash fee"&gt;40,000&lt;/span&gt; to such director, payable quarterly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
cash compensation paid to independent directors was $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zFQYNl4gmim" title="Stock based compensation"&gt;42,500&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IndependentDirectorMember_zwxvYeq51GPl" title="Stock based compensation"&gt;32,500&lt;/span&gt;, respectively, for the three months ended March 31, 2023 and
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation granted to members of the Company&#x2019;s Board of Directors, officers and affiliates is described at Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zIaapNhijKDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months ended March 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zGq9IBIsvPSd" style="display: none"&gt;Summary of Related Party Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20230331_zrPvHzzbK4n2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220331_zoenYFrgw2lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Related party costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--CashBasedMember_zhqsl2hIf9Ql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;242,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;226,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--StockBasedMember_zIvvdDw3Uiml" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Stock-based&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;276,980&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;339,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_zVPx2m1zwnb2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;519,480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;565,922&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfRevenue_zLVSWL4Be6M2" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Related party costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;519,480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;565,922&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_zygDuHHkbNS6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="From2020-10-012020-10-01_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:SalariesAndWages>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      unitRef="USD">62500</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_DrKovachMember"
      decimals="0"
      unitRef="USD">62500</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-07-302020-08-01_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-04-292021-05-01_custom_DrJamesSMiserMDMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">175000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_DrJamesSMiserMDMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">175000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_custom_EmploymentAgreementMember_srt_ChiefOperatingOfficerMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-03-31_custom_FormanMember"
      decimals="0"
      unitRef="USD">2583</us-gaap:PaymentsForRent>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_EricJFormanMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:SalariesAndWages
      contextRef="From2020-08-112020-08-12_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2021-04-292021-05-01_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">175000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2023-01-012023-03-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-01-012022-03-31_custom_EmploymentAgreementMember_custom_RobertNWeingartenMember"
      decimals="0"
      unitRef="USD">43750</us-gaap:OfficersCompensation>
    <us-gaap:ManagementFeePayable contextRef="AsOf2022-06-15" decimals="0" unitRef="USD">100000</us-gaap:ManagementFeePayable>
    <LIXT:ManagementFeePayableQuarterly contextRef="AsOf2022-06-15" decimals="0" unitRef="USD">40000</LIXT:ManagementFeePayableQuarterly>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_srt_DirectorMember"
      decimals="0"
      unitRef="USD">20000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfAuditCommitteeMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_ChairmanOfOtherCommitteesMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfAuditCommitteeMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2021-04-082021-04-09_custom_MemberOfOtherCommitteesMember"
      decimals="0"
      unitRef="USD">2500</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-03-31_custom_NewIndependentDirectorMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-01-012023-03-31_custom_NewIndependentDirectorMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-01-012023-03-31_custom_NewIndependentDirectorMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-03-31_custom_NewIndependentDirectorMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:CostOfRevenue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-03-31_custom_AnnualGrantOfOptionsMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">40000</us-gaap:CostOfRevenue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_IndependentDirectorMember"
      decimals="0"
      unitRef="USD">42500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_IndependentDirectorMember"
      decimals="0"
      unitRef="USD">32500</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zIaapNhijKDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors
for their services on the Board of Directors, for the three months ended March 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zGq9IBIsvPSd" style="display: none"&gt;Summary of Related Party Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20230331_zrPvHzzbK4n2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220331_zoenYFrgw2lc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Related party costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--CashBasedMember_zhqsl2hIf9Ql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Cash-based&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;242,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;226,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CostOfRevenue_hus-gaap--RelatedAndNonrelatedPartyStatusAxis__custom--StockBasedMember_zIvvdDw3Uiml" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Stock-based&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;276,980&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;339,672&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_zVPx2m1zwnb2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;519,480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;565,922&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfRevenue_zLVSWL4Be6M2" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Related party costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;519,480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;565,922&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-03-31_custom_CashBasedMember"
      decimals="0"
      unitRef="USD">242500</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-03-31_custom_CashBasedMember"
      decimals="0"
      unitRef="USD">226250</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-03-31_custom_StockBasedMember"
      decimals="0"
      unitRef="USD">276980</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-03-31_custom_StockBasedMember"
      decimals="0"
      unitRef="USD">339672</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">519480</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">565922</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">519480</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">565922</us-gaap:CostOfRevenue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zlx85rSHZnFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_82B_z8QWitmOLsRl"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services
of employees, contractors, and consultants of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which was subsequently
approved by the stockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options,
restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards to employees, officers, directors and
consultants of the Company and its affiliates, initially for a total of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200713__20200714__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zqsGmZmFaZR4" title="Number of restricted stock issued"&gt;2,333,333&lt;/span&gt; shares of the Company&#x2019;s common stock, under terms
and conditions as determined by the Company&#x2019;s Board of Directors. On October 7, 2022, the stockholders of the Company approved
an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zd0Fcox30a17" title="Common shares avaliable for issuable"&gt;1,800,000&lt;/span&gt; shares, to a total of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20221006__20221007__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zkv3MXQmhtR6" title="Shares total"&gt;4,133,333&lt;/span&gt;
shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2023, unexpired stock options for &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zwUO0BeNqqW1" title="Shares outstanding"&gt;2,603,125&lt;/span&gt; shares were issued and outstanding under the 2020 Plan and &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zWPVtAljTKfe" title="Shares were available for issuance"&gt;1,530,208&lt;/span&gt; shares
were available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the
Company&#x2019;s expectation of dividend payouts and is assumed to be zero. The estimated volatility is based on the historical volatility
of the Company&#x2019;s common stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as
the mid-point between the vesting period and the contractual term (the &#x201c;simplified method&#x201d;). The fair market value of the
common stock is determined by reference to the quoted market price of the common stock on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no stock options requiring an assessment of value issued during the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zLTxKhMnGe66" title="Stock options description"&gt;On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zlGbwraY7wR2" title="Stock options granted to purchase common stock, issued"&gt;58,333&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxL_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zsbhhFkNX5hc" title="Stock option vested exercisable term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;five&lt;/span&gt;&lt;/span&gt; years at an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4itUxTf3ZEi" title="Stock options are exercisable price per share"&gt;7.14&lt;/span&gt; per share, which was equal to the closing market
price of the Company&#x2019;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_90C_ecustom--FairValueOfStockOptions_c20200713__20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zj3y8XijbpV2" title="Fair value of stock options"&gt;400,855&lt;/span&gt; ($&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pp4d_c20200715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z4DZdMErs893" title="Stock price per share"&gt;6.8718&lt;/span&gt; per share), of which $&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z40vRAub5I0a" title="Stock options fully vested amount, fair value"&gt;100,214&lt;/span&gt; was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zikYZ5776hU1" title="Stock based compensation"&gt;24,710&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EricJFormanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z0elXYAyT83e" title="Stock based compensation"&gt;24,710&lt;/span&gt;, respectively, with respect to these stock options&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2020, in connection with an employment agreement entered into with &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8t4ey3Gs745" title="Stock options description"&gt;Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zgiC3QBpGR1g" title="Stock options granted to purchase common stock, issued"&gt;83,334&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of five years at an exercise price of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zqOuXVFQaYH8" title="Stock options are exercisable price per share"&gt;7.14&lt;/span&gt; per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_906_ecustom--FairValueOfStockOptions_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zo3V6BkEwHG5" title="Fair value of stock options"&gt;572,650&lt;/span&gt; ($&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pp4d_c20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zhNjUAEO79vg" title="Stock price per share"&gt;6.8718&lt;/span&gt; per share), of which $&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200730__20200801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zlinjwNgPBb6" title="Stock options fully vested amount, fair value"&gt;143,163&lt;/span&gt; was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z8IzHyUH93K7" title="Stock based compensation"&gt;35,300&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrJamesMiserMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zRf5njdLExFf" title="Stock based compensation"&gt;35,300&lt;/span&gt;, respectively, with respect to these stock options&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zBB3FWsB1Jk9" title="Stock options description"&gt;On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zt2BMBhQmeB1" title="Stock options granted to purchase common stock, issued"&gt;58,333&lt;/span&gt; shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of five years at an exercise price of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zVCYsW7Uhfzc" title="Stock options are exercisable price per share"&gt;7.14&lt;/span&gt; per share, which was equal to the closing market price of the
Company&#x2019;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $&lt;span id="xdx_90F_ecustom--FairValueOfStockOptions_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zT6QqmTpiKLa" title="Fair value of stock options"&gt;400,855&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp4d_c20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z3XicVaSMw2b" title="Stock price per share"&gt;6.8718&lt;/span&gt; per share), of which $&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200811__20200812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_za9nLHTwfxah" title="Stock options fully vested amount, fair value"&gt;100,214&lt;/span&gt; was attributable to the portion of the stock
options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair
value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months
ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations
of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zErm9K9REoHc" title="Stock based compensation"&gt;24,710&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertNWeingartenMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zdcf9cJX18Ak" title="Stock based compensation"&gt;24,710&lt;/span&gt;, respectively, with respect to these stock options&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 9, 2021, &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zrvmRZBOvdZ2" title="Stock options description"&gt;the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#x2019;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zWylQPsf99d" title="Number of fully vested option exercisable"&gt;250,000&lt;/span&gt; shares of the Company&#x2019;s
common stock, exercisable for a period of five years at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210409__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zAWO1g2FcVo2" title="Stock options are exercisable price per share"&gt;3.20&lt;/span&gt; per share (the closing market price on the grant date),
vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_906_ecustom--FairValueOfStockOptions_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zc6kHvPMLcB6" title="Fair value of stock options"&gt;753,611&lt;/span&gt; ($&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pp4d_c20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z8VDv2m48mg1" title="Stock price per share"&gt;3.0144&lt;/span&gt; per share), of which $&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210401__20210409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjk2FIIFMn56" title="Stock options fully vested amount, fair value"&gt;376,800&lt;/span&gt; was attributable to the portion of the stock options fully vested
on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock
options was being charged to operations ratably from April 9, 2021 through June 30, 2023. However, vesting of these stock options terminated
on October 30, 2022, the date that Mr. Schwartzberg died. During the three months ended March 31, 2023 and 2022, the Company recorded
charges to general and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zRD6RHW7oJCd" title="Stock based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrWinsonSzeChunHoMember_zuciQZy1fcd" title="Stock based compensation"&gt;41,764&lt;/span&gt;, respectively, with respect
to these stock options&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 11, 2021, &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210510__20210511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zad7V0JUW1ni" title="Stock options description"&gt;the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zkOHzOPHoWZb" title="Number of fully vested option exercisable"&gt;250,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of five
years at an exercise price of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zqf2w4989oV3" title="Stock options are exercisable price per share"&gt;2.80&lt;/span&gt; per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_90C_ecustom--FairValueOfStockOptions_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zp3ZJuW6vHp" title="Fair value of stock options"&gt;658,363&lt;/span&gt; ($&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pp4d_c20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_z5nwp5fFizVe" title="Stock price per share"&gt;2.6335&lt;/span&gt; per
share), of which $&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20210510__20210511__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember_zMhT266vInO" title="Stock options fully vested amount, fair value"&gt;329,188&lt;/span&gt; was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from May 11, 2021 through June 30, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general
and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z7IexJmAmKN1" title="Stock based compensation"&gt;37,983&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsReginaBrownMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zPVSljrJX9Ni" title="Stock based compensation"&gt;37,983&lt;/span&gt;, respectively, with respect to these stock
options&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2021, &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210628__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zI6p2Y2OysFb" title="Stock options description"&gt;the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOueVA0wQ0ai" title="Number of fully vested option exercisable"&gt;100,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__srt--TitleOfIndividualAxis__custom--NonOfficerDirectorsMember_zFbzYnPfXfOb" title="Number of fully vested option exercisable"&gt;500,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of five years at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zOXEiP2BSIt8" title="Stock options are exercisable price per share"&gt;3.03&lt;/span&gt; per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90C_ecustom--FairValueOfStockOptions_c20210601__20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z9K19CeHR6xa" title="Fair value of stock options"&gt;1,421,095&lt;/span&gt; ($&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pp5d_c20210630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_z5Ohjr1O2Tpc" title="Stock price per share"&gt;2.84225&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2021 through June 30,
2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the
consolidated statement of operations of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zrYAhUOntEn8" title="Stock based compensation"&gt;105,123&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20220101__20220331__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zKgMTJmcnpP" title="Stock based compensation"&gt;175,205&lt;/span&gt;, respectively, with respect to these stock options&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 17, 2022, &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_ztcIETdO0ZXf" title="Stock options description"&gt;the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zCXEfeY4t0l4" title="Number of fully vested option exercisable"&gt;250,000&lt;/span&gt; shares of the Company&#x2019;s common stock, exercisable for a period of five years
at an exercise price of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zNSvzku9Wr41" title="Stock options are exercisable price per share"&gt;0.74&lt;/span&gt; per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $&lt;span id="xdx_90B_ecustom--FairValueOfStockOptions_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zNxgZpx8zQOg" title="Fair value of stock options"&gt;158,525&lt;/span&gt; ($&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pp4d_c20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zLo2xH6GIDK6" title="Stock price per share"&gt;0.6341&lt;/span&gt; per
share), of which $&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue_c20220616__20220617__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_zOHi15HNMCX3" title="Stock options granted to purchase common stock, issued"&gt;79,263&lt;/span&gt; was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from June 17, 2022 through June 30, 2024. During the three months ended March 31, 2023, the Company recorded a total charge to general
and administrative costs in the consolidated statement of operations of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BasvanderBaanMember_z1W12hLGNXo6" title="Stock based compensation"&gt;9,588&lt;/span&gt; with respect to these stock options&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2022, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220601__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_z7LBvkZ1DYpb" title="Stock options description"&gt;the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220602__20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_z9e73flIIqfc" title="Purchase of shares"&gt;100,000&lt;/span&gt; shares (a total
of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zd7v5tMI1yn1" title="Number of fully vested option exercisable"&gt;500,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of five years at an exercise price of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pp2d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zQEanGW1Zgnk" title="Stock options are exercisable price per share"&gt;0.74&lt;/span&gt; per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_c20220601__20220630__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zy5GNVxYWvL4" title="Fair value of stock options"&gt;316,700&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pp5d_c20220630__srt--TitleOfIndividualAxis__srt--DirectorMember_zgmO8srEOh1h" title="Stock price per share"&gt;0.6334&lt;/span&gt; per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
During the three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated
statement of operations of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__srt--DirectorMember_z0UUw35na8ee" title="Stock based compensation"&gt;23,394&lt;/span&gt; with respect to these stock options&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zJpyxciYa1Uj" title="Number of fully vested option exercisable"&gt;200,000&lt;/span&gt; shares
(a total of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zYp1VHeTP13l" title="Number of fully vested option exercisable"&gt;800,000&lt;/span&gt; shares) of the Company&#x2019;s common stock, exercisable for a period of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dxL_c20221106__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zKW4qRcL13wa" title="Stock option vested exercisable term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;five&lt;/span&gt;&lt;/span&gt; years at an exercise price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zY2Bkw1ZDt87" title="Share price"&gt;2.00&lt;/span&gt;
per share, vesting &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zNZX3C3ZcIPc" title="Share based compensation vesting rights, percentage"&gt;25&lt;/span&gt;% on issuance and 25% on each anniversary date thereafter until fully vested, subject to continued service. The
total fair value of the &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zdtVs9fc8Eng" title="Stock options granted to purchase common stock, issued"&gt;800,000&lt;/span&gt; stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be
$&lt;span id="xdx_90E_ecustom--FairValueOfStockOptions_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zkgaTrPCwE0c" title="Fair value of stock options"&gt;262,560&lt;/span&gt; ($&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pp4d_c20221106__srt--TitleOfIndividualAxis__custom--FourOfficersMember_zd5pRXQK47mk" title="Stock price per share"&gt;0.3282&lt;/span&gt; per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the
three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated statement
of operations of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20230101__20230331__srt--TitleOfIndividualAxis__custom--FourOfficersMember_z4cvNTG6jTEi" title="Stock based compensation"&gt;16,172&lt;/span&gt; with respect to these stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2022, the Company issued a stock option, in the form of a warrant, to BioPharmaWorks to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221106_zcYl0u0JQlsk" title="Number of fully vested option exercisable"&gt;100,000&lt;/span&gt; shares of the Company&#x2019;s
common stock, which was fully vested upon issuance and is exercisable for a period of five years at $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221106__srt--TitleOfIndividualAxis__srt--DirectorMember_zVol09Nf1Mck" title="Stock options are exercisable price per share"&gt;0.5025&lt;/span&gt; per share (the closing market
price on the issue date). The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined
to be $&lt;span id="xdx_908_ecustom--FairValueOfStockOptions_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zTfkB7YQ5FPk" title="Fair value of stock options"&gt;43,264&lt;/span&gt; ($&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pp5d_c20221106__srt--TitleOfIndividualAxis__custom--FiveNonOfficerDirectorsMember_zowLfN7cmHWg" title="Stock price per share"&gt;0.4326&lt;/span&gt; per share) and was charged to general and administrative costs in the consolidated statement of operations on
that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr.
Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company&#x2019;s Board of Directors at the
Company&#x2019;s Annual Meeting of Stockholders held on October 7, 2022, and Gil Schwartzberg, a director of the Company, died on October
30, 2022. Accordingly, the unvested stock options for each such person ceased vesting effective as of the respective dates that their
service on the Company&#x2019;s Board of Directors terminated. Furthermore, the expiration date of all vested stock options owned by such
persons are contractually scheduled to expire one year from the respective dates that their service on the Company&#x2019;s Board of Directors
terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zUkPbHeRX7Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the three months ended March 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zuBc1L43seP" style="display: none"&gt;Summary of Stock-based Compensation Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20230331_zSZh7j0mzpU4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20220331_zeIGOCKaCUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zuFEZ9VFZ4Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Related parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;276,980&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;339,672&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zPBmOzJM8fld" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-related parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_zqzNOapDc172" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;276,980&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;339,672&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zO4kBW9JbnM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFbHoJbCUcD" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2023 is as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_zC1BLKG8RLVh" style="display: none"&gt;Summary of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331_zI3VBGN0CW9g" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;3,894,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zI5mFDwxoStb" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;2.9183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230331_zJxWLckPa9el" style="text-align: right" title="Number of shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0866"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_z9c0e6id6qMa" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230331_z4bwHDiRcvJg" style="text-align: right" title="Number of shares, Exercised"&gt;(12,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zN72wDcIDXh7" style="text-align: right" title="Weighted average exercise price, exercised"&gt;0.5025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230331_z0VhiFm81I23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zWGHOq5LjYh8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options outstanding at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230331_zwEr2wT4jSKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;3,882,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zkiMipGUeKjc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;2.9260&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zYXAUwcsWQja" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;2.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCQIPksNcUE" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end"&gt;2,819,792&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z61mfmRsYcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end"&gt;3.2834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230331_z6HQldkB2dr" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end"&gt;2,913,542&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230331_zHj7mjfQG6x" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end"&gt;3.2431&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_z3TJtDZ276N8" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zWVnpF1wKIFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
deferred compensation expense for the outstanding value of unvested stock options was approximately $&lt;span id="xdx_902_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230101__20230331_zIV4eIrlg2jf" title="Total deferred compensation expense for outstanding value of unvested stock options"&gt;605,000&lt;/span&gt; at March 31, 2023, which
will be recognized subsequent to March 31, 2023 over a weighted-average period of approximately &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtM_c20230101__20230331_zDxF02tpXrm6" title="Stock option vested exercisable term"&gt;15&lt;/span&gt; months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z8Zbvsm0pQDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at March 31, 2023
are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zzNX2AxBd5o8" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zIt0gX5Bwdr2" style="width: 30%; text-align: right" title="Exercise Prices"&gt;0.5025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zkbYvjymyPB1" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"&gt;87,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zO9kuVSjLadl" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"&gt;87,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztpLw5PBn4X9" style="text-align: right" title="Exercise Prices"&gt;0.7400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zvyxXN8Whpvg" style="text-align: right" title="Options Outstanding (Shares)"&gt;575,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxmNYagyKaq3" style="text-align: right" title="Options Exercisable (Shares)"&gt;309,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zClDDRQs6NV2" style="text-align: right" title="Exercise Prices"&gt;1.6800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmpFB26ywZpk" style="text-align: right" title="Options Outstanding (Shares)"&gt;33,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zI9bxUmLn6A5" style="text-align: right" title="Options Exercisable (Shares)"&gt;33,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zBv0FSJ1oCw9" style="text-align: right" title="Exercise Prices"&gt;2.0000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zooXVbWkFGBj" style="text-align: right" title="Options Outstanding (Shares)"&gt;800,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zIr6vOixStH" style="text-align: right" title="Options Exercisable (Shares)"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zgNhR6kwcRKg" style="text-align: right" title="Exercise Prices"&gt;2.0600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuzOZz9BuKF9" style="text-align: right" title="Options Outstanding (Shares)"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7DSWOFTHca" style="text-align: right" title="Options Exercisable (Shares)"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zgYzBlBZvaq6" style="text-align: right" title="Exercise Prices"&gt;2.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zguXgay8hEa8" style="text-align: right" title="Options Outstanding (Shares)"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztLIUhhVhDFc" style="text-align: right" title="Options Exercisable (Shares)"&gt;234,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zSuxmGK9nMQ7" style="text-align: right" title="Exercise Prices"&gt;3.0000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWRSacMmGvV2" style="text-align: right" title="Options Outstanding (Shares)"&gt;666,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXHT8PLGZtd4" style="text-align: right" title="Options Exercisable (Shares)"&gt;666,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zR5GUdjSw1t2" style="text-align: right" title="Exercise Prices"&gt;3.0300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJkGCAYecpWa" style="text-align: right" title="Options Outstanding (Shares)"&gt;425,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zXMtIq5inzi7" style="text-align: right" title="Options Exercisable (Shares)"&gt;387,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z87ELwmJPxWh" style="text-align: right" title="Exercise Prices"&gt;3.2000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_znFYhgeqSkWg" style="text-align: right" title="Options Outstanding (Shares)"&gt;203,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zKQV6zJri1N2" style="text-align: right" title="Options Exercisable (Shares)"&gt;203,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMtmv8ArPDa" style="text-align: right" title="Exercise Prices"&gt;3.2100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z8WWZkHqOjqj" style="text-align: right" title="Options Outstanding (Shares)"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z6f7uZNKweo8" style="text-align: right" title="Options Exercisable (Shares)"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zq9fHiMX3wY5" style="text-align: right" title="Exercise Prices"&gt;6.0000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zLBvxdQ2qHcj" style="text-align: right" title="Options Outstanding (Shares)"&gt;166,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zu7lbE10h0Ad" style="text-align: right" title="Options Exercisable (Shares)"&gt;166,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zt1IzT7CU0Zc" style="text-align: right" title="Exercise Prices"&gt;6.6000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zBy6oHJCDvs2" style="text-align: right" title="Options Outstanding (Shares)"&gt;41,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zM79bdnAnJ9j" style="text-align: right" title="Options Exercisable (Shares)"&gt;41,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwYWnoEjoUp1" style="text-align: right" title="Exercise Prices"&gt;7.1400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zhXAHeT12fy" style="text-align: right" title="Options Outstanding (Shares)"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z70h0X14xT58" style="text-align: right" title="Options Exercisable (Shares)"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zubRnZBLyXu4" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices"&gt;12.0000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z427t7cWs6U3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;83,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPRX2edysUp1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;83,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,882,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331_zZN7lnr5V0kk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;2,913,542&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_znbkrW7VZ6ll" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
intrinsic value of exercisable but unexercised in-the-money stock options at March 31, 2023 was approximately $&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20230331_znqCdrVy3NOj" title="Intrinsic value of exercisable but unexercised in-the-money stock options"&gt;56,500&lt;/span&gt;, based on a fair
market value of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2d_c20230101__20230331_znioS8RrAiag" title="Fair market value, per share"&gt;0.83&lt;/span&gt; per share on March 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
stock options to acquire &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20230331_zfAoknifgeLa" title="Outstanding stock options to acquire shares of common stock not vested"&gt;968,750&lt;/span&gt; shares of the Company&#x2019;s common stock had not vested at March 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-07-132020-07-14_custom_TwoThousandTwentyStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">2333333</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-062022-10-07_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">4133333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2603125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-03-31_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1530208</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember">On
July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman
was granted stock options to purchase 58,333 shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis.
The options are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market
price of the Company&#x2019;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the
portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $24,710 and $24,710, respectively, with respect to these stock options</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="INF"
      unitRef="Shares">58333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="2"
      unitRef="USDPShares">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-07-132020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">400855</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-07-15_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="4"
      unitRef="USDPShares">6.8718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-08-112020-08-12_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">100214</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">24710</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_EricJFormanMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">24710</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember">Dr. James S. Miser, M.D., Dr. Miser was granted stock options
to purchase 83,334 shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options are exercisable
for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the Company&#x2019;s
common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively,
with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant
to the Black-Scholes option-pricing model, was determined to be $572,650 ($6.8718 per share), of which $143,163 was attributable to the
portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested
portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During
the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated
statement of operations of $35,300 and $35,300, respectively, with respect to these stock options</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="INF"
      unitRef="Shares">83334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="2"
      unitRef="USDPShares">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">572650</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="4"
      unitRef="USDPShares">6.8718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-07-302020-08-01_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">143163</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">35300</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_DrJamesMiserMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">35300</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember">On
August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock
options to purchase 58,333 shares of the Company&#x2019;s common stock. The options can be exercised on a cashless basis. The options
are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the
Company&#x2019;s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final
25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the portion of the stock
options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair
value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months
ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations
of $24,710 and $24,710, respectively, with respect to these stock options</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="INF"
      unitRef="Shares">58333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="2"
      unitRef="USDPShares">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">400855</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="4"
      unitRef="USDPShares">6.8718</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-08-112020-08-12_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">100214</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">24710</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_RobertNWeingartenMember_custom_EmploymentAgreementMember"
      decimals="0"
      unitRef="USD">24710</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-04-012021-04-09_custom_DrWinsonSzeChunHoMember_srt_DirectorMember">the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director&#x2019;s resignation.
In connection with his appointment to the Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation
package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase 250,000 shares of the Company&#x2019;s
common stock, exercisable for a period of five years at an exercise price of $3.20 per share (the closing market price on the grant date),
vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $753,611 ($3.0144 per share), of which $376,800 was attributable to the portion of the stock options fully vested
on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock
options was being charged to operations ratably from April 9, 2021 through June 30, 2023. However, vesting of these stock options terminated
on October 30, 2022, the date that Mr. Schwartzberg died. During the three months ended March 31, 2023 and 2022, the Company recorded
charges to general and administrative costs in the consolidated statement of operations of $0 and $41,764, respectively, with respect
to these stock options</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-04-09_srt_DirectorMember_custom_DrWinsonSzeChunHoMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-04-09_srt_DirectorMember_custom_DrWinsonSzeChunHoMember"
      decimals="2"
      unitRef="USDPShares">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-04-012021-04-09_custom_DrWinsonSzeChunHoMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">753611</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-04-09_srt_DirectorMember_custom_DrWinsonSzeChunHoMember"
      decimals="4"
      unitRef="USDPShares">3.0144</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-04-012021-04-09_custom_DrWinsonSzeChunHoMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">376800</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_srt_DirectorMember_custom_DrWinsonSzeChunHoMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_srt_DirectorMember_custom_DrWinsonSzeChunHoMember"
      decimals="0"
      unitRef="USD">41764</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember">the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board
of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Ms. Brown was granted stock options to purchase 250,000 shares of the Company&#x2019;s common stock, exercisable for a period of five
years at an exercise price of $2.80 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($2.6335 per
share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from May 11, 2021 through June 30, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general
and administrative costs in the consolidated statement of operations of $37,983 and $37,983, respectively, with respect to these stock
options</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="2"
      unitRef="USDPShares">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">658363</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-05-11_srt_DirectorMember_custom_MsReginaBrownMember"
      decimals="4"
      unitRef="USDPShares">2.6335</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2021-05-102021-05-11_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">329188</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">37983</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_MsReginaBrownMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">37983</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-06-282021-06-30_custom_FiveNonOfficerDirectorsMember">the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 100,000 shares (a total
of 500,000 shares) of the Company&#x2019;s common stock, exercisable for a period of five years at an exercise price of $3.03 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $1,421,095 ($2.84225 per share), which is being charged to operations ratably from July 1, 2021 through June 30,
2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the
consolidated statement of operations of $105,123 and $175,205, respectively, with respect to these stock options</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_custom_NonOfficerDirectorsMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="2"
      unitRef="USDPShares">3.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2021-06-012021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">1421095</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="5"
      unitRef="USDPShares">2.84225</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">105123</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">175205</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember">the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the
Board of Directors, and in accordance with the Company&#x2019;s cash and equity compensation package for members of the Board of Directors,
Mr. Baan was granted stock options to purchase 250,000 shares of the Company&#x2019;s common stock, exercisable for a period of five years
at an exercise price of $0.74 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder
vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value
of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($0.6341 per
share), of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged
to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably
from June 17, 2022 through June 30, 2024. During the three months ended March 31, 2023, the Company recorded a total charge to general
and administrative costs in the consolidated statement of operations of $9,588 with respect to these stock options</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="2"
      unitRef="USDPShares">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">158525</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-17_custom_BasvanderBaanMember"
      decimals="4"
      unitRef="USDPShares">0.6341</us-gaap:SharePrice>
    <LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue
      contextRef="From2022-06-162022-06-17_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">79263</LIXT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_BasvanderBaanMember"
      decimals="0"
      unitRef="USD">9588</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-06-012022-06-30_srt_DirectorMember">the Board of Directors, in accordance with the Company&#x2019;s cash and equity compensation package for members of the
Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 100,000 shares (a total
of 500,000 shares) of the Company&#x2019;s common stock, exercisable for a period of five years at an exercise price of $0.74 per share
(the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested,
subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,
was determined to be $316,700 ($0.6334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024.
During the three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated
statement of operations of $23,394 with respect to these stock options</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-06-022022-06-30_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-06-30_srt_DirectorMember"
      decimals="5"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_srt_DirectorMember"
      decimals="2"
      unitRef="USDPShares">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-06-012022-06-30_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">316700</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-06-30_srt_DirectorMember"
      decimals="5"
      unitRef="USDPShares">0.6334</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_srt_DirectorMember"
      decimals="0"
      unitRef="USD">23394</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-11-06_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="INF"
      unitRef="Shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_srt_DirectorMember"
      decimals="INF"
      unitRef="USDPShares">2.00</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="INF"
      unitRef="Shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-11-052022-11-06_custom_FourOfficersMember"
      decimals="0"
      unitRef="USD">262560</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_custom_FourOfficersMember"
      decimals="4"
      unitRef="USDPShares">0.3282</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_FourOfficersMember"
      decimals="0"
      unitRef="USD">16172</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-11-06" decimals="INF" unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-11-06_srt_DirectorMember"
      decimals="INF"
      unitRef="USDPShares">0.5025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <LIXT:FairValueOfStockOptions
      contextRef="From2022-11-052022-11-06_custom_FiveNonOfficerDirectorsMember"
      decimals="0"
      unitRef="USD">43264</LIXT:FairValueOfStockOptions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-06_custom_FiveNonOfficerDirectorsMember"
      decimals="5"
      unitRef="USDPShares">0.4326</us-gaap:SharePrice>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_89A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zUkPbHeRX7Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock-based compensation costs for the three months ended March 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zuBc1L43seP" style="display: none"&gt;Summary of Stock-based Compensation Costs&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20230331_zSZh7j0mzpU4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20220331_zeIGOCKaCUL6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartiesMember_zuFEZ9VFZ4Mg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Related parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;276,980&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;339,672&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonRelatedPartiesMember_zPBmOzJM8fld" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-related parties&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_zqzNOapDc172" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;276,980&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;339,672&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_custom_RelatedPartiesMember"
      decimals="0"
      unitRef="USD">276980</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_RelatedPartiesMember"
      decimals="0"
      unitRef="USD">339672</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">276980</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">339672</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFbHoJbCUcD" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity, including options issued in the form of warrants, during the three months ended March 31, 2023 is as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_zC1BLKG8RLVh" style="display: none"&gt;Summary of Stock Option Activity Including Options Form of Warrants&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock options outstanding at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331_zI3VBGN0CW9g" style="width: 14%; text-align: right" title="Number of shares, stock options outstanding, at the beginning"&gt;3,894,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230331_zI5mFDwxoStb" style="width: 14%; text-align: right" title="Weighted average exercise price, stock options outstanding, at the beginning"&gt;2.9183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20230331_zJxWLckPa9el" style="text-align: right" title="Number of shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0866"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230331_z9c0e6id6qMa" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230331_z4bwHDiRcvJg" style="text-align: right" title="Number of shares, Exercised"&gt;(12,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20230331_zN72wDcIDXh7" style="text-align: right" title="Weighted average exercise price, exercised"&gt;0.5025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230331_z0VhiFm81I23" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230331_zWGHOq5LjYh8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options outstanding at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20230331_zwEr2wT4jSKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options outstanding, at the end"&gt;3,882,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230331_zkiMipGUeKjc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options outstanding, at the end"&gt;2.9260&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331_zYXAUwcsWQja" title="Weighted average remaining contractual life (in years), stock options outstanding"&gt;2.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zCQIPksNcUE" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end"&gt;2,819,792&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221231_z61mfmRsYcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end"&gt;3.2834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20230331_z6HQldkB2dr" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, stock options exercisable, at the end"&gt;2,913,542&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230331_zHj7mjfQG6x" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, stock options exercisable, at the end"&gt;3.2431&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230331_z3TJtDZ276N8" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">3894792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">2.9183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.5025</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">3882292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">2.9260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-01to2023-03-31">P2Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2819792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">3.2834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">2913542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">3.2431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-03-31">P2Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">605000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-03-31">P15M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z8Zbvsm0pQDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at March 31, 2023
are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zzNX2AxBd5o8" style="display: none"&gt;Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zIt0gX5Bwdr2" style="width: 30%; text-align: right" title="Exercise Prices"&gt;0.5025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zkbYvjymyPB1" style="width: 30%; text-align: right" title="Options Outstanding (Shares)"&gt;87,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zO9kuVSjLadl" style="width: 30%; text-align: right" title="Options Exercisable (Shares)"&gt;87,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztpLw5PBn4X9" style="text-align: right" title="Exercise Prices"&gt;0.7400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zvyxXN8Whpvg" style="text-align: right" title="Options Outstanding (Shares)"&gt;575,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxmNYagyKaq3" style="text-align: right" title="Options Exercisable (Shares)"&gt;309,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zClDDRQs6NV2" style="text-align: right" title="Exercise Prices"&gt;1.6800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmpFB26ywZpk" style="text-align: right" title="Options Outstanding (Shares)"&gt;33,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zI9bxUmLn6A5" style="text-align: right" title="Options Exercisable (Shares)"&gt;33,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zBv0FSJ1oCw9" style="text-align: right" title="Exercise Prices"&gt;2.0000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zooXVbWkFGBj" style="text-align: right" title="Options Outstanding (Shares)"&gt;800,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zIr6vOixStH" style="text-align: right" title="Options Exercisable (Shares)"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zgNhR6kwcRKg" style="text-align: right" title="Exercise Prices"&gt;2.0600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zuzOZz9BuKF9" style="text-align: right" title="Options Outstanding (Shares)"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7DSWOFTHca" style="text-align: right" title="Options Exercisable (Shares)"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zgYzBlBZvaq6" style="text-align: right" title="Exercise Prices"&gt;2.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zguXgay8hEa8" style="text-align: right" title="Options Outstanding (Shares)"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ztLIUhhVhDFc" style="text-align: right" title="Options Exercisable (Shares)"&gt;234,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zSuxmGK9nMQ7" style="text-align: right" title="Exercise Prices"&gt;3.0000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWRSacMmGvV2" style="text-align: right" title="Options Outstanding (Shares)"&gt;666,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXHT8PLGZtd4" style="text-align: right" title="Options Exercisable (Shares)"&gt;666,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zR5GUdjSw1t2" style="text-align: right" title="Exercise Prices"&gt;3.0300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJkGCAYecpWa" style="text-align: right" title="Options Outstanding (Shares)"&gt;425,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zXMtIq5inzi7" style="text-align: right" title="Options Exercisable (Shares)"&gt;387,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z87ELwmJPxWh" style="text-align: right" title="Exercise Prices"&gt;3.2000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_znFYhgeqSkWg" style="text-align: right" title="Options Outstanding (Shares)"&gt;203,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zKQV6zJri1N2" style="text-align: right" title="Options Exercisable (Shares)"&gt;203,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPMtmv8ArPDa" style="text-align: right" title="Exercise Prices"&gt;3.2100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z8WWZkHqOjqj" style="text-align: right" title="Options Outstanding (Shares)"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z6f7uZNKweo8" style="text-align: right" title="Options Exercisable (Shares)"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zq9fHiMX3wY5" style="text-align: right" title="Exercise Prices"&gt;6.0000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zLBvxdQ2qHcj" style="text-align: right" title="Options Outstanding (Shares)"&gt;166,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zu7lbE10h0Ad" style="text-align: right" title="Options Exercisable (Shares)"&gt;166,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zt1IzT7CU0Zc" style="text-align: right" title="Exercise Prices"&gt;6.6000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zBy6oHJCDvs2" style="text-align: right" title="Options Outstanding (Shares)"&gt;41,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zM79bdnAnJ9j" style="text-align: right" title="Options Exercisable (Shares)"&gt;41,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwYWnoEjoUp1" style="text-align: right" title="Exercise Prices"&gt;7.1400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zhXAHeT12fy" style="text-align: right" title="Options Outstanding (Shares)"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z70h0X14xT58" style="text-align: right" title="Options Exercisable (Shares)"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zubRnZBLyXu4" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Prices"&gt;12.0000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z427t7cWs6U3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Outstanding (Shares)"&gt;83,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zPRX2edysUp1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options Exercisable (Shares)"&gt;83,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,882,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230331_zZN7lnr5V0kk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable (Shares)"&gt;2,913,542&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">0.5025</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">87500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">87500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">0.7400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">575000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">309375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">1.6800</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">33333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">33333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="USDPShares">2.0000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">800000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="USDPShares">2.0600</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="USDPShares">2.8000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">234375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="USDPShares">3.0000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">666667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">666667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="USDPShares">3.0300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">425000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">387500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="USDPShares">3.2000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">203125</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">203125</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="USDPShares">3.2100</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="USDPShares">6.0000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">166667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">166667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="USDPShares">6.6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">41667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">41667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="USDPShares">7.1400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-012023-03-31_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="USDPShares">12.0000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="Shares">83333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-03-31_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="Shares">83333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">2913542</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">56500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-01to2023-03-31"
      decimals="2"
      unitRef="USDPShares">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">968750</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zWMGNo1W8oQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_82A_zy0kSECwz3Dd"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2023 and 2022, the Company did not record any provision for income taxes as the Company incurred losses
during those periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount
of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has recorded a full
valuation allowance against its deferred tax assets for all periods presented as the Company believes it is more likely than not the
deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIqhr8JbhDm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_825_zXPqc4ca75w7"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Claims&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may be subject to legal claims and actions from time to time as part of its business activities. As of March 31, 2023 and December
31, 2022, the Company was not subject to any pending or threatened legal claims or actions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
Commitments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2023, the Company&#x2019;s unpaid remaining contractual commitments pursuant to clinical trial agreements and
clinical trial monitoring agreements, as described below, aggregated $&lt;span id="xdx_90B_eus-gaap--ContractualObligation_iI_c20230331_zvFayusOmba3" title="Contractual commitment"&gt;7,900,000&lt;/span&gt;,
which are currently scheduled to be incurred through December 31, 2025. The Company&#x2019;s ability to conduct and fund these
contractual commitments is subject to the timely availability of sufficient capital to fund such expenditures, as well as any
changes in the allocation or reallocation of such funds to the Company&#x2019;s current or future clinical trial programs. The
Company expects that the full amount of these expenditures will be incurred only if such clinical trial programs are conducted as
originally designed and their respective enrollments and duration are not modified or reduced. Clinical trial programs, such as the
types that the Company is engaged in, can be highly variable and can frequently involve a series of changes and modifications over
time as clinical data is obtained and analyzed, and are frequently modified, suspended or terminated before the clinical trial
endpoint. Accordingly, such contractual commitments as discussed herein should be considered as estimates only based on current
clinical assumptions and conditions, and are typically subject to significant revisions over time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research
Institute Hospital Inc., Tampa, Florida, effective for a term of five years, unless terminated earlier by the Company pursuant to 30
days written notice. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial
to evaluate the therapeutic benefit of the Company&#x2019;s lead anti-cancer clinical compound LB-100 to be administered intravenously
in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application
(&#x201c;IND&#x201d;) to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of LB-100 in patients with low and intermediate-1
risk MDS who have failed or are intolerant of standard treatment. Patients with MDS, although usually older, are generally well except
for severe anemia requiring frequent blood transfusions. This Phase 1b/2 clinical trial utilizes LB-100 as a single agent in the treatment
of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic syndrome (del5qMDS) failing first line
therapy. The bone marrow cells of patients with del5qMDS are deficient in PP2A by virtue of an acquired mutation and are especially vulnerable
to further inhibition of PP2A by LB-100. The clinical trial began at a single site in April 2019 and the first patient was entered into
the clinical trial in July 2019. A total enrollment of 41 patients is planned. An interim analysis will be done after the first 21 patients
are entered. If there are 3 or more responders but fewer than 7, an additional 20 patients will be entered. If at any point there are
7 or more responders, this will be sufficient evidence to support continued development of LB-100 for the treatment of low and intermediate-1
risk MDS. Recruitment has been slow and the Covid-19 pandemic has further reduced recruitment of patients into the protocol. At the current
rate of accrual, the clinical trial is expected to be completed by June 30, 2025. However, with additional funds, the Company would consider
adding two additional MDS centers to the Phase 2 portion of the study to accelerate patient accrual.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zZCZK3IPmuyb" title="Advance amount related to milestone payment"&gt;6,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z4XJOgNO9yea" title="Advance amount related to milestone payment"&gt;3,332&lt;/span&gt;, respectively, pursuant to this agreement,
which have been included in research and development costs in the Company&#x2019;s consolidated statements of operations. As of March
31, 2023, total costs of $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zjfxH5kupvu8" title="Research and development costs"&gt;137,074&lt;/span&gt; have been incurred pursuant to this agreement. &lt;span id="xdx_903_eus-gaap--OtherCommitmentsDescription_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_zcDayiVBFC5e" title="Aggregate commitments expected, description"&gt;The Company&#x2019;s aggregate commitment pursuant to
this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_906_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalTrialResearchAgreementMember_z0tlZzGxLIU2" title="Aggregate commitments expected"&gt;575,000&lt;/span&gt; as of March 31, 2023, which is expected to be incurred
through December 31, 2025&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GEIS.
&lt;/b&gt;Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the
Spanish Sarcoma Group (Grupo Espa&#xf1;ol de Investigaci&#xf3;n en Sarcomas or &#x201c;GEIS&#x201d;), Madrid, Spain, to carry out a
study entitled &#x201c;Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue
sarcoma&#x201d;. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined
with doxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&#x201c;ASTS&#x201d;).
Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as
well as to provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over
a period of two years. As advanced sarcoma is a very aggressive disease, the design of the study assumes a median progression free survival
(PFS, no evidence of disease progression or death from any cause) of 4.5 months in the doxorubicin arm and an alternative median PFS
of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression
or death by adding LB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required
for final analysis is reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July
2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol,
it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing standards. These
standards were adopted subsequent to the production of the Company&#x2019;s existing LB-100 inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out
the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain. These tasks included
the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with documentation of each of the
steps involved by an independent auditor. The API was then transferred to a vendor that prepares the clinical drug product, also under
GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,
provide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal
application documenting all steps taken to prepare the clinical drug product for clinical use was submitted to the appropriate regulatory
authorities for review and approval before being used in a clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially
for subsequent multiple trials within the European Union, had cost approximately $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--OtherClinicalAgreementsMember_zRpBkw5pl514" title="Research and development costs"&gt;1,144,000&lt;/span&gt;. While the production of new inventory has
been completed, nominal amounts of trailing costs are expected to be incurred during the year ending December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&#xf1;ola de Medicamentos
y Productos Sanitarios or &#x201c;AEMPS&#x201d;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company&#x2019;s lead
clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas
(ASTS). Consequently, the GEIS clinical trial is currently scheduled to commence during the quarter ending June 30, 2023 and to be completed
by December 31, 2025. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&#xf3;n
Jim&#xe9;nez D&#xed;az University Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The Phase 1b section
of the protocol is expected to be completed by June 30, 2024, at which time the Company expects to have data on both response and toxicity
from this portion of the clinical trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interim analysis of this clinical trial will be done before full accrual of patients is completed to determine whether the study has
the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study
would have the potential to change the standard therapy for this disease after four decades of failure to improve the marginal benefit
of doxorubicin alone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement.
Through March 31, 2023, the Company has paid GEIS an aggregate of $&lt;span id="xdx_90D_ecustom--AmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_z6silH3m84G8" title="Amount related to milestone payment"&gt;415,823&lt;/span&gt; for work done under this agreement through the third milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2023 and 2022, the Company did not incur any costs pursuant to this agreement. Such costs, when incurred,
are included in research and development costs in the Company&#x2019;s consolidated statements of operations. As of March 31, 2023, total
costs of $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z0vSFGxU8Ee9" title="Research and development costs"&gt;415,823&lt;/span&gt; have been incurred pursuant to this agreement. The Company&#x2019;s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $&lt;span id="xdx_904_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrupoEspanolDeInvestigacionEnSarcomasMember_zvQGUdIN1oNh" title="Aggregate commitments expected"&gt;3,792,000&lt;/span&gt; as of March 31, 2023, which is expected to be incurred through
December 31, 2025. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations
between the United States Dollar and the Euro. Such fluctuations are recorded in the consolidated statements of operations as foreign
currency gain or loss, as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with the City of Hope National Medical
Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, &#x201c;City of Hope&#x201d;),
to carry out a Phase 1b clinical trial of LB-100, the Company&#x2019;s first-in-class protein phosphatase inhibitor, combined with a standard
regimen for treatment of untreated extensive- stage disease small cell lung cancer (ED-SCLC). LB-100 will be given in combination with
carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously untreated ED-SCLC patients.
The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (RP2D).
Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the safety of the LB-100 combination
and to look for potential therapeutic activity as assessed by objective response rate, duration of overall response, progression-free-survival
and overall survival.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. However, as
patient accrual was slower than expected, the Company has been seeking to add two additional sites to increase the rate of patient accrual.
Effective March 6, 2023, the Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, joined the City of Hope&#x2019;s ongoing Phase
1b clinical trial. The Company is continuing its efforts to add a third site. The addition of SCRI is expected to expedite and expand
the accrual of patients to this clinical trial, thus reducing the time required to demonstrate the feasibility, tolerability and efficacy
of adding LB-100 to the current standard treatment regimen. With the addition of SCRI, the Company expects that this clinical trial will
be completed by December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_znIuv3ZWtK3" title="Research and development expense"&gt;69,001&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z95vrSSdqXZ2" title="Research and development expense"&gt;0&lt;/span&gt;, respectively, pursuant to this agreement,
which are included in research and development costs in the Company&#x2019;s consolidated statements of operations. As of March 31, 2023,
total costs of $&lt;span id="xdx_909_eus-gaap--DeferredCosts_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zhSJuoqMJq5b" title="Total costs"&gt;447,512&lt;/span&gt; have been incurred pursuant to this agreement. The Company&#x2019;s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_zN4X1W8vrpSj" title="Aggregate commitments expected"&gt;2,433,000&lt;/span&gt; as of March 31, 2023, which is expected to be incurred through
December 31, 2024. If a significant number of patients fail during the dose-escalation process, an increase of up to 12 patients would
likely be necessary, at an estimated additional cost of approximately $&lt;span id="xdx_907_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--ClinicalResearchSupportAgreementMember_z2dO8V88muv7" title="Aggregate commitments expected"&gt;800,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently expects that enrollment in this clinical trial will range from approximately 18 to 30 enrollees, with 24 enrollees
as the most likely number. Should fewer than 42 enrollees be required, the Company has agreed to compensate City of Hope on a per enrollee
basis. If a significant improvement in outcome is seen with the addition of LB-100, this would be an important advance in the treatment
of a very aggressive disease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;National
Cancer Institute Pharmacologic Clinical Trial. &lt;/b&gt;In May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic
clinical trial. This study is being conducted and funded by the NCI under a Cooperative Research and Development Agreement, with the
Company being required to provide the LB-100 clinical compound.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with some further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&#x2019;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain is not known. Unfortunately,
many drugs potentially useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
NCI study is designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove one
or more tumors will receive one dose of LB-100 prior to surgery and have blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors show the biochemical changes expected to be present if LB-100 reaches its molecular
target. As a result of the innovative design of the NCI study, data from a few patients should be sufficient to provide a sound rationale
for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment regimen for GBMs. Five
patients have been entered and analysis of the blood and tissue will now proceed. If there is evidence in at least two of the patients
of penetration of LB 100 into tumor tissue, the study will be deemed as successful. Results of this study are currently being reviewed
by NCI and a report is expected by June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Clinical
Trial Monitoring Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;On September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc. (&#x201c;Theradex&#x201d;), an international
contract research organization (&#x201c;CRO&#x201d;), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019. At the current rate of
accrual, the clinical trial is expected to be completed by June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
under this work order agreement are estimated to be approximately $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20180910__20180912__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_zt1udJ4abCR8" title="Research and development costs"&gt;954,000&lt;/span&gt;, with such payments expected to be allocated approximately
94% to Theradex for services and approximately 6% for payments for pass-through costs. The costs of the Phase 1b/2 clinical trial being
paid to or through Theradex are being recorded and charged to operations based on periodic documentation provided by the CRO. During
the three months ended March 31, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9kiArgfFVQc" title="Research and development costs"&gt;9,287&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember__dei--LegalEntityAxis__custom--TheradexSystemsIncMember_z9nW8v9qP8Zk" title="Research and development costs"&gt;3,281&lt;/span&gt;, respectively, and as of March 31, 2023,
total costs of $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zMWQLYxPIMek" title="Research and development costs"&gt;136,575&lt;/span&gt; have been incurred. The Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts previously
paid to date, totaled approximately $&lt;span id="xdx_90B_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zIsQDJnprjT7" title="Aggregate commitments expected"&gt;826,000&lt;/span&gt; as of March 31, 2023, which is expected to be incurred through June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;City
of Hope. &lt;/b&gt;On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated
clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this
work order agreement are estimated to be approximately $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20210204__20210205__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zhJJFVUpoYv3" title="Research and development costs"&gt;335,000&lt;/span&gt;. During the three months ended March 31, 2023 and 2022, the Company incurred
costs of $&lt;span id="xdx_90B_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zLiQjtVNBYLh" title="Advance amount related to milestone payment"&gt;5,553&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zvZyeq9WD866" title="Advance amount related to milestone payment"&gt;4,500&lt;/span&gt;, respectively, and as of March 31, 2023, total costs of $&lt;span id="xdx_90C_eus-gaap--OtherCommitment_iI_pp0p0_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--WorkOrderAgreementMember_zDBYcR1gVe24" title="Aggregate commitments expected"&gt;63,994&lt;/span&gt; have been incurred. The Company&#x2019;s aggregate
commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_900_eus-gaap--OtherCommitment_iI_c20230331__dei--LegalEntityAxis__custom--CityOfHopeNationalMedicalCenterMember_zQhOqz4F5PT5" title="Aggregate commitments expected"&gt;273,000&lt;/span&gt; as of March 31, 2023, which
is expected to be incurred through June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Patent
and License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Moffitt.
&lt;/b&gt;Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement,
Moffitt granted the Company an exclusive license under certain patents owned by Moffitt (the &#x201c;Licensed Patents&#x201d;) relating
to the treatment of MDS and a non-exclusive license under inventions, concepts, processes, information, data, know-how, research results,
clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents
or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under
the Licensed Patents. The Company was obligated to pay Moffitt a non-refundable license issue fee of $&lt;span id="xdx_90F_ecustom--NonRefundableLicenseIssueFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zEXYnfz8iRp6" title="Non refundable license issue fee"&gt;25,000&lt;/span&gt; after the first patient
was entered into a Phase 1b/2 clinical trial to be managed and conducted by Moffitt. The clinical trial began at a single site in April
2019 and the first patient was entered into the clinical trial in July 2019. The Company is also obligated to pay Moffitt an annual license
maintenance fee of $&lt;span id="xdx_90F_ecustom--AnnualLicenseMaintenanceFee_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zwNxECXRbpkf" title="Maintenance fee"&gt;25,000&lt;/span&gt; commencing on the first anniversary of the Effective Date and every anniversary thereafter until the Company
commences payment of minimum royalty payments. The Company has also agreed to pay non-refundable milestone payments to Moffitt, which
cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones aggregating
$&lt;span id="xdx_908_ecustom--PaymentsOnNonrefundableMilestone_c20180818__20180820__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zgREugkczKsb" title="Payment on non refundable milestone"&gt;1,897,000&lt;/span&gt;, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in
the License Agreement. During the three months ended March 31, 2023 and 2022, the Company recorded charges to operations of $&lt;span id="xdx_906_eus-gaap--OperatingCostsAndExpenses_c20230101__20230331__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zk1uIhSK4Zf1" title="Operating costs and expenses"&gt;6,165&lt;/span&gt; and
$&lt;span id="xdx_902_eus-gaap--OperatingCostsAndExpenses_c20220101__20220331__dei--LegalEntityAxis__custom--MoffittCancerCenterandResearchInstituteHospitalIncMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zsmWPcFPAcq2" title="Operating costs and expenses"&gt;6,165&lt;/span&gt;, respectively, in connection with its obligations under the License Agreement. As of March 31, 2023, no milestones had yet been
attained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject
to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $&lt;span id="xdx_90A_eus-gaap--PaymentsForRoyalties_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__us-gaap--VestingAxis__custom--FirstFourYearsMember_zBUAbOZGmk05" title="Minimum payments for royalties"&gt;50,000&lt;/span&gt; in the first four years
after sales commence, and $&lt;span id="xdx_908_eus-gaap--PaymentsForRoyalties_pp0p0_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__us-gaap--VestingAxis__custom--FiveYearsAndThereafterMember_zOn47z2x1Cfi" title="Minimum payments for royalties"&gt;100,000&lt;/span&gt; in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating
to the status of Valid Claims, as such term is defined in the License Agreement. The Company&#x2019;s obligation to pay earned royalties
under the License Agreement commences on the date of the first sale of a royalty-bearing product, and shall automatically expire on a
country-by-country basis on the date on which the last valid claim of the Licensed Patents expires, lapses or is declared invalid, and
the obligation to pay any earned royalties under the License Agreement shall terminate on the date on which the last valid claim of the
Licensed Patents expires, lapses, or is declared to be invalid in all countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
Agreements with Officers&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
July and August 2020, the Company entered into one-year employment agreements with its executive officers, consisting of Dr. John S.
Kovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, which provided for aggregate annual compensation of $&lt;span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zvT95vuoCo92" title="Salary and compensation"&gt;640,000&lt;/span&gt;, payable
monthly (see Note 6). The employment agreements are automatically renewable for additional &lt;span id="xdx_902_ecustom--AgreementTermDescription_c20200701__20200831__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zX41iREGNv2" title="Agreement term description"&gt;one-year periods&lt;/span&gt; unless terminated by either
party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination for cause. These
employment agreements were automatically renewed for additional one-year periods in July and August 2021 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 9, 2021, the Board of Directors increased the annual compensation of Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten
under the employment agreements, such that the total aggregate annual compensation of all officers increased to $&lt;span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210408__20210409__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--Dr.JamesMember_zJTCDSpFDpI6" title="Annual compensation"&gt;775,000&lt;/span&gt;, effective May
1, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer, with an annual salary of $&lt;span id="xdx_90E_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__custom--FormanMember_zaWa8BkYwF27" title="Annual salary per year"&gt;200,000&lt;/span&gt;. Accordingly,
the total aggregate annual compensation of all officers increased to $&lt;span id="xdx_906_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__srt--OfficerMember_zVgydyHEjtZf" title="Compensation"&gt;800,000&lt;/span&gt;, effective November 6, 2022. In addition, effective October
1, 2022, Mr. Forman is being paid an office rent allowance of $&lt;span id="xdx_907_eus-gaap--PaymentsForRent_c20220929__20221001__srt--TitleOfIndividualAxis__custom--FormanMember_zPnJriJdKolb" title="Paid office rent"&gt;600&lt;/span&gt; per month.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total aggregate annual compensation of all officers increased to $&lt;span id="xdx_90F_eus-gaap--OfficersCompensation_c20221105__20221106__srt--TitleOfIndividualAxis__srt--OfficerMember_zkqYsYIWBkId" title="Compensation"&gt;800,000&lt;/span&gt;, effective November 6, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Significant Agreements and Contracts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NDA
Consulting Corp.&lt;/b&gt; On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice
in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel
D. Von Hoff, M.D., to become a member of the Company&#x2019;s Scientific Advisory Committee. The term of the agreement was for one year
and provided for a quarterly cash fee of $&lt;span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_pp0p0_c20131223__20131224__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zYQ3C6jeybc6" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt;. The agreement has been automatically renewed for additional one-year terms on its anniversary
date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $&lt;span id="xdx_90C_ecustom--ConsultingAndAdvisoryCashFee_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_z1YtMf3uXA3d" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--ConsultingAndAdvisoryCashFee_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NDAConsultingCorpMember_zjHgw7SNwwec" title="Consulting and advisory fee"&gt;4,000&lt;/span&gt; for the three months
ended March 31, 2023 and 2022, respectively, which were included in research and development costs in the consolidated statements of
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BioPharmaWorks&lt;/b&gt;.
Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged
BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize
its products and strengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company&#x2019;s
product pipeline; assisting in preparing technical presentations concerning the Company&#x2019;s products; consultation in drug discovery
and development; and identifying providers and overseeing tasks relating to clinical development of new compounds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioPharmaWorks
was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience.
The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated
by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the
Company agreed to pay BioPharmaWorks a monthly fee of $&lt;span id="xdx_900_ecustom--ConsultingAndAdvisoryCashFee_c20150912__20150914__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zDUdEzalikd1" title="Consulting and advisory fee"&gt;10,000&lt;/span&gt;, subject to the right of the Company to pay a negotiated hourly rate in
lieu of the monthly payment, and agreed to issue to BioPharmaWorks certain equity-based compensation (see Note 7). The Company recorded
charges to operations pursuant to this agreement of $&lt;span id="xdx_902_ecustom--ReimbursementExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zPeNH63cve56" title="Reimbursed expense"&gt;30,000&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--ReimbursementExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BioPharmaWorksLLCMember_zLN6tNjtDYh4" title="Reimbursed expense"&gt;30,000&lt;/span&gt; for the three months ended March 31, 2023 and 2022, respectively,
which were included in research and development costs in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Netherlands
Cancer Institute&lt;/b&gt;. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer
Institute, Amsterdam (see Note 6), one of the world&#x2019;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major
independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues,
to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.
The Company has agreed to fund the study and provide a sufficient supply of LB-100 to conduct the study. The study is expected to take
approximately two years to conduct. During the three months ended March 31, 2023 and 2022, the Company incurred charges in the amount
of $&lt;span id="xdx_901_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zWBQ47kasDXj" title="Advance amount related to milestone payment"&gt;52,203&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zmd0enjlXU9c" title="Advance amount related to milestone payment"&gt;54,230&lt;/span&gt;, respectively, with respect to this agreement, which amounts are included in research and development costs in
the Company&#x2019;s consolidated statements of operations. As of March 31, 2023, total costs of $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zAVcJcMJ0Pk8" title="Research and development costs"&gt;416,518&lt;/span&gt; have been incurred pursuant
to this agreement. The Company&#x2019;s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled
approximately $&lt;span id="xdx_908_eus-gaap--OtherCommitment_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--DevelopmentCollaborationAgreementMember__dei--LegalEntityAxis__custom--NetherlandsCancerInstituteMember_zdf5xgiWAoq7" title="Aggregate commitments expected"&gt;53,000&lt;/span&gt; as of March 31, 2023, which is expected to be incurred through June 30, 2025. As the work is being conducted in
Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;MRI
Global. &lt;/b&gt;The Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials
in the United States. On June 10, 2022, the contract was amended to reflect a new total contract price of $&lt;span id="xdx_909_ecustom--ContractPrice_c20220609__20220610__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zP5Nosi6JMdk" title="Contract price"&gt;273,980&lt;/span&gt; for services to be
rendered through April 30, 2023. During the three months ended March 31, 2023 and 2022, the Company incurred costs of $&lt;span id="xdx_90A_ecustom--AdvanceAmountRelatedToMilestonePayment_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zkEOu8Lvn6r3" title="Advance amount related to milestone payment"&gt;3,173&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--AdvanceAmountRelatedToMilestonePayment_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zVY3RwdB77vb" title="Advance amount related to milestone payment"&gt;756&lt;/span&gt;,
respectively, pursuant to this contract. As of March 31, 2023, total costs of $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zJ8481wLxdYa" title="Research and development costs"&gt;222,784&lt;/span&gt; have been incurred pursuant to this contract.
The Company&#x2019;s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $&lt;span id="xdx_90D_eus-gaap--OtherCommitment_iI_c20230331_zhaLRFPnCvwj" title="Aggregate commitments expected"&gt;53,000&lt;/span&gt;
as of March 31, 2023. Effective April 17, 2023, the contract was further amended to reflect a new total contract price of $&lt;span id="xdx_902_ecustom--ContractPrice_c20230415__20230417__us-gaap--TypeOfArrangementAxis__custom--MRIGlobalMember_zT3u8c1qQS37" title="Contract price"&gt;326,274&lt;/span&gt; for
services to be rendered through April 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;External
Risks Associated with the Company&#x2019;s Business Activities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Covid-19
Virus&lt;/b&gt;. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout
the world as businesses and governments implemented broad actions to mitigate this public health crisis. The extent to which the coronavirus
pandemic may impact the Company&#x2019;s business activities and capital raising efforts will depend on future developments, which are
uncertain and cannot be predicted. The Company is continuing to monitor this situation and will adjust its current business plans to
the extent additional information and guidance become available. The coronavirus pandemic has also presented a challenge to medical facilities
worldwide. Although the Company&#x2019;s clinical trials are conducted on an outpatient basis, the coronavirus pandemic appears to have
caused some delays in the Company&#x2019;s clinical trials, but the impact of the coronavirus pandemic appears to be subsiding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inflation
Risk. &lt;/b&gt;The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the
general economy. However, there is a risk that the Company&#x2019;s operating costs could become subject to inflationary and interest
rate pressures in the future, which would have the effect of increasing the Company&#x2019;s operating costs (including, specifically,
clinical trial costs), and which would put additional stress on the Company&#x2019;s working capital resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Supply
Chain Issues. &lt;/b&gt;The Company does not currently expect that supply chain issues will have a significant impact on its business activities,
including its ongoing clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Potential
Recession. &lt;/b&gt;There are various indications that the United States economy may be entering a recessionary period. Although unclear at
this time, an economic recession would likely impact the general business environment and the capital markets, which could, in turn,
affect the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance
become available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">7900000</us-gaap:ContractualObligation>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-03-31_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">6000</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-01-012022-03-31_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">3332</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">137074</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitmentsDescription contextRef="From2023-01-012023-03-31_custom_ClinicalTrialResearchAgreementMember">The Company&#x2019;s aggregate commitment pursuant to
this agreement, less amounts previously paid to date, totaled approximately $575,000 as of March 31, 2023, which is expected to be incurred
through December 31, 2025</us-gaap:OtherCommitmentsDescription>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-03-31_custom_ClinicalTrialResearchAgreementMember"
      decimals="0"
      unitRef="USD">575000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_OtherClinicalAgreementsMember"
      decimals="0"
      unitRef="USD">1144000</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:AmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-03-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      unitRef="USD">415823</LIXT:AmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_GrupoEspanolDeInvestigacionEnSarcomasMember_custom_CollaborationAgreementMember"
      decimals="0"
      unitRef="USD">415823</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-03-31_custom_CollaborationAgreementMember_custom_GrupoEspanolDeInvestigacionEnSarcomasMember"
      decimals="0"
      unitRef="USD">3792000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">69001</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">447512</us-gaap:DeferredCosts>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">2433000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-03-31_custom_ClinicalResearchSupportAgreementMember"
      decimals="0"
      unitRef="USD">800000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2018-09-102018-09-12_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      unitRef="USD">954000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      unitRef="USD">9287</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31_custom_WorkOrderAgreementMember_custom_TheradexSystemsIncMember"
      decimals="0"
      unitRef="USD">3281</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">136575</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-03-31_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">826000</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-02-042021-02-05_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">335000</us-gaap:ResearchAndDevelopmentExpense>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">5553</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-01-012022-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">4500</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember_custom_WorkOrderAgreementMember"
      decimals="0"
      unitRef="USD">63994</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-03-31_custom_CityOfHopeNationalMedicalCenterMember"
      decimals="0"
      unitRef="USD">273000</us-gaap:OtherCommitment>
    <LIXT:NonRefundableLicenseIssueFee
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">25000</LIXT:NonRefundableLicenseIssueFee>
    <LIXT:AnnualLicenseMaintenanceFee
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">25000</LIXT:AnnualLicenseMaintenanceFee>
    <LIXT:PaymentsOnNonrefundableMilestone
      contextRef="From2018-08-182018-08-20_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">1897000</LIXT:PaymentsOnNonrefundableMilestone>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-01-012023-03-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">6165</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2022-01-012022-03-31_custom_MoffittCancerCenterandResearchInstituteHospitalIncMember_custom_ExclusiveLicenseAgreementMember"
      decimals="0"
      unitRef="USD">6165</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2023-01-012023-03-31_custom_ExclusiveLicenseAgreementMember_custom_FirstFourYearsMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2023-01-012023-03-31_custom_ExclusiveLicenseAgreementMember_custom_FiveYearsAndThereafterMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:PaymentsForRoyalties>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember"
      decimals="0"
      unitRef="USD">640000</us-gaap:SalariesWagesAndOfficersCompensation>
    <LIXT:AgreementTermDescription contextRef="From2020-07-012020-08-31_custom_EmploymentAgreementMember_custom_ExecutiveOfficersMember">one-year periods</LIXT:AgreementTermDescription>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-04-082021-04-09_custom_EmploymentAgreementMember_custom_Dr.JamesMember"
      decimals="0"
      unitRef="USD">775000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_custom_FormanMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_srt_OfficerMember"
      decimals="0"
      unitRef="USD">800000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRent
      contextRef="From2022-09-292022-10-01_custom_FormanMember"
      decimals="0"
      unitRef="USD">600</us-gaap:PaymentsForRent>
    <us-gaap:OfficersCompensation
      contextRef="From2022-11-052022-11-06_srt_OfficerMember"
      decimals="0"
      unitRef="USD">800000</us-gaap:OfficersCompensation>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2013-12-232013-12-24_custom_NDAConsultingCorpMember"
      decimals="0"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2023-01-012023-03-31_custom_NDAConsultingCorpMember"
      decimals="0"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2022-01-012022-03-31_custom_NDAConsultingCorpMember"
      decimals="0"
      unitRef="USD">4000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ConsultingAndAdvisoryCashFee
      contextRef="From2015-09-122015-09-14_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      unitRef="USD">10000</LIXT:ConsultingAndAdvisoryCashFee>
    <LIXT:ReimbursementExpense
      contextRef="From2023-01-012023-03-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      unitRef="USD">30000</LIXT:ReimbursementExpense>
    <LIXT:ReimbursementExpense
      contextRef="From2022-01-012022-03-31_custom_CollaborationAgreementMember_custom_BioPharmaWorksLLCMember"
      decimals="0"
      unitRef="USD">30000</LIXT:ReimbursementExpense>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">52203</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-01-012022-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">54230</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">416518</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="AsOf2023-03-31_custom_DevelopmentCollaborationAgreementMember_custom_NetherlandsCancerInstituteMember"
      decimals="0"
      unitRef="USD">53000</us-gaap:OtherCommitment>
    <LIXT:ContractPrice
      contextRef="From2022-06-092022-06-10_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">273980</LIXT:ContractPrice>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2023-01-012023-03-31_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">3173</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <LIXT:AdvanceAmountRelatedToMilestonePayment
      contextRef="From2022-01-012022-03-31_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">756</LIXT:AdvanceAmountRelatedToMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">222784</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">53000</us-gaap:OtherCommitment>
    <LIXT:ContractPrice
      contextRef="From2023-04-152023-04-17_custom_MRIGlobalMember"
      decimals="0"
      unitRef="USD">326274</LIXT:ContractPrice>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zpy4Hi2NcUt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_82A_zH1SDycSCnqi"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC.
There were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;$WAHF45H=I[J/9Q_?0E%=I('3Z1>[E4VMCX\"BC4RL>6E41K[/'ZQPY#+6
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M9XQ,M=E'ZB!*P8(6\G3FN#K?R*NZ)KK(&!'U_@)=-1H(9^;U,\6-@Q!U=L%
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M!"VJRQ7!*6%*0'Z_I%2\+=2;Z^;'D\E_4$L#!!0    ( ,U#JE:5;^@G@P4
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M4! G"QR,E4P_YO';<SXU;*=6[;BT41VKZX'%=1(#$1@4C$W2\T,OB4>\[WD
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M(@OX^$#&K:GZ&2'&3G]XYUC+K^?UF.$@UP K6C+ZPVJFK%C(CA8 (N%Z; .
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MOUFK^-F P0TBMT[9'R]'PU!&YY*/2SO2(T\''GHS=,'/ F+2>BRSLG?#? 3
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MM #O*VO#\(4.&'^PN?T?4$L#!!0    ( ,U#JE87Q;M!JQD  (U+   9
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M$L!"@O"]>]!'I*V>A9LC\=DI5,L;U^F&^(K,9@6*K#HHURPZ*"2ZVS+"J!R
MZ-=> U1(%?#>1#' M %DA(JG(%# T;Y9L71V2]D).9^#3R8\(X%E@]I(:@3/
MDR# TEK+*4A3A_9%\@HT%,$D' 38"T;<6B1;JX<56ATGJMXB#X;GB&,H:A48
M/=/X(U!J?N^K!>\,I@\T"]7U=T7!!)V%\E:KAS(<#%&%L:K$>*,G@7 0(*#\
M]G4%X@NX6X'$L1H-DIA;T_B3!K*!^"I;\,-(V)2$AB2PTO1M!-(3R3\EQ0#S
MDNP$G%V"L!H+AKLF_"T(QXQ!AYMKR>JUSR2+9J36:@W< <9.D5+2F59.:Y1W
M^%:SY'CY/LB,#L2A!5K  0)M'M"%<*,5,VUG?0-/HR4K/3.86D#]8%QL0W<
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MPP%A,/9A"X !ZU/\"+A:2LV":P*B+*SRAAI8P#J0N'WXC+:@BY&+&()#5A4
MM\"27=5CP !AN4&//+CL$:2B&X :,HV5W++30FYG0K9/S1@G!3QZ(BNX,/(\
M(!VM:<'FSX%J'%1851PF>B:0OTQKO> ;1;BZIY@@<Z!D**$!LVH GN/(2#>O
MUI$9G'\Y/MFB#YX9""O^8* 90M)#^[@X>3'>LP]IV2(&O,C,!&,,R*N0%^=2
MPY*=B@Y A8A#X,/YI@^'5R'5"(AFM!/_0=IA$'V(?!S;L1/U(<Z&$N\>0\J<
MM'N*E4B@=VDYIN(13-D?A!-LA6FBRZ+X[V&.=YF":J0ETPGB*F/Q2$RD4,])
M'%)I.*(.?&#Q5Z1A).X\^8M&@C-8]=;UDK/F:&<(6S"_'2>' 6]*H*HUNW[3
M/@8E;Q2#T.\A49&1*!*=JBN)*G\7:?Z:HDC'87VQ#S]" @^B)42[<1/B@BCX
M+,L#!;/X)^3^GGBY-.&QQY :(/G_E+?BWR!J'DY:M<:&!NV&"WHB#\9_H0*P
MDQ*Q,SYJ&@.UL;$BOO;2=N@S.4L?8;D*X[UB"*G#E2'\A NX/U4)EFAO5*,A
MA>5 $8U,I8%1,9<V7,ER20 [0RL#<1[=QQ7>[4>6;0\]K-LBCX]!1FR7I&?D
MH$T'^_CLQ(-V))8 _ZC MN=\%QP<WJ.19QE$GUPI=OR4@Q3^W%"'>O1((C/V
M);#)=(K5>R;U8&@3 QKVX'*6N/0$SG8>%*C( Z9 #?3E<7-0.4I\NXVJU^JT
MP;9.-.?PP'9/KV0H9'""^U?,D*?K4)^CTA]9I\&I#! GE=:_8H)0?O"\8J\>
M"'8;JP&D!!] !BG6$A_4PFO)>Q UN/!>^7KG-9G#=[TJ/#PNJ6?T@*#%)!>$
M<RAU#X$PA 4HF_.^SA0.806>8_7+4##6-,K.V$FL-3'+YR8[4<<.+8IH;]1\
M3C5]UG-.V%>$*)*WQF"3"T!P1KQ!1;1 @3I28,X4F <*L$-(2C14N$V,J\^E
M0G:<=WB2! 7XB^U;K!\AQX%RVYV,YVB >?<](!<[(&\@HH9L^'S\LCQ_?@9_
M7Y23\Y?8S((=.CX'R^B_:O<E:Y=DV?I@'8FMD&55P8JEV2\ [WL$@[?;H=F1
M)@59]VL?PD8]1@F&12[9SE>L\8X,,==,=+H)P9AXTFU7'FP4L"T(QU,4LYTE
M "C6O/%.)]V7D1=R1$GM>N2"<H9HW@&;\9GX!QL8XKRLP 9J1_1<AXS80P__
M(/H3#3>.%3:.Q4<2V-#WI4/APR2DU56,YJF<R#R>:]ND%;W A,1-%(-<D#RR
MP "FCEHKIDWE.*E ?(^8:N*EIP"NG5R,7HO)Z]&%F)R/7HC)J]'S;R6RWT^1
MPX28F]X>%;X,N/,+!.DE #=^ 6".GP-P%^>C5V(\AO]N6S WJO@D'WS;* A]
M+*PAI)J>PI*FBOE%ZXU_6GS?LO667-M/BEA)0W;H.9)9V=E]1.UG7U\NBRZ+
M<GPFX@X56?>: ('"*,*4H6O89D;6-J37J$53!7Y/M8^VG @,/,J[Y6.-AU%&
M0?:8Z"UCR1WMK=F0'Z3P$&RZHCCM$$)>(GV$07H74O]:?T'G"-=:ZG'$%DZ-
MKA+;R02R6E/C+J'A1CKN4_A8Q6_;B0U5[F$3<C<$'&UV%#KO\^<]U;BRN%R3
M"(:DCL O25ZHA1":B>PV]C>.D'#!=\\1^(.]B:-,.Z##-$8<,0F#"&U)>R5)
MW5',D8H'L$?_"'*T@A X8/9-8GP#U^(@K@=]WI] -14\D!+?QL3]/H_N1^"]
MN1R>*;(??1@N (8A82 %(!1W"G27AWO8+5B"V&4O:N/0:="XPE8%^>0^F*I\
MV(%9"QZ%AZ!K0J'!+@'N0XU']2 CIM-M+.G+'M))7XX??$ &)E*.2JB9 1FZ
M;W$  GB+15#_/18L5M)U>8JUE"@CQRWD$/KY5'(@+-8_@]&D^J%52W1-:[3[
ME:JCI3I@?H+1X^Y@HR0V.:A\4G@3[^T*.AGM9D!X5$=@9 2(0* F"/=_L6F+
M>$>[R,SAZSG@5H$\<^R%I\VLGG*'!8<$6.;P,44M?[:+\:3=XI%IL9Z,*H3R
MZ3LD:,Q.V9B=HC$[!37T'1,/E@,MBGTP;X;)BW@AP$"[\"%FGDR %9R'%0-4
MVI&J4RL#. +[_GE02JZ>M'BU57/NLQ2<AAU$_I H=4E&!1<'#YI)TP[S)!%Y
M)T" Y]^IF6JFRA;^X@2STZE37WMO@/(E)1U)8RW*L0<'E9.UCVQBE'H,C(T&
M_9WNEEU9N"'0A!P ;>4@1SZ*!* Z,_MR>H4Y#*D17-V?3LK";6J]Q@$AA^L)
M7OYDPE"#B26$<B@ME$(UJ]IL%59@D[F9RVJM'19/X<1&=QT&8$0^5Q9)QVHO
MK$K[OX![2_(S$K]X(-:!EH"N]E55"F3( R@,6>$)\# :<N JC+P@@A00A-D7
MRE,75F(QF.@EZ$O6%!HR>@KW\60RJU8%&Q'WI\6\^5QJR\,3C-HWNR<DT[AY
MFC ?-8'$DE-.4&,Q^C_&&?$(9PJP#8QWJ+=@D$V%^(%=,P46M_*1"HU9<%F
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MS&RRX[[80-%+F)B:0X(! L7S&$-1B<4SM)G%^$7I[?.06%(Y7#>Q=N'=/'N
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MC[F?6VD#UN<:4=B\D(#N=OKZ?U!+ P04    " #-0ZI6BJ9;8(P+  "8(0
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M!KR?2]ET#T2@_S'&Y;\!4$L#!!0    ( ,U#JE94'62B%@,  /T&   9
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MNW<?!GZ2*TX=%!8,'0T_<;/;;MAV&S)U&'"I(1Z785GR]PFM=^#SPAC:;7R
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M''SK0[=2+V,43@%=&:HA))P.P[P2M1YOD(LUAI%>O+)*EVB1ZA#S<0 =G&,
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M:_/^>ZRC;:1K^IG_6J*,'+>07=3L*QP=8;$L'XPFE;6M6J//W*)#*E09+=6
M^0E&CYO\E9+8':2J7N9]C[<KZ/VT6P#A41V!D1$A0H&ZASS&@;,7>.YH%YDY
M_'L?<:M GCELQ=T65L^Y-8FS/BQS>)NBR1VVBW&G_9JFJ;'-@2J$\NE;BVC,
M3MF8G:(Q.P4U]*U&CY8#+8H-9&^&R8MX(< <)?/1>3^1!"NX#"LZK+0C5:<.
M&W $X/YU5'(NZM7X:ZV6W*#,. 4?//R0*#5)-@T_=AZT)TU[S)-$Y+W(!>Y_
MK1:JFBN;^1]G6)F8._6E]0:HOR2G+6EN3CGVX*!RLO0A5PR?CZ'QH$%_Y_O=
M !9NB( A?4);V<F1#V_'$^UN,'DZ.DG\ZKXQB\^G-Y1#(DT!]-'IS'%01\8S
M._A9"O]XLD)C'G%,TN%Z(BI_,F& RL0:5][5OG*AJDUI=@J[%\GTX'6QU0X;
M#[!CI9L&PU?BL<NSI-M[$)2FLR; H)J$?")^]4AL \.!)]IW)"C:(C>E,."'
M.\ -:K=&MG+X@ >DJ"7,V5$A964E-E*(7H*^]!JJ7<F)DB7<F6R_5<&01?BT
MF($OI;8\J,5'^VKGD10/@:<5G:-VFEARR@6(V,CYCW%&C' F P/&YPX%04Q1
MJ(G5L6NAP"T4/IRBD2ZN6_%HD7R0&%!V8V'':1=*G[0BC]6;C/;<Z^*E,NY5
M-11GABJ21RI]PV/CH<#89U#60X_9U4>^KSIT1L8V96 /\W[YM4^CFU+"HOL%
MSAHZ#_5T8_4";R GS%TR[3(>0V5_X[#3"P?"H @C0]^:KI"&:<DLSB7ZAD_G
M6]..>'JDW-^&)3*'E3'@?^^^C.\+_*'G ,)()1**YKJ;/K-[]L<SL)...(H:
MI^<*L368EI/;&8 QR3YQN]ZUJ!VH /T90H\]0)<T715&$_-O(P*N">-XS%RB
MKBY.-T;CY"JG9@,*'H^2]-/)>O4&EQQD?"7W1RL%X4+1GV(:)(/>JTYVY\T.
MB758A^Z(EZ='ZZ11BM(8E%^@0C@+ILR/A K.CGZALYB#XWDJ9@=4G"L$[%6$
MCP:A\.?3)98\HI/'^/;@=)0;_&;)*NW$3N-('T3)6T[H>"#;FVBRX7!N-OK9
M;]\LB/MM$7QTC9/O<,HOK4$B>4@]71BC,!PBZXNXYVN0.YPE+, #^H/M'WX?
M-J_KYC'#:G 3IO7)OO8ST3%L_E-9<YCV^S)%U-:^61NR7MZT ]E#C^MHE<^/
M!8WT7%W#DQ"]V=R_U 1U8UU0'^[4ZD$X<,^<./8XTY@,S^66N[ZH!I,QWMR<
M=D]]3<<?^WHC;4UCE$_>0\;Y5-R!M[E'E 9CP>]XZBMLD.UOD+(\E<Y-VTF0
MBMB5M'B#H]2T.$RNOKF[C[.:O@!)0@I1!F=T98ML@=LFXH9^AH]4!8H!E",=
M\,&VWT@V#:1J;1.J&2EOP 46V&5E\8YIU0,]K8D ?1<UK/$,!@5H)+?=0[H:
M8JW7C&7F40.K"U[ DGX$E',!V(A>.YC.AD+MS0PU0#L*Q4I;-W3=Q^B)FJPF
M.<+TY1C^/<] D6R<B^R%$4^I_[+D?B9F8322!PH 1VZZ8'2N5KJFAYIB7MEU
M7NG,3L2Z/ V:]<)C'([/T.S;B;@[@CS5GJ@Z@J4BN.-TGQQ/]$1-PD ]EZKJ
M!1KJR.N.5MA*5_XB"D!WZ2GU?B&4Y-*V'ZP_&(+OR1D*>K:A89 .97+5)-TL
M,B0]]-P76&S:\Y@<U2V&QJF%.)2HWG,W^[2>9#<'"A%/V</QP4<03E:^7X-E
MIGV. 7\7$H<R?1&J+S[BN/AD*<K4A^MQ;B*NF^Q(FR7O%6$C/_#'%*CK!K3Y
MH7 *T>?XI'A(K%"<FI*CS*#*6/]2**L&<AUZ_BH;MLLY2P"/KO<D()JJ*#JY
MC\? >WF1Y&)E]P#FWNGO_8 <QO;7/9%.YL[?]$3QMF\OHS6/5C8C*B(%.\HF
MO]WC,RQ.7./CN*C#&NW=760I)Z97LY?Y]/(J_$6CW3FJR.UI_O+L+#^?GHGS
M?#JE3_T[O1#DWDZ3>?#9B7_*(Q2!\=DDS @"Z//\Q8M9/GLY$[/\\O(2_EUE
MO]$LR&5^,9WF5Y<O\=/993Y]_GS4+W:/KD['GUU]BT''OT/0\39F9N^Z9U,&
M/>1W/,R*6V7C6_'ST;Y@QY',JM7)['(R<)F$2[TZ1'IAK<&T@#3LV#!"@$/E
MX!!QZ7K3<E+?]5WH^5?]!<*6+#QRY5UH"AB"9>-;A24&5&'VP#_3R%.\P]TF
M?,9,LP]) &)EOX05G(0D15H>3J6!B:7?$>>25\9J/\6:VBO0?W2SL;S+31QZ
M+GK)$U-<"&\I%7W/J$_9^OCQ3S2I/"_%U\4YX9DQGDEA&27<#]S[@X.+IR79
M%(=FD>W^\3,B,W4E "$?Q%/TSABQ%>>HGHLOX.SXT6-,'[E["+]VI4\B<&HI
MU]ZBQQL,/>'N0B64\L4.=Y\$=$)XA%E=.L:TF(;#A$<,&/?36(,!4A<TL!\,
M6<8E-+[LXWFPQ7I+XNT"Q6;8BD/(N>]24,=NGU3>)*(J1/9,TTH:EZ2PWM61
M/T1A V2DENK &H@4K6GQ&21CK9F'9WU(!1/(/@_#K/X[:#G;I^52/ZK89^HH
MF&<X\GZ<A+FH6LI[<2;>/]2"$GOJ;8 J5AV=SR?B4VT.9#-T@=A#HEP#TN@]
M@4*U20\Z1DX&D5B!M-- _GB7/,*943O@H>X_1_F7R7B^3T9=+RW7\[&@RO(X
M3L',/X=<82^=6(!%%-(3HFD<48[)1.OXX7FR/-Z$]:ID>QWNF-<S5<AF1C<X
M9*^]B/M0AL8$NMM215Y"<,9M-'QN&6AL5;/+>_E[!E81"QMAUTW;-<G3XEQ:
M-3O<:&\+U-=XK!"3IM/W[!=Z\5SF!ZL=!_.RW/G4)<K3X&/K>[./OABD:E^]
M[C^TW'\0/WW$](E_6,SG*['8O9$[?I*$K/_"8H02QHR><C@?6V!A?*!K*6Y#
M!09<1!*2=T3$A^5C <>!9V].J?Y6R\8W(#EU25 =S_F[-R%,QU^%\%'A'%GO
MA3S6U 9[5<<#FV\!F1T%B?,4'^0.@\XIL[[3YV01/FA:4!GGQL"?F.6_O;Z_
MZ=)\#A8'EWW:4!D_K+N^_Q27X=:G9\_S[#!(%D]^,QM(D&:79T]S\5K-&RJ
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MT<>U@OS X@UP?6D@W?1?<(/X@LM7_PM02P,$%     @ S4.J5B%5X5%. P
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M;HVG\1N6-=UW:-F WE?&^..& PPWZ/(_4$L#!!0    ( ,U#JE8]F.L ' ,
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MRX:: [4SH/NU4G:_<0$._V'S_P!02P,$%     @ S4.J5A#ZE^U2 P  I @
M !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULI5;;;MLP#'WW5Q#>,+1
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M$B%WH)+Y81 ,_1(H]]+$Q>8R342M&>4XET3590GR:8),;,=>WWL.W-!UH6W
M3Y,*UKA ?5O-I9GY'4M.2^2*"DXDKL;>57\TC6V^2[BCN%4[8V*=+(6XMY//
M^=@+K"!DF&G+ .:QP2DR9HF,C(>6T^N6M,#=\3/[M?-NO"Q!X52P[S37Q=B[
M\$B.*ZB9OA';3]CZ&5B^3##E_LFVS0T\DM5*B[(%&P4EY<T3'MLZ[ #Z\2N
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MAJX["B93>W=(OFV=$[B#0;VNP6M8\QIV\EJ"T'4[PUIE.Q"*K?#?M,##"(3
M,BX5CZ[)STM(5R!:*]0)_]0*]0364"*HE0B>A:6#/@7K":PAV*@6;/1_EA[=
ML^K(F[C!Z,C1_US68#6N68T[66&!4JQ-:=PK*@3-E.QT<"?>4PO2$U@C]4F=
M^N19.'C2IV ]@34$<YV[^X/S?QZNX@[=Z4X<QW>=(Q>W+/1=M[&PR>W@;N,^
MWLE?<EVP;B-WXSVU,'VA-;/W[K+WGH69*QI]B=836E.TNUN9VWF'Z;"S?]^E
MX['G3;QC.]]?Z 7Z<WPLVP>W]A3$QC0SDD2\R%1YK:UGZX;IS+0)1_/GNI$R
MW< =3-F%X:5UP]#S":P1TCD9H5=$V=B4 \5STQNLN,).PSQNL1D$H1?@^S7G
MZG:@-ZC;R_ O4$L#!!0    ( ,U#JE; %I=1D@4  #@F   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;,5:76_;-A3]*X0W#!VPQ1;ES\PQD(AM%V!9
MC7CM'HH^,-*U+40B/9*.LV$_?J2D2):B,%7 K'E(+(GWD/>0]X@GYOS Q:W<
M BATGR9,GO6V2NU.^WT9;B&E\H3O@.DG:RY2JO2EV/3E3@"-LJ TZ>/!8-Q/
M:<QZBWEV;RD6<[Y72<Q@*9#<IRD5?U] P@]G/:_W<.,ZWFR5N=%?S'=T RM0
M'W=+H:_Z)4H4I\!DS!D2L#[KG7NG!$]-0-;B4PP'>?09F51N.+\U%Y?166]@
M1@0)A,I 4/WG#@)($H.DQ_%7 =HK^S2!QY\?T-]ER>MD;JB$@"=_QI':GO6F
M/13!FNX3=<T/OT*1T,C@A3R1V6]T*-H.>BC<2\73(EB/((U9_I?>%T0<!6B<
M]@!<!.!FP/") +\(\+\V8%@$##-F\E0R'@A5=#$7_("$::W1S(>,S"Q:IQ\S
M,^\K)?336,>IQ2J?;\37:!5O6+R.0\H4.@]#OF<J9ANTY$D<QB#1&P**QHE$
MOU,AJ)FN']'/Z..*H#??_SCO*ST:@]D/BYXO\I[Q$SW[Z(HSM97H+8L@JL?W
M=19E*O@AE0ML!;RBX@3YWD\(#[#?,I[@Z\-Q2SBQAQ,(GPJO9>.7$^-G>*,G
M\):"1_M0H4N6%[<IDL^_Z4;H4D$JO[01GB/Z[8A&04[ECH9PUM,2(4'<06_Q
MPW?>>/!+&ULNP8@CL!J3PY+)H0U]$5"Y1>_(98!B)O>"LA#:R,M!QAF(4<N[
M!1X-],^\?W=,B[6OKK0X JO1,BII&3U/R^IR^0PM.<CPB):,E28MUKZZTN((
MK$;+N*1E;*5E215H :0L0EKWS M.:V "&YID]]9Q8FZL00NBN0ZY5+*-M_$C
MWGQOX@^;O(T?K3K?&V%_4F]&K&-^(2.3DI&)E9&/3$#(];OA'XB0HO?H!ABL
MX_:T)X_R:69L[:SK2K%U5TMV6B8[M5>%GL_L94@3/<.?KR"] ?$%_8NNX0[8
M'M %L'"K7YFWQP\?Q#K@NHJ8$KE<7\>R:M5&EG4H7?7:)1AQ!%:;@EDY!3/G
M;[Z92R9=@A%'8#4FO4&UNQL\LYR/%Z0P"W('PMS2F_K6/5N.-SNNJ!.O4<)?
MTXC81_;2S(_VM9XU\_=:I$0AVN>1WCG'4N6[5O3V7KLF":]=W?8!=EV43M&(
M*[3ZY.!J<K#S$B\@7='I$HVX0JO365D%S[I_?D&5YWBF1(\J&(]GS4)O;S<;
M-VO]-?;W7K7!]^P[_/^WUG6KE>+A+?JP,P\E>J\WS\KLC3@BL=XK*2[RS6'
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M/4:BNP4J"\3[-2'\,) +5/VR_P]02P,$%     @ S4.J5I-?'FCW P  QA(
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M)/.?J]$_[B&9 _^I!OR&;"1"PD$,;:FBTSYLOXADDD?B'HC$0_>,RE"@&QI
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M)^@FU5XXV2@"-.'4!W2K5Z#[;PH.74F(Q:\F=45NISFW?GW.1$I\&!GJ_1#
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M-=ZF_);LOT.5D"/Y0I(R]43[TM81'L,MXR2KP&*>)7GYQH^5$ V X.D&6!7
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M'V?7-T7UQ,GEQ6UZ;3_9XK?;#WGYU<F#,ITM['(URY9!;J]>';WNOS3CTVK
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M$61707VTP[^%B!8X4"U"-8%J,:I)5%.HIE$M035#:>Z'79LFQ^!038X!VN1
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MFAN:II8Q\M<RQ.)VGFTN/OCZ.K=V_>C1A=*B_#@PV==T<N/?7D3;&Z@6H9I
MM1C5)*HI5-.HEJ":H30W@TW)8W2HJV*,T)8'JD6H)E M1C6):@K5-*HEJ&8H
MS8U=T_(8[76WDU4Z3_-OK>E"RQRH%J&:0+5XU'(YD9:;,DIT5H5J&M425#.4
MYN:FJ6F,?JRFX1_>.39H30/5!*K%J"913:&:'FW76\;;.ZC)?HL9:MV<.(1-
M 2/T%S#VV8-*TH5=!9^.@[>S<@5>!&^/(^_NE'_*KA%"M0C5!*K%J"913:&:
M1K4$U0REN8%LZAGAH>H9(5K/0+4(U02JQ:@F44VAFD:U!-4,I;FQ:^H9H;^>
ML7-WRC^^<[K0?@:J"52+44VBF@JWKQ?2;]G5T^BL":H92G-STS0T0G]#8]?N
ME']XY]B@50Q4$Z@6HYI$-85JNM8>[R>-AJ?AT]VI_18SU+JY<6C*$Z'_FAAZ
M.<EMNK+5K>72G6\I:%\"U:):<_YI/-VNZ0ETUAC5)*HI5-.HEJ":H30W0TT3
M(O0W(78=DA#Y;!(DQ\$>MSOPS]0Y86AI M4$JL6H)E%-H9I&M035#*6Y.6S*
M%>'X4$<BT#X%JD6H)E M1C6):@K5-*HEJ&8HS8U=TZ<(_1?-V'TD JU-H%J$
M:@+58E23M>9L(+=<;%2ALVI42U#-4)J;FZ80$?[8;4+\PSO'!NU#H)I M1C5
M)*HI5-.U]O2#:5M'(K87:ST2<8B>0]CT'$)_SZ';D0BT](!J4;A]'KW]2 1:
M9T UB6H*U32J):AF*,W)T+@I1XQ_K!SQYF9FJQMTVSQ=W^O^_?IN._X[C/BG
M[!HU5(M03:!:C&H2U12J:51+4,U0FAO(IAPQ/E0Y8HR6(U M0C6!:C&J2513
MJ*91+4$U0VEN[)IRQ/C'KETQ?N:^&T_OP.B?IG-LT-8#JL6H)E%-H9I&M035
M#*6YL6FZ$6-_-V+7YN/'K'Q0!.^.@]]MN?E8OJ=9_^DL_WR=W\30,@6J"52+
M44VBFD(UC6H)JAE*<]/85#/&A[JNQ1CM::!:A&H"U6)4DZBF4$VC6H)JAM+<
MV#5MCK&_S;'S=)9_?.=TH1T-5!.H%J.:'&]?=*/U=!8ZJT:U!-4,I;FY:=H7
MXQ^[XXA_>.?8H!T+5!.H%J.:1#6%:KK6'D>ZK5B[WV*&6C<W#DTK8NQO170Z
MG>6W.F<#;4B,6WH#;:>ST%EC5).HIE!-HUJ":H;2-ADZ6=U86T1ID5Y>+&Q^
M;=_8^7P53+*[9<E7!_<>G@UR>U5FK/_R]>#H9.MYW7^9]*OG3QKF\N(VO;9O
MT_QZMEP%<WM5DKWCT_(],9]=WSQ\462WKX[Z1\'GK"BRQ?KAC4VG-J\6*+]_
ME67%]R^J">ZS_,MZM2__!U!+ P04    " #-0ZI6J)NTLNT"  !]"P  &0
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M]R+;S&;:7'1Z(>P#>&);5!(0_GTEVQ@,MK8F7B[ 'SJOCAZ=(W0TVC'^*E8
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MO4$BS0*6Q[I:*86DB8[_&T0EDBM <UB&2:*>5&'.NO/2[O2:NYVX@Z'7'ZH
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MB?5&[<EXOP?YXP;+\;0NSZ36T0)NH)J):A:JV:CFH)J+:AZJ^:@6H%I(:<*
M=5+<S&'2Y&8.7Q$]J_:;#F)1;8IJ"JJIJ*;EVG%8+!T6B=^<Z6B7!JJ9J&:A
MFHUJ#JJYJ.:AFH]J :J%E":6W2+Q.ZE._#:,GE5KC8LLFN]%-0755%33<NUX
M0FWZN2C]6'1:9]'EUE'-1#4+U6Q4<U#-134/U7Q4"U MI#2QSG:+.EMG5?8Z
MPU@TW(MJ4U134$U%-2W7CL-B^^M-IQ4676L=U4Q4LU#-1C4'U5Q4\U#-1[4
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MQVGVF9OH4[28/X=IYNOU]N)E##0+C&K37#O^<"^/.^>?[A6T6Q75-%334<U
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M;]O(H<;Q^_,I"+<H6B"-)4J4Y&UB(&N^#3G#!,GV% ?%N6!DVB96$G5(*B]
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MS)AOBC);[@97]V"9KN[_C+_M_D,<#!B.GQA@[@:8IPX8[0:,3ATPW@T8GSK
MV@VP3ATPV0V8G#I@NALP/77 ;#=@=NJ B]V BU,'# </S]S@Y"'[)_OHV9X^
M->3AZ1X^?KZ?_HUZ>,*')S_CPX>G?+A]SL_O?WVWO_MV7,:7;_+LJY'7MZ^\
M^HOM";0=7_W*IZOZ7/]4YM7?IM6X\O(J6R[3LCIYR\*(5]?&5;8JT]5MLIJG
M26'\U4[*.%T41A3G>5R?E7\S_F[\\Y-M_/7/?WMS7E9WH&;.Y[N#R?N#F4\<
MS#14Q=\5AK.Z3JX[QBO]^)%F_'GUP/>/WGQX]+^:6O#=.G]M#*>O#'-@CCKN
MSY5^>)1]>6T,)MOA9L=P6S_\_;RLA@^?'.[HAP>;577G!T\.=T]X[(.+[?!A
MQW!//]Q-/E?#K2>'^_KAGY)U=>?->OAPUC%</'/G-[>OJZ%/#@]..?IX.]SJ
M&![JA]O)O#KZ_?"N7QMYPIT?W3_O@ZZS0#]<Q?E^>-?1H].'FYIS:+1/D-'6
MLYY,D,4B_IS=QX/QKLJ)*C[J0-GFR>'W[\N[)#?*NWAEM ?]6U:F(<ID6?QO
MQP/Z]?X.C+KO0'TU]$NQCN?)V[/J<J=(\B_)V>5?_C2<#/[1=4J3F$UB#HFY
M).:1F$]B@L0"$@M)3)*8(K$(PEK1,]Y'SUBG7]87*WDU6]C$"V.^OY#I2A"M
MTS=!2,PF,8?$7!+S2,PG,4%B 8F%)"9)3-UCDRU6KR9\N9Q>#.I_WIQ_.0P'
MZ*"M<+#VX6!IP^%C)<;Y_&Y[&7*=?$D6V7I[&3+/BK+H"@FMUS<D2,PF,8?$
M7!+S2,PG,4%B 8F%)"9)3-UCXX.0&,XN!C/K44981UDRMF9CJXF2UMD_V9_]
M$^W9_^[V-D]NXS(YN# HC.3;.IF7G4L/OVJ]OF<_B=DDYI"82V(>B?DD)D@L
M(+&0Q"2)J<G1V6^-CB\0H$.V(F*ZCXBI-B*VKQ6LC'^K9/DYR3L7'K1 WTP@
M,9O$'!)S2<PC,9_$!(D%)!:2F"0Q16(1A+6B8[:/CME+KWG.R.@A,9O$'!)S
M2<PC,9_$!(D%)!:2F"0Q16(1A+6BYV(?/1?/K'DNU\FJB.NF1%=N:$?WS8V+
MH[F9V;',8Y/'=$C,)3&/Q'P2$R06D%A(8I+$%(E%$-9*A.&@Z7 ,M)GP(4ZO
MC>SF)ITG1O[$*R!ZHF\PH)J]TPYS9O(X9!STD"ZJ>:CFHYI M0#50E23J*9V
MVN$*AFG-1H\6,*ACML_\@_;64'OFO]^>]+EV$4-/]#[S2<U&-0?57%3S4,U'
M-8%J :J%J"913:%:1&GM*#&;*#%?>DUC=P^H)"(U&]4<5'-1S4,U']4$J@6H
M%J*:1#6%:A&EM9.H*90.M:6Q9Y<X],-[Q\CH:/(QZUKD0(_JH)J+:AZJ^:@F
M4"U M1#5)*HI5(LHK1T03>US^$SO,RV_&]F-X6?K1#_U07N?J&:CFH-J+JIY
MJ.:CFD"U -5"5).HIE MHK1VGC1-T:'UXE,?M%R*:C:J.:CFHIJ':CZJ"50+
M4"U$-8EJ"M4B2FLG4=-:'=*U53W8.UC0XBJJ.:CFHIJ':CZJ"50+4"U$-8EJ
M:GA<836G'1U6ZJCMR&A:K$-]C=5SQ"?]) AML:*:C6H.JKFHYJ&:CVH"U0)4
M"U%-HII"M8C2VCG25%J'+]YI':*E5E2S4<U!-1?5/%3S44V@6H!J(:I)5%.H
M%E%:.XF:ANM07W%]M\PV5<SDR:*:"%T;968LTT52E%D5+NOX^U/O\=>KO=.%
MU&Q4<U#-134/U7Q4$Z@6H%J(:A+5U$X[G F-A];,/"K#_8P:K-G48$U]#3:R
MW]7[EQ6;1;V%6?5EOM9.C/1<W\! -1O5'%1S4<U#-1_5!*H%J!:BFD0UA6H1
MI;5CI>G8FL.7GAB9:$47U6Q4<U#-134/U7Q4$Z@6H%J(:A+5%*I%E-9.(K-)
M(FWQ[O+@XJ:.GOCZ2UID^7?C)DDZ4P6MVZ*:C6H.JKFHYJ&:CVH"U0)4"W=:
M:V.@HQ=?)'I,M=/&VF-&S]VJ?78WM5=3VYJ[O*I^D,[CA?%;GE;__ICL]B][
M=YLG]]<7VLD,6?"[0C4;U1Q4<U'-0S4?U02J!:@6HII$-85J$:6U0Z:ISIKC
M%Y_,H*5;5+-1S4$U%]4\5/-13:!:@&HAJDE44Z@645H[B9K2K:G?G_7=]9=X
M-4^,^,=>[='KO5,&+=2BFH-J+JIYJ.:CFD"U -5"5).HILSCC5LG'9.@XUN-
M1B/SB4E04X U]078_:SGY%V;]6#O($ +L*CFH)J+:AZJ^:@F4"U M1#5)*JI
MG7:X C,<30?3\>,H^!D%6+,IP)KZ JR^,_^J2I%BGJ?KI]Y-K-=[YP=:CT4U
M!]5<5/-0S4<U@6H!JH6H)E%-/7/>_G:7&/5;_>/5][_\:68.I_\HC+CC7#;6
MF[S8Q-479?9?Y5U:WVJW(OK*J&8*Q6X*41C5G?J29IMB\;V:.:3;N<1U9;VJ
MOBCC136YB-?K//N6+JL?5K?YLS6U7E57-D9<U.\F5MOKCH</UGIE?+U+J^_3
M)DIJ[W-BI*OY)L^3Z^J^Y-GF]LZPD_EV7?9A;-<GBD74?]IV2#;M7E/;V?N!
M-Q;IP=ZYB)9U4<U!-1?5/%3S44V@6H!J(:I)5%,[[?"ZJDJBCBG6SZCAFDT-
MU]37<.\7@/>O2NU?ABKTKT.A+5Q4LU'-0347U3Q4\U%-H%J :B&J2513J!91
M6OLS0YNN[FCPTJ]#C=!Z+ZK9J.:@FHMJ'JKYJ"90+4"U$-4DJBE4BRBMG41-
MO7>DWT*W_XJS'NP=+&A;%]4<5'-1S4,U']4$J@6H%J*:1#6UTUJ?&3@<=U3P
MJ,.V,\-L,N.Y(N[^0B1;=13TC/\8SV[+H#]$[Q1!V[FHYJ":BVH>JOFH)E M
M0+40U22J*52+**T=-4TK>#1Z\8D267"\0C4;U1Q4<U'-0S4?U02J!:@6HII$
M-85J$:6UDZBI#H_TN^[^P$0);0*CFHUJ#JJYJ.:AFH]J M4"5 M13:*:VFG/
M[LA ';4=&4W'=_1,Q[?WJ\YZL'=DH+5>5'-0S44U#]5\5!.H%J!:B&H2U=2H
MH[ [O3 [UE9^QA:XHZ8!/-(W@$]86_DUS8P/=W&^C(U_9?GOA2'EE7ZM!>T(
MHYJ-:@ZJN:CFH9J/:@+5 E0+44VBFD*UB-+:T=,TB4?3%U]K0=O&J&:CFH-J
M+JIYJ.:CFD"U -5"5).HIE MHK1V$C5UW9&^KMMSIQ>]UCM5T*XNJCFHYJ*:
MAVH^J@E4"T;'#=;A\4?FA>A!):HI5(LHK1T7355WI*_J?DS2Y>=-7B37V\65
M5=&=$F@U%]5L5'-0S44U#]5\5!.H%J!:B&H2U=3H>(/<T7$>1L_>K'7ZCYLR
M[5B_\>V^H[]_B>;39KW.\O+$O:/T?-]@0#4;U1Q4<U'-0S4?U02J!:@6HII$
M-85J$:6U8Z9IRHY??"/<,5JM134;U1Q4<U'-0S4?U02J!:@6HII$-85J$:6U
MD\ALDDC?O^W_NK(>[!TL:-L6U1Q4<U'-0S4?U02J!:@6HII$-34^W@UW-NB8
M_%!';4=&TZ,=:]MQO>9(QG^,DS]B7G_8WL%":C:J.:CFHIJ':CZJ"50+4"U$
M-8EJ"M4B2FO'3U.>';_XOKMCM&V+:C:J.:CFHIJ':CZJ"50+4"U$-8EJ"M4B
M2FLG4=/)'>L[N?OKGY-K_'JP=["@G5Q4<U#-134/U7Q4$Z@6H%J(:A+5U+AC
MJ]V+P6#X>.IT?+.G7C-J:K9C?<WV!Y90T!(MJMFHYJ":BVH>JOFH)E M0+40
MU22JJ9UV>'Z;X]&H8PWE9_1CQTT_=OS,CIWU-IJ:ZP2TVXIJ-JHYJ.:BFH=J
M/JH)5 M0+40UB6IJI[7>[C>>6D/S<3[\C-;JN&FMCO6MU?K-.,;[_#K)3RV>
MH+U55+-1S4$U%]4\5/-13:!:@&HAJDE44Z@645H[5YIZZ_CBQ1=/T6XLJMFH
MYJ":BVH>JOFH)E M0+40U22J*52+**V51%;3M+7T3=O^BZ=ZL&^PH)J-:@ZJ
MN:CFH9J/:@+5 E0+44VBFMIIK<TB1Q-K:CV:%%%';4=&TYJU]/O+]E]HU8.]
M(P,MP:*:@VHNJGFHYJ.:0+4 U4)4DZBFK./]96=FQX<;4D=M1X;91(:^WJI=
M1^E33M,?IW>2H*U75'-0S44U#]5\5!.H%J!:B&H2U12J1936SINF&VN-7GI]
MQ2++?%>H9J.:@VHNJGFHYJ.:0+4 U4)4DZBF4"VBM'82-3592[_'[!_\4'B]
MWCMET HLJCFHYJ*:AVH^J@E4"U M1#6):LHZWG#6LJS'V\UVW&IL/;6_@=54
M5BVZLJH'>P<!6EE%-0?57%3S=MKA-D&CT?$'7?KH406J!:@6HII$-85J$:6U
M(Z.IMUITO54/]HX,M-Z*:@ZJN:CFH9J/:@+5 E0+44VBFK*.ZZV3T<7%^/'%
MP\\HMUI-N=72EUN?6W3][2[)X^ODF_'I>U$O<[PRQ&K^6K_\BA9B4<U&-0?5
M7%3S4,U'-8%J :J%J"913:%:1&GMY&EJL];LQ9=?T:(MJMFHYJ":BVH>JOFH
M)E M0+40U22J*52+**V=1$W1UGIN']G>"RUH;Q;5;%1S4,U%-0_5_)UVN&QS
M81U_"*] CQJ@6HAJ$M64=;P-[(4YFSZ>#G5L%FO.AMUKJ9.FP3K1-UB=;_/%
MIJBO&60ZKW>*[I[MN&E>E(:;;7+C?ZI(*+3S'/TA^X8 JMFHYJ":BVH>JOFH
M)E M0+40U22J*52+**T=/4T3=O+B^\=.T.HLJMFHYJ":BVH>JOFH)E M0+40
MU22J*52+**V=1&:31/J"K4I7Z7*S?*B2%,9-EAMY]CU>E&G2.<_1@[V#!6W2
MHIJ#:BZJ>:CFHYI M0#50E23J*8FQ_O'6AW;QU(';2=&4Y&=:(MOIT^;JEO<
M3YC>5=<T]6M&27Q35A<SVOD36>&[0C4;U1Q4<U'-0S4?U02J!:@6HII$-85J
M$:6U,Z@IQTY>? _9"5J@134;U1Q4<U'-0S4?U02J!:@6HII$-85J$:6UDZ@I
MY$[TA=P?F#^AA5Q4LU'-0347U3Q4\U%-H%J :B&J2513D^/-88==G[]!';4=
M&4TA=Z(OY)XX@5+9S4U:EL95_3:@W+BJ_KKZH[Z^V;\V+59%F9:;,C'\K%BG
M]9:48C773[#0;B^JV:CFH)J+:AZJ^:@F4"U M1#5)*HI5(LHK9U1305X,GWQ
M"19:"48U&]4<5'-1S4,U']4$J@6H%J*:1#6%:A&EM9.HJ01/]#OI1MG*R).;
MS>HZ_KQ(C,7NDBDMBDUBW"2='^^N)WM'"]KQ134'U5Q4\U#-1S6QTPZ+?>;Q
MVS$#]* AJDE44Z@645H[,YKR[D1?WE5Q6DV65MO]$YZ*"+2MBVHVJCFHYJ*:
MAVH^JHG)<>NT,R+0LBZJ2513J!916BLBIDWY=ZHO_WZX7Z\UJJN+5?L*8[^]
M2E=LZ-6^L8%J-JHYJ.:BFH=J/JJ)G79X93&<74R/@P,];(AJ$M44JD64U@Z.
MIKH[U6]B^WZ=U L<J]O[=P)MUT/JS12J24GGRSUZKG=BH#U<5'-0S44U#]5\
M5!.H%J!:B&H2U=3T> O;R7#R>,_KYV[5C@&SB0%];]99KA?9_25$YZLWSK=D
MOMFN@[Z_N4GGR3/O&](?K7=*H*5:5'-0S44U#]5\5!.H%J!:B&H2U12J1936
M3IVF>SL=O?3+,E.R)WB%:C:J.:CFHIJ':CZJ"50+4"U$-8EJ"M4B2FLG4=/
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MH&7\H!4$K>('K2%H'3]H T&;^$&4HHRI@J07K!5H3<@U*?":$&Q2(#8AV:3
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ S4.J5IE<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #-0ZI6: TZHDL&  #B(P  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ S4.J5B]KWHQ2!0
MGA,  !@              ("!C@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( ,U#JE8Q4_3EIP,  %X-   8              " @184
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #-0ZI6;\4(
M]JX$  #"#P  &               @('S%P  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ S4.J5I-JESMX @  V04  !@
M ("!UQP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,U#
MJE:Q9Q;[[00  $@9   8              " @84?  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " #-0ZI6E6_H)X,%  "S%@  &
M        @(&H)   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ S4.J5GYUU8C&"   +!@  !@              ("!82H  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,U#JE:>/*FR+PH  +P9   8
M              " @5TS  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " #-0ZI6%\6[0:L9  "-2P  &0              @('"/0  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,U#JE:!\O6;$@,
M -P&   9              " @:17  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ S4.J5ADSKRC=!   V L  !D              ("!
M[5H  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #-0ZI6
M3:#JR44(  "I%@  &0              @($!8   >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,U#JE:*IEM@C L  )@A   9
M      " @7UH  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ S4.J5E0=9*(6 P  _08  !D              ("!0'0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #-0ZI6#:!TOV06  !^.
M&0              @(&-=P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( ,U#JE;V<A45@ (  +T%   9              " @2B.  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ S4.J5G8MF5>^
M&@  [%(  !D              ("!WY   'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " #-0ZI6(57A44X#  !-!P  &0
M@('4JP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,U#
MJE8]F.L ' ,  ,\&   9              " @5FO  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ S4.J5A#ZE^U2 P  I @  !D
M         ("!K+(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " #-0ZI64;!-:NP"  "F!@  &0              @($UM@  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,U#JE8MG@)?E00  $0-
M   9              " @5BY  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ S4.J5@K2;&@\ @  \@0  !D              ("!)+X
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #-0ZI6V#Y9
M7GD"   ,!@  &0              @(&7P   >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( ,U#JE:,>R%@6@,  &H.   9
M  " @4?#  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MS4.J5L 6EU&2!0  ."8  !D              ("!V,8  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " #-0ZI61/=<O (#   ["P  &0
M            @(&AS   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( ,U#JE:37QYH]P,  ,82   9              " @=K/  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ S4.J5H.](O'^ @
M)@P  !D              ("!"-0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " #-0ZI6Y/WMCW0)  "450  &0              @($]
MUP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,U#JE;.
M-JM X@(  -X*   9              " @>C@  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ S4.J5BQTG[GE#0  :N   !D
M     ("! >0  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,U#JE;RA%:/[!4  %A\ 0 9              "
M@=LE 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ S4.J
M5KY,Z=-: P  .!4   T              ( !_CL! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #-0ZI6EXJ[',     3 @  "P              @ &#/P$
M7W)E;',O+G)E;'-02P$"% ,4    " #-0ZI6Y%)$WZD#  #>&0  #P
M        @ %L0 $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ S4.J5K>]
MPDN! 0  *1<  !H              ( !0D0! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ S4.J5F/6BA2; 0  E!<  !,
M     ( !^T4! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "X +@!Y#
&QT<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>234</ContextCount>
  <ElementCount>210</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Research and Development Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ResearchAndDevelopmentCosts</Role>
      <ShortName>Research and Development Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Research and Development Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ResearchAndDevelopmentCostsTables</Role>
      <ShortName>Research and Development Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/ResearchAndDevelopmentCosts</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Organization and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Organization and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/BusinessDetailsNarrative</Role>
      <ShortName>Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/Business</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails</Role>
      <ShortName>Schedule of Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/StockholdersEquityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Summary of Related Party Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfRelatedPartyCostsDetails</Role>
      <ShortName>Summary of Related Party Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Summary of Stock-based Compensation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails</Role>
      <ShortName>Summary of Stock-based Compensation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Summary of Stock Option Activity Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails</Role>
      <ShortName>Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lixte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 -  form10-q.htm 58, 59</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>ex10-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>lixt-20230331.xsd</File>
    <File>lixt-20230331_cal.xml</File>
    <File>lixt-20230331_def.xml</File>
    <File>lixt-20230331_lab.xml</File>
    <File>lixt-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="500">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 500,
    "http://xbrl.sec.gov/dei/2023": 33
   },
   "contextCount": 234,
   "dts": {
    "calculationLink": {
     "local": [
      "lixt-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lixt-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lixt-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lixt-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lixt-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 418,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 35,
    "http://lixte.com/20230331": 4,
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 43
   },
   "keyCustom": 32,
   "keyStandard": 178,
   "memberCustom": 71,
   "memberStandard": 20,
   "nsprefix": "LIXT",
   "nsuri": "http://lixte.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://lixte.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Research and Development Costs",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://lixte.com/role/ResearchAndDevelopmentCosts",
     "shortName": "Research and Development Costs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://lixte.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://lixte.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://lixte.com/role/Stock-basedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://lixte.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://lixte.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://lixte.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://lixte.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "LIXT:AdvancesOnResearchAndDevelopmentContractServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "LIXT:ResearchDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Research and Development Costs (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://lixte.com/role/ResearchAndDevelopmentCostsTables",
     "shortName": "Research and Development Costs (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "LIXT:ResearchDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://lixte.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Related Party Transactions (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://lixte.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://lixte.com/role/Stock-basedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Organization and Basis of Presentation (Details Narrative)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
     "shortName": "Organization and Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Business (Details Narrative)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://lixte.com/role/BusinessDetailsNarrative",
     "shortName": "Business (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Schedule of Research and Development Costs (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
     "shortName": "Schedule of Research and Development Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ResearchDevelopmentTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-03-31_country_US",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_custom_CommonStockWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Schedule of Warrants Outstanding (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
     "shortName": "Schedule of Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_custom_CommonStockWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://lixte.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "LIXT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://lixte.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-04-12_custom_PlacementAgentsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Summary of Related Party Costs (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails",
     "shortName": "Summary of Related Party Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-03-31_custom_CashBasedMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-15",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ManagementFeePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Related Party Transactions (Details Narrative)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-06-15",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ManagementFeePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Summary of Stock-based Compensation Costs (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails",
     "shortName": "Summary of Stock-based Compensation Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-03-31_custom_RelatedPartiesMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Summary of Stock Option Activity Including Options Form of Warrants (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails",
     "shortName": "Summary of Stock Option Activity Including Options Form of Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
     "shortName": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://lixte.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://lixte.com/role/StatementsOfOperationsParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://lixte.com/role/StatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://lixte.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "LIXT:GeneralAndAdministrativeStockBasedCompensationExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://lixte.com/role/OrganizationAndBasisOfPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://lixte.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 95,
   "tag": {
    "LIXT_AdvanceAmountRelatedToMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance amount related to milestone payment.",
        "label": "Advance amount related to milestone payment"
       }
      }
     },
     "localname": "AdvanceAmountRelatedToMilestonePayment",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_AdvancesOnResearchAndDevelopmentContractServices": {
     "auth_ref": [],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances on research and development contract services.",
        "label": "Advances on research and development contract services"
       }
      }
     },
     "localname": "AdvancesOnResearchAndDevelopmentContractServices",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_AgreementTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement term description.",
        "label": "Agreement term description"
       }
      }
     },
     "localname": "AgreementTermDescription",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "LIXT_AmountRelatedToMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related to milestone payment.",
        "label": "Amount related to milestone payment"
       }
      }
     },
     "localname": "AmountRelatedToMilestonePayment",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_AnnualGrantOfOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Grant of Options [Member]",
        "label": "Annual Grant of Options [Member]"
       }
      }
     },
     "localname": "AnnualGrantOfOptionsMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_AnnualLicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company is obligated to pay annual license maintenance fee.",
        "label": "Maintenance fee"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFee",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_AnnualNetRevenueDividedByConvertedOrRedeemedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual net revenue divided by converted or redeemed shares.",
        "label": "Annual net revenue"
       }
      }
     },
     "localname": "AnnualNetRevenueDividedByConvertedOrRedeemedShares",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "LIXT_BasvanderBaanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BasvanderBaan [Member]",
        "label": "BasvanderBaan [Member]"
       }
      }
     },
     "localname": "BasvanderBaanMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_BioPharmaWorksLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio Pharma Works LLC [Member]",
        "label": "Bio Pharma Works LLC [Member]"
       }
      }
     },
     "localname": "BioPharmaWorksLLCMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_CashBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Based [Member]",
        "label": "Cash Based [Member]"
       }
      }
     },
     "localname": "CashBasedMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_CashSIPCInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash SIPC insured amount.",
        "label": "Cash SIPC insurance"
       }
      }
     },
     "localname": "CashSIPCInsuredAmount",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_ChairmanOfAuditCommitteeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chairman of Audit Committee [Member]",
        "label": "Chairman of Audit Committee [Member]"
       }
      }
     },
     "localname": "ChairmanOfAuditCommitteeMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ChairmanOfOtherCommitteesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chairman of Other Committees [Member]",
        "label": "Chairman of Other Committees [Member]"
       }
      }
     },
     "localname": "ChairmanOfOtherCommitteesMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_CityOfHopeNationalMedicalCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "City of Hope [Member]",
        "label": "City of Hope [Member]"
       }
      }
     },
     "localname": "CityOfHopeNationalMedicalCenterMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ClinicalResearchSupportAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Research Support Agreement [Member]",
        "label": "Clinical Research Support Agreement [Member]"
       }
      }
     },
     "localname": "ClinicalResearchSupportAgreementMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ClinicalTrialResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial Research Agreement [Member]",
        "label": "Clinical Trial Research Agreement [Member]"
       }
      }
     },
     "localname": "ClinicalTrialResearchAgreementMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement [Member]",
        "label": "Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_CommonStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options [Member]"
       }
      }
     },
     "localname": "CommonStockOptionsMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_CommonStockParValue0.0001PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "CommonStockParValue0.0001PerShareMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrant [Member]",
        "label": "Common Stock Warrant [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants [Member]",
        "label": "Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ConsultingAndAdvisoryCashFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting and advisory quarterly cash fee.",
        "label": "Consulting and advisory fee"
       }
      }
     },
     "localname": "ConsultingAndAdvisoryCashFee",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_ContractPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract price.",
        "label": "Contract price"
       }
      }
     },
     "localname": "ContractPrice",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_DevelopmentCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Collaboration Agreement [Member]",
        "label": "Development Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "DevelopmentCollaborationAgreementMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_Dr.JamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr.James [Member]",
        "label": "Dr.James [Member]"
       }
      }
     },
     "localname": "Dr.JamesMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_DrJamesMiserMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. James Miser [Member]",
        "label": "Dr. James Miser [Member]"
       }
      }
     },
     "localname": "DrJamesMiserMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_DrJamesSMiserMDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. James S. Miser, M.D [Member]",
        "label": "Dr. James S. Miser, M.D [Member]"
       }
      }
     },
     "localname": "DrJamesSMiserMDMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_DrKovachMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Kovach [Member]",
        "label": "Dr. Kovach [Member]"
       }
      }
     },
     "localname": "DrKovachMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_DrWinsonSzeChunHoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr Winson SzeChun Ho [Member]",
        "label": "Dr Winson SzeChun Ho [Member]"
       }
      }
     },
     "localname": "DrWinsonSzeChunHoMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_EmploymentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Agreement [Member]",
        "label": "Employment Agreement [Member]"
       }
      }
     },
     "localname": "EmploymentAgreementMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_EricJFormanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eric J. Forman [Member]",
        "label": "Eric J. Forman [Member]"
       }
      }
     },
     "localname": "EricJFormanMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive License Agreement [Member]",
        "label": "Exclusive License Agreement [Member]"
       }
      }
     },
     "localname": "ExclusiveLicenseAgreementMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExecutiveOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officers [Member]",
        "label": "Executive Officers [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficersMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eight [Member]",
        "label": "Exercise Price Eight [Member]"
       }
      }
     },
     "localname": "ExercisePriceEightMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eleven [Member]",
        "label": "Exercise Price Eleven [Member]"
       }
      }
     },
     "localname": "ExercisePriceElevenMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five [Member]",
        "label": "Exercise Price Five [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiveMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member]",
        "label": "Exercise Price Four [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Fourteen [Member]",
        "label": "Exercise Price Fourteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourteenMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Nine [Member]",
        "label": "Exercise Price Nine [Member]"
       }
      }
     },
     "localname": "ExercisePriceNineMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One [Member]",
        "label": "Exercise Price One [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven [Member].",
        "label": "Exercise Price Seven [Member]"
       }
      }
     },
     "localname": "ExercisePriceSevenMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Six [Member]",
        "label": "Exercise Price Six [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Ten [Member]",
        "label": "Exercise Price Ten [Member]"
       }
      }
     },
     "localname": "ExercisePriceTenMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise PriceThirteen [Member]",
        "label": "ExercisePriceThirteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceThirteenMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three [Member]",
        "label": "Exercise Price Three [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twelve [Member]",
        "label": "Exercise Price Twelve [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwelveMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two [Member]",
        "label": "Exercise Price Two [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_FairValueOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of stock options.",
        "label": "Fair value of stock options"
       }
      }
     },
     "localname": "FairValueOfStockOptions",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_FirstFourYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Four Years [Member]",
        "label": "First Four Years [Member]"
       }
      }
     },
     "localname": "FirstFourYearsMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_FiveNonOfficerDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Non Officer Directors [Member]",
        "label": "Five Non Officer Directors [Member]"
       }
      }
     },
     "localname": "FiveNonOfficerDirectorsMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_FiveYearsAndThereafterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Years And Thereafter [Member]",
        "label": "Five Years And Thereafter [Member]"
       }
      }
     },
     "localname": "FiveYearsAndThereafterMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_FormanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forman [Member]",
        "label": "Forman [Member]"
       }
      }
     },
     "localname": "FormanMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_FourOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Officers [Member]",
        "label": "Four Officers [Member]"
       }
      }
     },
     "localname": "FourOfficersMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_GeneralAndAdministrativeStockBasedCompensationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative stock based compensation expenses.",
        "label": "General and administrative costs"
       }
      }
     },
     "localname": "GeneralAndAdministrativeStockBasedCompensationExpenses",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GEIS [Member]",
        "label": "GEIS [Member]"
       }
      }
     },
     "localname": "GrupoEspanolDeInvestigacionEnSarcomasMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices": {
     "auth_ref": [],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in advances on research and development contract services.",
        "label": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices",
        "negatedLabel": "Advances on research and development contract services"
       }
      }
     },
     "localname": "IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_IncreaseDecreaseInResearchAndDevelopmentContractLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in research and development contract liabilities.",
        "label": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities",
        "verboseLabel": "Research and development contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentContractLiabilities",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_IndependentDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Independent Director [Member]",
        "label": "Independent Director [Member]"
       }
      }
     },
     "localname": "IndependentDirectorMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_MRIGlobalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MRI Global [Member]",
        "label": "MRI Global [Member]"
       }
      }
     },
     "localname": "MRIGlobalMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ManagementFeePayableQuarterly": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management fee payable quarterly.",
        "label": "ManagementFeePayableQuarterly",
        "verboseLabel": "Cash board fee payable"
       }
      }
     },
     "localname": "ManagementFeePayableQuarterly",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_MemberOfAuditCommitteeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member of Audit Committee [Member]",
        "label": "Member of Audit Committee [Member]"
       }
      }
     },
     "localname": "MemberOfAuditCommitteeMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_MemberOfOtherCommitteesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member of Other Committees [Member]",
        "label": "Member of Other Committees [Member]"
       }
      }
     },
     "localname": "MemberOfOtherCommitteesMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Moffitt Cancer Center and Research Institute Hospital Inc [Member]",
        "label": "Moffitt Cancer Center and Research Institute Hospital Inc [Member]"
       }
      }
     },
     "localname": "MoffittCancerCenterandResearchInstituteHospitalIncMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_MsReginaBrownMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ms.Regina Brown [Member]",
        "label": "Ms.Regina Brown [Member]"
       }
      }
     },
     "localname": "MsReginaBrownMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_NDAConsultingCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NDA Consulting Corp [Member]",
        "label": "NDA Consulting Corp [Member]"
       }
      }
     },
     "localname": "NDAConsultingCorpMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_NetherlandsCancerInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Netherlands Cancer Institute [Member]",
        "label": "Netherlands Cancer Institute [Member]"
       }
      }
     },
     "localname": "NetherlandsCancerInstituteMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_NewIndependentDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Independent Director [Member]",
        "label": "New Independent Director [Member]"
       }
      }
     },
     "localname": "NewIndependentDirectorMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_NonOfficerDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Officer Directors [Member]",
        "label": "Non Officer Directors [Member]"
       }
      }
     },
     "localname": "NonOfficerDirectorsMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_NonRefundableLicenseIssueFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company is obligated to pay non refundable license issue fee..",
        "label": "Non refundable license issue fee"
       }
      }
     },
     "localname": "NonRefundableLicenseIssueFee",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_NonRelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Related Parties [Member]",
        "label": "Non Related Parties [Member]"
       }
      }
     },
     "localname": "NonRelatedPartiesMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share tranche of the series a convertible preferred stock receive a per share dividend.",
        "label": "Principal Cash Obligations and Commitments"
       }
      }
     },
     "localname": "NumberOfShareTrancheOfSeriesConvertiblePreferredStockReceivePerShareDividend",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "LIXT_OtherClinicalAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Clinical Agreements [Member]",
        "label": "Other Clinical Agreements [Member]"
       }
      }
     },
     "localname": "OtherClinicalAgreementsMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_PaymentsOnNonrefundableMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.",
        "label": "Payment on non refundable milestone"
       }
      }
     },
     "localname": "PaymentsOnNonrefundableMilestone",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_PlacementAgentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agents [Member]",
        "label": "Placement Agents [Member]"
       }
      }
     },
     "localname": "PlacementAgentsMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_PrepaidInsurancePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Insurance [Policy Text Block]",
        "label": "Prepaid Insurance"
       }
      }
     },
     "localname": "PrepaidInsurancePolicyTextBlock",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LIXT_ReimbursementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement expense.",
        "label": "Reimbursed expense"
       }
      }
     },
     "localname": "ReimbursementExpense",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_RelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Parties [Member]",
        "label": "Related Parties [Member]"
       }
      }
     },
     "localname": "RelatedPartiesMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_RepaymentOfDeferredOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of deferred offering costs.",
        "label": "RepaymentOfDeferredOfferingCosts",
        "negatedLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "RepaymentOfDeferredOfferingCosts",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_ResearchAndDevelopmentContractLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development contract liabilities current.",
        "label": "Research and development contract liabilities"
       }
      }
     },
     "localname": "ResearchAndDevelopmentContractLiabilitiesCurrent",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_ResearchDevelopmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Development [TableTextBlock]",
        "label": "Schedule of Research and Development Costs"
       }
      }
     },
     "localname": "ResearchDevelopmentTableTextBlock",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ResearchAndDevelopmentCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LIXT_RobertNWeingartenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Robert N. Weingarten [Member]",
        "label": "Robert N. Weingarten [Member]"
       }
      }
     },
     "localname": "RobertNWeingartenMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Warrants Outstanding And Exercisable [Table Text Block]",
        "label": "Schedule of Warrants Outstanding and Exercisable"
       }
      }
     },
     "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LIXT_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share dased payment awarrd non option equity instruments exercisable number.",
        "label": "Number of Shares, Warrants exercisable, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option exercised in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option forfeited or expired in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option grants in period weighted average exercise price per share.",
        "label": "Weighted Average Exercise Price, Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option outstanding weighted average exercise price.",
        "label": "Weighted Average Exercise Price, Warrants exercisable, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option outstanding weighted average number of share.",
        "label": "Share based compensation arrangement by share based payment award non option outstanding weighted average number of share",
        "periodEndLabel": "Weighted Average Exercise Price, Warrants Outstanding, Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Warrants Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LIXT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options outstanding period increase decrease value.",
        "label": "Stock options granted to purchase common stock, issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseValue",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.",
        "label": "Weighted Average Remaining Contractual Life (in Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "LIXT_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for Non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Life (in Years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "LIXT_StockBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Based [Member]",
        "label": "Stock Based [Member]"
       }
      }
     },
     "localname": "StockBasedMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_StockOptionsGrantedtoDirectorsAndCorporateOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options Granted to Directors and Corporate Officers [Member]",
        "label": "Stock Options Granted to Directors and Corporate Officers [Member]"
       }
      }
     },
     "localname": "StockOptionsGrantedtoDirectorsAndCorporateOfficersMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_TheradexSystemsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Theradex Systems, Inc. [Member]",
        "label": "Theradex Systems, Inc. [Member]"
       }
      }
     },
     "localname": "TheradexSystemsIncMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_TwoThousandTwentyStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Incentive Plan [Member]",
        "label": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated Preferred Stock [Member]",
        "label": "Undesignated Preferred Stock [Member]"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_VendorFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor Four [Member]",
        "label": "Vendor Four [Member]"
       }
      }
     },
     "localname": "VendorFourMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_VendorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor One [Member]",
        "label": "Vendor One [Member]"
       }
      }
     },
     "localname": "VendorOneMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_VendorThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor Three [Member]",
        "label": "Vendor Three [Member]"
       }
      }
     },
     "localname": "VendorThreeMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_VendorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor Two [Member]",
        "label": "Vendor Two [Member]"
       }
      }
     },
     "localname": "VendorTwoMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_WarrantsToPurchaseCommonStockParValue0.0001PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockParValue0.0001PerShareMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "LIXT_WorkOrderAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work Order Agreement [Member]",
        "label": "Work Order Agreement [Member]"
       }
      }
     },
     "localname": "WorkOrderAgreementMember",
     "nsuri": "http://lixte.com/20230331",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r609",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://lixte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefOperatingOfficerMember": {
     "auth_ref": [
      "r641",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]"
       }
      }
     },
     "localname": "ChiefOperatingOfficerMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r641",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r190",
      "r583",
      "r654",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r274",
      "r410",
      "r439",
      "r474",
      "r475",
      "r537",
      "r540",
      "r544",
      "r545",
      "r547",
      "r568",
      "r569",
      "r578",
      "r581",
      "r584",
      "r587",
      "r653",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r190",
      "r583",
      "r654",
      "r695",
      "r696"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r191",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r272",
      "r274",
      "r305",
      "r306",
      "r307",
      "r386",
      "r410",
      "r439",
      "r474",
      "r475",
      "r537",
      "r540",
      "r544",
      "r545",
      "r547",
      "r568",
      "r569",
      "r578",
      "r581",
      "r584",
      "r587",
      "r590",
      "r648",
      "r653",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r272",
      "r274",
      "r305",
      "r306",
      "r307",
      "r386",
      "r410",
      "r439",
      "r474",
      "r475",
      "r537",
      "r540",
      "r544",
      "r545",
      "r547",
      "r568",
      "r569",
      "r578",
      "r581",
      "r584",
      "r587",
      "r590",
      "r648",
      "r653",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r471",
      "r472",
      "r473",
      "r539",
      "r542",
      "r546",
      "r549",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r582",
      "r590",
      "r654",
      "r695"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r471",
      "r472",
      "r473",
      "r539",
      "r542",
      "r546",
      "r549",
      "r556",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r582",
      "r590",
      "r654",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r641",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable and accrued expenses, including $44,972 and $46,982 to related parties at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Related parties accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration": {
     "auth_ref": [
      "r629",
      "r635",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates related and nonrelated party status for accounts payable classified as current.",
        "label": "Accounts Payable, Current, Related and Nonrelated Party Status [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountsPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [
      "r128",
      "r129",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r128",
      "r129",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r75",
      "r586",
      "r699"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r459",
      "r637",
      "r638",
      "r639",
      "r682",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense included in -"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r61",
      "r62",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r309",
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated share based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r120",
      "r140",
      "r169",
      "r181",
      "r185",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r342",
      "r344",
      "r357",
      "r429",
      "r496",
      "r586",
      "r597",
      "r650",
      "r651",
      "r686"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r117",
      "r124",
      "r140",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r342",
      "r344",
      "r357",
      "r586",
      "r650",
      "r651",
      "r686"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r25",
      "r119",
      "r571"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "verboseLabel": "Cash and Cash Equivalents, at Carrying Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/BusinessDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r86",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r86"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash FDIC insurance"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r114",
      "r121",
      "r122",
      "r123",
      "r140",
      "r158",
      "r159",
      "r161",
      "r163",
      "r167",
      "r168",
      "r222",
      "r241",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r252",
      "r253",
      "r256",
      "r259",
      "r267",
      "r357",
      "r450",
      "r451",
      "r452",
      "r453",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r484",
      "r505",
      "r529",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r618",
      "r633",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r167",
      "r252",
      "r253",
      "r254",
      "r256",
      "r259",
      "r265",
      "r267",
      "r450",
      "r451",
      "r452",
      "r453",
      "r581",
      "r618",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise Prices",
        "verboseLabel": "Warrant exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants Outstanding Shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r69",
      "r430",
      "r483"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r235",
      "r236",
      "r558",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Shares were available for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r594",
      "r595",
      "r637",
      "r638",
      "r682",
      "r697",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r74",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r74",
      "r484",
      "r502",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r74",
      "r432",
      "r586"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value; authorized \u2013 100,000,000 shares; issued and outstanding \u2013 16,659,093 shares and 16,646,593 shares at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r190",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r190",
      "r445",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r190",
      "r557",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r70",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r33",
      "r36",
      "r64",
      "r65",
      "r190",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.",
        "label": "Contractual commitment"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BusinessDetailsNarrative",
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Preferred stock convertible into common stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r17",
      "r44",
      "r73",
      "r94",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Preferred stock, issuable upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r82",
      "r140",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r357",
      "r650"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Related party costs",
        "verboseLabel": "Annual cash fee"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r34",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "auth_ref": [
      "r53",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.",
        "label": "Total deferred compensation expense for outstanding value of unvested stock options"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r101",
      "r628"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Total costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r275",
      "r279",
      "r310",
      "r311",
      "r312",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r4",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Summary of Stock-based Compensation Costs"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r132",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r157",
      "r158",
      "r161",
      "r162",
      "r163",
      "r165",
      "r355",
      "r356",
      "r428",
      "r437",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per common share \u2013 basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Annual compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r7",
      "r115",
      "r128",
      "r129",
      "r130",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r166",
      "r223",
      "r224",
      "r269",
      "r313",
      "r314",
      "r315",
      "r335",
      "r336",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r440",
      "r441",
      "r442",
      "r459",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r5",
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r250",
      "r265",
      "r352",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r436",
      "r579",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r526"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.",
        "label": "Foreign currency gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r84",
      "r507"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Compensation to related parties, including stock-based compensation of $276,980 and $339,672 for the three months ended March 31, 2023 and 2022, respectively"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r233",
      "r234",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r234",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r324",
      "r328",
      "r330",
      "r333",
      "r337",
      "r338",
      "r339",
      "r340",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332",
      "r334",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase) decrease in -"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in -"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other prepaid expenses and current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidInsurance": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Insurance",
        "negatedLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r40",
      "r411",
      "r412",
      "r413",
      "r415",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Patent and Licensing Legal and Filing Fees and Costs"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r66",
      "r105",
      "r131",
      "r172",
      "r368",
      "r513",
      "r596",
      "r700"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r133",
      "r135",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Patent and licensing legal and filing fees and costs"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r79",
      "r103",
      "r434",
      "r586",
      "r634",
      "r646",
      "r683"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r118",
      "r140",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r343",
      "r344",
      "r345",
      "r357",
      "r586",
      "r650",
      "r686",
      "r687"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ManagementFeePayable": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fee payable for management of fund or trust.",
        "label": "Cash board fee payable"
       }
      }
     },
     "localname": "ManagementFeePayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r107",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r80",
      "r88",
      "r104",
      "r116",
      "r125",
      "r126",
      "r130",
      "r140",
      "r147",
      "r149",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r160",
      "r169",
      "r180",
      "r184",
      "r186",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r356",
      "r357",
      "r435",
      "r504",
      "r527",
      "r528",
      "r576",
      "r596",
      "r650"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lixte.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows",
      "http://lixte.com/role/StatementsOfOperations",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficersCompensation": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Compensation"
       }
      }
     },
     "localname": "OfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating costs and expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r169",
      "r180",
      "r184",
      "r186",
      "r576"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r100",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Aggregate commitments expected"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Aggregate commitments expected, description"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r83",
      "r438"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other costs and expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Paid office rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Minimum payments for royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Costs of public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockConversionBasis": {
     "auth_ref": [
      "r44",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.",
        "label": "Preferred stock, conversion description"
       }
      }
     },
     "localname": "PreferredStockConversionBasis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r253",
      "r538",
      "r541",
      "r543",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred stock dividend, percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r697",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r73",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r73",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r73",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r73",
      "r484",
      "r502",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r73",
      "r431",
      "r586"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, $0.0001 par value; authorized \u2013 10,000,000 shares; issued and outstanding \u2013 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares \u2013 729,167 shares"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other prepaid expenses and current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r572",
      "r580",
      "r647"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r1"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r1"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Gross proceeds from sale of transaction"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r15"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r632"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedAndNonrelatedPartyStatusAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r373",
      "r374",
      "r375",
      "r376",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r503",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by related and nonrelated party status.",
        "label": "Related and Nonrelated Party Status [Axis]"
       }
      }
     },
     "localname": "RelatedAndNonrelatedPartyStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedAndNonrelatedPartyStatusDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r373",
      "r374",
      "r375",
      "r376",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r503",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated party status."
       }
      }
     },
     "localname": "RelatedAndNonrelatedPartyStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r273",
      "r373",
      "r374",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r503",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r373",
      "r374",
      "r375",
      "r376",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r503",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.",
        "label": "Related Party [Member]"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r508",
      "r509",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r273",
      "r373",
      "r374",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r503",
      "r536",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r456",
      "r457",
      "r458",
      "r510",
      "r511",
      "r512",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r71",
      "r322",
      "r694"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development costs",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ResearchAndDevelopmentCosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r76",
      "r96",
      "r433",
      "r443",
      "r444",
      "r454",
      "r485",
      "r586"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r115",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r223",
      "r224",
      "r313",
      "r314",
      "r315",
      "r335",
      "r336",
      "r346",
      "r348",
      "r349",
      "r351",
      "r354",
      "r440",
      "r442",
      "r459",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r170",
      "r171",
      "r179",
      "r182",
      "r183",
      "r187",
      "r188",
      "r190",
      "r270",
      "r271",
      "r414"
     ],
     "calculation": {
      "http://lixte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Annual salary"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Increase in annual salary",
        "verboseLabel": "Salary and compensation"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Net proceeds from issuance of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Number of common stock shares issued during period"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r190",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r67",
      "r68",
      "r508",
      "r509",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/SummaryOfRelatedPartyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Summary of Related Party Costs"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r276",
      "r278",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r13",
      "r14",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summary of Stock Option Activity Including Options Form of Warrants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r93",
      "r95",
      "r96",
      "r121",
      "r122",
      "r123",
      "r167",
      "r252",
      "r253",
      "r254",
      "r256",
      "r259",
      "r265",
      "r267",
      "r450",
      "r451",
      "r452",
      "r453",
      "r581",
      "r618",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r188",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock based compensation",
        "verboseLabel": "Total stock-based compensation costs"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStock-basedCompensationCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r52",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Stock options description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r276",
      "r278",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Number of Shares, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Number of Shares, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Shares, Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r8",
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Warrants Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares, Warrants Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Common shares avaliable for issuable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of shares, stock options exercisable, at the end",
        "verboseLabel": "Number of fully vested option exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted average exercise price, stock options exercisable, at the end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Number of shares, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options, grants in period, gross",
        "verboseLabel": "Stock options granted to purchase common stock, issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Fair market value, per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Shares outstanding",
        "periodEndLabel": "Number of shares, stock options outstanding, at the end",
        "periodStartLabel": "Number of shares, stock options outstanding, at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "verboseLabel": "Stock options granted to purchase common stock, issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, stock options outstanding, at the end",
        "periodStartLabel": "Weighted average exercise price, stock options outstanding, at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Stock options are exercisable price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Purchase of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r275",
      "r283",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r316",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails",
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Options Exercisable (Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Options Outstanding (Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "verboseLabel": "Exercise Prices"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfExercisePricesOfCommonStockOptionsOutstandingAndExercisableIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Fair market value of stock",
        "verboseLabel": "Stock price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based payment award, award vesting period",
        "verboseLabel": "Share based compensation vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Intrinsic value of exercisable but unexercised in-the-money stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (in years), stock options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Outstanding stock options to acquire shares of common stock not vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (in years), stock options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Stock option vested exercisable term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Stock options fully vested amount, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r114",
      "r121",
      "r122",
      "r123",
      "r140",
      "r158",
      "r159",
      "r161",
      "r163",
      "r167",
      "r168",
      "r222",
      "r241",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r252",
      "r253",
      "r256",
      "r259",
      "r267",
      "r357",
      "r450",
      "r451",
      "r452",
      "r453",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r484",
      "r505",
      "r529",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r618",
      "r633",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r7",
      "r23",
      "r115",
      "r128",
      "r129",
      "r130",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r166",
      "r223",
      "r224",
      "r269",
      "r313",
      "r314",
      "r315",
      "r335",
      "r336",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r440",
      "r441",
      "r442",
      "r459",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r166",
      "r414",
      "r448",
      "r470",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r506",
      "r507",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r529",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r166",
      "r414",
      "r448",
      "r470",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r506",
      "r507",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r529",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheetsParenthetical",
      "http://lixte.com/role/Cover",
      "http://lixte.com/role/ScheduleOfResearchAndDevelopmentCostsDetails",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r73",
      "r74",
      "r96",
      "r450",
      "r529",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock issued new issue shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r7",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Number of restricted stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r73",
      "r74",
      "r96",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options, shares",
        "negatedLabel": "Number of shares, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity",
      "http://lixte.com/role/SummaryOfStockOptionActivityIncludingOptionsFormOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r23",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r90",
      "r486",
      "r502",
      "r530",
      "r531",
      "r586",
      "r597",
      "r634",
      "r646",
      "r683",
      "r701"
     ],
     "calculation": {
      "http://lixte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets",
      "http://lixte.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r139",
      "r251",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r266",
      "r269",
      "r353",
      "r532",
      "r534",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed.",
        "label": "Cash paid for -"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationRelatedText",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r250",
      "r265",
      "r352",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r436",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://lixte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r325",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r108",
      "r109",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r157",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding \u2013 basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://lixte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org//985-730/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(4)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "47",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r606": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r607": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r608": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r609": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r611": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r612": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r613": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r614": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r615": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r616": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r617": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001493152-23-016069-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-016069-xbrl.zip
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MXO]4O#85;RMIW3)+O6#]DZ9>OM]02P,$%     @ S4.J5C%TX; ="   S$4
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MS#Q$F:& RF, *7WH,*PR(*7Q8GU /L4B+JAE'V?E\D-0"R,!C\!ND0=6=NH
MK_A$0G*RELZC #9^JCG4PR-/I#[8(W#!FCTZ0"8<Q4(,IHQ4A!0EQ))K+([,
MS-6S]H'3?(ZU.Y@C%9 !"$8" 9@VE0'E434E@9!SE;-/PB9<Z81":Q0?6O
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M*1OY]QV:&8,:TO/2!,EO+7CPLE8+)Y1*0R)>IX,*%:Q \LU>,R$GKZ )9)J
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M9K9B]#TD?0>9?1A)WT_^'U!+ P04    " #-0ZI6*P*3R(<$   7&P  "@
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MIWDS\]"J^WTE%?/7FT;&/:H!Z]4SQE_3#+M<+'P5 8=9%7X3M\0-RJ ""F;
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M/;K<I0I"DA^=^R39&"K"^ .G:BJA/\K/'U#2B8XJA/XE2Q)1J4+!/^'".L!
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MUWEW%_,7\[>8BR5_?:88"9.+A1<P^?U,\A)2A,;4B"H2P[H"<U,_&#3I&-[
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M::KA*SB%(>(%::LQQ?QDB&2X9R^$?K[(9S/I+,,Y0UB0 ,#,HLML^H1 :\M
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M5OO!R8K"_<(2"!N':\IFFTB3E>H]]Z2==_ZHS:MJ.'T=5ZMW[WC06@YJ%2>
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M_,_MA5PMSIO<*\QZ7]S$&8H@8VX5_)P8Q;X=.#++MQGX)I@(%4"7"* ,GT$
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M$1Q6ME)11KT[Y?9G8W+=V0Y6V0UA9;]W="Y?RI*2);W"7F 5AMX(&5:AJ#*
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M#@) 6V!_^5DVII?-'FQ^0P]L]'E(11$, WQQO(@^0*2=Q> *X#LQR@ URC0
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MF1: RC"-J#GEO\QA_/[#=O2.TNZ8704S15@#S_;=8'7?I W%SMA=/Z&29QD
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M=*D8:>/TJ"VHC9*[F9\<9 =B"68OK;K\\%+/-XAJ+J:<=YW1L"S$EW/?6W@
M;!<)D0S40#3QIC%$I6!4GXDNRH $GS3TKW])>](:__Q1*)W_'?64<!VG3\ZK
ML811I$V7X/DP,C 2Z-#VZXBO)=CNPM.%5.:,C^]N<+#S<[+9M>?G;(/QLVG4
MX(X,A3%Z#XVN$_YN=.%?S+#"[$)$N,\^#D6YV>@5\M_%XFUWFPW6%]O)M];
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M,A<>:>@]094G-/X[/=,/=P)4Z19;JJHF_;/1O71,].EI?Q=NX!YCQN>*)C[
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MBP9?O_O=[5QW3SA3-A%>=XOS=2N=-LW_F<WX"3#,DT_\*2C"4]X]+<]^I:-
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MUVG17'?7?)EI#>A4H&]4]JNC,J!WT^0/WR \UH9N_F@P S&<8A>84@O3TW_
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MGL'UMS[%-M$)F6PA3'>*HLKC;$_: M7I89X%!;98%%)"29@JL"%N9-0SV#%
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M:$V#@+T!!!#1O9/9ENACJ,4%;'/,^8"#@"\%S,G$]G #"/5,C)) C!MJ)GG
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MQRX[B#9.0T#/&.[M/=R]C0;BJ/C^)%]?WPGK +5YT!0+@]? +.YEH)[\3ZR
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M"WM\QOXIR\)4T>D  *N>72^&\I+*9#+POP@-<,$CVMQ-<71*G&QT3#*N%I&
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M)+DI&X8?&T+^@I]E&^C3G3JU<=Y#((8!FUOL=@W]"^EE2U:'X_#U[N[L*EU
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MBFN*Y$/[&J$OC?UGO+UT>Y?:ZP,(;E"JWL7 (K,,/1&@/>V30Q%O]$Y^"G,
M_HT\O+U5-E?0T9;0Q4-#I;C'K)1] 'Y$VH#1SH A91R?D<\YN^CD2YQ=&HD(
M1[_5;!Q&L/@LSY3S.DZ9:Q]&_558C0>?=YV#$/B2#S\H,UOR!M)=PML\P%]-
M8#18>AZ%:*59UPQ^'P;PT=ZDM"9;YUAK-1N^-P%&FL!D%3D)@[Y:=8ZMA^CE
MRU;NFA63.N)7Q1V<$K PF/OQ$.Z<T^[]IS-U^>$5Q2Y29@[P7^*-50Y3@IL<
M*1A^5A@T5!ZRI2Q8Z?.&F[&!4XPQP]9Y^W*EW6J),/=\V*4@-:>;>.<JBO,T
MG&#^%!C 64"\A<X3M"B'?+ZXN<H/8'XK;2<)TC-G- $=RY^DX]!+<9KI)/(3
M] P_>[=W\OP)W'68-&A-ZEL_S'WUVZ__9V7%.0A4Z/_7.8;S? &#(=_OPR =
MF"%EKL"/SLJ*SEWU@_.KYZKS8LT3&W1W*=O0Z8/&(FF+I.3AOV&F??WO\C?Z
M(*6]<0IST3^]@+/TLR$NMO7O.A8Q.UT[B\=UN9$SZ@'[=-5+G_NEM'%ZRUXX
M'T'B_]?924"3Z[]PCD _YFT]BG$#.RW[K?_HU_!/14*F3L;\]3^PT75[#OK;
MV0I+W/\"7>.9R2[#LF2+]<E;0]A?QBGQ5RU26*C0\:,74$]$SAY&S<81J#ID
M%DV+TP0L)A!9/J>0 JL7]R,\\FGU9-4YB&-6,/>2_-39$1XM&C:%W8 E'U)Z
MCAB,, 3.CI\?CT-19YN-9R@:@"4='NW13^T7STLB:;8<<JXHAD2>U$H+7$-9
M7#0;)"] *C@7P]@9>BC,P8ACY1B52=0Q0H5Y@&1F8:*4EX <17<H2E@0RJ7O
MP%"@B8;9D(S1',0U*J)Q".S/I0%/8:X)_9*L/;BX:@P:+NYCJH#'H=&@1H'G
MH.X>D"M!J_%.+\2C@*V/TD%.&BP::V 'S-XVV!\,&Z9Z8]"Z!&48%'@,<N*@
M8E^:%5%H]BJ;Y^B]<]'2 _9#0=K2B[X*GW6_/I\CD.&)[E>4RK3OM-H@ <T/
M?E04.8=#GK )WXLCA3<I@=F0G'&F)JI'HYWVE;:^88G'QYT=U+G.@R3CA%FX
M7)+=!GI0GHG!*#8$V98!'=-Y'N*) 3LG76B0)S@K&',8] )M?^OA>9=YOI63
MZ*E3_&16['\:9$A@<$62(,2+N6U"V[P)LCCRS]M*+Z<45,:'@=[D,%\<!PPU
MN#"HNA:F,4YSO5UL&) -'$<4H2F\$_'9!B.V(M.@L.)]W'9O@(IR,;-.,5"S
M01O&TUMU#DD51#*&_];P&E',&ZWU&&LT4LJ&&J@+&@]V9-.EH_#9CO-P(^Q3
MY4G8P^,6HL:,%FGQK69CL^9CR.FLM5@>&; !?1+<:!SF8TPR(%LVB#!)RX>K
M&,9CO6]R>09Q4KXK^+?+.,LJZ.7])&>[F#(0>I@4D>KWF!7#;%;@_($A^W#[
M^_2<)C7Q6""C-N/8I$]V$ X#[#N+0;6" V5OA3&@$V2;2/1]&,(+W1HSGUP:
MY.PQSC74TD-%SH$)$!?0P5I+.]5>QQ?(KER^>-;QD1>J$E\BLU_;_$ PI# Z
MV45LOXCWEM4TX\1BOM9Q* 6$;QK^.LUR?\+IJ< (%"U.WQ59X1TJ^3S'I9YQ
M)_E.QF?8C],LK2ULZ/ZC=/7NCG^.AN4.>2,_J! M[(_Q.Q#@\/=(21[Q)?@7
MJ.^_'UBIR.4*86UDDXVM36QC8>M2X;]W__[?VN'Q*)_TC M>9J>=I0G/#^EV
MI&<(9#N9YY=_>_CGQ_]>;977 Y^XRJINZMO?F.?7IW.O*T^ZP9EVS)EV[N),
MU_]\\_[TZ/WV1'F+=*8=<Z:=^SM3+,VNJV"4\J3"&8^.X7')3P5RQ03#3%2'
M5&T2A*P[DF:#P[ 'B[SXE@QF;B"JZG2V?42>"CH)4-$SB= !\XC'B@V5<GJ$
M283 4"'I2;/9C1V,,YL:^7O%[/8Q^)&J^V S7P;?7G?/\O%Y7N!*?9B[:9=%
M_.8N:7%X2GMMTVUMKL_D*B5Z8@DRFPI7I\IQ[)KK]ZAT6?D5>Q2ZI:##?1QQ
M?\^;!'^\/-CMJH+KZ&!Q*<2BM357HLLTQ5^NGDYYTQ,L$]"<[:($J.G0:\UB
M[,-"!:+$,QSRH>MLWS&&;\@I[% \'TX7;[Y<9.W&F%T)NS'[J&<AD-S*N;:R
M\._OK[Z]/?S4N>*Y7G9U*[._"G3'75[1[N:LUN$B^&O2T\!\('$P;7OH:XS4
M,".R/Y5'S!]Z O[]QZ?[_]K[[=7^X<E4((]<$GQ@[>WY83P,"?1B\2L6P3L*
MKD66@S%.5@Z!\ (2]Y40F([T-1LG\(T@'3HG0&^P N<5$-'8>?8JR<>QLP_K
M_G__M[/>?A&'0-+%X/T ?[WV(H+9Z5<IRU$<E[A&[;ET@9;]) #V"]_") #T
M9&*9@Q/G8(=B,2B:J; &O.R^'N(#B.EX1'5A8S)O#_]S>"@F>.%J&(=YZOCQ
MMSC)>T$?%)]ST&#L?WLAJIKP0^$O(P.?]4K0@^(!,%.J.8.9\$IDYNR>D@H)
MMJF#M,8; .OA! /X#+,$/!G:8M'WM)VNT*WB]2>D@J3>0'$"C*P%/MW#+ 70
M_<A)9ZT"DP**B3HR3ZQ)L1_BDHK3,.[!Q(P/EBL^D!#"LD>F;@_,T([V0>^<
M?#1'"62[-[6WQE6#'Q]1/8@WX0"OV?'2=W%$FA6E%:RW=!"8?:A!!E10<EMC
MC0G[VL4ATI^ # /1U<?D(PZ0\BDDF,K 86E*R"6WD'G:*1[&KUO[NPJ4#6>"
M'!LS0%0(LS&'$J48:J7L$!4-/2K9H4PC#-AF^2A&3PVG%].R[7/#)1&5C\=>
MPB[6/FQ%*OE*."MX:\F)'X 3(XMJ-H;DZ(]4=A$G9WAZ"=47H:4C+C8X)^);
MDGB>Q*!C[><)6$R<[40:-6I.(RQN2I&98Z+/F2Y%0^ .[4T%$I(8#I)G$$7Q
MN8?LGWE@P%2!UZ-<CE4D)5!-&S!BG+QX%,DK&]I\A!4#B6CXVAK4P:-Z/N92
M)IE.K+.^A&Y*"C>(3[?\&L_S-#:,4#)%2JIENTMS:F^V;%]L+3?E/"Y/ZL5H
MKA<Q\P<R3 N6)>(*%6 '7IJPNLS[[P<IWC$6HYP25W:)4GH4)I(YY(B..*D-
MWXXI"0T]X,EY<(YY'<^.#TY<)XH+3SC><?Y"Z3UD*<#EAL*JX-SZ7IZJYQ10
M6.UJ)Y\<1TE&)2/)3,.0F$HB(@H]-_@^Q9HVYXY!@E 'KV \5/<5/$X12$JC
MP]!-FNF4+RO/"W15XDGL60CYX^261^]YL4+,-)0E]B::%UN1' P#XIY*N&0Z
M5")G,(9?8@VD3I<#W1:D1YEFNJU_Z\?;K8Z#W:JR5&)]*"%U\6-8C![@WSW,
M>UWRTX>NX4$L!\L +6P6S@^=OO@Z]#$:T14S!;C*^9I["?(4=H[;T966%5V1
M%U"-;C;P;WSYM78+UF,>HDH\T7@#&5+P.6$GV<HV3=#$I8.,5L(!?WDR)4Z.
M=X?NK(+5X#)Z7HG".<#D-AM!9JAV.CL6]C4?8%(HYM_"3@<1TCG.LN#F.0;H
M3%JR7A"HQ*!H]DE!0J7%#,3P)*SZ<8YR2N)%?N-<4!S0C\?D! 1M26+F16B,
MQ%,11*JZ)=0WY"+FYA=SOG=\CF4>R^P\%DHD(W>[16)>A<BF- <MY$F]J"H(
M99N4<[IA1,*9P3%@5#_FF*0Q[SC(-<K#+!BC5N^E9RE,0OD2"_#../F;5'R3
M5X.V"4W53$'(4FR9<@H-BW2MI@G)RZ>TTYSGD4XB3,,/4KE4IY@F4KXZ8_+&
MH(K_[-6[X^?Z$GALI<NMB\/X%*X_/ ^WFJ*ISW:.#Y^+!>/'_1Q-'5-T@$))
M!L*;J,:ISFZG@#'JCC =2C;'P"PH@G ZK%G!L)35D*&$Y(06J7Z/2>_!'6>V
M MQV3( I)27-Q]0BV3S,MTEC7GJS :NSLL+-I"^?4NW8Q21382;%[("QP'G1
MT8$M38P7K5_4#; "!'BDUC6) $ [0(4E]'IDAJ69SK;'[W'VNH]Y54$OSXH_
M:/Y59,Z*^HZ?S5FWF59?4:ED+QXH>EZ1@66V@RJ40J0Q/+4,R#5BY9@V>_9>
MTV?-7_#[N$' ;D>8J>SKV=H++D043$5DE(9Y0$FJ. W"7!*I0^@IG&/.&("P
MZQ7]_/%K0M?(X6TO<WAO-X>WO<SA7>;P/JIE[*1D*T_7N6(:'U>NV=Z-*:5[
M/D>W38JRPYR4$)9.XQB]A904*?FJA99=:$(D?DAA$,G$/B78AD\12""7# ^,
M3%\6ISNXG[@[!]%D9XJ";AVU^S!^>7;1'8?=]OKB!=SGSOW&D7:WO;X^+Y"W
MBMV0V)5=,:O*5#=$SQLYT$T>(?J;1NS=D&@NDF8BF;^<@T'9I/6Q0-M\1M^9
M(P 5U<C@_4,J+MG6#'!4,-G>][,8#Z>]5H<]XD414$+?]B)H3K2#.$,38E#O
MP![I(^()W;G7"CT9SC$3'Y@T]&3@E>)Z'@;VZ#T/;T4,Q#C1K\0IL#F@>B\)
M8CN\M[/_[M@$A=A%4J X6M4)21'#TRFJ;*T9D[,>@@ +XJQJ5AVW<:?"?2[Z
M?M-*")#"4NXMQL*:C6?HE'^^BKA.J:X5=F>9RNB)G%&)?XF#BUU8A8>+LS\K
M2<; +"9UY?N'188\BCR>F,E,QN(3#LA).CU%AI$A89$OY?ZS55/4J]3D/@/E
M'<!!%/'?9N--,(*?U^!G]=W9PQ\W7WC?48KAT:"Y9^I#GW$@&/;QT]B*"-1E
ML!?)VG4!!TU@8&WVN6*FXGB[3I+VNHO+XOP*QA*R'1T%OBD%>JBB'/8'#(2A
MY,^G2DZ)@WD@\[DL"#6.<C[V?=MF2^9[K;X#-<&*&D>U7>XA-CA#/7!"?;GB
M(+7(CB(R7.&L,.1!P>DB)D5J -%PG*:!A8XQC"_(J9M34"R17W-(#Q,&C)]I
M5DH$3L$3I]$4GT0/"'PQ(/\6S:398&<\T3M/2!1:XF"$P2#SUE5>7'XD3"-(
M37B,RV$&<8YQH[[G,XP#5C"A.Q)&PZ!I+)]A(B#/!I6IT:6>GN_C]V@\TALR
MG9]8P@T@>2-V%7NM$-XCSE.=YYU:S1GZPT"=$U5C_1C&4DQ:N$:;P.((00H@
M5YE)2FTV/DJFVQPT(\I*H;Q'FA=&5DT.85WV\IZ56/]#51+RWC'(],E'=-@*
M[MO+B?V7LFU%R5:HDT5QN*>L)*LXVH]T=I6VM#;2('R]-MI:?U6D-N_\:);]
M;99,7&,U-[6]UMM==ZLSN_4#4A\E=!"79F=_.5G6L>'(X4_ Q<R6+07S@BSC
M-H&AR3;FK PRG^=EO9\P8$^*F&24FZ -:Y>+.!^B%,.I5&)@ZMNL4HSM6W()
MW34ONWKFN)WS.ITQ?GYR\.K;IZU]M;UXOJ?K[(=./I^SVKOBF->L"[E)O<)T
MB=.MUBNLWWZ]PCRJNT>)?_[[JT_^X5$[/AH^8$7$O,VX/\F_YFYN=^Z@?$+K
M \U&C6=EAZ/JI%$$J81<"PP^X/&2$$KU[:)WLJN)_@)BA'/5"L^M!;F&)B1F
M*+++"!UY88XX<41$Z!DNN@-\@KV #YYD! *WAT>2F.)X_)+(+GL$^IP!\R^2
M02^7/[B5,CF0-GIVE*H!:\->"83&: 6QEYK3@BSCU]YON^2+@@-]#2>ZZE3*
M3;PHQQ1,Q+@!&F]7LGN^@3%$Z))%W8@1J"<" E$#&[<KO@G\HG.D\W/8MXQ8
MS.3;(QB+H]W#%4[,)0I$#T6B0-.B]%T-@F8>]\LCRX#. ?J$V?OQ#(/L16&M
MN*GMMTPU"J&36/4GA3.QFHL\WT=-SE0XP95^Z*447,P0NW$\C-/QT,LXGY:P
M3V)8A*[M,$G;XCMI-H"-PUF*Q]5V28-4)#!Q'\XCXZU9P?=.38*SDXXP.043
M$9PP1Y[$._=L?V_E9/?M[O-5[1/27JM3&(2J26S7$4X)+KB7].(Q9O\">:DL
M1J>0SRP-)O$=N,7W?.3UZ/@.]G963%(DXI1HWPWF>AHBDY6YDC&CI7NQ+IFF
M\9>1:8^N-2ZWJ<P=^UBP?6L(KO#K!]\P[$5M3\1AL+9"X5N]O3 'R@YV/&*&
MZ(;WK; $??/9A^/.'A:Y"%81.J.!3,P$OA'L",8()$]4BJ+AB^U.#1@+X3 1
MOBD';'!XP7$"ZF'HJ*(*"/]5J@3RV+4M(8 PCL\XB:IPQUE%,J8"!3DR=K%)
MV=,=DYSAXQ!O=4)JE0%_19Y_3EA+YA'73OM>P83XE2(A'N>C7]"_73+^!5D&
M>>JJ+FLOU?$>=K^Q<K2M63]=IPHN3$E/RBA-LZ1^F[(,B6J1C]O*QT9G=G5(
M2H$+8X-H5-1E5QUWC/RCU!G%R C]IHJ"@U$L^KBNJ*)!-'Y/%>6FV2AD'Z]^
MPW8:@F[J#1'M%!3*0M(5"*?/3G8_8'[GD9<.S^%VPP7YJ")L+*'@QR\Q<?:J
M!#22(HY.8UP(\9IF8TK2E(M]*&9 ^$I4(X1:_0"N/<>@<",\\5?A#O"K>EOP
MRSC3JIZ+/_L8]:.$=>)B[%2IBUEH0VTZ_3=/&6))!RXI6%8DMY<+3O"! 9R+
M1#)0"" "D<0U:")2#,D]KNQJ$I/,*4GOTW!RFJVO.I^U+*AN0E6E*<%SU\=U
M4-DNQPFKQL#Z,OSP2/V 5P!,:OV8V\Q7P<H*M1G:QU+FBL6/G.'] /F"5HQ%
MC66M^-H>,:%>/4_1RJ=\8]%A?K[V]^?L?VN7N\:4^+?N$0GE2IM2P628O^0;
M@S%MNZU6^WIH3-?SLTZA,"TDP6QWSY.3$__KGW]W'I!B9F,W+0[%S.E"?VV8
MIX>/*J!9/!_@R:9VW0IS%Y^NN%<7DJR')V_R^.N[-U^[!>[<QV+!EU%P:;U7
M<I<N#IVNKV^ZW?9,4+(GX/I_>677_T+2YM'ZG^W/6^?)^.3+ _KW%X=@.^[Z
MVMJ]^OC7&3"W5!5?%#8:TP@3E^S,370:K8A;"@\!B+2OR"L>%68I>O(XV]%V
M$6&&%=P"[G#;PT($?--+)B[C]II>+[YM]%(] %I+\^_#YIU!=UU&RAW__=8?
M6UNC_'SSX<&[[H8ZM^;WXWJBGK!K5.%UEE5XMUN%UUE6X2VK\![5,DI8($4I
M1,D)9R'NSP #HC@*"22!U"FC"FUQ#R@92"F-(-99+W[5;$B?^5%,4&0D;EFR
MKSHGW&;-PMA?[Q2O<C-Y=FY.>ZCM/E$CM&-1OI6BE)CFBCA&9L1F@S!":E0-
MR8+6>Q'G61^;/F #153++^I<G$5H,A!U@CI#$0X5"#L<5FI:ZCM7S$1->J("
M[/$MX]?>;UH5A\O$D=TB)'%<@J(HPSMRM/\0 ST3"U#21.2G!GMVM'OXW(H1
M><YI&,0][$*"):[/7KU\][P,?E$-,DF#%<'BF,Z1T4U#V:U.L]D]E,Q<Q+04
M_P208<G99+F+[&YM!7REOI/\/3L8H4M\[;!JM:!LZ<U_ +H^9OBO9F-$WT5.
MU4LPJ8BP%%/G&=+>R$N?DU>,N%1_Z $'C4XE'$B<;-7YX/E2PE;.KJ#0T5"-
M8CL^SB A\,OO0, C) P=:!2,&@NX4M>S2%">9(?%*&5^/%%S2:BT&TT*A=E1
M=&,(99+K7H1F4^3KNE^);L=TZC'JIUP,F\MC^KKNUF(W",35P)B8>J$A)D?>
M%T2 99Y/+L)JD-X4]=&C(JM,[D4!@0DG0QB8^&=81WWZ2P2CAY=EO6@A96*Z
M VIF2#B!A*1)0YN,$0RH$@:C/ECT2MI'9IWJI)!G7.P:C$9YI/_HPAA!JNUT
MNZ**= _A!R,X;EV!)$(W+;6O@M7;8K.$(;/J[&B8,!F.2DYPL(BR.DK-M>"C
MG)WBI6G<#XHT%H,,6L")6KD<IT25W/$*#G"8PP7#5!TD LSLXS7"W%/-ZN@J
M\9%9+9:+N"KH*DHBM/0M*7750\D2^4(&*:7.GT7Q1;3J?$)PVRR/2/UR\?IB
M>CT2H@UY@% T@YQIK;1]L'X:C<PB^R.1\0,:)XB &1?TSC;VLEG- ZGR**N-
M:#<]IDL%C721,4^-_+WLBA.J4XS$E"@=SR\8O[!2JSO<T..ZL#PY1<Y/:5LC
MNJ#8Z$SS0A$5;"%P7S[BE974L3$63'+G*AX.&07[NT/=K:]\#:0W]/3:BD[>
M/#:B5JF4+^Z<VDYNP*8U<)XU5G3R!0ABY&BLDDAOZXKO4G\D,&MBC,N4,D-&
M<0B;&GK8^QJH1&4,DHKA(Y!&6GX5.+,5,%1SK"[7-;.5A091P;B*7M164S!+
MO0)+AGAZ(LJE8LP3"^;6<T*<6U+3J;!"/E4Y4)L4,CL91/,<(*<# M4=6T0E
M(0XEY>6F$;B%VFC1!%,#D1<P/W;LEKJVH9=9X\$&U*XN!.,IHRPE78ONZ<9O
M*&:%[1KKS6'L1%R418"N51!L*HU1ZZ7^WVG>1P8)[!6;I>$1%V7* FR;*,O>
MUDHQ@H>)@H%'3FN'7U,:K^TNKQ3&WP,\R"-DN+=LXOT:_*:-MV:#P?G?Q1&J
M3WAV!5C-K_\)?D.K[E&M[XG(P*D&[.\C>':<<0RIW:EKODX%'X*'PMCBA,A9
M*9K^B.JJK[XY)Y,4AH,Y8 ]U@[VO_URT4O"D V5D/ ,8#\$81)$S$">GH,A_
ME\QXG0O_X7TQ"A8(,Y'1G&>W164.PNW/F346)CUPBV)7/DYCA7 CSYOT[:Q#
M'JFT[2SU;=1IGXC#?TM]&Q\]S3Z1JT<)%\V&5<)=>YFX%ZV.F/+I7A(D7;M.
M\E9[J[7=;F'R%OW4N7KD]#-,]SW.=JJ <'XN@K[ZPAB +>@8:];._3?K7F_W
MPX/U-FMOK;2V02DS/W5T['7F<N7OLY9UTVCL=G<N!IMVNV!1G(&AJ' !L%KC
M/KL];8II-K;7_XV/&![-O:>3<X('-EBLAL(V_LWE&?HS_(\T7=%0 W06 J*K
MLZRNP'Y1C^6D&&+7/):9E&<P8$V-'['I(>K<_%91T&< .+B_ KK%2F#%HM0;
M'RT(C57GGK)OKW4?;XYC>/OW<?LLV$E.!P=__-Y?O/+S>[^/;F=K\WI9M-<[
M^!OW,KV#@X\^;YUO?SW>^OOLP0Y^9J+L?1_\&AS\S/3I:D8L,<^;9:'N/C";
M^/[N\^]O__IV?/A./=RI7_NZW[R=Z(;;W>Q>(W?T=A)$9[6R+&3A'26(_CA]
M'*:_[[V)QLF7CP^8 G?;=+#5N:19]0\E9-ZW[;6TLZX(&/ ^<@Y4+R&H@&X=
M4H!$ KA;QQ7<'!7'0REA)K [5YI<A*EJ5FR%6%_VCG[8/NK %%FD#Q_L[>BD
M@$(ICPF8]'28:367BI[9X39&K!;$>47Y4UB=B(EX.V;G]6J&T,1:)_F%/W7O
M.8%]-I,;OGES\,>G<?S7^17JRNY("(($!)UGW?S4O5$J^VUSRK6UN=U]M3GE
MW(8U-0\#[*4%:,@Y 3?"-5P0>GL;_/XE^^/HY5]O+0@D26_S?A3\\$K;<X>%
MC;=-@EVWVYV-]%5K@W5O1"T/6]$XFUK._YZHK]N?][8V-A:)6FZGJ/&VJ67=
M[<[SGUW1<'.N8[?5J.#C<6O<>K!*K=FDM/?RK_Z']ND?JK/^2&JS?IP^L*!)
MU95(K[G;V^NW9PM2]^8?, 9O5BS8NM=BP>^_#]]__;Y^T#W^V%UP KIQN=[F
MC8OUFHV?T#B\1BG5VK*4ZG9+J=:6I5372DUYE%DG/'5] H]V <?4&87QUMX&
M?;2#E_E B^(L*^<#%>!B._DIS,'IM.IR@DHY+C"7?;SX5%(P=;[LOM)?<8Y+
MVE'-\VZS(0\[IZ#D9I6VUH2VIC\6RLO261I8L\>IZJ2&Q!=1*;G'>88#21:1
M?-=WF#A3TP.*^\93F#@N5YN1\-\[D:Q#4!!69LV$6Z)AH!KQ,H$OCQ& 78KJ
M\3R"B#44ZH^'&:LNY::O#.,+MTA_XN37U+4\A_RL3C[",D#G62PYNEYD[ZA9
MV7,K&YU;R.JL=LKME#;!E*6*-8ZA%XR,OW!Z-,I<QC_D"*YH.<?<4H-F3#
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MI-)=&QL#6159E'V%SCCC7BN "' .E?1S\IY1I&*L+1#V?^QY$7RXV=A;=?Z
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MY#5(?>(DS]YY?A+XSU<K@SC7&"-@P)=A/,*L--0D@&-A;[PW'IB."5:)9CQ
MM/(2](X8=/J8>D,SVS+;C.ESNAZCM$C7P6V&MU8." @_$1SKB//=62L4,/E^
M#$+H.V(;D=N-MEKO8,D%Q8H;N601_\$20/BQ%<LLJL?5! *P[)4_O%"A8\AU
M7L(SP#C0=('/-!N\PRX2:X!,/U%51!V2J'H@EHI>LH)N8X%*.Q[BKK9[CBZ8
M\?K]A.#QT;FIQSG%=BT<@'CG3;@D]]&SA"?"V4B3*HZQT!2FB9W*3!0'#;@N
M XEZ)'72/$:'=&GGV8?CSM[S&HRF@A%)=+!4S=YL1#BT()Z0]J,U*D8B*[(
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MHU= W3B=JGYVL0RTE%#"MH%=?UE*])7F)*BK!"-.>#5XG"R_*(W2H21>72-
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M\QK'N0VT254,C;#G$G'C @W%4 R'ERUP%7K;7 '6C;F5)1)-T:(-#Y^I0GK
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M$S)Q'(Q5&'"/E']M;<#%W5A>@ 59QO_?WK<VM:TE:W]WE?^#:D[F%#EEV-A
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M<-W.65B2<]H-%RM^7R^/\CNW;3^_%$ "$""];+W=![>MY^V%JJ\[>+7;VT!
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MWFCV&A^7H8Y,..T*,5.2+PZ>F &/_=S'$"0AH<L"UIV;WX)Q3]8 4W=>:U8
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MD*XD%3D"S;3#S@SGKAA*;(OA;&S7V4\[5,YXN[.^@D".2><BJT/N#8W&;HH
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MN"[WJW$@W9K1@JS>%.8PW=<A=T9RK!FIR3.YFS 70G5.BNDG,S:6N"$2KL6
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M>LRY!JT748$J4MXZN._Y9X.:(FL8+SS+N4+T &G4U*+6\285.?<)_#K!F%1
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M)3'HML?LQQ^S?>1>NAT'0M]X<(0!W$3]M3]"-="_N[6IG9+8ZP8&UI80U&1
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M_6=PZV'L"=Q9>>BD>7EH@'#^(G4G_B/#] UJ0C0Q4T!QG1R))"M6&;K1I6*
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M7;3]S.X+W4H#=MOKXI4MEJ^%4L*BE@QYLSF&&%RBK R93ND.2H86GPB:]*>
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MJ<[=J0 7!;$M3+<T3,V6O)FY,<ZXK)L/3=\6.>TVKUA+'MY+RS9#Y\R]U>U
MP8Y+!5N5MHKD0B2_Z,JZ]XU%:K]Z99GM= P!_,T.APL-L^SY!A<?MW%,-O\[
M:QV J3DNH31&!3@V1^L3/"J!PQ4ERME8^$;IQ9?W4,0]5P="']!S?K-Y#3![
M+_H>&&F1[$L]-$L%B-L,1"TVN2:@1I3&V(*KAUD2H:M] WPB840I29[5&G8
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M.(X__S1,QC?\PR2?1O3#_P%02P,$%     @ S4.J5G+WTG9"#P  :*$  !$
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M:Y#1&H+;"JS:'+0.#EM'ATG+Z^YO@U4CGRX"4*ZLB1\<'R,:^# %%EQQ,;V
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M"IC9#M\UL\.:ML-'SIJZ\^(](Z%'$>?9&K%.2H9)$T2SG5X^G9V>1U':'/V
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M8+<@+Q>N'WK@70D^5;--& G=&UT2P3 HE7<@^A,B(-9F/.$].5FSE0NY?\*
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M6L>'^POIK3G=A(FU&C9C(FFW!1,5=VZ4]2^KT-6#=J:FG5;<W6'LM+1-&_Q
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M:@5M0L)6![J'&=$GW'NCB_BK&@P]D2\5%NF_V9A,(;5XUAK_3B#SU,,E&!G
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M;V="0-_GH2_W3%+>'GXD7M3CMZ3=5K-1)[+*C0GID/!'EA=+[$4N&IR#-[Z
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MO?YJ&#PEB %[R/YR>(:IX5(VLS9S@J:_OF(4M.OCDS<G><=_J1 ESTMJP''
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MK2W*\8GIXZX=KZAQ^8<@L3:)%:E*,7L F,X>GKB4)8^Z;\# ,H"']+9'2V9
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M3 #2_5LE85DAS/0^E]44LN]!,L]\.&:.\V!YCR^B)! $9W@"RCHQ?R0CQD"
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MT>JDI#)![/-@51@XG_KM5JUB(VOC[-Q)JG]Q3XVG,TV!@5/'@OA-/8L]M0-
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M33N T%0E+F7QM.>[ %"-DCDB*Z[6C(C+ PC;]+A,FEPN"!7=I9Y++@!5F=K
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M>XL%1TH0A%*$!GIAH_@]^P][W8/^YO\#4$L#!!0    ( ,U#JE;V!4&^LU<
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MI B&<6/02@RD2KO2+DN?*\ZE-^_?O^5\NCC_[[M?%\D3G2+I&B2_P26F;<-
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MBV<HR^5Q"^0#6!*/7@1W%9I%+^:*X5<IUX0%M1$LEO:FHW6EI.<# 1W4P0'
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M9M,!I#QS-;=/J=?)E!#7@G07E9IY!NR:%$]I@I,/+Y_H-'N>MV%8"W8S022
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MO*M61F)[J:(+K#**;79U5C/$AA/'?QV1*W);L?2M_&'<9CFG-D16-7BIQL>
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M)SP6RL*.Y[<VXPU>12D[OSHN\HI$<;6)LCM,5N_V'>.]"Y*#N NP>U/OY:;
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MO:1<I@\YBQ]QFBQL"K"ZU1'ML!.[:J F!K,G<Y%&]VF6L@WMXPU%K B&&EL
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M/R&OD1 +W,Q_B5:XO/U(C2/Y>*)M;844M$;70U2U/9=&MZ\15SA"'U^?A+5
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M,PG#ZAD'I'(&P8X*D)1UQVGU<K7\N5CC2PXKRC[BA%GH8XI,&Q'OI 6LOT9
MECJ./;A7+!'3#MM;]?39G"3=;M8L!;QU5#FI >NO,9BE#FO<C/;(K5:',NJB
M\I$'".DZK/\[L)Y1@E.&UW.Q\-&2IJ8>"L!J:PTZ==1B^-:^)G@=I0F_?L&6
M9M=%EL8O^H-_BSRLOG #*SW_++10JX;^(11#IYJOUP77$6&W5C6C0R4$JU<,
M".7X"[&DJ65#WVAPZ@"-'*P^,(-4W66 U!6#M.RI\TYH7Q96E]B!FG="&Q40
M[NX=2;>.H*NS:U*"U5<C$&L=7:Z[=7=AN+F?"_+;%4DPL?693A!6/UE02@^&
M47'$Y8%TQ]TC)E&"GV]?R@JORO,\UG2'3A!6=UA0#KNC$4>U_!'+[O(ZO!.P
MW.0)"P&]H%8W+_%Y66[P&98OVYB$876, U+%XQKK*']!:8F*^RQ]:+:>U]$+
M?^.+M.6A3!1(16F)+!ORZS WMHOE,JVJ8^;2$[&'%.5)8X"IMU^EU:;"/Q?E
M.JVB3#_8IA8$J\]WK(5T05P4AT1Y2!3(;]ZU4UQ;)FH*90,ZL"<99YLR?6I(
M;WV7Q2P/JX?=P,I>9:V%:C4@<Z%(P%EC^ABEE%\YXYK*\AID8761'>@8NQN)
M'*6-O5UMR^-6-\C^DCA_+*]R.L=LYX3V9%/>8+(HP.H_1[2Z3HS8R.I.FZ\Z
MTZ9TB%NB+X\IM:,Q[>>B0O<8Q00G_!GRZ('V=5DA:FAS^I^D>(DRODQOWAVX
M?^$/T-8?/JIOFO)Y.HH?V9W2IXBDQ:9$<;- 8;8[+E8KMLBD_]G""92 *R5E
MQ8)]_D[KJ,_U(0O!(HP!H9S9@XJ*^RU<.'C.%8YBD2?,+\?14G_8:!*&UAU6
MI,J$*Z)#V(ND6ZW06V+QAN6]M-R>U,C!ZA4S2,4VF)"&<9FR]9;8(\HGN(Q)
MNNY6=.ND: 1A]84%I12+U/J*_%GU9*L0*%?@:Y%I3ST:^C_#:G@E-D5^0)$>
M,&R\4%YNJ+O!GWU>)$]I69 7=IJL<LU-PK ZP &I[-<U*G6F<J&T??6)^F[E
M8S!G_/)DL47($N+HCK#4<K"ZQPQ2.L(Z6:!.[S#YL,FXTN+Z,2*KB.TYEQ<7
MQYJNT,C!Z@HS2"DQ5UH@(8ZX/*(*@=,?I*O[#2GYO%4_1* X5Y>%8/6" :%\
MKMX1;1Y*"#-!=U-^CP@[==2#U4/C0$MS?2<'!<3 U$O,+@Q0R$DI-H';_5[=
M-&-1@-5YCFCE!YU:M69O?+L/'MAKXYGP>?" RDW;_@JK(U30%(Z82/._9D)A
MCIMNSG_*BGL6M:P^1>K_#JN-U>"D,Y^;<R3$ *3I,F3!&0K :FL-.DV.KI#Y
M;C;EJX<H6O^Z*$M<E<<;0@8WKI0"O[[[-;O/O+5W#W?=SF9<TAX&ESI"M5S0
M1M:W+KAFM;1GH&;L/"!C(*PL!:AY#>"&3=T1#<U?'N'^6&0))N7I/S=I]:)J
M>%GJU_\ T_ &<-(F-/_Y""VJBJ3WFXH?NE4%"Y<-UP4=-BSRQ*U#;#HPQX49
MJF&4\'TZ(1ZHDZ[6F"WC\@?5:Y!:(4#=H,<FW2AO)%$C&KK-S_.X6.&+HC2W
M^E8,8KLKT.E;7@BC;YGX=X&:_YS%AN%2M=>F$0'4[#ID\KMT0J[A>JAIF"46
M[^8P5\["0Z%?WX-I;STV9:YUZO=T9&&\^PCAZ=?P';KOFN@>@IQ>=#!S. 0^
MO+BHMI V+5!&TQFL]GW/;QOE[]@+G](M36B=USQ[69M_RCR>4$>_K)]6TB%T
MLEL%1G9\71AWX$6JHB#[#!JK%N:I7[!&?GP5[-;=N<Q EN$25RQ:Y)H43VF"
MDP\OGTI,[5WKBB_B*GV2.#!>&Y %F !:<5Z&>":*IA 6NOPM*X<._N_0=B&S
M+>OK>+X9R-AUQJE]NEFC"&L4GJ7L7L344:C0AC\*3:!'CL*VJ'"CL*DL0\G^
MC^WA/449NR9!)X:*I'&%$_;#@E]JZ_RA(ZE^SXO^=[9)^(96_,@>Z;J)*GQ*
MN1PKSP[\(@#$LT 55^4M.A)L[91_A+:?1D*DOHS8_6-?0V!""L>37ST6R% #
M#3%L2( [1/*W-3I)RW511ME/I-BLF3>5EO3;=)+=4!,NYMO!4_<AO@]@@@Q:
M[?EHOZ5V PEQ3%RSBPIM804D/'LA=&!+]$FK1BD"LZWN>)6IW/BKI[*-$ZFL
MPJ>TZNP:%"M\%ST[]*).%E#'62$J%K;L0(9J .P<]=NIXF%42D^*G;(J?<+7
MM$HU.[7G"^.* =2ENZ!7GE&\$GG_ZLO#J/,4+?BN=W@V][)I&W&LSJ)=R4;<
MDMX>S%QNAI%Z/K\+R)?P6ET3&[N?[U&2KOR4K&4@CA"%\4K@J,,H4 =)[RR.
MRG(T!_7<=MO*G8I\QNP-*9PLGJ@W](!%K:Z6O !IW\?;EP'$306J\/[?W&8)
MC,2[V[UGM[_4:% DX*"<XV&)IGE90<+,HSP253K#[)T %GCVM^:ZH<1&HS0
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MIR9B8_;!=9V9OLSTV9!O-9YQ65[;U;5[7BIH$I*P39$:D'39_>L/0%(2*1)
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M\/-5THR#PN,NE+^(*E1"T-(:G#+"!?Y+J<7*CK+-77^;5X]D$O:KVD,!<".
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MMK6D3^EZ2E*/ALF5.*>)F^-V$ZJ1*0"6XG7RQW+XR79\)-OJ)7VC2<J=&_+
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M0P+"M_&@V!\DZ[3+0"Y=HRI78W<N.;;FBODFG+_'7J(ZLVFZ86<4Z[[*)!Q
MQVDWKY*L0HZV J8N\:OKBGV]9X(7F!/HF%VSV"<D2,XYN1=)DO%=FF_2TNU9
MM=H,!\).0V6V_CIQR0%TFX<CD#>>MB-V9J:^1T28*QW:\P?\**_LA)V(R$QG
M:JEW"2'S(SRH,WJNG8Z0&9S>AZ@YA[PPQ1Y@M"@W'= 3VO1:D76R75J-!EN;
MNA=Z^I=> +FXJU7OW:LW0J4T7425>WC8JXY^%/2D*28H=F&02ZCF00WZ[4_>
M _UIJ"-:K82C(R,[JVQ5A?D9KM(5BI4CUR9 5N"#5N0\VA"VF>Q)G*2J&RYE
M+W2?'".H  Q 1ZFR]OG9/Z&<?SDWRT>+8&:\ET&&@>+HQ$U))Q:A ]L:;;?=
MC(F?,9J*5RLO#,65^7[\I<+8[#LPNMN7D3TZ#!O=% =7HY[?N7%[,U#8\N%=
M#FSW*Q*<<@&/%D45@<*$OR+?\E\I0P!@_<'O_BZ(@QE3T!=\U5 LI70CN\H'
M1E4O*%Y.7/5 &(".4BX]LC3!&\&KM($BX,1=3I,X]-#^;+7RV--L?D/R[*_7
M'A/^W]P@5Z8I?=^(["_&$5E*RY$F^5"3?"SLI*15XBJF::*/\M?WQ([[E\WP
M^*GV&VA& */AW'"QAJ(KS1Y@1#-^7@')=!O*!RS-E^YF&^@@W7LPZVG&3TE0
MSG$:B5S8K#)A\=B6:<)+09V?+:YJLM%3&6AFJ8MS 79W UT#*3;#TF[<RXF7
M+/.,3^J@O?U6V$[X1I)5"]UKI]=6=8<\4DW+WF8S; ?ISOR548Q^M!*FN-"\
MN6NPZNV\U@PY3 AJ[#1>S5MHQ3YLR38]6#:U#_MGKOI!JSJ@.]G47DY>+R>O
MEY/7R\G+U9/7'1][-J\4*5*?M23-GQ]V$D+1SU.5&26%:>;M?E(E59?;Q'@@
M-S!6RNL>AL8D6LJXOUJ'<5'M:\%(_G%UPG!Y>^PS5T?IJV4#UW'#SC$A86EE
M>?%_[986_\?7.V%ISN8742 B!C,OE*A!WE;2U(WE,8@*E!-I)Z>9*39?:+K,
MB1#T+.GZ+CZ+4I&467:9U$:0;A!D/.48Z+'2D69'S9VR?\8/GK]4ZK;]1F@*
MK0O?FLJLG69+-TFG[!_>BB2WGVA"V*=3#9];VZ(%<@_%;@4';%7[8-3_QWG,
M5EZDWK6;[=#"!X?AMI1RE!WZ9$G)?+;./2VCQ6P^ISZ7 1DBO(>R UX$6G]L
M=+1970Z E=!I$5@(!AMF%=A8 !+>WL3\&^G5%\(QY<894;-9VAHOTF08CFO8
M@*)]3BDC/A]*I7#VV^"YM@ZB8]I)MI5!=.E1L<[XT3X+:"JB5VB::BIKZ3KA
M.9,.LQ!@3+&.R*8@>O%Q=5Y$;2\\A]&A,5&RQ1(HQ4>,%HFZ"Y[WZ#!P0!AB
M&0N3Y:'I T5C^#?_8=&PNC1Z7Z&?T\B+?.J%%U&2LDS_Z"'M\(SN_'2DHF=+
MSNF9$R;NG6\)>Z!^?O)IF7 BW@B2]E_I_,V&_8H;\J&1]_V'KT$Y8.>J4<36
M1 %9"\>32&*H[J<G57:!*EYKP?DVI+N6IA3 ,:N9*S_F$7/SHERD>I-4=8 "
M92U,V#90>FZA[Y\OSMIVG;7_A.W>\^*L[8"S]J"^6CIGD+:V4%5K+;-&)P=D
M!4%NJ4^-,@%I4= 8;BRW$?SJ6JFO)#C&AQNH0&MMW8#/7&@5F-D]')B># 8X
M%EA+3B$7GJK-:-VR'R*GD)?7&8V"+]Y"F2BBT?(PXR]D%*-#43X6)Z+&&>'4
MJ+,XM;?&=D/LB(F*='1<-@*32PN7&C.<8+VQJZKT7$L0UJ#CN,GQ=AZS&_ZG
M'+)&0T<"_DS1D1",#L0G+_(*Q^1S0O@DU6%([:VQ"Y]TA$1%NJW7L)9/_F<F
MW#=8^"1[#5/WP:Y=8LI\ $D-" XP$YA(X9-']U;5;R4PX/AIUZ34#=-O'@O*
MR\S\:C.YB(I<61]9G*BL01L?PZZQTG47M,=X=%V=3_Q>3]O]/FWY?WXEB7"#
M+/+M02J46?H<=K&7/H)EB_GHHF4UZ-]:0E)+4?_/9;LQW3'PB\0,JO05BPLG
M>5Z>\N.HH4/T>?3^I,BC5QET4AW5C91ZNUGGR=:WLRN!SN?84)N M ]]Q\5.
M"G%*YERF@V,2\;^DUR$7]1U)"3@9!&@8-^[&AY$$:8H($"?P4T,TI[F;94/+
MM8@]K+L;B'>2]CV @03C9XCXWM\KNT/<X9T2/5'?RSOE6.^4E2]1C=MX>U.7
M7F$4T5P*,BW=15YM]UX(<Z6M7;J/5WAVJHE%/W^/?("S!8:1>=/U$#?$\1SQ
M %A<-$ZYQGV@Z=-%Y(>9*-)7WC^*0-I=>0SEJ?#/NE/AI!ASLOG69/NQ\C?)
M1'Q.M-]\\.6\Z-1YL>=E=J4&9%%ZQ]X;0LNGL'61E0.G+40ZZ[=U44TEY=N:
M@U>0G3CSA8AK<A),N>[V%J16.F@4"59/ -NB=%VP(?!]]^)>?V<<ZVT7W[G)
M2>%M!\/10T$UNZ 179;4ZI"3P#Y,XDCG\##BBZZJZ%OE&)1LIJ]2@1W&PG9)
MLR-(G9EJOMW^5&RW$5F(^;J]U>K6S[9\';(F-)P'MF>?F\JP$YCX^K"GA7+V
MN*9%]>01;,;6CV'[ SII."I@<5_D]"NM01R:XC2<";:/H:NJLQ.@[DNRP]>@
M7]_CNTDZJ3I;.37(Y=!9Y+B]^DQN0@U$VYK#J.NBK>/?\Q'X+J[Q6G[=$/&@
MSW]^$D<Y8ID7WA&V>J\1_K$G@Y<HV_HZP,'UX&V.<J4+OS?;-D?+I_#2B;NL
MEZ68/"=IPS$9P!. 2N;W]0!EB)\;\MIC9Y#3*]L9WMG;\3M-!BK'!_A4A8,K
M>I36UI6]MN22G+NK.*J^KU0,FVD45(CNX<WWEX8W7SDAX9ZWF=*DF)/X43&K
MFJ-?,JE,;,+_F%2F]N+\=VC.?UN!;-]=BF>_:98N8T9_)\%G+NFL(J5Y#,;Q
M4TV:;\0Z!D>7V?FN&R$0EL/1[+ ./WZM!UU-JB[U 6^VON>&$(ZSQ$&V:G^6
MXL?@#<Q$=;">E8^]B.6P_$2/%QQTL>D"#JU\S!&1M+>T;:I'N[&1M>_-(G6%
M(UEC;&]VBRND5J93R2M;55&K'[W[%L,!JC3&]HG% *C!JU$ XDT-UE"M.;:O
M'@I(37Z- =-YG*E354M;8WL%88#4Y-8H&-$'@Y54;8WM4(""48-;8V!T2Q_A
M$%4:H[\M8D#48-8H"(D,=08859NCOT^@H-1DV!@XG8F7#CA.M>90G)Z5Y=#"
ML#%PNJ(F9Z1J:RA*S\IT:+)K%"O<1.7=F2N\9V4Y-)@UBKH+S?:E>GN\TM:8
M"J^%9>/<.9#0Q!*OM\<KM(QZ]=!DV3BW#Y2EQ$CY[?6 PO6L3(EVMHUU#V$&
MV'X/]#*M6!<2PP/FUD/-Y_6:L/)]=$45GBEVOXJ<@,FNKX#-9QL)?L\P17Q'
M!A7NT[-YQ=^L="H;2=95$WA6+UJCRKT>UN>EIS?T5MPD<<2X;0+8F9H.7XSE
ML*([&[=7@BC=;Z^$/VY*'W:N,C5/X1\:GL+Y:#GWZB4@-OZ\D^V(+YZ]!^#9
M"PGI[^G$:_ )-QR 4/QU#;CDJFLN( :IH9L'# ^[/#276^.U-U0DV*5+GK0%
MF?P#:A_8O6;?!\)[1#OJ8@JA<D=)% A3ZLI;=?0Q[?LU-R2G5>H'2\*CHM^.
M?^C=M_AN&6<)/\G=?>/3>"H2"$:B^""W!<4DE)>7!OW=/',/LPBJ5YG&++5S
M8$Y86E$-_%\[M<#_\545OL!_?W !!YU5=IW8RHEY9"RDRVPS0>@ZLHQ'G5_M
MO-Q,M:?.ZL3,3]XC764K%3OWFJ IIGUV-9C92@OZ_=KW7L?,CLW8H<;9AY<:
M9]]+C;,S1OU_B&!\C3W6T@X[[@!6?4M*H*5W^E/V#V[%)9]H0M2A FT-T7-Y
MP7@JI]$24V]B_HWTZ@NAT8)/3>/X(&T-9:^UU.S @GQJ:JT)[A<:)7%T^SLY
M66;1W]418]+64!Z/4IA=)<)*:BWQ^%-R0Q8T\HY9_$TMPZTMH<]RUM[E8+Q5
M4(EN8XK3]FQ>L:G4YJ2DN1MFAFW+44)\I7X%T@UQA:YI%%S%D;?[2=7>DJZP
MS:6;Z4!NX*Z4X?T;8U,2+9F9JW48%U*W8"3_N-K<E+?'-CL[2E_-)M5Q ^7F
M[DZ\],_F%U% 'VB0>:'\%D_2U(WE8?-&3T)X1>80\?I"TV6^0POI6]+U77P6
MI51QD&XC2#<(_BVA4DY56.E(P[A5/*6,^'PHU;7B?AL\$[L+5QNXM)-LR>(6
M\<U<1<_F<^H3MOFTNMZXI@_4"A^^'$U_]@/(LPJ'*10#P.#B*M"09A4"OM<]
M>,*9\=C3W/FUMH2FA!G^##H,VQ7DVU)!<<9*I#5ZIZ4AM)B@E4>D(92-E'CT
MJP!E2<,;DJ2,^BD)\F:Y4?B1Q8G*4:WC>$Z&RG3QW3,I&:GE+[YX=.7+Q@6\
M]"!_\&@H3A/G,<N+J2H$R-H7G7>1Z2QCED$Z7"ELK=^KTV V/N9F+ FF[.FA
M>8;1?H=1,L_5E(<.B*L4%G0=62F2<.*M:>J%6QN#L <2<*5^GJ49(\(8\2)5
M+9H.0V&7^[8F,)W9BBX0G5ER2A*?T5S>+2B=VNC8SQCNZ9D6YKLA23V*TOS*
MCSDDR NUK(DX[=S%XD=.U2 :<H[8E;KM2K4C3'9I;?0P*(Q9,E(]N;[S<C/5
MKP,6Y#" V[JE]2C[U0LS\6Q<*;<ENZJ5M<:NMST\^$IR75)%$+5@MD1'SM<X
MU!*5+9<#O4KHO>MNKEBV4FS=F&K[(KIOM^.VD1PE-]1+@W.F%HBSZ<NMF0:.
M _C<*FI_?U?HD*K:H^]Z$@-SP/O70E%>1#XCO/$I*?[,E:;$7AWKXXZF_N]K
M_XZ+W>&JR^*"^#IC_E+\ZCQF^8\M:$OIE]!CO-Q3EAI4W!"W+O9C_A]A/?)U
M=2-N#A*^ND0Z#&^A.P@._SE'JVE@VO<0? [_?&IS7QCEZ5OV::A$'^AM_ABX
M';1TGY83EO!(.(/N7$.KC<3];J02WOXC.UH59P#9'(KKA[NM-P]W%U'*:)10
MW_;UG>J;Z)'M[FWP8*3<$,;!G/7VWJGR7YYZ*=G>78[E8PF8B*/%J1S8Q3MB
MZH8L]UBN5W'TD%^YUYV@[6E5Z0?!OL&'*9OV,,).(B]\ VDJ)BUBX(6+"C>%
M2>13DL 2R?^XGTB^,N*$6]:3VICN9)-7$;XE1Y\\WG 8[%SQ)W'(:8@+SC<3
M(/B27U>S(8"3Q@_W+3?2$722&&FR^.&X@Y\U?@!:&FJX;:D-^14W9,K>RFSX
M@ _)//SD\L\S_9-E(5#G@<++/O^2!^K@\D"=\";4]\([1KU0!))P@I>PE%"P
MKMC1A@-DAS+AD25GV%FZ)&PSC^VGU=D+-'VPXUT&  ;$%4N(5%0\YQ=LP2B[
M8'NI#[%0 #RQ!4<I!9OE>9NMUS$#)K>#=L;V4AY0E\'X9 FL+S'[;29X!8-'
MWAS=NVD 1'3,L(3!V:,?9@FW/R^I+UZI@&D@=;W0R\0/D0T2QAI;P(R>F=-"
M1JX!P;"=FE.6?9L\D#!>B^]UV.K!O:'9#5S>4PQ992N5]\W%QS"^]T)U&N_]
M5M!L 2X?4"2DH[^+?>_U8RQ? W4H)#-PN:N.LO!22&:$0C(?6;:.SY*U%\7A
M*;G(7R_IPO.%8U)TRZGF7U=?(!B-@)UH %8)H0-3;"5>/9V><,')PC1/*<#6
MZK2KLM90^\&:O0WCNX9:6YE5:7R]]-C*$V>LY/+R1)U=5=8:RF-DV=90.Z@U
MD!#_]2)^>!,06BA__I>=SN?_^'I)%EYXEB<CE6SPO%6CD1M:WOX.WD;[H+7>
M] "=J5/1\R9G+N69;^-8@Z=G0Z:/E]TT\B_,YG^/U^0JIUU8W8&X4COAL]>4
M& /V1;MG;+"PY0+1A'Q+>OUN29@7D,?;IT2\8U]$OKITL;0YWOTA@-,Z*FV=
MH^/YG*;IB4@@QPI0O2C8W!=?1-Q@2K.4_#U.\A1T.N9W'P[O*A$ 3E\NV;(J
MB7@2"_E4DF)JVYFHS4MM-[Q[*@ 84*K1+T3*T#OUC4>MT?=B$+71CE[7K)R-
M[KIBKYD;D+6(6CNO[5I+YY0EJ:@Y\-]<,>JJO+0UQ2ONTLZFIO91D6BQB$[^
M-;[JA)E O+G.]%1W@7+9FO<!@,MZDE^JM#FMXU_*M>'O#@Z7:Y,Z*A _$Z(&
M*MDC;7WHU:DT;+#U"LY>%Y7%U:6GZXV@K![^K# ,J]N)ME:,BJTT9;_J3<#U
M$!SE;AO!*!MWN9!4A1[WFD!9[V+MKR8UCIR)*^FT9_<A7=02%;9%#[4V1Z[9
M92-RJA'YH^"3)>4T#1[$?<IT%6=16KY"W<6?:,BM]3@B99BL1&U!.V/7PK*)
MG0D?'%F/VP"'**@X=FDSR&BZ88>!C+! 08Q#A[>(F=B%P((JK"@[81=H&@%:
M --< Q8,)G[!I/$!M+UM=MLO!]HHK45L6=\H#V2'W"4$2U+%.\Y>,VP'N1%6
M62MC;+UTQM$-F6=1(&X:RT"-O+;M.9'E7%9WP8Z_L[VZ( RSI0^CB)]:RF]^
MXH?3E$3"))9#I>R!7=+%NA[4L\L24*6F3681IX-MI66KB25HZ;MA1T[:A@S*
M./2]:[8F@DKAA)ODU)?G$\4^INB"7D)E#--1QS%T3#?"=QZSF_C)"U.J@K.]
M-7HEE!&05/$)'<1;+_08G] 7;T$$S9MG'F"!&U!O]+HE(X!LPD<'BY)L8R9%
M:4GUW4QN*DB;HX?&6[>2-)Q"7]%%Y#(AQR0B<YK3;5JWRF (]#(;(ZQM8XZB
MRX"9%N^GM0_RWD=)N2,@5NT&Y<UJHR%ZP8:1K2K[5ZN[*$).P31XH$G,GDZ\
M9"F_2U!W0:];8'N?A'#,$E@WA*[N,Y80]0NB:-O>%#W#OVUP5!RRMX)R/P)9
M==Y29JIMT#/6C[!&FCPQ2NE=_D;\1V00YS_Y_U!+ 0(4 Q0    ( ,U#JE84
M7_]AVP$    '   *              "  0    !E>#$P+3$N:'1M4$L! A0#
M%     @ S4.J5C%TX; ="   S$4   H              ( ! P(  &5X,S$M
M,2YH=&U02P$"% ,4    " #-0ZI6!!J]Y+L'  !&.0  "@
M@ %("@  97@S,2TR+FAT;5!+ 0(4 Q0    ( ,U#JE8K I/(AP0  !<;   *
M              "  2L2  !E>#,R+3$N:'1M4$L! A0#%     @ S4.J5BLK
M?56(!   @AH   H              ( !VA8  &5X,S(M,BYH=&U02P$"% ,4
M    " #-0ZI6O_3$,'Z% 0#14@X #               @ &*&P  9F]R;3$P
M+7$N:'1M4$L! A0#%     @ S4.J5G+WTG9"#P  :*$  !$
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L &QI>'0M,C R,S S,S%?<')E+GAM;%!+!08     "P + )T"  !P? (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
